"Rank","NCT Number","Title","Acronym","Status","Study Results","Conditions","Interventions","Outcome Measures","Sponsor/Collaborators","Gender","Age","Phases","Enrollment","Funded Bys","Study Type","Study Designs","Other IDs","Start Date","Primary Completion Date","Completion Date","First Posted","Results First Posted","Last Update Posted","Locations","Study Documents","URL"
1,"NCT05501834","Anxiety Surrounding Supracondylar Pin Removal in Children: A Randomized Controlled Trial",,"Not yet recruiting","No Results Available","Supracondylar Humerus Fracture|Anxiety","Other: Supracondylar Pin Removal Before Imaging","Face, Legs, Activity, Cry and Consolability (FLACC) scale|Heart rate|Spielberger State-Trait Anxiety Inventory (STAI-5)","Boston Children's Hospital","All","3 Years to 8 Years   (Child)","Not Applicable","68","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB-P00039559","September 1, 2022","September 1, 2023","January 1, 2024","August 15, 2022",,"August 15, 2022",,,"https://ClinicalTrials.gov/show/NCT05501834"
2,"NCT05501821","Study of KBA1412 in Participants With Advanced Solid Malignant Tumors",,"Recruiting","No Results Available","Advanced Solid Tumor Malignancy","Drug: KBA1412|Drug: Pembrolizumab","Part A & B & C: Frequency and severity of AEs as assessed by CTCAE v5.0|Part A: Frequency and type of DLT s using the CTCAE v5.0|Number of participants with an antitumor response to KBA1412 monotherapy (Part B) or to KBA1412 in combination with pembrolizumab (Part C)|Part A: Number of participants with an antitumor response to KBA1412 monotherapy|Pharmacokinetic of KBA1412 monotherapy (Part A & B) and KBA1412 in combination with pembrolizumab (Part C), area under the concentration versus time curve (AUC)|Incidence and prevalence of anti-KBA1412 antibodies for KBA1412 monotherapy (Part A & B) and KBA1412 in combination with pembrolizumab (Part C)|Change in biomarkers for KBA1412 monotherapy (Part A & B) and KBA1412 in combination with pembrolizumab (Part C) pre- and post-dose in tumor tissue","Kling Biotherapeutics B.V.","All","18 Years and older   (Adult, Older Adult)","Phase 1","106","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","KBA1412-101","August 2022","January 2025","January 2025","August 15, 2022",,"August 15, 2022","University Hospital Ghent, Ghent, Belgium",,"https://ClinicalTrials.gov/show/NCT05501821"
3,"NCT05501808","Color Stability of Two Different Resin Matrix Ceramics: Randomized Clinical Trial.",,"Completed","No Results Available","Dental Restoration","Procedure: cerasmart|Procedure: enamic","color change|patient satisfaction","Fayoum University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","102","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","COST 315","June 1, 2021","June 1, 2022","August 1, 2022","August 15, 2022",,"August 15, 2022","Faculty of Dentistry- Fayoum University, Fayoum, Egypt",,"https://ClinicalTrials.gov/show/NCT05501808"
4,"NCT05501795","The Accuracy of Flap Thickness Versus the Pre-determined Surgical Planning Using WaveLight® FS200",,"Recruiting","No Results Available","Myopia","Device: WaveLight® FS200 femtosecond laser","The resultant thickness of the FS200 created LASIK flap compared to plan at the surgical visit.|The resultant diameter of the FS200 created LASIK flap compared to plan|Pre-operative Pachymetry as measured by the EX500 versus the Oculus Pentacam","Stephen Wexler|Sengi|Bismarck Lasik","All","18 Years and older   (Adult, Older Adult)",,"55","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","SW-22-001","August 9, 2022","August 2023","August 2023","August 15, 2022",,"August 15, 2022","Bismarck Lasik, Bismarck, North Dakota, United States",,"https://ClinicalTrials.gov/show/NCT05501795"
5,"NCT05501782","Evaluation of Intuitive Eating and Hedonic Hunger in University Students",,"Not yet recruiting","No Results Available","INTUITIVE EATING|Hedonic Hunger","Other: questionnaire","Intuitive eating scale (IES-2)|Power of food scale (PFS)|Food Craving Questionnaire (FCQ)|Pittsburg Sleep Quality Scale (PUKI)|Warwick-Edinburgh Mental Well-Being Scale (WEMWBS)","Istanbul Medeniyet University","All","18 Years to 36 Years   (Adult)",,"100","Other","Observational","Observational Model: Case-Crossover|Time Perspective: Prospective","2022/0145","September 1, 2022","December 1, 2022","December 1, 2022","August 15, 2022",,"August 15, 2022",,,"https://ClinicalTrials.gov/show/NCT05501782"
6,"NCT05501769","ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer",,"Not yet recruiting","No Results Available","Breast Cancer","Drug: ARV-471 in combination with Everolimus","Incidence of dose limiting toxicities of ARV-471 in combination with everolimus|Recommended Phase 2 Dose (RP2D) for ARV-471 in combination with everolimus|Number of participants with adverse events as a measure of safety and tolerability of ARV-471 in combination with everolimus|Incidence of laboratory abnormalities as a measure of safety and tolerability of ARV-471 in combination with everolimus|Overall response rate (ORR) in participants|Clinical benefit rate (CBR) in participants|Duration of response (DOR) in participants|Maximum plasma concentrations (Cmax) of ARV-471 and everolimus|Time to maximum plasma concentrations (Tmax) of ARV-471 and everolimus|Area under the concentration-time curve over 24 hours at steady state (AUC(0-24)) of ARV-471 and everolimus","Arvinas Estrogen Receptor, Inc.|Pfizer|Arvinas Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 1","32","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ARV-471-mBC-102","August 2022","August 2023","February 2024","August 15, 2022",,"August 15, 2022","Clinical Trial Site, San Diego, California, United States|Clinical Trial Site, Santa Monica, California, United States|Clinical Trial Site, Lake Mary, Florida, United States|Clinical Trial Site, Ann Arbor, Michigan, United States|Clinical Trial Site, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT05501769"
7,"NCT05501756","Precision Alemtuzumab Dosing for Allogeneic Hematopoietic Cell Transplantation",,"Not yet recruiting","No Results Available","Allogeneic Hematopoietic Cell Transplantation","Drug: Alemtuzumab","Alemtuzumab levels|CD4+ T cell count","Children's Hospital Medical Center, Cincinnati","All","6 Weeks to 30 Years   (Child, Adult)","Phase 2","60","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2022-0447","September 2022","September 2027","January 2028","August 15, 2022",,"August 15, 2022",,,"https://ClinicalTrials.gov/show/NCT05501756"
8,"NCT05501743","Evaluation of the Efficacy of an Intra-articular Injection of Autologous Microfat Combined With Autologous Platelet-enriched Plasma in the Treatment of Radiocarpal Osteoarthritis: a Randomized Controlled Non-inferiority Trial Versus Total Wrist Denervation (Established Standard Treatment).","AMIPREP-2","Not yet recruiting","No Results Available","Arthrosis","Drug: Intra-articular injection of microfat and PRP|Procedure: Total denervation of the wrist","Pain intensity measured on the visual analog scale (EVA)|Combined assessment of function and pain by the PRWE score|Assessment of upper limb function by the DASH score|Assessment of wrist strength by dynamometry|Measurement of wrist joint amplitudes|Overall change perceived by the patient|Patient satisfaction|MRI evaluation of cartilage lesions in the ""study treatment"" group","Assistance Publique Hopitaux De Marseille","All","18 Years and older   (Adult, Older Adult)","Phase 2","36","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2021-006817-12","September 2022","September 2025","March 2026","August 15, 2022",,"August 15, 2022","Assistance Publique Hôpitaux Marseille, Marseille, Bouches-du-Rhône, France",,"https://ClinicalTrials.gov/show/NCT05501743"
9,"NCT05501730","Use of the Quantra QPlus Sytem in Cardiac Surgery",,"Completed","No Results Available","Cardiovascular Diseases","Diagnostic Test: Quantra QPlus System","Blood product utilization|Cost of blood products","HemoSonics LLC","All","18 Years and older   (Adult, Older Adult)",,"128","Industry","Observational","Observational Model: Other|Time Perspective: Retrospective","HEMCS-038","June 15, 2021","November 21, 2021","December 15, 2021","August 15, 2022",,"August 15, 2022","Yavapai Regional Medical Center, Prescott, Arizona, United States",,"https://ClinicalTrials.gov/show/NCT05501730"
10,"NCT05501717","Safety, PK/PD, and Immunogenicity Study of SC ALXN2030 in Healthy Participants",,"Not yet recruiting","No Results Available","Healthy","Drug: ALXN2030|Drug: Placebo","Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs)|Maximum Observed Plasma Concentration (Cmax)|Time to Maximum Observed Plasma Concentration (Tmax)|Area Under the Plasma Concentration Versus Time Curve From Time 0 (Dosing) to the Last Quantifiable Concentration (AUCt)|Change from Baseline in Plasma Concentration of Complement Component 3 (C3) Protein|Change from Baseline in Serum Complement Functional Activity|Number of Participants With Treatment-Emergent Antidrug Antibodies (ADAs)","Alexion Pharmaceuticals","All","18 Years to 60 Years   (Adult)","Phase 1","48","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ALXN2030-HV-101","August 16, 2022","July 4, 2023","July 4, 2023","August 15, 2022",,"August 15, 2022",,,"https://ClinicalTrials.gov/show/NCT05501717"
11,"NCT05501704","ETHAN - ET for Male BC",,"Not yet recruiting","No Results Available","Male Breast Cancer|Hormone Receptor-positive Breast Cancer|Hormone Receptor Negative Breast Carcinoma","Drug: Tamoxifen|Drug: Anastrozole|Drug: Degarelix|Drug: Abemaciclib","Change in Ki-67|RCB index|Changes in estradiol levels|Changes in testosterone levels|Preoperative Endocrine Prognostic Index (PEPI) score","Jose Pablo Leone|Eli Lilly and Company|Translational Breast Cancer Research Consortium (TBCRC)|Dana-Farber Cancer Institute","Male","18 Years and older   (Adult, Older Adult)","Phase 2","60","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","22-225","February 2023","April 1, 2026","April 1, 2036","August 15, 2022",,"August 15, 2022","Dana Farber Cancer Institute, Boston, Massachusetts, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT05501704"
12,"NCT05501691","Effect of Diode Laser on Postoperative Sensitivity of NCCLs Composite Restorations",,"Recruiting","No Results Available","Dentin Hypersensitivity","Other: Placebo|Radiation: 445 nm Diode Laser Wavelength|Radiation: 660 nm Diode Laser Wavelength|Radiation: 970 nm Diode Laser Wavelength","To Clinically Assess Change in Dentin Hypersensitivity Between Baseline and After Exposure to Diode Laser Radiation.","Alexandria University","All","25 Years to 45 Years   (Adult)","Not Applicable","17","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care","0048-06/2022|IORG0008839","August 10, 2022","September 29, 2022","February 20, 2023","August 15, 2022",,"August 15, 2022","Dentistry, Alexandria, Egypt",,"https://ClinicalTrials.gov/show/NCT05501691"
13,"NCT05501678","Trial of Diphenhydramine for Sleep in Children With Autism",,"Not yet recruiting","No Results Available","Autism|Autism Spectrum Disorder","Drug: Diphenhydramine|Drug: Placebo","Change from baseline in sleep latency as measured by polysomnography (PSG)|Change from baseline in duration of non-rapid eye movement (NREM) sleep as measured by polysomnography (PSG)|Change from baseline in sleep efficiency as measured by polysomnography (PSG) and actigraphy","Stanford University|National Institutes of Health (NIH)","All","8 Years to 17 Years   (Child)","Phase 2","26","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","IRB-66941","October 1, 2022","June 30, 2027","June 30, 2027","August 15, 2022",,"August 15, 2022",,,"https://ClinicalTrials.gov/show/NCT05501678"
14,"NCT05501665","Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung Cancer",,"Not yet recruiting","No Results Available","Lung Non-Small Cell Carcinoma|Stage IV Lung Cancer AJCC v8","Procedure: Biospecimen Collection|Drug: Carboplatin|Procedure: Computed Tomography|Other: Fludeoxyglucose F-18|Drug: Nab-paclitaxel|Biological: Pembrolizumab|Drug: Pemetrexed|Procedure: Positron Emission Tomography|Radiation: Radiation Therapy|Other: [18-F] (fluoropropyl)-L-glutamate (FSPG) PET scan","Incidence of adverse events|Best overall response rate|Progression free survival (PFS)|Overall survival|New metastasis free survival|Quantitative and qualitative markers of planning and treatment resource utilization","Vanderbilt-Ingram Cancer Center|National Cancer Institute (NCI)|Varian Medical Systems","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","25","Other|NIH|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","VICCTHOP2185|NCI-2022-05101|P30CA068485","September 1, 2022","October 1, 2025","October 1, 2026","August 15, 2022",,"August 15, 2022","Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT05501665"
15,"NCT05501652","ALLEVIATE-HF-HD Study",,"Recruiting","No Results Available","Heart Failure","Device: ALV1System","Primary Safety Endpoint|Primary Efficacy Endpoint","Alleviant Medical, Inc.","All","40 Years and older   (Adult, Older Adult)","Phase 1","10","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CIP-0005","June 30, 2022","December 30, 2022","April 30, 2023","August 15, 2022",,"August 15, 2022","Tbilisi Heart and Vascular, Tbilisi, Georgia",,"https://ClinicalTrials.gov/show/NCT05501652"
16,"NCT05501639","Exacerbation Risk in Asthma",,"Completed","No Results Available","Asthma","Drug: tiotropium|Drug: long-acting β2-agonists (LABA)|Drug: inhaled corticosteroids (ICS)","Time to first severe exacerbation|Time to first moderate-or-severe exacerbation|Proportion of patients with exacerbation|Rate of exacerbation at 6 months and one year|Proportions of patients with Health care resource utilization (HCRU)|Mean monthly HCRU|Proportion of patients with use of rescue medications","Boehringer Ingelheim","All","12 Years and older   (Child, Adult, Older Adult)",,"1899","Industry","Observational","Observational Model: Cohort|Time Perspective: Retrospective","0205-0547","May 14, 2021","November 2, 2021","November 2, 2021","August 15, 2022",,"August 15, 2022","eMax Health, White Plains, New York, United States",,"https://ClinicalTrials.gov/show/NCT05501639"
17,"NCT05501626","Evaluation of Theta-burst Stimulation Efficacy, Safety and Tolerability in Major Depressive Episodes of Bipolar I Disorder",,"Active, not recruiting","No Results Available","Bipolar Disorder, Type 1","Device: Active Theta Burst Stimulation (TBS)|Device: Sham Theta Burst Stimulation (TBS)","Primary Outcome Measure","University of Sao Paulo","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","StudyTBS","July 10, 2022","August 2024","August 2024","August 15, 2022",,"August 15, 2022","Institute of Psychiatry, University of Sao Paulo, Sao Paulo, Brazil",,"https://ClinicalTrials.gov/show/NCT05501626"
18,"NCT05501613","Early Multimodal Neuromonitoring Foi Spontaneous ICH",,"Recruiting","No Results Available","Intracerebral Hemorrhage|Critically Ill|Intracranial Pressure|Cerebral Perfusion Pressure|Prognostic","Diagnostic Test: Multimodal Neuromonitoring","Survival|Funcional Outcome","Universidade do Porto","All","18 Years and older   (Adult, Older Adult)",,"60","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","202201","January 2015","October 1, 2022","November 1, 2022","August 15, 2022",,"August 15, 2022","Centro Hospitalar Universitário de São João, Porto, Portugal",,"https://ClinicalTrials.gov/show/NCT05501613"
19,"NCT05501600","Neural Correlates of Lidocaine Analgesia","NeuCLA","Recruiting","No Results Available","Anesthesia|Pain","Device: Peripheral Nerve Stimulation|Drug: Lidocaine IV","Brain activation to painful stimulation difference: drug-free condition minus lower-dose lidocaine|Resting-state functional connectivity difference: drug-free minus lower-dose lidocaine|Brain activation to painful stimulation difference: drug-free condition minus higher-dose lidocaine|Resting-state functional connectivity difference: drug-free minus higher-dose lidocaine|Pain score difference, drug-free condition minus lower-dose lidocaine condition|Pain score difference, drug-free condition minus higher-dose lidocaine condition|Memory performance difference, drug-free minus lower-dose lidocaine condition|Memory performance difference, drug-free minus higher-dose lidocaine condition","Keith M. Vogt, MD, PhD|National Institute of General Medical Sciences (NIGMS)|University of Pittsburgh","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1","30","Other|NIH","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","STUDY21120115|R35GM146822","August 15, 2022","July 1, 2023","July 1, 2023","August 15, 2022",,"August 15, 2022","University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT05501600"
20,"NCT05501587","Measures of Respiratory Health Registry","MRH","Recruiting","No Results Available","Respiratory Disease|Cystic Fibrosis",,"To validate new lung function testing technologies","University of British Columbia","All","0 Years to 99 Years   (Child, Adult, Older Adult)",,"1000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","H18-00812","October 11, 2018","May 2028","May 2028","August 15, 2022",,"August 15, 2022","British Columbia Children's Hospital, Vancouver, British Columbia, Canada",,"https://ClinicalTrials.gov/show/NCT05501587"
21,"NCT05501574","An Open Label Trial Evaluating Tacrolimus Inhalation Powder in Adult Lung Transplant Recipients",,"Not yet recruiting","No Results Available","Lung Transplant Rejection","Drug: Tacrolimus Inhalation Powder","Number of participants experiencing Adverse Events, Serious Adverse Events, and withdrawals due to Adverse Events|Number of participants who experience laboratory test abnormalities|Number of participants who experience physical examination abnormalities|Number of participants who experience pulse oximetry abnormalities|Number of participants who experience vital sign abnormalities|Mean change from baseline in chest radiology|Mean change from baseline in blood serum creatinine|Mean change from baseline in estimated glomerular flow rate (eGFR)|Mean change from baseline in forced expiratory volume (FEV1)|Mean change from baseline in forced vital capacity (FVC)|Mean change from baseline in FEV1/FVC ratio|Number of participants meeting treatment stopping rules of acute allograft rejection|Change from baseline in FEV1 percent predicted|PK of tacrolimus in whole blood AUC0-6|PK of tacrolimus in whole blood AUClast|PK of tacrolimus in whole blood Cmax|PK of tacrolimus in whole blood Tmax|Incidence of all-cause mortality|Incidence of allograft-related mortality|Incidence of all-cause hospitalizations|Incidence of acute allograft-related hospitalizations","TFF Pharmaceuticals, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 2","24","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TFF-T2-001","September 15, 2022","December 31, 2024","December 31, 2024","August 15, 2022",,"August 15, 2022","St Vincent's Hospital, Darlinghurst, New South Wales, Australia|Prince Charles Hospital, Brisbane, Queensland, Australia|The Alfred Hospital, Melbourne, Victoria, Australia",,"https://ClinicalTrials.gov/show/NCT05501574"
22,"NCT05501561","Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults ≥50 Years of Age",,"Not yet recruiting","No Results Available","Influenza, Human","Biological: Experimental: IIV-A Investigational IIV-A will be administered as a single dose intramuscularly on Day 1|Biological: Experimental: aIIV-B Investigational aIIV-B will be administered as a single dose intramuscularly on Day 1|Biological: Experimental: aIIV-C Investigational aIIV-C will be administered as a single dose intramuscularly on Day 1|Biological: Active Comparator: Licensed IIV IIV will be administered as a single dose intramuscularly on Day 1","Immunogenicity Endpoint: Hemagglutination inhibition (HI) titers against vaccine A and B influenza strains|The Percentage of Subjects with Solicited Local and Systemic Reactions|The Percentage of Subjects with Unsolicited Adverse Events|The Percentage of Subjects with Serious Adverse Events (SAEs), AEs Leading to Withdrawal, Adverse Events of Special Interest (AESI) and Medically Attended Adverse Events (MAAEs)|Immunogenicity Endpoint: Microneutralization (MN) titers against vaccine A and B influenza strains","Seqirus","All","50 Years and older   (Adult, Older Adult)","Phase 2","1000","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","V201_07","September 1, 2022","November 5, 2022","April 12, 2023","August 15, 2022",,"August 15, 2022","AMR Tempe, Tempe, Arizona, United States|Marvel Clinical Research, Huntington Beach, California, United States|California Research Center, San Diego, California, United States|The Lynn Institute of The Rockies, Colorado Springs, Colorado, United States|Clinical Research Consulting, LLC, Milford, Connecticut, United States|Innovative Research of West Florida, Inc., Clearwater, Florida, United States|Velocity Clinical Research - New Smyrna Beach, Edgewater, Florida, United States|CenExel RCA, Hollywood, Florida, United States|Health Awareness INC, Jupiter, Florida, United States|Global Health Research Center, Miami Lakes, Florida, United States|Precision Clinical Research, Sunrise, Florida, United States|Global Health Research Center, Tampa, Florida, United States|Platinum Research Network, LLC, Savannah, Georgia, United States|Meridian Clinical Research - Savannah, Savannah, Georgia, United States|AMR El Dorado, El Dorado, Kansas, United States|AMR Lexington, Lexington, Kentucky, United States|Meridian Clinical Research, Baton Rouge, Louisiana, United States|Meridian Clinical Research, Baton Rouge, Louisiana, United States|Medpharmics, LLC, Metairie, Louisiana, United States|Rockville Internal Medicine Group, Rockville, Maryland, United States|MedPharmics LLC, Biloxi, Mississippi, United States|Healthcare Research Network, Hazelwood, Missouri, United States|The Center for Pharmaceutical Research, Kansas City, Missouri, United States|Sundance Clinical Research, LLC, Saint Louis, Missouri, United States|Meridian Clinical Research, Bellevue, Nebraska, United States|Meridian Clinical Research, Grand Island, Nebraska, United States|Meridian Clinical Research, LLC, Lincoln, Nebraska, United States|Alliance for Multispecialty Research, LLC, Las Vegas, Las Vegas, Nevada, United States|Meridian Clinical Research (Binghamton, NY), Binghamton, New York, United States|Meridian Clinical Research, LLC, Endwell, New York, United States|Velocity Clinical Research - Syracuse, Syracuse, New York, United States|M3 Wake Research, Inc., Raleigh, North Carolina, United States|Meridian Clinical Research, LLC, Cincinnati, Ohio, United States|Meridian Clinical Research, LLC, Cincinnati, Ohio, United States|Aventiv Research, Inc. Columbus, Columbus, Ohio, United States|Lynn Health Science Institute, Oklahoma City, Oklahoma, United States|Velocity Clinical Research - Medford, Medford, Oregon, United States|Velocity Clinical Research, Gaffney, Gaffney, South Carolina, United States|Velocity Clinical Research - Greenville, Greenville, South Carolina, United States|Velocity Clinical Research, Spartanburg, Spartanburg, South Carolina, United States|Meridian Clinical Research - Dakota Dunes, Dakota Dunes, South Dakota, United States|AMR Coastal Clinical Research, Knoxville, Tennessee, United States|DM Clinical Research, Tomball, Texas, United States|JBR Clinical Research, Salt Lake City, Utah, United States|Velocity Clinical Research - West Jordan, West Jordan, Utah, United States",,"https://ClinicalTrials.gov/show/NCT05501561"
23,"NCT05501548","Phase II Study of PARP Inhibitor Olaparib and IV Ascorbate in Castration Resistant Prostate Cancer",,"Not yet recruiting","No Results Available","Prostate Cancer|Castration-resistant Prostate Cancer","Drug: Olaparib|Dietary Supplement: Vitamin C","PSA50 response|Safety and tolerability of olaparib in combination with IV ascorbic acid in patients with mCRPC|PSA doubling time in patients with mCRPC receiving olaparib in combination with IV ascorbic acid|Radiographic progression free survival (rPFS) of patients with mCRPC receiving olaparib in combination with IV ascorbic acid|PSA progression free survival (PSA PFS) of patients with mCRPC receiving olaparib in combination with IV ascorbic acid|Overall survival of patients with mCRPC receiving olaparib in combination with IV ascorbic acid","Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|AstraZeneca|McGuff Pharmaceuticals, Inc.|The Marcus Foundation","Male","18 Years and older   (Adult, Older Adult)","Phase 2","15","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","J21127|IRB00292465|ESR 19-20448","September 2022","September 2027","September 2027","August 15, 2022",,"August 15, 2022","Sibley Memorial Hospital, Washington, District of Columbia, United States|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT05501548"
24,"NCT05501535","Refraction Changes After Using ND: YAG LASER In Treatment of Posterior Capsular Opacification In Pseudo Phakic Eye",,"Recruiting","No Results Available","Posterior Capsule Opacification","Device: ND:YAG LASER","objective refractive changes in sphere and cylinder refraction","Sohag University","All","40 Years to 70 Years   (Adult, Older Adult)",,"50","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","Soh-Med-22-08-05","October 1, 2021","October 1, 2022","November 1, 2022","August 15, 2022",,"August 15, 2022","Sohag university hospital, Sohag, Egypt",,"https://ClinicalTrials.gov/show/NCT05501535"
25,"NCT05501522","A Phase III Study to Assess the Safety, Reactogenicity, and Immunogenicity of Heterologous Booster Vaccination of a SARS-CoV-2 Recombinant Protein Nanoparticle Vaccine(GBP510) Adjuvanted With AS03 in Adults Aged 18 Years and Older",,"Not yet recruiting","No Results Available","COVID-19","Biological: GBP510 adjuvanted with AS03|Other: Placebo (Normal Saline)","Geometric Mean Titer(GMT) of neutralizing antibody to the SARS-CoV-2 measured by wild-type virus neutralization assays|GMFR of neutralizing antibody to SARS-CoV-2 measured by wild-type virus neutralization assay from baseline (Visit 2) to each subsequent time point post booster vaccination.|Percentage of participants with ≥4-fold rise in wild-type virus neutralizing antibody titer to SARS-CoV-2 from baseline (Visit 2) to each subsequent time point post booster vaccination.|GMT of SARS-CoV-2 RBD-binding IgG antibody measured by ELISA at each time point post booster vaccination|GMFR of SARS-CoV-2 RBD-binding IgG antibody measured by ELISA from baseline (Visit 2) to each subsequent time point post booster vaccination|Percentage of participants with ≥4-fold rise in ELISA SARS-CoV-2 RBD-binding IgG titer from baseline (Visit 2) to each subsequent time point post booster vaccination|Cell-mediated response for both Th1 and Th2 cytokines measured by Enzyme-Linked ImmunoSpot (ELISpot)/ FluoroSpot, and for both CD4+ and CD8+ T-cells measured by Fluorescence-activated cell sorting(FACS)|Occurrence of immediate systemic reactions in the 30 minutes post each vaccination|Occurrence of solicited local/systemic Adverse Events(AEs)|Occurrence of unsolicited AEs|Occurrence of Serious Adverse events(SAEs), Medically attended Adverse Events(MAAEs), AEs leading to study withdrawal, and Adverse Events of Special Interests(AESIs)","SK Bioscience Co., Ltd.|Coalition for Epidemic Preparedness Innovations|International Vaccine Institute|GlaxoSmithKline","All","18 Years and older   (Adult, Older Adult)","Phase 3","840","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","GBP510_004","September 2022","December 2022","December 2023","August 15, 2022",,"August 15, 2022",,,"https://ClinicalTrials.gov/show/NCT05501522"
26,"NCT05501509","Comparison of Coracoclavicular Fixation With Versus Without Acromioclavicular Stabilization for Repair of Acute Acromioclavicular Joint Dislocations: A Randomized Controlled Clinical Trial",,"Recruiting","No Results Available","Acromioclavicular Joint Dislocation|Acromioclavicular Joint|Coracoclavicular Fixation|Acromioclavicular Stabilization","Procedure: Coracoclavicular fixation with acromioclavicular stabilization for the management of an unstable acromiclavicular luxation|Procedure: Coracoclavicular fixation for the management of an unstable acromiclavicular luxation","Clinical impact in dairy life|Complication rates|Evolution of adduction force after surgery|Need of postoperative analgesic|Results of the radiological variable after surgey|Revision surgery rate","Universidad de La Frontera","All","15 Years to 65 Years   (Child, Adult, Older Adult)","Not Applicable","240","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","101","January 1, 2022","November 30, 2022","July 31, 2023","August 15, 2022",,"August 15, 2022","Hernán Henríquez Aravena Hospital, Temuco, Chile","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/09/NCT05501509/Prot_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/09/NCT05501509/ICF_001.pdf","https://ClinicalTrials.gov/show/NCT05501509"
27,"NCT05501496","Conservative Versus Intramedullary Nailing for Pediatric Tibial Shaft Fractures","CINPED","Not yet recruiting","No Results Available","Fracture of Tibia","Procedure: intramedullary nailing|Procedure: casting","Malunion|Pediatric Quality of Life Inventory|number of reinterventions|complication","Turku University Hospital|Helsinki University Central Hospital|Kuopio University Hospital|Oulu University Hospital|Tampere University Hospital","All","6 Years to 15 Years   (Child)","Not Applicable","66","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","ETMK105/1801/2017","October 1, 2022","December 31, 2032","December 31, 2035","August 15, 2022",,"August 15, 2022","Juho-Antti Ahola, Helsinki, Finland|Turku Children's Hospital, Turku, Finland","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/96/NCT05501496/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT05501496"
28,"NCT05501483","Adipose Tissue Heterogeneity and Its Link to Type 2 Diabetes","DiaSpax","Not yet recruiting","No Results Available","Type 2 Diabetes","Drug: Pioglitazone 45 mg|Drug: Empagliflozin 25 MG|Drug: Semaglutide 7 MG","Changes in fat cell lipolysis after 6 months of treatment|Changes in fat cell heterogeneity after 6 months of treatment","Karolinska Institutet|Karolinska University Hospital","All","30 Years to 65 Years   (Adult, Older Adult)","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Karolinska University Hospital|2021-002367-21","September 1, 2022","September 1, 2024","December 31, 2032","August 15, 2022",,"August 15, 2022","Karolinska University Hospital, Stockholm, Sweden",,"https://ClinicalTrials.gov/show/NCT05501483"
29,"NCT05501470","Maternal Probiotic Intervention to Improve Gut Health (MPIGH)",,"Not yet recruiting","No Results Available","Environmental Enteric Dysfunction|Probiotic","Drug: VSL#3|Device: CapsCan|Drug: Placebo","Reduction in inflammation and epithelial damage in pregnant women with environmental enteropathy|Reduction in enteropathogen colonisation|Impact on the structure and function of the microbiome|Reduction in permeability|Impact of the host metabolome in pregnant woman|Rate of weight gain in the 2nd trimester of pregnancy|Variability in endpoints across geographies and participating laboratories","Institut Pasteur de Dakar|Bill and Melinda Gates Foundation|International Centre for Diarrhoeal Disease Research, Bangladesh|Aga Khan University|University of Zambia","Female","18 Years and older   (Adult, Older Adult)","Phase 2","76","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","2022-01","October 2022","April 2023","October 2023","August 15, 2022",,"August 15, 2022","Centre de santé de Wakhinane, Guédiawaye, Dakar, Senegal",,"https://ClinicalTrials.gov/show/NCT05501470"
30,"NCT05501457","The Effect of Different Muscle Training on Activities of Daily Living in COPD",,"Recruiting","No Results Available","Quality of Life|Anxiety","Device: Muscle strengthening with neuromuscular electrical stimulation","6 Minute Walk Test (6 MWT):|Modified Borg Scale (MBS):|St. George's Respiratory Questionnaire (SGRQ):|Beck Depression Inventory (BDI):","Hitit University","All","18 Years to 75 Years   (Adult, Older Adult)","Not Applicable","45","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","HititUApayas","July 15, 2022","October 1, 2022","November 1, 2022","August 15, 2022",,"August 15, 2022","Hititi University Sungurlu Vocational School, Corum, Turkey",,"https://ClinicalTrials.gov/show/NCT05501457"
31,"NCT05501444","Antiperspirant in the Treatment of Residual Limp Hyperhidrosis for Prosthetic Users",,"Recruiting","No Results Available","Hyperhidrosis|Residual Limbs","Other: Topical antiperspirant","Hyperhidrosis Disease Severity Scale (HDSS)|Sweating Intensity Visual Scale (SIVS)|Numerical Ranking Scale (NRS 100)","Sophies Minde Ortopedi","All","18 Years and older   (Adult, Older Adult)","Not Applicable","10","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","FoU_2022_Hyperhidrosis","August 9, 2022","December 31, 2022","August 31, 2023","August 15, 2022",,"August 15, 2022","Sophies Minde Ortopdi AS, Oslo, Norway",,"https://ClinicalTrials.gov/show/NCT05501444"
32,"NCT05501431","Personalized Parkinson Project PSP Cohort","PPP-PSP","Recruiting","No Results Available","Progressive Supranuclear Palsy|Brain Diseases|Neurodegenerative Diseases|Movement Disorders","Device: Verily Study Watch","Annual change in digital biomarkers for gait|Annual change in digital biomarkers for bradykinesia|Annual change in digital biomarkers for falls|Annual change in digital biomarkers for rising from a chair|Annual change in digital biomarker for motor performance|Annual change in cognition|Annual change in D-KEFS trail making test|Annual change in semantic fluency|Annual change in quality of life|Annual change in Activities of Daily Living (ADL) performance","Radboud University Medical Center|UCB Pharma|Verily Life Sciences LLC","All","50 Years and older   (Adult, Older Adult)",,"100","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","NL75356.091.20","May 1, 2021","December 2023","June 2024","August 15, 2022",,"August 15, 2022","Radboud University Medical Center, Nijmegen, Netherlands",,"https://ClinicalTrials.gov/show/NCT05501431"
33,"NCT05501418","Evaluate the Safety and Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cells in Patients With COVID-19","UMSC01","Active, not recruiting","No Results Available","COVID-19 Infection","Biological: Allogeneic umbilical cord mesenchymal stem cells|Biological: Controlled normal saline","Two Co-Primary Efficacy Endpoints|Secondary Efficacy Endpoints|Secondary Safety Endpoints","Ever Supreme Bio Technology Co., Ltd.","All","20 Years to 80 Years   (Adult, Older Adult)","Phase 1|Phase 2","75","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","ES-CMSC01-C1101","August 5, 2020","December 31, 2023","December 31, 2023","August 15, 2022",,"August 15, 2022","China Medical University Hospital, Taichung, Non-US, Taiwan",,"https://ClinicalTrials.gov/show/NCT05501418"
34,"NCT05501405","Brain and Oculometric Markers of Emotional Facial Expression Recognition Deficits","FERmarkers","Recruiting","No Results Available","Autism|Psychotic Disorders","Other: Electroencephalogram and eye-tracking recordings","Fast Periodic Visual Stimulation Task (FPVS-EEG)|Eye-tracking task","Hôpital le Vinatier","All","10 Years to 50 Years   (Child, Adult)","Not Applicable","210","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science","2021-A01367-34","March 30, 2022","March 25, 2026","September 30, 2026","August 15, 2022",,"August 15, 2022","centre de réhabilitation - Hôpital le Vinatier, Lyon, Rhône, France",,"https://ClinicalTrials.gov/show/NCT05501405"
35,"NCT05501392","South Texas Early Prevention Studies PreK","STEPSPreK","Completed","No Results Available","Childhood Obesity","Behavioral: STEPS-PreK","cardiorespiratory fitness","University of Texas Rio Grande Valley|Department of Health and Human Services","All","3 Years to 5 Years   (Child)","Not Applicable","1277","Other|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","STEPS","September 28, 2018","March 17, 2020","June 30, 2020","August 15, 2022",,"August 15, 2022","University of Texas Rio Grande Valley, Edinburg, Texas, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/92/NCT05501392/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/92/NCT05501392/SAP_001.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/92/NCT05501392/ICF_002.pdf","https://ClinicalTrials.gov/show/NCT05501392"
36,"NCT05501379","Comparison of the Physical Activity in Cancer Patients Assessed by Questionnaire and Motion Tracker","OncoPhys","Recruiting","No Results Available","Lymphoma|Pancreas Cancer|Colorectal Cancer","Other: No intervention - observational study only","Comparison of physical activity assessments within 1 week after initiation of cancer therapy|Comparison of physical activity assessments 12 weeks after initiation of cancer therapy|Comparison of changes in physical activity between assessements within 1 week and 12 weeks after initiation of cancer therapy|Physical activity assessed by accelerometer|Physical activity assessed by questionnaire|Relation of Eastern Co-operative Oncology Group (ECOG) Performance Status to physical activity assessed by accelerometer|Relation of Eastern Co-operative Oncology Group (ECOG) Performance Status to physical activity assessed by questionnaire|Relation of Karnofsky Performance Status (KPS) to physical activity assessed by accelerometer|Relation of Karnofsky Performance Status (KPS) to physical activity assessed by questionnaire|Relation of age to physical activity assessed by accelerometer|Relation of age to physical activity assessed by questionnaire|Relation of sex to physical activity assessed by accelerometer|Relation of sex to physical activity assessed by questionnaire|Relation of quality of life to physical activity assessed by accelerometer|Relation of quality of life to physical activity assessed by questionnaire|Therapy-related quality of life|Relation of fatigue to physical activity assessed by accelerometer|Relation of fatigue to physical activity assessed by questionnaire|Therapy-related fatigue|Relation of sleep duration to physical activity assessed by accelerometer|Relation of sleep duration to physical activity assessed by questionnaire|Relation of sleep efficiency to physical activity assessed by accelerometer|Relation of sleep efficiency to physical activity assessed by questionnaire|Therapy-related sleep duration|Therapy-related sleep efficiency|Changes in fatigue between assessements before and 12 weeks after initiation of cancer therapy|Changes in quality of life between assessements before and 12 weeks after initiation of cancer therapy|Relation of tumor entity to changes in physical activity between assessements within 1 week and 12 weeks after initiation of cancer therapy|Relation of cancer therapy modality to changes in physical activity between assessements within 1 week and 12 weeks after initiation of cancer therapy","University Medicine Greifswald","All","18 Years and older   (Adult, Older Adult)",,"60","Other","Observational","Observational Model: Other|Time Perspective: Prospective","BB 067/22","August 2022","July 2024","October 2024","August 15, 2022",,"August 15, 2022","University Medicine Greifswald, Greifswald, Germany",,"https://ClinicalTrials.gov/show/NCT05501379"
37,"NCT05501366","Strategies to Augment Ketosis: Optimization of Ketone Delivery Strategies","STAK: OK'd","Not yet recruiting","No Results Available","Ketosis","Dietary Supplement: Ketone Supplement|Behavioral: Beverage Tolerability Questionnaire (BTQ) and satiety visual analogue scale|Biological: Blood Draw|Other: Breath Reading|Other: Heart Rate Variability|Other: CGM/CKM|Radiation: DXA|Other: Urine Analysis","Total Plasma Ketone AUC|Capillary d-BHB concentrations|AcAc, R-BHB and S-BHB changes across trials|Continuous Ketone and Glucose Monitoring|Ketone Excretion|Ketone in breathe expiration|Alanine Change|Lactate Change|Free Fatty Acid Change|Heart Rate Variability|Satiety Visual Analogue Scale|Beverage tolerability questionnaire (BTQ)|Insulin|Ghrelin|Acid-Base Balance|Respiratory Gas Exchange|Whole blood clinical chemistry","Ohio State University Comprehensive Cancer Center","Male","20 Years to 30 Years   (Adult)","Not Applicable","15","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","2022H0160|CDMRP-PR212399-A","September 2022","September 2026","September 2027","August 15, 2022",,"August 15, 2022","The Ohio State University, Columbus, Ohio, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/66/NCT05501366/Prot_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/66/NCT05501366/ICF_001.pdf","https://ClinicalTrials.gov/show/NCT05501366"
38,"NCT05501353","Explore Biomarkers Associated With Prognosis of Recurrent and Metastatic CRC After Surgery by Multi-omics Methods",,"Not yet recruiting","No Results Available","Colorectal Cancer Metastatic","Other: no intervention","molecular markers related to prognosis|the correlation between ctDNA mutations with methylation status and recurrence|Compare the difference of DNA with ctDNA in predicting postoperative recurrence through statistical method","Second Affiliated Hospital, School of Medicine, Zhejiang University|Guangzhou Burning Rock Dx Co., Ltd.|Guangdong Living Environment Harmless Treatment Center Co., Ltd.","All","18 Years to 99 Years   (Adult, Older Adult)",,"125","Other|Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","2022-0465","September 1, 2022","September 1, 2027","September 1, 2027","August 15, 2022",,"August 15, 2022",,,"https://ClinicalTrials.gov/show/NCT05501353"
39,"NCT05501340","PD-1 Inhibitor Intraperitoneal Perfusion Combined With PRaG Therapy for Malignant Ascites",,"Not yet recruiting","No Results Available","Malignant Ascites","Drug: Serplulimab|Drug: Molgramostim|Radiation: Hypofractionated radiotherapy/Sterotactic body radiotherapy","Dose-limiting toxicity（DLT）by CTCAE5.0|Treatment Related Severe Adverse Effects|OS|PFS|ascites control rate","Second Affiliated Hospital of Soochow University","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1|Phase 2","40","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","JD-LK-2022-033-02","September 1, 2022","December 31, 2022","September 1, 2024","August 15, 2022",,"August 15, 2022",,,"https://ClinicalTrials.gov/show/NCT05501340"
40,"NCT05501327","Dose Regimen Study of SLI-F06 in Healthy Volunteers",,"Enrolling by invitation","No Results Available","Scar|Wound Healing","Drug: SLI-F06","Scarless Labs Observer Scale|POSAS Observer Scale|Scarless Labs Patient Scale","Scarless Laboratories, Inc.","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","30","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","SLI-F06-002","July 25, 2022","July 25, 2023","October 25, 2023","August 15, 2022",,"August 15, 2022","California Dermatology & Clinical Research Institute, Encinitas, California, United States",,"https://ClinicalTrials.gov/show/NCT05501327"
41,"NCT05501314","Remote Home Monitoring Acute Pancreatitis","REMAP","Not yet recruiting","No Results Available","Acute Pancreatitis|Telemedicine|Healthdot|Patient Discharge|Monitoring","Other: Early discharge with remote home monitoring.","Incidence (%) of unplanned hospital readmissions.|2. Incidence (%) of pancreatitis related complications. These complications include necrotizing pancreatitis, infection, pseudocysts, new onset diabetes, recurrence of pancreatitis, cholecystitis or cholangitis.|3. Mortality (%) of patients discharged home with remote monitoring.|Length of stay in the hospital|The amount of extra contacts between VMC-nurse or physician and the patient, in addition to the usual call once per day as documented in the smartphone app.|The amount of laboratory or imaging tests|Amount of adjustments in analgesics needed during home monitoring","Rijnstate Hospital|University of Twente|Philips Research Eindhoven","All","18 Years and older   (Adult, Older Adult)","Not Applicable","70","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","NL81630.091.22","October 2022","October 2024","April 2025","August 15, 2022",,"August 15, 2022","Rijnstate Hospital, Arnhem, Gelderland, Netherlands",,"https://ClinicalTrials.gov/show/NCT05501314"
42,"NCT05501301","Immune Tolerance After Pediatric Liver Transplantation",,"Recruiting","No Results Available","Immune Tolerance|Liver Transplant; Complications","Other: IS weaning off","Ratio of immune tolerance|Ratio of acute rejection","RenJi Hospital","All","1 Year to 18 Years   (Child, Adult)",,"200","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","IIT-2022-0004","August 1, 2022","July 31, 2025","July 31, 2025","August 15, 2022",,"August 15, 2022","Ren Ji Hospital affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT05501301"
43,"NCT05501288","Huashi Baidu Granule in the Treatment of Pediatric Patients With Mild Coronavirus Disease 2019",,"Completed","No Results Available","Coronavirus Disease 2019","Drug: Huashi Baidu granule|Drug: compound pholcodine oral solution","Time for SARS-CoV-2 nucleic acid negative conversion|Symptom score, antibiotic use, and side effects","Shanghai Children's Medical Center","All","3 Years to 18 Years   (Child, Adult)","Not Applicable","108","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SCMCIRB-K2022046-1","May 1, 2022","June 30, 2022","June 30, 2022","August 15, 2022",,"August 15, 2022","Shanghai children's medical center, Shanghai, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT05501288"
44,"NCT05501275","Evaluation of Life Quality in Post Stroke Patients",,"Enrolling by invitation","No Results Available","Stroke|Quality of Life","Behavioral: psychotherapy","Change in the Health-Related Quality of Life (HRQoL) in patients after stroke","Palacky University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","500","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Supportive Care","PalackyU","September 14, 2021","June 30, 2023","June 30, 2023","August 15, 2022",,"August 15, 2022","Palacky University, Olomouc, Czechia",,"https://ClinicalTrials.gov/show/NCT05501275"
45,"NCT05501262","Comparative Effectiveness of Cryoablation Versus Steroid and Lidocaine Alone for Treatment of Morton's Neuroma",,"Recruiting","No Results Available","Morton Neuroma","Device: Cryoablation|Procedure: Nerve block","Changes in quality of life|Réponse in pain|Changes to function|Changes pain and function due to neuroma|Incidence of Treatment - Emergent Adverse Events","Oregon Health and Science University","All","18 Years to 105 Years   (Adult, Older Adult)","Not Applicable","32","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","STUDY00024090","July 25, 2022","July 30, 2023","December 31, 2023","August 15, 2022",,"August 15, 2022","Oregon Health Sciences University, Portland, Oregon, United States",,"https://ClinicalTrials.gov/show/NCT05501262"
46,"NCT05501249","Aquatic Exercise for Cognition and Mobility in Older Adults",,"Recruiting","No Results Available","Aging Well|Aging Problems|Cognitive Change|Gait, Unsteady|Mobility Limitation","Behavioral: Aquatic Integrated Cognitive Motor Training","Stroop Effect Test: Change from baseline to the end of intervention/control period|Trail Making Test A and B: Change from baseline to the end of intervention/control period|Digit Backwards Test : Change from baseline to the end of intervention/control period|Gait Measurements: Change from baseline to the end of intervention/control period|Functional Outcome Measures: Change from baseline to the end of intervention/control period|Vital Sign measurements: Change from baseline to the end of intervention/control period|Anthropometric measurements: Change from baseline to the end of intervention/control period|Neurotrophic Growth Factors: Change from baseline to the end of intervention/control period|Numeric Pain Rating Scale: Change from baseline to the end of intervention/control period|Global Rating of Change Questionnaire: Change from baseline to the end of intervention/control period|Activities-specific balance confidence scale: Change from baseline to the end of intervention/control period","Emily Dunlap|University of Texas at Austin","All","65 Years and older   (Older Adult)","Not Applicable","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","STUDY00001403","February 1, 2022","February 28, 2023","February 28, 2023","August 15, 2022",,"August 15, 2022","The University of Texas at Austin, Austin, Texas, United States",,"https://ClinicalTrials.gov/show/NCT05501249"
47,"NCT05501236","Ansa Cervicalis and Hypoglossal Nerve Stimulation in OSA",,"Not yet recruiting","No Results Available","Obstructive Sleep Apnea","Device: Grass S88 Muscle Stimulator","Basic physiologic measurements during Drug Induced Sleep Endoscopy (DISE) - Airway cross sectional diameter|Basic physiologic measurements during Drug Induced Sleep Endoscopy (DISE) - Airflow data|Basic physiologic measurements during Drug Induced Sleep Endoscopy (DISE) - Upper airway pressure changes|Basic physiologic measurements during Drug Induced Sleep Endoscopy (DISE) - Respiratory effort data|Basic physiologic measurements during Polysomnography (PSG) - Airflow data|Basic physiologic measurements during Polysomnography (PSG) - Electroencephalogram (EEG)|Basic physiologic measurements during Polysomnography (PSG) - Electrocardiogram (EKG)|Basic physiologic measurements during Polysomnography (PSG) - Electroocoulogram (EOG)|Basic physiologic measurements during Polysomnography (PSG) - Electromyography (EMG)|Basic physiologic measurements during Polysomnography (PSG) - Respiratory effort data|Basic physiologic measurements during Polysomnography (PSG) - Video data|Amount of current needed for adequate stimulation","Vanderbilt University Medical Center","All","18 Years and older   (Adult, Older Adult)","Not Applicable","100","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","212305","August 2022","December 2027","July 2028","August 15, 2022",,"August 15, 2022",,,"https://ClinicalTrials.gov/show/NCT05501236"
48,"NCT05501223","Physician-initiated Medication Review in a Type 2 Diabetes Outpatient Clinic",,"Recruiting","No Results Available","Polypharmacy","Other: Medication review|Other: Standard care","Number of medications used at baseline compared to number of medications used at follow-up. Resulting in a rate of medications used at baseline compared to follow-up i.e. no. medication at follow-up/no. at baseline.|EQ5D index score. (a Euro Quality of Life 5-dimension 5-level (EQ-5D-5L) scale). The score is retrieved by using the validated EQ5D questionnaire which translates to a corresponding EQ5D index score using country specific value sets.","Bispebjerg Hospital","All","Child, Adult, Older Adult","Not Applicable","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","P-2020-1012","November 1, 2020","November 2022","November 2022","August 15, 2022",,"August 15, 2022","Bispebjerg Hospital, Copenhagen, Denmark",,"https://ClinicalTrials.gov/show/NCT05501223"
49,"NCT05501210","Vibration on Patellofemoral Joint Pain After ACLR",,"Recruiting","No Results Available","Anterior Cruciate Ligament Injuries|Anterior Cruciate Ligament Rupture|Anterior Cruciate Ligament Tear|Patellofemoral Pain","Device: WBV|Device: PEMF","Change of The Knee injury and Osteoarthritis Outcome Score Patellofemoral subscale (KOOS-PF)|Isokinetic muscle strength|Muscle thickness|The Numeric Pain Rating Scale (NPRS)","Chinese University of Hong Kong","All","18 Years to 60 Years   (Adult)","Not Applicable","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2020.674","March 1, 2022","March 1, 2024","June 1, 2024","August 15, 2022",,"August 15, 2022","The Chinese University of Hong Kong, Hong Kong, Hong Kong",,"https://ClinicalTrials.gov/show/NCT05501210"
50,"NCT05501197","Effects of Different Telerehabilitation Methods on Pain, Functional Limitation, Muscle Strength, Balance, and Quality of Life in Patients With Meniscus Degeneration",,"Not yet recruiting","No Results Available","Meniscus; Degeneration","Other: Exercise Therapy via video conference|Other: Exercise Therapy via mobile application","The Lysholm score|Visual analogue scale (VAS)|12-Item Short Form Survey (SF-12)|30 Seconds Sit To Stand Test|2 Minute Walk Test|Quadriceps and Hamstring Muscle Strength","Marmara University","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","09.2022.602/2","August 8, 2022","December 27, 2022","April 15, 2023","August 15, 2022",,"August 15, 2022",,,"https://ClinicalTrials.gov/show/NCT05501197"
51,"NCT05501184","SYNCHRONOUS AND ASYNCHRONOUS TELEREHABILITATION METHODS IN PATIENTS WITH CERVICAL DISC HERNIATION",,"Completed","No Results Available","Cervical Disc Herniation","Other: Synchronous Exercise Program|Other: Asynchronous Exercise Program","Numerical Pain Rating Scale (NPRS)|Neck Disability Index (NDI)|Tampa Scale of Kinesiophobia (TSK)|Cervical Mobility|Short Form-36 (SF-36)","Marmara University","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","26.05.2022/67","February 1, 2022","July 15, 2022","August 11, 2022","August 15, 2022",,"August 15, 2022","Marmara University, Istanbul, Turkey",,"https://ClinicalTrials.gov/show/NCT05501184"
52,"NCT05501171","Psychological Mobile App for Patients With AML",,"Not yet recruiting","No Results Available","AML|Acute Myeloid Leukemia","Behavioral: DREAMLAND|Behavioral: CERENA","Anxiety Symptoms|Depression Symptoms|Quality of Life in Patients with Leukemia|Symptom Burden|Post-Traumatic Stress Disorder (PTSD) Symptoms","Massachusetts General Hospital|Blue Note Therapeutics","All","18 Years and older   (Adult, Older Adult)","Not Applicable","180","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Care Provider, Investigator)|Primary Purpose: Supportive Care","22-257","October 2022","July 1, 2026","July 1, 2027","August 15, 2022",,"August 15, 2022","Massachusetts General Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT05501171"
53,"NCT05501158","CYP2D6 Genotypes and Breast Cancer Clinical Outcomes in the Indonesian Population",,"Active, not recruiting","No Results Available","Breast Cancer","Drug: Tamoxifen","Overall Survival rate|Progression Survival rate","Nalagenetics Pte Ltd|SJH Initiatives|Fakultas Farmasi Universitas Indonesia|MRCCC Siloam Hospitals Semanggi","Female","Child, Adult, Older Adult","Not Applicable","150","Industry|Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ID-TMS-02-20201012","January 1, 2021","April 30, 2024","June 30, 2024","August 15, 2022",,"August 15, 2022","MRCCC Siloam Hospitals Semanggi, Jakarta, DKI Jakarta, Indonesia",,"https://ClinicalTrials.gov/show/NCT05501158"
54,"NCT05501145","Clinical Features, Outcomes, and Therapeutics of Pregnancy-Related Aortic Dissection",,"Completed","No Results Available","Aortic Dissection|Pregnancy Related","Procedure: cesarean section and aortic repair","30-day mortality","Nanjing Medical University|Beijing Anzhen Hospital|Shanghai Zhongshan Hospital|Guangdong Province Hospital","Female","18 Years to 45 Years   (Adult)",,"75","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","5A Plan VII","January 1, 2022","July 31, 2022","July 31, 2022","August 15, 2022",,"August 15, 2022","Beijing Anzhen Hospital, Beijing, China|Department of Obstetrics and Gynecology, Guangdong Provincial People's Hospital, Guangzhou, China|Department of Cardiac Surgery, Affiliated Hospital of Qingdao University, Qingdao, China|Department of Obstetrics and Gynecology, Zhongshan Hospital, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT05501145"
55,"NCT05501132","Efficacy of Transcranial Direct Current Stimulation in Obsessive-compulsive Disorder",,"Completed","No Results Available","Obsessive-Compulsive Symptom","Device: transcranial direct current stimulation","Yale-Brown Obsessive-Compulsive (Y-BOCS) rating scale|Beck Anxiety Questionnaire (BAI)|Response inhibition task|Working memory task|Beck Depression Questionnaire (BDI-II)|Quality of Life Questionnaire (WHOQUL)|electroencephalogram (EEG) power spectrum","The National Brain Mapping Laboratory (NBML)|Ardabil University of Medical Sciences|Leibniz Research Centre for Working Environment and Human Factors","All","18 Years to 50 Years   (Adult)","Phase 1","37","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","IR.ARUMS.REC.1399.102","August 1, 2020","June 1, 2021","February 25, 2022","August 15, 2022",,"August 15, 2022","Ardabil University of Medical Sciences, Ardabīl, Iran, Islamic Republic of",,"https://ClinicalTrials.gov/show/NCT05501132"
56,"NCT05501119","SUPPORT-D Intervention for Persons With Alzheimer's Disease and Their Caregivers.",,"Not yet recruiting","No Results Available","Alzheimer Disease","Behavioral: A Program of SUPPORT-D (dementia)","Change in Alzheimer's Disease Knowledge Scale (ADKS) score|Acceptability of Intervention Measure (AIM) score|Change in feasibility score|Change Zarit caregiver burden score|Change in Perceived Stress scale score|Change in Symptom burden physical function score|Change in Symptom burden anxiety score|Change in Symptom burden depression score|Change in Symptom burden fatigue score|Change in Symptom burden sleep quality score|Change in Symptom burden satisfaction with social role score|Change in Symptom burden pain score|Change in Quality of life-Alzheimer's Disease (QoL-AD) score|Change in self-efficacy for caregiving score|Change in Safety assessment scale score|Change in technology literacy score|Number of participants completing advance care planning documents|Appropriateness of Intervention score","Medical University of South Carolina|National Center for Advancing Translational Science (NCATS)","All","18 Years and older   (Adult, Older Adult)","Not Applicable","60","Other|NIH","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","Pro00120938|KL2TR001452|UL1TR001450","August 15, 2022","December 30, 2022","January 31, 2023","August 15, 2022",,"August 15, 2022",,,"https://ClinicalTrials.gov/show/NCT05501119"
57,"NCT05501106","Reducing Postpartum Hemorrhage After Vaginal Delivery",,"Not yet recruiting","No Results Available","Postpartum Hemorrhage|Vaginal Delivery","Other: Integrated Improvement strategies","Rate of postpartum hemorrhage after vaginal delivery|Rate of consequent adverse outcomes|Rate of adherence to essential clinical practices|Acceptability to the interventions","Peking University Third Hospital|Shandong Provincial Hospital|Chongqing Health Center for Women and Children|Tianjin Central Hospital of Gynecology Obstetrics|Fujian Provincial Maternity and Children's Hospital","Female","18 Years to 49 Years   (Adult)","Not Applicable","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","PKUTH22-08-09","September 1, 2022","August 31, 2024","December 31, 2024","August 15, 2022",,"August 15, 2022","Peking University Third Hospital, Beijing, Beijing, China",,"https://ClinicalTrials.gov/show/NCT05501106"
58,"NCT05501093","Diabetes Reversal and the Subgingival Microbiota",,"Recruiting","No Results Available","Diabetes type2|Bariatric Surgery Candidate","Other: sample collection","Bacterial composition|Bacterial mRNA profiling","University of Pennsylvania|National Institute of Dental and Craniofacial Research (NIDCR)|Temple University|Ohio State University","All","25 Years to 65 Years   (Adult, Older Adult)",,"234","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","825975|1R01DE026603-01A1","March 11, 2019","December 31, 2022","June 30, 2023","August 15, 2022",,"August 15, 2022","Temple University, Philadelphia, Pennsylvania, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT05501093"
59,"NCT05501080","The Effect of SAAE on Ventricular Remodeling in PA Patients",,"Not yet recruiting","No Results Available","Primary Aldosteronism","Other: Super selective adrenal artery embolization|Drug: Spironolactone","LVMI|LVH|ABPM|Biochemical indicators","Second Affiliated Hospital of Nanchang University","All","18 Years to 60 Years   (Adult)","Not Applicable","112","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IIT-2022-073","September 1, 2022","September 1, 2025","December 31, 2025","August 15, 2022",,"August 15, 2022",,,"https://ClinicalTrials.gov/show/NCT05501080"
60,"NCT05501067","Tai Chi Exercise on Hand Grip Strength and Functional Fitness Among Elderly Post COVID",,"Recruiting","No Results Available","Post Covid","Other: tai chi exercise|Other: regular aerobic exercise training","hand grip strength|functional fitness","Beni-Suef University","All","60 Years to 80 Years   (Adult, Older Adult)","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","Elderly Post Covid","August 10, 2022","November 30, 2022","February 28, 2023","August 15, 2022",,"August 15, 2022","National Institute For Longevity Elderly Sciences, Banī Suwayf, Egypt",,"https://ClinicalTrials.gov/show/NCT05501067"
61,"NCT05501054","Phase 1b/2 Trial of Ipilimumab, Nivolumab, and Ciforadenant (Adenosine A2a Receptor Antagonist) in First-line Advanced Renal Cell Carcinoma.",,"Not yet recruiting","No Results Available","Renal Cell Carcinoma","Drug: Ipilimumab|Drug: Nivolumab|Drug: Ciforadenant","To establish the objective response rate (ORR)","M.D. Anderson Cancer Center","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","15","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2022-0093|NCI-2022-06736","February 28, 2023","November 1, 2026","November 1, 2026","August 15, 2022",,"August 15, 2022","M D Anderson Cancer Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT05501054"
62,"NCT05501041","Measuring Symptom Relief After Radiofrequency Ablation of the Thyroid",,"Enrolling by invitation","No Results Available","Thyroid",,"Change in symptoms before and after ablation","Mayo Clinic","All","18 Years and older   (Adult, Older Adult)",,"300","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","22-007581","August 22, 2022","August 22, 2025","December 30, 2025","August 15, 2022",,"August 15, 2022","Mayo Clinic Rochester, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT05501041"
63,"NCT05501028","NLP to Aid in the Evaluation and Diagnosis of FGIDs",,"Enrolling by invitation","No Results Available","Functional Gastrointestinal Disorders",,"Latent themes present in patient descriptions of FGIDs symptoms","Massachusetts General Hospital|Massachusetts Institute of Technology","All","18 Years and older   (Adult, Older Adult)",,"700","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2018P001542","August 9, 2018","June 1, 2023","June 1, 2023","August 15, 2022",,"August 15, 2022","Massachusetts General Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT05501028"
64,"NCT05501015","Functional Oral-Pharyngeal Rehabilitation of Patients With Dysphagia Using Ice-chips, a Prospective Randomized Study",,"Recruiting","No Results Available","Post Extubation Dysphagia","Other: Ice chips","Rehabilitating dysphagia","Atlantic Health System","All","18 Years to 100 Years   (Adult, Older Adult)","Not Applicable","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","1795792-2","May 2, 2022","October 31, 2023","October 31, 2023","August 15, 2022",,"August 15, 2022","Morristown Medical Center, Morristown, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT05501015"
65,"NCT05501002","[Trial of device that is not approved or cleared by the U.S. FDA]",,"Withheld","No Results Available",,,,"[Redacted]",,,,,,,,"CLIN-0029",,,,"August 15, 2022",,"August 15, 2022",,,"https://ClinicalTrials.gov/show/NCT05501002"
66,"NCT05500989","PlacEntal Acute Atherosis RefLecting Subclinical Atherosclerosis","PEARLS","Recruiting","No Results Available","Pre-Eclampsia|HELLP Syndrome|Intrauterine Growth Restriction|Pregnancy","Other: Venapuncture","Relationship between placental acute atherosis and subclinical coronary atherosclerosis at 1 year postpartum|Relationship between placental acute atherosis and subclinical coronary atherosclerosis at 15 years postpartum|Relationship between decidual vasculopathy and subclinical coronary atherosclerosis at 1 year postpartum|Relationship between placental decidual vasculopathy and subclinical coronary atherosclerosis at 15 years postpartum|Relationship between placental acute atherosis and clinical coronary atherosclerosis at 1 year postpartum|Relationship between placental acute atherosis and clinical coronary atherosclerosis at 15 years postpartum|Relationship between placental decidual vasculopathy and clinical coronary atherosclerosis at 1 year postpartum|Relationship between placental decidual vasculopathy and clinical coronary atherosclerosis at 15 years postpartum|Incidence of placental acute atherosis at 1 year postpartum|Incidence of placental acute atherosis at 15 years postpartum|Incidence of placental decidual vasculopathy at 1 year postpartum|Incidence of placental decidual vasculopathy at 15 years postpartum|Incidence of subclinical coronary atherosclerosis at 1 year postpartum|Incidence of subclinical coronary atherosclerosis at 15 years postpartum|Incidence of clinical coronary atherosclerosis at 1 year postpartum|Incidence of clinical coronary atherosclerosis at 15 years postpartum","Maastricht University Medical Center","Female","18 Years and older   (Adult, Older Adult)",,"534","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","Modified NL52556.068.15|METC 152019","November 2016","October 2024","October 2024","August 15, 2022",,"August 15, 2022","Maastricht University Medical Center (MUMC+), Maastricht, Netherlands",,"https://ClinicalTrials.gov/show/NCT05500989"
67,"NCT05500976","Metabolomics Initiative: Mediterranean-amplified vs Habitual Western Diet on Food Signatures, Health, and Microbiome","Mini-MED","Not yet recruiting","No Results Available","Dietary Habits","Other: Semi-controlled dietary intervention","Foodomics|Cardiometabolic Health - IL-6|Cardiometabolic Health - TNF-alpha|Cardiometabolic Health - C-reactive protein|Cardiometabolic Health - alpha-1-acid glycoprotein|Cardiometabolic Health - Total Cholesterol|Cardiometabolic Health - LDL Cholesterol|Cardiometabolic Health - HDL Cholesterol|Cardiometabolic Health - Triglycerides|Cardiometabolic Health - Blood Pressure|Cardiometabolic Health - Insulin|Cardiometabolic Health - Glucose|Cardiometabolic Health - Adipokines|Gut Microbiota","University of Colorado, Denver|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|National Cattlemen's Beef Association|Purdue University","All","30 Years to 69 Years   (Adult, Older Adult)","Not Applicable","40","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","21-4563|R01DK113957|2070","August 15, 2022","March 31, 2023","December 31, 2023","August 15, 2022",,"August 15, 2022",,,"https://ClinicalTrials.gov/show/NCT05500976"
68,"NCT05500963","Reducing Fatigue in People With Multiple Sclerosis by Treatment With TENS",,"Not yet recruiting","No Results Available","Multiple Sclerosis","Device: Transcutaneous electrical nerve stimulation","Fatigue|Walking limitations|Walking endurance|Mobility|Quality of life questionnaire|Muscle strength","University of Colorado, Boulder","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","22-0394","April 2023","March 2027","March 2028","August 15, 2022",,"August 15, 2022",,,"https://ClinicalTrials.gov/show/NCT05500963"
69,"NCT05500950","Color Doppler Ultrasound in Lacrimal Sac Space-occupying Lesions",,"Completed","No Results Available","Dacryocystitis; Chronic|Lacrimal Sac Space-occupying Lesions|Color Doppler Ultrasound|Computed Tomography","Other: CDU and CT-DCG or CT examination","Morphological changes of color Doppler ultrasound in lacrimal sac space-occupying lesions|Morphological changes of CT or CT-DCG in lacrimal sac space-occupying lesions","Wenzhou Medical University","All","10 Years and older   (Child, Adult, Older Adult)",,"21","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","CDU in lacrimal sac","January 1, 2018","April 30, 2022","April 30, 2022","August 15, 2022",,"August 15, 2022","Eye Hospital and School of Ophthalmology and Optometry,Wenzhou Medical University, Wenzhou, Zhejiang, China",,"https://ClinicalTrials.gov/show/NCT05500950"
70,"NCT05500937","Effect of UDCA on the New Onset Diabetes and Glucose Intolerance Induced by Statin",,"Recruiting","No Results Available","Diabetes Mellitus","Drug: UDCA","Changes of HbA1c|Concentration of blood lipid|Concentration of fasting blood glucose|Concentration of fasting islets|Concentration of bile acids|Rate of MACE","First Affiliated Hospital Xi'an Jiaotong University","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2|Phase 3","1000","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","XJTU1AF2018LSK-92","March 1, 2021","December 31, 2023","December 31, 2024","August 15, 2022",,"August 15, 2022","First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shanxi, China",,"https://ClinicalTrials.gov/show/NCT05500937"
71,"NCT05500924","Effects of Ankle Mobilization on Body Structure, Function, Activities and Participation of Children With Cerebral Palsy",,"Recruiting","No Results Available","Diplegic Cerebral Palsy With Spasticity","Other: Intervention group","Change of Ankle Range of Motion|Change in the Six minutes walking test: The six-minute walk test (6MWT) measures the distance an individual is able to walk over a total of six minutes on a hard, flat surface|Change inTime up and go (TUG) test: The TUG test is a reliable and responsive measure of balance and mobility for children with CP|Change in the Pediatric Quality of Life: it is measured by measure by CP-specific questionnaire. We will use The Arabic-CP-QOL-questionnaire|Change in the Gross Motor Function Measure (GMFM) scale which is designed to measure changes in gross motor function over time or with intervention in children with cerebral palsy.","Eastern Mediterranean University","All","4 Years to 14 Years   (Child)","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ETK00-2022-0160","July 30, 2022","February 2023","February 2023","August 15, 2022",,"August 15, 2022","Palestine Ahliya university, Bethlehem, Palestinian Territory, occupied",,"https://ClinicalTrials.gov/show/NCT05500924"
72,"NCT05500911","Bioactive Surfaces vs. Conventional Surfaces in Implants Placed in Atrophic Maxilla With Simultaneous Sinus Lift",,"Recruiting","No Results Available","Edentulous; Alveolar Process, Atrophy|Edentulous Alveolar Ridge Atrophy","Procedure: sinus lift|Procedure: implant placement","Marginal bone loss|Implant stability|insertion torque curve|Apical Bone regeneration|Evaluation the effects of bioactive implant surface (NINA- MultiNeO NH) in Apical Bone regeneration performed under the schneiderian membrane lining the maxillary sinus. Apical Bone regeneration defines the osseoinductive potential of a surface.","Studio Odontoiatrico Associato Dr. P. Cicchese e L. Canullo","All","30 Years to 80 Years   (Adult, Older Adult)","Not Applicable","40","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ABT2","April 22, 2022","February 1, 2024","February 1, 2024","August 15, 2022",,"August 15, 2022","Studio Odont.Associato Dr.P.Cicchese E L.Canullo, Rome, Italy/Rome, Italy",,"https://ClinicalTrials.gov/show/NCT05500911"
73,"NCT05500898","Drug-Drug Interaction of DWP16001 in Combination With DWC202204 and DWC202205 in Healthy Male Adults",,"Not yet recruiting","No Results Available","Healthy","Drug: DWP16001|Drug: DWC202204+DWC202205|Drug: DWP16001+DWC202204+DWC202205","Cmax,ss of DWP16001|AUCtau,ss of DWP16001|Cmax,ss of DWC202204 and DWC202205|AUCtau,ss of DWC202204 and DWC202205","Daewoong Pharmaceutical Co. LTD.","Male","19 Years and older   (Adult, Older Adult)","Phase 1","53","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","DW_DWP16001108","August 26, 2022","October 31, 2022","February 28, 2023","August 15, 2022",,"August 15, 2022",,,"https://ClinicalTrials.gov/show/NCT05500898"
74,"NCT05500885","The Clinical Effectiveness of Pulse Electromagnetic Field Therapy in the Management of General Foot and Ankle Comorbidities",,"Not yet recruiting","No Results Available","Hallux Valgus and Bunion|Ankle Sprains","Device: PEMF device, Quantum Tx, Singapore|Other: Standard rehabilitation for CAI/Ankle Sprain|Other: Foot exercise for Hallux Valgus|Device: SHAM PEMF device, Quantum Tx, Singapore","Chronic Ankle Instability tool test for chronic ankle instability and ankle sprain|Visual analog scale test for chronic ankle instability and ankle sprain|The Manchester-Oxford Foot Questionnaire (MOxFQ) for Hallux Valgus|Visual analog scale test for Hallux Valgus|Y balance test for chronic ankle instability and ankle sprain|Single leg stance/foot lift test for chronic ankle instability and ankle sprain|Dorsiflexion Range of motion for chronic ankle instability and ankle sprain|Foot muscle strength for chronic ankle instability, ankle sprain and Hallux Valgus patients|Ultrasound imaging for ligament quality and intrinsic muscle among chronic ankle instability, ankle sprain and Hallux Valgus patients|Static balance for hallux valgus patients|Single leg heel raise test for hallux valgus patients|Timed Up and go test for Hallux Valgus patients|Serum evaluation for inflammation markers for Hallux Valgus patients|Short Form 36 questionnaire (SF-36) for CAI, Ankle sprain and Hallux Valgus patients|Foot and ankle outcome questionnaire for CAI, Ankle sprain and Hallux Valgus patients|X ray imaging for Hallux Valgus patients|Hallux range of motion","Chinese University of Hong Kong","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2022.263-T","September 2022","August 2025","August 2025","August 15, 2022",,"August 15, 2022","Prince of Wales Hospital, Hong Kong, Hong Kong",,"https://ClinicalTrials.gov/show/NCT05500885"
75,"NCT05500872","Blood Flow Restriction After Anterior Cruciate Ligament Reconstruction (ACLR)","ACLR","Not yet recruiting","No Results Available","Anterior Cruciate Ligament Rupture|Quadriceps Muscle Atrophy","Other: Cross-education and blood flow restriction training|Other: Cross-education","Change from Baseline Muscle Strength at 12th week|Change from Baseline Muscle Thickness at 12th week|Change from Baseline Knee Function at 12th week","Hacettepe University","All","18 Years to 45 Years   (Adult)","Not Applicable","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","KA-19118","August 30, 2022","March 1, 2023","May 1, 2023","August 15, 2022",,"August 15, 2022","Hacettepe University, Ankara, Turkey",,"https://ClinicalTrials.gov/show/NCT05500872"
76,"NCT05500859","Swiss Secondary Prevention and Rehabilitation Registry","SwissPR","Recruiting","No Results Available","Cardiovascular Diseases (CVD)","Other: Data collection at Baseline, 3 months after baseline (BL), 1-year follow-up, Telephone follow-up and questionnaire 3 years and 5 years after BL","Change in Guideline recommended medical therapy|Change in predefined secondary prevention benchmark performance measures (BPM) at one year after CR: LDL-Cholesterol target value|Change in predefined secondary prevention benchmark performance measures (BPM) at one year after CR: blood-pressure (systolic and diastolic)|Change in smoking status|Change in predefined secondary prevention benchmark performance measures (BPM) at one year after CR: exercise/ week|Percentage of patients reaching the predefined secondary prevention benchmark after CR|Change in physical activity|Change in medical therapy between visits|Change in quality of life questionnaire/ score between visits|Change in Thrombolysis in Myocardial Infarction Risk Score for Secondary Prevention (TRS 2P) between visits|Change in total mortality after 1, 3 and 5 years|Change in total MACE after 1, 3 and 5 years","University Hospital, Basel, Switzerland","All","Child, Adult, Older Adult",,"4000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2019-02057; me19Pfister","December 20, 2019","December 2035","December 2035","August 15, 2022",,"August 15, 2022","University Hospital Basel, Division of Outpatient Cardiology, Basel, Switzerland",,"https://ClinicalTrials.gov/show/NCT05500859"
77,"NCT05500846","Targeted Cryoablation of Prostate Cancer Lesions: An Investigator-initiated Trial","PROCRY","Recruiting","No Results Available","Prostate Cancer","Device: The Visual Ice Cryoablation System","Combination of the responses in PSA, MRI, and Prostate biopsy","Osamu Ukimura|Kyoto Prefectural University of Medicine","Male","20 Years to 85 Years   (Adult, Older Adult)","Not Applicable","50","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CTREC-URO-181202|jRCT2052210088","October 19, 2021","February 29, 2024","December 31, 2024","August 15, 2022",,"August 15, 2022","University Hospital, Kyoto Prefectural University of Medicine, Kyoto, Japan|Kyoto Miniren Chuo Hospital, Kyoto, Japan",,"https://ClinicalTrials.gov/show/NCT05500846"
78,"NCT05500833","Multidimensional Characterization of Dyspnea in Children","DYSPED","Not yet recruiting","No Results Available","Study Focus on Patients Aged Between 6-17 Years, Experiencing Dyspnea and Presenting With Acute Respiratory Insufficiency or Chronic Respiratory Insufficiency","Other: Multidimentional observation scale (MDP)","Validate the Multidimensional Dyspnea Profale (MDP) self-evaluation scale in children aged between 12 and 17 years presenting with acute or chronic dyspnea.|Validate the Respiratory Distress Observation Scale (RDOS) hetero-evaluation scale in patients aged between 12-17 years presenting with acute dyspnea.|Provide a multidimensional description of dyspnea using the MDP scale in children aged 12-17 y/o.|Study the correlation between MDP and RDOS scores and Dyspnea-visual analogue scale (VAS).|Validate the use of a simplified MDP in children aged between 6-11 y/o presenting with acute or chronic dyspnea.|Provide a multidimensional description of dyspnea in children aged between 6-11 y/o.|Study the correlation between the simplified MDP and the dyspnea-VAS.|Study the association between dyspnea scores and different clinical features, the use of treatments and results of explorations|Study the impact of dyspnea on quality of life using the PedSQL scale in children presenting with chronic dyspnea and their families.|Study the correlation between dyspnea scores in children and their parents' anxity scores using the STAI-Y questionnaire.","Assistance Publique - Hôpitaux de Paris","All","6 Years to 17 Years   (Child)",,"400","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","APHP220874","October 1, 2022","October 1, 2025","October 1, 2025","August 15, 2022",,"August 15, 2022",,,"https://ClinicalTrials.gov/show/NCT05500833"
79,"NCT05500820","Study With CIN-107 Following Multiple Oral Ascending Doses in Healthy Subjects",,"Completed","No Results Available","Hypertension","Drug: CIN-107|Drug: Matching Placebo","Maximum plasma concentration (Cmax)|Time to maximum plasma concentration (Tmax)|Area under the curve from time 0 to the time of last quantifiable plasma concentration (AUC[0-last])|Area under the curve from time 0 to infinity|Area under the curve over a dosing interval (tau)|Area under the plasma concentration-time curve (AUC) from time 0 to 24 hours|Percent of AUC extrapolated|Terminal phase elimination half-life|Apparent plasma clearance|Apparent volume of distribution|The cumulative amount of CIN-107 and CIN-107-M excreted in the urine (Ae)|Renal clearance (CLR Calculated as Ae/AUC) of CIN-107 and CIN-107-M|Fraction of the dose excreted renally (fe)|Number of patients experiencing adverse events (AEs)|Number of patients experiencing adverse drug reactions|Number of patients experiencing serious adverse events (SAEs)|Plasma concentration of aldosterone|Plasma renin activity|Plasma concentration of cortisol (free and total)|Plasma concentration of ACTH (Adrenocorticotropic hormone)","CinCor Pharma, Inc.","All","18 Years to 55 Years   (Adult)","Phase 1","56","Industry","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CIN-107-111","December 19, 2019","April 3, 2020","April 3, 2020","August 15, 2022",,"August 15, 2022","Medpace Clinical Pharmacology Unit, Cincinnati, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT05500820"
80,"NCT05500807","Emicizumab for Severe Von Willebrand Disease (VWD) and VWD/Hemophilia A","BCDI-XII","Not yet recruiting","No Results Available","Von Willebrand Disease, Type 3|Concomitant VWD and Hemophilia","Drug: Emicizumab","Emicizumab is efficacious for prophylaxis in severe VWD & concomitant VWD/hemophilia A|Emicizumab is safe for prophylaxis in severe VWD & concomitant VWD/Hemophilia A|Reduced treatment burdent vs VWF/FVIII prophylaxis|Decreased bleed occurrence|Diminish bleed severity","Bleeding and Clotting Disorders Institute Peoria, Illinois|Genentech, Inc.","All","2 Years to 90 Years   (Child, Adult, Older Adult)","Phase 1","40","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BCDI-XII","November 2022","November 2025","March 2026","August 15, 2022",,"August 15, 2022","Bleeding and Clotting Disorders Institute, Peoria, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT05500807"
81,"NCT05500794","Meditation in Inflammatory Dermatosis","MediDermIn","Not yet recruiting","No Results Available","Atopic Dermatitis|Psoriasis|Pruritus","Other: MBSR (Mindfulness-Based Stress Reduction)","Pruritus assessed by Visual Analogue Scale (VAS)|Pruritus assessed by 5-D Itch Scale 5-D (5-D IQ)|Number of dermatocorticoides tubes|Number of scratches per day (including nights)|Psorasis Area and severity index (PASI Index) for psoriasis group|SCORAD Index for atopic dermatitis|Stress evaluation assessed by Perceived Stress Scale|Quantification of inflammatory stress markers in saliva|Quantification of inflammatory stress markers in serum","Assistance Publique - Hôpitaux de Paris","All","18 Days and older   (Child, Adult, Older Adult)","Not Applicable","72","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","APHP211191","September 2022","March 2023","May 2023","August 15, 2022",,"August 15, 2022","Hôpital Saint-Louis, Paris, France",,"https://ClinicalTrials.gov/show/NCT05500794"
82,"NCT05500781","Online Program for Coaching Girls: Coaching HER",,"Recruiting","No Results Available","Intervention|Waitlist Control","Behavioral: Coaching HER","Change in coaches' self-efficacy in tackling gender stereotypes|Change in coaches' self-efficacy in tackling gender essentialist beliefs|Total feasibility, acceptability, and adherence of the intervention (assessed via a self-report questionnaire)","University of Minnesota|Dove Self-Esteem Project, Unilever|Nike|Laureus|University of West England","All","18 Years and older   (Adult, Older Adult)","Not Applicable","158","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Prevention","STUDY00015642","May 1, 2022","August 2022","August 2022","August 15, 2022",,"August 15, 2022","University of Minnesota, Minneapolis, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT05500781"
83,"NCT05500768","Efficacy of the hYpothermic Compression Bandage in the Surgical Wound of Cardiac Devices","EYRA","Completed","No Results Available","Pocket Hematoma","Procedure: hypothermic compression bandage|Procedure: Conventional compression bandage","Appearance of hematoma|Appearance of severe hematoma","Hospital Clinic of Barcelona","All","18 Years and older   (Adult, Older Adult)","Not Applicable","310","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","EYRA trial","May 1, 2018","May 31, 2019","July 31, 2022","August 15, 2022",,"August 15, 2022","Hospital Clínic, Barcelona, Spain",,"https://ClinicalTrials.gov/show/NCT05500768"
84,"NCT05500755","Clinical and Radiographic Evaluation of Dentsply Sirona PrimeTaper Implants",,"Recruiting","No Results Available","Dental Implants","Device: Implant Treatment","Implant Survival Rate|Implant Success Rate|Biological and mechanical complications events","Aula Dental Avanzada","All","18 Years to 99 Years   (Adult, Older Adult)",,"150","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","DSPT","July 26, 2022","September 1, 2025","September 2, 2025","August 15, 2022",,"August 15, 2022","Clínica Dental esteve, Alicante, Spain",,"https://ClinicalTrials.gov/show/NCT05500755"
85,"NCT05500742","Anti-age Dietary Supplements in Healthy Older Adults: the proBNPage Reduction Randomized Trial","PBAR","Not yet recruiting","No Results Available","Aging","Dietary Supplement: Coenzyme Q10|Dietary Supplement: Selenium|Dietary Supplement: Resveratrol|Dietary Supplement: TA-65 MD|Other: Placebo-1|Other: Placebo-2","Change from baseline ProBNPage at 6 months|Change from baseline ProBNPage at 12 months|Change from baseline ProBNPage at 18 months|Change from baseline ProBNPage at 24 months|Handgrip strength change|Step test change|Euro QoL 5 dimension change","IRCCS Azienda Ospedaliero-Universitaria di Bologna|University of Bologna|Azienda Usl di Bologna","All","65 Years to 80 Years   (Older Adult)","Not Applicable","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","PBAR-2022","August 2022","November 2024","November 2024","August 15, 2022",,"August 15, 2022",,,"https://ClinicalTrials.gov/show/NCT05500742"
86,"NCT05500729","Hamstring/Quadriceps Ratio in CrossFit","HQCROSS","Not yet recruiting","No Results Available","Healthy Volunteers","Other: Hamstrings maximal voluntary isometric contraction.|Other: Quadriceps maximal voluntary isometric contraction","Hamstrings maximal voluntary isometric contraction|Quadriceps maximal voluntary isometric contraction.|Hamstring / Quadriceps Ratio","Camila Velo Etcheverry|Maimonides University","All","20 Years to 40 Years   (Adult)",,"60","Other","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","5738","August 22, 2022","November 1, 2022","December 20, 2022","August 15, 2022",,"August 15, 2022","Maimonides University, Ciudad Autonoma de Buenos Aires, Caba, Argentina",,"https://ClinicalTrials.gov/show/NCT05500729"
87,"NCT05500716","The Effect of Vagus Nerve Stimulation on Temporomandibular Joint Dysfunction",,"Not yet recruiting","No Results Available","Temporomandibular Joint Dysfunction Syndrome|Autonomic Nervous System Imbalance","Other: Auricular Non-Invazive Vagus Nerve Stimulation + Traditional Rehabilitation Program for TMD","Heart Rate Variability|Pain and Trigger Points|Range of motion|Perceived Stress scale|Neck Disability Index","Alper Percin|Bahçeşehir University","Female","18 Years to 45 Years   (Adult)","Not Applicable","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","STUDYAP0001","August 15, 2022","June 15, 2023","June 30, 2023","August 15, 2022",,"August 15, 2022","Bahçeşehir University, Istanbul, Beşiktaş, Turkey",,"https://ClinicalTrials.gov/show/NCT05500716"
88,"NCT05500703","Brain Regions and Functional Neuronal Network Characteristics of Dexmedetomidine Analgesia",,"Not yet recruiting","No Results Available","Epilepsy|Radiofrequency Ablation","Drug: Dexmedetomidine Injectable Solution|Drug: Sodium Chloride 0.9% Inj","Measurement of analgesia relative brain regions assessed by T1-MPRAGE, T2-SPACE, and BOLD under fMRI scanning|systolic blood pressure (SBP),|diastolic blood pressure (DBP)|mean arterial pressure (MAP),|heart rate (HR)","China International Neuroscience Institution","All","20 Years to 50 Years   (Adult)","Phase 4","12","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Health Services Research","CINI-AD-20220706","August 15, 2022","September 15, 2022","September 20, 2022","August 15, 2022",,"August 15, 2022",,,"https://ClinicalTrials.gov/show/NCT05500703"
89,"NCT05500690","Understanding Effects of Folic Acid on the Methylosome and Transcriptome of Women With Spina Bifida Affected Pregnancies",,"Not yet recruiting","No Results Available","Pregnancy; Spina Bifida, Fetal|Environmental Exposure","Dietary Supplement: Folic Acid Tablet","Changes in DNA Methylation patterns|Changes in serum folate concentration","Boston Children's Hospital|National Institute of Neurosciences and Hospital, Dhaka","Female","18 Years and older   (Adult, Older Adult)","Not Applicable","50","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","IRB-P00043006","January 2023","December 2024","November 2025","August 15, 2022",,"August 15, 2022","National Institute of Neurosciences and Hospital, Dhaka, Bangladesh",,"https://ClinicalTrials.gov/show/NCT05500690"
90,"NCT05500677","Lidocaine Spray for Pain Control in Rib Fractures",,"Completed","No Results Available","Rib Fractures|Analgesia","Drug: Lidocaine topical","Pain control","Ankara City Hospital Bilkent","All","18 Years and older   (Adult, Older Adult)","Phase 4","48","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment",,"June 1, 2021","November 30, 2021","November 30, 2021","August 15, 2022",,"August 15, 2022","Ankara City Hospital, Ankara, Turkey",,"https://ClinicalTrials.gov/show/NCT05500677"
91,"NCT05500664","The Effect of Aromatherapy on Anxiety in Patients",,"Completed","No Results Available","Anxiety|Pain","Drug: Lavender Oil","change of Speilberger State-Trait Anxiety Inventory|change of Pain visual analog scale","Assiut University","All","40 Years to 70 Years   (Adult, Older Adult)","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","IRB00202205","January 20, 2022","May 30, 2022","June 30, 2022","August 15, 2022",,"August 15, 2022","Emad Zarief Kamel Said, Assiut, Egypt",,"https://ClinicalTrials.gov/show/NCT05500664"
92,"NCT05500651","Dance and Movement Therapy in Patients With Schizophrenia","DMTinSchizo","Not yet recruiting","No Results Available","Schizophrenia|Negative Symptoms in Schizophrenia|Disabilities Mental|Dance Therapy","Other: Dance and Movement Therapy (DMT)","The Scale for the Assessment of Negative Symptoms (SANS)|Disability Evaluation Schedule (WHO-DAS-II)","Amasya University","All","Child, Adult, Older Adult","Not Applicable","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention","AmasyaU8","September 2022","September 2022","February 2023","August 15, 2022",,"August 15, 2022",,,"https://ClinicalTrials.gov/show/NCT05500651"
93,"NCT05500638","Effect of VR-ESMEPP on Parents' Seizure Management","VR-ESMEPP","Completed","No Results Available","Virtual Reality|Epilepsy|Seizure|Child|Nurse|Parents","Behavioral: Virtual Reality","Effects on knowledge about epilepsy change|Effects on skill about epileptic seizure time|Effects on motivation change","Akdeniz University","All","Child, Adult, Older Adult","Not Applicable","91","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","2012-KAEK-20-730","August 6, 2018","August 16, 2019","February 7, 2020","August 15, 2022",,"August 15, 2022","Aysegul ISLER DALGIC, Antalya, Konyaaltı, Turkey",,"https://ClinicalTrials.gov/show/NCT05500638"
94,"NCT05500625","Endoscopic Ultrasound-guided Coil With Cyanoacrylate Injection Versus Balloon-Occluded Retrograde Transvenous Obliteration in Managing Patients With Gastric Varices",,"Not yet recruiting","No Results Available","Gastric Varix","Procedure: Endoscopic ultrasound-guided coil embolization combined with endoscopic cyanoacrylate injection|Procedure: Ballon-occluded retrograde transvenous obliteration","Gastric varices bleeding control|Time of procedure","Assiut University","All","18 Years to 75 Years   (Adult, Older Adult)","Not Applicable","70","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","EUSCCIBRTOMPGV","August 30, 2022","August 30, 2024","January 30, 2025","August 15, 2022",,"August 15, 2022",,,"https://ClinicalTrials.gov/show/NCT05500625"
95,"NCT05500612","MRI Hypoxia Study for GBM Radiation Therapy","MANGO","Not yet recruiting","No Results Available","Glioblastoma Multiforme",,"Determination of spatial correlation of hypoxic tumour volume between MRI and 18F-FMISO|Repeatability of voxel-wise levels of hypoxia in the tumour|The predicted patient outcomes of the biologically-adapted Radiotherapy (RT) plan will be compared with the actual patient outcomes|Correlation between the percentage of hypoxic tumour volume and clinical outcome|Correlation between the percentage change of hypoxic tumour volume during treatment and clinical outcome","University of Sydney|The Brain Cancer Group","All","18 Years and older   (Adult, Older Adult)",,"20","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","ETH11794","August 2022","August 2024","August 2025","August 15, 2022",,"August 15, 2022","North Shore Private Hospital, St Leonards, New South Wales, Australia|Royal North Shore Hospital, St Leonards, New South Wales, Australia",,"https://ClinicalTrials.gov/show/NCT05500612"
96,"NCT05500599","Effects on Recovery of Children of Intravenous Formulation of Fentanyl Citrate and Midazolam Orally for Premedication",,"Enrolling by invitation","No Results Available","Separation Anxiety","Drug: Fentanyl Citrate","effect of both premedicants on recovery|time of onset and level of sedation,|acceptance of premedication|Time to recovery","Alexandria University","All","2 Years to 8 Years   (Child)","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care","0305335","March 1, 2022","September 30, 2022","October 31, 2022","August 15, 2022",,"August 15, 2022","Ahmed S. Shehab, Alexandria, Egypt",,"https://ClinicalTrials.gov/show/NCT05500599"
97,"NCT05500586","The Effects of Glucagon on Hepatic Metabolism",,"Not yet recruiting","No Results Available","Obesity|Type2diabetes|NAFLD","Drug: Glucagon response study","Rate of Amino acid catabolism in the presence / absence of glucagon|Effect of Diabetes on amino-acid catabolism","Adrian Vella|Mayo Clinic","All","25 Years to 65 Years   (Adult, Older Adult)","Phase 1|Phase 2","60","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","22-000113","October 1, 2022","September 30, 2024","December 31, 2024","August 15, 2022",,"August 15, 2022","Mayo Clinic in Rochester, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT05500586"
98,"NCT05500573","Sex Selection of Human Spermatozoa",,"Recruiting","No Results Available","Infertility|IVF","Procedure: Sperm Sorting","Rate of gender bearing spermatozoa after 4-layer density gradient|Rate of embryos of the desired gender in couples|Rate of offspring of the desired gender in couples","Weill Medical College of Cornell University","All","18 Years to 89 Years   (Adult, Older Adult)","Not Applicable","2000","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1306014043","November 6, 2013","December 31, 2023","December 31, 2024","August 15, 2022",,"August 15, 2022","Center for Reproductive Medicine- Weill Cornell Medicine, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT05500573"
99,"NCT05500560","Effect of COVID-19 on Endothelial Function",,"Recruiting","No Results Available","COVID-19|Endothelial Dysfunction",,"Natural logarithm of reactive hyperemia index (Ln-RHI)|Area under the Curve (AUC) of the Reactive Hyperemia index (RHI) measurements during hospitalization, at 2 months after discharge and at 6 months after discharge.|Reactive Hyperemia Index (RHI)|Rate of endothelial dysfunction (LnRHI≤0.51)|Change in RHI index (ΔRHI) from hospitalization to 6 months|Duration (days) of hospitalization for COVID-19|Incidence of thrombotic events|Incidence of cardiovascular events|Mortality","University Hospital of Patras","All","18 Years to 90 Years   (Adult, Older Adult)",,"60","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","16/02-02-2022","March 2, 2022","March 30, 2023","March 30, 2023","August 15, 2022",,"August 15, 2022","University Hospital of Patras, Patras, Achaia, Greece",,"https://ClinicalTrials.gov/show/NCT05500560"
100,"NCT05500547","Clinical Performance of One-shade Universal Dental Resin Composite as Posterior Restoration",,"Completed","No Results Available","Carious Teeth","Other: US Public Health Service ""USPSH"" criteria for assessment of success of resin composite restorations","USPSH criteria","Minia University","All","25 Years to 45 Years   (Adult)","Not Applicable","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","RSAnwar","July 15, 2021","July 15, 2022","July 15, 2022","August 15, 2022",,"August 15, 2022","Ruba Salah Anwar, Minya, Egypt",,"https://ClinicalTrials.gov/show/NCT05500547"
101,"NCT05500534","TELAXMAN - Laser Lithotripsy With Automatic Real-time Stone Recognition",,"Not yet recruiting","No Results Available","Lithotripsy, Laser","Device: Laser lithotripsy with stone recognition|Other: Laser lithortripsy","Visual assessment of stone-free status;|Visual assessment of stone, tissue and endoscope recognition accuracy during laser lithotripsy|Safety of device - assessment of device deficiencies|Safety of device - assessment of adverse events during the intervention|Safety of device - assessment of adverse events during the follow up time|New risk identification during the intervention|New risk identification during the follow up time|Total laser emitted energy (J)|Procedure duration (min)|PULS classification of potential lesions visible via endoscopy immediately after the procedure|Usability and workflow assessment (surgeon's questionnaire)","LISA Laser Products GmbH","All","18 Years and older   (Adult, Older Adult)","Not Applicable","50","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TELAXMAN","September 2022","February 2023","May 2023","August 15, 2022",,"August 15, 2022","Universitätsklinikum Freiburg, Freiburg, Germany",,"https://ClinicalTrials.gov/show/NCT05500534"
102,"NCT05500521","Association Between Severe-to-profound Hearing Loss and the Balance Function of the Inner Ear",,"Recruiting","No Results Available","Hearing Loss, Sensorineural, Severe|Hearing Loss, Sensorineural, Profound|Vestibular Disorder","Diagnostic Test: Caloric irrigation|Diagnostic Test: vHIT|Diagnostic Test: VEMP","Video head impuls test (vHIT)|Cervical vestibular evoked myogenic potential (cVEMP).|Ocular vestibular evoked myogenic potential (oVEMP).|Caloric irrigation","Värmland County Council, Sweden","All","50 Years to 85 Years   (Adult, Older Adult)",,"100","Other","Observational","Observational Model: Case-Control|Time Perspective: Retrospective","Hearing-vestibular","August 2, 2022","June 2024","June 2024","August 15, 2022",,"August 15, 2022","Department of otorhinolaryngology, Karlstad, Sweden",,"https://ClinicalTrials.gov/show/NCT05500521"
103,"NCT05500508","Oral AMXT 1501 Dicaprate in Combination With IV DFMO",,"Recruiting","No Results Available","Cancer|Solid Tumor|Solid Carcinoma|Advanced Cancer|DIPG Brain Tumor|Ovary Cancer|Breast Cancer|Papillary Thyroid Cancer|Head and Neck Cancer|Gastric Cancer|Nsclc|Mesotheliomas Pleural|Mesothelioma Peritoneum|Esophageal Cancer|Diffuse Midline Glioma, H3 K27M-Mutant|Endometrial Cancer|Cervical Cancer|Melanoma|Colorectal Cancer","Drug: AMXT1501|Drug: DFMO","Determine DLTs and RP2Ds in AMXT 1501 in combination with IV DFMO|Determine safety and tolerability of AMXT1501 in combination with IV DFMO|Determine the PK using AUC of AMXT 1501 and IV DFMO|Determine the PK using Cmax of AMXT 1501 and IV DFMO|Characterize investigator defined response Overall Response Rate (ORR) using RECIST v1.1|Characterize investigator defined Duration of Response (DOR)|Characterize AMXT1501 and IV DFMO on the expression of immune related gene signatures","Aminex Therapeutics, Inc.","All","12 Years and older   (Child, Adult, Older Adult)","Phase 1|Phase 2","56","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AMXT1501-102","August 8, 2022","October 30, 2023","December 31, 2023","August 15, 2022",,"August 15, 2022","MD Anderson Cancer Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT05500508"
104,"NCT05500495","The Association Between Intestinal Perfusion and Prolonged Mechanical Ventilation in Patients After Cardiac Valve Surgery",,"Completed","No Results Available","Patient After Cardiac Valve Surgery|Patient With Prolonged Mechanical Ventilation","Other: no intervention","hours of mechanical ventilation|ICU residence time","Peking Union Medical College Hospital","All","18 Years to 80 Years   (Adult, Older Adult)",,"100","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","ZS-3088","January 1, 2021","March 1, 2022","March 1, 2022","August 15, 2022",,"August 15, 2022","Peking union medical college hospital, Beijing, Beijing, China",,"https://ClinicalTrials.gov/show/NCT05500495"
105,"NCT05500482","Vellore Typhoid Vaccine Impact Trial","VEVACT","Not yet recruiting","No Results Available","Typhoid Fever","Biological: Typhoid conjugate Vaccine","Total effect|Overall effect|Effect in children 1 to 14 years|Effect on all febrile illness requiring healthcare visits|Safety outcomes","Christian Medical College, Vellore, India|Bill and Melinda Gates Foundation|University College, London|Imperial College London","All","1 Year to 30 Years   (Child, Adult)","Phase 4","72000","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Prevention","14247[INTERVEN]","October 15, 2022","June 30, 2025","December 31, 2025","August 15, 2022",,"August 15, 2022","Christian Medical College Vellore, Vellore, Tamil Nadu, India",,"https://ClinicalTrials.gov/show/NCT05500482"
106,"NCT05500469","Endothelial Cell Loss in Pseudophakic Patients Receiving a Paul Glaucoma Drainage Device With Its Tube Inserted in the Anterior Versus Posterior Chamber: a Randomized Controlled Trial",,"Not yet recruiting","No Results Available","Glaucoma","Device: Paul glaucoma drainage device (GDD)","Change of endothelial cell density (ECD)|ECD|Intraocular pressure|Position of the tube|Adverse events","Oogziekenhuis Rotterdam","All","18 Years to 75 Years   (Adult, Older Adult)","Not Applicable","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","OZR-2022-03|NL81305.078.22|MEC-2022-0364","September 2022","August 2026","August 2026","August 15, 2022",,"August 15, 2022","Oogziekenhuis Rotterdam, Rotterdam, Netherlands",,"https://ClinicalTrials.gov/show/NCT05500469"
107,"NCT05500456","The Effectiveness of Clear Aligner and Traditional Fixed Appliances in Achieving Good Occlusion in Complex Orthodontic Cases",,"Completed","No Results Available","Crowding, Tooth","Device: Clear aligners|Device: Fixed appliances","Change in PAR index|Changes in Little's irregularity index|Treatment time","Damascus University","All","18 Years to 25 Years   (Adult)","Not Applicable","36","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","UDDS-Ortho-13-2022","May 11, 2019","March 1, 2021","December 15, 2021","August 15, 2022",,"August 15, 2022","University of Damascus, Damascus, Syrian Arab Republic",,"https://ClinicalTrials.gov/show/NCT05500456"
108,"NCT05500443","The DANish COronary DEcalcification (DANCODE) Trial","DANCODE","Not yet recruiting","No Results Available","Coronary Artery Disease","Dietary Supplement: Vitamin K2 (Menaquinone-7)","Coronary artery calcium (CAC) score, all participants|CAC score, men only|CAC score, women only|CAC score below 1000 at baseline, all|CAC score above 1000 at baseline, all|Coronary plaque burden|Cardiac events|Stroke|All-cause mortality|Aortic valve calcification (AVC) score","Odense University Hospital","All","Child, Adult, Older Adult","Not Applicable","400","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","DANCODE","November 2022","March 2026","November 2029","August 15, 2022",,"August 15, 2022","Department of Cardiology, Odense University Hospital, Odense, Odense C, Denmark",,"https://ClinicalTrials.gov/show/NCT05500443"
109,"NCT05500430","Evaluation of Air Abrasion Surface Pretreatment in the Repairing Capacity of Defective Composite Restoration",,"Not yet recruiting","No Results Available","Repair","Device: Air abrasion sandblasting aluminum oxide particles (Al2O3) AquaCare single (Velopex, Medivance Instruments Ltd., London, UK)","Change in the clinical performance","Cairo University","All","20 Years to 50 Years   (Adult)","Not Applicable","39","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","repair defective restoration","September 1, 2022","September 1, 2023","October 1, 2023","August 15, 2022",,"August 15, 2022",,,"https://ClinicalTrials.gov/show/NCT05500430"
110,"NCT05500417","Safety and Immunogenicity of CJCV2 With and Without ALFQ",,"Not yet recruiting","No Results Available","Campylobacter Infection","Drug: ALFQ|Biological: CJCV2","Occurrence of Medically-Attended Adverse Events (MAAE)|Occurrence of New-Onset Chronic Medical Conditions (NOCMC)|Occurrence of Potentially Immune-Mediated Medical Conditions (PIMMC)|Occurrence of Serious Adverse Events (SAE)|Occurrence of solicited local Adverse Events (AE)|Occurrence of solicited systemic Adverse Events (AE)|Occurrence of vaccine-related unsolicited Adverse Events (AE)|Maximum C. jejuni capsule-specific serum antibody titer (Immunoglobulin G (IgG))|Peak fold rise from baseline in C. jejuni capsule-specific serum antibody titer (Immunoglobulin G (IgG))|Proportion of subjects with a >/= 4-fold rise from baseline in C. jejuni capsule-specific serum antibodies (Immunoglobulin G (IgG))","National Institute of Allergy and Infectious Diseases (NIAID)","All","18 Years to 50 Years   (Adult)","Phase 1","60","NIH","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","19-0003|5UM1AI148372-03","August 22, 2022","August 21, 2024","August 21, 2024","August 15, 2022",,"August 15, 2022","Cincinnati Children's Hospital Medical Center - Infectious Diseases, Cincinnati, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT05500417"
111,"NCT05500404","Diagnostic Accuracy of Placental Thickness in Lower Uterine Segment Measured By Ultrasound in Prediction of Placenta Accreta Spectrum in Patients With Placenta Previa. A Diagnostic Test Accuracy Study",,"Recruiting","No Results Available","Screening Test for Placenta Accreta Spectrum","Diagnostic Test: Ultrasound measurment of placental thickness","Placental thickness threshold","Ain Shams Maternity Hospital","Female","20 Years to 40 Years   (Adult)",,"40","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","5","December 1, 2021","August 31, 2022","August 31, 2022","August 15, 2022",,"August 15, 2022","AinShams university maternity hospital, Cairo, Egypt",,"https://ClinicalTrials.gov/show/NCT05500404"
112,"NCT05500391","Assessment of Compliance With Monitoring Conducted by a Physician in Person or by a Nurse in Remote Monitoring","SUR-CAN","Not yet recruiting","No Results Available","Stage I Testicular Seminoma|Stage I Testicular Nonseminomatous Germ Cell Tumor|Gastrointestinal Stromal Tumors|Ovarian Germ Cell Tumor|Adenocarcinoma, Clear Cell|Borderline Ovarian Tumor|Sex Cord-Stromal Tumor|Mucinous Adenocarcinoma of Ovary|Carcinoma, Small Cell|Carcinosarcoma, Ovarian|Serous Tumor of Ovary|Glioma|Neuroendocrine Tumors|Aggressive Fibromatosis of Abdominal Wall (Disorder)","Other: Oncological Follow-up","2-year compliance to the customized surveillance plan|5-year compliance to the customized surveillance plan|Drop-out rate|Description of the use of care|Occurrence and management of oncological events|Progression-free survival|Overall survival|Support care needs identified","Centre Oscar Lambret|Canceropôle Nord Ouest|Groupement Interrégional de Recherche Clinique et d'Innovation","All","18 Years and older   (Adult, Older Adult)","Phase 2","88","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","SUR-CAN-2201","January 2023","June 2026","June 2029","August 15, 2022",,"August 15, 2022","CHU Amiens, Amiens, France|Centre François Baclesse, Caen, France|Centre Oscar Lambret, Lille, France",,"https://ClinicalTrials.gov/show/NCT05500391"
113,"NCT05500378","The Effects of a Specific Exercise Program on Subjects With Cervicogenic Headache",,"Recruiting","No Results Available","Cervicogenic Headache","Other: Head extension and rotation movement","MSK US image","Florida Gulf Coast University","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","40","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2021-21","July 1, 2022","October 1, 2022","October 1, 2022","August 15, 2022",,"August 15, 2022","Florida Gulf Coast University, Fort Myers, Florida, United States",,"https://ClinicalTrials.gov/show/NCT05500378"
114,"NCT05500365","In Silico Pace Mapping To Optimise Ventricular Tachycardia Ablation",,"Not yet recruiting","No Results Available","Ventricular Tachycardia","Procedure: Catheter ablation therapy","Performance of in silico derived pace map","Guy's and St Thomas' NHS Foundation Trust|King's College London","All","18 Years to 99 Years   (Adult, Older Adult)",,"25","Other","Observational","Observational Model: Other|Time Perspective: Prospective","v1.0","October 1, 2022","April 1, 2025","October 1, 2025","August 15, 2022",,"August 15, 2022",,,"https://ClinicalTrials.gov/show/NCT05500365"
115,"NCT05500352","Acute Changes in Plasma Glucose and Cardiovascular Disease in Diabetes",,"Active, not recruiting","No Results Available","Diabetes|Hypoglycemia|Hyperglycemia|Cardiovascular Diseases|Sudden Cardiac Death","Other: Hyperglycemia with slow decline in plasma glucose in type 1 diabetes|Other: Hyperglycemia with rapid decline in plasma glucose in type 1 diabetes|Other: Rebound hyperglycemia in type 1 diabetes|Other: Rebound euglycemia in type 1 diabetes|Other: Hypoglycemia in type 1 diabetes|Other: Hypoglycemia in type 2 diabetes|Other: Hypoglycemia in healthy controls|Other: Hyperglycemia in type 2 diabetes|Other: Hyperglycemia in healthy controls","Change in the global work during hypoglycemia in individuals with type 1 diabetes, type 2 diabetes, and without diabetes, respectively.|Primary secondary outcome: Change in mechanical dyssynchrony during hypoglycemia in individuals with type 1 diabetes, type 2 diabetes, and without diabetes, respectively.|Change in the global work during recovery in individuals with type 1 diabetes.|Change in mechanical dyssynchrony during recovery in individuals with type 1 diabetes.|Change in the global work during hyperglycemia in individuals with type 1 diabetes, type 2 diabetes and without diabetes, respectively.|Change in mechanical dyssynchrony during hyperglycemia in individuals with type 1 diabetes, type 2 diabetes and without diabetes, respectively.","Steno Diabetes Center Copenhagen","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","86","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Investigator)|Primary Purpose: Basic Science","H18034040_part2","July 1, 2022","May 1, 2023","December 1, 2023","August 15, 2022",,"August 15, 2022","Steno Diabetes Center Copenhagen, Herlev, Denmark",,"https://ClinicalTrials.gov/show/NCT05500352"
116,"NCT05500339","Effectiveness of a mHealth App for Supporting the First 1000 Days of Life","CARE1000","Not yet recruiting","No Results Available","Health-Related Behavior","Other: M-health App|Other: Standard care","Between groups differences in the adherence of pregnant women to Tetanus, Diphtheria, Pertussis (TDaP) vaccination|Between groups differences in women knowledge|Between groups differences in women behaviors|Between groups differences in Health literacy level|Between groups differences in social and health impact|Appreciation of the mHealth App|MHealth app usage data","IRCCS Burlo Garofolo","Female","18 Years and older   (Adult, Older Adult)","Not Applicable","360","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","04\2022","September 1, 2022","March 31, 2023","December 31, 2025","August 15, 2022",,"August 15, 2022",,,"https://ClinicalTrials.gov/show/NCT05500339"
117,"NCT05500326","Ivermectin Therapy for Scabies Infection in Children Younger Than 5 Years of Age (ITCHY Study)","ITCHY","Not yet recruiting","No Results Available","Scabies; Itch|Scabies","Drug: Ivermectin Tablets","Ivermectin drug exposure - Area under the concentration-time curve (AUC0- ∞ )|Proportion of participants with at least one ivermectin-related adverse event|The proportion of participants whose scabies infection has improved after treatment with ivermectin","Murdoch Childrens Research Institute|Burnet Institute|Lao Tropical and Public Health Institute","All","2 Years to 5 Years   (Child)","Phase 4","100","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","84086","September 2022","September 2023","March 2024","August 15, 2022",,"August 15, 2022","Mad District Hospital, Mauengmad village, Mad District, Vientiane Province, Lao People's Democratic Republic|Meuangkhy Health Centre, Meaunkhi village, Mad District, Vientiane Province, Lao People's Democratic Republic|Namphaen Health Centre, Namphen village, Mad District, Vientiane Province, Lao People's Democratic Republic|Banvang Health Centre, Vang Village, Meun District, Vientiane Province, Lao People's Democratic Republic|Meuangmeun Health Centre, Meuangmeun village, Meun District, Vientiane Province, Lao People's Democratic Republic|Nady Health Centre, Nadi village, Mad District, Vientiane, Lao People's Democratic Republic|Napakuang Health Centre, Napakouang village, Mad District, Vientiane, Lao People's Democratic Republic|Meun District Hospital, Phonsivilay village, Meun District, Vientiane, Lao People's Democratic Republic",,"https://ClinicalTrials.gov/show/NCT05500326"
118,"NCT05500313","The Effect of Education and Counseling Based on HypnoBreastfeeding",,"Active, not recruiting","No Results Available","Hypno-breastfeeding Education","Behavioral: Hypno-breastfeeding Education|Behavioral: Experimental: Standart Breastfeeding Education","Level of breastfeeding self-efficacy|Level of breastfeeding motivation|Breastfeeding Process Evaluation Form","Mersin University","Female","18 Years to 40 Years   (Adult)","Not Applicable","80","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","NS","July 27, 2021","August 15, 2021","September 15, 2022","August 15, 2022",,"August 15, 2022","Gozde Gokce Isbir, Mersin, Turkey",,"https://ClinicalTrials.gov/show/NCT05500313"
119,"NCT05500300","Electrical Stimulation With Different Currents and Electromagnetic Fields",,"Recruiting","No Results Available","Healthy","Device: Neo-Russian|Device: Aussie|Device: RBS|Device: RBS-IPI|Device: HIFEM","Maximal Voluntary Isometric Contraction (MVIC)|Maximal Electrical Induced Contraction (MEIC)|Visual Analogue Scale|Fatigue index","Maimonides University","Male","18 Years to 30 Years   (Adult)","Not Applicable","30","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","5891","August 22, 2022","December 1, 2022","December 1, 2022","August 15, 2022",,"August 15, 2022","Maimonides University, Ciudad Autonoma de Buenos Aires, Caba, Argentina",,"https://ClinicalTrials.gov/show/NCT05500300"
120,"NCT05500287","Virtual Care In Pediatric Asthma",,"Completed","No Results Available","Asthma in Children","Other: Virtual Care","Change from baseline in symptom number|Change from baseline in quality of life","Ege University","All","7 Years to 17 Years   (Child)","Not Applicable","97","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","IRB.E.57802","March 14, 2021","February 20, 2022","April 20, 2022","August 15, 2022",,"August 15, 2022","Ege University, İzmir, Turkey",,"https://ClinicalTrials.gov/show/NCT05500287"
121,"NCT05500274","Social Network Diffusion of COVID-19 Prevention for Diverse Criminal Legal Involved Communities",,"Not yet recruiting","No Results Available","COVID-19","Other: Education|Other: Motivational","COVID-19 Testing|COVID-19 Vaccination","University of Chicago","All","18 Years and older   (Adult, Older Adult)","Not Applicable","800","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","IRB22-0732","September 2022","September 2023","November 2023","August 15, 2022",,"August 15, 2022",,,"https://ClinicalTrials.gov/show/NCT05500274"
122,"NCT05500261","Intranasal Dexmedetomidine for Severe Dental Anxiety: a Randomized Trial",,"Not yet recruiting","No Results Available","Dental Anxiety","Drug: Dexmedetomidine","Change of MDAS score|Change of plasma cortisol concentration|Change of NTI score|Change of OAA/S score|Change of blood pressure (BP)|Change of heart rate (HR)|Pain score|Percentage of thinking feasible of intranasal dexmedetomidine by participants","Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","SYSKY-2022-119-03","August 15, 2022","July 23, 2023","July 23, 2023","August 15, 2022",,"August 15, 2022",,,"https://ClinicalTrials.gov/show/NCT05500261"
123,"NCT05500248","Prospective RAndomized Controlled Trial to Inform About CADx-assisted Leave-in-situ Safety and Effectiveness in Real-world Colonoscopy",,"Not yet recruiting","No Results Available","Colonic Neoplasms","Behavioral: Leave In Situ|Behavioral: Standard","Adenoma Detection Rate (ADR)|Positive Predictive Value (PPV)|Adenoma Detection Rate (ADR) in the rectosigmoid tract.","University of Roma La Sapienza","All","18 Years and older   (Adult, Older Adult)","Not Applicable","1000","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Prevention","PRACTICE","September 1, 2022","February 28, 2023","April 30, 2023","August 15, 2022",,"August 15, 2022","Ospedale Dei Castelli, Ariccia, Rome, Italy",,"https://ClinicalTrials.gov/show/NCT05500248"
124,"NCT05500235","Comparing Smartphone to In-person Training to Scale up a Tobacco Control Program for Teachers in India",,"Not yet recruiting","No Results Available","Tobacco Use Cessation","Behavioral: Smart phone based training|Behavioral: In person training","Tobacco use cessation among teachers","Harvard School of Public Health (HSPH)|Healis-Sekhsaria Institute for Public Health","All","22 Years and older   (Adult, Older Adult)","Not Applicable","1800","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","IRB20-2157","June 2023","December 2023","June 2025","August 15, 2022",,"August 15, 2022","Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Healis Sekhsaria Institute for Public Health, Mumbai, India",,"https://ClinicalTrials.gov/show/NCT05500235"
125,"NCT05500222","A Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis",,"Not yet recruiting","No Results Available","NASH|Cirrhosis, Liver","Drug: Resmetirom","Incidence Of adjudicated Composite Clinical Outcome event","Madrigal Pharmaceuticals, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 3","700","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","MGL-3196-19","August 2022","August 2025","November 2025","August 15, 2022",,"August 15, 2022","Arkansas Gastroenterology, North Little Rock, Arkansas, United States",,"https://ClinicalTrials.gov/show/NCT05500222"
126,"NCT05500209","Chatbot-based Internet Intervention for Stress Among University Students (Stressbot)",,"Not yet recruiting","No Results Available","Stress, Psychological","Behavioral: Personal resources' enhancement: self-efficacy","Change on Perceived Stress Scale 4 (PSS-4)|Change on Brunnsviken Brief Quality of Life Scale (BBQ)|Coping Self-Efficacy Scale (CSES)","University of Social Sciences and Humanities, Warsaw","All","18 Years and older   (Adult, Older Adult)","Not Applicable","300","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Stressbot","October 2022","June 2023","June 2023","August 15, 2022",,"August 15, 2022",,,"https://ClinicalTrials.gov/show/NCT05500209"
127,"NCT05500196","Impact of Gastric Length of Myotomy During POEM on Gastroesophageal Reflux: A Randomized Controlled Trial",,"Recruiting","No Results Available","Gastric Reflux","Device: Per Oral Endoscopy Myotomy (POEM)","Impact of Gastric Length of myotomy during poem on Gastroesophageal reflux|Ph metry test for gastroesophageal reflux|Symptoms of Gastro esophageal reflux disease|High resolution manometry parameters(LES pressures and IRP)","Asian Institute of Gastroenterology, India","All","18 Years to 75 Years   (Adult, Older Adult)",,"86","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","POEM 005","July 7, 2021","November 7, 2022","January 10, 2023","August 15, 2022",,"August 15, 2022","Asian Institute of Gastroenterology Pvt Ltd/Aih Hospitals, Hyderabad, Telangana, India",,"https://ClinicalTrials.gov/show/NCT05500196"
128,"NCT05500183","Cognitively Enriched Walking Program",,"Recruiting","No Results Available","Healthy Aging|Cognitive Decline|Physical Inactivity","Behavioral: Cognitively enriched walking program|Behavioral: walking program","objective cognitive functioning T1|objective cognitive functioning T2|objective cognitive functioning T3|cognitive functioning T4|subjective cognitive functioning T1 - Cognitive Failures Questionnaire|subjective cognitive functioning T1 - Cognitive and Leisure Activities Scale (CLAS)|subjective cognitive functioning T2 - Cognitive Failures Questionnaire (CFQ)|subjective cognitive functioning T2 - Cognitive and Leisure Activities Scale (CLAS)|subjective cognitive functioning T3 - Cognitive Failures Questionnaire (CFQ)|subjective cognitive functioning T3 - Cognitive and Leisure Activities Scale (CLAS)|subjective cognitive functioning T4 - Cognitive Failures Questionnaire (CFQ)|subjective cognitive functioning T4 - Cognitive and Leisure Activities Scale (CLAS)|Psychosocial wellbeing questionnaires T1|Psychosocial wellbeing questionnaires T2|Psychosocial wellbeing questionnaires T3|Psychosocial wellbeing questionnaires T4|Physical activity assessment (objective + subjective) T1|Physical activity assessment (objective + subjective) T2|Physical activity assessment (objective + subjective) T3|Physical activity assessment (objective + subjective) T4|General health questionnaires T1 - General Health|General health questionnaires T1 - Sleep Disturbances|General health questionnaires T2 - General Health|General health questionnaires T2 - Sleep Disturbances|General health questionnaires T3 - General Health|General health questionnaires T3 - Sleep Disturbances|General health questionnaires T4 - General Health|General health questionnaires T4 - Sleep Disturbances","University Ghent|Research Foundation Flanders|KU Leuven","All","65 Years and older   (Older Adult)","Not Applicable","113","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Prevention","WALKYOURBRAIN","July 1, 2022","September 2023","January 2024","August 15, 2022",,"August 15, 2022","Ghent University, Ghent, East-Flanders, Belgium|KU Leuven, Leuven, Vlaams Brabant, Belgium",,"https://ClinicalTrials.gov/show/NCT05500183"
129,"NCT05500170","Benefits of Nicotinamide Riboside Upon Cognition and Sleep",,"Not yet recruiting","No Results Available","Cognitive Impairment|Sleep Quality","Dietary Supplement: Nicotinamide riboside|Dietary Supplement: Placebo","Sleep Quality Assessment|Cognitive function","State University of New York at Buffalo","All","65 Years to 85 Years   (Older Adult)","Not Applicable","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Supportive Care","FP00006694","November 30, 2022","November 30, 2024","January 30, 2025","August 15, 2022",,"August 15, 2022","State University of New York at Buffalo, Buffalo, New York, United States|University at Buffalo State University of New York, Buffalo, New York, United States",,"https://ClinicalTrials.gov/show/NCT05500170"
130,"NCT05500157","Assessment of Treatment With Laparoscopic Fenestration or Aspiration Sclerotherapy for Large Symptomatic Hepatic Cysts","ATLAS","Not yet recruiting","No Results Available","Liver Cyst|Polycystic Liver Disease|Autosomal Dominant Polycystic Kidney|Autosomal Dominant Polycystic Liver Disease","Procedure: aspiration sclerotherapy versus laparoscopic fenestration","PLD-Q 4 weeks|PLD-Q score 1, 6 and 12 months after intervention|PLD-Q invididual symptoms|SF-36 MCS|SF 36 PCS|EQ-5D-5L|Liver and cyst volume|Liver and cyst volume at recurrence|Cyst volume with US|Adverse events|Technical success|Hospital stay|Re-intervention rates|Cost-effectiveness iPCQ|Cost-effectiveness iMCQ","Radboud University Medical Center","All","18 Years to 75 Years   (Adult, Older Adult)","Not Applicable","70","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2020-7134","October 1, 2022","October 1, 2023","October 1, 2024","August 12, 2022",,"August 12, 2022",,,"https://ClinicalTrials.gov/show/NCT05500157"
131,"NCT05500144","Return to Work With Post Stroke Communication Disorders","ConQueSt","Recruiting","No Results Available","Stroke","Other: Not applicable- no intervention administered","Experiences of returning or attempting to return to the workplace with post-stroke communication disorders","NHS Grampian","All","18 Years to 100 Years   (Adult, Older Adult)",,"18","Other","Observational","Observational Model: Other|Time Perspective: Other","1-017-22","July 1, 2022","February 1, 2023","June 30, 2023","August 12, 2022",,"August 12, 2022","NHS Grampian, Aberdeen, Aberdeenshire, United Kingdom",,"https://ClinicalTrials.gov/show/NCT05500144"
132,"NCT05500131","The Association Between Restricted Ankle Joint Dorsiflexion and Dynamic Knee Valgus","TOBROD","Completed","No Results Available","Knee Injuries|Ankle Injuries and Disorders|Movement, Abnormal|Adolescent Development","Behavioral: Observation","Ankle joint dorsiflexion|Dynamic lower extremity valgus|Age|Age categories|Gender|Weight|Height|Wingspan|Body mass index|Hypermobility","University Rovira i Virgili","All","12 Years to 17 Years   (Child)",,"791","Other","Observational","Observational Model: Ecologic or Community|Time Perspective: Cross-Sectional","123/2018_3","October 1, 2018","May 20, 2019","June 30, 2019","August 12, 2022",,"August 12, 2022","Federación Catalana de Baloncesto, Barcelona, Spain",,"https://ClinicalTrials.gov/show/NCT05500131"
133,"NCT05500118","Establishment of a Decision Aid Tool for Asymptomatic Small Leiomyoma and Analysis of Influencing Factors for Clinical Decision-making Using HIFU",,"Recruiting","No Results Available","Leiomyoma, Uterine|High-Intensity Focused Ultrasound Ablation|Patients Decision Aids","Other: Patients Decision Aids","Patient satisfaction after using PDAs","Shenzhen Maternity & Child Healthcare Hospital","Female","18 Years to 55 Years   (Adult)",,"120","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","2021KFKT030","August 31, 2022","August 31, 2024","August 31, 2027","August 12, 2022",,"August 12, 2022","Shenzhen Maternal and Child Health Hospital, Shenzhen, Guangdong, China",,"https://ClinicalTrials.gov/show/NCT05500118"
134,"NCT05500105","Remote Delivery of a Visuospatial Intervention to Reduce Traumatic Intrusive Memories After PICU",,"Not yet recruiting","No Results Available","Intrusion Symptom","Other: Simple cognitive task intervention","Number of intrusive memories of traumatic event(s) - change in number of intrusive memories is being assessed.|Impact of Events Scale-Revised (IES-R; Weiss and Marmar, 1997)|Intrusive memory ratings|Patient Health Questionnaire-9 item (PHQ-9; Kroenke et al., 2001)|Generalised Anxiety Disorder-7 item questionnaire (GAD-7; Spitzer et al., 2006)|Work and Social Adjustment Scale (WSAS; Mundt et al., 2002)","Queen's University, Belfast","All","18 Years and older   (Adult, Older Adult)","Not Applicable","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","EPS 22_57","August 9, 2022","February 13, 2023","March 27, 2023","August 12, 2022",,"August 12, 2022","Queen's University Belfast, Belfast, United Kingdom",,"https://ClinicalTrials.gov/show/NCT05500105"
135,"NCT05500092","An Open Label, Randomized Study of Neoadjuvant Nivolumab and Chemotherapy, With or Without Sub-ablative Stereotactic Body Radiation Therapy, for Resectable Stage IIA to IIIB Non-small Cell Lung Cancer","CA209-6K6","Not yet recruiting","No Results Available","Resectable Stage IIA to IIIB Non-small Cell Lung Cancer","Drug: Nivolumab|Radiation: (8gy x 3)|Drug: Platinum Doublet","Complete Pathological Response|Major Pathological Response|Event Free Survival","Montefiore Medical Center|Bristol-Myers Squibb","All","18 Years and older   (Adult, Older Adult)","Phase 2","60","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2021-13627","August 2022","July 2025","August 2027","August 12, 2022",,"August 12, 2022",,,"https://ClinicalTrials.gov/show/NCT05500092"
136,"NCT05500079","Transctunaous Pulsed Radiofrequency Therapy in Carpal Tunnel Syndrome",,"Active, not recruiting","No Results Available","Peripheral Neuropathy|Chronic Pain","Device: Wrist splint|Other: Pulsed radiofrequency current","Change From Baseline in Pain on the Visual Analog Scale (VAS) at Week 2 and 4|Boston Carpal Tunnel Syndrome Questionnaire before treatment","Diskapi Teaching and Research Hospital","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Carpal Tunnel Syndrome","August 1, 2021","September 30, 2022","June 1, 2023","August 12, 2022",,"August 12, 2022","Diskapi Yildirim Beyazıt Teaching and Research Hospital, Ankara, Dişkapi, Turkey",,"https://ClinicalTrials.gov/show/NCT05500079"
137,"NCT05500066","AEQUALIS™ FLEX REVIVE™ Study (REVIVE)","REVIVE","Not yet recruiting","No Results Available","Rheumatoid Arthritis|Osteoarthritis Shoulder|Fractures Humerus|Avascular Necrosis|Correction of Functional Deformity|Traumatic Arthritis|Revision of Other Devices if Sufficient Bone Stock Remains|Rotator Cuff Tears","Device: Aequalis Flex Revive Shoulder System","Average Improvement from Baseline to last follow-up visit in ASES Score|Constant Score|SANE|EQ 5-D|Patient Satisfaction|Radiographic Findings","Stryker Trauma GmbH","All","18 Years and older   (Adult, Older Adult)",,"110","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","20F-W-REVIVE-RM","December 2, 2022","January 6, 2028","January 3, 2036","August 12, 2022",,"August 12, 2022",,,"https://ClinicalTrials.gov/show/NCT05500066"
138,"NCT05500053","A Study of the Characteristics of Patients Diagnosed With Recurrent Symptomatic Genital Herpetic Disease",,"Active, not recruiting","No Results Available","Genital Herpes|Patient Engagement",,"Baseline characteristics of patients who have recurrent symptomatic genital herpetic disease|Acceptance to patients of clinical trial procedures|Interest in participation in genital herpes vaccine trials","Rational Vaccines Inc","All","18 Years to 64 Years   (Adult)",,"200","Industry","Observational","Observational Model: Ecologic or Community|Time Perspective: Retrospective","RVx-001-PSS","August 3, 2022","December 2022","January 2023","August 12, 2022",,"August 12, 2022","Solent NHS Trust, Southampton, UK, United Kingdom",,"https://ClinicalTrials.gov/show/NCT05500053"
139,"NCT05500040","Changes in Faecal Calprotectin Levels and Participation-related Scores Following Three Weeks of Inpatient Rehabilitation",,"Recruiting","No Results Available","Crohn Disease|Ulcerative Colitis","Behavioral: Multimodal Rehabilitation","Faecal Calprotectin|Ced Disk|European Quality of Life 5 Dimensions 5 Level (EQ-5D-5L)|Patient Health Questionnaire-4 (PHQ-4)|Work ability index (WAI)","Pensionsversicherungsanstalt","All","Child, Adult, Older Adult",,"200","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","0008-CED","August 9, 2022","November 30, 2023","February 28, 2024","August 12, 2022",,"August 12, 2022","Rehabilitationszentrum Bad Aussee, Vienna, Styria, Austria",,"https://ClinicalTrials.gov/show/NCT05500040"
140,"NCT05500027","sCD8, as a Novel Biomarker for Pancreatic Cancer",,"Recruiting","No Results Available","Serum Biomarker|Pancreatic Cancer","Diagnostic Test: serum test","Differentiation expression of serum sCD58 and TGfbeta1 among pancreatic cancer and other conditions","Peking Union Medical College Hospital","All","18 Years to 85 Years   (Adult, Older Adult)",,"2000","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","JS-2954","May 1, 2021","December 2024","December 2025","August 12, 2022",,"August 12, 2022","Peking Union Medical College Hospital, Beijing, Beijing, China",,"https://ClinicalTrials.gov/show/NCT05500027"
141,"NCT05500014","Effect of Altitude on Iron Absorption in Iron Depleted Women","PotatoAlt","Recruiting","No Results Available","Iron Deficiency Anemia|Iron Deficiency (Without Anemia)|Altitude Hypoxia","Other: Biofortified potato, not genetically modified","Iron absorption|Serum ferritin (SF)|soluble transferrin receptor (sTfR)|C-Reactive Protein (CRP)|alpha acid glycoprotein (AGP)","Swiss Distance University of Applied Sciences|ETH Zurich (Switzerland)|Instituto de Investigacion Nutricional, Peru","Female","18 Years to 40 Years   (Adult)","Not Applicable","80","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","2022/01","August 20, 2022","October 31, 2022","December 31, 2022","August 12, 2022",,"August 12, 2022","Instituto International Nutrition, Huancavelica, Peru|Insituto National de Nutrition, Lima, Peru",,"https://ClinicalTrials.gov/show/NCT05500014"
142,"NCT05500001","Supporting Patients by Family Education in Psychotic Illness: A Prospective Cohort Study",,"Not yet recruiting","No Results Available","Psychotic Disorders|Family Members|Anosognosia|Paranoia","Behavioral: Supporting Patients by Family Education in Psychotic Illness Group","Family Burden Interview Schedule|Positive and Negative Symptom Schedule|Manchester Short Assessment of Quality of Life|Inpatient Readmission Rate|Inpatient Length of Stay|Inpatient Admission Frequency|Emergency Department Visit Frequency|Community Appointment Frequency|Crisis Service Frequency|Justice System Interactions|Resource Intensity Weight (RIW)","University of Alberta|Alberta Health services|Families Supporting Adults with Mental Illness-Alberta","All","17 Years to 27 Years   (Child, Adult)","Not Applicable","100","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","Pro00110691","September 1, 2022","September 1, 2025","September 1, 2025","August 12, 2022",,"August 12, 2022",,,"https://ClinicalTrials.gov/show/NCT05500001"
143,"NCT05499988","The Importance of Blastocyst Diamater and Its Correlation to Reproductive Outcomes in PGT-A Cases",,"Recruiting","No Results Available","Infertility",,"Blastocoele re-expansion degree|Pregnancy rate|Implantation rate|Blastocyst survival rate","Ganin Fertility Center","All","18 Years to 45 Years   (Adult)",,"1000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","GFC-006","August 7, 2022","December 31, 2023","December 31, 2023","August 12, 2022",,"August 12, 2022","Ganin Fertility Center, Cairo, Egypt",,"https://ClinicalTrials.gov/show/NCT05499988"
144,"NCT05499975","Comprehensive Health Assessment for my Cancer Treatment Plan","CHAMP-F","Not yet recruiting","No Results Available","Cancer|Older Adults","Other: Self-reported online geriatric assessment (CHAMP)","Completeness of the CHAMP tool|Time to fill out the CHAMP tool|Satisfaction with the CHAMP tool|Change in proposed treatment plan|Changes in supportive care strategies","University Health Network, Toronto","All","65 Years and older   (Older Adult)","Not Applicable","210","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","4011","September 15, 2022","June 10, 2023","June 30, 2023","August 12, 2022",,"August 12, 2022",,,"https://ClinicalTrials.gov/show/NCT05499975"
145,"NCT05499962","SNS and PrEP Initiation and Adherence in Black SMM",,"Recruiting","No Results Available","HIV","Behavioral: Social Networking Strategies","Feasibility of Intervention as measured by Weiner et al., 2017.|Acceptability of Intervention as measured by Weiner et al., 2017.|Recruited Network Members|Network members on PrEP|Comfortability of the Intervention as measured by an adaptation of Weiner et al., 2017.","Us Helping Us, People Into Living, Inc.","Male","18 Years and older   (Adult, Older Adult)","Not Applicable","30","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","21-USHE-104","March 1, 2022","May 2023","September 2023","August 12, 2022",,"August 12, 2022","Us Helping Us, People Into Living, Inc., Washington, District of Columbia, United States",,"https://ClinicalTrials.gov/show/NCT05499962"
146,"NCT05499949","The Franciscus Obesity NASH Study","FONS","Not yet recruiting","No Results Available","NAFLD|NASH - Nonalcoholic Steatohepatitis|Obesity, Morbid","Diagnostic Test: NASH screening|Diagnostic Test: Cardiac dysfunction screening|Diagnostic Test: Liver biopsy","Change from baseline in liver steatosis and fibrosis 5 years after bariatric surgery|Change from baseline in liver steatosis and fibrosis after lifestyle intervention|Change from baseline in liver steatosis and fibrosis 1 year after bariatric surgery|Change from baseline in liver steatosis and fibrosis 3 years after bariatric surgery|Change from baseline in liver steatosis and fibrosis according to the type of bariatric surgery|Change from baseline in liver steatosis and fibrosis according to the genetic profile|Change from baseline in liver fibrosis according to gender and ethnicities|Change from baseline in liver steatosis and fibrosis according to the gut microbiota|Association between NAFLD/NASH and vascular dysfunction|Association between NAFLD/NASH and cardiac dysfunction|Association between change in NAFLD/NASH and change in cardiac dysfunction|Correlation between histology and transient elastogrpahy measurement in a population with morbid obesity","Franciscus Gasthuis|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|Erasmus Medical Center|Leiden University Medical Center","All","18 Years to 65 Years   (Adult, Older Adult)",,"300","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","FONS","September 1, 2022","June 1, 2023","January 1, 2029","August 12, 2022",,"August 12, 2022","Franciscus Gasthuis, Rotterdam, Zuid Holland, Netherlands",,"https://ClinicalTrials.gov/show/NCT05499949"
147,"NCT05499936","68Ga-FAPI PET/CT for the Detection of Adenoid Cystic Carcinoma(ACC)",,"Recruiting","No Results Available","68Ga-FAPI PET/CT|Metastatic Adenoid Cystic Carcinoma","Drug: 68Ga-FAPI","Standardized uptake value of 68Ga-FAPI in ACC|lesions detected by 68Ga-FAPI PET/CT","Peking Union Medical College Hospital","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","30","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","PUMCHFAPI-ACC","October 1, 2021","October 1, 2022","December 31, 2022","August 12, 2022",,"August 12, 2022","Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China",,"https://ClinicalTrials.gov/show/NCT05499936"
148,"NCT05499923","Quantitative Measurement of ARI",,"Completed","No Results Available","Orthodontic Appliance Complication","Device: Debonding","Adhesive remnant index|Patient reported outcome: Pain","CMH Lahore Medical And Dental College","All","12 Years to 30 Years   (Child, Adult)","Not Applicable","148","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","ERC/CMH/LMC/621","October 1, 2021","June 1, 2022","June 21, 2022","August 12, 2022",,"August 12, 2022","Haris Khan, Lahore, Punjab, Pakistan",,"https://ClinicalTrials.gov/show/NCT05499923"
149,"NCT05499910","Neuro Strengths-Based Approach to Autism","NSBAA","Not yet recruiting","No Results Available","Autism Spectrum Disorder","Behavioral: NSBAA","Measurable change in the participant's satisfaction with their ability to write neuro-strength-based goals|Measurable change in participants' knowledge of the clinical reasoning for the goals they write|Measurable change in the completeness of the goals:","Baio Enterprises|Baio Institute","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","STUDY00015835","August 15, 2022","November 2022","December 2022","August 12, 2022",,"August 12, 2022",,,"https://ClinicalTrials.gov/show/NCT05499910"
150,"NCT05499897","The Effect of Interscalene Block on Wound Healing and Immunity in Open Shoulder Surgeries",,"Recruiting","No Results Available","Block, Immunity and Anesthesia","Procedure: ultrasoud guided interscalene block|Procedure: general anesthesia","immunity|wound healing","Yuzuncu Yıl University","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","40","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Other","2022/14","August 1, 2022","January 1, 2023","April 1, 2023","August 12, 2022",,"August 12, 2022","Van Yüzüncü Yil University, Van, Bardakçı, Turkey",,"https://ClinicalTrials.gov/show/NCT05499897"
151,"NCT05499884","Feasibility and Potential Aids of Intra-operative Endo-vaginal Ultrasound When Performing Rectal Shaving for Endometriosis","ECHOENDO","Not yet recruiting","No Results Available","Endometriosis","Procedure: Endovaginal ultrasound","Questioning the choice of surgical technique (performing a more complete procedure, such as discoid or segmental resection, immediately or after shaving)|anatomo-pathological analysis of the operating piece.","University Hospital, Lille","Female","18 Years and older   (Adult, Older Adult)","Not Applicable","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2021_0273|2022-A01264-39","December 2022","December 2024","December 2024","August 12, 2022",,"August 12, 2022",,,"https://ClinicalTrials.gov/show/NCT05499884"
152,"NCT05499871","Effect of Forefoot Strike Pattern and Minimalist Footwear in Endurance Runners on Foot-ankle Strength, Running Economy and Injury.",,"Enrolling by invitation","No Results Available","Running|Wounds and Injuries|Oxygen Consumption","Behavioral: Footstrike pattern modification toward a more forefootstrike pattern.|Device: Transition to minimalist footwear.|Other: Control","Change in foot-ankle strength|Change in running economy|Running-related-injuries","University of Liege","All","18 Years to 55 Years   (Adult)","Not Applicable","75","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","09082022","June 1, 2022","September 12, 2022","September 30, 2023","August 12, 2022",,"August 12, 2022","Guillaume Abran, Liège, Belgium",,"https://ClinicalTrials.gov/show/NCT05499871"
153,"NCT05499858","Evaluating Effectiveness of Spices and Herbs to Increase Vegetable Intake Among Military",,"Not yet recruiting","No Results Available","Dietary Intake","Other: Spiced|Other: Plain","Vegetable consumption","Uniformed Services University of the Health Sciences|University of Maryland, Baltimore|Nova Institute for Health|Henry M. Jackson Foundation for the Advancement of Military Medicine|Pennington Biomedical Research Center|McCormick Science Institute","All","18 Years and older   (Adult, Older Adult)","Not Applicable","400","U.S. Fed|Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","USUHS- 2022-105","September 6, 2022","February 28, 2023","March 31, 2023","August 12, 2022",,"August 12, 2022","Naval Support Activity Bethesda, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT05499858"
154,"NCT05499845","Effects of Different Anesthesia on Odor Memory",,"Completed","No Results Available","Smell Functions|Odor Memory","Diagnostic Test: butanol threshold test and smell identification tests","Butanol Threshold Test|Odor Identification Test","Zonguldak Bulent Ecevit University","All","18 Years to 60 Years   (Adult)",,"97","Other","Observational","Observational Model: Other|Time Perspective: Prospective","2013/02","January 1, 2013","June 30, 2013","July 1, 2013","August 12, 2022",,"August 12, 2022","Gamze Küçükosman, Zonguldak, Turkey",,"https://ClinicalTrials.gov/show/NCT05499845"
155,"NCT05499832","Safety and Efficacy of Intra-arterial Tenecteplase for Noncomplete Reperfusion of Intracranial Occlusions","TECNO","Not yet recruiting","No Results Available","Ischemic Stroke","Drug: Tenecteplase","Early reperfusion of the residual intracranial occlusion(s)|Late reperfusion of the residual intracranial occlusion(s)|Degree of disability or dependence assessed by the modified ranking scale (mRS) (shift analysis)|Normalized change in National Institute of Health Score Scale (NIHSS)|Change in National Institute of Health Score Scale (NIHSS)|Quality of life as assessed by the EuroQol 5D-3L (EQ-5D-3L)|All-cause mortality","University Hospital Inselspital, Berne","All","18 Years and older   (Adult, Older Adult)","Phase 3","156","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","2022-00388","September 1, 2022","July 31, 2025","October 31, 2025","August 12, 2022",,"August 12, 2022","Universitätsspital Bern, Bern, Switzerland",,"https://ClinicalTrials.gov/show/NCT05499832"
156,"NCT05499819","Effect of Beans Compared to Beef on Satiety in Older Adults",,"Recruiting","No Results Available","Older Adults","Other: Canned black beans, drained and rinsed|Other: Canned red kidney beans, drained and rinsed|Other: Extra-lean ground beef","Subjective appetite sensations|Food intake at an ad libitum pizza meal|24-hour energy intake","University of Guelph|Ontario Bean Growers","All","60 Years and older   (Adult, Older Adult)","Not Applicable","35","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other","REB-22-03-028","May 18, 2022","May 18, 2023","May 18, 2023","August 12, 2022",,"August 12, 2022","Human Nutraceutical Research Unit, Guelph, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT05499819"
157,"NCT05499806","Cohort Study on the Effects of Aging in Acquired Brain Injury Patients","BRAINReADAPT","Enrolling by invitation","No Results Available","Acquired Brain Injury|Subarachnoid Hemorrhage|Traumatic Brain Injury|Cerebrovascular Accident",,"Prevalence of the ABI-effect|Cognitive functions of patients and healthy volunteers","University Medical Center Groningen|ZonMw: The Netherlands Organisation for Health Research and Development","All","50 Years to 67 Years   (Adult, Older Adult)",,"800","Other","Observational","Observational Model: Cohort|Time Perspective: Other","NL79072.042.21","March 18, 2022","March 1, 2023","February 1, 2024","August 12, 2022",,"August 12, 2022","Isala klinieken, Zwolle, Overijssel, Netherlands|Revalidatiecentrum Heliomare Wijk aan Zee, Wijk Aan Zee, Netherlands",,"https://ClinicalTrials.gov/show/NCT05499806"
158,"NCT05499793","Impact of Ginger on Menopausal Symptoms",,"Completed","No Results Available","Menopause","Dietary Supplement: Zingiber Officinale powder|Dietary Supplement: Placebo","Impact of Zingiber Officinale on hot flush in menopausal women|Impact of Zingiber Officinale on Night sweating in menopausal women|Impact of Zingiber Officinale on estrogen levels in menopausal women|Impact of Zingiber Officinale on body weight in menopausal symptoms","University of Duhok","Female","45 Years to 60 Years   (Adult)","Not Applicable","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","24102021-10-36","December 1, 2021","March 1, 2022","June 1, 2022","August 12, 2022",,"August 12, 2022","University of Duhok College of Pharmacy, Duhok, Kurdistan Region, Iraq",,"https://ClinicalTrials.gov/show/NCT05499793"
159,"NCT05499780","Study on Performance and Safety of Sentinox in the Prevention of Acute Respiratory Infections (ARI)",,"Not yet recruiting","No Results Available","Healthy Volunteers","Device: Sentinox","To evaluate the performance of self-administered Sentinox intranasal spray in preventing ARI caused by at least one respiratory virus|To assess the performance of Sentinox in preventing ARI caused by different respiratory viruses|To assess the performance of Sentinox intranasal administration against bacterial infection|To assess the performance of Sentinox in preventing clinically defined ARI without microbiological confirmation|To evaluate subjects' satisfaction of self -administering Sentinox|To evaluate the tolerability and safety of Sentinox","APR Applied Pharma Research s.a.","All","18 Years to 63 Years   (Adult)","Not Applicable","1458","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","STX-2022","October 1, 2022","March 30, 2024","June 1, 2024","August 12, 2022",,"August 12, 2022","Ospedale Policlinico San Martino IRCCS, Genova, Italy",,"https://ClinicalTrials.gov/show/NCT05499780"
160,"NCT05499767","HEPPI: Effectiveness of a Cognitive-Emotional Intervention for Homebound Older Adults","HEPPI","Recruiting","No Results Available","Mild Cognitive Impairment|Depressive Symptoms|Anxiety State","Behavioral: HEPPI","Changes in Episodic Memory|Changes in Depressive Symptomatology|Changes in Anxious Symptomatology|Changes in General Cognitive Function|Changes in Attentional Control|Changes in Subjective Memory Complaints|Changes in Perceived Quality of Life|Changes in Functional Status|Changes in Loneliness","University of Coimbra|Foundation for Science and Technology (FCT)","All","65 Years and older   (Older Adult)","Not Applicable","198","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Supportive Care","HEPPIEffectiv/CINEICC|SFRH/BD/146170/2019","September 1, 2021","March 2023","March 2023","August 12, 2022",,"August 12, 2022","Center for Research in Neuropsychology and Cognitive Behavioral Intervention (CINEICC), Coimbra, Portugal",,"https://ClinicalTrials.gov/show/NCT05499767"
161,"NCT05499754","Effect of Different Supralottic Airway Devicess on Optic Nerve Sheath Diameter",,"Completed","No Results Available","Intracranial Pressure Increase|Supraglottic Airway Device|Optic Nerve Sheath Diameter","Other: pLMA: PROSEAL LARYNGEAL MASK, sLMA : SUPREMA LARYNGEAL MASK, I-jel =I-GEL","OPTIC NERVE SHEATH DIAMETER","Zonguldak Bulent Ecevit University","All","18 Years to 65 Years   (Adult, Older Adult)",,"90","Other","Observational","Observational Model: Other|Time Perspective: Prospective","2019/09","July 1, 2019","July 30, 2020","July 30, 2020","August 12, 2022",,"August 12, 2022","Gamze Küçükosman, Zonguldak, Turkey",,"https://ClinicalTrials.gov/show/NCT05499754"
162,"NCT05499741","Forehead Temperature-Regulating Therapy for Insomnia in Adults With Tourette's Disorder",,"Not yet recruiting","No Results Available","Tourette's Disorder|Insomnia","Device: Forehead Temperature-Regulating Therapy","Actigraphy - Sleep Onset Latency|Actigraphy - Wake After Sleep Onset|Depression Anxiety Stress Scale (DASS)-21 - Depression|Depression Anxiety Stress Scale (DASS)-21 - Anxiety|Epworth Sleepiness Scale (ESS)","University of California, Los Angeles|Brain & Behavior Research Foundation","All","18 Years to 50 Years   (Adult)","Not Applicable","25","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","22-000432|30464","August 2022","August 2024","September 2024","August 12, 2022",,"August 12, 2022","Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles, Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT05499741"
163,"NCT05499728","Telerehabilitation After Shoulder Arthroplasty",,"Enrolling by invitation","No Results Available","Arthritis Shoulder Glenohumoral Joint|Rotator Cuff Tear Arthropathy|Arthropathy Shoulder","Other: Telerehabilitation; physical therapy via telecommunication device (i.e. online video conferencing)","Shoulder range of motion|American Shoulder and Elbow Surgeons score|PROMIS Pain Interference|PROMIS Global Health score|Visual Analog Scale for Pain","Olivia C. O'Reilly|University of Iowa","All","18 Years and older   (Adult, Older Adult)","Not Applicable","140","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","202104097","August 18, 2021","July 31, 2025","January 1, 2026","August 12, 2022",,"August 12, 2022","Brendan Patterson, Iowa City, Iowa, United States",,"https://ClinicalTrials.gov/show/NCT05499728"
164,"NCT05499715","A Phase I Clinical Study to Evaluate the Safety, the Tolerability, the Pharmacokinetic Characteristics and the Efficacy of ScTIL Injection (Genetically Modified Tumor Infiltrating Lymphocytes) in the Treatment of Advanced Malignant Solid Tumors",,"Not yet recruiting","No Results Available","Advanced Tumor of Digestive Tract or Urinary System","Biological: ScTIL injection","Objective Response Rate (ORR)|Disease Control Rate (DCR)|Duration of Response (DOR)|Progression-Free Survival (PFS)|Overall survival (OS)|Adverse events (AEs)|Detection of Lentivirus Copy Number","Chinese Academy of Medical Sciences|Beijing ChineoMedical Technology Co., Ltd","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1","48","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ScTIL-008-2022","September 30, 2022","May 30, 2024","August 30, 2024","August 12, 2022",,"August 12, 2022","Cancer Hospital & Institute, Chinese Academy of Medical Sciences, Beijing, China",,"https://ClinicalTrials.gov/show/NCT05499715"
165,"NCT05499702","The Effects of Glucagon on Hepatic Metabolism in People With Type 2 Diabetes After Caloric Restriction",,"Not yet recruiting","No Results Available","Type2diabetes","Behavioral: Caloric Restriction|Drug: Hyperglycemic clamp","Rate of leucine oxidation in response to rising glucagon concentrations","Adrian Vella|Mayo Clinic","All","25 Years to 65 Years   (Adult, Older Adult)","Phase 2","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","22-000233","December 1, 2022","December 30, 2024","March 31, 2025","August 12, 2022",,"August 12, 2022","Mayo Clinic in Rochester, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT05499702"
166,"NCT05499689","Transcutaneous Pulsed Radiofrequency in Migraine",,"Active, not recruiting","No Results Available","Migraine Disorders","Drug: Bupivacaine Hydrochloride|Other: Transcutaneous pulsed radiofrequency qurrent","The Migraine Disability Assessment Test|Visual analog scale (VAS)","Diskapi Teaching and Research Hospital","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Transcutaneous GON","June 22, 2021","December 22, 2022","June 22, 2023","August 12, 2022",,"August 12, 2022","Diskapi Yildirim Beyazıt Teaching and Research Hospital, Ankara, Altındğ, Turkey",,"https://ClinicalTrials.gov/show/NCT05499689"
167,"NCT05499676","Helping HAND: Healing Anorexia Nervosa Digitally",,"Not yet recruiting","No Results Available","Anorexia Nervosa","Device: SilverCloud Health Mobile Intervention|Device: Social Networking Intervention: Facebook","1. Effectiveness of the mobile app conditions, compared to referral to usual care, in changing eating disorder psychopathology, as assessed by the Eating Disorder Examination-Questionnaire.|Effectiveness of the mobile app conditions, compared to referral to usual care, in changing eating disorder behaviors.|Effectiveness of the mobile app conditions, compared to referral to usual care, in changing Body Mass Index (BMI).|Effectiveness of the mobile app conditions, compared to referral to usual care, in changing depression and suicidal ideation, as assessed by the Patient Health Questionnaire.|Effectiveness of the mobile app conditions, compared to referral to usual care, in changing clinical impairment, as assessed by the Clinical Impairment Assessment.","Washington University School of Medicine|National Institute of Mental Health (NIMH)","Female","18 Years and older   (Adult, Older Adult)","Not Applicable","90","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","202202113|R34MH127203","October 1, 2022","December 1, 2023","December 1, 2023","August 12, 2022",,"August 12, 2022","Palo Alto University, Palo Alto, California, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Columbia University, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT05499676"
168,"NCT05499663","Title: Leveraging Technology to Address Health Outcomes of Cancer Survivors","POSTHOC","Not yet recruiting","No Results Available","Survivorship|Cancer|Symptoms and Signs","Behavioral: POSTHOC app","Cumulative number of times participants log/view data in the app|Usefulness|Likely to recommend|Cumulative Symptom Burden","University of Maryland, Baltimore|National Cancer Institute (NCI)|Charles River Analytics","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","54","Other|NIH|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","HP-00100473|75N91021C00019-0-9999-1","November 2022","July 2025","July 2026","August 12, 2022",,"August 12, 2022",,,"https://ClinicalTrials.gov/show/NCT05499663"
169,"NCT05499650","The Effects of Exercise on Quality of Life and Fluid Dynamics in Patients With Aortic Dissection",,"Not yet recruiting","No Results Available","Aortic Dissection","Behavioral: Supervised Exercise Regiment","Health related Quality of Life (HRQOL) scores|Physical Activity Scale for the Elderly (PASE) scores|Aortic Shear Stress|Maximal oxygen consumption during Exercise (V02 Max)|Number of aortic related hospitalization","University of Maryland, Baltimore|University of Maryland, College Park","All","18 Years to 88 Years   (Adult, Older Adult)","Not Applicable","5","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HP-00099260","September 15, 2022","June 30, 2023","June 30, 2024","August 12, 2022",,"August 12, 2022",,,"https://ClinicalTrials.gov/show/NCT05499650"
170,"NCT05499637","[68Ga]Ga-PentixaFor PET/CT in Acute Myocardial Inflammation",,"Not yet recruiting","No Results Available","Acute Cellular Graft Rejection|Cardiac Sarcoidosis|Myocarditis Due to Drug","Drug: [68Ga]Ga-PentixaFor PET/CT","Imaging results obtained by [68Ga]Ga-PentixaFor PET/CT - lesion number|Imaging results obtained by [68Ga]Ga-PentixaFor PET/CT - lesion site|Imaging results obtained by [68Ga]Ga-PentixaFor PET/CT - SUV|to assess toxicity data","John O. Prior|University of Lausanne Hospitals","All","18 Years and older   (Adult, Older Adult)","Phase 2","69","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","2022-00425","August 2022","July 2023","September 2023","August 12, 2022",,"August 12, 2022","Centre Hospitalier Universitaire Vaudois, Lausanne, Vaud, Switzerland",,"https://ClinicalTrials.gov/show/NCT05499637"
171,"NCT05499624","POMCO2 Clinical Study MicroTrend System pCO2 Sensor",,"Not yet recruiting","No Results Available","Hypoperfusion","Device: MicroTrend System","Correlation between POMCO2","ExoStat Medical, Inc.|Bright Research Partners","All","22 Years and older   (Adult, Older Adult)","Not Applicable","15","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","EXO-CL-5000","September 2022","October 2022","October 2022","August 12, 2022",,"August 12, 2022","Captain James A. Lovell Federal Health Care Center, North Chicago, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT05499624"
172,"NCT05499611","Impact of Optical Genome Mapping in Acute Myeloblastic Leukemia","COALA","Not yet recruiting","No Results Available","Acute Myeloblastic Leukemia",,"Proportion of patients with more abnormalities detected by OGM than by conventional cytogenetics|Average number of additional abnormalities detected by OGM compared to conventional techniques|Proportion of patients reclassified as complex and/or monosomal karyotype according to current ELN definitions|Proportion of patients for whom a change in therapeutic management could have been proposed|Comparison of overall survival and event-free survival curves of patients reclassified to the unfavorable group to those of the intermediate and unfavorable groups in a historical cohort|Interobserver reproducibility for interpretation of OGM results (Fleiss Kappa coefficient)","University Hospital, Bordeaux","All","18 Years to 65 Years   (Adult, Older Adult)",,"120","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","CHUBX 2022/28","October 2022","April 2023","October 2023","August 12, 2022",,"August 12, 2022",,,"https://ClinicalTrials.gov/show/NCT05499611"
173,"NCT05499598","Evaluation of Modified Minimally Invasive Surgical Technique and Platelet Rich Fibrin With or Without Vitamin Pool A and C for Management of Periodontal Intrabony Defects",,"Not yet recruiting","No Results Available","Intrabony Periodontal Defect","Procedure: Experimental: Modified minimally invasive surgical technique with PRF and vitamins A and C|Procedure: Modified minimally invasive surgical technique with PRF","Radiographic linear defect depth (mm)|Probing depth (mm)|Clinical Attachment Level (mm)|Gingival Recession Depth (mm)","Cairo University","All","18 Years to 60 Years   (Adult)","Not Applicable","28","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","PERAUG2022","September 2022","November 1, 2022","October 30, 2023","August 12, 2022",,"August 12, 2022","Cairo University, Cairo, Egypt",,"https://ClinicalTrials.gov/show/NCT05499598"
174,"NCT05499585","Treating Pediatric NAFLD With Nutrition",,"Recruiting","No Results Available","Non-Alcoholic Fatty Liver Disease|Liver Diseases|Liver Fat|Hepatic Steatosis|Nutritional and Metabolic Disease","Other: Nutrition","Change in hepatic steatosis measured by liver MRI-PDFF|Change in serum alanine transaminase (ALT)|Change in serum aspartate transaminase (AST)|Change in serum gamma-glutamyl transpeptidase (GGT)|Change in serum total cholesterol|Change in serum LDL-cholesterol|Change in serum HDL-cholesterol|Change in serum triglycerides|Change in plasma fatty acid levels|Change in subcutaneous adipose tissue (SCAT)|Change in visceral adipose tissue (VAT)","University of California, San Diego","All","10 Years to 17 Years   (Child)","Not Applicable","20","Other","Interventional","Allocation: N/A|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","803602","August 2022","December 2023","March 2024","August 12, 2022",,"August 12, 2022","UC San Diego, La Jolla, California, United States",,"https://ClinicalTrials.gov/show/NCT05499585"
175,"NCT05499572","Usability of Levodopa Cyclops™ vs INBRIJA® in Parkinson's Patients","DPI-6","Not yet recruiting","No Results Available","Usability","Device: Inhalation maneuver with placebo Inbrija and placebo Cyclops","Correct performance of inhalation maneuvers|Inhaler preference of Parkinson patients","Martini Hospital Groningen","All","18 Years and older   (Adult, Older Adult)",,"16","Other","Observational","Observational Model: Other|Time Perspective: Prospective","NL82043.099.22","October 1, 2022","October 1, 2023","October 1, 2023","August 12, 2022",,"August 12, 2022",,,"https://ClinicalTrials.gov/show/NCT05499572"
176,"NCT05499559","Effects of 12-week Digital Treatment in Patients With Hand OA on Pain and Function",,"Recruiting","No Results Available","Hand Osteoarthritis|Wrist Osteoarthritis|Thumb Osteoarthritis|Finger Osteoarthritis","Behavioral: Joint Academy digital treatment","Change of pain intensity|Functional Index for Hand OsteoArthritis (FIHOA)","Joint Academy|Lund University","All","18 Years and older   (Adult, Older Adult)",,"500","Industry|Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","HandOA2022","April 1, 2022","October 15, 2022","December 1, 2022","August 12, 2022",,"August 12, 2022","Joint Academy, Malmö, Skåne, Sweden",,"https://ClinicalTrials.gov/show/NCT05499559"
177,"NCT05499546","Virtual Scale Function SCALE EYE: Variability and Systematic Differences","SCALE EYE","Not yet recruiting","No Results Available","Polyp of Colon","Device: SCALE EYE","Differences in residual variance expert endoscopists|Systematic differences expert endoscopists|Differences in residual variance and systematic differences fellow endoscopists|Inter-observer variability|SCALE EYE measurement accuracy compared to snare measurement|SCALE EYE measurement accuracy compared to snare measurement for different polyp size groups|SCALE EYE success rate|SCALE EYE measurement time|SCALE EYE satisfaction score","Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","All","18 Years and older   (Adult, Older Adult)","Not Applicable","66","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","NL81269.018.22","September 2022","December 2022","February 2023","August 12, 2022",,"August 12, 2022","Academic Medical Centre, Amsterdam, Noord-Holland, Netherlands",,"https://ClinicalTrials.gov/show/NCT05499546"
178,"NCT05499533","Hybrid Funnel Technique a Innovative Technique for Implant Site Preparation.",,"Recruiting","No Results Available","Missing Teeth|Edentulous Alveolar Ridge|Tooth Loss","Procedure: implant site preparation","Marginal bone loss|Implant stability|Insertion torque curve","Luigi Canullo|Studio Odontoiatrico Associato Dr. P. Cicchese e L. Canullo","All","30 Years to 85 Years   (Adult, Older Adult)","Not Applicable","80","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ABT3","July 29, 2022","December 30, 2023","December 30, 2023","August 12, 2022",,"August 12, 2022","Studio Odont.Associato Dr.P.Cicchese E L.Canullo, Rome, Italy/Rome, Italy",,"https://ClinicalTrials.gov/show/NCT05499533"
179,"NCT05499520","Project RESIST: Evaluating the Effects of Anti-smoking Inoculation Messages Among Young Adult Sexual Minority Women",,"Not yet recruiting","No Results Available","Cigarette Smoking Behavior","Other: Culturally Tailored Anti-Smoking Messages","Change in intention to quit smoking|Change in intention to purchase cigarettes","Abramson Cancer Center of the University of Pennsylvania|National Cancer Institute (NCI)|Harvard School of Public Health (HSPH)|Stanford University|Dana-Farber Cancer Institute|Fenway Community Health","All","18 Years to 30 Years   (Adult)","Not Applicable","3000","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Single (Participant)|Primary Purpose: Prevention","11022|R01CA237670","September 15, 2022","May 15, 2023","June 15, 2023","August 12, 2022",,"August 12, 2022","University of Pennsylvania, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT05499520"
180,"NCT05499507","The Path to Optimal Black Maternal Heart Health: Comparing Two CVD Risk Reduction Interventions (Change of HEART)",,"Not yet recruiting","No Results Available","Pregnancy Related|Hypertension|Obesity|Racism","Behavioral: COH|Behavioral: COH+","Change in blood pressure at 6-weeks postpartum.|Change in blood pressure at 12-months postpartum.|Change in body weight at 6-weeks postpartum.|Change in body weight at 12-months postpartum.|Change in emotional support at 6-weeks postpartum.|Change in emotional support at 12-months postpartum.|Change in informational support at 6-weeks postpartum.|Change in informational support at 12-months postpartum.|Change in Perinatal Mood and Anxiety Disorders (PMADs) at 6-weeks postpartum.|Change in PMADs at 12-months postpartum.|Mothers autonomy in decision making at baseline.|Mothers autonomy in decision making at 6-weeks postpartum.|Respectful maternity care at baseline.|Respectful maternity care at 6-weeks postpartum.|Obstetric mistreatment at baseline.|Obstetric mistreatment at 6-weeks postpartum|Blood pressure control at 6-weeks postpartum for patients with hypertension (HTN) at baseline.|Blood pressure control at 12-months postpartum for patients with hypertension at baseline.|Incident hypertension at 6-weeks postpartum for patients who were normotensive at baseline.|Incident hypertension at 12-months postpartum for patients who were normotensive at baseline.|Breast/Chestfeeding initiation.|Breast/Chestfeeding duration.|Breastfeeding support/self-efficacy at 6-weeks postpartum.|Breastfeeding support/self-efficacy at 12-months postpartum.|Mode of delivery.|Infant birth weight.|Preterm birth.|Blood pressure change at 32-34 weeks gestation.|Blood pressure change at 1 week postpartum.|Blood pressure change at 12 weeks postpartum.","Temple University|Patient-Centered Outcomes Research Institute","Female","18 Years and older   (Adult, Older Adult)","Not Applicable","432","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","27919","November 1, 2022","July 10, 2026","October 10, 2026","August 12, 2022",,"August 12, 2022",,,"https://ClinicalTrials.gov/show/NCT05499507"
181,"NCT05499494","Clinical Evaluation of Bioactive Injectable Resin Composite in Posterior Restorations",,"Not yet recruiting","No Results Available","Dental Restoration Failure","Other: Beautifil Flow Plus X F00 injectable composite|Other: Tetric N ceram resin composite","Change in the clinical performance","Cairo University","All","20 Years to 50 Years   (Adult)","Not Applicable","26","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","Injectable resin composite","August 2022","February 2024","March 2024","August 12, 2022",,"August 15, 2022","Faculty of dentistry, Cairo University, Cairo, Egypt",,"https://ClinicalTrials.gov/show/NCT05499494"
182,"NCT05499481","Short Against Long Antibiotic Therapy for Infected Orthopedic Sites","SALATIO","Not yet recruiting","No Results Available","Orthopedic Devices Associated With Misadventures|Infection, Surgical Site|Antibiotic Side Effect","Drug: Antibiotic","Clinical remission related to the duration of total, postdebridement, antibiotic use|Microbiological recurrence in relation to the total, postdebridement, antibiotic use|Description of all clinical failures of any sort|Adverse events in each study arm, and in relation to the antibiotics used|Length of hospital stay in acute care surgery (without rehabilitation)","Balgrist University Hospital","All","18 Years and older   (Adult, Older Adult)","Phase 3","240","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BASEC 2022-01012","September 15, 2022","September 15, 2024","September 30, 2025","August 12, 2022",,"August 12, 2022","Balgrist University Hospital, Zurich, Switzerland",,"https://ClinicalTrials.gov/show/NCT05499481"
183,"NCT05499468","Evaluating a Physician Opinion Leader Intervention to Increase Utilization of Coaching/Therapy During Residency","POL","Not yet recruiting","No Results Available","Workplace Culture|Help-Seeking Behavior|Social Stigma|Education, Medical, Continuing","Other: Popular-Opinion Leader-led encouragement during training meetings and informal conversation","Number of participants enrolled in WellConnect program|Score in ""Disclosure and Help-Seeking"" Subscale of the Opening Minds Stigma Scale for Health Care Providers (from administratively collected institutional wellness survey data)|Response to standardized question from the National Comorbidity Survey (""Attitudes Regarding Help Seeking"" item) from administratively collected institutional wellness survey data|Stanford Professional Fulfillment Index Score (from administratively collected institutional wellness survey data)|Self-Valuation Index Score (from administratively collected institutional wellness survey data)","Stanford University|The Physicians Foundation","All","Child, Adult, Older Adult","Not Applicable","493","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","60993","August 30, 2022","October 11, 2022","October 11, 2022","August 12, 2022",,"August 12, 2022","Stanford Medicine, Palo Alto, California, United States",,"https://ClinicalTrials.gov/show/NCT05499468"
184,"NCT05499455","SleepPOSAtive Trial",,"Recruiting","No Results Available","Obstructive Sleep Apnea of Child","Device: Positional Sleep Belt|Device: Control","Obstructive apnea-hypopnea index|Comfort score|Arousal index|Oxygen desaturation index|Percentage of total sleep time supine","The Hospital for Sick Children","All","4 Years to 18 Years   (Child, Adult)","Not Applicable","40","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment","REB1000077578","February 13, 2022","June 1, 2024","June 1, 2024","August 12, 2022",,"August 12, 2022","The Hospital for Sick Children, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT05499455"
185,"NCT05499442","EEG Motor Movement and Imagery Dataset for Stroke",,"Recruiting","No Results Available","Acute Stroke",,"EEG characteristics of motor|Action Research Arm Test|Fugl-meyer Assessment","Xuanwu Hospital, Beijing","All","18 Years and older   (Adult, Older Adult)",,"120","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","haojunwei8","January 1, 2022","December 1, 2023","December 31, 2023","August 12, 2022",,"August 12, 2022","Xuanwu Hospital, Beijing, Beijing, Beijing, China",,"https://ClinicalTrials.gov/show/NCT05499442"
186,"NCT05499429","Non-invasive Transcranial Focused Low-intensity Ultrasound Stimulation in Patients With Mild Lewy Body Dementia","tFUS in DLB","Not yet recruiting","No Results Available","Lewy Body Dementia","Device: Transcranial low intensity focused ultrasound stimulation","Clinical Global Impression Scale|resting EEG|head MRI","Xuanwu Hospital, Beijing","All","50 Years to 85 Years   (Adult, Older Adult)","Not Applicable","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","[2022]110","September 2022","January 2026","November 2026","August 12, 2022",,"August 12, 2022","Xuanwu Hospital, Capital Medical University., Beijing, China",,"https://ClinicalTrials.gov/show/NCT05499429"
187,"NCT05499416","Effect of Bimekizumab in Patients With Psoriasis Vulgaris and Active Psoriatic Arthritis",,"Not yet recruiting","No Results Available","Psoriasis Vulgaris|Active Psoriatic Arthritis","Drug: Bimekizumab","Physician Global Assessment (PGA) x Body Surface Area (BSA)|Proportion of patients achieving MDA|Physician Global Assessment (PGA)|Body Surface Area (BSA)|Psoriasis Area and Severity Index (PASI)|American College of Rheumatology (ACR)|Tender joints count (TJC)|Swollen joints count (SJC)|Physician's Global Assessment of Arthritis Visual Analogue Scale (MDGA VAS)|Patient's Assessment of Arthritis Pain Visual Analogue Scale (patient pain VAS)|Patient's Global Assessment of Arthritis Visual Analogue Scale (PtGA VAS)|Spondyloarthritis Research Consortium of Canada Enthesitis Index (SPARCC)|Leeds Enthesitis Index (LEI)|Dactylitis Count|Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)|Health Assessment Questionnaire-Disability Index (HAQ-DI)|Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F)","Innovaderm Research Inc.|Ciusss de L'Est de l'Île de Montréal","All","18 Years and older   (Adult, Older Adult)","Phase 4","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","INNO-5031","September 2022","September 2023","April 2024","August 12, 2022",,"August 12, 2022",,,"https://ClinicalTrials.gov/show/NCT05499416"
188,"NCT05499403","Treatment faIlure in Osteoporosis","TAILOR","Recruiting","No Results Available","Osteoporosis|Treatment Failure",,"incidence of treatment failure (TF)|risk factors (odds ratio)","Centre Hospitalier Universitaire Vaudois","Female","Child, Adult, Older Adult",,"400","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","TAILOR","May 1, 2022","December 30, 2022","January 31, 2023","August 12, 2022",,"August 12, 2022","Patrizia D'amelio, Lausanne, Switzerland",,"https://ClinicalTrials.gov/show/NCT05499403"
189,"NCT05499390","A Phase III Trial of AK112 in Advanced Non-Small Cell Lung Cancer",,"Not yet recruiting","No Results Available","Advanced Non-small-cell Lung Cancer","Drug: AK112|Drug: Pembrolizumab","PFS assessed by IRRC per RECIST v1.1|OS|ORR assessed by IRRC per RECIST v1.1|DoR assessed by IRRC per RECIST v1.1|DCR assessed by IRRC per RECIST v1.1|TTR assessed by IRRC per RECIST v1.1|PFS assessed by investigator per RECIST v1.1|ORR assessed by the investigator per RECIST v1.1|DoR assessed by the investigator per RECIST v1.1|DCR assessed by the investigator per RECIST v1.1|TTR assessed by the investigator per RECIST v1.1|AE|ADA|PD-L1 expression","Akeso","All","18 Years and older   (Adult, Older Adult)","Phase 3","388","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","AK112-303","September 15, 2022","June 17, 2024","June 17, 2025","August 12, 2022",,"August 12, 2022","Shanghai Pulmonary Hospital, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT05499390"
190,"NCT05499377","The Abuse Liability of a Novel Heated Tobacco Product (IQOS) and Its Feasibility as a Menthol Cigarette Substitute",,"Not yet recruiting","No Results Available","Tobacco Use","Device: Tobacco product administration and assessment","Change in Average Daily Cigarette Use|Willingness to Substitute from Cigarettes to HTPs|Plasma Nicotine Delivery|Puff Topography (Puff Duration)|Cigarette Craving Suppression","Virginia Commonwealth University|National Institute on Drug Abuse (NIDA)","All","21 Years and older   (Adult, Older Adult)","Not Applicable","50","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","HM20024873","October 2022","March 2024","March 2024","August 12, 2022",,"August 12, 2022","Virginia Commonwealth University, Richmond, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT05499377"
191,"NCT05499364","TinCat LGBTQ+ Smoking Cessation Via Asynchronous Telehealth",,"Not yet recruiting","No Results Available","Tobacco Use Disorder|Tobacco Use Cessation","Behavioral: TinCat|Behavioral: Quit.gov program","Tobacco use","University of Texas at Austin","All","18 Years and older   (Adult, Older Adult)","Not Applicable","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","STUDY00003092","January 1, 2023","April 30, 2023","June 30, 2023","August 12, 2022",,"August 12, 2022",,,"https://ClinicalTrials.gov/show/NCT05499364"
192,"NCT05499351","A Study of Booster Immunization With COVID-19 Vaccine,Inactivated Co -Administration With Influenza Vaccine and Pneumococcal Polysaccharide Vaccine",,"Completed","No Results Available","COVID-19","Biological: Adult group in immunogenicity and safety study of combined immunization|Biological: Elderly group in immunogenicity and safety study of combined immunization|Biological: Adult group in safety observation study of combined immunization|Biological: Elderly group in safety observation study of combined immunization","Immunogenicity index of seroconversion rate of the neutralizing antibody|Immunogenicity index of seropositivity rate of the neutralizing antibody|Immunogenicity index of GMT of the neutralizing antibody|Immunogenicity index of GMI of the neutralizing antibody|Immunogenicity index of seroconversion rate of 23 pneumonia antibodies|Immunogenicity index of GMC increase of 23 pneumonia antibodies|Immunogenicity index of seroconversion rate of 4 influenza antibodies|Immunogenicity index of GMT of 4 influenza antibodies|Immunogenicity index of GMI of 4 influenza antibodies|Immunogenicity index of protection rate of 4 influenza antibodies","Sinovac Biotech Co., Ltd","All","18 Years and older   (Adult, Older Adult)","Phase 4","3000","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","PRO-nCOV-MA4005-BJ","October 15, 2021","December 5, 2021","May 5, 2022","August 12, 2022",,"August 12, 2022","Beijing Centers for Diseases Control and Prevention, Beijing, China",,"https://ClinicalTrials.gov/show/NCT05499351"
193,"NCT05499338","Motivation as a Strategy for Adherence to a Stretching Program for Basketball Players","MOTBAS","Completed","No Results Available","Motivation|Sports Physical Therapy|Muscle Tightness","Procedure: Stretching program","Extensibility of the posterior musculature|Adductor extensibility|Gastrocnemius and soleus extensibility|Hamstring extensibility|Extensibility of the quadriceps|Extensibility of the psoas|Motivation|Adherence to the programme|Age|Gender|Height|Hypermobility","University Rovira i Virgili","All","12 Years to 13 Years   (Child)","Not Applicable","21","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Prevention","123/2018_2","September 1, 2019","May 27, 2020","June 30, 2020","August 12, 2022",,"August 12, 2022","Federación Catalana de Baloncesto, Barcelona, Spain",,"https://ClinicalTrials.gov/show/NCT05499338"
194,"NCT05499325","Requests for Medical Termination of Pregnancy for Psychological or Social Maternal Reasons",,"Not yet recruiting","No Results Available","Pregnancy Related",,"age|place of life|social security|level of studies|occupation / resources|marital status|number of children|native country|recent life events|migratory route|medical and surgical history|gynecological follow-up, and follow-up of the current pregnancy","Centre Hospitalier de Saint-Denis","Female","Child, Adult, Older Adult",,"120","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","CHSD_0028_MATER","August 17, 2022","August 17, 2022","November 30, 2022","August 12, 2022",,"August 12, 2022","Hôpital DELAFONTAINE, Saint-denis, Ile De France, France",,"https://ClinicalTrials.gov/show/NCT05499325"
195,"NCT05499312","An Innovative Chinese Herbal Formula for the Treatment of Gout",,"Not yet recruiting","No Results Available","Gout","Drug: HKIIM-KU formula|Drug: Placebo","Serum uric acid|Pain Visual Analogue Scale|Health Assessment Questionnaire Disability Index|Short Form-36 Physical Summary Scale|No. of patients with new flare|Time to first new flare|Number of patients using rescue medication|Time to first use of rescue medication|Adverse events|Clinical pattern/syndrome according to Chinese medicine theory","Chinese University of Hong Kong","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Gout Study","September 2022","August 2024","February 2025","August 12, 2022",,"August 12, 2022",,,"https://ClinicalTrials.gov/show/NCT05499312"
196,"NCT05499299","Volatility and Heterogeneity of Vaccine Sentiments Means Continuous Monitoring is Needed When Measuring Message Effectiveness",,"Completed","No Results Available","Vaccine-Preventable Diseases|Vaccine Refusal","Behavioral: Google ads","Number of bookings following each message delivery within 6 hours|Number of bookings following each message delivery within 3 hours|Number of bookings following each message delivery within 12 hours","The University of Hong Kong","All","Child, Adult, Older Adult","Not Applicable","127000","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Health Services Research","UW21-428","July 1, 2021","October 31, 2021","April 1, 2022","August 12, 2022",,"August 12, 2022","The University of Hong Kong, Hong Kong, Hong Kong",,"https://ClinicalTrials.gov/show/NCT05499299"
197,"NCT05499286","A Mindfulness-Based Intervention to Improve CPAP",,"Recruiting","No Results Available","Obstructive Sleep Apnea (Moderate to Severe)|Obstructive Sleep Apnea","Other: Mindfulness Program","The effectiveness of MBI for CPAP adherence.|The effects of increased adherence on mental, physical, and psychosocial statuses.","The Hospital for Sick Children","All","13 Years to 18 Years   (Child, Adult)","Not Applicable","102","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Other","1000068799","June 28, 2020","January 2023","January 2024","August 12, 2022",,"August 12, 2022","Hospital for Sick Children, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT05499286"
198,"NCT05499273","Pediatric Neck Rescue Access Comparison",,"Recruiting","No Results Available","Tracheostomy Complication|Anesthesia","Procedure: scalpel-bougie tracheostomy|Procedure: rapid sequence tracheotomy","Performance Time|rate of cricoid injuries|Succes rate|rate of thyroid injuries|number of tracheal ring damaged","University Hospital Inselspital, Berne|Gaslini Children's Hospital","All","25 Years to 65 Years   (Adult, Older Adult)","Not Applicable","30","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other","Riva-Ulmer2022","May 25, 2022","September 30, 2022","March 30, 2023","August 12, 2022",,"August 15, 2022","University Hospital Bern, Bern, Switzerland",,"https://ClinicalTrials.gov/show/NCT05499273"
199,"NCT05499260","A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CB03-154 in Healthy Participants",,"Recruiting","No Results Available","Healthy Volunteers","Drug: CB03-154|Drug: Placebo","To evaluate the safety and tolerability of CB03-154 following single and multiple ascending oral dose administration.|Maximum Plasma Concentration (Cmax) of CB03-154|Area Under the Plasma Concentration Versus Time Curve (AUC) of CB03-154","Shanghai Zhimeng Biopharma, Inc.","All","18 Years to 55 Years   (Adult)","Phase 1","70","Industry","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CB03-154-101","May 2, 2022","March 2, 2023","March 2, 2023","August 12, 2022",,"August 12, 2022","Frontage Clinical Services, Inc., Secaucus, New Jersey, United States|Nucleus Network Pty Limited, Melbourne, Australia",,"https://ClinicalTrials.gov/show/NCT05499260"
200,"NCT05499247","A Proof-of-Concept, Safety and Efficacy Study of SkinQ Glow Bright Wonder Mask in Healthy Human Subjects",,"Not yet recruiting","No Results Available","Healthy Human Volunteers With Visibly Tanned Skin","Other: SkinQ Glow Bright Wonder Mask","To assess the instant change in skin colour, and tone|Surface evaluation of the living skin SELS® (Surface Evaluation of the Living Skin)|To assess the instant change in skin pores|Instant change in skin brightness, skin tanning|Local Irritation (erythema, scaling, itching, and burning)|Skin Pigmentation|Sensorial Evaluations","NovoBliss Research Pvt Ltd","All","18 Years to 55 Years   (Adult)","Not Applicable","38","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","NB220018-SQ","August 23, 2022","August 27, 2022","August 27, 2022","August 12, 2022",,"August 12, 2022",,,"https://ClinicalTrials.gov/show/NCT05499247"
201,"NCT05499234","Epidural Tap in Labor Analgesia FOR LABOR ANALGESIA",,"Recruiting","No Results Available","Labor Pain","Drug: Dolantin|Drug: Paracetamol","Change the need of bupivacaine for epidural analgesia.|Complication comparison","Medipol University","Female","18 Years to 45 Years   (Adult)","Phase 1","70","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Supportive Care","KARAASLANP","August 1, 2022","September 15, 2022","November 30, 2022","August 12, 2022",,"August 12, 2022","Istanbul Medipol University, Istanbul, Bağcılar, Turkey",,"https://ClinicalTrials.gov/show/NCT05499234"
202,"NCT05499221","Bone Anchored Carriere Motion Appliance",,"Recruiting","No Results Available","Malocclusion, Angle Class II","Device: Carriere motion appliance","Treatment duration|Skeletal changes|Dental changes","Mansoura University","All","11 Years to 16 Years   (Child)","Not Applicable","32","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","A01040122","January 26, 2022","June 26, 2023","October 26, 2023","August 12, 2022",,"August 12, 2022","MansouraU, faculty of dentistry, orthodontics department, Mansoura, Egypt",,"https://ClinicalTrials.gov/show/NCT05499221"
203,"NCT05499208","Rotation and Movement System, Postpartum Cesarean Sections","Rotation","Recruiting","No Results Available","Breast Feeding, Exclusive","Other: Giving side position with patient turning and movement system","The Effect of Turning and Movement System on Breastfeeding Success, Pain and Comfort in Postpartum Cesarean Section","Kars Harakani State Hospital|Ataturk University","Female","18 Years to 35 Years   (Adult)","Not Applicable","150","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","KarsHarakani Lazoglu0001","December 1, 2020","June 30, 2021","October 28, 2022","August 12, 2022",,"August 12, 2022","Kars Harakani State Hospital, Kars, Turkey",,"https://ClinicalTrials.gov/show/NCT05499208"
204,"NCT05499195","Adjuvant Radiotherapy for pT1b Esophageal Cancer After Submucosal Endoscopic Resection",,"Completed","No Results Available","Esophageal Cancer",,"Overall Survival (OS)|Disease-free Survival (DFS)","Chinese Academy of Medical Sciences","All","Child, Adult, Older Adult",,"159","Other","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","NCC2690","March 1, 2021","May 15, 2022","June 30, 2022","August 12, 2022",,"August 12, 2022","National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China",,"https://ClinicalTrials.gov/show/NCT05499195"
205,"NCT05499182","Latino Teen Depression Treatment Study",,"Not yet recruiting","No Results Available","Depression",,"Preferred implementation strategy to improve depression treatment use generated from qualitative interviews/focus groups|Number of barriers to depression treatment use generated from qualitative interviews/focus groups","Duke University","All","13 Years and older   (Child, Adult, Older Adult)",,"35","Other","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","Pro00110026","September 1, 2022","March 31, 2023","March 31, 2023","August 12, 2022",,"August 12, 2022",,,"https://ClinicalTrials.gov/show/NCT05499182"
206,"NCT05499169","Coach Pilot Study: Assessing Cognitive Function and Related Small Vessel Disease Markers After Intracerebral Hemorrhage","COACH","Recruiting","No Results Available","Cerebral Amyloid Angiopathy|Intracerebral Hemorrhage|Hypertensive Hemorrhage, Intracranial|Cognitive Decline",,"Cognitive decline (according to the neuropsychological assessment)|Burden of SVD markers on MRI markers at baseline, at six months and at 12 months|Concentrations of p-tau181 in CSF at baseline, at six months and at 12 months|Concentrations of Aβ40 in CSF at baseline, at six months and at 12 months|Concentrations of Aβ42 in CSF at baseline, at six months and at 12 months|Concentrations of t-tau in CSF at baseline, at six months and at 12 months","Leiden University Medical Center","All","55 Years and older   (Adult, Older Adult)",,"32","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","P20.109","April 3, 2022","April 3, 2024","April 3, 2025","August 12, 2022",,"August 12, 2022","Leiden University Medical Center, Leiden, Zuid-Holland, Netherlands","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/69/NCT05499169/Prot_000.pdf","https://ClinicalTrials.gov/show/NCT05499169"
207,"NCT05499156","Safety of Injection of Placental Mesenchymal Stem Cell Derived Exosomes for Treatment of Resistant Perianal Fistula in Crohn's Patients",,"Active, not recruiting","No Results Available","Perianal Fistula in Patients With Crohn's Disease","Other: placenal MSC derived exosomes","Safety of injected exosomes|clinical Efficacy of injected exosomes|inflammatory markers","Tehran University of Medical Sciences","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1|Phase 2","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","IRCT20200413047063N3","January 20, 2022","August 2022","September 2022","August 12, 2022",,"August 12, 2022","Division of Colorectal Surgery, Department of Surgery, Tehran University of Medical Sciences, Tehran, Iran, Tehran, Iran, Islamic Republic of",,"https://ClinicalTrials.gov/show/NCT05499156"
208,"NCT05499143","ImpACT for Developmental Coordination Disorder","ImpactDCD","Not yet recruiting","No Results Available","Developmental Coordination Disorder","Other: Online questionnaire","Impact of Developmental Coordination Disorder (DCD)","University Ghent","All","4 Years to 18 Years   (Child, Adult)",,"700","Other","Observational","Observational Model: Case-Only|Time Perspective: Cross-Sectional","ONZ-2022-0203","August 16, 2022","June 30, 2023","June 30, 2023","August 12, 2022",,"August 12, 2022","Ghent University, Ghent, Belgium",,"https://ClinicalTrials.gov/show/NCT05499143"
209,"NCT05499130","A Study to Test the Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn's Disease","RELIEVE UCCD","Not yet recruiting","No Results Available","Crohn Disease|Colitis, Ulcerative","Drug: TEV-48574|Drug: Placebo","Number of participants with moderate to severe UC who show clinical remission as defined by the Mayo score|Number of participants with moderate to severe CD who show an endoscopic response as defined by the Endoscopic Score for Crohn's Disease|Number of participants with moderate to severe UC with a clinical response as defined by a decrease from baseline in Mayo score|Number of participants with moderate to severe UC with Endoscopic improvement as defined by Mayo score|Number of participants with moderate to severe UC in Endoscopic remission as defined by Mayo score|Number of participants with moderate to severe UC with a clinical response as defined as a decrease from baseline in 2-item patient-reported outcome (PRO2)|Number of participants with moderate to severe UC in Clinical remission as defined by PRO2 score|Number of participants with moderate to severe UC with Histological remission defined as a Robarts Histopathology Index of ≤5|Number of participants with moderate to severe UC with Histological remission defined as Geboes index score ≤3.1|Number of participants with moderate to severe CD with a clinical response with a decrease from baseline in Crohn's Disease Activity Index|Number of participants with moderate to severe CD in clinical remission as defined by CDAI score|Number of participants with moderate to severe CD with Endoscopic remission as defined by SES-CD score|Number of participants with moderate to severe CD with a clinical response as defined by PRO2 score|Number of participants with moderate to severe CD in clinical remission as defined by PRO2 score|Number of participants with moderate to severe CD with an Endoscopic response as defined by the Modified Multiplier-Simple Endoscopic Score (MM-SES-CD)|Number of participants with moderate to severe CD with a Histologic response as defined by Global Histologic Activity score|Number of Participants Who Experience Adverse Events|Number of participants who report the use of concomitant medications|Number of participants who stopped taking the investigational medicinal product (IMP) due to adverse events|Number of participants with infusion device-related adverse events and malfunctions|Number of Participants with Treatment Emergent Anti-Drug Antibodies (ADA)|Number of ADA positive participants with the presence of neutralizing ADA","Teva Branded Pharmaceutical Products R&D, Inc.","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","280","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","TV48574-IMM-20036|2021-006881-19","August 25, 2022","August 27, 2024","October 10, 2024","August 12, 2022",,"August 12, 2022",,,"https://ClinicalTrials.gov/show/NCT05499130"
210,"NCT05499117","Efficacy and Safety of Light Therapy in the Treatment of Non-seasonal Depressive Disorder in Chinese Population",,"Recruiting","No Results Available","Major Depressive Disorder","Device: Light terapy|Device: pseudo-light therapy","remission of acute phase","Shanghai Mental Health Center","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","2021-HY-006","February 1, 2022","July 31, 2023","July 31, 2023","August 12, 2022",,"August 12, 2022","Shanghai Mental Health Center, Shanghai, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT05499117"
211,"NCT05499104","A Trial Comparing a Cellulose Dressing to Two Standard of Care Dressings in Treating Split Thickness Donor Sites in Burn and Wound Patients.",,"Completed","No Results Available","Donor Sites|Wound Heal|Wound Drainage|Pain Management","Device: NovaDress|Device: Mepilex Ag|Device: Xeroform","Pain and Healing|Absorbent ability|Conformability|Adherence|Management of bloody exudate|Ease of removal|Cost","Joseph M. Still Research Foundation, Inc.|Innovatech Engineering, LLC","All","18 Years and older   (Adult, Older Adult)","Phase 3","93","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","JMSRF-NCMIS-P01","July 16, 2021","January 24, 2022","February 4, 2022","August 12, 2022",,"August 12, 2022","Joseph M. Still Research Foundation, Augusta, Georgia, United States",,"https://ClinicalTrials.gov/show/NCT05499104"
212,"NCT05499091","Functional Study of Rare Disease Related Candidate Genes - ORIGIN","ORIGIN","Recruiting","No Results Available","Rare Diseases|Genetic Disease","Procedure: Skin biopsy, blood sample, urine sample","Identification of at least 80 new genes implicated in rare diseases via high-throughput sequencing technics and through functional studies.|Collecting biological samples to build up a biobank|Candidat gene validation through functional studies.","University Hospital, Angers","All","Child, Adult, Older Adult","Not Applicable","1200","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","49RC22_0061","June 14, 2022","June 14, 2042","June 14, 2045","August 12, 2022",,"August 12, 2022","Centre Hospitalo-Universitaire d'Angers, Angers, France",,"https://ClinicalTrials.gov/show/NCT05499091"
213,"NCT05499078","Pilot Study to Assess Performance and Safety of SULFEX 13081.22 Nasal Spray in Patients With Dry or Irritated Nose",,"Recruiting","No Results Available","Nose Dry Feeling of|Nose Irritation","Device: SULFEX 13081.22","Nasal symptoms severity|Safety data on SULFEX 13081.22 nasal spray|Performance of SULFEX 13081.22 nasal spray|Nasal symptoms relief/reduction|Onset of relief|Duration of relief (long lasting).|Previous nasal state of well-being assessment|Medical device usability|Product attributes|Patient satisfaction","Church & Dwight Company, Inc.|EVAMED","All","18 Years and older   (Adult, Older Adult)","Not Applicable","40","Industry|Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ST-20-F10","July 18, 2022","December 2022","December 2022","August 12, 2022",,"August 12, 2022","Pharmacie Lair, Vire, Normandie, France|Pharmacie Plaisance, Paris, France",,"https://ClinicalTrials.gov/show/NCT05499078"
214,"NCT05499065","Real-time Margin Assessment in Head and Neck Cancer","LIGHTNING","Not yet recruiting","No Results Available","Head and Neck Cancer|Head and Neck Squamous Cell Carcinoma","Procedure: Fluorescence guided detection of tumor positive margins|Drug: Cetuximab-IRDye800","Enhanced intra-operative margin detection","University Medical Center Groningen","All","18 Years and older   (Adult, Older Adult)","Phase 2","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","10968","January 1, 2023","January 1, 2025","January 10, 2025","August 12, 2022",,"August 12, 2022","University Medical Center Groningen, Groningen, Netherlands",,"https://ClinicalTrials.gov/show/NCT05499065"
215,"NCT05499052","Trial to Assess the Pattern of Use of REKOVELLE® in Women Undergoing In Vitro Fertilisation (IVF) or Intracytoplasmic Sperm Injection (ICSI) Procedures in Routine Clinical Practice","NORSOS","Not yet recruiting","No Results Available","Controlled Ovarian Stimulation","Drug: REKOVELLE®","Use of the algorithm-based individualized dosing regimen (daily dose of REKOVELLE® administered)|Daily dose of REKOVELLE®|Number of days of treatment with REKOVELLE®|REKOVELLE® Dose changes|Use of the Algorithm dosing Application|Use of GnRH protocol for Lutenizing Hormone surge suppression|Type of drug used for triggering of follicle maturation|Luteal phase support|Rate of ongoing pregnancy (≥1 intrauterine viable fetus 10-11 weeks after embryo transfer) in the fresh cycle|Rate of ongoing pregnancy (≥1 intrauterine viable fetus 10-11 weeks after embryo transfer) following the fresh cycle, including also the first frozen embryo transfer|Number of oocytes retrieved|Number of oocytes/embryos/blastocysts frozen|Number of embryos/blastocysts transferred|Quality of fresh embryos or blastocysts transferred (excellent, good, fair, other)|Positive signs of pregnancy (clinical pregnancy)|Positive signs of pregnancy (Positive Human chorionic gonadotropin (hCG) test or urine pregnancy test)|Pregnancy loss in women with embryo/blastocyst transfer (biochemical pregnancy, spontaneous/elective abortion, ectopic pregnancy, vanishing twin)|Cycle cancellation before or after oocyte pick-up and reason for cycle cancellation|Adverse drug reactions (ADRs)|Ovarian hyperstimulation syndrome (OHSS) (including mild/moderate/severe)|Preventive interventions for early OHSS|Assessment of overall subject experience and convenience with REKOVELLE® by the Subject Questionnaire (assessed by the subject)","Ferring Pharmaceuticals","Female","18 Years and older   (Adult, Older Adult)",,"200","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","000411","August 11, 2022","February 9, 2024","February 9, 2024","August 12, 2022",,"August 12, 2022",,,"https://ClinicalTrials.gov/show/NCT05499052"
216,"NCT05499039","High Flow Nasal Cannula Versus Non-Invasive (NIV)in Both Hypoxemic and Hypercapnic Respiratory Failure.","Highflow","Not yet recruiting","No Results Available","Acute Hypoxemic Respiratory Failure|Acute Hypercapnic Respiratory Failure","Device: High flow nasal cannula (HFNC)|Device: Non-Invasive Mechanical Ventilation (NIV)","Evaluation of HFNC and NIV in correction of Acidosis .|Evaluation of HFNC and NIV in correction of Hypercapnia.|Evaluation of HFNC and NIV in management of Acute hypoxemic respiratory failure.|Evaluation of HFNC and NIV in correction of Hypoxemia.|Endotracheal intubation rate.|In hospital mortality.|duration of intervention|hospital coast|duration of ICU stay .|development of complications","Assiut University","All","18 Years to 95 Years   (Adult, Older Adult)","Not Applicable","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","HFNC VS NIV","October 10, 2022","October 10, 2024","October 20, 2024","August 12, 2022",,"August 15, 2022","Assiut University, Assiut, Egypt",,"https://ClinicalTrials.gov/show/NCT05499039"
217,"NCT05499026","Safety and Efficacy of CDCA in CTX Chenodeoxycholic Acid (CDCA) in Patients Affected by Cerebrotendinous Xanthomatosis (CTX)",,"Completed","No Results Available","Cerebrotendinous Xanthomatoses","Drug: Chenodeoxycholic Acid","Serum Cholestanol Levels","Leadiant Biosciences Ltd.","All","Child, Adult, Older Adult",,"28","Industry","Observational","Observational Model: Cohort|Time Perspective: Retrospective","CDCA-STUK-15-001","December 9, 2014","June 3, 2015","June 3, 2015","August 12, 2022",,"August 12, 2022",,,"https://ClinicalTrials.gov/show/NCT05499026"
218,"NCT05499013","Study to Assess SLN124 in Patients With Polycythemia Vera","SLN","Not yet recruiting","No Results Available","Polycythemia Vera","Drug: SLN124|Drug: Placebo","Incidence of treatment-emergent adverse events (AEs)|Assessment of the number of phlebotomies at intervals|Pharmacokinetic: area under the plasma concentration (AUC)|Pharmacokinetic: peak plasma concentration (Cmax)|Pharmacodynamic: change in haematocrit|Pharmacodynamic: Change in Transferrin saturation (TSAT)|Pharmacodynamic: Change in Hepcidin","Silence Therapeutics plc","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","65","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","SLN124-004","October 2022","December 2024","June 2025","August 12, 2022",,"August 12, 2022",,,"https://ClinicalTrials.gov/show/NCT05499013"
219,"NCT05499000","The Effect of Emotional Freedom Technique on Premenstrual Syndrome",,"Recruiting","No Results Available","Premenstrual Syndrome|Emotional Problem","Behavioral: Emotional freedom technique","Subjective Units of Experience- (SUE)|Descriptive Data- (KBF)|Premenstrual Syndrome Scale- (PMSS)","Inonu University","Female","18 Years to 25 Years   (Adult)","Not Applicable","51","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","Faculty of Health Science","September 1, 2022","October 1, 2022","October 30, 2022","August 12, 2022",,"August 12, 2022","Inonu University Faculty of Health Sciences, Malatya, Turkey",,"https://ClinicalTrials.gov/show/NCT05499000"
220,"NCT05498987","Ultrasound Achilles Tendon Assessment",,"Not yet recruiting","No Results Available","Ultrasonography|Achilles Tendon","Device: Monopolar 448 kilohertz radiofrequency stimulation","Change from Baseline in Achilles Tendon measured by quantified elastography imaging at 3 months. time (t) 1(prior to treatment), t2 (immediately after the treatment), t3 (3 months later).","Universidad de Granada","All","18 Years to 50 Years   (Adult)","Not Applicable","28","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","MCuevasCervera","October 14, 2022","June 14, 2023","June 12, 2024","August 12, 2022",,"August 12, 2022","Ana Gonzalez Muñoz, Málaga, Malaga, Spain",,"https://ClinicalTrials.gov/show/NCT05498987"
221,"NCT05498974","China Diabetes Type 1 Study (CD1S) by China Alliance for Type 1 Diabetes",,"Recruiting","No Results Available","Type1diabetes|Diabetes","Other: Standard type 1 diabetes management model constructed by China Alliance for Type 1 Diabetes in each center","Change in serum hemoglobin A1c level|Albumin-to-creatinine ratio in urine sample|Arteriosclerotic cardiovascular diseases|Electromyography|PHQ-9|GAD-7|WHO-5|PAID|Change in C-peptide|Change in titer of autoantibodies|Fasting blood glucose|Systolic blood pressure|Diastolic blood pressure|Change in lipid profiles|Metabolomics","Second Xiangya Hospital of Central South University","All","Child, Adult, Older Adult",,"20000","Other","Observational","Observational Model: Other|Time Perspective: Other","CD1S","January 1, 2022","December 31, 2035","December 31, 2035","August 12, 2022",,"August 12, 2022","Gansu Provincial People's Hospital, Lanzhou, Gansu, China|Shenzhen Second People's Hospital, Shenzhen, Guangdong, China|Hainan General Hospital, Haikou, Hainan, China|the First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China|The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, Henan, China|The Second Xiangya Hospital, Central South University, Changsha, Hunan, China|The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China|Heji Hospital Affiliated to Changzhi Medical College, Changzhi, Shanxi, China|The First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang, China|The First People's Hospital of Yunnan, Kunming, Yunnan, China|Zhejiang Provincial People's Hospital, Hangzhou, Zhejiang, China",,"https://ClinicalTrials.gov/show/NCT05498974"
222,"NCT05498961","The Effect of Gallstone Characteristics for the Severity of Gallstone Pancreatitis",,"Recruiting","No Results Available","Acute Gallstone Pancreatitis","Other: Gallstone characteristics","Number of severity of GSP patients|Modified computed tomography severity index (MCTSI) score|Gallstone size|Number of stones","Hepatopancreatobiliary Surgery Institute of Gansu Province","All","18 Years to 90 Years   (Adult, Older Adult)",,"300","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","acute gallstone pancreatitis","August 10, 2022","December 31, 2022","December 31, 2022","August 12, 2022",,"August 12, 2022","Hepatopancreatobiliary Surgery Institute of Gansu Province, Lanzhou, Gansu, China",,"https://ClinicalTrials.gov/show/NCT05498961"
223,"NCT05498948","PMS Promotes the Recovery of Patients After Heart Valve Replacement","PMS","Recruiting","No Results Available","Heart Valve Diseases","Dietary Supplement: Probiotic mixture","The AGI score|Intra-abdominal pressure (IAP)|Characteristics of gut microbiomes|Return time of bowel sounds|Number of bowel sounds|First defecation time|Bristol Stool Form Scale score|Proportion of cocci and bacilli in feces|Procalcitonin (PCT)|Interleukin-6|Interleukin-10|High sensitivity troponin(hs TnI)|N-terminal precursor brain natriuretic peptide(NT-ProBNP)|Trimethylamine oxide(TMAO)|Intestinal fatty acid-binding protein (IFABP)|Left ventricular ejection fraction (LVEF)","Hepatopancreatobiliary Surgery Institute of Gansu Province","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","PMS","August 20, 2022","February 15, 2023","February 15, 2023","August 12, 2022",,"August 15, 2022","Hepatopancreatobiliary Surgery Institute of Gansu Province, Lanzhou, Gansu, China",,"https://ClinicalTrials.gov/show/NCT05498948"
224,"NCT05498935","Prolonged Cardiopulmonary Bypass Time as a Predictive Factor for AGI After Heart Valve Replacement",,"Recruiting","No Results Available","Heart Valve Diseases","Other: CPB time","Cardiopulmonary bypass (CPB) time|The AGI score|Number of bowel sounds|First defecation time|Proportion of cocci and bacilli in feces|Alanine aminotransferase (ALT)|Aspartate aminotransferase (AST)|Left ventricular ejection fraction (LVEF)","Hepatopancreatobiliary Surgery Institute of Gansu Province","All","18 Years to 70 Years   (Adult, Older Adult)",,"1400","Other","Observational","Observational Model: Case-Control|Time Perspective: Retrospective","CPB-AGI","August 10, 2022","January 1, 2023","January 1, 2023","August 12, 2022",,"August 15, 2022","Hepatopancreatobiliary Surgery Institute of Gansu Province, Lanzhou, Gansu, China",,"https://ClinicalTrials.gov/show/NCT05498935"
225,"NCT05498922","Effect of Mechanical Ventilation on Lung Development of Alveolar Stage",,"Completed","No Results Available","Mechanical Ventilation|Abnormal Lung Development","Procedure: Peak pressure when mechanical ventilation was switched around a reasonable range","Tidal Volume (Vt)|Pulmonary compliance|Mean airway pressure (MAP)","Xinhua Hospital, Shanghai Jiao Tong University School of Medicine","All","up to 3 Years   (Child)",,"100","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","XH-21-12","April 27, 2021","March 31, 2022","May 31, 2022","August 12, 2022",,"August 12, 2022","Department of Anesthesia, Shanghai Xinhua hospital, Shanghai, Shanghai, China","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/22/NCT05498922/Prot_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/22/NCT05498922/ICF_001.pdf","https://ClinicalTrials.gov/show/NCT05498922"
226,"NCT05498909","A Real-world Registry Study of Multidisciplinary Collaborative Diagnosis and Treatment Model for Cardioembolic Stroke","CSMDT","Active, not recruiting","No Results Available","Cardioembolic Stroke|Multidisciplinary Communication","Other: Multidisciplinary joint diagnosis and treatment mode","Composite end point of cardiovascular and cerebrovascular events|Cardiovascular and cerebrovascular death, All-cause death, Cardiac insufficiency, Cognitive dysfunction","Xiao Huang|Second Affiliated Hospital of Nanchang University","All","Child, Adult, Older Adult",,"1200","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2022-01","August 1, 2022","September 1, 2023","June 30, 2024","August 12, 2022",,"August 12, 2022","The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/09/NCT05498909/Prot_000.pdf","https://ClinicalTrials.gov/show/NCT05498909"
227,"NCT05498896","Investigate the Contribution of Ipatasertib to Neoadjuvant Chemotherapy Plus Atezolizumab in TNBC","BARBICAN","Active, not recruiting","No Results Available","Triple Negative Breast Cancer","Drug: Atezolizumab|Drug: Ipatasertib|Drug: Paclitaxel|Drug: Doxorubicin|Drug: Cyclophosphamide","pCR|ORR","Queen Mary University of London|Westdeutsche Studiengruppe GmbH (WSG)|MedSIR|Hoffmann-La Roche","Female","18 Years and older   (Adult, Older Adult)","Phase 2","146","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","012418QM|2018-000977-62","December 19, 2018","January 29, 2021","January 30, 2026","August 12, 2022",,"August 12, 2022","Barts Health NHS Trust, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT05498896"
228,"NCT05498883","Quality of Life Evaluation With the SRI Questionnaire of ALS Patient With Non-invasive Ventilation","Quality EvALS","Not yet recruiting","No Results Available","Amyotrophic Lateral Sclerosis","Other: Score completion","SRI questionnaire in patients who have indication for starting NIV|SRI of patients with total ventilatory dependence in ALS|Zarit burden interview in both groups","Assistance Publique - Hôpitaux de Paris","All","18 Years and older   (Adult, Older Adult)","Not Applicable","44","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","APHP220697","October 1, 2022","October 1, 2024","October 1, 2024","August 12, 2022",,"August 12, 2022","Pneumology departement, Pitié-Salpêtrière hospital, GHU APHP-Sorbonne Université, Paris, France",,"https://ClinicalTrials.gov/show/NCT05498883"
229,"NCT05498870","iPACK for Post-op Pain Following ACL Reconstruction",,"Recruiting","No Results Available","ACL Injury|Post Operative Pain","Drug: Adductor Canal Block (ACB) Only|Drug: Adductor Canal Block (ACB) + iPACK Block","Pain Scores|total postoperative opioid consumption (total MME)|Range of Motion (degrees)|Terminal knee extension (degrees)","Medical University of South Carolina","All","12 Years and older   (Child, Adult, Older Adult)","Phase 4","82","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","Pro00121103","July 27, 2022","August 1, 2024","January 1, 2025","August 12, 2022",,"August 12, 2022","Medical University of South Carolina, Charleston, South Carolina, United States",,"https://ClinicalTrials.gov/show/NCT05498870"
230,"NCT05498857","Intramuscular Ephedrine in the Prevention of Hypotension in Patients Undergoing Spinal Anesthesia",,"Recruiting","No Results Available","Ephedrine|Intramuscular|Hypotension|Spinal Anesthesia","Drug: Intramuscular ephedrine|Drug: Placebo","Number of participants with adverse events as hypotension","Hospital de Base","All","18 Years and older   (Adult, Older Adult)","Phase 4","202","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","i.m. ephedrine","July 15, 2022","July 2023","July 2023","August 12, 2022",,"August 12, 2022","Hospital de Base do Distrito Federal, Brasília, DF, Brazil",,"https://ClinicalTrials.gov/show/NCT05498857"
231,"NCT05498844","Adherence to Nutritional Treatment Following MI Using Telemedicine Treatment (ADNUT)","ADNUT","Not yet recruiting","No Results Available","Cardiovascular Diseases|Acute MI","Behavioral: Medical Nutrition Therapy (counselling)","Increase in I-MEDAS score|Adherance to nutrition treatment","Ariel University|Prof. Robert Klempfner, The Chaim Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel|Prof. Yaacov Henkin, Soroka University Medical Center, Beer Sheva, Israel|Dana Dishon, RD, MSc, The Chaim Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel|Dana Weiner, RD, MS, The Chaim Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel","All","25 Years to 75 Years   (Adult, Older Adult)","Not Applicable","90","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SMC-8448-21","August 21, 2022","August 31, 2023","August 31, 2024","August 12, 2022",,"August 15, 2022",,,"https://ClinicalTrials.gov/show/NCT05498844"
232,"NCT05498831","Evaluation of a New Pain Management Protocol Involving Intranasal Sufentanil in the Emergency Room.","SUURGE","Not yet recruiting","No Results Available","Acute Pain","Other: Pain assessment at 15 minutes, 30 minutes, 60 minutes, 120 minutes after initial assessment by the triage nurse","Proportion of patients with effective pain relief 30 minutes after initial assessment by nurse|Time from initial pain assessment by nurse to administration of intranasal sufentanil compared to Intravenous morphine titration|Number of adverse events","Groupe Hospitalier de la Region de Mulhouse et Sud Alsace","All","18 Years and older   (Adult, Older Adult)",,"320","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","GHR 1260","September 2022","November 2022","November 2022","August 12, 2022",,"August 12, 2022",,,"https://ClinicalTrials.gov/show/NCT05498831"
233,"NCT05498818","The Effects of Synaquell on Brain Function of Ice Hockey Players",,"Not yet recruiting","No Results Available","Healthy","Dietary Supplement: Synaquell|Dietary Supplement: Placebo","Change in N100 Amplitude|Change in N100 Latency|Change in P300 Amplitude|Change in P300 Latency|Change in N400 Amplitude|Change in N400 Latency|Change in blood biomarker|Change in King-Devick Test (KDT) scores","Mayo Clinic","All","13 Years to 19 Years   (Child, Adult)","Not Applicable","150","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Supportive Care","22-003414","October 1, 2022","April 1, 2023","May 1, 2023","August 12, 2022",,"August 12, 2022","Mayo Clinic in Rochester, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT05498818"
234,"NCT05498805","PD-1 Inhibitors With or Without Radiation in Advanced Melanoma",,"Not yet recruiting","No Results Available","the Efficacy and Safety of PD-1 Inhibitors With or Without Radiotherapy in Patients With Advanced Melanoma","Radiation: Radiation","progression free survival","Fudan University","All","18 Years and older   (Adult, Older Adult)","Phase 2","92","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Fudan-MM002","August 15, 2022","October 15, 2024","August 15, 2025","August 12, 2022",,"August 12, 2022","Fudan University Shanghai Cencer Center, Shanghai, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT05498805"
235,"NCT05498792","Study of CBL0137 in Combination With Ipilimumab and Nivolumab Therapy in Melanoma",,"Not yet recruiting","No Results Available","Locally Advanced or Metastatic Melanoma","Drug: CBL0137|Drug: Ipilimumab|Drug: Nivolumab","Initial assessment of safety and tolerability of the combination of CBL0137 with Nivolumab and Ipilimumab. Initial assessment of safety and tolerability of the combination of CBL0137 with Nivolumab and Ipilimumab.","Fox Chase Cancer Center|Incuron","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","12","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MEL-212","October 2022","March 2024","September 2024","August 12, 2022",,"August 12, 2022",,,"https://ClinicalTrials.gov/show/NCT05498792"
236,"NCT05498779","Ablation of Hepatocellular Carcinoma: a Nationwide Study",,"Active, not recruiting","No Results Available","Hepatocellular Carcinoma|Ablation|Hepatitis C","Procedure: Ablation therapy","Overall survival related to tumor size|Overall survival related to HCV virus","Rigshospitalet, Denmark","All","18 Years to 100 Years   (Adult, Older Adult)",,"490","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","-A10492","June 1, 2022","August 15, 2022","August 15, 2022","August 12, 2022",,"August 12, 2022","Rigshospitalet, Copenhagen, Denmark",,"https://ClinicalTrials.gov/show/NCT05498779"
237,"NCT05498766","Effect and Safety of Adjuvant Huaier Granule Versus SOX in Gastric Cancer Patients",,"Not yet recruiting","No Results Available","Gastric Cancer","Drug: Huaier granule|Drug: Oxaliplatin|Drug: Tegafur, Gimeracil and Oteracil Potassium","3-year DFS rate|1, 2-year DFS rate|1, 2, 3-year OS rate|1, 2, 3-year local recurrence-free survival rate|1, 2, 3-year distant metastasis-free survival rate|Quality of life score|Incidence and severity of adverse events and serious adverse events|Incidence and severity of adverse reactions, serious adverse reactions, suspicious and unexpected serious adverse reactions","Wuhan Union Hospital, China|LinkDoc Technology (Beijing) Co. Ltd.","All","18 Years to 75 Years   (Adult, Older Adult)",,"828","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","HE-202205","November 30, 2022","November 30, 2027","May 31, 2028","August 12, 2022",,"August 12, 2022","Wuhan Union Hospital, Wuhan, Hubei, China",,"https://ClinicalTrials.gov/show/NCT05498766"
238,"NCT05498753","Development, ADL, Participation, and Quality of Life in Preterm Infants: A Longitudinal Follow Up Study",,"Not yet recruiting","No Results Available","Preterm Birth",,"Change from baseline general development for Healthy child and preterm infants at 6 months 1|Change from baseline general development for Healthy child and preterm infants at 6 months 2|Change from baseline general development for Healthy child and preterm infants at 6 months 3|Change from baseline general development for Healthy child and preterm infants at 6 months 4|Change from baseline functions for preterm infants at 6 months","Chang Gung Memorial Hospital","All","6 Months to 3 Years   (Child)",,"1000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","202101737B0","February 21, 2023","December 31, 2024","March 31, 2025","August 12, 2022",,"August 12, 2022","Chang Gung Memorial Hospital, Taoyuan, Taiwan",,"https://ClinicalTrials.gov/show/NCT05498753"
239,"NCT05498740","Post-marketing Study in Femoral Popliteal Artery of Drug Coated Balloon Used for Treatment of Lower Limb Ischemia","UltraFuture I","Recruiting","No Results Available","Peripheral Arterial Disease (PAD)","Device: Drug eluting Balloon","rate of device success|rate of procedural success|rate of technical success|rate of primary patency of target lesion|rate of Clinically-driven TLR|rate of TLR|rate of Clinically-driven TVR|rate of TVR|change in Rutherford clinical category (target limb)|change in ankle brachial index(ABI)|rate of SAE|rate of All-cause mortality|rate of Major amputation|rate of target lesion thrombosis|Rate of adverse events","Zhejiang Zylox Medical Device Co., Ltd.","All","18 Years to 85 Years   (Adult, Older Adult)","Not Applicable","200","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","04202106","May 4, 2022","December 2022","December 2024","August 12, 2022",,"August 12, 2022","Xuanwu hospital, Beijing, China|Affiliated Hospital of Chengde Medical College, Chengde, China|The Third People's Hospital of Chengdu, Chengdu, China|The First Affiliated Hospital of Dalian Medical University, Dalian, China|The Second Affiliated Hospital of Dalian Medical University, Dalian, China|Guangzhou Huaqiao hospital, Guangzhou, China|Hospital of Traditional Chinese Medicine affiliated to Guangzhou Medical University, Guangzhou, China|The Third Affiliated Hospital of Guangzhou Medical University, Guangzhou, China|The First Affiliated Hospital of Harbin Medical University, Ha'erbin, China|Hangzhou First People's Hospital, Hangzhou, China|First Hospital of Lanzhou University, Lanzhou, China|Ningbo huamei hospital, Ningbo, China|Qingdao Municipal Hospital, Qingdao, China|Ruian People's Hospital, Rui'an, China|Shanghai Ninth People'S Hospital, Shanghai, China|Zhongshan Hospital, Shanghai, China|Northern Theatre General Hospital, Shenyang, China|Tianjin Medical University General Hospital, Tianjin, China|Tianjin People's Hospital, Tianjin, China|Weifang People's Hospital, Weifang, China|The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China|The Second Affiliated Hospital of Wenzhou Medical University, Wenzhou, China|The First Affiliated Hospital of Xi 'an Jiaotong University School of Medicine, Xi'an, China|People's Hospital of Xinjiang Uygur Autonomous Region, Xinjiang, China",,"https://ClinicalTrials.gov/show/NCT05498740"
240,"NCT05498727","Evaluation of the Integration of Ag-RDTs for COVID-19 in MNCH, HIV and TB Services in Cameroon and Kenya",,"Not yet recruiting","No Results Available","COVID-19","Diagnostic Test: Integration of SARS-CoV 2 Testing in HIV, MNCH and TB Clinics","Proportion of pediatric and adult clinic attendees tested for SARS-CoV-2|SARS-CoV-2 detection rate|Effect of integrated SARS-CoV-2 Ag-RDT testing on routine service delivery indicators|Factors associated with proportion of clinic attendees screened and tested with SARS-CoV-2 Ag-RDT, linked to care and treatment among the attendees following the integration of SARS-CoV-2 Ag-RDT in MNCH, HIV and TB clinics.|Individual-level factors associated with SARS-CoV-2 infection, disease status, and outcomes","Elizabeth Glaser Pediatric AIDS Foundation|UNITAID|Kenya Ministry of Health|Ministry of Public Health, Cameroon","All","2 Years and older   (Child, Adult, Older Adult)",,"255000","Other","Observational","Observational Model: Other|Time Perspective: Other","EG0276","August 1, 2022","March 30, 2023","September 30, 2023","August 12, 2022",,"August 12, 2022",,,"https://ClinicalTrials.gov/show/NCT05498727"
241,"NCT05498714","Improved Bowel Cleansing Method for Colonoscopy Based on High Risk Population of Bowel Preparation",,"Recruiting","No Results Available","Bowel Preparation Before Colonoscopy","Drug: PEG+lactulose|Drug: CSP＋lactulose","Boston Bowel Preparation Scale|Adenoma Detection Rate|Polyp Detection Rate|Rate of adverse events|Cecal intubation rate|Cecal intubation time|Withdrawal time|defecation frequency|patient satisfaction Assessment","Renmin Hospital of Wuhan University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","150","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Screening","WDRY2022-K082","July 18, 2022","June 30, 2023","June 30, 2023","August 12, 2022",,"August 12, 2022","Renmin Hospital of Wuhan University, Wuhan, Hubei, China",,"https://ClinicalTrials.gov/show/NCT05498714"
242,"NCT05498701","A Study Comparing Two Forms of Tafamidis Without Food and the Amount of Tafamidis in the Blood With Food",,"Not yet recruiting","No Results Available","Healthy","Drug: Tafamidis free acid tablet (Test)|Drug: Tafamidis meglumine capsule (Reference)","Area under the concentration-time curve (AUCinf)|Maximum observed plasma concentration (Cmax)","Pfizer","All","18 Years and older   (Adult, Older Adult)","Phase 1","22","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","B3461103","August 25, 2022","January 26, 2023","January 26, 2023","August 12, 2022",,"August 12, 2022",,,"https://ClinicalTrials.gov/show/NCT05498701"
243,"NCT05498688","The Acute Effect of Low-carb Diet on the Plasma Fatty Acid Composition in Type 2 Diabetes",,"Recruiting","No Results Available","Type 2 Diabetes","Dietary Supplement: Low carbohydrate","Plasma fatty acid composition|Plasma glucose, serum insulin and plasma ketones|Plasma free fatty acid, total, LDL and HDL cholesterol, triglycerides and other lipoprotein fractions|Gut hormones (serum/plasma Glucagon Like Peptide 1 (GLP1), Glucose-Dependent Insulinotropic Polypeptide (GIP), Cholecystokinin (CCK), Peptide YY (PYY), ghrelin)|Subjective appetite","Odense University Hospital|Aalborg University Hospital","All","18 Years and older   (Adult, Older Adult)","Not Applicable","12","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","S-20220003","August 2022","December 2022","December 2022","August 12, 2022",,"August 12, 2022","Odense University Hospital, Odense, Denmark",,"https://ClinicalTrials.gov/show/NCT05498688"
244,"NCT05498675","Effect of Sacubitril/Valsartan on Cardiac Function in Hypertensive Patients Stratified by BMI: A Real World Study",,"Recruiting","No Results Available","Sacubitril/Valsartan|Hypertension|Obesity","Drug: Sacubitril / Valsartan Oral Tablet [Entresto]|Drug: ACEI/ARB","Changes on left ventricular ejection fraction (LVEF)|Changes on left ventricular end-systolic diameter (LVESD)|Changes on left ventricular end-diastolic diameter (LVEDD)|Changes on cardiac systolic function|Major adverse cardiac events|Changes on hypertension-mediated target organ damage|Changes on blood pressure","Beijing Friendship Hospital","All","18 Years to 70 Years   (Adult, Older Adult)",,"180","Other","Observational","Observational Model: Cohort|Time Perspective: Other","2022-P2-173-01","September 1, 2021","March 1, 2024","September 1, 2024","August 12, 2022",,"August 12, 2022","Beijing Friendship Hospital, Capital Medical University, Beijing, Beijing, China",,"https://ClinicalTrials.gov/show/NCT05498675"
245,"NCT05498662","An Observational Study of the T3 Pro Dental Implant System","Spike","Not yet recruiting","No Results Available","Tooth Loss","Device: T3 Pro dental implant system","Integration success/ implant survival at 2 years; primary stability|Crestal bone regression","ZimVie","All","18 Years and older   (Adult, Older Adult)",,"60","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","2201","October 30, 2022","October 30, 2025","December 30, 2025","August 12, 2022",,"August 12, 2022","Louisiana State University Health Sciences Center, New Orleans, Louisiana, United States",,"https://ClinicalTrials.gov/show/NCT05498662"
246,"NCT05498649","Performance of Dailies Total1® Contact Lenses for Astigmatism in Symptomatic Habitual Reusable Toric Lens Wearers",,"Recruiting","No Results Available","Astigmatism","Device: DT1fA","CLDEQ-8 Questionnaire Score","Keith Wan|Sengi|Scripps Poway Eyecare and Optometry","All","18 Years to 38 Years   (Adult)",,"93","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","KW-22-001","August 2, 2022","August 2023","August 2023","August 12, 2022",,"August 15, 2022","Scripps Poway Eyecare & Optometry, San Diego, California, United States",,"https://ClinicalTrials.gov/show/NCT05498649"
247,"NCT05498636","SPEL as Introductive Treatment Following Immune-chemotherapy as Consolidated Therapy for R/R DLBCL With p53 and/or c-Myc Expression",,"Not yet recruiting","No Results Available","DLBCL","Combination Product: Selinexor combined with Prednisone, Etoposide, and Lenalidomide","CR rate|ORR|AE","The Affiliated Hospital of Qingdao University","All","16 Years to 80 Years   (Child, Adult, Older Adult)","Phase 1|Phase 2","67","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","202201","August 1, 2022","July 30, 2025","December 31, 2025","August 12, 2022",,"August 12, 2022","the affiliated hospital of Qingdao University, Qingdao, Shandong, China",,"https://ClinicalTrials.gov/show/NCT05498636"
248,"NCT05498623","MR Fingerprinting for Diagnostic of Prostate Cancer",,"Not yet recruiting","No Results Available","Prostate Cancer|Magnetic Resonance Imaging",,"MRF compared to T1, T2 and proton density generated to the PIRADS scoring","Norwegian University of Science and Technology|St. Olavs Hospital","Male","18 Years to 100 Years   (Adult, Older Adult)",,"200","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","218665","September 1, 2022","January 30, 2023","December 2024","August 12, 2022",,"August 12, 2022",,,"https://ClinicalTrials.gov/show/NCT05498623"
249,"NCT05498610","A Research Study of How the Medicine NNC0480-0389 Taken With Semaglutide Works in the Body of Healthy Chinese Men",,"Recruiting","No Results Available","Diabetes Mellitus, Type 2","Drug: NNC0480 0389|Drug: Semaglutide","AUC0-∞,NNC0480-0389,SD Area under the NNC0480-0389 plasma concentration-time curve from time 0 to infinity after a single dose (SD)|Cmax,NNC0480-0389,SD Maximum plasma concentration of NNC0480-0389 after a single dose|AUC0-∞,sema,SD Area under the semaglutide plasma concentration-time curve from time 0 to infinity after a single dose|Cmax,sema,SD The maximum plasma concentration of semaglutide after a single dose","Novo Nordisk A/S","Male","18 Years to 55 Years   (Adult)","Phase 1","24","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NN9389-4774|U1111-1264-4516","August 11, 2022","February 5, 2023","February 5, 2023","August 12, 2022",,"August 12, 2022","Novo Nordisk Investigational Site, Beijing, Beijing, China",,"https://ClinicalTrials.gov/show/NCT05498610"
250,"NCT05498597","AMT-151 in Patients With Selected Advanced Solid Tumours",,"Not yet recruiting","No Results Available","Advanced Solid Tumor|Advanced Cancer|Advanced Carcinoma|Ovarian Cancer|Ovarian Carcinoma|Ovarian Epithelial Cancer|Ovarian Endometrioid Adenocarcinoma|Endometrial Cancer|Endometrial Adenocarcinoma|Endometrial Serous Adenocarcinoma|Endometrial Endometrioid Adenocarcinoma|Endometrial Clear Cell Adenocarcinoma|Lung Adenocarcinoma|Triple Negative Breast Cancer|Pancreatic Ductal Adenocarcinoma|Malignant Pleural Mesothelioma|Ovarian Clear Cell Carcinoma|Ovarian Clear Cell Adenocarcinoma|Ovarian Mucinous Adenocarcinoma","Drug: AMT-151","Recommended Phase 2 Dose (RP2D)|Maximum Tolerated Dose (MTD)|Incidence of Adverse Events|Overall Response Rate (ORR) according to the Response Evaluation Criteria in Solid Tumours (RECIST) v1.1|Disease Control Rate (DCR) according to the RECIST v1.1|Progression-free Survival (PFS)|Time to Treatment Response (TTR)|Duration of Response (DoR)|Overall Survival (OS)|Concentration of anti-drug antibodies (ADA)|Maximum observed concentration (C[max])|Area under the curve (AUC)|Terminal half-life (t[1/2])|Time to maximum concentration (Tmax)","Multitude Therapeutics Inc.|Tigermed Consulting Co., Ltd","All","18 Years and older   (Adult, Older Adult)","Phase 1","30","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AMT-151-01","October 1, 2022","January 1, 2024","October 30, 2024","August 12, 2022",,"August 12, 2022",,,"https://ClinicalTrials.gov/show/NCT05498597"
251,"NCT05498584","Targeting LOXL2 and Cardiac Fibrosis for Post-acute Heart Failure Treatment- A Prospective Study",,"Recruiting","No Results Available","Heart Failure; With Decompensation","Behavioral: exercise based cardiac rehabilitation","all-cause mortality|HF readmission|enothelial function improvement|Change From Baseline to Month 6 and Month 12 for the Kansas City Cardiomyopathy Questionnaire 12 (KCCQ 12) Clinical Summary Score","Chang Gung Memorial Hospital","All","20 Years to 100 Years   (Adult, Older Adult)",,"130","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","202002486B0A3","August 1, 2022","August 30, 2025","August 30, 2026","August 12, 2022",,"August 12, 2022","Chang Gung Memorial Hospital Heart Failure Center, Kaohsiung, Taiwan",,"https://ClinicalTrials.gov/show/NCT05498584"
252,"NCT05498571","Risk Prediction Model of Cardiovascular Events in Patients With Schizophrenia",,"Recruiting","No Results Available","Schizophrenia",,"cardiovascular events","Shanghai Mental Health Center","All","18 Years and older   (Adult, Older Adult)",,"1500","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","2020-YJ13","December 1, 2021","December 31, 2022","December 31, 2022","August 12, 2022",,"August 12, 2022","Shanghai Mental Health Center, Shanghai, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT05498571"
253,"NCT05498558","The Selection of Pregnancy for Patients After Tubal Ectopic Pregnancy Treatment","TSOPFPATEPT","Not yet recruiting","No Results Available","Tubal-preserving Treatment of Tubal Ectopic Pregnancy|Tubal Pregnancy|Pregnancy Preparation","Other: No intervention.","Rate of tubal pregnancy within12 months in both groups of patients.|Rates of pregnancy and miscarriage within 12 months in both groups of patients.","Shanghai First Maternity and Infant Hospital|Shanghai Seventh People's Hospital|Shanghai Zhoupu Hospital|Shanghai Pudong Hospital","Female","18 Years to 41 Years   (Adult)",,"400","Other","Observational","Observational Model: Other|Time Perspective: Prospective","ShanghaiFMIH2022-LSD","January 1, 2023","October 30, 2023","December 31, 2023","August 12, 2022",,"August 12, 2022","Shanghai First Maternity and Infant Hospital, Shanghai, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT05498558"
254,"NCT05498545","Universal BCMA-targeted LUCAR-B68 Cells in Patients With Relapsed/Refractory Multiple Myeloma",,"Not yet recruiting","No Results Available","Relapsed/Refractory Multiple Myeloma","Biological: LUCAR-B68 cells product","Incidence, severity, and type of treatment-emergent adverse events (TEAEs)|Dose-limiting toxicity (DLT) rate|Recommended Phase 2 dose (RP2D) finding|CAR positive NK cells in peripheral blood and bone marrow|CAR transgene levels in peripheral blood|Overall response rate (ORR)|Duration of Response (DOR)|Time to Response (TTR)|Progress Free Survival (PFS)|Overall Survival (OS)|Incidence of anti- LUCAR-B68 antibody","Second Affiliated Hospital of Xi'an Jiaotong University|Nanjing Legend Biotech Co.","All","18 Years and older   (Adult, Older Adult)","Phase 1","34","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BM2L202201","September 2022","December 2024","March 2027","August 12, 2022",,"August 12, 2022","Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China",,"https://ClinicalTrials.gov/show/NCT05498545"
255,"NCT05498532","Functional MRI Evaluation in Pyeloureteral Junction Syndrome in Children",,"Not yet recruiting","No Results Available","Stricture of Pelviureteric Juncture","Diagnostic Test: Functional MRI","MRI and scintigraphy differential renal function correlation|MRI and scintigraphy differential renal function correlation in operated patient|Time difference in patient operated for PUJS depending on MRI realisation ou MRI and scintigraphy realisation|performance of MRI in detecting polar vessel","Central Hospital, Nancy, France","All","1 Day to 17 Years   (Child)",,"270","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","2022PI108","September 1, 2022","September 15, 2022","December 30, 2022","August 12, 2022",,"August 12, 2022","CHRU Nancy, Vandœuvre-lès-Nancy, Lorraine, France",,"https://ClinicalTrials.gov/show/NCT05498532"
256,"NCT05498519","A First-in-Human, Phase 1 Study of SY-4798 in Patients With Advanced Solid Tumor",,"Recruiting","No Results Available","Advanced Solid Tumor","Drug: SY-4798","Incidence of dose limiting toxicities (DLTs)|Incidence of adverse events (AEs) and serious adverse events (SAEs)|Overall Response Rate (ORR) as assessed by RECIST 1.1 criteria|Duration of response (DOR)|Pharmacokinetics (Cmax) for SY-4798|Pharmacokinetics (Tmax) for SY-4798|Pharmacokinetics (AUC0-t) for SY-4798|Pharmacokinetics (t½) for SY-4798|Pharmacokinetics (Cl/F) for SY-4798","Shouyao Holdings (Beijing) Co. LTD","All","18 Years and older   (Adult, Older Adult)","Phase 1","80","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SY-4798-I-01","April 15, 2021","April 15, 2023","April 15, 2023","August 12, 2022",,"August 12, 2022","Shanghai East Hospital, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT05498519"
257,"NCT05498506","Multiple Firings in Double-stapled Colorectal Anastomosis",,"Not yet recruiting","No Results Available","Rectal Cancer",,"the number of linear stapler cartridges","Shanghai Minimally Invasive Surgery Center","All","Child, Adult, Older Adult",,"350","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","MISC-DST","September 1, 2022","December 31, 2022","December 31, 2022","August 12, 2022",,"August 15, 2022",,,"https://ClinicalTrials.gov/show/NCT05498506"
258,"NCT05498493","Cognitive Rehabilitation for Post-COVID-19 Cognitive Impairment",,"Not yet recruiting","No Results Available","Cognitive Impairment","Behavioral: Cognitive Rehabilitation|Behavioral: Brain Health Education Program","Trail Making Test - Part B|Wisconsin Card Sorting Task (WCST)-64|Acceptability Scale|Enrollment yield|Dropout number|Staff Practicality|Treatment Credibility and Expectancy Questionnaire.|Resting state functional connectivity (rsFC)|National Alzheimer's Coordinating Center (NACC) battery's Number Span|Paced Auditory Serial Addition Task (PASAT)|Trail Making Test, Part A|The Symbol Digit Modalities Text (SDMT)|The Hopkins Verbal Learning Test-Revised (HVLT-R)|NACC battery's verbal phonemic and category fluency tests|NACC battery's abbreviated Multilingual Naming Test (MINT)|Wide Range Achievement Test, reading subtest, 4th edition (WRAT-4)","Icahn School of Medicine at Mount Sinai","All","18 Years and older   (Adult, Older Adult)","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","STUDY-20-00857","September 2022","June 2023","June 2023","August 12, 2022",,"August 12, 2022","Icahn School of Medicine at Mount Sinai, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT05498493"
259,"NCT05498480","Study of Relatlimab in Combination With Nivolumab in Chinese Participants","RELATIVITY-111","Not yet recruiting","No Results Available","Advanced Solid Tumors","Biological: Relatlimab|Biological: Nivolumab","Number of Participants with Adverse Events (AEs)|Number of Participants with Immune-mediated Adverse Events (IMAEs)|Number of Participants with Serious Adverse Events (SAEs)|Number of Deaths|Number of Participants with AEs Leading to Discontinuation|Number of Participants with Dose-Limiting Toxicities (DLTs)|Number of Participants with Clinical Laboratory Abnormalities|Maximum Observed Plasma Concentration (Cmax) of Relatlimab|Time of Maximum Observed Plasma Concentration (Tmax) of Relatlimab|Trough-observed serum concentration (Ctrough) of Relatlimab|Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 by Investigator|Disease Control Rate (DCR) per RECIST v1.1 by Investigator|Duration of Response (DOR) per RECIST v1.1 by Investigator|Best Overall Response (BOR) per RECIST v1.1 by Investigator|Ctrough of Nivolumab|Observed Serum Concentration at End of Infusion (Ceoi) of Nivolumab|Percentage of Participants Positive for Anti-drug Antibodies (ADAs) to Relatlimab|Percentage of Participants Positive for ADAs to Nivolumab","Bristol-Myers Squibb","All","18 Years and older   (Adult, Older Adult)","Phase 1","12","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CA224-111","August 30, 2022","December 15, 2025","December 15, 2025","August 12, 2022",,"August 12, 2022","Local Institution, Shanghai, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT05498480"
260,"NCT05498467","The Role of Interleukin-1 Beta Targeted Therapy for Patients Suffering From Allergic Contact Dermatitis",,"Not yet recruiting","No Results Available","Allergic Contact Dermatitis","Drug: Anakinra|Drug: Sodium Chloride 9mg/ml Injection","Clinical reaction","Herlev and Gentofte Hospital","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","LEOSIC","September 1, 2022","April 1, 2023","August 1, 2023","August 12, 2022",,"August 12, 2022",,,"https://ClinicalTrials.gov/show/NCT05498467"
261,"NCT05498454","Contribution of Online Stress and Pain Mindfulness Treatment to ACT Process Change and Outcomes in Chronic Pain",,"Not yet recruiting","No Results Available","Chronic Pain","Behavioral: Breathworks Mindfulness (Health or Stress Arm)","Differential contribution of mindfulness for stress and mindfulness for pain courses on Acceptance and Commitment Therapy (ACT) process 1: Acceptance utilising The 7-item Acceptance and Action Questionnaire v.2|Differential contribution of mindfulness for stress and mindfulness for pain courses on Acceptance and Commitment Therapy (ACT) process 1a: Pain Acceptance utilisikng the 8-item Chronic Pain Acceptance Questionnaire|Differential contribution of mindfulness for stress and mindfulness for pain courses on Acceptance and Commitment Therapy (ACT) process 2: Contact with the Present Moment: The Mindful Attention Awareness Scale will be utilised.|Differential contribution of mindfulness for stress and mindfulness for pain courses on Acceptance and Commitment Therapy (ACT) process 3: Self in context: The Self Experience Questionnaire will be utlised.|Differential contribution of mindfulness for stress and mindfulness for pain courses on Acceptance and Commitment Therapy (ACT) process 4: Cognitive fusion: the Cognitive Fusion Questionnaire|Differential contribution of mindfulness for stress and mindfulness for pain courses on Acceptance and Commitment Therapy (ACT) process 5: Values: The Chronic Pain Values Inventory|Differential contribution of mindfulness for stress and mindfulness for pain courses on Acceptance and Commitment Therapy (ACT) process 6: Committed Action: The 8-item Committed Action Questionnaire|IMMPACT consistent, changes in Pain Intensity (How sore the participant is) will be evaluated utilising the Brief Pain Inventory - Short Form (BPI)|IMMPACT consistent, changes in Pain Interference (on functioning and aspects of quality of life) will be evaluated utilising the Brief Pain Inventory - Short Form (BPI)|IMMPACT consistent measurement of change in emotional functioning: depression screening utilizing the Beck Depression Inventory - Fast Screen (BDI-FS)|IMMPACT consistent measurement of change in emotional functioning: catastrophizing, utilizing Pain Catastrophizing Scale (PCS)|IMMPACT consistent measurement of change in patient's ratings of global functioning|IMMPACT consistent measurement of change in participants' disposition via subjective impression of change on pain, interference from pain, resilience on a scale of -100% (worse) to + 100% better.|IMMPACT consistent measurement of change in pain medication changes utilizing name and amount (mg/g) of pain / mood medication|Accident and Emergency (A&E) and primary care GP visits","Government of Jersey|Liverpool John Moores University|Breathworks CIC|Primary Care Body (Jersey, United Kingdom)","All","18 Years and older   (Adult, Older Adult)","Not Applicable","96","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","MT/LC 11/10/2019","August 2022","December 2022","April 2023","August 12, 2022",,"August 12, 2022",,"""Study Protocol, Statistical Analysis Plan, and Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/54/NCT05498454/Prot_SAP_ICF_000.pdf","https://ClinicalTrials.gov/show/NCT05498454"
262,"NCT05498441","Personalized High-Definition Transcranial Direct Current Stimulation (HD-tDCS) Treatment for Major Depressive Episode","PRHDTDCSTMDE","Not yet recruiting","No Results Available","Major Depressive Episode","Device: High-Definition Transcranial Direct Current Stimulation (HD-tDCS)|Drug: Quetiapine, lithium and divalproate","Change from baseline in depressive symptoms assessed by Hamilton depression rating scale 17 items (HAMD-17) at week 1 and week 2.|Change from baseline in neurocognitive function using Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) test at week 2.|Change from baseline in the amplitude of low-frequency fluctuation (ALFF) values measured by resting-state functional magnetic resonance imaging (fMRI) at week 1 and week 2.|Change from baseline in the Clinical Global Impression-Severity scale (CGI-S) at week 1 and week 2.|Change from baseline in the Montgomery-Asberg Depression Rating Scale (MADRS) at week 1 and week 2.","Jiangsu Province Nanjing Brain Hospital","All","13 Years to 18 Years   (Child, Adult)","Not Applicable","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","81725005-3","September 1, 2022","September 30, 2023","September 30, 2023","August 12, 2022",,"August 12, 2022","Affiliated Nanjing Brain Hospital, Nanjing Medical University, Nanjing, Jiangsu, China",,"https://ClinicalTrials.gov/show/NCT05498441"
263,"NCT05498428","A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer","PALOMA-2","Not yet recruiting","No Results Available","Carcinoma, Non-small-Cell Lung","Drug: Amivantamab|Drug: Lazertinib|Drug: Carboplatin|Drug: Pemetrexed","Cohorts 1, 2, and 3: Objective Response Rate (ORR) Based on Investigator Assessment (INV)|Cohort 4: Number of Participants with Adverse Events (AEs)|Cohort 4: Number of Participants with AEs by Severity|Cohort 4: Number of Participants with Abnormalities in Clinical Laboratory Values|Cohort 4: Number of Participants with Abnormalities in Clinical Laboratory Values by Severity|Cohorts 1, 2, and 3: Number of Participants with AEs|Cohorts 1, 2, and 3: Number of Participants with AEs by Severity|Cohorts 1, 2, and 3: Number of Participants with Abnormalities in Clinical Laboratory Values|Cohorts 1, 2, and 3: Number of Participants with Abnormalities in Clinical Laboratory Values by Severity|Cohorts 1, 2, and 3: ORR Based on Independent Central Review (ICR)|Cohorts 1, 2, and 3: Duration of Response (DoR)|Cohorts 1, 2, and 3: Time to Response (TTR)|Cohorts 1, 2, and 3: Clinical Benefit Rate (CBR)|Cohorts 1, 2, and 3: Progression-free Survival (PFS)|Overall Survival (OS)|Cohorts 1, 2, and 3: Serum Concentration Immediately Prior to the Next Dose Administration (Ctrough) of Amivantamab|Cohort 4: Cancer Therapy Satisfaction as Assessed by Modified Therapy Administration Satisfaction Questionnaire - Intravenous (TASQ-IV)|Cohort 4: Cancer Therapy Satisfaction as Assessed by Modified Therapy Administration Satisfaction Questionnaire - Subcutaneous (TASQ-SC)|Cohort 4: Patient-reported Status as Assessed by Patient Global Impression of Change (PGIC) Scale Score|Cohort 4: Patient-reported Status as Assessed by Patient Global Impression of Symptom Severity (PGIS) Scale Score","Janssen Research & Development, LLC","All","18 Years and older   (Adult, Older Adult)","Phase 2","260","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CR109264|2022-000526-21|61186372NSC2002","November 7, 2022","May 21, 2024","May 31, 2024","August 12, 2022",,"August 12, 2022","University of Kansas Cancer Center, Westwood, Kansas, United States|Hunter Holmes McGuire Veterans Affairs Medical Center, Richmond, Virginia, United States|Beijing Cancer Hospital of Peking University, Beijing, China|Jilin cancer hospital, Changchun, China|West China Hospital, Sichuan University, Chengdu, China|The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China|Harbin medical university cancer hospital, Harbin, China|Liuzhou people&#39;s Hospital, Liuzhou, China|The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China|Yantai Yuhuangding Hospital, Yantai, China|Rambam Medical Center Department of Pediatric Pulmonology Meyer Childern's Hospital, Haifa, Israel|Shizuoka Cancer Center, Shizuoka, Japan|The Cancer Institute Hospital of JFCR, Tokyo, Japan|Wakayama Medical University Hospital, Wakayama, Japan|University Malaya Medical Centre, Kuala Lumpur, Malaysia|Hospital Tengku Ampuan Afzan, Kuantan, Malaysia|Hospital Umum Sarawak, Kuching, Malaysia|Beacon Hospital Sdn. Bhd., Petaling Jaya, Malaysia|Hosp. Univ. A Coruña, A Coruña, Spain|General University Hospital of Alicantet, Alacant, Spain|Hosp. Univ. Vall D Hebron, Barcelona, Spain|Hosp. Del Mar, Barcelona, Spain|Hosp. de La Santa Creu I Sant Pau, Barcelona, Spain|Inst. Cat. Doncologia-H Duran I Reynals, Barcelona, Spain|Hosp. Gral. Univ. Gregorio Marañon, Madrid, Spain|Hosp. Univ. Ramon Y Cajal, Madrid, Spain|Hosp. Univ. La Paz, Madrid, Spain|Hosp. Univ. 12 de Octubre, Madrid, Spain|Hosp. Regional Univ. de Malaga, Malaga, Spain|Hosp. Virgen Macarena, Sevilla, Spain|Hosp. Clinico Univ. de Valencia, Valencia, Spain|Bristol Haematology and Oncology Centre, Bristol, United Kingdom|Torbay Hospital-Devon, Devon, United Kingdom|Edinburgh Cancer Centre Western General, Edinburgh, United Kingdom|Leicester Royal Infirmary, Leicester, United Kingdom|University College London Hospitals, London, United Kingdom|Sarah Cannon Research Institute, London, United Kingdom|Southampton University Hospital, Southampton, United Kingdom",,"https://ClinicalTrials.gov/show/NCT05498428"
264,"NCT05498415","Feasibility, Acceptability, and Efficacy of the Sleep Move Stand Study","SMS","Not yet recruiting","No Results Available","Physical Inactivity|Sedentary Behavior|Sleep|Cognitive Function","Behavioral: Education|Behavioral: Health coaching|Behavioral: Activity Monitor","Physical activity|Sedentary Behavior|Sleep|Cognitive function","University of Iowa","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention","201812789","September 1, 2022","December 31, 2022","June 1, 2023","August 12, 2022",,"August 12, 2022",,,"https://ClinicalTrials.gov/show/NCT05498415"
265,"NCT05498402","Effect of IAM With an I-gel® on Ventilation Parameters in Simulated Pediatric OHCA",,"Not yet recruiting","No Results Available","Pediatric ALL|Cardiac Arrest|Cardiopulmonary Arrest|Resuscitation|Pediatric Emergency Medicine","Device: i-gel ® device|Device: bag-valve-mask ventilation","Alveolar ventilation per minute|The proportion, and number of ventilations below, within and over the target volume|The time to the first efficient ventilation|The time to the first compression|The chest compression fraction|The chest compression rate|The proportion of chest compressions below, within and over the target rate|The compression depth|The proportion of chest compressions below and within the target depth|The proportion of complete chest recoil|The time to first epinephrine injection|The proportion of scenarios in which epinephrine is administered within 5 minutes","Geneve TEAM Ambulances|ESAMB - College of Higher Education in Ambulance Care|Ambulances de la Ville de Sion|University Hospital, Geneva","All","Child, Adult, Older Adult","Not Applicable","44","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","CPR-6","January 15, 2023","January 15, 2023","March 1, 2023","August 12, 2022",,"August 12, 2022",,,"https://ClinicalTrials.gov/show/NCT05498402"
266,"NCT05498389","EMB-01 in Combination With Osimertinib in Patients With EGFR Mutant Lung Cancer",,"Not yet recruiting","No Results Available","Metastatic Lung Non-Small Cell Carcinoma|Advanced Lung Non-Small Cell Carcinoma|Stage IV Lung Cancer AJCC v8|Stage IVA Lung Cancer AJCC v8|Stage IVB Lung Cancer AJCC v8|Stage III Lung Cancer AJCC v8|Stage IIIA Lung Cancer AJCC v8|Stage IIIB Lung Cancer AJCC v8|EGFR Mutation-Related Tumors","Drug: EMB-01|Drug: Osimertinib","Maximum tolerated dose (MTD) of EMB-01 and osimertinib (Phase Ib only)|Rate of Adverse Events (AE) and Serious Adverse Events (SAE)|Recommended phase II dose (RP2D) of EMB-01 and osimertinib (Phase Ib)|Objective Response Rate (ORR) (Phase II only)|Best Overall Response (BOR)|Duration of Response (DoR)|Clinical Benefit Rate (CBR)|Progression Free Survival (PFS)|Cmax|Tmax|Ctrough|Immunogenicity profile of EMB-01","Shanghai EpimAb Biotherapeutics Co., Ltd.|Labcorp Drug Development, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","115","Industry","Interventional","Allocation: N/A|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","EMB01X202","October 2022","July 2024","December 2024","August 12, 2022",,"August 12, 2022","Chao Family Comprehensive Cancer Center, University of California Irvine School of Medicine, Orange, California, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China",,"https://ClinicalTrials.gov/show/NCT05498389"
267,"NCT05498376","The Leadless AV Versus DDD Pacing Study","LEAVE DDD","Not yet recruiting","No Results Available","Cardiac Pacemaker|Arrhythmias, Cardiac|Heart Diseases|Cardiovascular Diseases","Device: Conventional pacemaker DDD|Device: Leadless pacemaker Micra AV","Exercise capacity|Total implantation time|Total fluoroscopy time|Total fluoroscopy dosage|Pacing thresholds|Sensing values|Impedance values|Duration of exercise|VO2max|VE/VCO2|VE/VO2|Maximum atrial heart rate|Left ventricular ejection fraction (LVEF)|Degree of tricuspid valve regurgitation|Degree of mitral valve regurgitation|Quality of Life scores measured with the EQ-5D-5L Questionnaire|AV synchrony|Laboratory|Safety outcomes","University Hospital Inselspital, Berne|University of Bern","All","70 Years and older   (Older Adult)","Phase 4","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2021-D0050","September 1, 2022","May 31, 2024","February 28, 2026","August 12, 2022",,"August 12, 2022","Inselspital, Bern University Hospital, Bern, Switzerland",,"https://ClinicalTrials.gov/show/NCT05498376"
268,"NCT05498363","Bacteriophage Therapy of Difficult-to-treat Infections","BT100","Completed","No Results Available","Bacterial Infections","Biological: Bacteriophage therapy","Clinical improvement|Microbial eradication|Adverse reactions","Queen Astrid Military Hospital","All","1 Month to 91 Years   (Child, Adult, Older Adult)",,"100","Other","Observational","Observational Model: Case-Only|Time Perspective: Retrospective","BT100","January 1, 2008","December 31, 2021","December 31, 2021","August 12, 2022",,"August 12, 2022",,,"https://ClinicalTrials.gov/show/NCT05498363"
269,"NCT05498350","Randomized Trial Comparing Early ""Trigger"" Versus Delayed ""Trigger"" Timing in Cycles of Controlled Ovarian Stimulation.",,"Recruiting","No Results Available","Infertility, Female","Procedure: Ovulatory trigger timing","Good-quality blastocysts|Delayed blastocyst formation","Fertility Center of Las Vegas","Female","18 Years to 34 Years   (Adult)","Not Applicable","150","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","FCLV-2022-1","August 10, 2022","August 31, 2024","November 30, 2025","August 12, 2022",,"August 12, 2022","Fertility center of Las Vegas, Las Vegas, Nevada, United States",,"https://ClinicalTrials.gov/show/NCT05498350"
270,"NCT05498337","Vital Pulp Therapy With Different Materials for Young Permanent Teeth",,"Not yet recruiting","No Results Available","Vital Pulp Therapy","Other: calcium hydroxide|Other: MTA|Device: Diode Laser","Root completion|Root lengthening and thickening","Mansoura University","All","7 Years to 9 Years   (Child)","Not Applicable","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","Vital pulp therapy","September 1, 2022","September 1, 2023","March 1, 2024","August 12, 2022",,"August 15, 2022",,,"https://ClinicalTrials.gov/show/NCT05498337"
271,"NCT05498324","External Validation of the 4C Mortality Score for Hospitalised Patients With COVID-19 in a Tunisian Cohort","4C","Completed","No Results Available","COVID-19 Pandemic",,"The primary outcome was all-cause in-hospital mortality rate|The 4C Mortality Score's predictive accuracy to prognosticate in-hospital mortality was measured by the athe area under the receiver operating characteristic curver (AUROC) with 95% confidence intervals.|ICU admission rate","University of Monastir","All","18 Years to 90 Years   (Adult, Older Adult)",,"1500","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","4C Score","November 1, 2020","December 1, 2021","December 1, 2021","August 12, 2022",,"August 12, 2022","Fattouma Bourguiba University Hospital, Monastir, Tunisia",,"https://ClinicalTrials.gov/show/NCT05498324"
272,"NCT05498311","Breast Cancer With Intraoperative Radiotherapy Followed by Hypofractionated External Beam Radiotherapy","IORT_BREAST","Recruiting","No Results Available","Breast Cancer","Radiation: Intraoperative Radiotherapy (IORT)|Procedure: Breast conservative surgery|Radiation: External Beam Hypofractionated Radiotherapy (EBRT)","Changes in Cosmetic results - BCCT|Changes in Cosmetic results - Self Evaluation using YBT|Changes in Quality of life (QOL) - General|Toxicity (acute and late)|Local control|Changes in Quality of life (QOL) - Breast","Institut Català d'Oncologia","Female","45 Years and older   (Adult, Older Adult)","Phase 2","89","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IORT BREAST CANCER","October 20, 2016","December 2023","December 2024","August 12, 2022",,"August 15, 2022","Evelyn Martínez, Hospitalet de Llobregat, Barcelona, Spain",,"https://ClinicalTrials.gov/show/NCT05498311"
273,"NCT05498298","A Clinical Study to Investigate the Reliability of Fetal Heart Rate and Maternal Heart Rate Signals Extracted From Biopotential Data",,"Recruiting","No Results Available","Pregnancy Related","Device: Biopotentials measurement with gtec device","Reliability in fetal heart rate extraction|Reliability in maternal heart rate extraction","Bloom Technologies","Female","18 Years and older   (Adult, Older Adult)","Not Applicable","100","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","LOV-02-2022-US","August 3, 2022","December 2022","December 2022","August 12, 2022",,"August 12, 2022","Valley Perinatal Services, Phoenix, Arizona, United States",,"https://ClinicalTrials.gov/show/NCT05498298"
274,"NCT05498285","Post-ACL Reconstruction Rehab UPSCALER App RCT HPUPM",,"Not yet recruiting","No Results Available","ACL Injury","Behavioral: UPSCALER app","KOOS score","Hospital Pengajar Universiti Putra Malaysia","All","18 Years and older   (Adult, Older Adult)","Not Applicable","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment","JKEUPM-2022-294","September 1, 2022","August 31, 2023","August 31, 2023","August 12, 2022",,"August 12, 2022","Hospital Pengajar Universiti Putra Malaysia, Serdang, Selangor, Malaysia",,"https://ClinicalTrials.gov/show/NCT05498285"
275,"NCT05498272","Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With BRCA1/2 Gene Alterations","NePtune","Not yet recruiting","No Results Available","Prostate Cancer|BRCA1 Mutation|BRCA2 Mutation|Prostatic Adenocarcinoma|High-Risk Cancer","Drug: Olaparib|Drug: LHRH agonist","Pathological Complete Response (pCR) rate|Minimal Residual Disease (MRD) rate|Compare changes in Prostate specific antigen (PSA)|Surgical pathologic outcomes at RP|Residual Cancer Burden (RCB) at RP|Event Free Survival (EFS)|Treatment Free Survival post RP|Pathologic Response (pCR and/or MRD) with biochemical Progression Free Survival (PFS).|Time to Testosterone Recovery post RP|Assess adverse events|Intra- and Post-Operative Complications|Assess Cardiovascular Adverse Events","Rana McKay, MD|AstraZeneca|University of California, San Diego|Hoosier Cancer Research Network","Male","18 Years and older   (Adult, Older Adult)","Phase 2","32","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HCRN GU20-436","December 2022","July 2023","July 2024","August 12, 2022",,"August 12, 2022",,,"https://ClinicalTrials.gov/show/NCT05498272"
276,"NCT05498259","Orelabrutinib With R-CHOP-like Regimen for Patients With Newly Diagnosed Untreated Non-GCB DLBCL",,"Recruiting","No Results Available","Diffuse Large B-Cell Lymphoma","Drug: Orelabrutinib|Biological: Rituximab|Drug: CHOP-like Regimen","Mini response rate|Complete Response Rate|Overall Response Rate (ORR)|Progression-free survival（PFS）|Incidence of Treatment-Emergent Adverse Events, Treatment-Related Adverse Events and Serious Adverse Events","The First Affiliated Hospital of Soochow University","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","46","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Jinzm 002","July 27, 2022","January 1, 2024","January 1, 2025","August 12, 2022",,"August 12, 2022","the First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China",,"https://ClinicalTrials.gov/show/NCT05498259"
277,"NCT05498246","Bipolar Coagulation Versus Suture Renorrhaphy in Laparoscopic Partial Nephrectomy",,"Completed","No Results Available","Nephrectomy","Procedure: laparoscopic partial nephrectomy","To compare between bipolar coagulation of tumor bed in laparoscopic partial nephrectomy versus suture renorrhaphy","Benha University","All","18 Years to 75 Years   (Adult, Older Adult)","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","Lap in partial nephrectomy","December 5, 2020","December 10, 2021","December 25, 2021","August 12, 2022",,"August 12, 2022","Mohamed Kadry Mostafa, Banhā, Qalubia, Egypt",,"https://ClinicalTrials.gov/show/NCT05498246"
278,"NCT05498233","Pharmacokinetics and Bioequivalence of Doxylamine + Pyridoxine, Film-coated, Enteric-soluble Tablets, and Diclectin, Delayed Release Tablets, in Healthy Volunteers",,"Recruiting","No Results Available","Pregnancy Related|Nausea","Drug: Doxylamine + Pyridoxine","Pharmacokinetics - Cmax (Doxylamine)|Pharmacokinetics - Cmax (Pyridoxal-5-phosphate)|Pharmacokinetics - tmax (Doxylamine)|Pharmacokinetics - tmax (Pyridoxal-5-phosphate)|Pharmacokinetics - AUC0-t (Doxylamine)|Pharmacokinetics - AUC0-t (Pyridoxal-5-phosphate)|Pharmacokinetics - AUC0-inf (Doxylamine)|Pharmacokinetics - AUC0-inf (Pyridoxal-5-phosphate)|Pharmacokinetics - AUCextr (Doxylamine)|Pharmacokinetics - AUCextr (Pyridoxal-5-phosphate)|Pharmacokinetics - t1/2 (Doxylamine)|Pharmacokinetics - t1/2 (Pyridoxal-5-phosphate)|Pharmacokinetics - kel (Doxylamine)|Pharmacokinetics - kel (Pyridoxal-5-phosphate)|Pharmacokinetics - MRT (Doxylamine)|Pharmacokinetics - MRT (Pyridoxal-5-phosphate)|Bioequivalence - ratio of Cmax (Doxylamine)|Bioequivalence - ratio of Cmax (Pyridoxal-5-phosphate)|Bioequivalence - ratio of AUC0-t (Doxylamine)|Bioequivalence - ratio of AUC0-t (Pyridoxal-5-phosphate)|Bioequivalence - ratio of AUC0-inf (Doxylamine)|Bioequivalence - ratio of AUC0-inf (Pyridoxal-5-phosphate)|Safety and Tolerability: adverse event (AE) number and frequency|serious adverse event (SAE) number and frequency|Safety and Tolerability: vital signs - systolic blood pressure (SBP)|Safety and Tolerability: vital signs - diastolic blood pressure (DBP)|Safety and Tolerability: vital signs - respiratory rate (RR)|Safety and Tolerability: vital signs - heart rate (HR)|Safety and Tolerability: vital signs - body temperature|Safety and Tolerability: physical examination results|Safety and Tolerability: 12-lead electrocardiogram (ECG) - heart rate|Safety and Tolerability: 12-lead electrocardiogram (ECG) - PQ interval|Safety and Tolerability: 12-lead electrocardiogram (ECG) - QRS complex|Safety and Tolerability: 12-lead electrocardiogram (ECG) - corrected QT interval (QTc)|Safety and Tolerability: urinalysis - color|Safety and Tolerability: urinalysis - transparency|Safety and Tolerability: urinalysis - pH|Safety and Tolerability: urinalysis - specific gravity|Safety and Tolerability: urinalysis - protein|Safety and Tolerability: urinalysis - glucose|Safety and Tolerability: urinalysis (microscopy) - red blood cells|Safety and Tolerability: urinalysis (microscopy) - white blood cells|Safety and Tolerability: urinalysis (microscopy) - epithelial cells|Safety and Tolerability: urinalysis (microscopy) - cylinders|Safety and Tolerability: urinalysis (microscopy) - mucus|Safety and Tolerability: urinalysis (microscopy) - bacteria|Safety and Tolerability: complete blood count - hemoglobin|Safety and Tolerability: complete blood count - red blood cells|Safety and Tolerability: complete blood count - hematocrit|Safety and Tolerability: complete blood count - platelets|Safety and Tolerability: complete blood count - white blood cells|Safety and Tolerability: complete blood count - erythrocyte sedimentation rate|Safety and Tolerability: complete blood count - neutrophils|Safety and Tolerability: complete blood count - lymphocytes|Safety and Tolerability: complete blood count - eosinophils|Safety and Tolerability: complete blood count - monocytes|Safety and Tolerability: complete blood count - basophils|Safety and Tolerability: blood test results - total protein|Safety and Tolerability: blood test results - creatinine|Safety and Tolerability: blood test results - glucose|Safety and Tolerability: blood test results - total bilirubin|Safety and Tolerability: blood test results - total cholesterol|Safety and Tolerability: blood test results - alanine transaminase (ALT)|Safety and Tolerability: blood test results - aspartate transaminase (AST)|Safety and Tolerability: blood test results - alkaline phosphatase (ALP)","Valenta Pharm JSC","Female","18 Years to 49 Years   (Adult)","Not Applicable","28","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other","DIP-05-01-2022","July 11, 2022","December 31, 2022","December 31, 2022","August 12, 2022",,"August 12, 2022","Llc ""Certa Clinic"", Moscow, Russian Federation",,"https://ClinicalTrials.gov/show/NCT05498233"
279,"NCT05498220","Polatuzumab Vedotin With R-GDP in Relapsed/Refractory Diffuse Large B-cell Lymphoma",,"Not yet recruiting","No Results Available","Diffuse Large B-cell Lymphoma","Drug: Polatuzumab vedotin (PV)|Drug: Rituximab|Drug: Hyaluronidase|Drug: Gemcitabine|Drug: Cisplatin|Drug: Dexamethasone|Drug: GCSF","Overall response rate (ORR)|Complete response rate (CR)|Progression free survival (PFS)|Overall Survival (OS)|Number of participants with adverse events","UNC Lineberger Comprehensive Cancer Center|Genentech, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 2","44","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LCCC2033","September 27, 2022","August 2028","August 2028","August 11, 2022",,"August 11, 2022","Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT05498220"
280,"NCT05498207","Identification of Biomarkers for Stress Vulnerability and Resilience",,"Not yet recruiting","No Results Available","Healthy","Behavioral: Maya App","Change in anxiety symptoms based on the General Anxiety Disorder-7 Scale (GAD-7) between the intervention arm and the no intervention arm|Change in depressive symptoms based on the Patient Health Questionnaire-9 (PHQ-9) between the intervention arm and the no intervention arm|Change in anxiety symptoms based on the Spielberger State and Trait Anxiety Inventory (STAI) between the intervention arm and the no intervention arm","University of Michigan|Pritzker Consortium|Weill Medical College of Cornell University","All","18 Years to 22 Years   (Adult)","Not Applicable","400","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HUM00211856","August 2022","September 2024","September 2024","August 11, 2022",,"August 11, 2022","University of Michigan, Ann Arbor, Michigan, United States",,"https://ClinicalTrials.gov/show/NCT05498207"
281,"NCT05498194","Computational Prediction and Experimental Validation of Gastric Cancer Associated Neoantigens",,"Not yet recruiting","No Results Available","Gastric Cancer|Neoantigens","Diagnostic Test: ratio of predicted neoantigens","The neoantigen landscape of patients with gastric cancer|The ratio of predicted neoantigens being presented by HLA-I|The ratio of predicted neoantigens being immunogenic.","University Medical Center Ho Chi Minh City (UMC)","All","15 Years to 18 Years   (Child, Adult)",,"50","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","62/GCN-HDDD","August 15, 2022","December 31, 2023","December 31, 2023","August 11, 2022",,"August 11, 2022","University Medical Center Ho Chi Minh City, Ho Chi Minh City, Vietnam",,"https://ClinicalTrials.gov/show/NCT05498194"
282,"NCT05498181","Angiotensin-Neprilysin Inhibition in Hemodialysis Initiation",,"Not yet recruiting","No Results Available","Hemodialysis","Drug: Sacubitril-valsartan","Change in left atrial volume index from baseline to 16 weeks|Change in IVC collapsibility index from baseline to 16 weeks|Change in pre-dialysis NTpro-BNP from baseline to 16 weeks|Change in eGFR from baseline to 16 weeks, assessed by 24-hour averaged urien urea and creatinine clearance|Adverse Events|Serious Adverse Events|Inter-dialytic hypotension (symptomatic SBP <90 mmHg or hypotension requiring adjustment in blood pressure medications or treatment in an emergency or hospitalized setting)|Intra-dialytic hypotension (defined as nadir SBP <90 mmHg if pre-HD SBP≤160 mmHg, or nadir SBP <100 mmHg if pre-HD SBP >160 mmHg)|Hyperkalemia (pre-dialysis serum potassium >5.5 mmol/L)|Angioedema|Proportion of participants able to complete the full 16 weeks of treatment|Proportion of participants able to reach maximum dose titration|Study medication discontinuation rates|Changes in SMaRRT-HD and Dialysis Symptom Index questionnaire scores from baseline to 16 weeks|Rates of recruitment, withdrawal, and loss-to-follow-up|Reasons for ineligibility|Adherence to the study drug administration schedule","Brigham and Women's Hospital|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","All","18 Years and older   (Adult, Older Adult)","Phase 2","100","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2021P003592|R01DK129749","September 1, 2022","March 31, 2025","July 30, 2025","August 11, 2022",,"August 11, 2022",,,"https://ClinicalTrials.gov/show/NCT05498181"
283,"NCT05498168","Computational Prediction and Experimental Validation of Esophageal Cancer Associated Neoantigens",,"Not yet recruiting","No Results Available","Esophageal Cancer|Neoantigen","Genetic: ratio of predicted neoantigens","The neoantigen landscape of patients with esophageal cancer|The ratio of predicted neoantigens being presented by HLA-I|The ratio of predicted neoantigens being immunogenic","University Medical Center Ho Chi Minh City (UMC)","All","15 Years to 90 Years   (Child, Adult, Older Adult)",,"50","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","61/GCN-HDDD","September 1, 2022","December 31, 2023","December 31, 2023","August 11, 2022",,"August 11, 2022","University Medical Center Ho Chi Minh City, Ho Chi Minh City, Vietnam",,"https://ClinicalTrials.gov/show/NCT05498168"
284,"NCT05498155","Study of Neoadjuvant Olaparib Monotherapy and Olaparib and Durvalumab Combination in HER2 Negative BRCAm Breast Cancer","OlympiaN","Not yet recruiting","No Results Available","Breast Cancer","Drug: Neoadjuvant Olaparib monotherapy group|Combination Product: Neoadjuvant combination therapy with olaparib plus durvalumab","To evaluate the efficacy, measured by pCR (pathological complete response) rate, of olaparib monotherapy and olaparib plus durvalumab combination therapy, as assessed by central pathology review.|To evaluate the efficacy, measured by pCR rate, of olaparib monotherapy and olaparib plus durvalumab combination therapy as assessed by local pathology review|To evaluate the efficacy, measured by RCB (residual cancer burden), of olaparib monotherapy and olaparib plus durvalumab combination therapy as assessed by central pathology review|To evaluate the efficacy, measured by RCB, of olaparib monotherapy and olaparib plus durvalumab combination therapy as assessed by local pathology review|To evaluate the efficacy of olaparib monotherapy and olaparib plus durvalumab combination therapy in terms of change from baseline tumour volume. Tumour volume will be assessed by local radiology review.|To evaluate the efficacy of olaparib monotherapy and olaparib plus durvalumab combination therapy by assessment of EFS (event-free survival).|Safety and tolerability profile of olaparib monotherapy and olaparib plus durvalumab combination therapy by assessment of advers events and seriuos advers events (AEs/SAEs)|The number of participants with adverse events /serious adverse events of olaparib monotherapy and olaparib plus durvalumab combination therapy.|Safety and tolerability profile of olaparib monotherapy when given as adjuvant therapy to participants who achieve pCR by assessment of AEs/SAEs|The number of participants with adverse events / serious adverse events of olaparib monotherapy when given as adjuvant therapy to participants who achieve pCR.|Systolic blood pressure (SBP), diastolic blood pressure (DBP)|Body Temperature|Pulse rate (heart rate)|Weight","AstraZeneca","All","18 Years to 130 Years   (Adult, Older Adult)","Phase 2","80","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","D931CC00001|2021-005231-22","September 9, 2022","April 5, 2024","October 9, 2026","August 11, 2022",,"August 11, 2022","Research Site, Wien, Austria|Research Site, Bruxelles, Belgium|Research Site, Poitiers, France|Research Site, Hamburg, Germany|Research Site, Jerusalem, Israel|Research Site, Napoli, Italy|Research Site, Sevilla, Spain",,"https://ClinicalTrials.gov/show/NCT05498155"
285,"NCT05498142","Predicting the Risk of Venous Thromboembolism in Critically Ill Patients",,"Active, not recruiting","No Results Available","Venous Thromboembolism|Critical Illness",,"Number of patients with in-hospital VTE","University Medical Center Groningen","All","18 Years and older   (Adult, Older Adult)",,"7600","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","VTEICU","March 2015","August 2023","August 2023","August 11, 2022",,"August 15, 2022",,,"https://ClinicalTrials.gov/show/NCT05498142"
286,"NCT05498129","School Feeding to Improve Cognitive Performance in Disadvantaged Children",,"Completed","No Results Available","Cognitive Performance","Other: School meal|Other: School meal plus micronutrient powder|Other: No school meal","Ravens Colour Matrices test for assessment of Cognitive function|Height|Mass|Mid upper arm circumference|Height for age|Weight for age|Haemoglobin","University of Central Lancashire|Khyber Medical University","All","Child, Adult, Older Adult","Not Applicable","210","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science","School Feeding","September 1, 2017","July 15, 2018","December 1, 2018","August 11, 2022",,"August 11, 2022","Jonathan Sinclair, Preston, Lancashire, United Kingdom",,"https://ClinicalTrials.gov/show/NCT05498129"
287,"NCT05498116","Effect of Montelukast on Kidney and Vascular Function in Type 1 Diabetes",,"Not yet recruiting","No Results Available","Albuminuria","Drug: Montelukast|Other: Placebo","Change in Albuminuria|Change in Brachial artery flow mediated dilation (FMD)|Change in Large Elastic Artery Stiffness","University of Colorado, Denver","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 4","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","22-1027","October 2022","October 2025","October 2025","August 11, 2022",,"August 11, 2022",,,"https://ClinicalTrials.gov/show/NCT05498116"
288,"NCT05498103","Use of Methazolamide to Lower Intraocular Pressure",,"Not yet recruiting","No Results Available","Glaucoma, Open-Angle","Drug: Methazolamide 25 MG|Drug: Methazolamide 50 MG","Significant change in Intraocular Pressure from Baseline|Change in Plasma levels of methazolamide|Change in Plasma levels of electrolytes|Change in Urinary pH|Change in Urine electrolytes|Number of treatment emergent adverse events","University of Colorado, Denver","All","50 Years to 90 Years   (Adult, Older Adult)","Phase 4","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","22-0721","August 15, 2022","July 31, 2023","August 7, 2023","August 11, 2022",,"August 11, 2022","Sue Anschutz-Rodgers Eye Center, Aurora, Colorado, United States",,"https://ClinicalTrials.gov/show/NCT05498103"
289,"NCT05498090","Interrogating Fatty Acid Metabolism Impairment and Clinical Correlates in Males With Klinefelter Syndrome",,"Not yet recruiting","No Results Available","Klinefelter Syndrome","Drug: Fenofibrate 145 mg","maximal rate of fat oxidation|skeletal muscle fat oxidation|differentially-expressed genes in plasma|differentially-expressed genes in skeletal muscle tissue","University of Colorado, Denver|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","Male","15 Years to 40 Years   (Child, Adult)","Phase 4","44","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","21-2860","September 1, 2022","June 30, 2025","August 30, 2025","August 11, 2022",,"August 11, 2022","University of Colorado - Anschutz Medical Campus, Aurora, Colorado, United States",,"https://ClinicalTrials.gov/show/NCT05498090"
290,"NCT05498077","Immediate Effects of a 10-minute Body Scan Meditation on People Who Has Central Sensitization",,"Active, not recruiting","No Results Available","Chronic Pain","Procedure: Body scan meditation","Global Rating of Change|Pain pressure Threshold|Neck Disability Index|Oswestry Disability Index|Pain Body Diagram|Numeric Pain Rating Scale","Therapeutic Neuroscience Research Group|Rockhurst University|Evidence in Motion","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","15","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PSFMcConahay","May 1, 2021","December 1, 2022","December 1, 2022","August 11, 2022",,"August 11, 2022","Whole Body Health Physical Therapy, Portland, Oregon, United States",,"https://ClinicalTrials.gov/show/NCT05498077"
291,"NCT05498064","A Real World Study of Ensartinib in Advanced ALK-positive NSCLC",,"Recruiting","No Results Available","Carcinoma, Non-Small-Cell Lung|Anaplastic Lymphoma Kinase I1171N|Ensartinib","Drug: Ensartinib","Progression free survival (PFS)|The objective response rate (ORR)|Overall survival (OS)|12 month/24 month/36 month/48 month-overall survival (OS) rate OS|Incidence of patients experiencing adverse events (AE)","Peking Union Medical College Hospital|Betta Pharmaceuticals Co., Ltd.","All","18 Years and older   (Adult, Older Adult)",,"490","Other|Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","BD-EN-IV007","May 13, 2022","December 31, 2025","December 1, 2028","August 11, 2022",,"August 11, 2022","Department of Respiratory and Critical Care Medicine, Peking Union Medical College Hospital, Beijing, Beijing, China",,"https://ClinicalTrials.gov/show/NCT05498064"
292,"NCT05498051","Fluorescent Sentinel Lymph Node Identification in Colon Carcinoma Using Submucosal Bevacizumab-800CW.","IBIZA-1","Not yet recruiting","No Results Available","Colonic Neoplasms|Sentinel Lymph Node|Fluorescence|Colorectal Neoplasms","Procedure: Sentinel lymph node identification","Identification rate of SLN(s) or lymph node metastases|Safety of SLN identification|Amount of fluorescence in lymph node metastases compared to lymph node without metastases|false-negative SLNs|true-negative SLNs|sensitivity|upstaged patients|aberrant lymph node status|accuracy|negative predictive value|number of SLNs identified","Meander Medical Center","All","18 Years and older   (Adult, Older Adult)","Not Applicable","5","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","R21.116|2021-006700-32","September 1, 2022","March 1, 2023","May 1, 2023","August 11, 2022",,"August 11, 2022",,,"https://ClinicalTrials.gov/show/NCT05498051"
293,"NCT05498038","Exercise Reset for Concussion in a Military Environment",,"Not yet recruiting","No Results Available","Brain Concussion","Behavioral: Aerobic Exercise","Persistent Post Concussive Symptoms (PPCS) (Yes/No)|Days until Recovery","State University of New York at Buffalo|United States Department of Defense|Children's Hospital of Philadelphia|University of Pennsylvania|University of North Carolina, Chapel Hill|Geneva Foundation|Quadrant Biosciences Inc.|Center for Neuroscience and Regenerative Medicine (CNRM)|Axon Medical Technologies LLC","All","18 Years to 40 Years   (Adult)","Not Applicable","168","Other|U.S. Fed|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","TP210003","March 1, 2023","March 1, 2026","March 1, 2026","August 11, 2022",,"August 12, 2022",,,"https://ClinicalTrials.gov/show/NCT05498038"
294,"NCT05498025","The Effect of a Charcoal Deactivation Pouch on Opioid Disposal After Cesarean Delivery",,"Not yet recruiting","No Results Available","Pain, Acute|Opioid Misuse|Obstetric Pain|Cesarean Section Complications","Other: Deterra activated charcoal pouch","Actual pouch use","Geisinger Clinic","Female","18 Years to 55 Years   (Adult)","Not Applicable","50","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","2022-0487","September 1, 2022","June 1, 2023","June 1, 2023","August 11, 2022",,"August 11, 2022",,,"https://ClinicalTrials.gov/show/NCT05498025"
295,"NCT05498012","CBD Effects on Periodontal Health of Patients With Chronic Periodontitis","Stoma-CBD","Completed","No Results Available","Chronic Periodontitis","Combination Product: placebo dental gel, placebo toothpaste|Combination Product: Cannabidiol dental gel, Cannabidiol toothpaste|Combination Product: Placebo toothpaste, Corsodyl dental gel","Effect of cannabidiol on periodontal health (Russell's periodontal index ) of patients with chronic periodontitis|Effect of cannabidiol on periodontal health (plaque/gingival indices) of patients with chronic periodontitis|Effect of cannabidiol on periodontal health (bleeding) of patients with chronic periodontitis|Effect of cannabidiol on periodontal health (modified gingival index) of patients with chronic periodontitis|Effect of cannabidiol on oral microbiota|Cannabidiol oral cavity side effects and gingival immune system","Palacky University|CB21 Pharma Ltd.","All","35 Years to 65 Years   (Adult, Older Adult)","Phase 1|Phase 2","90","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Supportive Care","#3620","November 5, 2020","January 27, 2022","February 1, 2022","August 11, 2022",,"August 11, 2022","Department of Dentistry, Olomouc University Hospital, Olomouc, Czech Republic, Czechia",,"https://ClinicalTrials.gov/show/NCT05498012"
296,"NCT05497999","Racial Inequality in Inhaler Fills for COPD - A Trial of Reduced Cost-Sharing",,"Active, not recruiting","No Results Available","Chronic Obstructive Pulmonary Disease","Other: Proactive Outreach|Other: No Proactive Outreach","Maintenance inhaler adherence|Frequency of acute moderate-to-severe exacerbations|Number of short-acting inhaler filled|Total spending","Harvard Medical School (HMS and HSDM)|Humana Co.Ltd.","All","Child, Adult, Older Adult","Not Applicable","14000","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","22-0916","January 7, 2020","December 31, 2022","December 31, 2022","August 11, 2022",,"August 11, 2022","University of Chicago, Chicago, Illinois, United States|Humana, Inc., Louisville, Kentucky, United States|Harvard Medical School, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT05497999"
297,"NCT05497986","Conventional Low Flow Oxygenation Versus High Flow Nasal Cannula in Hypercapnic Respiratory Failure",,"Not yet recruiting","No Results Available","Hypercapnic Respiratory Failure|Acute Copd Exacerbation","Device: High flow nasal cannula|Device: Conventional low flow oxygenation","Proportion of patients progressing to NIV in each cohort|Venous blood gas PCO2|Venous blood gas pH|Respiratory rate|Heart rate|Mean arterial pressure|Incidence of intubation|Admission to the intensive care unit|In-hospital mortality|Intensive care unit length of stay|Hospital length of stay|Patient comfort|Shortness of breath","Hôpital de Verdun","All","18 Years and older   (Adult, Older Adult)","Not Applicable","84","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","Verdun2022_01","October 2022","January 2024","July 2024","August 11, 2022",,"August 11, 2022","CISSS-de-la-Montérégie-Centre, Longueuil, Quebec, Canada|CIUSSS de l'Est-de-l'ïle-de-Montréal, Montréal, Quebec, Canada|Hôpital de Verdun, Montréal, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT05497986"
298,"NCT05497973","Psychosocial eHealth in Advanced Lung Cancer",,"Not yet recruiting","No Results Available","Lung Cancer, Nonsmall Cell, Stage IIIA|Lung Cancer Non-Small Cell Stage IIIB|Lung Cancer Non-Small Cell Stage III|Lung Cancer Stage IV|Lung Cancer","Behavioral: E-health ecosystem of stepped psychosocial care|Behavioral: Usual psychosocial care","Changes in Emotional distress|Changes in Spirituality|Changes in Demoralization|Changes in Adjusted LC Health-Related Quality Of Life|Changes in Quality of life (QoL)|Changes in Symptom control|Changes in Medication adherence|Platform satisfaction|Platform usability|Changes in Emotional wellbeing","Institut Català d'Oncologia|Asociación Española contra el Cáncer|Institut d'Investigació Biomèdica de Bellvitge","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","152","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","PRYES211395OCHO","October 2022","July 2023","June 2024","August 11, 2022",,"August 11, 2022","Institut Català d'Oncologia, L'Hospitalet De Llobregat, Catalunya, Spain",,"https://ClinicalTrials.gov/show/NCT05497973"
299,"NCT05497960","Vivo Prediabetes Study: Online, Live, and Interactive Strength Training for Older Adults With Prediabetes",,"Not yet recruiting","No Results Available","PreDiabetes|Older Adults|Muscle Loss|Muscle Weakness","Behavioral: Vivo workout","Intervention engagement assess by workout attendance older adults with prediabetes|Intervention engagement assessed by self- reported barriers and facilitators|Program satisfaction|Leg strength assessed through a 30 second chair rise test|Health-related quality of life measured via the Short Form (SF)-36|Sleep measured via the Pittsburgh Sleep Quality Index (PSQI)|Satisfaction with Life measured by the 5 item SWL questionnaire|Exercise Efficacy|Profile of Mood Survey (POMS)|Perceived Stress Scale Center for Epidemiologic Studies Depression Scale (CES-D)","Eric Levian|Duke University|Impactiv, Inc.","All","60 Years and older   (Adult, Older Adult)","Not Applicable","30","Industry|Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","Pro00110021","September 1, 2022","March 31, 2023","May 15, 2023","August 11, 2022",,"August 11, 2022","Duke University Medical Center, Durham, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT05497960"
300,"NCT05497947","Evaluation of the French Translation of Swallowing (SOAL-VF) Patient Reported Outcomes (PRO) After Total PharyngoLaryngectomy","SOAL-VF","Recruiting","No Results Available","Pharyngeal Cancer|Swallowing Disorder|Larynx Cancer",,"SOAL- VF","Centre Hospitalier de Valence","All","18 Years and older   (Adult, Older Adult)",,"225","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","0007","July 3, 2021","July 5, 2022","July 3, 2023","August 11, 2022",,"August 11, 2022","Ch Valence, Valence, Drome, France",,"https://ClinicalTrials.gov/show/NCT05497947"
301,"NCT05497934","The Effects of Glycerol as an Optical Clearing Agent for Visualization of the Middle Ear",,"Not yet recruiting","No Results Available","Tympanosclerosis|Thickened Ears|Healthy|Surgery","Drug: Glycerol","Change in optical attenuation rate of the tympanic membrane|Change in acoustic mobility of the umbo|Change in B-mode signal-to-noise ratio of the cochlear promontorium","Nova Scotia Health Authority|Dalhousie University","All","18 Years and older   (Adult, Older Adult)","Phase 1","50","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","1028201","October 1, 2022","October 1, 2023","March 31, 2024","August 11, 2022",,"August 11, 2022",,,"https://ClinicalTrials.gov/show/NCT05497934"
302,"NCT05497921","Crossover Study to Evaluate the Efficacy of LED in Treating the Signs of Contact/Irritant Dermatitis of the Hand",,"Not yet recruiting","No Results Available","Contact Dermatitis of Hand","Device: handLITE LED device","Reduction in the signs and symptoms of contact/irritant dermatitis of the hand according to a Modified SCORAD system|Subjective assessment of treatment response (POEM)","Steven Baker|Ismart","All","21 Years to 75 Years   (Adult, Older Adult)","Not Applicable","25","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ASIRC_Hlcd06_02","August 31, 2022","April 30, 2023","August 31, 2023","August 11, 2022",,"August 11, 2022","Dr Glynis Ablon MD, FAAD, Manhattan Beach, California, United States",,"https://ClinicalTrials.gov/show/NCT05497921"
303,"NCT05497908","Feasibility of TAP for XLIF Surgery",,"Not yet recruiting","No Results Available","Pain, Postoperative","Procedure: TAP block via lateral approach|Procedure: TAP block via posterior approach","Identification rate of the correct transverse abdominis plane block|Total morphine consumption|Patient recruitment rate|Adherence rate to protocol|total operation room time|Assessment of the number of patients with local anesthestia systemic toxicity (LAST)|Number of patients in need of additional analgesic drugs at PACU|Incision region pain scores|Lumbar back pain scores|time to first mobilisation|quality of recovery","Jessa Hospital","All","18 Years and older   (Adult, Older Adult)","Not Applicable","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Prevention","f/2022/050","September 1, 2022","April 30, 2023","August 31, 2023","August 11, 2022",,"August 11, 2022",,,"https://ClinicalTrials.gov/show/NCT05497908"
304,"NCT05497895","The Assessment of Clinical Efficacy of Topical Application of 5% Thymoquinone Gel for Gingivitis Patients",,"Not yet recruiting","No Results Available","Gingivitis","Biological: 5% thymoquinone (TQ) gel|Biological: SRP and placebo|Procedure: Only SRP-one stage prophylaxis","Plaque index|Papillary bleeding index|Number of participants with drug related adverse events|Number of participants non compliant/withdraw from the study","King Abdulaziz University","All","18 Years to 40 Years   (Adult)","Early Phase 1","70","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","KAAU","September 2022","October 2022","November 2022","August 11, 2022",,"August 11, 2022","Qassim University, Buraydah, Saudi Arabia",,"https://ClinicalTrials.gov/show/NCT05497895"
305,"NCT05497882","Computer-Based Learning to Enhance Dementia Care in Prison",,"Not yet recruiting","No Results Available","Dementia|Prisoners","Behavioral: E-Learning Prototype for Dementia Care","Focus Groups|System Usability Scale","Klein Buendel, Inc.|National Institute on Aging (NIA)|Penn State University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","52","Industry|NIH|Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","336|R41AG078103","September 2022","May 2023","May 2023","August 11, 2022",,"August 11, 2022","Barbara Walkosz, Golden, Colorado, United States|Penn State University, University Park, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT05497882"
306,"NCT05497869","Effects of Active Release Technique (ART) on Pectoralis Minor Tightness in Post Mastectomy Women.",,"Not yet recruiting","No Results Available","Postgastrectomy Syndrome","Other: active release group|Other: active control group","NPRS|Shoulder Pain and Disability Index (SPADI)|pectoralis minor length through vernier caliper|pectoralis minor length through Rigid standard plastic transparent right angle","Riphah International University","Female","40 Years to 60 Years   (Adult)","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","RiphahIU Shafaq","August 2022","December 2022","January 2023","August 11, 2022",,"August 11, 2022","Federal Breast Cancer Screening center (PIMS), Islamabad, Capital, Pakistan",,"https://ClinicalTrials.gov/show/NCT05497869"
307,"NCT05497856","Comparison of Integrated Neuromuscular Inhibition Technique With Myofascial Release on Rhomboids Trigger Points",,"Not yet recruiting","No Results Available","Trigger Point Pain, Myofascial","Other: Integrated neuromuscular inhibition technique|Other: Myofascial Release","NPRS|Pain Pressure threshold|shoulder pain and disability index (SPADI)","Riphah International University","All","25 Years to 45 Years   (Adult)","Not Applicable","32","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","RiphahIU Naqash Shabbir","August 10, 2022","September 2022","September 2022","August 11, 2022",,"August 11, 2022","Benazir Bhutto Hospital, Rawalpindi, Punjab, Pakistan",,"https://ClinicalTrials.gov/show/NCT05497856"
308,"NCT05497843","Chiauranib for Advanced or Unresectable Soft Tissue Sarcoma(STS)",,"Recruiting","No Results Available","Soft Tissue Sarcoma","Drug: Chiauranib","Progression-free survival of 12 weeks(PFS12w)|Overall response rate (ORR)|Progression-free survival (PFS)|Duration of response (DOR)|Disease control rate (DCR)|Overall survival (OS)|Safety and Tolerability","Chipscreen Biosciences, Ltd.","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","30","Industry","Interventional","Allocation: N/A|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CAR204","August 2, 2022","February 2024","June 2024","August 11, 2022",,"August 12, 2022","Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China",,"https://ClinicalTrials.gov/show/NCT05497843"
309,"NCT05497830","Machine Learning for Risk Stratification in the Emergency Department (MARS-ED)","MARS-ED","Not yet recruiting","No Results Available","Acute Pain|Emergencies","Other: RISK-INDEX","RISK-INDEX performance|Policy changes","Maastricht University Medical Center","All","18 Years and older   (Adult, Older Adult)","Not Applicable","2070","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","NL78478.068.21|METC 21-068","September 1, 2022","January 1, 2024","March 1, 2024","August 11, 2022",,"August 11, 2022","Maastricht University Medical Centre+, Maastricht, Limburg, Netherlands",,"https://ClinicalTrials.gov/show/NCT05497830"
310,"NCT05497817","A Study to Evaluate Caregiver Connections Via Technology for Patients With Alzheimer's and Other Types of Dementia",,"Not yet recruiting","No Results Available","Caregiver Stress|Dementia|Alzheimer Dementia|Lewy Body Dementia|Parkinson Disease Dementia|Frontotemporal Dementia","Behavioral: Algorithm|Behavioral: Random Match","Match Satisfaction Questionnaire|Change over time from Baseline Resilience to 12 months|Change over time from Baseline Quality of Life to 12 months|Scale of Perceived Social Support|Survey of Executive Skills","Mayo Clinic|National Institute on Aging (NIA)|Minnesota HealthSolutions","All","18 Years and older   (Adult, Older Adult)","Not Applicable","355","Other|NIH|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Supportive Care","20-013202|R44AG065088","September 2022","September 2024","December 2024","August 11, 2022",,"August 11, 2022","Mayo Clinic Rochester, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT05497817"
311,"NCT05497804","Combination Treatment Therapy Approaches for the Treatment of High-Risk Multiple Myeloma, REACH Trial",,"Not yet recruiting","No Results Available","ISS Stage III Plasma Cell Myeloma|Plasma Cell Myeloma","Procedure: Bone Marrow Aspiration and Biopsy|Drug: Carfilzomib|Procedure: Computed Tomography|Biological: Daratumumab|Drug: Dexamethasone|Drug: Lenalidomide|Procedure: Magnetic Resonance Imaging|Procedure: Positron Emission Tomography","Rate of sustained minimal residual disease (MRD) negativity|Overall response rate (>= confirmed very good partial response ([VGPR])|Overall survival|Progression-free survival|Incidence of adverse events","Mayo Clinic|National Cancer Institute (NCI)","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2","75","Other|NIH","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MC210811|NCI-2022-06150|P30CA015083","August 20, 2022","November 20, 2027","November 20, 2028","August 11, 2022",,"August 11, 2022","Mayo Clinic in Rochester, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT05497804"
312,"NCT05497791","Laser Transcranial and Neuromuscular Electrical Stimulation","LTNMES","Completed","No Results Available","Stroke","Device: transcranial laser stimulation associated with NMES|Other: Placebo","Subjective pain scale|Cognitive status|Grip strength|Gross manual dexterity|Dynamic balance|Spasticity|Functional status|Quality of Life status|Well-Being status","University of Sao Paulo","All","35 Years to 75 Years   (Adult, Older Adult)","Not Applicable","18","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","Stroke","May 1, 2019","December 20, 2019","December 20, 2019","August 11, 2022",,"August 11, 2022","Fernanda Rossi Paolillo, São Carlos, São Paulo, Brazil",,"https://ClinicalTrials.gov/show/NCT05497791"
313,"NCT05497778","A Phase 1b Study of Gemcitabine and Nab-paclitaxel in Combination With IM156 in Patients With Advanced Pancreatic Cancer.",,"Not yet recruiting","No Results Available","Pancreas Cancer","Drug: Gemcitabine|Drug: Nab paclitaxel|Drug: IM156","National Cancer Institute Common Terminology Criteria for Adverse Events, Version 5.0","M.D. Anderson Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 1","25","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2022-0130|NCI-2022-06636","February 28, 2023","January 8, 2025","January 8, 2025","August 11, 2022",,"August 11, 2022","MD Anderson Cancer Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT05497778"
314,"NCT05497765","An Intervention Study of Compound Silymarin in Patients With Non-alcoholic Fatty Liver Disease",,"Recruiting","No Results Available","Nonalcoholic Fatty Liver Disease","Dietary Supplement: Silibinin extract, mixed power of pueraria, schisandra and salvia miltiorrhiza|Dietary Supplement: Silibinin extract|Dietary Supplement: Placebo","Liver enzymes|Lipid profile|T-Lymphocytes' composition|Bile acid metabolism","Guangzhou Medical University|The First Dongguan Affiliated Hospital of Guangdong Medical University","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","129","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","GDMUSPH001","August 1, 2022","July 31, 2023","January 31, 2024","August 11, 2022",,"August 11, 2022","Department of Nutrition, School of Public Health, Guangdong Medical University, Dongguan, Guangdong, China",,"https://ClinicalTrials.gov/show/NCT05497765"
315,"NCT05497752","Effectiveness of Cervical Rehabilitation Program on Neck Pain, ROM and Disability After Thyroidectomy.",,"Not yet recruiting","No Results Available","Thyroiditis, Postpartum","Other: cervical rehabilitation program|Other: control group","NPRS|Neck disability index|neck flexion ROM|neck Extension ROM|neck Rt side flexion ROM|neck Lt side flexion ROM|neck Rt Rotation ROM|neck Lt Rotation ROM","Riphah International University","All","30 Years to 50 Years   (Adult)","Not Applicable","52","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","RiphahIU Tayyaba Sultan","August 2022","December 2022","January 2023","August 11, 2022",,"August 11, 2022","Heavy Industrial Taxila Hospital, Rawalpindi, Punjab, Pakistan",,"https://ClinicalTrials.gov/show/NCT05497752"
316,"NCT05497739","Intraperitoneal Chemotherapy Guided by the Detection of DNA in Peritoneal Lavage Fluid in Patients With Gastric Cancer",,"Recruiting","No Results Available","Gastric Cancer","Drug: Intraperitoneal chemotherapy|Drug: Adjuvant systemic chemotherapy","The incidence of peritoneal metastasis|Peritoneal metastasis-free survival|Disease-free survival|Overall survival|The safety","Cancer Institute and Hospital, Chinese Academy of Medical Sciences","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","68","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","21/458-3129","June 28, 2022","June 20, 2024","June 20, 2024","August 11, 2022",,"August 11, 2022","National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Beijing, Beijing, China",,"https://ClinicalTrials.gov/show/NCT05497739"
317,"NCT05497726","Fluorescent Sentinel Lymph Node Identification in Colon Carcinoma Using Intravenous Bevacizumab-800CW","IBIZA-2","Not yet recruiting","No Results Available","Colorectal Neoplasms|Colon Neoplasm|Sentinel Lymph Node|Fluorescence","Procedure: Sentinel lymph node detection using intravenous bevacizumab-800CW","Feasibility of SLN(s) or lymph node metastases with intravenous bevacizumab-800CW|Safety of SLN(s) or lymph node metastases with intravenous bevacizumab-800CW|Amount of fluorescence in lymph node metastases compared to lymph node without metastases|False-negative SLNs|True-negative SLNs|Sensitivity|Upstaging|Aberrant lymph node status|Accuracy|Negative predictive value (NPV)|Number of SLN identified","Meander Medical Center","All","18 Years and older   (Adult, Older Adult)","Not Applicable","5","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","R21.117|2021-006796-41","November 1, 2022","January 1, 2023","March 1, 2023","August 11, 2022",,"August 11, 2022",,,"https://ClinicalTrials.gov/show/NCT05497726"
318,"NCT05497713","Mindset Interventions to Facilitate Taking Cold Showers","MICS","Not yet recruiting","No Results Available","Psychological","Other: Mindsets","Showering behaviour concerning frequency (Baseline)|Showering behaviour concerning duration (Baseline)|Showering behaviour concerning motivation (Baseline)|Showering behaviour concerning frequency (Week 1)|Showering behaviour concerning frequency (Week 2)|Showering behaviour concerning frequency (Week 3)|Showering behaviour concerning frequency (Week 4)|Showering behaviour concerning frequency (Week 5)|Showering behaviour concerning frequency (Week 6)|Showering behaviour concerning frequency (Week 7)|Showering behaviour concerning frequency (Week 8)|Showering behaviour concerning frequency (Week 9)|Showering behaviour concerning frequency (Week 10)|Showering behaviour concerning frequency (Week 11)|Showering behaviour concerning frequency (Week 12)|Showering behaviour concerning duration (Week 1)|Showering behaviour concerning duration (Week 2)|Showering behaviour concerning duration (Week 3)|Showering behaviour concerning duration (Week 4)|Showering behaviour concerning duration (Week 5)|Showering behaviour concerning duration (Week 6)|Showering behaviour concerning duration (Week 7)|Showering behaviour concerning duration (Week 8)|Showering behaviour concerning duration (Week 9)|Showering behaviour concerning duration (Week 10)|Showering behaviour concerning duration (Week 11)|Showering behaviour concerning duration (Week 12)|Showering behaviour concerning motivation (Week 1)|Showering behaviour concerning motivation (Week 2)|Showering behaviour concerning motivation (Week 3)|Showering behaviour concerning motivation (Week 4)|Showering behaviour concerning motivation (Week 5)|Showering behaviour concerning motivation (Week 6)|Showering behaviour concerning motivation (Week 7)|Showering behaviour concerning motivation (Week 8)|Showering behaviour concerning motivation (Week 9)|Showering behaviour concerning motivation (Week 10)|Showering behaviour concerning motivation (Week 11)|Showering behaviour concerning motivation (Week 12)|WHO Five Well-Being Index|Questionnaire for positive aspects of well-being in adults|International Physical Activity Questionnaire|Pittsburgh Sleep Quality Index|Skin quality questionnaire|Sickness absence and illness days","Jens Gaab|University Hospital, Basel, Switzerland","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","eknz2022-00952","October 2022","December 2023","December 2024","August 11, 2022",,"August 15, 2022","University of Basel Faculty of Psychology Division for Clinical Psychology and Psychotherapy, Basel, Basel-Stadt, Switzerland",,"https://ClinicalTrials.gov/show/NCT05497713"
319,"NCT05497700","Comparative Efficacity of Ephedrine Versus Norepinephrine to Correct Anesthesia Induction Related Hypotension",,"Not yet recruiting","No Results Available","Hypotension on Induction","Drug: Ephedrine versus norepinephrine","Number of boluses","Brugmann University Hospital","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 3","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","VASO_IRC","October 1, 2022","September 30, 2023","October 30, 2023","August 11, 2022",,"August 11, 2022","CHU Brugmann, Brussels, Belgium",,"https://ClinicalTrials.gov/show/NCT05497700"
320,"NCT05497687","Strength-building Lifestyle-integrated Intervention",,"Not yet recruiting","No Results Available","Sarcopenia|Coronary Artery Disease","Other: Resistance exercise","Physical performance (measured by the Short Physical Performance Battery)|Muscle mass|Muscle strength|Cardiac-specific functional status|Cardiac-specific health-related quality of life (HRQoL)|Psychological distress|MACCE and hospital readmission rates","The University of Hong Kong","All","60 Years and older   (Adult, Older Adult)","Not Applicable","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Other","UW22-516","September 1, 2022","August 31, 2023","November 30, 2023","August 11, 2022",,"August 11, 2022","The School of Nursing, Hong Kong, Hong Kong","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/87/NCT05497687/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT05497687"
321,"NCT05497674","Effects of Rifampicin and Probenecid On The Pharmacokinetic Profile Of Rongliflozin In Healthy Subjects",,"Completed","No Results Available","Type 2 Diabetes Mellitus","Drug: Rongliflozin|Drug: Rifampin|Drug: Probenecid","rongliflozin: area under the drug-time curve (AUC) ratios of geometric means of rongliflozin+rifampicin relative to rongliflozin alone.|rongliflozin: The peak concentration (Cmax) ratios of geometric means of rongliflozin+rifampicin relative to rongliflozin alone.|rongliflozin: AUC ratios of geometric means of rongliflozin+probenecid relative to rongliflozin alone.|rongliflozin:Cmax ratios of geometric means of rongliflozin+probenecid relative to rongliflozin alone.|The time to peak (Tmax) of Rongliflozin.|pharmacology (PD) of rongliflozin: cumulative urine glucose excretion every 24 hours|the number of participants with adverse events (AE) in Cohort A|the number of participants with adverse events (AE) in Cohort B","Sunshine Lake Pharma Co., Ltd.","All","18 Years to 45 Years   (Adult)","Phase 1","28","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","DJT1116PG-DM-108","February 21, 2022","July 20, 2022","August 1, 2022","August 11, 2022",,"August 11, 2022","The First Hospital of Jilin University, Jilin, Changchun, China",,"https://ClinicalTrials.gov/show/NCT05497674"
322,"NCT05497661","Ultrasound Patellar Tendon Assessment",,"Not yet recruiting","No Results Available","Patellofemoral Pain|Ultrasonography","Other: 448kilohertz Capacitive Resistive Radiofrequency Stimulation in a Sporty Population.|Other: Placebo comparator","Change from Baseline in patellar tendon measured by quantified elastography imaging at 3 months [ Time Frame: Time Frame: time (t) 1(prior to treatment), t2 (immediately after the treatment), t3 (3 months later)] ]","Universidad de Granada","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","28","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Prevention","UGranadaPatellarTendon","October 14, 2022","June 14, 2023","June 12, 2024","August 11, 2022",,"August 11, 2022","Clínica Ana González, Málaga, Spain",,"https://ClinicalTrials.gov/show/NCT05497661"
323,"NCT05497648","Evaluating Impact and Implementation of Choose to Move (Phase 3)","CTM","Completed","No Results Available","Aging|Physical Inactivity|Mobility Limitation|Loneliness|Social Isolation","Behavioral: Choose to Move","Change in physical activity|Change in loneliness|Change in social isolation|Change in physical functioning|Change in physical activity (PAAQ)|Change in health-related quality of life (EQ-5D-5L Profile)|Change in health-related quality of life (EQ-5D-5L Level Sum Score)|Change in health-related quality of life (EQ-5D-5L Visual Analogue Scale)|Change in mobility limitations|Change In sitting time|Change in social network|Change in grip strength (subset)|Change in lower extremity function (subset)|Change in physical activity (CHAMPS)","University of British Columbia|Canadian Institutes of Health Research (CIHR)|Ministry of Health, British Columbia","All","60 Years and older   (Adult, Older Adult)","Not Applicable","1216","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","H15-02522|PJT-153248","January 16, 2018","May 25, 2021","May 25, 2021","August 11, 2022",,"August 11, 2022","Centre for Hip Health and Mobility, Vancouver, British Columbia, Canada",,"https://ClinicalTrials.gov/show/NCT05497648"
324,"NCT05497635","A Study of STSA-1002 in Healthy Subjects",,"Not yet recruiting","No Results Available","Healthy Subject","Drug: STSA-1002 Injection|Drug: Placebo","Incidence of Adverse Events、Clinically Significant Laboratory Abnormalities、Clinically Significant Electrocardiogram、Vital Signs And Physical Examination Abnormalities.|Maximum plasma concentration (Cmax)|Area under the plasma concentration-time curve from time 0 to the collection time point t of the last measurable concentration (AUC0-t)|Area under the plasma concentration-time curve from time 0 to infinity (AUC0-∞)|Time of maximum concentration (Tmax)|Elimination half-life (t1/2)|Mean residence time (MRT)|Clearance (CL)|Apparent volume of distribution (Vz)|Maximum Concentration of the Analyte in Plasma at steady state(Cmax, ss)|Minimum Measured Concentration of the Analyte in Plasma at Steady State(Cmin, ss)|Time-averaged concentration at steady state(Cav, ss)|Area under the concentration curve from time 0 extrapolate to infinite time(AUCinf,ss)|Degree of fluctuation(DF)|Accumulation factor|Change from baseline in concentration of free C5a and anti-drug antibody|Change from baseline in concentration of Myeloperoxidase（MPO）、Neutrophil elastase（NE）、Proteinase3（PR3）、 C-X-C chemokine receptor 1(CXCR1)","Staidson (Beijing) Biopharmaceuticals Co., Ltd","All","18 Years to 45 Years   (Adult)","Phase 1","26","Industry","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","STSA-1002-03","September 2022","March 2023","June 2023","August 11, 2022",,"August 11, 2022","Beijing Shijitan Hospital, Capital Medical University, Beijing, Beijing, China|The Second Affiliated Hospital Of Xingtai Medical College, Xingtai, Hebei, China",,"https://ClinicalTrials.gov/show/NCT05497635"
325,"NCT05497622","Quantitative Ultrasound Biomarkers to Assess Upper Trapezius Muscles in Patients With Chronic Pain",,"Not yet recruiting","No Results Available","Chronic Neck Pain","Diagnostic Test: Quantitative Ultrasound|Diagnostic Test: Osteopathic TART Assessment|Procedure: Osteopathic Manipulation Treatment","Ultrasound diagnostic performance evaluation|Ultrasound echo-intensity|Ultrasound shear wave velocity|Ultrasound longitudinal strain ratios","Rocky Vista University, LLC|American Osteopathic Association","All","18 Years and older   (Adult, Older Adult)","Not Applicable","108","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","IRB #2022--095","August 1, 2022","March 31, 2024","March 31, 2024","August 11, 2022",,"August 11, 2022","Ultrasound Research Laboratory, Ivins, Utah, United States",,"https://ClinicalTrials.gov/show/NCT05497622"
326,"NCT05497609","The Muscle in Children With Cerebral Palsy - Longitudinal Exploration of Microscopic Muscle Structure.","CPBiopsyBTX","Recruiting","No Results Available","Cerebral Palsy|Muscle Contraction|Muscle Spasticity","Other: no intervention. Care as ususal","Muscle fiber area|Muscle fiber types based on myosin heavy chain isoforms|Extracellular matrix, area|Capillaries per fiber area|Mitochondria: NADH staining, morphology|Clinical assessment, contracture","Eva Ponten|Region Stockholm","All","2 Years to 18 Years   (Child, Adult)",,"50","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","BTX muskel CP","January 15, 2006","December 15, 2026","December 15, 2027","August 11, 2022",,"August 11, 2022","Karolinska University Hospital, Stockholm, Sweden",,"https://ClinicalTrials.gov/show/NCT05497609"
327,"NCT05497596","The Association Between Human Microbiome and Vitamin D in Chronic Urticaria",,"Recruiting","No Results Available","Urticaria","Other: Vitamin D|Other: Placebo","Levels of vitamin D|Single nucleotide polymorphism of vitamin D receptor and vitamin D binding protein.|Microbiome Microbiome|Total IgE|Allergen-specific IgE|Quality of Life Assessment|The Urticaria Activity Score 7 (UAS7)","China Medical University Hospital","All","0 Years to 18 Years   (Child, Adult)","Not Applicable","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","CMUH111-REC3-066","August 15, 2022","March 31, 2025","March 31, 2025","August 11, 2022",,"August 15, 2022","China Medical University Hospital, Taichung, Taiwan",,"https://ClinicalTrials.gov/show/NCT05497596"
328,"NCT05497583","Universal Adhesive for Restoring Cervical Lesions",,"Not yet recruiting","No Results Available","Universal Adhesive","Other: Universal Adhesive","Primary outcome (Clinical Performance and marginal staining)|Fractures and Retention","Cairo University","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","28","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","universal adhesive","October 2022","April 2024","May 2024","August 11, 2022",,"August 11, 2022",,,"https://ClinicalTrials.gov/show/NCT05497583"
329,"NCT05497570","Injection of Tenoxicam Versus Arthrocentesis Alone in the Treatment of Temporomandibular Joint Osteoarthritis",,"Completed","No Results Available","Arthrocentesis","Drug: Tenoxicam Injectable Product","Pain on Tmj (Visual analog scale(VAS) was used.)|Maximum Mouth Opening(MMO) (A ruler was used)|Joint sounds (Visual analog scale was used to measure.)","Ataturk University","All","22 Years to 64 Years   (Adult)","Phase 1","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","3525","May 3, 2019","November 7, 2021","April 21, 2022","August 11, 2022",,"August 11, 2022","Ataturk University, Erzurum, Turkey",,"https://ClinicalTrials.gov/show/NCT05497570"
330,"NCT05497557","A Study to Evaluate the Impact of Omeprazole on the Pharmacokinetics of Sotorasib Co-administered With an Acidic Beverage in Healthy Volunteers",,"Not yet recruiting","No Results Available","Healthy Volunteers","Drug: Omeprazole|Drug: Sotorasib","Maximum Observed Plasma Concentration (Cmax) of Sotorasib|Area Under the Plasma Concentration-time Curve from Time Zero to Infinity (AUCinf) of Sotorasib|Area Under the Plasma Concentration-time Curve from Time Zero to Time of Last Quantifiable Concentration (AUClast) of Sotorasib|Number of Participants with an Adverse Event (AE)","Amgen","All","18 Years to 60 Years   (Adult)","Phase 1","14","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","20220024","August 4, 2022","August 14, 2022","August 14, 2022","August 11, 2022",,"August 11, 2022",,,"https://ClinicalTrials.gov/show/NCT05497557"
331,"NCT05497544","ORE - 30 Seconds (Oncologists Recommend Exercise in 30 Secs)","ORE","Recruiting","No Results Available","Lung Cancer","Behavioral: Exercise recommendation group|Behavioral: Exercise recommendation plus guidebook group","Exercise level|Sedentary behavior|Quality of life","Universita di Verona","All","18 Years and older   (Adult, Older Adult)","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care","26622","July 1, 2022","September 1, 2023","July 1, 2025","August 11, 2022",,"August 11, 2022","University of Verona, Verona, Italy",,"https://ClinicalTrials.gov/show/NCT05497544"
332,"NCT05497531","Pilot Comparing ctDNA IDV vs. SPV Sample in Pts Undergoing Biopsies for Hepatobiliary and Pancreatic Cancers",,"Not yet recruiting","No Results Available","Hepatobiliary Cancer|Pancreatic Cancer|Hepatocellular Carcinoma|Cholangiocarcinoma|Ampullary Cancer|Pancreatic Carcinoma","Diagnostic Test: ctDNA Blood Collection","Comparison of the amount of ctDNA in draining vein plasma sample to peripheral vein sample through ratio of mean allele frequency|Number of unique alterations found in hepatic or portal vein plasma compared to number of alterations found in peripheral vein plasma|Number of unique alterations found in ctDNA compared to number of alterations derived next generation sequencing (NGS)","University of California, Irvine","All","18 Years and older   (Adult, Older Adult)","Not Applicable","15","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","UCI 21-124 [HS# 1491]|1491","August 2022","April 2023","April 2023","August 11, 2022",,"August 11, 2022","Chao Family Comprehensive Cancer Center, University of California, Irvine, Orange, California, United States",,"https://ClinicalTrials.gov/show/NCT05497531"
333,"NCT05497518","A National Registry for People With All Stages of Kidney Disease: the National Kidney Foundation (NKF) Patient Network",,"Recruiting","No Results Available","Chronic Kidney Disease|Dialysis|Kidney Transplant|Alport Syndrome","Other: Observational study - registry","Total number of enrolled participants","Tufts Medical Center|National Kidney Foundation","All","18 Years to 120 Years   (Adult, Older Adult)",,"50000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","10-500-1060","February 25, 2021","February 24, 2070","February 24, 2070","August 11, 2022",,"August 11, 2022","Geisinger Clinic, Danville, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT05497518"
334,"NCT05497505","Evaluation of Clinical Implementation of Machine Learning Based Decision Support for ICU Discharge","MIRACLE","Recruiting","No Results Available","Critical Illness","Device: Pacmed Critical","area under the receiver operating characteristic curve (AUROC)|calibration curve (goodness-of-fit)|Number of changes in ready-for-discharge decision after reviewing decision support|Readmission rate within 7 days after ICU discharge|Mortality rate within 7 days after ICU discharge|Length of ICU stay|Length of hospital stay|Estimation of intra-cluster correlation|Average score on the 3-point Likert-scale 'confidence of risk estimation' with and without decision support|Number of risk determinants, categorized by organ system as determined by physicians vs model|Software usage metrics","Patrick J. Thoral|Leiden University Medical Center|Amsterdam UMC, location VUmc","All","18 Years and older   (Adult, Older Adult)",,"1500","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2021.0528","March 10, 2022","June 2023","June 2023","August 11, 2022",,"August 11, 2022","Amsterdam UMC, location VUmc, Amsterdam, NH, Netherlands|Leiden University Medical Center (LUMC), Leiden, ZH, Netherlands",,"https://ClinicalTrials.gov/show/NCT05497505"
335,"NCT05497492","Comparison of the Effects of Esketamine, Sufentanil, or Lidocaine on Tussis Reflection During Upper Gastroscopy",,"Not yet recruiting","No Results Available","Anesthesia","Drug: propofol|Drug: propofol and sufentanil|Drug: propofol and esketamine|Drug: propofol and lidocaine","the frequency of tussis, nausea and vomiting, and/or body movements observed at the insertion of the endoscope into the pharyngeal cavity or within 5 minutes of endoscope insertion.|recovery time|propofol dosage during operation|incidence of perioperative adverse events|incidence of postoperative adverse events|MMSE scores after operation","Beijing Friendship Hospital|Beijing Tiantan Hospital","All","18 Years to 99 Years   (Adult, Older Adult)","Not Applicable","400","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","lumen208","October 1, 2022","January 30, 2023","March 30, 2023","August 11, 2022",,"August 11, 2022",,,"https://ClinicalTrials.gov/show/NCT05497492"
336,"NCT05497479","Study Evaluating Techniques for Measuring Tear Production","MTP","Completed","No Results Available","Dry Eye Disease","Drug: 0.003% AR-15512 to be administered in both eyes|Drug: Vehicle to be administered in both eyes","Unanesthetized Schirmer test|Anesthetized Schirmer test","Aerie Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 1","40","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","21-110-A","December 9, 2021","December 10, 2021","December 10, 2021","August 11, 2022",,"August 11, 2022","Eye Research Foundation, Newport Beach, California, United States",,"https://ClinicalTrials.gov/show/NCT05497479"
337,"NCT05497466","PUMCH Study Into Individualized Scanning for Coronary Artery Disease","COE","Not yet recruiting","No Results Available","Coronary Artery Disease|Coronary Computed Tomographic Angiography",,"The diagnostic quality produced by individualized scan and injection protocol.|Objective evaluation on image quality|Subjective evaluation on image quality|contrast media dose in ml|contrast media flow rate in ml/s|contrast media peak flow rate [ml/s]|Time-to-peak of contrast media [s]|iodine delivery rate (IDR) in mgI/s|Patient radiation dose:volume CT dose index (CTDIvol) in mGy|Patient radiation dose: size-specific dose estimates (SSDEs) of chest in mGy|Patient radiation dose: dose length product (DLP) in mGy*cm|Patient radiation dose: effective dose (ED) in mSv","Peking Union Medical College Hospital|Bayer","All","18 Years and older   (Adult, Older Adult)",,"300","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","HS-2806 COE V1.3","January 1, 2023","June 30, 2024","June 30, 2024","August 11, 2022",,"August 11, 2022",,,"https://ClinicalTrials.gov/show/NCT05497466"
338,"NCT05497453","A Phase 1/2 Study to Evaluate OTX-2002 in Patients With Hepatocellular Carcinoma and Other Solid Tumor Types Known for Association With the MYC Oncogene","MYCHELANGELO I","Not yet recruiting","No Results Available","Hepatocellular Carcinoma|Solid Tumor|Hepatocellular Carcinoma Non-resectable|Hepatocellular Carcinoma Recurrent|Hepatocellular Cancer|Liver Cancer|Liver, Cancer of, Non-Resectable","Drug: OTX-2002|Drug: Tyrosine kinase inhibitor One|Drug: Tyrosine kinase inhibitor Two|Drug: Immune Checkpoint Blockade","Determine Dose limiting toxicities (DLT)and maximum tolerated dose ( MTD) (Part 1 escalation and Part 2 safety run-in)|Incidence of TEAEs including all AEs,Grade 3-5 AEs, drug-related AEs, and SAEs (Part 1 escalation and Part 2 safety run-in)|Overall response rate (ORR)(for Part 1 and Part 2 expansion)|Duration of Response (DOR) (for Part 1 and Part 2 expansion)","Omega Therapeutics","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","190","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","OTX-2002-101","August 2022","June 2025","December 2028","August 11, 2022",,"August 11, 2022","Next Oncology, San Antonio, Texas, United States",,"https://ClinicalTrials.gov/show/NCT05497453"
339,"NCT05497440","Evaluation of All'InCath in Peripheral Vasculature Percutaneous Transluminal Angioplasty.",,"Not yet recruiting","No Results Available","Vascular Diseases","Device: All'InCath CBC 035M Balloon Dilatation Catheter","Periprocedural Serious adverse events|Vascular patency|Duration of the intervention (PTA)|Level of radiation exposure during PTA (mGy).|Dose of contrast agent injected at the targeted location (mL).|Investigator's feedback|Major adverse events during hospitalization until discharge","NexStep Medical","All","18 Years and older   (Adult, Older Adult)","Not Applicable","30","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CSP-0003","October 2022","March 2023","March 2023","August 11, 2022",,"August 11, 2022",,,"https://ClinicalTrials.gov/show/NCT05497440"
340,"NCT05497427","Normative Database and Test-Retest Reliability for BrainCheck Assessments","NDTR","Not yet recruiting","No Results Available","Cognitive Change|Cognitive Decline|Cognitive Deterioration|Neurocognitive Deficit","Device: BrainCheck Assessment","Mean, standard deviation, and percentiles of values of BrainCheck Assessments|Test-retest reliability of BrainCheck Assessment values between two different time points","BrainCheck, Inc.","All","50 Years and older   (Adult, Older Adult)","Not Applicable","1200","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","Pro00064230","August 2022","November 2022","March 2023","August 11, 2022",,"August 11, 2022",,,"https://ClinicalTrials.gov/show/NCT05497427"
341,"NCT05497414","Neuroimaging Sleep and Mood in Depression",,"Recruiting","No Results Available","Major Depression","Behavioral: Sleep deprivation","Change in fMRI signals in thalamus region of interest (ROI) from baseline to post intervention|Change in fMRI signals in amygdala ROI from baseline to post intervention|Change in tasked evoked responses in amygdala ROI from baseline to post intervention|Change in cerebrospinal fluid (CSF) flow measurements from baseline to post intervention|Change in Montgomery-Asberg Depression Rating from baseline to post intervention|Change in whole-brain voxelwise fMRI activity from baseline to post intervention|Change in EEG dynamics from baseline to post intervention|Change in dot probe task performance from baseline to post intervention|Change in blood biomarkers of C-reactive protein from baseline to post intervention|Change in blood levels of Interleukin 6 from baseline to post intervention|Change in Magnetic Resonance Spectroscopy (MRS) measurement of lactate from baseline to post intervention|Change in MRS measurement of myo-inositol from baseline to post intervention|Change in Positive and Negative Affect Scale 21 (PANAS-21) rating from baseline to post intervention|Change in Positive and Negative Affect Scale 21 (PANAS-21) rating during intervention|Change in Shame Inventory rating from baseline to post intervention|Change in Shame Inventory rating during intervention|Change in Anxiety Sensitivity Index (ASI-3) rating from baseline to post intervention|Change in Anxiety Sensitivity Index (ASI-3) rating during intervention|Change in Depression, Anxiety, and Stress Scale (DASS-21) rating from baseline to post intervention|Change in Depression, Anxiety, and Stress Scale (DASS-21) rating during intervention|Patient health questionnaire (PHQ-9)","Boston University Charles River Campus|One Mind|Brain & Behavior Research Foundation|1907 Foundation","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","60","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","5562E","January 31, 2022","July 2024","July 2024","August 11, 2022",,"August 11, 2022","Boston University, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT05497414"
342,"NCT05497401","A Controlled Study to Evaluate the Efficacy of Allogeneic MesenCure for the Treatment of Patients With COVID-related Pneumonia",,"Not yet recruiting","No Results Available","Covid-related Pneumonia","Biological: MesenCure|Other: Placebo","Mortality|CRP reduction|Invasive ventilation","BonusBio Group Ltd","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 3","300","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","MCS-03","October 2022","December 31, 2023","July 2024","August 11, 2022",,"August 11, 2022",,,"https://ClinicalTrials.gov/show/NCT05497401"
343,"NCT05497388","Efficacy of Serious Game Interventions on HCV Education for HIV Patients",,"Enrolling by invitation","No Results Available","HIV Infections","Other: Serious Game","The effect of ""serious game-assisted teaching"" intervention program on MSM.","National Taiwan University Hospital","Male","20 Years to 45 Years   (Adult)","Not Applicable","162","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention","202206084RIND","August 1, 2022","February 28, 2023","August 31, 2023","August 11, 2022",,"August 11, 2022","Yi Ting Chen, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT05497388"
344,"NCT05497375","EtCO2 Level to Control Intraoperative Bleeding and Improve the Quality of Surgical Field Vision in Septorhinoplasty","EtCO2","Not yet recruiting","No Results Available","Anesthesia|Carbon Dioxide|Surgical Blood Loss","Diagnostic Test: The amount of intraoperative bleeding|Diagnostic Test: Quality of the intraoperative surgical field|Diagnostic Test: Surgeon Satisfaction|Diagnostic Test: Heart rate|Diagnostic Test: Mean arterial pressure|Diagnostic Test: Peripheral oxygen saturation","Total amount of intraoperative bleeding|Quality of the intraoperative surgical field|Surgeon Satisfaction|Heart rate|Mean arterial pressure|Peripheral oxygen saturation","Bezmialem Vakif University","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","70","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","muhittincalim3","August 20, 2022","September 15, 2022","September 30, 2022","August 11, 2022",,"August 11, 2022","Muhittin Calim, Istanbul, Fatih, Turkey",,"https://ClinicalTrials.gov/show/NCT05497375"
345,"NCT05497362","Non-invasive Brain Stimulation as a Treatment for Dysarthria Post-stroke",,"Completed","No Results Available","Dysarthria|Stroke","Device: Real tDCS|Device: Sham tDCS","Perceptual speech assessments|Acoustic measurement: Fundamental frequency (F0)|Acoustic measurement: Frequency perturbation (jitter %)|Acoustic measurement: Intensity perturbation (shimmer %)|Acoustic measurement: Noise to harmonic ratio (NHR)|Acoustic measurement: Harmonic to noise ratio (HNR)|Kinematic measurement: Duration|Kinematic measurement: Distance|Kinematic measurement: Maximum velocity|Kinematic measurement: Maximum acceleration|Kinematic measurement: Maximum deceleration","The University of Hong Kong|The Hong Kong Polytechnic University","All","18 Years to 75 Years   (Adult, Older Adult)","Not Applicable","9","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","UW16-126","April 1, 2016","June 30, 2017","June 30, 2017","August 11, 2022",,"August 11, 2022","University of Hong Kong, Hong Kong, Hong Kong",,"https://ClinicalTrials.gov/show/NCT05497362"
346,"NCT05497349","Use of Leukocyte-Rich PRP or Leukocyte-Free PRP in the Treatment of Hip Osteoarthritis","PRP22-Hip","Not yet recruiting","No Results Available","Hip Osteoarthritis","Other: Leukocyte Rich- PRP injection|Other: Leukocyte Poor- PRP injection","Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC)|Visual Analogue Scale (VAS)|Harris Hip Scale (HHS)|EQ-5D (EuroQoL) Current Health Assessment|Patient Acceptable Symptom State (PASS)","Istituto Ortopedico Rizzoli","All","35 Years to 70 Years   (Adult, Older Adult)","Not Applicable","230","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","PRP22-Hip","September 2022","March 2023","September 2026","August 11, 2022",,"August 11, 2022",,,"https://ClinicalTrials.gov/show/NCT05497349"
347,"NCT05497336","A Study of IBI351 in Combination With Cetuximab in Subjects With KRAS G12C Mutated Metastatic Colorectal Cancer",,"Not yet recruiting","No Results Available","Colorectal Cancer","Drug: IBI351","Incidence of DLTs (Dose-limiting Toxicity) in the Combined Dose Escalation Phase|Objective response rate (ORR)|incidence of serious treatment-emergent AEs (TEAEs) , treatment-related adverse event(TRAE), adverse events (SAEs)|Number of participants with abnormality in vital signs|Number of participants with abnormality in hematology parameters|Number of participants with abnormality in clinical chemistry parameters|Number of participants with abnormality in routine urinalysis parameters|Number of participants with abnormality in ECG parameters","Innovent Biologics (Suzhou) Co. Ltd.","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1","102","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CIBI351B301","August 30, 2022","August 30, 2022","September 30, 2024","August 11, 2022",,"August 11, 2022","The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China",,"https://ClinicalTrials.gov/show/NCT05497336"
348,"NCT05497323","Effectivity and Safety of Combination Cream of Salicylic Acid,Aqua Posae Filiformis,Niacinamide,Lipohydroxy Acid,Procerad,and Zinc PCA",,"Recruiting","No Results Available","Acne Vulgaris","Drug: Combination Cream|Drug: Adapalene 0,1% cream","Change of acne severity|Change of Level Of Seborrhea|Change of erythema|Change of quality of life|Facial Analysis Examination With Janus Facial Analysis System","Dr.dr.Irma Bernadette, SpKK (K)|Indonesia University","Female","15 Years to 50 Years   (Child, Adult)","Phase 1","300","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","EffectivityCombiAquaPosae","August 1, 2022","October 31, 2022","December 31, 2022","August 11, 2022",,"August 11, 2022","Rumah Sakit Pusat Angkatan Darat Gatot Soebroto, Jakarta, DKI Jakarta, Indonesia|Rumah Sakit Umum Pusat Cipto Mangunkusumo, Jakarta, DKI Jakarta, Indonesia|Rumah Sakit Umum Daerah Dr. Moewardi, Surakarta, Jawa Tengah, Indonesia|Rumah Sakit Umum Daerah Saiful Anwar, Malang, Jawa Timur, Indonesia|Rumah Sakit Umum Pusat Dr. M. Djamil, Padang, Sumatera Barat, Indonesia",,"https://ClinicalTrials.gov/show/NCT05497323"
349,"NCT05497310","Effectiveness and Safety of Therapy Based on Attenuated ATO Plus Low-Dose ATRA in Patients With APL.",,"Recruiting","No Results Available","Promyelocytic Leukemia","Drug: Arsenic trioxide|Drug: all-trans retinoic acid","Safety of therapy|Overall response|Progression-free survival|Event-free survival|Rate of treatment discontinuation due to toxicity.","Hospital Universitario Dr. Jose E. Gonzalez","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","15","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HE22-00019","July 1, 2022","June 30, 2025","July 31, 2025","August 11, 2022",,"August 11, 2022","Hopsital Universitario Dr. Jose E. Gonzalez, Centro Universitario contra el Cancer, Monterrey, Nuevo Leon, Mexico",,"https://ClinicalTrials.gov/show/NCT05497310"
350,"NCT05497297","A Study to Evaluate the Pharmacokinetics of HSK7653 in Subjects With Renal Impairment",,"Recruiting","No Results Available","Renal Impairment","Drug: HSK7653 tablets","Cmax|AUC0-t|AUC0-inf|Tmax|t1/2|Vz/F|CL/F|Ae|Fe|CLr|DPP4 inhibition AUEC|DPP4 inhibition Emax|DPP4 inhibition E336h|The number of volunteers with adverse events as a measure of safety","Haisco Pharmaceutical Group Co., Ltd.","All","18 Years to 79 Years   (Adult, Older Adult)","Phase 1","64","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HSK7653-106","August 4, 2022","October 30, 2022","November 3, 2022","August 11, 2022",,"August 12, 2022","Beijing Jishuitan Hospital, Beijing, China",,"https://ClinicalTrials.gov/show/NCT05497297"
351,"NCT05497284","To Assess the Efficacy of the Investigational Products Compared to Placebo in Participants With IPF",,"Not yet recruiting","No Results Available","Idiopathic Pulmonary Fibrosis","Drug: LTP001|Drug: Placebo|Drug: Standard of Care (SoC)","Change from baseline to end of treatment epoch in Forced Vital Capacity (FVC) expressed in percent predicted|Change from baseline to end of treatment epoch in Forced Vital Capacity (FVC)|Time to progression|Number of participants with absolute decline of ≥10% predicted in FVC|Change from baseline to the end of treatment epoch in DLCO|Change from baseline to the end of treatment epoch in 6-minute walk distance|Change from baseline to the end of treatment epoch in scores from the K-BILD questionnaire|Change from baseline to the end of treatment epoch in scores from Leicester Cough questionnaire|Change from baseline to the end of treatment epoch in scores from the the R-Scale for IPF questionnaire|Change from baseline to the end of treatment epoch in scores from the Living with IPF questionnaire (Impacts)|Change from baseline to the end of treatment epoch in scores from the Living with IPF questionnaire (Symptoms)","Novartis Pharmaceuticals|Novartis","All","40 Years and older   (Adult, Older Adult)","Phase 2","94","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CADPT09A12201","October 5, 2022","January 31, 2025","February 3, 2025","August 11, 2022",,"August 11, 2022",,,"https://ClinicalTrials.gov/show/NCT05497284"
352,"NCT05497271","Confirmation of Association Between Cystic Fluid Analysis With Pancreatic Cystic Lesions",,"Recruiting","No Results Available","Pancreatic Cyst|Molecular, Chemical Analysis of Cystic Fluid",,"diagnostic accuracy by cystic fluid analysis|Overall survival|Disease free survival|Malignant transformation rate|Prediction for treatment response in case of surgical resected or EUS-guided ethanol ablated pancreatic cysts|Cytology of cystic fluid|Chemical profile of CEA in cystic fluid|Chemical profile of Amylase in cystic fluid|Chemical profile of glucose in cystic fluid|DNA mutation profile of cystic fluid","Seoul National University Hospital","All","18 Years and older   (Adult, Older Adult)",,"500","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","H-2206-213-1336","January 1, 2017","December 31, 2025","December 31, 2025","August 11, 2022",,"August 12, 2022","Seoul National University Hospital, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT05497271"
353,"NCT05497258","AI Assisted Doctors to Improve the Accuracy of Abdominal Pain Diagnosis",,"Not yet recruiting","No Results Available","Artificial Intelligence|Diagnoses Disease","Device: Artificial intelligence assistant system","Accuracy of diagnosis|Total diagnostic accuracy|Determine the cost required for diagnosis|Determine the time required for diagnosis","Renmin Hospital of Wuhan University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","9","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Device Feasibility","EA-22-007","August 15, 2022","September 1, 2022","October 1, 2022","August 11, 2022",,"August 11, 2022","Renmin Hospital of Wuhan University, Wuhan, Hubei, China",,"https://ClinicalTrials.gov/show/NCT05497258"
354,"NCT05497245","Development of Mobile Application Based Breastfeeding Education Program and Evaluation of the Program Effectiveness",,"Active, not recruiting","No Results Available","Breastfeeding, Exclusive","Other: mobile app-based breastfeeding education","breastmilk exclusive|breastfeeding problem|baby's physical development","Istanbul University-Cerrahpasa","Female","18 Years and older   (Adult, Older Adult)","Not Applicable","73","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","121S326","November 1, 2021","August 1, 2022","August 1, 2022","August 11, 2022",,"August 11, 2022","Istanbul University-Cerrahpasa, Istanbul, Turkey",,"https://ClinicalTrials.gov/show/NCT05497245"
355,"NCT05497232","Clinical Analysis of Simultaneous Pancreas-kidney Transplantation for End-stage Renal Disease Associated With Diabetes Mellitus",,"Recruiting","No Results Available","Diabetes Mellitus；Uremia","Procedure: simultaneous pancreas-kidney transplantation","Patient survival & pancreas graft survival & renal graft survival","Second Affiliated Hospital of Guangzhou Medical University","All","16 Years to 65 Years   (Child, Adult, Older Adult)","Not Applicable","200","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2022-hg-ks-17","September 1, 2022","January 1, 2023","January 1, 2024","August 11, 2022",,"August 11, 2022","1Department of Organ Transplantation, Second Affiliated Hospital of Guangzhou Medical University,, Guangzhou, Guangdong, China",,"https://ClinicalTrials.gov/show/NCT05497232"
356,"NCT05497219","Reference Values for Videofluoroscopic Measures of Swallowing","NIA_RV","Not yet recruiting","No Results Available","Dysphagia, Oropharyngeal","Diagnostic Test: Videofluoroscopic Swallowing Study (VF)","Number of participants with unsafe swallowing|Number of participants with impaired swallowing efficiency|Number of participants with delayed airway closure (""Time-to-laryngeal-vestibule-closure"")|Number of participants with poor pharyngeal constriction","University Health Network, Toronto|University of Florida|McMaster University","All","18 Years and older   (Adult, Older Adult)",,"540","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","21-6019|R01AG077481","November 2022","November 2026","November 2026","August 11, 2022",,"August 11, 2022",,,"https://ClinicalTrials.gov/show/NCT05497219"
357,"NCT05497206","Robotic Instrumentation in THA",,"Not yet recruiting","No Results Available","Osteoarthritis, Hip","Device: One of the following hip implants may be used within this arm of the study: G7 Acetabular System, Taperloc Complete System, Avenir and Avenir Complete Systems, and Echo Bi-Metric System","Accuracy of implant position|Evaluation of Patient safety|Patient Reported Outcome Measure (Oxford Hip Score)|Patient Reported Outcome Measure (HOOS-Jr)|Numeric Pain Rating Scale (NPRS)|Subject Satisfaction|Clinical performance will be assessed with evaluation of range of motion.|Clinical performance will be assessed with evaluation of stability using the Trendelenburg test.|Clinical performance will be assessed by testing leg length discrepancy.","Zimmer Biomet","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","176","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","CMU2021-26TDS","April 2023","December 2025","December 2025","August 11, 2022",,"August 11, 2022",,,"https://ClinicalTrials.gov/show/NCT05497206"
358,"NCT05497193","Clinical Efficacy and Safety of Perampanel Monotherapy in the Treatment of Children With Focal Epilepsy",,"Active, not recruiting","No Results Available","Focal Epilepsy","Drug: perampanel","clinical efficacy after drug treatment:|EEG changes after drug treatment|safety after drug treatment","Yang Xinwei|Xijing Hospital","All","4 Years to 18 Years   (Child, Adult)",,"280","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","20222126","July 1, 2021","March 20, 2023","October 20, 2023","August 11, 2022",,"August 11, 2022","XI Jing Hospital, Xi'an, Shan XI, China",,"https://ClinicalTrials.gov/show/NCT05497193"
359,"NCT05497180","Use of Passive Myofunctional Appliances for Snoring and Mild Obstructive Sleep Apnea",,"Recruiting","No Results Available","Sleep Apnea, Obstructive","Device: passive myofunctional appliance|Device: standard oral appliance","Snoring volume","University of Alberta","All","18 Years and older   (Adult, Older Adult)","Phase 1","40","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","00117371","July 23, 2022","July 2024","July 2025","August 11, 2022",,"August 12, 2022","Enjoy Dental, Edmonton, Alberta, Canada",,"https://ClinicalTrials.gov/show/NCT05497180"
360,"NCT05497167","Development and Evaluation of ""Period Kits"" for Adolescents With Intellectual and Developmental Disabilities",,"Not yet recruiting","No Results Available","Autistic Spectrum Disorder|Patient Empowerment|Menstrual Discomfort","Other: Period Kit","Period kit acceptability","Tufts Medical Center|Tufts University","Female","5 Years to 17 Years   (Child)","Not Applicable","50","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","STUDY00002861","August 1, 2022","August 1, 2023","September 1, 2023","August 11, 2022",,"August 11, 2022","Tufts Medical Center, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT05497167"
361,"NCT05497154","Physical Therapists Identifying Patients With Opioid Misuse",,"Not yet recruiting","No Results Available","Opioid Misuse|Musculoskeletal Pain","Behavioral: Training Arm","Change in the Drug and Drug Problems Perception Questionnaire (DDPPQ)","University of Utah","All","18 Years and older   (Adult, Older Adult)","Not Applicable","12","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","3394","October 2022","May 31, 2023","July 31, 2023","August 11, 2022",,"August 11, 2022",,,"https://ClinicalTrials.gov/show/NCT05497154"
362,"NCT05497141","Dawneo Neoblazar® Transcatheter Tricuspid Valve Edge-to Edge Repair System Pivotal Clinical Trial in Patients With Severe Tricuspid Regurgitation",,"Recruiting","No Results Available","Tricuspid Regurgitation","Device: Neoblazar® Transcatheter Tricuspid Valve Edge-to Edge Repair System","Rate of Implantation Success|Initial Success|NYHA Functional Class|Six-minute walk test|Reduction in TR grade","Xiamen Cardiovascular Hospital, Xiamen University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","98","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2022YLK17","July 22, 2022","August 22, 2023","October 22, 2023","August 11, 2022",,"August 11, 2022","Xiamen Cardiovascular Hospital Xiamen University, Xiamen, Fujian, China",,"https://ClinicalTrials.gov/show/NCT05497141"
363,"NCT05497128","Standard Cut Rate 27-Gauge System Versus Ultrahigh-Speed 27-Gauge System in Macular Surgery",,"Not yet recruiting","No Results Available","Macular Disease","Device: Ultrahigh-speed cut rate 27-gauge system|Device: Standard cut rate 27-gauge system","Efficiency of core vitrectomy|Intraoperative complications|Postoperative complications|Efficiency of peripheral vitrectomy|Efficiency of surgery","Seoul National University Bundang Hospital|Alcon Research","All","19 Years and older   (Adult, Older Adult)","Not Applicable","66","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","B-2112-728-001","September 2022","August 2023","August 2023","August 11, 2022",,"August 15, 2022","Seoul National University Bundang Hospital, Seongnam, Gyunggi-do, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT05497128"
364,"NCT05497115","Testing a Scalable Model of Care to Improve Patients Access to Mental Health Services After Traumatic Injury",,"Not yet recruiting","No Results Available","Posttraumatic Stress Disorder|Depression","Behavioral: Trauma Resilience and Recovery Program","Change from Baseline PTSD Checklist for DSM-5 8- item (PCL8-5) at 3-,6-, and 12-month|Demographics|Injured Trauma Survivor Screen (ITSS)|Electronic Medical Record Data (EMR)|The Kessler 6 (K6)|PROMIS Emotional and Instrumental Support|The Major Experiences and Everyday Discrimination Scale|National Health Interview Survey Adult Access to Health Care and Utilization Module|The California Health Interview Survey (CHIS) question|Patient Health Questionnaire-9 (PHQ-9)|Acceptance of Treatment Referral and Initiation of Treatment|PROMIS Pain Intensity and Interference Scale|Stigma Scale for Receiving Psychological Help|NIDA Quick Screen; alcohol, tobacco, prescription and illicit drug use|PROMIS Self-Efficacy|PROMIS Sleep Disturbance|PROMIS General Life Satisfaction|PROMIS Global Health|Occupational Status|Job Insecurity|Food Insecurity|National Adverse Childhood Experiences Questions|Neighborhood Environment","Medical University of South Carolina|George Washington University","All","16 Years and older   (Child, Adult, Older Adult)","Not Applicable","350","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20901","September 2022","August 31, 2025","August 31, 2025","August 11, 2022",,"August 11, 2022","George Washington University Hospital, Washington, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT05497115"
365,"NCT05497102","Carfilzomib, Lenalidomide, and Dexamethasone Re-induction Followed by the 2nd ASCT in Multiple Myeloma Patients Relapsed After the 1st ASCT","KMM1911","Recruiting","No Results Available","Multiple Myeloma","Drug: Lenalidomide maintenance","2-year progression free survival rate|Complete response rate after KRd #6|Complete response rate after ASCT|Overall response rate|Time to response|Duration of response|Overall survival|Safety of KRd induction therapy, 2nd ASCT, and lenalidomide maintenance therapy|Rate of the successful stem cell harvest","Samsung Medical Center","All","20 Years to 70 Years   (Adult, Older Adult)","Phase 2","58","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SMC 2019-12-037","November 8, 2021","May 2024","December 2025","August 11, 2022",,"August 12, 2022","Samsung Medical Center, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT05497102"
366,"NCT05497089","Temelimab as a Disease Modifying Therapy in Patients With Neuropsychiatric Symptoms in Post-COVID 19 or PASC Syndrome",,"Not yet recruiting","No Results Available","Post-COVID-19 Syndrome","Drug: Temelimab 54mg/kg|Drug: Placebo","Composite endpoint: improvement in cognitive impairment or fatigue in PASC patients|Fatigue|Cognitive function|Anxiety|Depression|Quality of Life|Functional impairment|Post-COVID-19 Functional Status|Safety and tolerability of Temelimab in PASC patients","GeNeuro SA","All","18 Years and older   (Adult, Older Adult)","Phase 2","200","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","GNC-501|2022-000618-32","August 8, 2022","March 31, 2023","March 31, 2023","August 11, 2022",,"August 11, 2022","Geneva University Hospital, Geneva, Switzerland",,"https://ClinicalTrials.gov/show/NCT05497089"
367,"NCT05497076","the Efficacy and Safety of Dalpiciclib Combined With Third-generation EGFR-TKI in Patients With EGFR Mutation and Meningial Metastasis in Non-small Cell Lung Cancer Progressing Through Third-generation TKI and Platinum-containing Two-drug Chemotherapy",,"Not yet recruiting","No Results Available","Non-small Cell Lung Cancer Confirmed by Histopathology or Cytology|The TNM (8th) Phase is IV|With EGFR Mutations|Meningeal Progression Occurred After Previous Platinum-containing Two-drug Chemotherapy and Third-generation EGFR-TKI Treatment|Male or Female|The Age of 18 Years Old or More|ECOG PS 0 to 2 Points",,"9 of participants|ORR|CNS PFS|PFS|OS","Fujian Cancer Hospital","All","18 Years and older   (Adult, Older Adult)",,"9","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","LM20220606","September 1, 2022","January 1, 2024","July 1, 2024","August 11, 2022",,"August 11, 2022",,,"https://ClinicalTrials.gov/show/NCT05497076"
368,"NCT05497063","Bioequivalence Study of Sulfadoxine/ Pyrimethamine Dispersible Tablets in Healthy Subjects Under Fasting Conditions",,"Not yet recruiting","No Results Available","Bioequivalence","Drug: Sulfadoxine/Pyrimethamine dispersible tablets, 250 mg sulfadoxine / 12.5 mg pyrimethamine & 500 mg sulfadoxine / 25 mg pyrimethamine|Drug: G-COSPE® tablets","Bioequivalence based on Peak Plasma Concentration (Cmax) for Sulfadoxine and Pyrimethamine.|Area under the plasma concentration versus time curves (AUC0 - 72) for Sulfadoxine and Pyrimethamine|Obtaining the Tmax (Time to reach maximum concentration) for Sulfadoxine and Pyrimethamine|Number of participant with treatment related adverse events as assessed by CTCAE v4.0.","Emzor Pharmaceutical Industries Limited","All","18 Years to 50 Years   (Adult)","Phase 1","70","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","1100-2021","December 2022","February 2023","February 2023","August 11, 2022",,"August 11, 2022",,,"https://ClinicalTrials.gov/show/NCT05497063"
369,"NCT05497050","The Effect of Nursing Empowerment Program",,"Recruiting","No Results Available","Phenylketonurias","Behavioral: Family education","Change from Baseline in Evaluation Of Coping Attitudes (COPE) at week 10","Cukurova University","All","1 Day to 3 Years   (Child)","Not Applicable","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","FAHRİ AŞKAN PHD THESIS","July 18, 2022","November 30, 2022","December 30, 2022","August 11, 2022",,"August 11, 2022","Van Yuzuncu Yıl University, Van, Tuşba, Turkey",,"https://ClinicalTrials.gov/show/NCT05497050"
370,"NCT05497037","Safety and Efficacy of Carpal Stim in Treating Carpal Tunnel Syndrome",,"Recruiting","No Results Available","Carpal Tunnel Syndrome","Device: PRF stimulation|Device: Sham stimulation","Effectiveness: The responder rate of the PRF group and Sham-Control group|Safety: Incidence of adverse events (AEs) and serious AEs (SAEs)|Safety: Change in Nerve Conduction Velocity 14th day compared to baseline|Proportion in responder in treatment and sham-controlled groups|Change in NRS score in treatment and sham-controlled groups compared to baseline|Change in PGIC scale in treatment and sham-controlled compared to baseline|Change in GSS score in treatment and sham-controlled compared to baseline|Change in BCTQ-SSS score in treatment and sham-controlled compared to baseline|Change in BCTQ-FSS score in treatment and sham-controlled compared to baseline","GiMer Medical","All","20 Years and older   (Adult, Older Adult)","Not Applicable","47","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","CTS001","March 9, 2022","December 31, 2022","December 31, 2022","August 11, 2022",,"August 11, 2022","Hualien Tzu Chi Hospital, Hualien City, Taiwan|Chung Shan Medical University Hospital, Taichung, Taiwan|National Cheng Kung University Hospital, Tainan, Taiwan|Veterans General Hospital-Taipei, Taipei, Taiwan|Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan",,"https://ClinicalTrials.gov/show/NCT05497037"
371,"NCT05497024","Older Men's Decision Making About Active Surveillance for Prostate Cancer - Aim 3: Decision Aid Cognitive and Usability Testing",,"Not yet recruiting","No Results Available","Prostate Cancer","Behavioral: Interviews|Behavioral: Surveys","Number of Participants With Treatment-Related Adverse Events as Assessed by CTCAE v4.0, Change From Baseline in Pain Scores on the Visual Analog Scale at 6 Weeks","M.D. Anderson Cancer Center|American Cancer Society, Inc.","Male","65 Years and older   (Older Adult)","Not Applicable","45","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","2022-0375|NCI-2022-06569","January 31, 2023","May 31, 2023","May 31, 2023","August 11, 2022",,"August 11, 2022","M D Anderson Cancer Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT05497024"
372,"NCT05497011","A Study to Evaluate the Safety and Efficacy of PiCSO in Anterior STEMI Patients (PiCSO-AMI-II)","PiCSO-AMI-II","Not yet recruiting","No Results Available","STEMI - ST Elevation Myocardial Infarction|Anterior Wall Myocardial Infarction","Device: PiCSO Impulse System","12% performance goal rate of PiCSO device or PiCSO procedure related adverse events reported through 30 days|Difference in myocardial infarct size|Major Adverse Cardiac Event (MACE) at 30 days as well as 1, 2 and 3 years post index PCI|Individual components of the MACE|Classification of all-cause death|Time to death and heart failure hospitalization|Myocardial infarct size (% of LV mass) assessed by CMR at 6 months post index PCI|Occurrence and extent of microvascular obstruction and hemorrhage|Myocardial function (LVEF, LVESV, LVEDV)|Myocardial Salvage Index and myocardial infarct size|ST-segment resolution|Device success and procedural success rate|Changes in quality of life|Utilization of health resources","Miracor Medical SA","All","18 Years and older   (Adult, Older Adult)","Not Applicable","300","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MIR-CIP 0003","March 30, 2023","July 31, 2025","June 30, 2028","August 11, 2022",,"August 11, 2022",,,"https://ClinicalTrials.gov/show/NCT05497011"
373,"NCT05496998","Transcatheter Mitral Valve Replacement in Patients With Severe Symptomatic Mitral Regurgitation - APOLLO-EU Trial","APOLLO-EU","Not yet recruiting","No Results Available","Mitral Regurgitation","Device: Medtronic Intrepid™ TMVR TF System","Safety: all-cause mortality at 1-year post-procedure.|Efficacy: Percentage of subjects with none/trace or mild mitral regurgitation at 30 days post-procedure.|Rate of all-cause mortality (Safety).|Disabling stroke (Safety).|Acute Kidney Injury (stage 3 or with renal replacement) (Safety).|Reoperation or reintervention (Safety).|Major access site vascular complications (Safety).|Mitral valve regurgitation (Efficacy).|NYHA functional class (Efficacy).|Quality of Life (QoL) as assessed by KCCQ (Efficacy).|Cardiovascular hospitalizations (Efficacy).","Medtronic Cardiovascular","All","18 Years and older   (Adult, Older Adult)","Not Applicable","360","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MDT22008TMV005","November 2022","November 2026","March 2032","August 11, 2022",,"August 11, 2022",,,"https://ClinicalTrials.gov/show/NCT05496998"
374,"NCT05496985","Chinese Validation of the Simplified Evaluation of CONsciousness Disorders（SECONDs）",,"Completed","No Results Available","Brain Diseases|Vegetative State|Unconsciousness|Central Nervous System Diseases","Diagnostic Test: Simplified Evaluation of CONsciousness Disorders (SECONDs)","Assess the reliability and validity of the Chinese version of the SECONDs|Diagnose the level of consciousness in patients through SECONDs and CRS-R|Diagnose the level of consciousness in patients through CRS-R","Hangzhou Normal University","All","18 Years to 85 Years   (Adult, Older Adult)","Not Applicable","49","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Diagnostic","YCYY-20211021-003","December 20, 2021","March 14, 2022","March 14, 2022","August 11, 2022",,"August 11, 2022","International Vegetative State and Consciousness Science Institute, Hangzhou Normal University, Hangzhou, Zhejiang, China",,"https://ClinicalTrials.gov/show/NCT05496985"
375,"NCT05496972","Survey Assessment of Patient and Provider Impressions of Telemedicine in Radiation Oncology",,"Recruiting","No Results Available","Hematopoietic and Lymphoid Cell Neoplasm|Malignant Solid Neoplasm","Behavioral: Survey Administration","Patient satisfaction survey with telemedicine in radiation oncology (RO)|Provider satisfaction survey with telemedicine in radiation oncology (RO)","M.D. Anderson Cancer Center","All","18 Years and older   (Adult, Older Adult)",,"200","Other","Observational","Observational Model: Case-Only|Time Perspective: Cross-Sectional","2020-1063|NCI-2021-09908","April 21, 2021","December 31, 2022","December 31, 2022","August 11, 2022",,"August 11, 2022","MD Anderson Cancer Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT05496972"
376,"NCT05496959","177-Lutetium-PSMA Before Stereotactic Body Radiotherapy for the Treatment of Oligorecurrent Prostate Cancer, The LUNAR Study","LUNAR","Not yet recruiting","No Results Available","Oligometastatic Prostate Carcinoma|Prostate Adenocarcinoma|Recurrent Prostate Adenocarcinoma|Stage IVB Prostate Cancer AJCC v8","Drug: Lutetium Lu-177 PNT2002|Other: Quality-of-Life Assessment|Radiation: Stereotactic Body Radiation Therapy","Prostate-specific membrane antigen positron emission tomography/computerized tomography (PSMA PET/CT)-based progression-free survival (PFS)|Disease progression|PSA-based progression|Incidence of adverse events (AEs)|Patient-reported quality of life|Androgen deprivation therapy-free survival (ADT-FS)|Time to progression|Time to local progression (TTLP)|Time to new metastasis (TNM)|Overall survival (OS)|Local control (LC)|Regional control (RC)|Duration of complete response (CR) or partial response (PR)","Jonsson Comprehensive Cancer Center|POINT Biopharma","All","18 Years and older   (Adult, Older Adult)","Phase 2","100","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","22-000750|NCI-2022-05748","September 1, 2022","September 1, 2024","September 1, 2025","August 11, 2022",,"August 11, 2022","UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT05496959"
377,"NCT05496946","The Efficiency of Two Different Simulation Methods",,"Completed","No Results Available","Nursing Education","Other: Head bathing skill","Standardized patient|Model with Low Closeness to Reality","Istanbul Medeniyet University|Istanbul University-Cerrahpasa","All","18 Years and older   (Adult, Older Adult)","Not Applicable","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Health Services Research","IMU16","December 25, 2021","February 8, 2022","July 30, 2022","August 11, 2022",,"August 11, 2022","Istanbul Medeniyet University- Faculty of Health Sciences, Istanbul, Kartal, Turkey",,"https://ClinicalTrials.gov/show/NCT05496946"
378,"NCT05496933","Colombia National Porphyria Registry",,"Active, not recruiting","No Results Available","Rare Diseases|Porphyrias",,"Incidence|Prevalence|Life quality","Fundación Grupo de Investigación en Cuidados Intensivos y Obstetricia|Recordati Rare Diseases","All","Child, Adult, Older Adult",,"100","Other|Industry","Observational","Observational Model: Case-Only|Time Perspective: Cross-Sectional","0112-2020","April 1, 2021","December 21, 2021","December 30, 2022","August 11, 2022",,"August 11, 2022","Gestion Salud, Cartagena, Bolivar, Colombia",,"https://ClinicalTrials.gov/show/NCT05496933"
379,"NCT05496920","Assessing Ultra-low Dose PET/CT and CT-less PET Using a Long Axial Field-of-view PET/CT System","ULD-PET","Not yet recruiting","No Results Available","PET/CT","Diagnostic Test: FD-PET/CT|Diagnostic Test: LD-PET/CT","Intra-rater correlation coefficient|Lesion uptake|Image quality|Subjective quality|Agreement|Diagnostic accuracy","University Hospital Inselspital, Berne","All","18 Years and older   (Adult, Older Adult)","Not Applicable","42","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","2022-D0038","September 2022","November 2022","January 2023","August 11, 2022",,"August 11, 2022","Inselspital, Universitätsspital Bern, Bern, Switzerland",,"https://ClinicalTrials.gov/show/NCT05496920"
380,"NCT05496907","Psychosis and Type 2 Diabetes Study (PODS)",,"Not yet recruiting","No Results Available","Type 2 Diabetes|Severe Mental Disorder","Behavioral: Diabetes specialist nurse-led collaborative care intervention","Effectiveness of Intervention using HbA1c levels|Blood Pressure|Body Mass Index (BMI)|Mental Health Outcome","King's College London","All","18 Years and older   (Adult, Older Adult)","Not Applicable","50","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","289799","August 2022","February 2023","March 2023","August 11, 2022",,"August 11, 2022","Herne Hill Group Practice, London, United Kingdom|Knight's Hill, London, United Kingdom|Brixton Hill, London, United Kingdom|Northwood Group Practice, London, United Kingdom|Binfield Road Practice, London, United Kingdom|Springfield Medical Centre, London, United Kingdom|Beckett House, London, United Kingdom|Grantham Practice, London, United Kingdom|Stockwell Group Practice, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT05496907"
381,"NCT05496894","A Study of Mitoxantrone Hydrochloride Liposome Injection for Relapsing Multiple Sclerosis",,"Not yet recruiting","No Results Available","Relapsing Multiple Sclerosis","Drug: Mitoxantrone Hydrochloride Liposome Injection","The cumulative number of new Gadolinium (Gd)-enhancing lesions at the end of 48 weeks of Mitoxantrone Hydrochloride Liposome Injection treatment in brain MRI.|Annualized Relapse Rate (ARR)|Number of Relapses|Time to Onset of Confirmed Disability Progression for at least 6 Months|Time to Onset of Confirmed Disability Progression for at least 3 Months|Proportion of participants with ≥ 20% improvement from baseline in T25FW walking speed.|Change from baseline to Week 48 in T25FW walking speed.|Number of new or enlarged T2 lesions.|Change from baseline in brain MRI Gd-enhancing T1 lesion volume at Weeks 12、24、36、48.|Change from baseline in brain MRI T2 lesion volume at Weeks 12、24、36、48.|Number of participants with treatment-related adverse events as assessed by CTCAE v5.0|Plasma concentration of Mitoxantrone Hydrochloride Liposome Injection.|Descriptive analysis of the rate of change in the number or proportion of B cells from baseline to different time points in different dose groups.|Descriptive analysis of the rate of change in the number or proportion of T cells from baseline to different time points in different dose groups.|Descriptive analysis of the rate of change in the number or proportion of NK cells from baseline to different time points in different dose groups.","CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.","All","18 Years to 55 Years   (Adult)","Phase 2","90","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HE071-CSP-030","August 2022","December 2024","August 2028","August 11, 2022",,"August 11, 2022","Xuanwu Hospital Capital Medical University, Beijing, Beijing, China",,"https://ClinicalTrials.gov/show/NCT05496894"
382,"NCT05496881","Exercise and Progressive Multiple Sclerosis",,"Recruiting","No Results Available","Progressive Multiple Sclerosis","Other: Exercise Group 1|Other: Exercise Group 2|Other: Exercise Group 3","Timed 25-Foot Walk Test|Motor Evoked Potential Amplitude","University of Regina|First Steps Wellness Centre|Saskatchewan Health Research Foundation|University of Saskatchewan","All","18 Years and older   (Adult, Older Adult)","Not Applicable","69","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care","2021-197","June 15, 2022","March 31, 2024","October 31, 2024","August 11, 2022",,"August 11, 2022","University of Regina, Regina, Saskatchewan, Canada",,"https://ClinicalTrials.gov/show/NCT05496881"
383,"NCT05496868","Add-on Reparixin in Adult Patients With ARDS",,"Not yet recruiting","No Results Available","Acute Respiratory Distress Syndrome, Adult","Drug: Reparixin 600mg|Other: Matching Placebo","Change in oxygenation index (OI) from baseline to day 7 of treatment|Ventilator free days (VFD) at day 28|Change in oxigenation index (OI) from baseline to day 4±1|Acute lung injury score [composite of PaO2/FIO2 ratio, PEEP, lung compliance (plateau airway pressure minus PEEP/TV) and extent of pulmonary infiltrates] at 2(±8h) day, 3(±8h) day, 7±1 day, 14±2 day (if still intubated)|Sequential Organ Failure Assessment (SOFA) score at 2(±8h) day, 3(±8h) day, 7±1 day, 14±2 day (if still intubated)|Ventilatory ratio (product of minute ventilation and PaCO2) at 2(±8h) day, 3(±8h) day, 7±1 day, 14±2 day (if still intubated)|Incidence of Extracorporeal Membrane Oxygenation (ECMO) by day 14±2|Use of vasoactive medications by day 14±2|Chest X-Rays assessment of pulmonary edema by ""radiographic assessment of lung edema"" (RALE) score at 2(±8h), 3(±8h), 7±1, 14±2 days|Percentage of patients achieving pressure support ventilation equal to 5 cm H20 with PEEP equal to 5 cm H20 for 2 hours (measure of weaning) by day 28±2|Intensive Care Unit free days by day 28±2|Hospital-free days by day 28±2|Incidence of tracheostomies by day 28±2|Incidence of transfer to long term acute care (LTAC) facility by day 28±2|All-cause mortality by day 28±2|All-cause mortality by day 60|Change from baseline to day 3(±8h), 7±1 day and 14±2 day in plasma levels of IL-6, IL-8, PAI-1, TNFr-1, ICAM-1 RAGE|Plasma levels (free and bound) of DF2156Y (acidic form of reparixin) and relevant metabolites (DF2108Y, S-isomer; DF2227Y, R-isomer)|Incidence of Treatment Emergent AEs (TEAEs) and SAEs (TESAEs) from the beginning of study treatment to up to the end of study participation.|eGFR, absolute value and change from screening to day 3(±8h), day 7±1, day 14±2, day 21±2 (if still receiving reparixin), day 28±2|Incidence of secondary infections defined as new by day 28±2","Dompé Farmaceutici S.p.A","All","18 Years and older   (Adult, Older Adult)","Phase 2","73","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","REP0122|2022-001612-25","September 2022","May 2023","September 2023","August 11, 2022",,"August 11, 2022",,,"https://ClinicalTrials.gov/show/NCT05496868"
384,"NCT05496855","Remote Care in People With Rheumatoid Arthritis","NOR-Flare","Not yet recruiting","No Results Available","Rheumatoid Arthritis","Other: Conventional follow-up|Other: Remote monitoring","Proportion with joint damage progression|Change in joint damage progression|Self-reported disease activity (intervention group)|Self-reported disease activity (control group)|Health-related quality of life|Proportion in remission/low disease activity (CDAI)|Proportion in remission/low disease activity (DAS28)|Disease activity in conjunction with consultation (DAS28)|Disease activity in conjunction with consultation (CDAI)|Health care utilization|Patient-reported disease flares (intervention group)|Patient-reported disease flares (control group)|Adverse events|Number of consultations/contacts at the hospital|Activity impairment (intervention group)|Activity impairment (control group)|Costs related to hospital visits|The need to take time off for hospital visits or video consultation|C-Reactive Protein (CRP) (intervention group)|C-Reactive Protein (CRP) (control group)|Modified Health Assessment Questionnaire (MHAQ)|PROMIS Physical function|Pain (intervention group)|Pain (control group)|Joint pain (intervention group)|Joint pain (control group)|Sleep impairment|Medication use|Swollen joint count|Tender joint count|Extra visits, telephone and video consultations|Withdrawals/early discontinuation|Physical activity|Fatigue|Patient acceptable symptom state|eHealth literacy|Patient-reported self-efficacy for using different digital devices, secure login and digital health services|Patient satisfaction with care|Patient satisfaction with remote monitoring","National Resource Center for Rehabilitation in Rheumatology","All","18 Years and older   (Adult, Older Adult)","Not Applicable","228","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","REK 457358","September 1, 2022","December 31, 2025","October 14, 2028","August 11, 2022",,"August 11, 2022","Diakonhjemmet Hospital, Oslo, Norway",,"https://ClinicalTrials.gov/show/NCT05496855"
385,"NCT05496842","Changes in Selected Function- and Participation-related Characteristics in Post-COVID Patients Following Pneumological Phase II Rehabilitation",,"Active, not recruiting","No Results Available","Post-COVID-19","Behavioral: Multimodal pulmonary rehabilitation","6-minute walk test|European Quality of Life 5 Dimensions 5 Level (EQ-5D-5L)|Patient Health Questionnaire-4 (PHQ-4)","Pensionsversicherungsanstalt","All","Child, Adult, Older Adult",,"779","Other","Observational","Observational Model: Case-Only|Time Perspective: Retrospective","0009 Post-COVID","October 1, 2020","January 31, 2022","January 31, 2023","August 11, 2022",,"August 11, 2022","Rehabilitationszentrum Weyer, Weyer, Upper Austria, Austria",,"https://ClinicalTrials.gov/show/NCT05496842"
386,"NCT05496829","IMPACT Trial: Intervention to iMProve AdherenCe Equitably",,"Recruiting","No Results Available","Breast Cancer","Behavioral: Multicomponent Adherence Intervention|Other: Usual Care","Number of Participants Adherent to Endocrine Therapy (ET) and CVD Medication at 24 Weeks|Number of Participants Adherent to ET and CVD Medication at 52 Weeks|Change in blood pressure at 24 weeks|Change in blood pressure at 52 weeks|Change in low-density lipoprotein (LDL) cholesterol|Changes in Patient-Reported Outcomes Measurement Information System (PROMIS)-29 at 24 weeks|Changes in Patient-Reported Outcomes Measurement Information System (PROMIS)-29 at 52 weeks|Changes in Treatment Satisfaction Questionnaire for Medication (TSQM) at 24 Weeks|Changes in Treatment Satisfaction Questionnaire for Medication (TSQM) at 52 Weeks|Changes in Medical Adherence Self-Efficacy Scale (MASES) at 24 Weeks|Changes in the Medical Adherence Self-Efficacy Scale (MASES) at 52 Weeks|Change in Regimen Complexity|Subject reasons using the DOSE-Nonadherence reasons for nonadherence questionnaire|Reasons for Medication Non-adherence using the DOSE-Nonadherence Reasons for Nonadherence Questionnaire at 24 Weeks|Reasons for Medication Non-adherence using the DOSE-Nonadherence Reasons for Nonadherence Questionnaire at 52 Weeks|Impact of events using the Impact of Events Scale (IES)","Columbia University","All","18 Years to 99 Years   (Adult, Older Adult)","Not Applicable","350","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","AAAT8817","August 31, 2021","October 31, 2025","October 31, 2026","August 11, 2022",,"August 11, 2022","Columbia University Medical Center, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT05496829"
387,"NCT05496816","Coagulation Disturbances in COVID-19 Septic Patients",,"Completed","No Results Available","Coagulation Disorder|COVID 19 Associated Coagulopathy|Sepsis|Septic Shock","Diagnostic Test: CAC in septic patients","Number of patients with coagulation disorder","Cantonal Hospital Zenica","All","18 Years to 85 Years   (Adult, Older Adult)",,"100","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","CAC","January 1, 2021","December 31, 2021","December 31, 2021","August 11, 2022",,"August 11, 2022","Cantonal Hospital, Zenica, Bosnia and Herzegovina",,"https://ClinicalTrials.gov/show/NCT05496816"
388,"NCT05496803","Impact of Systematic Nursing Guidance on the Psychological Effects of Parents of Children With Cardiac Catheterization.",,"Recruiting","No Results Available","Educational Videos|Catheterization|Congenital Heart Disease in Children|Parental Uncertainty|Parental Anxiety","Other: routine education plus digital video disk|Other: routine education","The change of parental uncertainty|The change of parental anxiety 1|The change of parental anxiety 2","Chung Shan Medical University Hospital|Chung Shan Medical University","All","20 Years to 48 Years   (Adult)","Not Applicable","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Other","CS2-22078","July 27, 2022","July 2023","July 2023","August 11, 2022",,"August 11, 2022","Chung Shan Medical University Hospital., Taichung, Taiwan",,"https://ClinicalTrials.gov/show/NCT05496803"
389,"NCT05496790","Role of LipoprotEin(a) in CardiovascuLar Diseases and Premature Acute Coronary Syndromes - (RELACS) Study","RELACS","Recruiting","No Results Available","Acute Coronary Syndrome|Lipoprotein Disorder|Acute Myocardial Infarction|Cardiovascular Diseases",,"Impact of Lp(a) on MACE|Each component of the primary enpoint|Lp(a) levels in premature ACS","University of Campania ""Luigi Vanvitelli""","All","18 Years to 60 Years   (Adult)",,"1000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","CECN/1385","January 1, 2021","September 30, 2022","December 2024","August 11, 2022",,"August 11, 2022","AORN S. Anna e S. Sebastiano, Caserta, Italy",,"https://ClinicalTrials.gov/show/NCT05496790"
390,"NCT05496777","Home-based Prehabilitation in Pancreatic Resection",,"Recruiting","No Results Available","Preoperative Physical Exercise Training|Aerobic Capacity|Aerobic Fitness|Functional Mobility|Cancer|Weight, Body|Cancer of Pancreas","Procedure: Home-based prehabilitation program","Participation rate|Reasons for non-participation|Adherence/compliance|Dropout rate|Reasons for dropout|Adverse events|Patient appreciation|Therapist appreciation|Aerobic capacity|Muscle function|Body composition|Functional mobility/muscle strength|Immune system function|Level of perceived fatigue|Quality of life","Nicole Hildebrand|University Medical Center Groningen|University of Turin, Italy|Academisch Ziekenhuis Maastricht","All","18 Years and older   (Adult, Older Adult)","Not Applicable","45","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","NL75340.068.20","January 1, 2022","January 1, 2023","January 1, 2023","August 11, 2022",,"August 11, 2022","Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Torino, Italy|University Medical Center Groningen, Groningen, Netherlands|Maastricht University Medical Center+, Maastricht, Netherlands",,"https://ClinicalTrials.gov/show/NCT05496777"
391,"NCT05496764","Local Injection of Steroid VS.Glucose 5% in Carpal Tunnel Syndrome",,"Recruiting","No Results Available","Carpal Tunnel Syndrome","Drug: Dexamethasone|Drug: Glucose Injection","the changes in visual analogue scale (pre - post- and follow up)|-To evaluate the effect of sonar guided steroid vs. glucose 5% injection on U/S (pre-post and follow up).|To evaluate the effect of sonar guided steroid vs. glucose 5% injection on neurophysiological studies (pre-post and follow up).","Assiut University","All","18 Years and older   (Adult, Older Adult)","Phase 4","52","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","22151125","December 1, 2021","January 2023","January 2023","August 11, 2022",,"August 11, 2022","Assiut University Hospital, Assiut, Egypt",,"https://ClinicalTrials.gov/show/NCT05496764"
392,"NCT05496751","Individual Variability in Response to Exercise in Adults",,"Not yet recruiting","No Results Available","Exercise|Cardiorespiratory Fitness","Behavioral: Low amount, low intensity exercise|Behavioral: Low amount, high intensity exercise","Cardiorespiratory Fitness|Change in cardiometabolic risk factors|Change in cardiometabolic risk factor|Change in body composition|Change in obesity phenotype|Change on body weight","Queen's University","All","25 Years to 65 Years   (Adult, Older Adult)","Not Applicable","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Ross2022","September 10, 2022","September 10, 2025","September 10, 2026","August 11, 2022",,"August 11, 2022",,,"https://ClinicalTrials.gov/show/NCT05496751"
393,"NCT05496738","A Preliminary Study to Evaluate PF-07264660 in Healthy Participants",,"Not yet recruiting","No Results Available","Healthy Volunteers","Drug: PF-07264660 intravenous single ascending dose|Drug: PF-07264660 subcutaneous multiple ascending dose|Other: Intravenous placebo|Other: subcutaneous placebo","Number of participants with treatment emergent treatment related adverse events (AE's)|Number of participants with treatment emergent treatment-related serious adverse events (SAE's)|Number of participants with change from baseline in blood pressure|Number of participants with change from baseline in pulse rate|Number of participants with change from baseline in temperature|Number of participants with change from baseline in clinical laboratory values|Number of participants with change from baseline in heart rate|Number of participants with change from baseline in QT interval|Number of participants with change from baseline in corrected QT interval|Number of participants with change from baseline in PR interval|Number of participants with change from baseline in QRS interval|Number of participants with change from baseline in area under the concentration versus time curve from time zero to the last quantifiable time point (AUClast) of single ascending doses of PF-07264660|Number of participants with change from baseline in maximum plasma concentration (Cmax) of PF-07264660 after a single dose|Number of participants with change from baseline in maximum plasma concentration (Cmax) of PF-07264660 after multiple doses|Number of participants with change from baseline in time to maximum plasma concentration (Tmax) of PF-07264660 after a single dose|Number of participants with change from baseline in time to maximum plasma concentration (Tmax) of PF-07264660 after multiple doses|Number of participants with change from baseline in terminal elimination half-life (t½) of PF-07264660 after a single dose|Number of participants with change from baseline in terminal elimination half-life (t½) of PF-07264660 after multiple doses|Number of participants with change from baseline in area under the serum concentration time profile from time 0 extrapolated to infinite time (AUCinf) of single ascending doses of PF-07264660|Number of participants with change from baseline in area under the concentration time profile from time zero to time tau (τ), the dosing interval (AUCtau) of multiple ascending doses of PF-07264660|Number of participants with change from baseline in incidence and titers of anti-drug antibodies against PF-07264660|Number of participants with change from baseline in incidence and titers of neutralizing antibodies against PF-07264660","Pfizer","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","75","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","C4521001","August 15, 2022","January 21, 2025","January 21, 2025","August 11, 2022",,"August 11, 2022",,,"https://ClinicalTrials.gov/show/NCT05496738"
394,"NCT05496725","Evaluate Bioequivalence of Micafungin (50mg/Vial)",,"Completed","No Results Available","Invasive Candidiasis","Drug: Micafungin","Peak plasma concentration (Cmax)|Area under the concentration-time curve from time zero to time of last quantifiable concentration (AUC 0-t)|Area under the concentration-time curve from time zero to infinity (AUC 0-∞)|Ratio of area under the concentration-time curve from time zero to time of last quantifiable concentration (AUC 0-t) to Area under the concentration-time curve from time zero to infinity (AUC 0-∞)","Yung Shin Pharm. Ind. Co., Ltd.","All","20 Years to 45 Years   (Adult)","Phase 4","14","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other","YSP-RNH3001-01","January 6, 2022","May 30, 2022","July 28, 2022","August 11, 2022",,"August 11, 2022","Taichung Veterans General Hospital, Taichung, Taiwan",,"https://ClinicalTrials.gov/show/NCT05496725"
395,"NCT05496712","Effect of Physical Activity in Pregnancy on Maternal and Fetal Human Milk Oligosaccharides: a Pilot Study",,"Recruiting","No Results Available","Pregnancy, Physical Activity",,"Human milk oligosaccharides (HMO) composition and concentration in maternal blood|Human milk oligosaccharides (HMO) composition and concentration in fetal blood|Human milk oligosaccharides (HMO) composition and concentration in maternal urine|Human milk oligosaccharides (HMO) composition and concentration in colostrum|Fetal growth|Birth weight|Fetal body fat mass|Fetal fat free mass|Subcutaneous adipose tissue thickness|Cord blood metabolic parameters - Glucose|Cord blood metabolic parameters- Insulin|Cord blood metabolic parameters - C-Peptide|Cord blood metabolic parameters - erythropoietin|Cord blood metabolic parameters - lipid profile|Cord blood metabolic parameters - Cytokines|Maternal body composition - BMI|Maternal body composition - weight gain|Maternal body composition - subcutaneous adipose tissue thickness|Maternal parameters - Glucose|Maternal parameters - Insulin|Maternal parameters - C-Peptide|Maternal parameters - Leptin|Maternal parameters - Adiponectin|Maternal parameters - Liquid profile|Maternal parameters - Cytokines|Placental outcomes - Utero-placental blood flow|Placental outcomes - fetal-placental blood flow|Placental outcomes - placental volume|Placental outcomes - Cytokine mRNA|Placental outcomes - Macrophage density|Placental outcomes - TREG density|Placental outcomes- transcriptomic profile|Placental outcomes - epigenomic profile|Vaginal Microbiome","Medical University of Graz","Female","18 Years and older   (Adult, Older Adult)",,"240","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","26-380 ex 13/14","July 1, 2014","August 2022","July 2023","August 11, 2022",,"August 11, 2022","Medical University of Graz, Graz, Styria, Austria",,"https://ClinicalTrials.gov/show/NCT05496712"
396,"NCT05496699","The Comparsion of MCkenzie and Mulligan Exercise in Patients With Non-Specific Neck Pain",,"Completed","No Results Available","Neck Pain","Behavioral: Mckenzie Exercises|Behavioral: Mulligan Exercise","Visual Analog Scale|Neck Disability Index|Evaluation of Muscle Strength|Tampa Kinesiophobia Scale|Fremantle Neck Awareness Questionnaire|Corbin Posture Analysis","Istinye University","All","18 Years to 45 Years   (Adult)","Not Applicable","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","IstinyeFTR","April 1, 2022","May 1, 2022","June 1, 2022","August 11, 2022",,"August 11, 2022","İstinye University, İstanbul, Turkey",,"https://ClinicalTrials.gov/show/NCT05496699"
397,"NCT05496686","Targeted Alpha Particle Radiotherapy for Metastatic Uveal Melanoma",,"Recruiting","No Results Available","Uveal Melanoma|Metastatic","Drug: 4.7 microCi 225Ac-MTI-201|Drug: 9.5 microCi of 225Ac-MTI-201|Drug: 19 microCi of 225Ac-MTI-201|Drug: 38 microCi of 225Ac-MTI-201|Drug: 76 microCi of 225Ac-MTI-201|Drug: 152 microCi of 225Ac-MTI-201|Drug: 254 microCi of 225Ac-MTI-201|Drug: 424 microCi of 225Ac-MTI-201|Drug: 564 microCi of 225Ac-MTI-201|Drug: 750 microCi of 225Ac-MTI-201|Drug: 998 microCi of 225Ac-MTI-201|Drug: 1327 microCi of 225Ac-MTI-201","Maximum Tolerated Dose (MTD) of 225Ac-MTI-201|Number of Participants Who Experienced Dose-Limiting Toxicities (DLTs)|The Number of Participants Who Experienced Serious or Non-Serious Adverse Events|Observed Rate of Renal Elimination of 225Ac-MTI-201|Observed Rate of Elimination from Blood of 225Ac-MTI-201|Number of Participants Who Experienced a Complete Response (CR), Partial Response (PR), Progressive Disease (PD), or Stable Disease (SD) According to Tumor Lesion Measurement","Modulation Therapeutics, Inc.|H. Lee Moffitt Cancer Center and Research Institute","All","18 Years and older   (Adult, Older Adult)","Phase 1","16","Industry|Other","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MCC 19868|MTI201-IA","July 21, 2022","December 25, 2023","February 25, 2029","August 11, 2022",,"August 11, 2022","H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States",,"https://ClinicalTrials.gov/show/NCT05496686"
398,"NCT05496673","Meningitis: Burden, Causes, Screening and Prevention in Rural Northern Uganda",,"Not yet recruiting","No Results Available","Meningitis","Diagnostic Test: Pastorex Latex Agglutination Test|Diagnostic Test: Biofire PCR for meningitis|Diagnostic Test: Immy CrAg Lateral Flow Assay","number of participants with meningitis who died during hospitalization|number of participants with meningitis who died during the first 6 months of hospital admission|number of participants who were screened using the CrAg diagnostic test who were cryptococcal antigen positive|number of participants who develop overt cryptococcal meningitis|Number of participants with overt cryptococcal meningitis who die","University of Rochester|Fogarty International Center of the National Institute of Health|Infectious Disease Institute at Makerere University|Lira University|National Institute of Allergy and Infectious Diseases (NIAID)","All","0 Years and older   (Child, Adult, Older Adult)","Not Applicable","10400","Other|NIH","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","STUDY00007296","September 1, 2022","September 1, 2027","September 1, 2027","August 11, 2022",,"August 11, 2022","Lira Regional Referral Hospital, Lira, Uganda",,"https://ClinicalTrials.gov/show/NCT05496673"
399,"NCT05496660","The Effect of NHE and KT on the Hamstring Strength and Sprint Performance in Collegiate Sprinters",,"Completed","No Results Available","Hamstring Injury","Other: NHE+KT|Other: NHE","isokinetic hamstring eccentric peak torque|30m sprint performance|Hecc/Qcon Ratio","Tianjin University of Sport","Male","18 Years to 25 Years   (Adult)","Not Applicable","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention","NHE_KT","July 1, 2021","March 31, 2022","July 31, 2022","August 11, 2022",,"August 11, 2022","Tianjin University of Sport, Tianjin, China",,"https://ClinicalTrials.gov/show/NCT05496660"
400,"NCT05496647","Vırtual Reality, Music Therapy and Stress Ball-related Pain and Anxiety",,"Completed","No Results Available","Pain|Anxiety","Other: Virtual Reality|Other: Music Therapy|Other: Stress Ball Application|Other: Control","Pain Severity|Anxiety Intensity|Patient Information Form|Life Information Tracking Form|Patient Satisfaction Evaluation Form","Marmara University","Female","18 Years and older   (Adult, Older Adult)","Not Applicable","160","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","MarmaraU-OZ-2022","June 15, 2022","July 30, 2022","July 30, 2022","August 11, 2022",,"August 11, 2022","Marmara University, İstanbul, Turkey",,"https://ClinicalTrials.gov/show/NCT05496647"
401,"NCT05496634","The Effect of Pilates on Biopsychosocial Characteristics in the Covid-19 Pandemic",,"Recruiting","No Results Available","COVID-19|Healthy|Sedentary|Exercise|Pilates","Behavioral: Sedantary|Behavioral: Exercise therapy","Cognitive Exercise Therapy Approach- Biopsychosocial Questionnaire (CETA-BQ)|Beck Depression Inventory (BDI)|Coronavirus Anxiety Scale|Pittsburg Sleep Quality Index (PSQI)|Nottingham Health Profile (NHP)","Medipol University","All","20 Years to 50 Years   (Adult)","Not Applicable","54","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","E-10840098-772.02-840","January 5, 2022","August 30, 2022","September 28, 2022","August 11, 2022",,"August 11, 2022","Istanbul Medipol University, Istanbul, Turkey",,"https://ClinicalTrials.gov/show/NCT05496634"
402,"NCT05496621","Validity and Reliability of Turkish Version of Keele STarT MSK Tool",,"Completed","No Results Available","Musculoskeletal Diseases","Other: Questionnaire","The STarT Back Screening Tool|The Roland-Morris Questionnaire (RMDQ)|Short Form-36 (SF-36)|The Tampa Kinesiophobia Scale","Istinye University","All","18 Years to 85 Years   (Adult, Older Adult)","Not Applicable","30","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","003","February 1, 2019","May 1, 2019","November 1, 2019","August 11, 2022",,"August 11, 2022","İstinye University, İstanbul, Turkey",,"https://ClinicalTrials.gov/show/NCT05496621"
403,"NCT05496608","Treatment of Intrabony Defects With Dense Leukocyte Platelet-Rich Fibrin (L-PRF) Membrane With or Without Collagen Membranes",,"Completed","No Results Available","Periodontal Bone Loss|Periodontal Diseases","Procedure: L-PRF|Procedure: OFD|Procedure: CM","Gingival index|Plaque index|Probing depth|Clinical attachment level|CEJ to base of defect|CEJ to alveolar crest|PDGF|VEGF","Future University in Egypt","All","30 Years to 50 Years   (Adult)","Not Applicable","63","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","Ainshams University","January 1, 2021","November 30, 2021","February 1, 2022","August 11, 2022",,"August 15, 2022","Ainshams University, Cairo, Egypt",,"https://ClinicalTrials.gov/show/NCT05496608"
404,"NCT05496595","DCBY02 as a Monotherapy in Patients With Advanced or Metastatic Solid Tumors",,"Not yet recruiting","No Results Available","Advanced or Metastatic Solid Tumors","Drug: DCBY02","Part 1A/2A: Incidence and severity of adverse events graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v5.0|Part 1A: The proportion of patients experiencing dose limiting toxicity (DLT) events|Part 1A: Objective response rate (ORR) as determined per Investigator assessment|Part 1A: Duration of response (DOR) as determined per Investigator assessment|Part 1A: Disease control rate (DCR) as determined per Investigator assessment|Part 1A: Progression free survival (PFS) as determined per Investigator assessment|Part 1A: Overall survival (OS)|Part 1A/2A: Pharmacokinetic parameters of DCBY02: maximum observed concentration (Cmax)|Part 1A/2A: Pharmacokinetic parameters of DCBY02: area under the concentration-time curve (AUC)|Part 1A/2A: Pharmacokinetic parameters of DCBY02: clearance (CL)|Part 1A/2A: Pharmacokinetic parameters of DCBY02: volume of distribution (Vz)|Part 1A/2A: Pharmacokinetic parameters of DCBY02: half-life (t1/2)|Part 1A/2A: Incidence of anti-drug antibody (ADA) and neutralizing antibodies (NAbs) against DCBY02","DynamiCure Biotechnology","All","18 Years and older   (Adult, Older Adult)","Phase 1","96","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","DC-6001-101 (Part A)","September 2022","September 2024","October 2024","August 11, 2022",,"August 11, 2022",,,"https://ClinicalTrials.gov/show/NCT05496595"
405,"NCT05496582","The Association of Transgelin-2, Metallothionein-2 and Ezrin With Asthma",,"Not yet recruiting","No Results Available","Asthma","Diagnostic Test: No intervention","Difference in gene expression of transgelin-2, metallothionein-2 and ezrin between controls and asthmatic patients|Association of transgelin-2, metallothionein-2 and ezrin with asthma","Shanghai University of Traditional Chinese Medicine|Xiangya Hospital of Central South University|National Natural Science Foundation of China","All","14 Years to 75 Years   (Child, Adult, Older Adult)",,"100","Other","Observational","Observational Model: Case-Control|Time Perspective: Retrospective","SHUTCM-0806","August 2022","August 2024","August 2025","August 11, 2022",,"August 11, 2022","Xiangya Hospital, Central South University, Changsha, Hunan, China|Yueyang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT05496582"
406,"NCT05496569","TQB3616 Capsules in the Treatment of Dedifferentiated Liposarcoma",,"Not yet recruiting","No Results Available","Dedifferentiated Liposarcoma","Drug: TQB3616 capsule|Drug: TQB3616 placebo","Progression-free survival (PFS) assessed by an independent review committee|Progression-free survival assessed by the investigator.|Overall survival|Duration of disease remission|Objective response rate|Disease control rate|Progression-free survival after crossover in control subjects|Adverse events , abnormal laboratory values, and serious adverse events","Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","118","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","TQB3616-II-03（stage2）","December 2022","April 2024","December 2024","August 11, 2022",,"August 11, 2022","Peking University First Hospital, Beijing, Beijing, China|Peking University People's Hospital, Beijing, Beijing, China|Zhongshan Hospital Fudan University, Shanghai, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT05496569"
407,"NCT05496556","Influence of Food Preferences on the Occurrence of Undernutrition in Treated Patients for Bronchopulmonary Carcinoma Non-small Cell Stage IV","ONCOGOU","Not yet recruiting","No Results Available","Non-small Cell Bronchopulmonary Carcinoma at Stage IV and Benefiting From First-line Treatment According to Current French Recommendations","Other: Test Leeds Food Preference Questionnaire (LFQP-France)","Measurement of implicit wanting by the LFQP-France questionnaire|The occurrence of undernutrition within 6 months after inclusion, in patients not undernourished at inclusion|The impact of food preferences (liking and explicit wanting) assessed by the LFQP-France questionnaire on the prevalence and incidence of undernutrition in the 6 months after inclusion.|The impact of food preferences (liking, explicit lwanting and implicit wanting) assessed by the LFQP-France questionnaire on the severity of undernutrition|the impact of food preferences (liking, explicit wanting and implicit wanting) assessed by the LFQP-France questionnaire on quality of life|The impact of the type of 1st line treatment on food preferences (chemotherapy based on platinum salt versus immunotherapy versus targeted therapy)","Centre Georges Francois Leclerc","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","190","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","2021-A01952-39","November 1, 2022","November 1, 2025","November 1, 2025","August 11, 2022",,"August 11, 2022",,,"https://ClinicalTrials.gov/show/NCT05496556"
408,"NCT05496543","Acupuncture for Functional Constipation in Older Adults : A Randomized Controlled Clinical Trial",,"Not yet recruiting","No Results Available","Constipation - Functional","Device: acupuncture|Device: sham acupuncture","The change in the mean number of CSBMs per week compared to baseline during the 8-week treatment period|Bristol Stool Scale|Patient Assessment of Constipation-Symptoms (PAC-SYM)|Patient Assessment of Constipation Quality of Life Questionnaire (PAC-QOL)|Self-rating Anxiety Scale（SAS）|Self-rating Depression Scale（SDS）|Weekly usage of emergency bowel medications|Incidence of adverse events","Shanghai University of Traditional Chinese Medicine|Shanghai Municipal Hospital of Traditional Chinese Medicine|Longhua Hospital","All","60 Years to 80 Years   (Adult, Older Adult)","Not Applicable","84","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","21Y11923900","September 2022","September 2024","September 2024","August 11, 2022",,"August 11, 2022","Longhua Hospital, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT05496543"
409,"NCT05496530","Custom Needle Preparation for Suprachoroidal Steroid Injection (One Year Results)",,"Recruiting","No Results Available","Diabetic Macular Edema|Vogt Koyanagi Harada Disease|Retinal Vein Occlusion","Drug: Suprachoroidal triamcinolone acetonide injection","Visual acuity|Central macular thickness","Benha University","All","30 Years to 80 Years   (Adult, Older Adult)","Not Applicable","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Rc-11-22","July 10, 2022","July 30, 2023","August 15, 2023","August 11, 2022",,"August 11, 2022","Ahmed Abdelshafy Tabl, Banhā, Benha, Egypt",,"https://ClinicalTrials.gov/show/NCT05496530"
410,"NCT05496517","Ovarian Cancer Individualized Scoring System Scoring System","OCISS","Not yet recruiting","No Results Available","Ovarian Cancer",,"Cancer-specific survival (CSS) rate at 5 years|Cancer-specific survival (CSS) rate at 3 years|Recurrence-free survival (RFS) rate at 5 years|Recurrence-free survival (RFS) rate at 3 years","Assiut University","Female","18 Years to 80 Years   (Adult, Older Adult)",,"1000","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","MOGGE-GO03","November 11, 2022","August 11, 2023","November 22, 2023","August 11, 2022",,"August 11, 2022","Alexandria University Main Hospital, Alexandria, Egypt|Assiut Hospitals university, Assiut, Egypt",,"https://ClinicalTrials.gov/show/NCT05496517"
411,"NCT05496504","Pulmonary Hypertension and Arrhythmia",,"Completed","No Results Available","Arrhyhtmias in Patients With Pulmonary Hypertension","Other: Holter ECG","Arrhythmias during Holter ECG|Relation between arrhythmias and PH group, echocardiographic data, right heart catheterization data.","Asklepios Neurological Clinic Bad Salzhausen|University of Giessen","All","18 Years and older   (Adult, Older Adult)",,"222","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","PH09_08_2022","September 1, 2013","December 31, 2015","December 31, 2015","August 11, 2022",,"August 11, 2022",,,"https://ClinicalTrials.gov/show/NCT05496504"
412,"NCT05496491","Neoadjuvant Chemoradiotherapy and Consolidation Chemotherapy for Rectal Cancer: A Randomized Controlled Trial",,"Not yet recruiting","No Results Available","Rectal Neoplasms","Radiation: Neoadjuvant Chemoradiotherapy|Drug: Adjuvant Chemotherapy|Drug: Consolidation Chemotherapy","Disease Free Survival|Complete Pathological Response|Postoperative Complication|Length of Hospital Stay|Readmission|Negative Resection Margin|Overall Survival|Chemotherapy Toxicity|Local Recurrence|Treatment Compliance","Larissa University Hospital","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","84","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NCCCRC","August 30, 2022","August 30, 2025","August 30, 2025","August 11, 2022",,"August 12, 2022","Department of Surgery, University Hospital of Larissa, Larissa, Greece","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/91/NCT05496491/Prot_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/91/NCT05496491/ICF_001.pdf","https://ClinicalTrials.gov/show/NCT05496491"
413,"NCT05496478","Assesment of Complications and Surgery Timing in Postcovid Thoracotomy Patients: Single Center Experience",,"Completed","No Results Available","Thoracotomy",,"number of patients who had postoperative complication","Ankara University","All","18 Years to 85 Years   (Adult, Older Adult)",,"71","Other","Observational","Observational Model: Other|Time Perspective: Retrospective","30250","June 1, 2022","July 30, 2022","August 5, 2022","August 11, 2022",,"August 11, 2022","Ankara University, Ankara, Cankaya, Turkey",,"https://ClinicalTrials.gov/show/NCT05496478"
414,"NCT05496465","Safety and Efficacy of Intranasal Epinephrine After Administration of ARS -1 in Subjects With Frequent Urticaria Flares",,"Recruiting","No Results Available","Urticaria","Drug: ARS-1|Drug: Placebo","Effect of ARS-1 versus placebo based on a patient reported pruritus/hive score","ARS Pharmaceuticals, Inc.","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","32","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","EPI U01","July 28, 2022","October 2022","November 2022","August 11, 2022",,"August 11, 2022","Bernstein Clinical Research Center, LLC, Cincinnati, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT05496465"
415,"NCT05496452","Beta-lactoglobulin, Immobilisation and Muscle Protein Synthesis",,"Not yet recruiting","No Results Available","Muscle Atrophy","Dietary Supplement: Beta-lactoglobulin","Muscle protein synthesis|Muscle mass","King's College London|University of Nottingham","All","18 Years to 35 Years   (Adult)","Not Applicable","24","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","BLGIMMPS","October 1, 2022","March 1, 2024","August 1, 2024","August 11, 2022",,"August 11, 2022",,,"https://ClinicalTrials.gov/show/NCT05496452"
416,"NCT05496439","Study of the Prognosis of Patients With Heart Failure With Preserved Ejection Fraction",,"Completed","No Results Available","Heart Failure With Preserved Ejection Fraction",,"death","Chongqing Medical University","All","18 Years and older   (Adult, Older Adult)",,"172","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2022-08","March 1, 2020","May 22, 2022","July 6, 2022","August 11, 2022",,"August 11, 2022","The First Affiliated Hospital of Chongqing Medical University, Chongqing, China",,"https://ClinicalTrials.gov/show/NCT05496439"
417,"NCT05496426","A Study of KL130008 in Adults With Severe Alopecia Areata",,"Not yet recruiting","No Results Available","Alopecia Areata","Drug: KL130008/Placebo","Percentage of Participants Achieving Severity of Alopecia Tool (SALT) ≤ 20 [ Time Frame: Week 24 ]|Percentage of Participants Achieving Severity of Alopecia Tool (SALT) ≤ 20 [ Time Frame: Week 36 ]|Percent Change from Baseline in SALT score [ Time Frame: Baseline, Week 24, 36 ]|Percentage of Participants Achieving 50% Improvement of Severity of Alopecia Tool (SALT50) [ Time Frame: Week 24, 36 ]|Percentage of Participants Achieving 75% Improvement of Severity of Alopecia Tool (SALT50) [ Time Frame: Week 24, 36 ]|Percentage of Participants Achieving Severity of Alopecia Tool (SALT) ≤ 10 [ Time Frame: Week 24, 36 ]|Measure for Eyebrow (EB) Hair Loss 0 or 1 with ≥2-point Improvement from Baseline [ Time Frame: Week 24, 36 ]|Measure for Eyelash (EL) Hair Loss 0 or 1 with ≥2-point Improvement from Baseline","Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","176","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","KL223-II-05|CTR20221881","October 31, 2022","December 31, 2024","December 31, 2024","August 11, 2022",,"August 11, 2022","The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangzhou, China",,"https://ClinicalTrials.gov/show/NCT05496426"
418,"NCT05496413","Investigating the Cognitive Source of Visual Working Memory Impairment in Schizophrenia",,"Recruiting","No Results Available","Memory Deficits Schizophrenia Neurostimulator; Complications","Device: STARSTIM","VWM dysfunction","Taipei Medical University Shuang Ho Hospital|Taipei Medical University","All","20 Years to 65 Years   (Adult, Older Adult)","Not Applicable","40","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","N202003153","August 11, 2022","July 31, 2023","July 31, 2023","August 11, 2022",,"August 11, 2022","Taipei Medical University Shuang Ho Hospital, New Taipei City, Taiwan",,"https://ClinicalTrials.gov/show/NCT05496413"
419,"NCT05496400","Anemia of Prematurity and Hemodynamics",,"Completed","No Results Available","Premature","Radiation: Echocardiographic and Doppler studies","1. Cardiac output:|2. Cerebral blood flow velocities|3. Intestinal blood flow velocities|4.Renal blood flow velocities","Marwa Mohamed Farag|Alexandria University","All","3 Weeks to 6 Weeks   (Child)",,"72","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","0106769","July 1, 2021","February 1, 2022","August 1, 2022","August 11, 2022",,"August 12, 2022","Neonatal Intensive Care Unit (NICU) of Alexandria University Maternity Hospital., Alexandria, Egypt",,"https://ClinicalTrials.gov/show/NCT05496400"
420,"NCT05496387","Effect of Neuromobılızatıon on Stiffness of Scıatıc Nerve",,"Enrolling by invitation","No Results Available","Neuromobılızatıon|Stiffness|Scıatıc Nerve|Nonspecific Low Back Pain","Other: Sciatic nerve neuromobilization techniques","SWE Imaging|The Sit-and-Reach Test|The Straight Leg Raise (SLR) Test|The Vertical Jump Test|The 3-Step Forward Test|The Flamingo Balance Test","Istinye University","All","18 Years to 64 Years   (Adult)","Not Applicable","36","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","6","August 15, 2022","October 15, 2022","November 15, 2022","August 11, 2022",,"August 12, 2022","Istinye University, Istanbul, Turkey",,"https://ClinicalTrials.gov/show/NCT05496387"
421,"NCT05496374","A Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of SPR720 as Compared With Placebo for the Treatment of Participants With Mycobacterium Avium Complex (MAC) Pulmonary Disease",,"Not yet recruiting","No Results Available","Nontuberculous Mycobacterial Pulmonary Disease (NTM-PD)","Drug: Placebo|Drug: SPR720 500 mg|Drug: SPR720 1000 mg","Slope of the Weekly Sputum Log10 Colony Forming Units Per Millilitre (CFU/mL) Change From Day 1 Through 56 in micro-Intent to Treat (m-ITT) Population|Slope of the Weekly Sputum Log10 CFU/mL Change From Days 1 Through 28 in micro-ITT Population|Slope of the Time to Positivity (TTP) using MGIT on Samples of Induced Sputum From Days 1 Through 56 (EOT) in micro-ITT Population|Change from Baseline in the Sputum Log10 CFU/mL in the micro-ITT Population|Change from Baseline in the Sputum TTP Using MGIT in micro-ITT Population|Time to Negative Sputum Culture in micro-ITT Population|Percent with Negative Sputum Culture in micro-ITT Population|Changes in Susceptibility in SPR719 From Days 1 through 56 (EOT) in the micro-ITT Population|Clinical Response in the micro-ITT Population|Clinical Response in the Clinically Evaluable (CE) Populations|Change From Baseline in 11-point Nontuberculous Mycobacteria Pulmonary Disease (NTM-PD) Symptoms and Impact Scale for Quality of Life (QOL) Assessments|Change From Baseline in 6-point Patient Global Impression of Severity (PGI-S) Scale for Quality of Life (QOL) Assessments|Change From Baseline in 7-point Patient Global Impression of Change (PGI-C) scale for Quality of Life (QOL) Assessments|Change From Baseline in Flu, COVID-19, or Other Illness Questionnaire (2 questions) for Quality of Life (QOL) Assessments|Change from Baseline in PROMIS® V1.0 Fatique Shortform 7a scale for Quality of Life (QOL) Assessments|Number of Participants with Treatment Emergent Adverse Events (TEAEs)|Maximum Plasma Concentration (Cmax) (Intensive PK group only)|Time to reach Cmax (Tmax) (Intensive PK group only)|Area Under the Concentration-time Curve (AUC0-τ) (Intensive PK group only)|Accumulation Ratio of SPR719 Cmax on Day 14 Compared to Day 1 (Intensive PK group only)|Accumulation Ratio of SPR719 AUC0-τ on Day 14 Compared to Day 1 (Intensive PK group only)","Spero Therapeutics","All","18 Years and older   (Adult, Older Adult)","Phase 2","31","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","SPR720-202","November 2022","November 2023","November 2023","August 11, 2022",,"August 11, 2022",,,"https://ClinicalTrials.gov/show/NCT05496374"
422,"NCT05496361","A Prospective, Multi-center and Randomized Controlled Trial of Tianyi Revascularization Device in Acute Ischemic Stroke",,"Completed","No Results Available","AIS|Acute Ischemic Stroke|Large Vessel Occlusion|Thrombectomy","Device: Tianyi Revascularization Device|Device: Solitaire FR Revascularization Device","Revascularization assessed by digital subtraction angiography of the occluded target vessel to mTICI 2b or 3 at immediate post-procedure|Times to revascularization（From groin puncture to final revascularization result）|NIHSS score at 24h, 7-day or discharge|Functional patient outcome at 90 days post-procedure as defined by a modified Rankin Score (mRS) 0-2|Device Technical Success","Suzhou Zenith Vascular Scitech Co., Ltd.","All","18 Years to 85 Years   (Adult, Older Adult)","Not Applicable","238","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","CTP-301","January 24, 2021","November 24, 2021","July 20, 2022","August 11, 2022",,"August 11, 2022","Shanghai Changhai Hospital, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT05496361"
423,"NCT05496348","Study of Oral Upadacitinib to Assess Change in Disease Activity in Adult Participants With Ulcerative Colitis","EUROPE","Not yet recruiting","No Results Available","Ulcerative Colitis",,"Percentage of participants achieving symptomatic remission per partial adapted Mayo score among those who achieved clinical response and/or intestinal ultrasound (IUS) response at week 8 of upadacitinib (UPA) induction","AbbVie","All","18 Years and older   (Adult, Older Adult)",,"400","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","P23-430","August 15, 2022","August 16, 2027","August 16, 2027","August 11, 2022",,"August 11, 2022",,,"https://ClinicalTrials.gov/show/NCT05496348"
424,"NCT05496335","A Study to Evaluate Sequential Administration of AGN-151586 and OnabotulinumtoxinA (BOTOX) Injections in Adult Participants for Treatment of Glabellar Lines",,"Not yet recruiting","No Results Available","Glabellar Lines","Drug: AGN-151586|Drug: BOTOX|Drug: Placebo","Percentage of Participants achieving ""none"" or ""mild"" on the Facial Wrinkle Scale (FWS) according to the investigator assessment of Glabellar Lines (GL) severity at maximum frown","AbbVie","All","18 Years and older   (Adult, Older Adult)","Phase 1","80","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","M23-365","August 31, 2022","April 26, 2023","April 26, 2023","August 11, 2022",,"August 11, 2022","The Eye Research Foundation /ID# 244430, Newport Beach, California, United States|Cosmetic Laser Dermatology /ID# 244425, San Diego, California, United States|AboutSkin Research, LLC /ID# 244416, Greenwood Village, Colorado, United States|Skin Research Institute LLC /ID# 244424, Coral Gables, Florida, United States|Baumann Cosmetic and Research Institute /ID# 244415, Miami, Florida, United States|DeNova Research /ID# 244421, Chicago, Illinois, United States|Advanced Dermatology /ID# 244427, Lincolnshire, Illinois, United States|Laser and Skin Surgery Center of Indiana /ID# 244423, Indianapolis, Indiana, United States|Bellaire Dermatology /ID# 244428, Bellaire, Texas, United States|Premier Clinical Research /ID# 244429, Spokane, Washington, United States",,"https://ClinicalTrials.gov/show/NCT05496335"
425,"NCT05496322","Continuous Vs Intermittent Non Invasive Blood Pressure Monitoring in Preventing Post Operative Organ Failure","NiMon","Not yet recruiting","No Results Available","Blood Pressure Determination|Hemodynamic Monitoring|Postoperative Complications","Device: Continuous Non Invasive Blood Pressure Monitoring|Device: Intermittent Non Invasive Blood Pressure Monitoring","Post operative myocardial injury|Post operative Acute kidney injury|Post operative death","University of Messina|Societa Italiana Anestesia Analgesia Rianimazione e Terapia Intensiva","All","18 Years and older   (Adult, Older Adult)","Not Applicable","1204","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","16-22","October 2022","January 2024","February 2024","August 11, 2022",,"August 11, 2022",,,"https://ClinicalTrials.gov/show/NCT05496322"
426,"NCT05496309","Causes and Mechanisms of Space Hemolysis at High Altitudes","ANEMIA","Recruiting","No Results Available","Anemia|Weightlessness",,"Hemolysis in astronauts is assessed using exhaled breath samples.|Change from baseline hemolysis in astronauts is assessed during spaceflight using exhaled breath samples.|Change from baseline hemolysis in astronauts is assessed after spaceflight, up to 1 month, using exhaled breath samples.|Hemolysis in astronauts is assessed using blood markers CBC, reticulocytes, haptoglobin, bilirubin (total+direct), LDH, ferritin, iron, and TIBC.|Change from baseline hemolysis in astronauts is assessed during spaceflight using blood markers CBC, reticulocytes, haptoglobin, bilirubin (total+direct), LDH, ferritin, iron, and TIBC.|Change from baseline hemolysis in astronauts is assessed after spaceflight, up to 1 month, using blood markers CBC, reticulocytes, haptoglobin, bilirubin (total+direct), LDH, ferritin, iron, and TIBC.","Ottawa Hospital Research Institute","All","24 Years to 55 Years   (Adult)",,"4","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","0220470-01H","August 2, 2022","November 30, 2022","November 30, 2023","August 11, 2022",,"August 12, 2022","Ottawa Hospital Research Institute, Ottawa, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT05496309"
427,"NCT05496296","Comparison of Transforming Powder Dressing to NPIAP Recommended Standard of Care Therapies in Stage 2, 3 and 4 Pressure Injuries",,"Not yet recruiting","No Results Available","Pressure Ulcers Stage II|Pressure Ulcers Stage III|Pressure Ulcer, Stage IV","Device: Altrazeal® Transforming Powder Dressing","Number of wound dressing changes|Wound healing|Complications (problems) from treating the pressure wound|Pain in the wound and from dressing changes.|Wound Quality of Life","ULURU Inc.|United States Department of Defense","All","18 Years to 85 Years   (Adult, Older Adult)","Not Applicable","300","Industry|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","U-C-TPD-2022-01","September 2022","March 2023","September 2023","August 11, 2022",,"August 11, 2022",,,"https://ClinicalTrials.gov/show/NCT05496296"
428,"NCT05496283","Effect of Denture Adhesives on Complete Denture Patients",,"Active, not recruiting","No Results Available","Complete Edentulism","Other: denture adhesive","Patient satisfaction form|oral health impact profile for edentulous patients (OHIP-EDENT)","University of Jordan","All","40 Years to 85 Years   (Adult, Older Adult)","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","NSEreifej","February 10, 2022","January 31, 2023","February 28, 2023","August 11, 2022",,"August 11, 2022","The University of Jordan, Amman, Jordan",,"https://ClinicalTrials.gov/show/NCT05496283"
429,"NCT05496270","Surgery Alone Versus Neoadjuvant Treatment Followed by Surgery For MRI-defined T3 Mid-low Rectal Cancer",,"Completed","No Results Available","Rectal Cancer","Procedure: total mesorectal excision","3-year diseases free survival|Margin-free （R0）resection rate|3-year overall survival rate|Number of participants with surgical complications|Local recurrence rate","Sun Yat-sen University","All","18 Years to 80 Years   (Adult, Older Adult)",,"1509","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","GIHSYSU-28","January 2014","January 2019","August 2022","August 11, 2022",,"August 11, 2022",,,"https://ClinicalTrials.gov/show/NCT05496270"
430,"NCT05496257","Calcium Hydroxide Versus Premixed Bioceramic Putty in Direct Pulp Capping of Primary Molars",,"Active, not recruiting","No Results Available","Direct Pulp Capping","Other: direct pulp capping in primary molars","Clinical findings","Minia University","All","4 Years to 6 Years   (Child)","Not Applicable","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","524_1/11/2021","November 2, 2021","November 2, 2023","December 2, 2023","August 11, 2022",,"August 11, 2022","Minia university, Minya, Egypt",,"https://ClinicalTrials.gov/show/NCT05496257"
431,"NCT05496244","ROBYN Study - Robotic Assisted Surgery in Gynecological Indications Compared to Conventional Laparoscopy","ROBYN","Not yet recruiting","No Results Available","GYN Disorders","Device: Laparoscopy|Device: Robotic-assisted surgery","Describe treatment decision|Describe patient outcome|Describe impact of patient factors on outcome|Complications of medical interest|Quality of Life Impact per patient reported questionnaires|Describe the impact of surgeon experience on outcome|Describe the performance and use of Intuitive instruments|Describe the performance and use of Intuitive systems","Intuitive Surgical","Female","18 Years and older   (Adult, Older Adult)",,"5000","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","1.0","November 2022","November 2026","December 2030","August 11, 2022",,"August 11, 2022",,,"https://ClinicalTrials.gov/show/NCT05496244"
432,"NCT05496231","A Study on the Immune Response and Safety of an Adjuvanted Human Papillomavirus Vaccine When Given to Healthy Women 16 to 26 Years of Age",,"Not yet recruiting","No Results Available","Cervical Intraepithelial Neoplasia","Biological: HPV9 High formulation|Biological: HPV9 Medium formulation|Biological: HPV9 Low formulation|Biological: Gardasil 9","Percentage of participants with Grade 3 solicited administration site events after dose 1|Percentage of participants with Grade 3 solicited administration site events after dose 2|Percentage of participants with Grade 3 solicited administration site events after dose 3|Percentage of participants with Grade 3 solicited systemic events after dose 1|Percentage of participants with Grade 3 solicited systemic events after dose 2|Percentage of participants with Grade 3 solicited systemic events after dose 3|Percentage of participants with Grade 3 unsolicited adverse events (AEs) after dose 1|Percentage of participants with Grade 3 unsolicited AEs after dose 2|Percentage of participants with Grade 3 unsolicited AEs after dose 3|Percentage of participants with any serious adverse events (SAEs)|Percentage of participants with clinically relevant biochemical and hematological abnormalities|Anti-HPV immunoglobulin G (IgG) antibody concentrations|Percentage of participants with solicited administration site events|Percentage of participants with solicited systemic events|Percentage of participants with unsolicited AEs|Percentage of participants with potential immune-mediated diseases (pIMDs)|Percentage of participants experiencing pregnancy and pregnancy related outcomes|Number of seroconverted participants for anti-HPV IgG antibodies|Anti-HPV neutralizing antibody titers|Number of seroconverted participants with anti-HPV neutralizing antibodies|Correlation between anti-HPV IgG antibody concentration and anti-HPV neutralizing antibody titers","GlaxoSmithKline","Female","16 Years to 26 Years   (Child, Adult)","Phase 2","1080","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","213749|2022-000090-15","August 15, 2022","March 29, 2024","March 29, 2024","August 11, 2022",,"August 11, 2022",,,"https://ClinicalTrials.gov/show/NCT05496231"
433,"NCT05496218","Metabolomic Profile in Women With and Without Endometriosis","METABOLENDO","Recruiting","No Results Available","Endometriosis|Endometriosis-related Pain|Infertility","Diagnostic Test: Blood samples","Determination of plasma metabolomic profile using an LC-MS/MS targeted metabolomic method|Relation between Plasma metabolomic profile and endometriosis phenotypes through a questionnaire|Plasma metabolomic profile and fertility in terms of pregnancy rate|Relation between Plasma metabolomic profile and pelvic pain evaluated through visual-analogue scale (VAS)|Plasma metabolomic profile and dietary exposure through food frequency questionnaire (FFQ)","Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico","Female","18 Years to 45 Years   (Adult)","Not Applicable","400","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","0009220 U","April 9, 2022","October 31, 2023","February 28, 2024","August 11, 2022",,"August 11, 2022","Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Milan, Italy",,"https://ClinicalTrials.gov/show/NCT05496218"
434,"NCT05496205","A SAD Study to Evaluate the Safety, Tolerability and PK/PD of iN1011-N17 in Healthy Volunteers",,"Recruiting","No Results Available","Osteoarthritis|Pain","Drug: iN1011-N17|Drug: Placebo","Incidence, severity and causality of adverse events (AEs) and serious adverse events (SAEs)|Number of participants with abnormal physical examination findings|Vital Signs (Blood Pressure)|Vital Signs (Pulse)|Vital Signs (Respiratory Rate)|Vital Signs (Body temperature)|12-lead electrocardiogram(ECG)|Number of participants with abnormal Laboratory tests (Hematology)|Number of participants with abnormal Laboratory tests (Biochemistry))|Maximum plasma concentration (Cmax)|Time to maximum plasma concentration (tmax)|Terminal half-life (t1/2)|Area under the plasma concentration curve (AUClast, AUCinf)|Apparent volume of distribution (Vz/F)|Apparent plasma elimination rate constant (λz)|Apparent clearance (CL/F)|Fraction excreted unchanged in urine (fe)|Amount of drug excreted unchanged in the urine (Ae)|Renal clearance (CLR)","iN Therapeutics Co., Ltd.","All","18 Years to 55 Years   (Adult)","Phase 1","104","Industry","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","DW_DWP17061101","September 30, 2020","August 24, 2022","August 24, 2022","August 11, 2022",,"August 11, 2022","Nucleus Network, Melbourne, Victoria, Australia",,"https://ClinicalTrials.gov/show/NCT05496205"
435,"NCT05496192","A Study of Nivolumab Intravenous (IV) to Subcutaneous (SC) Switch in Adjuvant Melanoma and Bladder Cancer",,"Not yet recruiting","No Results Available","Melanoma|Urothelial Carcinoma","Drug: Nivolumab/rHuPH20|Drug: Nivolumab","Proportion of Participants That Prefer Nivolumab SC at the First Assessment of Patient Preference Using Patient Experience and Preference Questionnaire (PEPQ) (Question 1)|Number of Participants with Adverse Events (AEs)|Proportion of Participants That Prefer Nivolumab SC at the Second Assessment of Patient Preference Using PEPQ (Question 1)","Bristol-Myers Squibb","All","18 Years and older   (Adult, Older Adult)","Phase 2","88","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CA209-6L6|2022-000294-67|U1111-1273-4725","October 11, 2022","June 24, 2024","June 24, 2026","August 11, 2022",,"August 11, 2022","Local Institution - 0001, Berlin, Germany",,"https://ClinicalTrials.gov/show/NCT05496192"
436,"NCT05496179","The Effect of Prucalopride on Gastric Emptying in Intensive Care Unit Patients",,"Completed","No Results Available","Enteral Feeding Intolerance","Drug: Prucalopride|Drug: Metoclopramide","Gastric residual volume|Determining the adequacy of enteral nutrition:|Incidence of infectious complications.|Length of ICU stay|Adverse drug events","Ain Shams University|Future University in Egypt","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1|Phase 2","70","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","Future University in Egypt","March 7, 2022","July 10, 2022","July 15, 2022","August 11, 2022",,"August 12, 2022","Kasr Al Ainy Hospital, Cairo, Egypt",,"https://ClinicalTrials.gov/show/NCT05496179"
437,"NCT05496166","The Efficiency of Surgery and Radiotherapy After SHR-1316 (Adebrelimab) and Platinum-containing Doublet Induction Therapy for Limited-stage Small Cell Lung Cancer",,"Not yet recruiting","No Results Available","Limited Stage Small Cell Lung Cancer","Combination Product: chemotherapy and SHR-1316(Adebrelimab) comnined with surgery or radiotherapy","progression-free survival|incidence of adverse events|pathological response|objective response rate|overall survival|recurrence free survival|the duration of response(DOR)|Health related quality of life (HRQol)","Shanghai Pulmonary Hospital, Shanghai, China|Jiangsu HengRui Medicine Co., Ltd.","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 3","348","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LungMate-015","August 1, 2022","August 1, 2027","August 1, 2030","August 11, 2022",,"August 11, 2022","Shanghai Pulmonary Hospital, Shang'ai, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT05496166"
438,"NCT05496153","The Clinical Effect of Adaptive Posture-balance Cardiac Rehabilitation Exercise on Cardiovascular Diseases",,"Completed","No Results Available","Cardiac Rehabilitation|Exercise Therapy|Balance Exercises|Cardiovascular Diseases","Behavioral: Adaptive posture-balance cardiac rehabilitation exercise","CPET|Quality of life|RMR","Chinese Academy of Medical Sciences","All","18 Years to 90 Years   (Adult, Older Adult)","Not Applicable","100","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Balance-based rehabilitation","December 1, 2020","March 31, 2021","October 31, 2021","August 11, 2022",,"August 11, 2022","Tianjin Chest Hospital, Tianjin, Tianjin, China",,"https://ClinicalTrials.gov/show/NCT05496153"
439,"NCT05496140","Remote School-Home Program to Improve Youth Attention and Behavior in Mexican Students",,"Not yet recruiting","No Results Available","ADHD|Oppositional Defiant Disorder","Behavioral: CLS-R-FUERTE","Change in Child Symptom Inventory-4 (CSI-4) Parent Checklist ADHD Combined type Symptom Severity Score|Change in Child Symptom Inventory-4 (CSI-4) Teacher Checklist ADHD Combined type Symptom Severity Score|Change in Child Symptom Inventory-4 (CSI-4) Parent Checklist (Oppositional Defiant Disorder) ODD Symptom Severity Score|Change in Child Symptom Inventory-4 (CSI-4) Teacher Checklist (Oppositional Defiant Disorder) ODD Symptom Severity Score|Change Impairment Rating Scale (IRS) Parent Questionnaire Overall Severity Score|Change Impairment Rating Scale (IRS) Teacher Questionnaire Overall Severity Score","University of California, San Francisco|National Institute of Mental Health (NIMH)","All","5 Years and older   (Child, Adult, Older Adult)","Not Applicable","200","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CLSRFUERTE 2|R21MH124066","September 1, 2022","June 30, 2023","July 31, 2023","August 11, 2022",,"August 11, 2022","UCSF, San Francisco, California, United States",,"https://ClinicalTrials.gov/show/NCT05496140"
440,"NCT05496127","Sensorimotor Exercises Practice and Yoga in Chronic Neck Pain",,"Enrolling by invitation","No Results Available","Chronic Pain|Neck Pain","Other: Sensorimotor Exercises and Yoga","Short Form 36 Quality of Life Scale|The Neck Disability Index|Tampa Kinesiophobia Scale|Numeric Pain Rating Scale|Joint Range of Motion Measurement|Joint Position Error Test","Medipol University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","E-10840098-772.02-34229","December 1, 2020","August 15, 2022","August 15, 2022","August 11, 2022",,"August 15, 2022","Istanbul Medipol University, Istanbul, Beykoz, Turkey",,"https://ClinicalTrials.gov/show/NCT05496127"
441,"NCT05496114","Medical Checklists in the Emergency Department",,"Not yet recruiting","No Results Available","Emergencies|Tricyclic Antidepressant Poisoning|Tricyclic Antidepressant Toxicity","Device: Checklist","Duration of the scenario|Number of indicated interventions performed by the emergency physician|Satisfaction of emergency physicians with the checklists","Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","All","Child, Adult, Older Adult","Not Applicable","72","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","W22_163","October 2022","June 2023","August 2023","August 11, 2022",,"August 11, 2022","Amsterdam University Medical Center, Amsterdam, Netherlands",,"https://ClinicalTrials.gov/show/NCT05496114"
442,"NCT05496101","CLI and FAR for Intraoperative Margin Assessment","CLI-FAR","Not yet recruiting","No Results Available","Breast Cancer Female","Procedure: Intraoperative CLI + FAR LightPath imaging","Margin status of WLE specimens|• Agreement between margin status of cavity shavings as determined by intraoperative CLI + FAR LightPath imaging and post-operative histopathology.","King's College London","Female","18 Years and older   (Adult, Older Adult)","Phase 2","60","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRAS 314460","October 30, 2022","December 31, 2024","December 31, 2024","August 11, 2022",,"August 11, 2022","Guy's and St Thomas NHS Trust, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT05496101"
443,"NCT05496088","Persistent AF Catheter Ablation: Re-PVI vs. Re-PVI + Continuous Complex Activity Mapping and Ablation - AF-CAM","AF-CAM","Recruiting","No Results Available","Atrial Fibrillation","Procedure: Re-PVI only|Procedure: Re-PVI + substrate ablation","Freedom from atrial arrhythmia","Asklepios proresearch|Asklepios Klinik St. Georg|Evangelisches Krankenhaus Düsseldorf","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","220","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","#3759","June 3, 2021","July 1, 2023","June 30, 2024","August 11, 2022",,"August 11, 2022","Asklepios Klinik St. Georg, Hamburg, Germany",,"https://ClinicalTrials.gov/show/NCT05496088"
444,"NCT05496075","Orlistat Reduces Uric Acid in Overweight/Obese Patients With Hyperuricemia",,"Not yet recruiting","No Results Available","Uric Acid","Drug: Orlistat|Drug: Orlistat placebo","level of uric acid","Shanghai 10th People's Hospital","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","orlistat reduces UA","August 15, 2022","August 15, 2023","February 14, 2024","August 11, 2022",,"August 11, 2022","Shanghai Tenth People's hospital, Shanghai, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT05496075"
445,"NCT05496062","Evaluation of the Toffee Nasal and Toffee Nasal Pillows Mask in Home, USA, 2022",,"Not yet recruiting","No Results Available","Obstructive Sleep Apnea","Device: F&P Toffee Nasal and Toffee Nasal Pillows Masks","Therapeutic Efficacy|Comfort","Fisher and Paykel Healthcare","All","22 Years and older   (Adult, Older Adult)","Not Applicable","90","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CIA-305","September 12, 2022","October 7, 2022","May 31, 2023","August 10, 2022",,"August 10, 2022","Clinical Site Partners, LLC - DBA CSP Miami, Miami, Florida, United States|Clayton Sleep Institute, Saint Louis, Missouri, United States",,"https://ClinicalTrials.gov/show/NCT05496062"
446,"NCT05496049","Efficacy of Triburter on Respiratory Muscle Function in Patients After CABG in Cardiac Rehabilitation Phase II",,"Recruiting","No Results Available","Thoracic Surgery|Postoperative Period|Weakness, Muscle","Device: Triburter|Device: Incentive spirometry","Change in respiratory muscles strength|Change in the lung function","Fundación Cardiovascular de Colombia","All","18 Years to 100 Years   (Adult, Older Adult)","Not Applicable","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CEI-2022-04334","August 1, 2022","December 23, 2022","January 23, 2023","August 10, 2022",,"August 10, 2022","Cardiac Rehabilitation, Piedecuesta, Santander, Colombia",,"https://ClinicalTrials.gov/show/NCT05496049"
447,"NCT05496036","Neoadjuvant PD-1 Blockade in Resectable Merkel Cell Carcinoma","MCC","Not yet recruiting","No Results Available","Merkel Cell Carcinoma","Drug: Pembrolizumab",": Pathologic Response Rate|Frequency and incidence of adverse events|Tumor infiltrating response (TIL)|Two Year Recurrence-Free Survival","Abramson Cancer Center of the University of Pennsylvania|Merck Sharp & Dohme LLC","All","18 Years and older   (Adult, Older Adult)","Phase 2","15","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","UPCC 01622","October 1, 2022","September 30, 2024","September 30, 2026","August 10, 2022",,"August 10, 2022","Penn Medicine, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT05496036"
448,"NCT05496023","Angiography-derived FFR GPS in Predicting Post-PCI Physiological and Clinical Outcomes","Angio-GPS","Recruiting","No Results Available","Coronary Artery Disease","Device: Percutaneous coronary intervention","Propotion of angio-FFR based physiological map successfully created|Correlation of predicted post-PCI angio-FFR by physiological map with angio-FFR after PCI|Agreement of predicted post-PCI angio-FFR by physiological map with angio-FFR after PCI|Correlation of pre-PCI angio-FFR with pre-PCI FFR|Agreement of pre-PCI angio-FFR with pre-PCI FFR|Correlation of post-PCI angio-FFR with post-PCI FFR|Agreement of post-PCI angio-FFR with post-PCI FFR|Correlation of pre-PCI angio-FFR derived pullback pressure gradient (PPG) with post-PCI angio-FFR|Correlation of pre-PCI angio-FFR derived pullback pressure gradient with post-PCI FFR|Target Vessel Failure","Shanghai Zhongshan Hospital","All","18 Years and older   (Adult, Older Adult)",,"329","Other","Observational","Observational Model: Case-Control|Time Perspective: Retrospective","ZS20220808|CHART2022-04","January 1, 2017","August 30, 2022","October 1, 2022","August 10, 2022",,"August 10, 2022","Zhongshan Hospital of Fudan University, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT05496023"
449,"NCT05496010","Comparing the Effectiveness of Dry Needling and Ischemic Compression on Tension Type Headache",,"Recruiting","No Results Available","Tension-Type Headache","Other: Dry Needling and Ischemic Compression Technique","Numeric Pain Rating Scale to assess headache intensity|Short Form-36 Questionnaire to measure Health related quality of life.|Short Form-36 Questionnaire to measure Health related quality of life|Diagnostic Ultrasound to measure muscle thickness","Ziauddin University","All","20 Years to 50 Years   (Adult)","Not Applicable","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Supportive Care","4541121AAREH","March 2, 2022","September 3, 2022","September 3, 2022","August 10, 2022",,"August 10, 2022","Ziauddin University, Karachi, Sindh, Pakistan",,"https://ClinicalTrials.gov/show/NCT05496010"
450,"NCT05495997","Cognitive Training in Parkinson's Disease",,"Not yet recruiting","No Results Available","Parkinson Disease","Behavioral: Mental Imagery Training|Behavioral: Psychoeducation","Change in Quality of life in Neurological Disorders (Neuro-QoL) Version 2 Cognitive Function scores|Change in task-specific whole-brain functional connectivity|Change in composite executive function test scores|Change in local and global functional connectivity-based graph measures","Yale University|National Institute of Neurological Disorders and Stroke (NINDS)","All","40 Years and older   (Adult, Older Adult)","Not Applicable","120","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","2000033352|1K23NS099478-01A1","October 2022","December 2027","December 2028","August 10, 2022",,"August 10, 2022",,,"https://ClinicalTrials.gov/show/NCT05495997"
451,"NCT05495984","Neuroplasticity in Maternal Opioid Use Disorder (OUD)",,"Not yet recruiting","No Results Available","Opioid Use Disorder","Behavioral: ERPs with electroencephalography (EEG)|Behavioral: MIO","Change in mothers' Event-related potentials (ERPs) elicited by unknown infant face and cry stimuli|Change in maternal mentalization measured by coding of reflective functioning (RF) on the one-hour Parent Development Interview (PDI)|Change in mothers' reflective functioning assessed using the self-report Parental Reflective Functioning Questionnaire (PRFQ)|Change in mothers' certainty about mental states assessed using the self-report Certainty about Mental States Questionnaire (CAMSQ)|Change in mothers' mind-mindedness assessed using the Five-Minute Speech Sample (MM)|Mothers' baseline substance use assessed using the Addiction Severity Index (ASI-Lite)|Change in mothers' depression assessed using the Edinburgh Postnatal Depression Scale (EPDS)|Change in mothers' depression assessed using the Patient Health Questionnaire-2 (PHQ-2)|Change in mothers' anxiety assessed using the Generalized Anxiety Disorder-7 (GAD-7)|Change in mothers' stress assessed using the Parenting Stress Index- Short Form (PSI-SF)|Mothers' experience of childhood maltreatment assessed using the Childhood Trauma Questionnaire (CTQ)|Mothers' experience of childhood adversity assessed using the Adverse Childhood Experiences Scale (ACES)|Change in mothers' internalized stigma assessed using the Brief Opioid Stigma Scale (BOSS)|Change in mothers' internalized stigma assessed using the Substance Use Stigma Mechanism Scale (SU-SMS)","Yale University|Alkermes, Inc.","Female","21 Years to 45 Years   (Adult)","Not Applicable","30","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2000033065","September 2022","August 31, 2024","August 31, 2024","August 10, 2022",,"August 10, 2022","Yale Child Studies Center, New Haven, Connecticut, United States",,"https://ClinicalTrials.gov/show/NCT05495984"
452,"NCT05495971","Extended Depth of Focus Contact Lenses for Presbyopia",,"Recruiting","No Results Available","Presbyopia","Device: NaturalVue Multifocal","LogMAR Visual Acuity","Visioneering Technologies, Inc","All","45 Years to 70 Years   (Adult, Older Adult)","Phase 4","50","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","VTI-2206","August 2022","December 2024","December 2024","August 10, 2022",,"August 10, 2022","VTI, Alpharetta, Georgia, United States",,"https://ClinicalTrials.gov/show/NCT05495971"
453,"NCT05495958","The Efficacy and Safety of Topical Vitamin D Drop on Meibomian Gland Function in Patients With Meibomian Gland Dysfunction",,"Active, not recruiting","No Results Available","Meibomian Gland Dysfunction","Drug: Topical Vitamin D eye drop|Drug: Topical placebo eye drop","Ocular Surface Disease Index score|Tear breakup time (TBUT)|schirmer1|Fluorescein staining test","Shahid Beheshti University of Medical Sciences","All","50 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","56","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","14014","July 25, 2022","October 30, 2022","December 30, 2022","August 10, 2022",,"August 10, 2022","Ophthalmic Research center, Tehran, Iran, Islamic Republic of",,"https://ClinicalTrials.gov/show/NCT05495958"
454,"NCT05495945","Ultrasonic Deep Brain Stimulation During Anesthetic Sedation",,"Recruiting","No Results Available","Mental Function","Device: Low-intensity focused ultrasound pulsation (LIFUP)|Combination Product: Functional Magnetic Resonance Imaging (fMRI) using Propofol","Blood Oxygen Level Dependent (BOLD) response to visual stimuli|Perceptual criterion derived from the Signal Detection Theory (SDT)|Sensitivity derived from the Signal Detection Theory (SDT)","University of Michigan","All","18 Years to 40 Years   (Adult)","Phase 2","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","HUM00213014","August 2022","August 2026","August 2026","August 10, 2022",,"August 10, 2022","University of Michigan, Ann Arbor, Michigan, United States",,"https://ClinicalTrials.gov/show/NCT05495945"
455,"NCT05495932","Mepolizumab Pharmacokinetics Among Patients With Severe Asthma","CESAM","Not yet recruiting","No Results Available","Asthma","Diagnostic Test: blood sample","Change in Mepolizumab serum concentration|Mepolizumab serum concentration|Complete blood cell count at 1 month|Complete blood cell count at 6 months|Comparison of lung function by airway obstruction|Comparison of asthma control by ACQ-6 score|Comparison of chronic rhinosinusitis by SNOT-22 score|Comparison of exacerbation rate|Number of days alive and not exacerbating|Comparison of change in oral corticosteroid|Presence/absence of a >50% reduction in exacerbation rate|Presence/absence of monoclonal antibody switching","University Hospital, Montpellier","All","18 Years and older   (Adult, Older Adult)","Not Applicable","50","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","RECHMPL 22_0035","October 2022","April 2025","April 2025","August 10, 2022",,"August 15, 2022","university Hospital of Montpellier, Montpellier, France|University Hospital of Tours, Tours, France",,"https://ClinicalTrials.gov/show/NCT05495932"
456,"NCT05495919","Nursing Education in the Pandemic",,"Completed","No Results Available","Anxiety|Satisfaction","Other: Control|Other: video interaction|Other: flipped training","Anxiety Severity|Satisfaction Severity","University of Beykent","All","18 Years to 25 Years   (Adult)","Not Applicable","90","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","202151","June 1, 2021","June 15, 2021","July 30, 2021","August 10, 2022",,"August 10, 2022","Beykent University, Istanbul, Beykent, Turkey",,"https://ClinicalTrials.gov/show/NCT05495919"
457,"NCT05495906","A Study of Reduced Dosing of the Nonavalent HPV Vaccine in Women Living With HIV","NOVA-HIV","Not yet recruiting","No Results Available","HPV|Human Papilloma Virus|Human Immunodeficiency Virus","Biological: Nonavalent HPV vaccine","Anti-HPV16/18 geometric mean titers (GMTs) at month 7|Anti-HPV16/18 GMTs at month 7 in Group 1 compared with month 13 in Group 2 (1 month post 3rd dose in both groups)|Anti-HPV16/18 GMTs at month 24 in both groups (i.e. routine and extended interval)|Quantitative summarization of survey responses regarding vaccine acceptability, comfort, and willingness to use HPV self-sampling as a screening methodology in future","University of British Columbia","Female","18 Years to 45 Years   (Adult)","Phase 3","450","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","H22-01707","September 2022","August 2024","August 2026","August 10, 2022",,"August 10, 2022","University of British Columbia, Vancouver, British Columbia, Canada",,"https://ClinicalTrials.gov/show/NCT05495906"
458,"NCT05495893","MMF Versus CYC in the Induction Therapy of Pediatric Active Proliferative LN","MyCITS","Recruiting","No Results Available","Mycophenolate Mofetil|Cyclophosphamide|Lupus Nephritis","Drug: Cyclophosphamide|Drug: Mycophenolate Mofetil","Effective rate of LN treatment|complete remission time|Incidence of LN treatment failure|Incidence of creatinine doubling|LN recurrence rate|SLE recurrence rate|SLE disease activity score|partial remission time","Second Xiangya Hospital of Central South University|Peking Union Medical College Hospital|Children's Hospital of Chongqing Medical University|Beijing Children's Hospital|Jiangxi Province Children's Hospital|The Affiliated Hospital of Qingdao University|Shenzhen Children's Hospital|The First Affiliated Hospital of Zhengzhou University|The Children's Hospital of Zhejiang University School of Medicine|The Second Hospital of Hebei Medical University","All","5 Years to 17 Years   (Child)","Phase 4","224","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2021YFC2702004","July 25, 2022","May 31, 2025","May 31, 2025","August 10, 2022",,"August 10, 2022","the Second Xiangya Hospital of Central South University, Changsha, Hunan, China",,"https://ClinicalTrials.gov/show/NCT05495893"
459,"NCT05495880","Forearm-Supported Head Extension to Decrease Dental Contact",,"Not yet recruiting","No Results Available","Dental Contact During Direct Laryngoscopy","Procedure: with forearm-support|Procedure: without forearm-support","Dental contact|Blade-to-tooth distance|Angle of head extension","Seoul National University Hospital","All","18 Years and older   (Adult, Older Adult)","Not Applicable","92","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","JHBahk_novel_intu","August 16, 2022","December 31, 2023","December 31, 2023","August 10, 2022",,"August 10, 2022",,,"https://ClinicalTrials.gov/show/NCT05495880"
460,"NCT05495867","Evaluation of Implant-prosthetic Rehabilitation Performed With Two Implants With Different Surface Characteristics",,"Recruiting","No Results Available","Missing Teeth|Edentulous Jaw|Edentulous Mouth","Procedure: implant placement","Marginal bone loss|Implant stability|insertion torque curve","Luigi Canullo|Studio Odontoiatrico Associato Dr. P. Cicchese e L. Canullo","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","40","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ABT1","April 22, 2022","September 15, 2023","September 15, 2023","August 10, 2022",,"August 11, 2022","Studio Odont.Associato Dr.P.Cicchese E L.Canullo, Rome, Italy/Rome, Italy",,"https://ClinicalTrials.gov/show/NCT05495867"
461,"NCT05495854","New Strategy for the Detection and Treatment of Helicobacter Pylori Infections in Primary Care Guided by a Non-invasive PCR in Stool",,"Not yet recruiting","No Results Available","Helicobacter Pylori Infection","Diagnostic Test: PCR test in the stool","Cure rate assessed by the result of a urea breath test carried out 6 weeks after the end of treatment (proof of Hp eradication)","Poitiers University Hospital","All","18 Years and older   (Adult, Older Adult)","Not Applicable","1100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","HEPYPRIM","October 1, 2022","February 1, 2023","February 1, 2023","August 10, 2022",,"August 10, 2022",,,"https://ClinicalTrials.gov/show/NCT05495854"
462,"NCT05495841","OPTiMASK: Comparison of Pre-oxygenation With Standard Face Mask Combined With High Flow Nasal Oxygen With Pre-oxygenation With Standard Face Mask Alone",,"Not yet recruiting","No Results Available","Surgery","Device: Pre-oxygenation","Lowest EtO2 value|SpO2 at the start and at the end of the procedure|Tolerance of the device|Lowest SpO2|Highest level of EtCO2|Rate of oxygen desaturation|Number of laryngoscopy attempts","Beth Israel Deaconess Medical Center","All","18 Years and older   (Adult, Older Adult)",,"80","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2022P000396","August 18, 2022","December 30, 2024","December 30, 2025","August 10, 2022",,"August 10, 2022","Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT05495841"
463,"NCT05495828","Orelabrutinib Therapy in Patients With r/r B-cell Lymphoma Intolerant to Other Bruton Tyrosine Kinase Inhibitors",,"Not yet recruiting","No Results Available","B-cell Lymphoma","Drug: Orelabrutinib","the adverse events of Special interest|ORR|DCR|DOR|PFS|OS","Peking University People's Hospital","All","18 Years and older   (Adult, Older Adult)",,"30","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","intolerant to BTK inhibitors","August 10, 2022","December 10, 2023","March 10, 2024","August 10, 2022",,"August 10, 2022","Deparment of Hematology, Peking University People's Hospital, Beijing, Beijing, China",,"https://ClinicalTrials.gov/show/NCT05495828"
464,"NCT05495815","Proper Duration of Suppressive Antibiotic Therapy After Debridement, Antibiotics, and Implant Retention","ProperSAT","Not yet recruiting","No Results Available","Suppressive Antibiotic Therapy|Periprosthetic Joint Infection|Debridement, Antibiotics, Implant Retention","Drug: 6 months of SAT|Drug: 12 months of SAT","Reoperation for infection recurrence|Antibiotic resistance, evidenced by change in antimicrobial sensitivity profile, developed by infecting organism after suppressive antibiotic therapy causing infection recurrence|Adverse drug reaction or intolerance, defined as any symptom or laboratory value derangement requiring a change in, or discontinuation of, antimicrobial therapy","University of Maryland, Baltimore|New England Baptist Hospital|OrthoCarolina Research Institute, Inc.|Vanderbilt University|University of Pennsylvania|University of Arkansas","All","18 Years and older   (Adult, Older Adult)","Not Applicable","102","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Maryland","September 2022","September 2023","September 2024","August 10, 2022",,"August 10, 2022",,,"https://ClinicalTrials.gov/show/NCT05495815"
465,"NCT05495802","Regional Database for Collecting Clinical-biological and Imaging Data ""Secondary Bone Oncology and Bone Localizations of Hematologic Diseases""","OOSLOH","Not yet recruiting","No Results Available","Bone Metastases",,"Percentage of alive patients|Percentage of patients without bone disease recurrence|Time to bone disease recurrence|Number of bone recurrence Number of bone recurrence|Epidemiological datas","University Hospital, Lille|Lille University Hospital Emergence Fund","All","18 Years and older   (Adult, Older Adult)",,"5000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2019_59|2021-A00829-32","December 2022","November 2032","December 2032","August 10, 2022",,"August 10, 2022",,,"https://ClinicalTrials.gov/show/NCT05495802"
466,"NCT05495789","The Effect of Virtual Reality and Music in High-Risk Pregnants on Non-Stress Test",,"Not yet recruiting","No Results Available","High Risk Pregnancy","Other: Virtual Reality|Other: Music","Change in anxiety|the degree of satisfaction|Non-Stress Test Parameters/ basal fetal heart rate|Non-Stress Test Parameters: number of accelerations|Non-Stress Test Parameters/ number of decelerations|Non-Stress Test Parameters/ reactive nst|Non-Stress Test Parameters / Test time (minutes) for reactive NST|Non-Stress Test Parameters / Non-reaktif NST","NESLİHAN YILMAZ SEZER|Ankara University","Female","18 Years and older   (Adult, Older Adult)","Not Applicable","102","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Care Provider, Outcomes Assessor)|Primary Purpose: Supportive Care","12/125","August 15, 2022","November 15, 2022","December 15, 2022","August 10, 2022",,"August 10, 2022",,,"https://ClinicalTrials.gov/show/NCT05495789"
467,"NCT05495776","Prospective Multicenter Registry Study to Assess the Frequency of Lynch Syndrome Among Patients With Colorectal Cancer","MSIRus22","Not yet recruiting","No Results Available","Colorectal Cancer|Lynch Syndrome|Hereditary Colorectal Cancer|MSI",,"Frequency of microsatellite instability and Lynch syndrome|Frequency of occurrence of microsatellite instability/deficiency|Spectrum of germinal mutations in Lynch syndrome|Spectrum of malignant neoplasms|Effectiveness of therapy with immune checkpoint inhibitors|Impact of the presence of microsatellite instability/deficiency","State Scientific Centre of Coloproctology, Russian Federation|The Loginov MCSC MHD|Pirogov National Medical and Surgical Center|Moscow City Oncological Hospital No. 62 MHD|City Clinical Oncological Hospital No. 1 MHD|MMCC Kommunarka MHD|D.D. Pletnev City Clinical Hospital MHD|Botkin Hospital MHD|Clinic K+31","All","18 Years and older   (Adult, Older Adult)",,"2500","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","01082022","August 1, 2022","August 1, 2025","December 31, 2028","August 10, 2022",,"August 10, 2022","State Scientific Centre of Coloproctology, Moscow, Russian Federation",,"https://ClinicalTrials.gov/show/NCT05495776"
468,"NCT05495763","The Ultrasonographic Changes of Intercostal Muscles and Diaphragm in Mechanically Ventilated Preterm Neonates",,"Recruiting","No Results Available","Assess the Impact of Mechanical Ventilation on Diaphragm and Intercostal Muscles Using Ultrasound",,"The impact of mechanical ventilation on diaphragm and intercostal muscles using ultrasound","Noha Saied Ibrahim|Ain Shams University","All","5 Minutes to 28 Days   (Child)",,"30","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","Noha ibrahim","August 2022","January 2023","January 2023","August 10, 2022",,"August 15, 2022","Ain Shams University, Cairo, Egypt",,"https://ClinicalTrials.gov/show/NCT05495763"
469,"NCT05495750","Suprazygomatic Maxillary Nerve Block Effect on Systemic Inflammatory Response in Cleft Palate Surgeries",,"Recruiting","No Results Available","Perioperative Inflammatory Response|Postoperative Pain","Drug: Bupivacaine 0.25% Injectable Solution","Interleukin 6 serum level.|Serum Cortisol level|Plasma glucose level|C-Reactive protein (CRP)|Total leucocytic count|CHIPPS score|The number of rescue analgesia doses postoperatively|time needed till the need of first dose recorded of rescue analgesia|Time needed to start oral feeding will be recorded","Alaa Mohamed Abdel Salam Ibrahim Soliman|Ain Shams University","All","1 Year to 5 Years   (Child)","Phase 4","30","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","FMASU MD 141/2022","June 24, 2022","February 1, 2023","May 30, 2023","August 10, 2022",,"August 10, 2022","Faculty of dentisry Ainshams univeristy, Cairo, Egypt",,"https://ClinicalTrials.gov/show/NCT05495750"
470,"NCT05495737","Meaning-Centered Psychotherapy at Home",,"Recruiting","No Results Available","Nurse-Patient Relations|Psychology, Social","Behavioral: Meaning-Centered Psychotherapy/MCP-PC Training|Behavioral: Meaning-Centered Psychotherapy/MCP-PC|Behavioral: Treatment As Usual/TAU","MPI Competency Ratings","Memorial Sloan Kettering Cancer Center","All","18 Years and older   (Adult, Older Adult)",,"80","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","22-019","August 8, 2022","August 8, 2024","August 8, 2024","August 10, 2022",,"August 10, 2022","Visiting Nurse Service of NY, New York, New York, United States|Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT05495737"
471,"NCT05495724","Disitamab Vedotin Combined With Tislelizumab for Her2 Overexpressing High-Risk Non-Muscle-Invasive Urothelial Bladder Carcinoma Which is Not Completely Resectable",,"Recruiting","No Results Available","Her2 Overexpressing High-Risk Non-Muscle Invasive Bladder Urothelial Carcinoma","Drug: Disitamab Vedotin Tislelizumab|Drug: Disitamab Vedotin","Complete Response (CR) Rate|Progress Free Survival（PFS）|Recurrence Free Survival（RFS）|Cystectomy-Free Survival (CFS)|Duration of Response (DOR)|Event-Free Survival（EFS）|Number of adverse events and severity by grade (CTCAE)|Her2 status|PD-1 expression status","Tianjin Medical University Second Hospital","All","18 Years and older   (Adult, Older Adult)","Phase 2","176","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TRUCE-04","July 23, 2021","February 2025","July 2025","August 10, 2022",,"August 10, 2022","Tianjin Medical University Second Hospital, Tianjin, Tianjin, China",,"https://ClinicalTrials.gov/show/NCT05495724"
472,"NCT05495711","hUC Mesenchymal Stem Cells (19#iSCLife®-UT) Therapy for Patients With Thin Endometrial Infertility",,"Recruiting","No Results Available","Infertility, Female","Biological: human umbilical cord mesenchymal stem cell complex collagen|Procedure: intrauterine injection","Irregular menstruation patients efficacy evaluation|Intrauterine adhesion patients efficacy evaluation","Sclnow Biotechnology Co., Ltd.","Female","20 Years to 39 Years   (Adult)","Phase 1","24","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SCLnow-XY-05","May 1, 2020","October 1, 2022","December 31, 2022","August 10, 2022",,"August 10, 2022","Xiangya Hospital Central South University, Changsha, Hunan, China",,"https://ClinicalTrials.gov/show/NCT05495711"
473,"NCT05495698","Triple Therapy Convenience by the Use of One or Multiple Inhalers and Digital Support in Chronic Obstructive Pulmonary Disease","TRICOLON","Not yet recruiting","No Results Available","Copd|Adherence, Medication","Drug: single-inhaler triple therapy (Trimbow)|Device: E-health application: Curavista app & FindAir e-device|Drug: multi-inhaler triple therapy (Qvar + Bevespi)","Adherence to ICS therapy|TAI questionnaire score|CCQ questionnaire|VAS score|PIH-NL|WPAI|EQ-5D-5L|HLS-EU-Q16|Number exacerbations|SABA use","Franciscus Gasthuis","All","40 Years and older   (Adult, Older Adult)","Not Applicable","300","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","FranciscusGasthuis","September 2022","September 2024","September 2024","August 10, 2022",,"August 10, 2022",,,"https://ClinicalTrials.gov/show/NCT05495698"
474,"NCT05495685","iDentification and vAlidation Model of Liquid biopsY Based cfDNA Methylation and pRotEin biomArKers for Pancreatic Cancer (DAYBREAK Study)",,"Recruiting","No Results Available","Cancer",,"The sensitivity and specificity of multi-cancer early detection by the combined model in cancer arm and benign disease arm|The difference of sensitivity and specificity in pancreatic cancer participants at different clinical stages.|Sensitivity and specificity for detecting pancreatic cancer of a cfDNA methylation-based model, in combination with other biomarkers.|Sensitivity and specificity for detecting pancreatic cancer of a the protein panel-based model, in combination with other biomarkers.|Sensitivity and specificity of the blood miRNA-based model in detecting pancreatic cancer.","Changhai Hospital|Guangzhou Burning Rock Bioengineering Ltd","All","40 Years to 75 Years   (Adult, Older Adult)",,"450","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","CHEC2022-030","March 24, 2022","December 31, 2023","June 30, 2024","August 10, 2022",,"August 10, 2022","Shanghai Changhai Hospital, Shanghai, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT05495685"
475,"NCT05495672","Circulating Tumor DNA Guided Therapeutic Strategies for CRC Patients With Small Pulmonary Nodules",,"Recruiting","No Results Available","Advanced Colorectal Cancer|Circulating Tumor DNA","Procedure: Local treatment","Progression-free survival (PFS) in advanced colorectal cancer patients with metastatic small pulmonary nodules under ctDNA guided therapeutic strategies|ctDNA positive rate in colorectal cancer patients with metastatic small pulmonary nodules|ctDNA positive prediction rate (Consistent with histopathological result as the standard for comparison)|The ctDNA clearance rate after local treatment|The ctDNA clearance rate after chemotherapy in patients achieving NED (Cohort 2)","Junjie Peng|Shanghai OrigiMed Co., Ltd.|Fudan University","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","100","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ctDNA-nedCRC-lung","August 1, 2022","December 1, 2023","December 1, 2025","August 10, 2022",,"August 10, 2022","Fudan University Shanghai Cancer Center, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT05495672"
476,"NCT05495659","Detection of Ureteral Stent Encrustation",,"Not yet recruiting","No Results Available","Ureteral Stent-Related Symptom",,"Number of participants with ureteral stent encrustation longer than 4mm measured by a ruler","Fifth Affiliated Hospital, Sun Yat-Sen University","All","12 Years to 80 Years   (Child, Adult, Older Adult)",,"156","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","FSYS-2022-K122-1","August 1, 2022","August 1, 2024","November 30, 2024","August 10, 2022",,"August 10, 2022",,,"https://ClinicalTrials.gov/show/NCT05495659"
477,"NCT05495646","Infection Related to Short-term Central Venous Catheters",,"Not yet recruiting","No Results Available","Catheter-Related Infections","Procedure: Central catheter insertion","Incidence of infection among short-term central venous catheters inserted in the scheduled perioperative setting.|Number of patients suffering from complications after the different techniques and operators.|Assess risk factors for catheter-related infection","Ángel Becerra|Dr. Negrin University Hospital","All","18 Years and older   (Adult, Older Adult)",,"150","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","150030","August 8, 2022","September 8, 2022","October 30, 2022","August 10, 2022",,"August 12, 2022","Ángel Becerra, Las Palmas De Gran Canaria, Las Palmas, Spain",,"https://ClinicalTrials.gov/show/NCT05495646"
478,"NCT05495633","SteamOne - Prospective Registry Database for Rezum Water Vapor Therapy of the Prostate","SteamOne","Recruiting","No Results Available","Benign Prostate Obstruction (BPO)","Other: Collection and evaluation of clinical (CROMs) and patient-reported outcomes (PROMs)|Other: Analysis of uroflowmetry data by Kesem Health iUFlow medical uroflowmetry device","Change in International Prostate Symptom Score/ Quality of Life (IPSS/ QoL)|Change of maximum urinary flow rate (Qmax) measured by uroflowmetry|Change of International Consultation on Incontinence Questionnaire for male lower urinary tract symptoms (ICIQ-MLUTS)|Change of Male Sexual Health Questionnaire (MSHQ)|Change of International Consultation on Incontinence Questionnaire Male Sexual Matters Associated with Lower Urinary Tract Symptoms Module (ICIQ-MLUTSsex)|Patient's postoperative recovery by QoR-15|Change in PROMIS Global Health 10 questionnaire|Change in ICIQ-S (International Consultation on Incontinence - Satisfaction)|Numeric pain Rating Scale (NRS)|Rezum side effects and Pain medication|Patients' preferences and expectations of Rezum Treatment|Questionnaire: BPO (BPH)/LUTS medication|Questionnaire: Reoperation|Questionnaire: Bladder catheter|Number of steam injections and injection points during Rezum treatment|Retreatment rate|Surgical safety by classification of intraoperative adverse events (ClassIntra®)|30-days postoperative complications by the Clavien-Dindo classification|Antimicrobial prophylaxis|Post voiding residual volume (PVR) measured by ultrasound|Change of prostate size|Change in bladder outlet obstruction index (BOOI)|Change in bladder contractility index (BCI)|Change in International Prostate Symptom Score (IPSS) for detrusor (bladder muscle) overactivity (DO)|MRI (magnetic resonance imaging) data|Prostate cancer (PCa) detected by positive prostate biopsy|Doctors' preferences, motivations and reasons to use Rezum|Change in ICIQ-Lower Urinary Tract Symptoms Quality of Life (ICIQ-MLUTS) score for detrusor (bladder muscle) overactivity (DO)","University Hospital, Basel, Switzerland|Boston Scientific Corporation","Male","18 Years and older   (Adult, Older Adult)",,"1000","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","2022-00544; bb21Ebbing","September 2022","August 2029","August 2029","August 10, 2022",,"August 10, 2022","University Hospital Basel, Department of Urology, Basel, Switzerland","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/33/NCT05495633/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/33/NCT05495633/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT05495633"
479,"NCT05495620","Long-term KRd in Relapsed and/or Refractory Multiple Myeloma",,"Not yet recruiting","No Results Available","Multiple Myeloma in Relapse|Multiple Myeloma, Refractory","Drug: Carfilzomib|Drug: Lenalidomide|Drug: Dexamethasone","Progression-free survival|Overall survival|Overall response rate, clinical benefit rate|Duration of response|Toxicity profile","Dong-A University Hospital|Amgen","All","19 Years and older   (Adult, Older Adult)",,"300","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Retrospective","DAUHIRB-22-081","August 1, 2022","January 31, 2023","September 30, 2023","August 10, 2022",,"August 10, 2022",,,"https://ClinicalTrials.gov/show/NCT05495620"
480,"NCT05495607","Continous Renal Replacement Therapy With the CARPEDIEM® in a French National Cohort of 25 Neonates and Small Infants",,"Completed","No Results Available","Hypoxic-Ischemic Encephalopathy|Sepsis|Kidney Diseases|Metabolic Disease|Twin to Twin Transfusion Syndrome|Cardiac Disease|Pulmonary Disease","Device: CARPEDIEN","Survival|Serum creatinine|Serum potassium|Blood urea nitrogen|Ammonia levels|Ultrafiltration flow|Blood flow|Anticoagulation|Number of sessions|Time of treatments|CKRT modality|Vascular access|Priming circuit|Size of the circuit|Death|Clotting circuit and other dysfunction circuit","Centre Hospitalier Universitaire de Nice","All","0 Years to 3 Years   (Child)",,"25","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","22-NEPHRO-01","December 1, 2018","January 1, 2022","January 1, 2022","August 10, 2022",,"August 10, 2022","CHU de Nice, Nice, France",,"https://ClinicalTrials.gov/show/NCT05495607"
481,"NCT05495594","Central Sensitization in Medical Students",,"Completed","No Results Available","Central Sensitisation",,"CENTRAL SENSITIZATION INVENTORY","Dokuz Eylul University","All","18 Years to 25 Years   (Adult)",,"324","Other","Observational","Observational Model: Other|Time Perspective: Cross-Sectional","TıpFakogrencisantralsensitzsyn","April 1, 2022","June 30, 2022","July 1, 2022","August 10, 2022",,"August 10, 2022","1Department of Physical Medicine and Rehabilitation, Medical Faculty of Dokuz Eylül University, İzmir, Turkey, Izmir, Turkey",,"https://ClinicalTrials.gov/show/NCT05495594"
482,"NCT05495581","A Study About How ASP5354 Affects the Body in Healthy Adults and in Adults Whose Kidneys do Not Work Well",,"Not yet recruiting","No Results Available","Healthy Volunteers|Renal Impairment","Drug: pudexacianinium chloride","Pharmacokinetics (PK) of ASP5354 in plasma: area under the concentration-time curve from time of dosing extrapolated to time infinity (AUCinf)|PK of ASP5354 in plasma: area under concentration-time curve from the time of dosing to the last measurable concentration (AUClast)|PK of ASP5354 in plasma: maximum concentration (Cmax)|PK of ASP5354 in plasma: apparent clearance (CL)|PK of ASP5354 in urine: cumulative amount of unchanged drug excreted in urine from time of dosing to time infinity after single dose (Aeinf)|PK of ASP5354 in urine: cumulative amount of unchanged drug excreted in urine from time of dosing to the last measurable amount (Aelast)|PK of ASP5354 in urine: cumulative amount of unchanged drug excreted in urine from time of dosing to time infinity after single dose as a percentage of total cumulative amount of unchanged drug excreted in urine (Aeinf%)|PK of ASP5354 in urine: cumulative amount of unchanged drug excreted in urine from time of dosing to the last measurable amount as a percentage of total cumulative amount of unchanged drug excreted in urine (Aelast%)|PK of ASP5354 in urine: renal clearance (CLr)|Number of participants with Adverse Events (AEs)|Number of participants with laboratory value abnomalities and/or AEs|Number of participants with vital signs abnormalities and/or AEs|Number of participants with electrocardiogram (ECG) abnormalities and/or AEs","Astellas Pharma Global Development, Inc.|Astellas Pharma Inc","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1","36","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","5354-CL-0004","August 31, 2022","August 31, 2023","August 31, 2023","August 10, 2022",,"August 10, 2022",,,"https://ClinicalTrials.gov/show/NCT05495581"
483,"NCT05495568","To Compare Pharmacokinetics, Efficacy, and Safety of CT-P17 With Humira in Patients With Moderate to Severe Chronic Plaque Psoriasis",,"Not yet recruiting","No Results Available","Moderate to Severe Chronic Plaque Psoriasis","Biological: CT-P17|Biological: EU-approved Humira","To demonstrate the pharmacokinetics (PK) similarity between patients receiving Humira continuously and those who alternate between Humira and CT-P17 in terms of Area under the concentration-time curve over the dosing interval (AUCtau, 25-27)|To demonstrate the pharmacokinetics (PK) similarity between patients receiving Humira continuously and those who alternate between Humira and CT-P17 in terms of Maximum serum concentration during the dosing interval (Cmax, 25-27)|To evaluate Pharmacokinetics (PK) Pharmacokinetics (PK) parameter: Time to maximum serum concentration during the dosing interval (Tmax, 25-27)|To evaluate Pharmacokinetics (PK) Pharmacokinetics (PK) parameter: Trough concentration (Ctrough)|To evaluate Efficacy: Mean % improvement from baseline in PASI (Psoriasis Area Severity Index) score|To evaluate Efficacy: Proportion of patients achieving at least 50/75/90/100% improvement from baseline in PASI (PASI 50/75/90/100)|To evaluate Efficacy: Proportion of patients with an sPGA (Static Physician's Global Assessment) score on a 5-point scale of clear (0) or almost clear (1)|To evaluate Safety: AEs (including serious AEs) by Common Terminology Criteria for Adverse Events (CTCAE) v5.0|To evaluate Safety: AEs of special interest by Common Terminology Criteria for Adverse Events (CTCAE) v5.0|To evaluate Safety: Immunogenicity of Switching and Humira maintenance will be assessed by anti-drug antibody and neutralizing antibody test in validated immunoassay.","Celltrion","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","366","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CT-P17 3.3|2022-002336-31","November 16, 2022","October 6, 2023","March 29, 2024","August 10, 2022",,"August 10, 2022",,,"https://ClinicalTrials.gov/show/NCT05495568"
484,"NCT05495555","The Cutting Efficiency of Hybrid Tips in Different Grades of Cataract",,"Recruiting","No Results Available","Cataract","Device: INTREPID® Hybrid tip","Phaco time|Aspiration time|Fluid use|Central corneal thickness","Justin Spaulding|Sengi|Cataract and Laser Institute of Southern Oregon","All","50 Years and older   (Adult, Older Adult)",,"50","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","JS-22-001","August 2022","September 2023","September 2023","August 10, 2022",,"August 10, 2022","Cataract & Laser Institute, Medford, Oregon, United States",,"https://ClinicalTrials.gov/show/NCT05495555"
485,"NCT05495542","The Effect of ShotBlocker on Injection Pain",,"Completed","No Results Available","Pain|Intramuscular Injection","Other: ShotBlocker","Visual analog scale|Visual patient satisfaction scale","Bornova No. 25 Mevlana Family Health Center","Female","18 Years and older   (Adult, Older Adult)","Not Applicable","146","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Supportive Care","3023010044","November 1, 2018","November 1, 2018","May 30, 2019","August 10, 2022",,"August 10, 2022","Merve, Izmir, Bornova, Turkey",,"https://ClinicalTrials.gov/show/NCT05495542"
486,"NCT05495529","Biliary or Digestive Protection by Room Air Interposition for Thermal Ablation of Central Hepatic Tumors",,"Completed","No Results Available","Radiology, Interventional|Liver Neoplasm|Carcinoma, Hepatocellular (RENI)|Neoplasm Metastasis|Ablation Techniques|Radiofrequency Ablation|Microwaves","Procedure: Thermal Ablation","Feasability|Security|Efficacity|Clinical success|Local and distant recurrence|Local tumorous recurrence free survival|Progression free survival","Centre Hospitalier Universitaire de Nice","All","Child, Adult, Older Adult",,"61","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","22Imagerie01","January 1, 2013","December 31, 2021","May 11, 2022","August 10, 2022",,"August 10, 2022","CHU de Nice, Nice, France",,"https://ClinicalTrials.gov/show/NCT05495529"
487,"NCT05495516","Search for Methods to Predict the Development of Heart Failure After Myocardial Infarction","PHFMI","Active, not recruiting","No Results Available","Myocardial Infarction","Genetic: without Intervention","cardiovascular death, nonfatal myocardial infarction, stroke of any type, hospitalization due to decompensation of chronic heart failure|total mortality","Novosibirsk State Medical University|Novosibirsk State University","All","18 Years to 70 Years   (Adult, Older Adult)",,"186","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","L-003","January 1, 2019","January 1, 2023","February 1, 2023","August 10, 2022",,"August 10, 2022","Novosibirsk State Medical University, Novosibirsk, Novosibirskaja Oblast' (oblast'), Russian Federation",,"https://ClinicalTrials.gov/show/NCT05495516"
488,"NCT05495503","Tolerance of Cyto-selective Difluoroethane-based Cryotherapy in the Treatment of Post-inflamamatory Hyperpigmentation (PIH).",,"Not yet recruiting","No Results Available","Post-inflammatory Hyperpigmentation","Device: Prototype (814A-v1)|Device: Prototype (814B-v1)|Device: Prototype (814C-v1)|Device: Prototype (814D-v1)","Change from baseline skin hyperpigmentation|Change from baseline skin hypopigmentation|Change from baseline skin appearance|Change from baseline skin sensation|Self-assesment of pain|Change from baseline spots visibility","Cryonove Pharma|DERMATECH|CEISO","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","12","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","CS5_2","August 15, 2022","October 15, 2022","October 15, 2022","August 10, 2022",,"August 10, 2022","Photobiology Laboratory, Sefako Makgatho Health Sciences University, Pretoria, Gauteng, South Africa",,"https://ClinicalTrials.gov/show/NCT05495503"
489,"NCT05495490","Osseodensification Versus Osteotome Internal Sinus Lifting in Delayed Implant Placement",,"Not yet recruiting","No Results Available","Maxillary Sinus Floor Augmentation","Procedure: Osseodensification Internal Sinus Lift|Procedure: Osteotome Internal Sinus Lift","Radiographic Assessment of Change in the Vertical Bone Height (Bone Gain).|Radiographic Assessment of Change in the Bone Density.|Clinical Assessment of Primary Stability of the Implants ( Insertion Torque Value) Measured by a Torque Wrench.|Clinical Assessment of Primary Stability of the Implants (Implant Stability Quotient ) Measured by an Osstell® Device.|Patient's Post-Operative Pain Assessment|Patient's Satisfaction Assessment.|Operator's Satisfaction Assessment","Ain Shams University","All","18 Years to 40 Years   (Adult)","Not Applicable","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","FDASU-Rec ID032230|1120","September 2022","October 2023","January 2024","August 10, 2022",,"August 10, 2022","Faculty of Dentistry- Assiut University, Assiut, Egypt|Faculty of Dentistry- Ain Shams University, Cairo, Egypt",,"https://ClinicalTrials.gov/show/NCT05495490"
490,"NCT05495477","Effects of NIV and CPAP on Ventilation Distribution, Measured by EIT, During Deep Sedation in Paediatric Patients","NIVEIT-ped","Recruiting","No Results Available","Respiratory Failure|Sedation|Mechanical Ventilation Complication","Device: EIT","Regional Ventilation Delay (pixels %), RDV|Inhomogeneity Index (pixels), GI|Gravity Centre(pixels %), GC","Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico","All","1 Year to 10 Years   (Child)","Not Applicable","20","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","2021/2178","April 20, 2021","June 28, 2023","October 30, 2024","August 10, 2022",,"August 10, 2022","Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico Milano, Milan, Italy",,"https://ClinicalTrials.gov/show/NCT05495477"
491,"NCT05495464","A Pilot ""Window-3"" Study of Acalabrutinib Plus Rituximab Followed by Brexucabtagene Autoleucel Therapy in Patients With Previously Untreated High-risk Mantle Cell Lymphoma",,"Not yet recruiting","No Results Available","Lymphoma|Mantle Cell Lymphoma","Drug: Acalabrutinib|Drug: Rituximab|Other: Brexucabtagene Autoleucel|Drug: Cyclophosphamide|Drug: Fludarabine Phosphate","Incidence of adverse events","M.D. Anderson Cancer Center|Kite, A Gilead Company|Acerta Pharma, LLC","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","20","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2020-0872|NCI-2022-06281","January 31, 2023","March 31, 2027","March 31, 2027","August 10, 2022",,"August 11, 2022","M D Anderson Cancer Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT05495464"
492,"NCT05495451","Feasibility and Impact of an Intensive Team-based Intervention on Type 2 Diabetes Reversal","DIABEPIC2","Active, not recruiting","No Results Available","Type 2 Diabetes","Behavioral: Moderate-carbohydrate Mediterranean diet, Personalized exercice prescription and training, Intermittent fasting","Feasibility of an intensive multidisciplinary program based on lifestyle changes in patients diagnosed with type 2 diabetes.|Proportion of diabetic participants in complete remission of diabetes.|Evolution of the HOMA-IR between the start of the program, the middle of the intervention (3 months) and the end of the intervention (6 months).","Montreal Heart Institute","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","36","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","ICM 2022-3018","January 21, 2022","March 21, 2023","May 21, 2023","August 10, 2022",,"August 10, 2022","EPIC Center of the Montreal Heart Institute, Montréal, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT05495451"
493,"NCT05495438","Impact and Safety of AI in Decision Making in the ICU: a Simulation Experiment","ICU","Recruiting","No Results Available","Sepsis","Other: Hypothetical AI","Influence of AI on ICU Clinicians|Participants' characteristics|Trust in AI|Confidence in participants' decisions|Proportion of time with attention on AI explanation","Imperial College London|University of York","All","18 Years and older   (Adult, Older Adult)",,"40","Other","Observational","Observational Model: Other|Time Perspective: Prospective","22CX7592","July 22, 2022","October 31, 2022","October 31, 2022","August 10, 2022",,"August 10, 2022","Imperial College Hospitals NHS Trust, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT05495438"
494,"NCT05495425","Clinical Study of NPC-12Y Gel in Patients With Skin Lesions Associated With TSC",,"Recruiting","No Results Available","Tuberous Sclerosis Complex","Drug: NPC-12Y gel|Drug: NPC-12Y placebo gel","Improvements in angiofibroma|Improvements in angiofibroma, color and size|Index of Facial Angiofibromas (IFA) score","Nobelpharma","All","3 Years and older   (Child, Adult, Older Adult)","Phase 3","40","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","NPC-12Y-1","June 1, 2022","November 30, 2023","September 30, 2024","August 10, 2022",,"August 10, 2022","Fujita Health University Hospital, Toyoake, Aichi, Japan|Gunma University Hospital, Maebashi, Gunma, Japan|Osaka University Hospital, Suita, Osaka, Japan|Seirei Hamamatsu General Hospital, Hamamatsu, Shizuoka, Japan|National Hospital Organization Nishi-Niigata Chuo Hospital, Niigata, Japan",,"https://ClinicalTrials.gov/show/NCT05495425"
495,"NCT05495412","Rebound for Respiratory in School Aged Children and Young People With Neurodisability","RforR","Recruiting","No Results Available","Neurologic Disorder|Respiratory Tract Infections","Other: Rebound therapy","Change in caregiver-reported respiratory symptoms between week 0, 6, 12 and week 18|Change in Clinical Respiratory Observations|Change in Chailey Levels of Ability|Change in Caregiver Priorities & Child Health Index of Life with Disabilities questionnaire|Change in self-reported general health|Change in self-reported change in postural management care plan|Change in self-reported change in respiratory management care plan|Number and category of (Serious) Adverse Events ((S)AE)|Overall Intervention Adherence","Jon Marsden|UCL Great Ormond Street Institute of Child Health|University of Plymouth","All","4 Years to 16 Years   (Child)","Not Applicable","6","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2698|NIHR301008","March 25, 2022","September 2022","September 2022","August 10, 2022",,"August 10, 2022","Bidwell Brook School, Dartington, Devon, United Kingdom|John Parkes Unit, Torbay Hospital, Torbay and South Devon NHS Foundation Trust, Torquay, Devon, United Kingdom|Mayfield School, Torquay, United Kingdom",,"https://ClinicalTrials.gov/show/NCT05495412"
496,"NCT05495399","Post Operative RT for Limited Spine Metastases",,"Not yet recruiting","No Results Available","Spine Metastases","Procedure: Spondylectomy|Radiation: SBRT","Local control|Overall survival|pain control|Quality of life assessment|Treatment related toxicity","National Taiwan University Hospital","All","20 Years and older   (Adult, Older Adult)","Not Applicable","111","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","202204039RINA","August 2022","July 2026","July 2027","August 10, 2022",,"August 12, 2022",,,"https://ClinicalTrials.gov/show/NCT05495399"
497,"NCT05495386","Investigation of Hyposafe H02 Device in Patients With Type 1 Diabetes",,"Not yet recruiting","No Results Available","Type 1 Diabetes","Device: Hyposafe hypoglycaemia notification device (H02)","To collect electrocardiogram (EEG) data to develop a hypoglycaemia notification algorithm.|To collect self-measured blood glucose (SMBG) data to develop a hypoglycaemia notification algorithm.|To collect continuous glucose monitoring (CGM) data to develop a hypoglycaemia notification algorithm.|To evaluate the safety of H02 in participants with type 1 diabetes.|To evaluate the performance of H02 in participants with type 1 diabetes.|To evaluate the surgeon satisfaction of H02 in participants with type 1 diabetes.","UNEEG Medical A/S","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","25","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","U010","September 1, 2022","January 1, 2024","March 1, 2024","August 10, 2022",,"August 10, 2022",,,"https://ClinicalTrials.gov/show/NCT05495386"
498,"NCT05495373","Can Saliva be the New Bio-fluid to Monitor Children's Oral Health?",,"Completed","No Results Available","Healthy",,"Oral hygiene|Periodontal status|Caries status","Hadassah Medical Organization","All","4 Years to 12 Years   (Child)",,"100","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","HMO-067617","January 1, 2020","January 1, 2022","February 1, 2022","August 10, 2022",,"August 10, 2022","Hadassah Medical Organization, Jerusalem, Israel, Jerusalem, Israel",,"https://ClinicalTrials.gov/show/NCT05495373"
499,"NCT05495360","Effect of Omega 3 Enriched Oral Nutritional Supplement on Nutritional Status of CRC and NSCLC Patients","OMENS","Not yet recruiting","No Results Available","Malnutrition|Oncology","Dietary Supplement: Oral Nutritional Supplement","Change in EPA concentration in the phospholipid fraction of the erythrocyte membrane [% of total fatty acids]|Change in protein intake [g/day] [key secondary outcome)|Change in protein intake [g/kg bw/day] [key secondary outcome)|Change in energy intake [kcal/day]|Change in energy intake [kcal/kg bw/day]|Provided vitamin D supplementation [µg/day] by the test product|Change in fatty acid profile in the phospholipid fraction of the cell membrane of erythrocytes [% of total fatty acids]","Nutricia Research","All","18 Years and older   (Adult, Older Adult)","Not Applicable","48","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","SBB20R&35115","October 2022","December 2023","December 2023","August 10, 2022",,"August 10, 2022","Universitair Ziekenhuis Brussel, Brussels, Belgium|AZ Delta, Roeselare, Belgium|Cork University Hospital, Cork, Ireland",,"https://ClinicalTrials.gov/show/NCT05495360"
500,"NCT05495347","Big Data Analysis of OSA Patients on Positive Airway Pressure (PAP) Treatment: Real-life Monitoring","TeleVAL","Recruiting","No Results Available","Obstructive Sleep Apnea|Positive Airway Pressure","Other: patients diagnosed with OSA","Characterize the phenotypes involved|Establish the percentage of patients who at the first connection to the TM achieved the optimal therapeutic pressure|Establish the Profile of patients who at the first connection to the TM achieved the optimal therapeutic pressure|Variations in AHI during the first year of follow-up and their relationship with patient characteristics.|Time to achieve the optimal therapeutic pressure described after the first connection|Evaluation of the impact of long-term telemonitoring of patients with OSA","Instituto de Investigación Marqués de Valdecilla","All","Child, Adult, Older Adult",,"2500","Other","Observational","Observational Model: Cohort|Time Perspective: Other","TeleVAL","July 1, 2022","December 31, 2022","December 31, 2022","August 10, 2022",,"August 10, 2022","Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain",,"https://ClinicalTrials.gov/show/NCT05495347"
501,"NCT05495334","Innovations in Genicular Outcomes Registry","iGOR","Recruiting","No Results Available","Knee Osteoarthritis","Procedure: Treatment for Knee OA","Pain intensity and interference scores via NRS (Numeric Rating Scale)|Pain intensity and interference scores via BPI-sf (Brief Pain Inventory-short form)|Opioid use via pre-and post-treatment analgesic medication use log|Functional status via KOOS-JR (Knee injury and Osteoarthritis Outcome Score for Joint Replacement)|Functional status via SANE (Single Assessment Numeric Evaluation)|Quality of Sleep via PROMIS-SD (PROMIS - Sleep Disturbance - Short Form 8b)|Adverse events related to pain therapies|General HRQOL via PROMIS-10 (PROMIS GLOBAL-10)|Patient Satisfaction|Physical therapy utilization and work productivity via PT/Work Productivity|Emergency Department (ED) visits|Reimbursement status|Post-operative pain scores NRS (Numeric Rating Scale)|Post-operative opioid consumption (analgesic medication use log)|Length of facility stay","Pacira Pharmaceuticals, Inc","All","Child, Adult, Older Adult",,"2000","Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","IOV-REG-001","September 23, 2021","March 31, 2025","March 31, 2025","August 10, 2022",,"August 10, 2022","Orthopedic Education and Research Institute of So Ca (Hoag), Irvine, California, United States|MidState Orthopedics and Sports Medicine, Alexandria, Louisiana, United States|Louisiana State University /Ochsner, New Orleans, Louisiana, United States|OrthoNebraska Clinics, Omaha, Nebraska, United States|Jersey City Medical Center, Jersey City, New Jersey, United States|Genesee Orthopedics and Plastic Surgery (St. Elizabeth Med Center/ Apex Surgical Center), New Hartford, New York, United States",,"https://ClinicalTrials.gov/show/NCT05495334"
502,"NCT05495321","Interleukin-2 on Refractory Dermatomyositis",,"Not yet recruiting","No Results Available","Dermatomyositis","Drug: Interleukin-2","Proportion of subjects achieving minimal improvement (TIS≥20).|MMT-8 (Manual Muscle Testing), (potential score 0 - 80);|CDASI activity score (cutaneous dermatomyositis disease area and severity index), (potential score 0-100 for cutaneous dermatomyositis disease area and 0-32 for severity index);|Physician's Global Disease Activity VAS, (potential score 0 - 10);|Patient's Global Disease Activity VAS, (potential score 0 - 80);|Health assessment question, (potential score 0 - 3);|Myositis disease activity assessment tool (MDAAT) - 2005, VERSION 2|CD4 T cells|Serum cytokines|glucocorticoid dosage|Rate of Participants with adverse effects associated with experimental drugs|Proportion of subjects meeting the definition of improvement (DOI)|Number of subjects achieving minimal improvement (TIS≥20).","Peking University People's Hospital","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","240","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","IIMIL2","September 1, 2022","September 1, 2025","September 1, 2026","August 10, 2022",,"August 10, 2022",,,"https://ClinicalTrials.gov/show/NCT05495321"
503,"NCT05495308","""Oncologic Results and Risk Factors for Recurrence in Patients With Locally Advanced Rectal Cancer and Pathologic Complete Response After Neoadjuvant Treatment. Results From an Observational Retrospective Multicenter Long-term Follow-up Study"".",,"Completed","No Results Available","Rectal Cancer, Adenocarcinoma|Rectal Cancer Stage II|Rectal Cancer Stage III|Distant Metastasis|Local Recurrence of Malignant Tumor of Rectum","Procedure: neoadjuvant treatment","The main objective of the study is to update long-term oncologic follow-up of those patients treated for LARC with nCRT and surgery (either TME or subtotal TME; S-TME) who had obtained a pCR.|To analyze operative and treatment data in search of related factors to adverse oncologic outcomes, like distant recurrence or tumor-related deaths.|To analyze demographic data in search of related factors to adverse oncologic outcomes, like distant recurrence or tumor-related deaths.|To analyze further demographic data in search of related factors to adverse oncologic outcomes, like distant recurrence or tumor-related deaths.|To analyze clinical data in search of related factors to adverse oncologic outcomes, like distant recurrence or tumor-related deaths.","Hospital San Carlos, Madrid","All","18 Years to 100 Years   (Adult, Older Adult)",,"4","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","C.I. 20/741-E","September 1, 2021","March 1, 2022","May 1, 2022","August 10, 2022",,"August 10, 2022","Hospital La Princesa, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT05495308"
504,"NCT05495295","First-in-human Trial of PhOx430, a First-in-class Acetylglucosaminyltransferase V Inhibitor, in Advanced Solid Tumours","PhAST","Recruiting","No Results Available","Malignant Tumor|Advanced Solid Tumor|Glioblastoma Multiforme|Metastatic Cancer","Drug: PhOx430","DOSE ESCALATION PRIMARY OUTCOME (Dose Limiting Toxicities (DLTs) at cycle 1)|DOSE EXPANSION PRIMARY OUTCOME (treatment-emergent Adverse Events)|DOSE ESCALATION SECONDARY OUTCOME #1 (treatment-emergent Adverse Events)|DOSE ESCALATION SECONDARY OUTCOME #2 (Plasma concentration levels of PhOx430)|DOSE ESCALATION SECONDARY OUTCOME #3 (Objective response rate)|DOSE EXPANSION SECONDARY OUTCOME #1 (Plasma concentration levels of PhOx430 )|DOSE EXPANSION SECONDARY OUTCOME #2 (Objective response rate)|DOSE ESCALATION SECONDARY OUTCOME #4 (progression-free survival)|DOSE ESCALATION SECONDARY OUTCOME #5 (overall survival)|DOSE EXPANSION SECONDARY OUTCOME #3 (progression-free survival)|DOSE EXPANSION SECONDARY OUTCOME #4 ( overall survival)","Phost'In Therapeutics","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 1","146","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PHOX-CLI_001|2021-004170-55","July 18, 2022","June 30, 2023","July 31, 2026","August 10, 2022",,"August 10, 2022","IRCCS Ospedale San Raffaele, Milano, Italy",,"https://ClinicalTrials.gov/show/NCT05495295"
505,"NCT05495282","Traditional Lecture Versus Procedural Video",,"Not yet recruiting","No Results Available","Educational Problems","Other: Microvideo","Rubric scores|Perceived effectiveness of learning modality","Carilion Clinic","All","25 Years to 70 Years   (Adult, Older Adult)","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","IRB-21-1513","August 6, 2022","August 6, 2023","August 6, 2023","August 10, 2022",,"August 10, 2022","Carilion Roanoke Community Hospital, Roanoke, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT05495282"
506,"NCT05495269","Safety and Tolerability Study of QLS-101 in Adolescents With Sturge-Weber Syndrome (SWS)-Related Glaucoma Due to Elevated Episcleral Venous Pressure (EVP)",,"Not yet recruiting","No Results Available","Sturge-Weber Syndrome|Glaucoma|Ocular Hypertension","Drug: QLS-101 ophthalmic solution, 2.0 %","Ocular safety|Systemic safety|Ocular hypotensive effectiveness","Qlaris Bio, Inc.","All","12 Years to 19 Years   (Child, Adult)","Phase 2","20","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","QC-205","September 1, 2022","February 1, 2023","February 28, 2023","August 10, 2022",,"August 10, 2022",,,"https://ClinicalTrials.gov/show/NCT05495269"
507,"NCT05495256","[Trial of device that is not approved or cleared by the U.S. FDA]",,"Withheld","No Results Available",,,,"[Redacted]",,,,,,,,"Respimetrix 2",,,,"August 10, 2022",,"August 10, 2022",,,"https://ClinicalTrials.gov/show/NCT05495256"
508,"NCT05495243","Phase 2a, 28-day Investigational Use Study of ARINA-1 in Non-CF Bronchiectasis With Excess Mucus and Cough",,"Not yet recruiting","No Results Available","Non-cystic Fibrosis Bronchiectasis","Drug: ARINA-1|Drug: Placebo","Incidence of treatment-emergent adverse events|Proportion of participants that experience each treatment-emergent adverse event|Compare quality of life (as measured by CAAT questionnaire) between the ARINA-1 and placebo arms|Compare quality of life (as measured by SGRQ) between the ARINA-1 and placebo arms|Compare quality of life (as measured by QOL-B) between the ARINA-1 and placebo arms|Compare blood inflammatory markers between the ARINA-1 and placebo arms|Compare changes in mucolytic use between ARINA-1 and placebo arms|Compare changes in airway clearance techniques between ARINA-1 and placebo arms|Compare FEV1 between the ARINA-1 and treatment arms|Compare FVC between the ARINA-1 and treatment arms|Compare FEF25-75 between the ARINA-1 and treatment arms|Compare PEF between the ARINA-1 and treatment arms|Compare sputum percent solids between the ARINA-1 and placebo arms","Renovion, Inc.","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2","50","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","RVN-301","August 2022","January 2023","March 2023","August 10, 2022",,"August 12, 2022","University of Alabama - Birmingham, Birmingham, Alabama, United States|National Jewish Hospital, Denver, Colorado, United States|Georgetown University, Washington, District of Columbia, United States|Louisiana State University, New Orleans, Louisiana, United States|Johns Hopkins, Baltimore, Maryland, United States|Oregon Health and Science University, Portland, Oregon, United States|Jefferson Hospital, Philadelphia, Pennsylvania, United States|Medical University of South Carolina, Charleston, South Carolina, United States|University of Texas - Tyler, Tyler, Texas, United States",,"https://ClinicalTrials.gov/show/NCT05495243"
509,"NCT05495230","OPTIMA FORMA Phase 3","OPTIMAFORMA3","Not yet recruiting","No Results Available","Chronic Condition|Chronic Conditions, Multiple","Behavioral: Person-centred integrated care intervention|Other: Usual care","Composite score HRQoL & patient-experienced quality of healthcare|Global Physical Health|Global Mental Health|Patient-experienced quality of care|Patient activation as measured by PAM|Health-related quality of life as measured by the EQ-5D-5L instrument|Health care use according to patient|BMI|HbA1c|Blood glucose|Blood LDL-cholesterol|Systolic and diastolic blood pressure|Positive affect of healthcare providers|Experience of healthcare providers","Radboud University Medical Center","All","18 Years and older   (Adult, Older Adult)","Not Applicable","800","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","2022-15788","January 1, 2023","April 1, 2024","April 1, 2024","August 10, 2022",,"August 10, 2022",,"""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/30/NCT05495230/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT05495230"
510,"NCT05495217","A Clinical Study for Comparison of the Effects Between Gasless Laparoscopy and Conventional Laparoscopy for Distal Gastric Cancer",,"Active, not recruiting","No Results Available","Gastrectomy|Laparoscopy","Device: Conventional Laparoscopy|Device: Gasless Laparoscopy","Operative time|Blood pressure|End-tidal carbon dioxide|Heart rate|Estimated blood loss|Complications|Death|Blood transfusion|Tumor size","Xue Yingwei|The Third Affiliated Hospital of Harbin Medical University","All","18 Years to 75 Years   (Adult, Older Adult)","Not Applicable","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","XJS2021-13","December 1, 2021","June 1, 2023","December 1, 2023","August 10, 2022",,"August 10, 2022","Harbin University Cancer Hospital, Harbin, Heilongjiang, China",,"https://ClinicalTrials.gov/show/NCT05495217"
511,"NCT05495204","External Comparison of Ibalizumab in Trials vs. Other Regimens in OPERA",,"Active, not recruiting","No Results Available","HIV-1-infection","Drug: Ibalizumab","Viral suppression|Viral undetectability","Epividian|Theratechnologies|FIECON","All","18 Years and older   (Adult, Older Adult)",,"200","Industry|Other","Observational","Observational Model: Other|Time Perspective: Other","COL2022-001","August 5, 2022","September 15, 2022","October 15, 2022","August 10, 2022",,"August 10, 2022","Epividian, Durham, North Carolina, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/04/NCT05495204/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT05495204"
512,"NCT05495191","Signal Intensity Gradient in Cerebral Arteries",,"Completed","No Results Available","Ischemic Stroke, Acute","Diagnostic Test: Signal intensity gradient","Change of signal intensity gradient at discharge or 7th day in the patients with the lenticulostriate artery infarction","Chonbuk National University Hospital|Korean Society of Neurosonology|Ministry of SMEs and Startups, Republic of Korea|Korean Neurological Association","All","18 Years and older   (Adult, Older Adult)",,"294","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","SIGLSA","May 10, 2021","May 5, 2022","July 23, 2022","August 10, 2022",,"August 10, 2022","Jeonbuk National University Hospital, Jeonju, Jeollabuk-do, Korea, Republic of","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/91/NCT05495191/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT05495191"
513,"NCT05495178","Courses of Hepatobiliary Manifestations After Proctocolectomy for Patients With Ulcerative Colitis.",,"Completed","No Results Available","Hepatobiliary Disease","Procedure: laparoscopic restorative proctocolectomy","severity of hepatobiliary manifestations after colectomy","Zagazig University","All","18 Years to 69 Years   (Adult, Older Adult)",,"167","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","hepatobiliary manifestations","June 1, 2013","June 1, 2018","June 1, 2022","August 10, 2022",,"August 12, 2022",,,"https://ClinicalTrials.gov/show/NCT05495178"
514,"NCT05495165","Early Education Programme in Malnourished Cancer Patients","NEHOTEL","Not yet recruiting","No Results Available","Nutrition Aspect of Cancer","Other: Therapeutic education for patients in nutrition","Rate of acceptance|Rate of patients' skills development during the therapeutic educative programme|Programme and environment (hosting) satisfaction questionnaire assessment|Acceptance of treatment assessment|Assessment of the programme's cost|Real cost estimation|Quality of Life Questionnaire related to cancer (QLQ C30) to assess the patients' quality of life|Quality of Life Questionnaire Head and Neck (QLQ H&N35) to assess the patients' quality of life|Number of therapeutic events completed|The count of adverse events related or not to treatment|Anthropomorphic markers (weight in kilograms)|Anthropomorphic markers (height in meters)|anthropomorphic markers (weight and height are used to calculate the BMI in kg/m^2)|Biological markers (quantity of albumine in blood)|Biological markers (quantity of lymphocyte in blood)|Biological markers (quantity of albumine and lymphocyte in blood are used to calculate the PNI with the formula [10 * taux albumine (g/dL)] + [nombre de lymphocytes totaux/µL * 0,05])|Food intake quantity and quality estimation with the Visual Analogue Scale (VAS)|Consumption of Nutritional Oral Complements (NOC)|Borg Rating Scale of Perceived Exertion (Borg) scale after a physical activity to assess the physical activity and the effectiveness of reinforcement tools|International Physical Activity Questionnaire (IPAQ) to assess the physical activity and the effectiveness of reinforcement tools|World Health Organisation (WHO) scale to evaluate the capacity to move to assess the physical activity and the effectiveness of reinforcement tools|Drawing test Questionnaire to assess the socio-aesthetic programme and the patients' self-esteem|Rosenberg Self-Esteem Scale (Rosenberg) questionnaire to assess the socio-aesthetic programme and the patients' self-esteem|Hospital Anxiety and Depression (HAD) scale to assess the sophrology programme and the patients' anxiety and depression|European Quality of Life-5 Dimensions Visual Analogue Scale (EQ-5D-VAS) to assess the sophrology programme and the patients' well-being","Beauvais Hospital","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","60","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","NEHOTEL","September 2022","June 2023","June 2024","August 10, 2022",,"August 12, 2022",,,"https://ClinicalTrials.gov/show/NCT05495165"
515,"NCT05495152","Adjuvant Sintilimab for Locally Advanced Esophageal Squamous Cell Carcinoma",,"Active, not recruiting","No Results Available","Esophageal Squamous Cell Carcinoma","Drug: Sintilimab","Disease-free Survival (DFS)","Henan Cancer Hospital","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 3","219","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HCHTOG2203","August 1, 2022","August 31, 2025","August 31, 2028","August 10, 2022",,"August 10, 2022","Henan Cancer Hospital, Zhengzhou, Henan, China",,"https://ClinicalTrials.gov/show/NCT05495152"
516,"NCT05495139","Gastric Bypass Stent Small-Sample-Size Study For Nonalcoholic Fatty Liver Disease",,"Not yet recruiting","No Results Available","Nonalcoholic Fatty Liver Disease","Device: Gastric Bypass Stent System in Treatment of Patients with Nonalcoholic Fatty Liver Disease","Changes of MRI-PDFF|Changes of liver stiffness measurement (LSM)|Changes of liver inflammation/injury indicators (ATL, ASL, GGT, ALP, TBil, and DBil)|Changes of blood glucose indicators (fasting insulin, fasting blood glucose, fasting C-peptide, and insulin resistance [e.g. HOMA-IR])|Changes of blood lipids indicators, including triglyceride, total cholesterol, low density lipoprotein cholesterol (LDL-C), high density lipoprotein cholesterol (HDL-C), apolipoprotein A1, apolipoprotein B, apolipoprotein CIII, and lipoprotein (a)|Changes of hepatic fibrosis indicators (PIIINP, Fibro Test/Fibro Sure, ELF, and NFS)|Percent changes of body weight and changes of BMI|Histological changes|Evaluation on the usability of the device","Hangzhou Tangji Medical Technology Co., Ltd.","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HZTJ03","September 1, 2022","May 30, 2023","November 30, 2023","August 10, 2022",,"August 10, 2022",,,"https://ClinicalTrials.gov/show/NCT05495139"
517,"NCT05495126","Evaluate Treatment Outcomes For AI-Enabled Information Collection Tool For Clinical Assessments In Mental Healthcare",,"Not yet recruiting","No Results Available","Mental Health Issue","Diagnostic Test: Standard Limbic Access pathway|Diagnostic Test: Limbic Access with AI pathway","Change from baseline depression score to after treatment|Change from baseline anxiety score to after treatment|Change in diagnosis|Clinical assessment times|Waiting times|Referral Dropout Rates|Assessment Dropout Rates|Treatment Dropout Rates","Limbic Limited|Insight Healthcare","All","16 Years and older   (Child, Adult, Older Adult)","Not Applicable","4000","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Diagnostic","Limbic-303303","September 1, 2022","December 31, 2022","March 31, 2023","August 10, 2022",,"August 10, 2022",,,"https://ClinicalTrials.gov/show/NCT05495126"
518,"NCT05495113","The Efficacy and Safety of tDCS in Patients With Mild Dementia",,"Recruiting","No Results Available","Mild Dementia","Device: YMS-201B (Device: Mind STIM)","The difference between the K-MMSE (Mini Mental State Examination) changes after stimulation for 26 weeks compared to the baseline of the test group(active tDCS) and the control group(Sham control)|The difference between the scale changes after stimulation for 26 weeks compared to the baseline of the test group(active tDCS) and the control group(Sham control)","Ybrain Inc.","All","55 Years to 90 Years   (Adult, Older Adult)","Not Applicable","118","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","YB_ST_SIT1901","December 1, 2019","September 30, 2022","December 30, 2022","August 10, 2022",,"August 10, 2022","The Catholic University of Korea at incheon, Incheon, Korea, Republic of|Korea University, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT05495113"
519,"NCT05495100","A Single-arm, Multicenter, Prospective Clinical Study of Mitoxantrone Liposome Combined With Chidamide and Azacitidine in the Treatment of Relapsed and Refractory Peripheral T-cell Lymphoma",,"Recruiting","No Results Available","Peripheral T Cell Lymphoma","Drug: Mitoxantrone liposome、Chidamide、Azacitidine","ORR","Second Affiliated Hospital, School of Medicine, Zhejiang University|Ningbo No. 1 Hospital|Jinhua Central Hospital|Huizhou Municipal Central Hospital","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","45","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2022-0453","August 11, 2022","August 11, 2023","August 11, 2024","August 10, 2022",,"August 10, 2022","Second Affiliated Hospital, School of Medicine, Zhejiang University, Zhejiang, Zhejiang, China",,"https://ClinicalTrials.gov/show/NCT05495100"
520,"NCT05495087","Intermittent Hypoxia Training: A Novel Therapy for Mild Cognitive Impairment",,"Not yet recruiting","No Results Available","Mild Cognitive Impairment|Memory Impairment","Device: IHT Treatment|Other: Sham-IHT Control","Overall Cognitive Function|Attention and Short-term Memory|Cognitive Function|Visual Orientation and Executive Function|Neurotoxic Protein|Neuroprotective Protein|Cerebral Vascular Function|Brain Morphology","University of North Texas Health Science Center|University of Texas Southwestern Medical Center|National Institute on Aging (NIA)","All","55 Years to 80 Years   (Adult, Older Adult)","Not Applicable","66","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","R01AG076675","August 15, 2022","April 30, 2025","April 30, 2025","August 10, 2022",,"August 10, 2022",,,"https://ClinicalTrials.gov/show/NCT05495087"
521,"NCT05495074","Design of a Genetic Score to Predict the Response to a Dietary Intervention in Adults With Metabolic Syndrome",,"Active, not recruiting","No Results Available","Metabolic Syndrome","Other: ATP III dietary intervention","Change in waist circumference|Change in serum glucose|Change in serum HDL cholesterol|Change in serum triglycerides|Change in systolic and diastolic blood pressure|Change in the serum amino acid profile|Change in body composition|Change in body weight|Change in serum insulin|Change in serum leptin|Change in serum glucagon|Change in serum adiponectin|Change of insulin resistance by HOMA index|Change of Body mass index","Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran|Universidad Autonoma de San Luis Potosí","All","18 Years to 60 Years   (Adult)","Not Applicable","100","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","FNU-3813-21-22-1","September 2, 2021","August 2023","August 2023","August 10, 2022",,"August 10, 2022","Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubiran., Mexico City, Mexico",,"https://ClinicalTrials.gov/show/NCT05495074"
522,"NCT05495061","A Comparative Confirmatory Study of STN1012600 in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension",,"Recruiting","No Results Available","Primary Open Angle Glaucoma, Ocular Hypertension","Drug: STN1012600 ophthalmic solution 0.002%|Drug: Latanoprost ophthalmic solution 0.005%","Change from baseline in mean diurnal intraocular pressure","Santen Pharmaceutical Co., Ltd.","All","18 Years and older   (Adult, Older Adult)","Phase 3","300","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment","101260005LT","August 9, 2022","May 31, 2023","May 31, 2023","August 10, 2022",,"August 10, 2022","Eyecare Nagoya, Aichi, Japan|Kitanagoya Eye Clinic, Aichi, Japan|Takahashi Eye Clinic, Aichi, Japan|Kawabata Eye Clinic, Chiba, Japan|Mitsuhashi Eye Clinic, Chiba, Japan|Shisui Ophthalmology Clinic, Chiba, Japan|Takeda Eye Clinic, Hokkaido, Japan|Kanamori Eye Clinic, Hyogo, Japan|Dannoue Eye Clinic, Kanagawa, Japan|Hodogaya iina Eye Clinic, Kanagawa, Japan|Honda Eye Clinic, Kanagawa, Japan|Yokosuka Chuoh Eye Clinic, Kanagawa, Japan|Kengun Sakuragi Eye Clinic, Kumamoto, Japan|Hideyuki Eye Clinic, Miyagi, Japan|Iwashita Eye Clinic, Osaka, Japan|Maeda Eye Clinic, Osaka, Japan|Nishi Eye Hospital, Osaka, Japan|Onoe Eye Clinic, Osaka, Japan|Sugasawa Eye Clinic, Osaka, Japan|Sugiura Eye Clinic, Osaka, Japan|Tahara Eye Clinic, Osaka, Japan|Tane Memorial Eye Hospital, Osaka, Japan|Kawaguchi Aozora Eye Clinic, Saitama, Japan|Omiya Hamada Eye Clinic West entrance Branch, Saitama, Japan|Omiya Hamada Eye Clinic, Saitama, Japan|Shibuya Ophthalmology Clinic, Saitama, Japan|Muramatsu Eye Clinic, Shizuoka, Japan|Nakamura Eye Clinic, Shizuoka, Japan|Ono Ophthalmic Clinic, Shizuoka, Japan|Saito Eye Clinic, Shizuoka, Japan|Yoshimura Eye & Internal Medical Clinic, Shizuoka, Japan|Dogenzaka Kato Eye Clinic, Tokyo, Japan|Hashida Eye Clinic, Tokyo, Japan|Kakinoki Eye Clinic, Tokyo, Japan|Seijo Clinic, Tokyo, Japan|Shimizu Eye Clinic, Tokyo, Japan|Shirayama Eye Clinic, Tokyo, Japan|Suitengu Fujita Ophthalmo Clinic, Tokyo, Japan|Tamagawa Eye Clinic, Tokyo, Japan|Tokiwadai Muranaka Eye Clinic, Tokyo, Japan|Ueda Eye Clinic, Tokyo, Japan|Watanabe Eye Clinic, Tokyo, Japan|IMAI Eye Clinic, Yamanashi, Japan",,"https://ClinicalTrials.gov/show/NCT05495061"
523,"NCT05495048","Transvaginal NOSES Versus Conventional Laparoscopic Surgery for Right Hemicolectomy",,"Not yet recruiting","No Results Available","Colon Cancer","Procedure: NOSES VIIIA|Procedure: laparoscopic surgery with mini-laparotomy","disease-free survival rate","Shanghai Minimally Invasive Surgery Center","Female","18 Years to 75 Years   (Adult, Older Adult)","Not Applicable","356","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NOSES VIIIA Trial","January 1, 2023","December 31, 2028","December 31, 2028","August 10, 2022",,"August 10, 2022",,,"https://ClinicalTrials.gov/show/NCT05495048"
524,"NCT05495035","Study for Safety and Efficacy of Olverembatinib Combined With APG-2575 in Children With Relapsed/Refractory Ph + ALL",,"Not yet recruiting","No Results Available","Lymphoblastic Leukemia, Acute, Childhood|Leukemia, Lymphoblastic, Acute, Philadelphia-Positive|Relapsed Leukemia|Refractory Leukemia","Drug: Olverembatinib, APG-2575, Dexamethasone","Dose-limiting toxicity (DLT)|Objective Response Rate (ORR)|Maximum plasma concentration (Cmax)|Area under the plasma concentration versus time curve (AUC)|R2PD of Olverembatinib and APG-2575|Minimal Residual Disease (MRD) negative rate","Institute of Hematology & Blood Diseases Hospital","All","1 Year to 18 Years   (Child, Adult)","Phase 1","22","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HQP1351ACE01","August 1, 2022","August 31, 2024","December 1, 2024","August 10, 2022",,"August 10, 2022","The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China|Qilu Hospital of Shandong University, Jinan, Shandong, China|Department of Pediatrics, Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Sciences, Tianjin, Tianjin, China|Department of Hematology/Oncology, Shanghai Jiaotong University School of Medicine Affiliated Shanghai Children's Medical Center, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT05495035"
525,"NCT05495022","The Effect of MBSR (Mindfulness-Based Stress Reduction) Program on Anxiety, Work-Related Emotional Burnout and Job Satisfaction in Midwives",,"Completed","No Results Available","Midwives|Mindfulness|Anxiety|Professional Burnout|Job Satisfaction","Behavioral: Mindfulness-based stress reduction (MBSR) program","Beck Anxiety Scale|Work-Related Emotional Burnout Scale|Minnesota Job Satisfaction Scale (MSQ) Short Form","Inonu University","Female","18 Years and older   (Adult, Older Adult)","Not Applicable","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","28-02-2022 / 26","June 4, 2022","July 1, 2022","August 1, 2022","August 10, 2022",,"August 15, 2022","Faculty of Health Science, Gaziantep, Şahinbey/ Gaziantep, Turkey",,"https://ClinicalTrials.gov/show/NCT05495022"
526,"NCT05495009","Virtual Reality, Labor Pain, Anxiety, Birth Perception",,"Completed","No Results Available","Labor Pain|Anxiety","Other: Standard of care+virtual reality glasses","pre-intervention pain at the start of the active phase was assessed by Visual Analogue Scale-Pain (VAS-P)|post-intervention pain at the start of the active phase was assessed Visual Analogue Scale-Pain (VAS-P)|pre-intervention anxiety at the start of the active phase was assessed by Visual Analogue Scale-Anxiety (VAS-A)|post-intervention anxiety at the start of the active phase was assessed by Visual Analogue Scale-Anxiety (VAS-A)|pre-intervention pain at the start of the transition phase was assessed by Visual Analogue Scale-Pain (VAS-P)|post-intervention pain at the start of the transition phase was assessed by Visual Analogue Scale-Pain (VAS-P)|pre-intervention anxiety at the start of the transition phase was assessed by Visual Analogue Scale-Anxiety (VAS-A)|post-intervention anxiety at the start of the transition phase was assessed by Visual Analogue Scale-Anxiety (VAS-A)|birth perception in the postpartum period was assessed by Mother's Perception of Birth Scale|pre-intervention systolic blood pressure (mmHg) at the start of the active phase was assessed.|post-intervention systolic blood pressure (mmHg) at the start of the active phase was assessed.|pre-intervention diastolic blood pressure (mmHg) at the start of the active phase was assessed.|post-intervention diastolic blood pressure (mmHg) at the start of the active phase was assessed.|pre-intervention pulse (minute) at the start of the active phase was assessed.|post-intervention pulse (minute) at the start of the active phase was assessed.|pre-intervention respiration (minute) at the start of the active phase was assessed.|post-intervention respiration (minute) at the start of the active phase was assessed.|pre-intervention fetal heart rate (minute) at the start of the active phase was assessed.|post-intervention fetal heart rate (minute) at the start of the active phase was assessed.|pre-intervention contraction frequency (minute) at the start of the active phase was assessed.|post-intervention contraction frequency (minute) at the start of the active phase was assessed.|pre-intervention contraction duration (minute) at the start of the active phase was assessed.|post-intervention contraction duration (minute) at the start of the active phase was assessed.|pre-intervention contraction severity (minute) at the start of the active phase was assessed.|post-intervention contraction severity (minute) at the start of the active phase was assessed.|pre-intervention systolic blood pressure (mmHg) at the start of the transition phase was assessed.|post-intervention systolic blood pressure (mmHg) at the start of the transition phase was assessed.|pre-intervention diastolic blood pressure (mmHg) at the start of the transition phase was assessed.|post-intervention diastolic blood pressure (mmHg) at the start of the transition phase was assessed.|pre-intervention pulse (minute) at the start of the transition phase was assessed.|post-intervention pulse (minute) at the start of the transition phase was assessed.|pre-intervention respiration (minute) at the start of the transition phase was assessed.|post-intervention respiration (minute) at the start of the transition phase was assessed.|pre-intervention fetal heart rate (minute) at the start of the transition phase was assessed.|post-intervention fetal heart rate (minute) at the start of the transition phase was assessed.|pre-intervention contraction frequency (minute) at the start of the transition phase was assessed.|post-intervention contraction frequency (minute) at the start of the transition phase was assessed.|pre-intervention contraction duration (minute) at the start of the transiton phase was assessed.|post-intervention contraction duration (minute) at the start of the transiton phase was assessed.|pre-intervention contraction severity (minute) at the start of the transition phase was assessed.|post-intervention contraction severity (minute) at the start of the transition phase was assessed.","Abant Izzet Baysal University","Female","18 Years to 35 Years   (Adult)","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","İBDH-KDÜ-MB-01","June 21, 2021","December 12, 2021","December 12, 2021","August 10, 2022",,"August 10, 2022","İzzet Baysal State Hospital, Obstetrics and Pediatrics Unit, delivery room service, Bolu, Center, Turkey",,"https://ClinicalTrials.gov/show/NCT05495009"
527,"NCT05494996","Psychometric Properties of the Chinese Version of the Five-item Relationship Satisfaction Scale",,"Not yet recruiting","No Results Available","Relationship, Family","Other: Questionnaires set","Relationship satisfaction","Sun Yat-sen University","All","18 Years and older   (Adult, Older Adult)",,"278","Other","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","wjn-RS5","August 30, 2022","August 30, 2023","October 1, 2023","August 10, 2022",,"August 11, 2022","XIAW, Guangzhou, Guangdong, China",,"https://ClinicalTrials.gov/show/NCT05494996"
528,"NCT05494983","Pain, Sleep and Gut Microbiota",,"Recruiting","No Results Available","Sensitization, Central|Peripheral Sensitization|Gut Microbiota|Sleep Quality","Other: Screening visit|Other: Peripheral sensitization session|Other: Central sensitization session","Correlation between composition of the intestinal microbiota and its metabolites and the susceptibility of sensitization at the peripheral and central levels.|Correlation between sleep quality and the susceptibility of sensitization at the peripheral and central levels.|Correlation between sleep duration and the susceptibility of sensitization at the peripheral and central levels.|Correlation between levels of systemic pro- and anti-inflammatory cytokines measured by multiplex assays and the susceptibility of sensitization at the peripheral and central levels.|Correlation between pupil diameter and the susceptibility of sensitization at the peripheral and central levels.|Correlation between heart rate variability and the susceptibility of sensitization at the peripheral and central levels.","Université Catholique de Louvain","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","140","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Other","PAIN,SLEEP,MICROBIOTA","July 4, 2022","January 4, 2024","January 4, 2026","August 10, 2022",,"August 15, 2022","UCLouvain, IONS, Woluwe-Saint-Lambert, Belgium",,"https://ClinicalTrials.gov/show/NCT05494983"
529,"NCT05494970","Accompaniment of Patients by Dental Assistants in the Evaluation of Oral Hygiene During and After Radiotherapy Treatment.","RadioT HBD","Not yet recruiting","No Results Available","ORL Cancer","Other: Accompaniment by the dental assistant.","Rate of patients with improved oral hygiene between the inclusion visit and 3 months post-radiotherapy.|Patient satisfaction with the oral hygiene information guide and the consultations performed by the dental assistant.|The motivation of the patients towards their oral health.","Institut Claudius Regaud|Ligue contre le cancer, France","All","18 Years and older   (Adult, Older Adult)",,"44","Other","Observational","Observational Model: Other|Time Perspective: Prospective","22VADS03","September 2022","June 2024","June 2024","August 10, 2022",,"August 12, 2022","Institut Universitaire du Cancer Toulouse - Oncopole, Toulouse, France",,"https://ClinicalTrials.gov/show/NCT05494970"
530,"NCT05494957","Clinical Study of New Intensive Treatment Regimen for Severe Nontuberculous Mycobacterial Pulmonary Disease","NTM-PD","Not yet recruiting","No Results Available","Nontuberculous Mycobacterial Lung Disease","Drug: New regimen(BdqCfzLzd+XY)","Treatment Outcome|Improvement rate of imaging","Shanghai Pulmonary Hospital, Shanghai, China|Shanghai Public Health Clinical Center|No.85 Hospital, Changning, Shanghai, China|Anhui Chest Hospital|Shanghai Pudong New Area Pulmonary Hospital, China|Huashan Hospital|Zhengzhou Sixth People's Hospital, China","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","40","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Q20-293","August 5, 2022","August 5, 2024","August 5, 2025","August 10, 2022",,"August 10, 2022","Shanghai Pulmonary Hospital, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT05494957"
531,"NCT05494944","Low Power ThULEP for Prostate Size More Than 80 gm",,"Completed","No Results Available","Benign Prostatic Hyperplasia","Procedure: ThuLEP","Timing of complete adenoma removal ( enucleation time in minutes)|International prostate symptoms score IPSS less than 7 which is good outcome|International Index of Erectile Function- 5 score more than 12 which is a good outcome","Kasr El Aini Hospital","Male","Child, Adult, Older Adult","Not Applicable","40","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Urology department","December 1, 2019","March 30, 2022","March 30, 2022","August 10, 2022",,"August 12, 2022","Samer Morsy, Cairo, Egypt",,"https://ClinicalTrials.gov/show/NCT05494944"
532,"NCT05494931","Effect of Superficial Keratotomy on Reducing Postoperative Pain Fallowing Conjuctival Flap",,"Completed","No Results Available","Reduced Corneal Sensation","Procedure: corneal neurotomy","postoperative pain 6 hours after conjunctival flap|postoperative pain 24 hours after conjunctival flap|postoperative pain 48 hours after conjunctival flap","Iran University of Medical Sciences","All","Child, Adult, Older Adult","Not Applicable","9","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Prevention","IR.IUMS.FMD.REC.1401.021","December 15, 2020","June 5, 2022","August 5, 2022","August 10, 2022",,"August 10, 2022","Eye Research Center, Tehran, Tehrani, Iran, Islamic Republic of",,"https://ClinicalTrials.gov/show/NCT05494931"
533,"NCT05494918","First-In-Human Study in Subjects With Advanced or Metastatic Solid Malignant Tumors",,"Not yet recruiting","No Results Available","Advanced Solid Tumors|Metastatic Solid Tumors","Drug: JSKN003","MTD|Preliminary RDE/RP2D|DLTs|Adverse Events|Cmax of JSKN003|Tmax of JSKN003|AUC of JSKN003|Terminal Elimination Half-life (t1/2)|ORR|TTR|DoR|PFS|Anti-JSKN003 antibody","Alphamab (Australia) Co Pty Ltd.","All","18 Years and older   (Adult, Older Adult)","Phase 1","45","Industry","Interventional","Allocation: N/A|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","JSKN003-101","August 12, 2022","October 30, 2024","December 30, 2024","August 10, 2022",,"August 12, 2022",,,"https://ClinicalTrials.gov/show/NCT05494918"
534,"NCT05494905","Virtual Reality vs Functional Strength Training in Children With Cerebral Palsy",,"Recruiting","No Results Available","Cerebral Palsy","Other: VR|Other: FST","Reaching kinematics at the baseline|Reaching kinematics at the end of the 6th week|Reaching kinematics at the end of the 12th week|Fine motor domain of Peabody Developmental Motor Scales-2nd edition at baseline|Fine motor domain of Peabody Developmental Motor Scales-2nd edition at the end of the 6th week|Fine motor domain of Peabody Developmental Motor Scales-2nd edition at the end of the 12th week|Daily use of affected hand at baseline|Daily use of affected hand at the end of the 6th week|Daily use of affected hand at the end of the 12th week|Muscle strength at baseline|Muscle strength at the end of the 6th week|Muscle strength at the end of the 12th week|Children's motivation and compliance","Georgia State University|Georgia Institute of Technology","All","5 Years to 17 Years   (Child)","Not Applicable","40","Other","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","H21384","February 1, 2017","December 2024","December 2024","August 10, 2022",,"August 10, 2022","Department of Physical Therapy, Georgia State University, Atlanta, Georgia, United States",,"https://ClinicalTrials.gov/show/NCT05494905"
535,"NCT05494892","Development of a Research Agenda for Rehabilitation Research",,"Enrolling by invitation","No Results Available","Research Agenda|Conditions Influencing Health Status",,"Identification of priorities in applied rehabilitation research|Weighting of the identified priorities in research","Pensionsversicherungsanstalt","All","Child, Adult, Older Adult",,"60","Other","Observational","Observational Model: Other|Time Perspective: Other","0004 Masterplan Reha-Forschung","April 1, 2021","December 30, 2022","March 15, 2023","August 10, 2022",,"August 15, 2022","Pensionsversicherungsanstalt, Vienna, Austria",,"https://ClinicalTrials.gov/show/NCT05494892"
536,"NCT05494879","Effectiveness of Microkinesitherapy in Seniors",,"Not yet recruiting","No Results Available","Microkinesitherapy","Behavioral: microkinesitherapy treatment","Change of the Senior Fitness Test|Change of the gait parameters|Change of the quality of life|Change of the mental health","The Opole University of Technology","All","50 Years to 100 Years   (Adult, Older Adult)","Not Applicable","24","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Micro_Poznan","August 17, 2022","August 30, 2022","July 18, 2023","August 10, 2022",,"August 10, 2022","Faculty of Physical Education and Physiotherapy, Opole University of Technology, Opole, Poland",,"https://ClinicalTrials.gov/show/NCT05494879"
537,"NCT05494866","A Trial of Cobicistat and Gemcitabine and Nab-Paclitaxel in Patients With Advanced Stage or Metastatic Pancreatic Ductal Adenocarcinoma","IntenSify","Not yet recruiting","No Results Available","CYP3A Inhibitor|Advanced Stage or Metastatic Pancreatic Ductal Adenocarcinoma","Drug: Cobicistat Oral Tablet","occurrence of DLTs","German Cancer Research Center|University Hospital Heidelberg","All","18 Years and older   (Adult, Older Adult)","Phase 1","18","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NH21","November 1, 2022","August 31, 2024","February 28, 2025","August 10, 2022",,"August 12, 2022","University Hospital Heidelberg, Heidelberg, BW, Germany",,"https://ClinicalTrials.gov/show/NCT05494866"
538,"NCT05494853","Novel Biomarker Assay for Biomarker Assay for HCC Detection","GTH_HCC","Not yet recruiting","No Results Available","Hepato-cellular Carcinoma",,"HCC screening positive","Genetron Health|Piedmont Transplant Institute. 1968 Peachtree Road, NW   77 Building, 6th Floor   Atlanta, GA 30309","All","18 Years and older   (Adult, Older Adult)",,"200","Industry|Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","GTH_HCC2022","December 1, 2022","December 1, 2024","December 1, 2025","August 10, 2022",,"August 10, 2022",,,"https://ClinicalTrials.gov/show/NCT05494853"
539,"NCT05494840","The Effect of Prenatal Haptonomy on Anxiety, Distress and Psychological Well-being",,"Not yet recruiting","No Results Available","First Pregnancy","Behavioral: Haptonomy","Pregnancy-Related Anxiety Questionnaire-Revised-2 (PRAQ-R2)|Tilburg Pregnancy Distress Scale (TPDS)|Psychological well-being scale","Hilal Özbek|Tokat Gaziosmanpasa University","Female","18 Years and older   (Adult, Older Adult)","Not Applicable","90","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Supportive Care","TR TOKAT01","September 1, 2022","September 30, 2022","September 30, 2023","August 10, 2022",,"August 10, 2022","Tokat Gaziosmanpasa University, Tokat, Turkey",,"https://ClinicalTrials.gov/show/NCT05494840"
540,"NCT05494827","The Impact of a Regular Borjomi® Consumption on an Anaerobic Performance",,"Completed","No Results Available","Healthy","Other: Regular consumption of natural mineral water Borjomi® with high bicarbonate content|Other: Regular consumption of processed drinking water Smart Spring®|Other: Regular consumption of still drinking water","Changes of Relative Peak Power (W/kg)|Changes of Fatigue Index (%)|Changes of Acid-Base Balance|Changes of Lactate levels|Changes of Attention stability","Zaynudin Zaynudinov, MD, PhD|LLC IDS Borjomi|Federal State Budgetary Scientific Institution ""Federal Research Centre of Nutrition, Biotechnology","All","18 Years to 45 Years   (Adult)","Not Applicable","51","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science","03/20","July 1, 2020","September 30, 2020","December 31, 2020","August 10, 2022",,"August 10, 2022","Department of Cardiovascular Pathology and Diet Therapy of Nutrition Clinic of The Federal Research Centre of Nutrition, Biotechnology and Food Safety, Moscow, Russian Federation",,"https://ClinicalTrials.gov/show/NCT05494827"
541,"NCT05494814","Sandhills Community Kitchen Evaluation: Using the Veggie Meter",,"Enrolling by invitation","No Results Available","Diet, Healthy","Other: Child Care Centers Served Meals Prepared by Central Kitchen","Change in produce intake","North Carolina State University|Duke University","All","3 Years to 5 Years   (Child)","Not Applicable","650","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","24444","January 1, 2024","January 1, 2026","January 1, 2026","August 10, 2022",,"August 10, 2022","North Carolina State University, Raleigh, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT05494814"
542,"NCT05494801","Natural History, Disease Progression, and Long-Term Neurologic Sequelae of Ebola Virus Disease (EVD) Survivors in PREVAIL III",,"Recruiting","No Results Available","Ebola Virus Disease",,"Neurological Sequelae|Harmonize data","National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC)","All","18 Years and older   (Adult, Older Adult)",,"250","NIH","Observational","Observational Model: Case-Control|Time Perspective: Prospective","10000727|000727-I","August 18, 2022","January 1, 2023","January 1, 2023","August 10, 2022",,"August 15, 2022","John F. Kennedy Medical Center, Monrovia, Liberia",,"https://ClinicalTrials.gov/show/NCT05494801"
543,"NCT05494788","Impact of CardiolRxTM on Recurrent Pericarditis",,"Not yet recruiting","No Results Available","NRS Pain Scores","Drug: CardiolRx","11-point NRS pain score|Normalized CRP levels|CRP change from baseline","Cardiol Therapeutics Inc.","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","25","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Cardiol 100-004","October 2022","June 2024","September 2024","August 10, 2022",,"August 15, 2022",,,"https://ClinicalTrials.gov/show/NCT05494788"
544,"NCT05494775","Effect of Corona Virus on Intravitreal Injections",,"Recruiting","No Results Available","Diabetic Macular Edema|Age-Related Macular Degeneration|Choroidal Neovascularization|Myopic Choroidal Neovascularisation|Diabetic Retinopathy","Drug: Anti-vascular endothelial growth factors (Anti-VEGFs)","Visual acuity|Central subfield thickness","Benha University","All","30 Years to 80 Years   (Adult, Older Adult)","Not Applicable","250","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Rc-11-2022","February 1, 2019","June 11, 2023","July 30, 2023","August 10, 2022",,"August 10, 2022","Ahmed Abdelshafy Tabl, Banhā, Benha, Egypt",,"https://ClinicalTrials.gov/show/NCT05494775"
545,"NCT05494762","Safety, Pharmacokinetics, and Antitumor Activity of BGB-B167 Alone and in Combination With Tislelizumab (BGB-A317) in Participants With Advanced Solid Tumors",,"Not yet recruiting","No Results Available","Solid Tumor","Drug: BGB-B167|Drug: Tislelizumab","Phase 1a: Number of Participants Experiencing Adverse Events (AEs)|Phase 1a: Number of Participants Experiencing Serious Adverse Events (SAEs)|Phase 1a: Number of Participants Experiencing AEs Meeting Protocol-defined Dose-limiting Toxicity (DLT) Criteria|Phase 1a: Maximum tolerated dose (MTD)|Phase 1a: Recommended Phase 2 doses (RP2Ds)|Phase 1b: Objective Response Rate (ORR)|Phase 1a: ORR|Phase 1a and 1b: Duration of Response (DOR)|Phase 1a and 1b: Disease Control Rate (DCR)|Phase 1a and 1b: Clinical Benefit Rate (CBR)|Phase 1b: Progression-free Survival (PFS)|Phase 1a and 1b: Serum Concentration of Tislelizumab|Phase 1a and 1b: Maximum observed serum concentration (Cmax) of BGB-B167|Phase 1a and 1b: Minimum observed serum concentration (Cmin) of BGB-B167|Phase 1a and 1b: Time to reach maximum observed serum concentration (Tmax) of BGB-B167|Phase 1a and 1b: Elimination half life (t1/2) of BGB-B167|Phase 1a and 1b: Area under the concentration-time curve in 1 dosing interval (AUCtau) of BGB-B167|Phase 1a and 1b: Total body clearance (CL) of BGB-B167|Phase 1a and 1b: Volume of distribution at steady state (Vss) of BGB-B167|Phase 1b: Number of Participants with AEs or SAEs|Phase 1a and 1b: Number of Participants with Antidrug Antibodies (ADAs)","BeiGene","All","18 Years and older   (Adult, Older Adult)","Phase 1","254","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BGB-A317-B167-101","August 2022","February 5, 2025","August 5, 2025","August 10, 2022",,"August 10, 2022","City of Hope National Medical Center, Duarte, California, United States|Tennessee Oncology, Nashville, Tennessee, United States|Blacktown Hospital, Blacktown, New South Wales, Australia|Ashford Cancer Centre Research, Kurralta Park, South Australia, Australia|Monash Health, Clayton, Victoria, Australia|Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia|Alfred Hospital, Melbourne, Victoria, Australia",,"https://ClinicalTrials.gov/show/NCT05494762"
546,"NCT05494749","Zirconia Reinforced Glass Ionomer in MIH",,"Recruiting","No Results Available","Molar Incisor Hypomineralization","Other: zirconomer|Other: HVGI-Equia Forte","Change in clinical success rate|Change in pain|Change in sensitivity|Finite element analysis","Hams Hamed Abdelrahman|Alexandria University","All","7 Years to 10 Years   (Child)","Not Applicable","88","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","MIH_2022","December 15, 2021","January 1, 2023","January 30, 2023","August 10, 2022",,"August 15, 2022","Alexandria Faculty of Dentistry, Alexandria, Egypt",,"https://ClinicalTrials.gov/show/NCT05494749"
547,"NCT05494736","MK-8527 Single-Dose Trial in HIV-1 Infected Participants (MK-8527-004)",,"Not yet recruiting","No Results Available","Human Immunodeficiency Virus","Drug: MK-8527","Change from baseline in plasma HIV-1 ribonucleic acid (RNA)|Number of participants experiencing ≥1 adverse event (AE)|Number of participants discontinuing from study due to an AE|Area Under the Concentration-Time Curve from Predose to 168 hours postdose (AUC0-168) of MK-8527 Triphosphate (MK-8527-TP) in Peripheral Blood Mononuclear Cells (PBMCs)|Area Under the Concentration-Time Curve from Predose to Last Measurable Concentration (AUC0-last) of MK-8527-TP in PBMCs|Area Under the Concentration-Time Curve from Predose to Infinity (AUC0-inf) of MK-8527-TP in PBMCs|Time to Maximum Concentration (Tmax) of MK-8527-TP in PBMCs|Maximum Concentration (Cmax) of MK-8527-TP in PBMCs|Concentration at 168 Hours Postdose (C168) of MK-8527-TP in PBMCs|Apparent terminal half-life (t½) of MK-8527-TP in PBMCs|AUC0-last of MK-8527 in Plasma|AUC0-inf of MK-8527 in Plasma|Tmax of MK-8527 in Plasma|Cmax of MK-8527 in Plasma|Clast of MK-8527 in Plasma|Apparent t½ of MK-8527 in Plasma|Correlation Between Intracellular C168 of MK-8527-TP in PBMCs and Change from Baseline in Plasma HIV-1 RNA","Merck Sharp & Dohme LLC","All","18 Years to 60 Years   (Adult)","Phase 1","20","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","8527-004|MK-8527-004","September 23, 2022","February 13, 2023","February 13, 2023","August 10, 2022",,"August 10, 2022",,,"https://ClinicalTrials.gov/show/NCT05494736"
548,"NCT05494723","Safety and Efficacy of YB-1113 in Treatment of POI",,"Not yet recruiting","No Results Available","POI","Drug: YB-1113","Incidence of treatment-emergent adverse events (AE)|Blood anti-Müllerian hormone (AMH) level|Day 3 follicle stimulating hormone (FSH) and estradiol (E2) levels|Antral follicle counts (AFC)","YB Life Science, LLC","Female","18 Years to 40 Years   (Adult)","Phase 1|Phase 2","6","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","YB1113-POI","January 9, 2023","July 9, 2024","August 30, 2024","August 10, 2022",,"August 10, 2022",,,"https://ClinicalTrials.gov/show/NCT05494723"
549,"NCT05494710","Bleomycin Electrosclerotherapy Treatment of Vascular Malformations: A Feasibility Study","BEST","Recruiting","No Results Available","Vascular Malformations","Other: Bleomycin electrosclerotherapy treatment","Change in Quality of life questionnaire scores between baseline and 6-8 weeks of treatment|Clinician assessment tool of treatment response|To collect documented side effects following electrosclerotherapy treatment.","South Tees Hospitals NHS Foundation Trust|Teesside University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","248206","December 1, 2020","December 1, 2022","December 1, 2022","August 10, 2022",,"August 10, 2022","South Tees Hospitals NHS Foundation Trust, Middlesbrough, United Kingdom",,"https://ClinicalTrials.gov/show/NCT05494710"
550,"NCT05494697","Ampligen Compared to No Treatment Following FOLFIRINOX in Subjects With Locally Advanced Pancreatic Adenocarcinoma",,"Not yet recruiting","No Results Available","Pancreatic Cancer","Drug: Rintatolimod","Progression Free Survival (PFS)|Overall Survival (OS)|Objective Response Rate (ORR)|Duration of Response (DoR)","AIM ImmunoTech Inc.|Amarex Clinical Research","All","18 Years and older   (Adult, Older Adult)","Phase 2","90","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AMP-270","September 2022","November 2026","January 2027","August 10, 2022",,"August 10, 2022",,,"https://ClinicalTrials.gov/show/NCT05494697"
551,"NCT05494684","Effectiveness of Multisensoral Nature-based Intervention in Hospitalized Children During Venous Blood Sampling",,"Not yet recruiting","No Results Available","Anxiety|Fear|Pain|Satisfaction","Other: Multisensoral Nature-based Intervention","Anxiety measured with mYPAS (the modifield Yale preoperative anxiety scale), change is being assessed. An external observer assesses the child's anxiety on video.|Fear measured with CFS (Children Fear Scale), change is being assessed. Child an parent assessment of fear.|Pain measured with FAS (Facial Affective Scale). Child and parent assessment of pain after blood sampling.|Parent's anxiety with STAI-Y1 (The State-Trait Anxiety Inventory), change is being assessed. Parent self-assessment of own anxiety.|Parent's satisfaction with VAS (A Visual Analogue Scale). Parent self-assessment of own satisfaction after blood sampling.|Child's anxiety, fear and pain with physiological measures: Heart Rate (HR, beats per minute), change is being assessed. Principal investigator measures values.|Child's anxiety, fear and pain with physiological measures: Oxygen saturation (02), change is being assessed. Principal investigator measures values.","University of Oulu","All","5 Years to 9 Years   (Child)","Not Applicable","53","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","08072402","September 1, 2023","December 31, 2024","May 31, 2025","August 10, 2022",,"August 15, 2022","Oulu Univeristy, Oulu, Finland",,"https://ClinicalTrials.gov/show/NCT05494684"
552,"NCT05494671","Studying Corneal Epithelial Stability Following Limbal Stem Cell Transplantation in Cases of Limbal Stem Cell Deficiency",,"Recruiting","No Results Available","Stem Cell Transplantation","Procedure: conjunctival limbal autologous transplant","the change of corneal epithelial thickness after stem cell transplantation over 9 months","Cairo University","All","15 Years to 70 Years   (Child, Adult, Older Adult)","Not Applicable","12","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","N-14-2022","January 1, 2022","October 2022","November 2022","August 10, 2022",,"August 11, 2022","Kasr Alainy, Cairo, Egypt",,"https://ClinicalTrials.gov/show/NCT05494671"
553,"NCT05494658","An Randomized Controlled Study (RCT) About the Effect of Preoperative Administration of Branched-chain Amino Acids (BCAA) on Postoperative Insulin Resistance in Colorectal Cancer (CRC) Patients",,"Not yet recruiting","No Results Available","Insulin Resistance|Colorectal Cancer","Dietary Supplement: BCAA|Dietary Supplement: water","The proportion of postoperative blood glucose>8mmol/L|Postoperative blood glucose|Homeostasis model assessment - insulin resistance （HOMA-IR）|Postoperative complications|Postoperative hospital stay","Shanghai Tong Ren Hospital","All","50 Years to 80 Years   (Adult, Older Adult)","Not Applicable","224","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2022-050-01","August 10, 2022","January 31, 2024","March 2, 2024","August 10, 2022",,"August 10, 2022",,,"https://ClinicalTrials.gov/show/NCT05494658"
554,"NCT05494645","Exparel Use in Peripheral Nerve Blocks and Local Infiltration for Foot and Ankle Surgery: A Randomized Controlled Trial",,"Recruiting","No Results Available","Pain, Postoperative|Pain, Acute Postoperative|Ankle Fractures|Ankle Injuries and Disorders","Drug: Exparel|Drug: Peripheral Nerve Block","Duration of block|number of opioid pills used by postoperative day # 4|PROMIS Scores|oral morphine equivalent use by postoperative day 4","St. Luke's Hospital, Pennsylvania","All","18 Years and older   (Adult, Older Adult)","Phase 4","300","Other","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","SLRI-2022-24","June 1, 2022","June 1, 2023","December 31, 2023","August 10, 2022",,"August 10, 2022","St. Luke's University Health Network, Bethlehem, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT05494645"
555,"NCT05494632","Interaural Mismatch in SSD CI Users",,"Recruiting","No Results Available","To Improve Speech Understanding in Noise and Localization in SSD-CI Recipients","Device: Treatment-modifications to CI speech processor program","Speech understanding in noise","Washington University School of Medicine|Cochlear","All","18 Years and older   (Adult, Older Adult)","Not Applicable","50","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","202206085","August 8, 2022","August 8, 2024","February 8, 2025","August 10, 2022",,"August 10, 2022","Washington University School of Medicine, Saint Louis, Missouri, United States",,"https://ClinicalTrials.gov/show/NCT05494632"
556,"NCT05494619","A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Crovalimab in Participants With Guillain-Barré Syndrome (GBS)",,"Not yet recruiting","No Results Available","Guillain-Barré Syndrome","Drug: Crovalimab|Drug: Placebo|Drug: Intravenous immunoglobulin therapy","Percentage of Participants who Reach Hughes Functional Grade (FG) Score ≤ 1 on the Guillain-Barré Syndrome Disability Scale (GBS-DS) at Week 24|Time to Recover Independent Walking Assessed Using the 10-Meter Walk Test (10-MW)|Functional Outcome on GBS-DS at Week 8|Percentage of Inflammatory Rasch-Built Overall Disability Scale (I-RODS) Responders at Week 24|Mean Post-Recovery Time|Duration of Ventilator Support|Percentage of Participants with Treatment Emergent Adverse Events|Percentage of Participants with Treatment Emergent Adverse Events Leading to Study Drug Discontinuation|Percentage of Participants with Anti-Drug Antibodies to Crovalimab|Serum Concentrations of Crovalimab","Hoffmann-La Roche|Chugai Pharmaceutical Co., Ltd. (Sponsor in Taiwan and Japan)","All","18 Years and older   (Adult, Older Adult)","Phase 3","154","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","BN43118|2021-002968-49","October 5, 2022","March 19, 2026","September 30, 2026","August 10, 2022",,"August 10, 2022",,,"https://ClinicalTrials.gov/show/NCT05494619"
557,"NCT05494606","An Observational Study to Assess Change in Disease Activity and Adverse Events of Upadacitinib in Adult Participants With Moderate to Severe Ulcerative Colitis (UC) in Real-World Practice","PROFUNDUS","Recruiting","No Results Available","Ulcerative Colitis",,"Median Time to Achieve the First Clinical Response (CR) per Partial Adapted Mayo Score|Percentage of Participants Achieving Clinical Response (CR) per Partial Adapted Mayo Score Among those who Achieved CR at Completion of Upadacitinib Induction (either at Week 8 or at Week 16)","AbbVie","All","18 Years to 75 Years   (Adult, Older Adult)",,"1000","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","P22-921","August 9, 2022","June 30, 2027","September 30, 2027","August 10, 2022",,"August 15, 2022","Hospital Britanico de Buenos Aires /ID# 249605, Ciudad Autonoma de Buenos Aire, Ciuadad Autonoma De Buenos Aires, Argentina|Blacktown Hospital /ID# 248354, Blacktown, New South Wales, Australia|Nepean Hospital /ID# 248351, Kingswood, New South Wales, Australia|Coral Sea Clinical Research institute /ID# 248352, North Mackay, Queensland, Australia|Austin Health /ID# 249133, Heidelberg, Victoria, Australia|The Royal Melbourne Hospital /ID# 248353, Parkville, Victoria, Australia|Dr. Heil /ID# 248273, Andernach, Germany|Krankenhaus Waldfriede /ID# 248307, Berlin-Zehlendorf, Germany|Praxis Dr. Michael Mross /ID# 248272, Berlin, Germany|Gastro Campus Research GbR /ID# 249867, Muenster, Germany|Bettenworth & Partner /ID# 248977, Münster, Germany|Krai Clinical Hospital /ID# 249238, Krasnoyarsk, Russian Federation|National Medical Research Center of Coloproctology n.a. A. N. Ryzhikh /ID# 249239, Moscow, Russian Federation|City Clinical Hospital No. 31 /ID# 249159, St. Petersburg, Russian Federation",,"https://ClinicalTrials.gov/show/NCT05494606"
558,"NCT05494593","A Study of ELAPRASE in Treatment-naïve Participants With Hunter Syndrome (Mucopolysaccharidosis [MPS] II)",,"Not yet recruiting","No Results Available","Mucopolysaccharidosis (MPS)|Hunter Syndrome","Drug: ELAPRASE|Drug: Rituximab|Drug: Methotrexate|Drug: Intravenous Immunoglobulin (IVIG)","Rate of Anti-Idursulfase Antibodies Formation, Including Anti-Idursulfase Antibodies That Have Enzyme Neutralizing Activity|Correlation Between Anti-drug Antibody (ADA) Responses and Iduronate-2-Sulfatase (IDS) Gene Mutations and Clinical Outcomes|Change From Baseline in Urinary Glycosaminoglycan (uGAG) Levels Normalized to Urine Creatinine|Change From Baseline in Normalized uGAG per Upper Limit of Normal for age (uGAG)/ULN)|Change From Baseline in Liver Volume","Takeda|Takeda Development Center Americas, Inc.","Male","up to 6 Years   (Child)","Phase 4","5","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TAK-665-4003","December 9, 2022","September 9, 2026","September 9, 2026","August 10, 2022",,"August 10, 2022",,,"https://ClinicalTrials.gov/show/NCT05494593"
559,"NCT05494580","Pamiparib Plus Surufatinib in Patients With Platinum-resistant Ovarian Cancer",,"Not yet recruiting","No Results Available","Ovarian Cancer|Ovarian Carcinoma|Platinum-resistant Ovarian Cancer|Fallopian Tube Carcinosarcoma|Primary Peritoneal Cancer","Drug: Pamiparib|Drug: Surufatinib","Maximum tolerated dose (MTD) (Phase Ib)|Recommended Phase 2 dose (RP2D) (Phase Ib)|Response Rate (ORR) (Phase II)|Progression-free Survival (PFS)|Disease Control Rate (DCR)|Duration of response (DOR)|Overall survival (OS)|Safety and tolerability|Patient Reported Outcomes (PROs)","Sun Yat-sen University|HUTCHMED","Female","18 Years to 75 Years   (Adult, Older Adult)","Phase 1|Phase 2","38","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","B2022-348-01","August 10, 2022","August 10, 2024","August 10, 2025","August 10, 2022",,"August 10, 2022",,,"https://ClinicalTrials.gov/show/NCT05494580"
560,"NCT05494567","Efficacy of Tadalafil/Solifenacin VS Tamsulosin/Solifenacin Combination Therapy for BPH/OAB",,"Active, not recruiting","No Results Available","Benign Prostatic Hyperplasia|Overactive Bladder","Drug: Tadalafil 5mg|Drug: Tamsulosin Hcl 0.4 mg|Drug: solifenacin 10 mg","Change in international prostate symptom score (IPSS) from baseline|Change in overactive bladder symptom score (OABSS) from baseline|Change in IPSS-quality of life (QoL) score from baseline|Change in ultrasound measurement of post-void residual urine (PVR) from baseline|Change in maximum flow rate (Qmax) from baseline|Adverse effects|change in international index of erectile function-15 (IIEF-15)|change in ejaculatory domain of male sexual health questionnaire (Ej-MSHQ)","Mansoura University","Male","45 Years and older   (Adult, Older Adult)","Phase 4","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","Tadalafil for BPH/OAB","November 8, 2021","August 2022","August 2022","August 10, 2022",,"August 10, 2022","Urology and Nephrology center, Mansoura, Egypt",,"https://ClinicalTrials.gov/show/NCT05494567"
561,"NCT05494554","Comparison of Mechanical Power Calculations of Volume Control and Pressure Control Modes",,"Completed","No Results Available","Ventilator-Induced Lung Injury","Device: Changing mechanical ventilation mode","Mechanical power values of different ventilation modes","Bakirkoy Dr. Sadi Konuk Research and Training Hospital","All","18 Years and older   (Adult, Older Adult)",,"36","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2019-02-23","January 1, 2020","December 27, 2021","January 22, 2022","August 10, 2022",,"August 10, 2022","Bakirkoy Dr. Sadi Konuk Research and Training Hospital, Istanbul, Turkey",,"https://ClinicalTrials.gov/show/NCT05494554"
562,"NCT05494541","Characteristics of Patients With Sickle Cell Disease",,"Completed","No Results Available","Sickle Cell Disease","Other: Crizanlizumab","Age|Number of patients: Gender|Number of patients: Geographic region|Number of patients: Insurance type|Number of patients by Charlson Comorbidity Index (CCI) score category|Number of patients by comorbidity|Number of patients with history of additional SCD-related comorbidities associated with organ damage|Number of patients : History of hydroxyurea use|Number of patients : History of L-glutamine use|Number of patients : History of Voxelotor use|Number of patients : SCD genotype|Proportion of patients with claims for hydroxyurea while on crizanlizumab therapy|Number of hydroxyurea claims|Proportion of patients with claims for L-glutamine while on crizanlizumab therapy|Number of L-glutamine claims|Proportion of patients with claims for voxelotor while on crizanlizumab therapy|Number of voxelotor claims","Novartis Pharmaceuticals|Novartis","All","16 Years to 99 Years   (Child, Adult, Older Adult)",,"540","Industry","Observational","Observational Model: Cohort|Time Perspective: Retrospective","CSEG101AUS17","August 30, 2021","October 27, 2021","October 27, 2021","August 10, 2022",,"August 10, 2022","Novartis Investigative Site, East Hanover, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT05494541"
563,"NCT05494528","Comparing P1101 to Entecavir in Patients With HBeAg(-) Hepatitis B Under Long-term Nucleos(t)Ide Analogue Therapy",,"Recruiting","No Results Available","Chronic Hepatitis B Virus Infection","Drug: Ropeginterferon alfa-2b|Drug: Entecavir","Undetectable HBsAg|HBsAg level|HBsAg and anti-HBs level|Reappearance of HBsAg|HBV DNA level|HBV DNA and ALT level|Sustained suppression of HBV DNA|HBeAg and anti-HBe level","National Taiwan University Hospital|PharmaEssentia","All","20 Years to 75 Years   (Adult, Older Adult)","Not Applicable","90","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","202003098MIPD","May 4, 2021","December 30, 2023","December 30, 2024","August 10, 2022",,"August 10, 2022","Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, Taiwan|China Medical University Hospital, Taichung, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|Taipei Medical University Hospital, Taipei, Taiwan|Taipei Veterans General Hospital, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT05494528"
564,"NCT05494515","Enhancing Early Swallowing Recovery in Older Dysphagic Patients Afetr Anterior Cervical Spine Surgery",,"Not yet recruiting","No Results Available","Hypopharyngeal Pressure Changes Between Before and After Swallowing Rehabiliation","Procedure: the early swallowing rehabilitation program","The difference in pre-and postoperative hypopharyngeal pressure","National Taiwan University Hospital","All","60 Years to 80 Years   (Adult, Older Adult)","Not Applicable","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Other","202206073RINB","August 22, 2022","August 22, 2027","August 22, 2028","August 10, 2022",,"August 12, 2022",,,"https://ClinicalTrials.gov/show/NCT05494515"
565,"NCT05494502","Impact of Erector Spinae Plane Block on Chronic Postsurgical Pain in Breast Cancer Patients",,"Not yet recruiting","No Results Available","Breast Neoplasms|Mastectomy|Nerve Block|Dexmedetomidine|Pain, Postoperative|Chronic Pain|Prognosis","Procedure: Erector spinae plane block|Procedure: Control group","Incidence of chronic postsurgical pain (CPSP) at 6 months after surgery|Progression-free survival (long-term outcomes)|Incidence of chronic postsurgical pain (CPSP) at 3 and 12 months after surgery|Incidence of neuropathic pain at 3, 6, and 12 months after surgery|Overall survival (long-term outcome)|Event-free survival (long-term outcome)|Quality of life (long-term outcome)","Peking University First Hospital|Peking University Cancer Hospital & Institute","All","18 Years to 85 Years   (Adult, Older Adult)","Not Applicable","1206","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Prevention","2022-191","August 2022","January 2024","July 2027","August 10, 2022",,"August 12, 2022","Peking University First Hospital, Beijing, Beijing, China|Beijing Cancer Hospital, Beijing, Beijing, China",,"https://ClinicalTrials.gov/show/NCT05494502"
566,"NCT05494489","Assistive Soft Robotic Glove (EsoGLOVE) Intervention for Stroke Patients",,"Not yet recruiting","No Results Available","Stroke","Device: EsoGLOVE with Trigno Biofeedback (EMG sensors)","Fugl-Meyer Upper Extremity Scale (FML-UE)|Stroke Impact Scale (SIS)|Duruoz Hand Index|Stroke Upper Limb Capacity Scale (SULCS)|Out-of-Pocket Spending Questionnaire","National University Hospital, Singapore","All","30 Years to 90 Years   (Adult, Older Adult)","Not Applicable","130","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","2020/01105","August 15, 2022","June 29, 2023","June 29, 2023","August 10, 2022",,"August 10, 2022",,,"https://ClinicalTrials.gov/show/NCT05494489"
567,"NCT05494476","Stability of the Marginal Bone Around Subcrestal Implants",,"Completed","No Results Available","Alveolar Bone Loss|Dental Implant Failure Nos","Procedure: implant insertion","marginal bone loss","International Piezosurgery Academy|University of Trieste","All","20 Years and older   (Adult, Older Adult)","Not Applicable","22","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention","MEGADEPTH","October 23, 2020","December 15, 2021","July 15, 2022","August 10, 2022",,"August 10, 2022","Dr. Claudio Stacchi Office, Gorizia, Friuli Venezia Giulia, Italy",,"https://ClinicalTrials.gov/show/NCT05494476"
568,"NCT05494463","Miller Blade for Intubation in Adults",,"Recruiting","No Results Available","Intubation Complication","Device: Miller blade","Evaluation of view of entrance to larynx comparing Miller and Macinthosh blade in adults","Medical University of Lodz","All","18 Years to 90 Years   (Adult, Older Adult)","Not Applicable","1000","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","RNN/103/22/KE","May 20, 2022","December 1, 2022","February 1, 2023","August 10, 2022",,"August 10, 2022","Medical University of Lodz, Poland, Łódź, Poland",,"https://ClinicalTrials.gov/show/NCT05494463"
569,"NCT05494450","An Open, Non-comparative, Multicenter Investigation to Evaluate the Safety and Performance of Exufiber Ag+, a Gelling Fiber Silver Dressing, When Used in Medium to High Exuding Chronic Wounds",,"Recruiting","No Results Available","Pressure Ulcer|Diabetic Foot Ulcer|Venous Leg Ulcer","Device: ExufiberAG+","evaluate the safety and performance of Exufiber Ag+ in medium to high exuding chronic wounds","Molnlycke Health Care AB","All","18 Years and older   (Adult, Older Adult)","Not Applicable","102","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ExufiberAg+02","January 1, 2022","December 31, 2022","May 31, 2023","August 10, 2022",,"August 10, 2022","Center for Clinical Research, San Francisco, California, United States|Sycamore Wound Care and Hyperbaric Center, Miamisburg, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT05494450"
570,"NCT05494437","Effect of PP-01 on Cannabis Withdrawal Syndrome",,"Not yet recruiting","No Results Available","Cannabis Withdrawal","Combination Product: PP-01 High Dose|Combination Product: PP-01 Low Dose|Drug: Placebo|Drug: Nabilone|Drug: Gabapentin","Evaluation of a patient reported outcome measure of cannabis withdrawal over 5 days","PleoPharma, Inc.","All","18 Years to 55 Years   (Adult)","Phase 2","225","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CAN-002","August 2022","September 2023","September 2023","August 10, 2022",,"August 12, 2022",,,"https://ClinicalTrials.gov/show/NCT05494437"
571,"NCT05494424","Cognitive Rehabilitation in Post-COVID-19 Condition","TRAINCOVID","Not yet recruiting","No Results Available","COVID-19","Behavioral: Goal Management Training (GMT)","The Metacognition Index from the Behavior Rating Inventory of Executive Function - Adult Version (BRIEF-A)|The Behaviour regulation Index from Behavior Rating Inventory of Executive Function - Adult Version (BRIEF-A)|Cambridge Neuropsychological Test Automated Battery (CANTAB), subtests: the Stop Signal Task, Spatial Working Memory, Intra-Extra Dimensional Set Shift and Rapid Visual Information Processing|The Hospital Anxiety and Depression Scale|The Generalized Self-Efficacy Scale|Fatigue Severity Scale|The Perceived Deficits Questionnaire|Everyday Memory Questionnaire|RAND 36-Item Short Form Health Survey (RAND-36)|EuroQol five-dimension scale questionnaire (EQ-5D)","Lovisenberg Diakonale Hospital|University of Oslo|Icahn School of Medicine at Mount Sinai|University of Toronto|UiT The Arctic University of Norway|Oslo University Hospital","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","240","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","Traincovid","January 2023","July 2024","January 2029","August 10, 2022",,"August 12, 2022",,,"https://ClinicalTrials.gov/show/NCT05494424"
572,"NCT05494411","Named Patient Program for Mitomycin for Pyelocalyceal Solution",,"Available","No Results Available","Urothelial Cancer of Renal Pelvis|Urothelial Carcinoma of the Renal Pelvis and Ureter|Urothelial Carcinoma Ureter|Urothelial Carcinoma Ureter Recurrent|Urothelial Carcinoma|Urothelial Carcinoma Recurrent","Drug: Mitomycin for pyelocalyceal solution",,"UroGen Pharma Ltd.|Tanner Pharma Group","All","18 Years and older   (Adult, Older Adult)",,,"Industry|Other","Expanded Access:Individual Patients",,"UT003",,,,"August 10, 2022",,"August 10, 2022",,,"https://ClinicalTrials.gov/show/NCT05494411"
573,"NCT05494398","Targeting the Neurobiology of Restricted and Repetitive Behaviors in Children With Autism Using N-acetylcysteine: Open Label",,"Not yet recruiting","No Results Available","Autism Spectrum Disorder","Drug: N-acetylcysteine","Change in glutamatergic neurometabolites (Glx) measured by proton spectroscopy Magnetic Resonance Imaging (MRI)|Change in restricted and repetitive behaviors as measured by Children's Yale Brown Obsessive Compulsive Scale - Autism Spectrum Disorder (CYBOCS-ASD)|Change in Gamma band amplitude and synchronization measured by electroencephalography (EEG)|Change in restricted repetitive behavior subtypes as measured by the Restricted Behavior Scale - Revised (RBS-R)","Stanford University|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","3 Years to 12 Years   (Child)","Phase 2|Phase 3","48","Other|NIH","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB-64292","September 2022","September 2027","September 2028","August 10, 2022",,"August 10, 2022",,,"https://ClinicalTrials.gov/show/NCT05494398"
574,"NCT05494385","Effect of Perioperative Gabapentin on Postoperative Opioid Requirements",,"Recruiting","No Results Available","Postoperative Pain","Drug: Preoperative Gabapentin/Postoperative Placebo|Drug: Preoperative Gabapentin/Postoperative Gabapentin","Opioid Prescription at Discharge|Opioid Refill Requests|Inpatient Pain Scores|Inpatient Morphine Milligram Equivalents|Length of Stay|Nausea|Sedation","Indiana University","Female","18 Years and older   (Adult, Older Adult)","Phase 4","130","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","OBGYN-IIR-PERI-OP-GABAPENTIN","July 27, 2021","May 2023","June 2023","August 10, 2022",,"August 10, 2022","Indiana University School of Medicine, Indianapolis, Indiana, United States",,"https://ClinicalTrials.gov/show/NCT05494385"
575,"NCT05494372","Assessment of Intraoperative Nursing Safety Precautions for Open Heart Surgery Patients on Cardiopulmonary Bypass Machine",,"Recruiting","No Results Available","Nursing Safety on Cardiopulmonary Bypass","Other: safety precautions","assessment of nursing safety precautions for cardiac surgery patients on cardiopulmonary bypass machine","Assiut University","All","18 Years to 60 Years   (Adult)",,"60","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","Nursing safety on CBP","September 4, 2021","September 10, 2022","October 15, 2022","August 10, 2022",,"August 11, 2022","Faculty of Nursing, Assiut, Egypt",,"https://ClinicalTrials.gov/show/NCT05494372"
576,"NCT05494359","The Diagnostic Value of Nitrogen Element (N) in Esophagus Cancer","N","Not yet recruiting","No Results Available","Esophageal Cancer","Diagnostic Test: The nitrogen isotope","15 Nitrogen/14 Nitrogen (15 N/14 N),28 N/14 N, 29 N/14 N,30 N/14 N, 28 N/ 15 N , 29 N/15 N,30 N/15 N, 29 N/28 N,30 N/18 N,30 N/29 N ratio|The number of 15 Nitrogen, 14 Nitrogen, 28 Nitrogen, 29 Nitrogen, 30 Nitrogen|The differentiation type of the tumor|The stage of the cancer","Hepatopancreatobiliary Surgery Institute of Gansu Province","All","18 Years to 80 Years   (Adult, Older Adult)",,"120","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","Nitrogen element","August 18, 2022","December 1, 2023","December 1, 2023","August 10, 2022",,"August 11, 2022","Hepatopancreatobiliary Surgery Institute of Gansu Province, Lanzhou, Gansu, China|Wuwei Tumor Hospital, Wuwei, Gansu, China|Clinical Research Centre, The Seventh Affiliated Hospital, Shenzhen, Guangdong, China",,"https://ClinicalTrials.gov/show/NCT05494359"
577,"NCT05494346","Safety and Performance Assessment of the Decongestant Seawater Spray Pocket Valve Enriched With Essential Oils in Patients With Acute Rhinitis Associated With Nasal Obstruction","DEVALPO","Not yet recruiting","No Results Available","Acute Rhinitis|Nasal Obstruction|Rhinosinusitis|Rhinopharyngitis|Allergic Rhinitis","Device: Measurement of peak nasal flow.","Performance of the Gilbert Laboratories pocket valve spray.|Change of nasal obstruction between Day 0 and Day 3|Immediate change of nasale obstruction at D0 on first use (Arm A)|Subjective feeling of reduced nasal obstruction on each day of use (arms A+B).|Subjective feeling of nasal cavity cleansing (freshness) each day of use (arms A+B).|Subjective feeling of nasal secretion thinning on each day of use (arms A+B).|Subjective feeling of relief of nasal irritation (mucous membrane) on each day of use (arms A+B).|Subjective feeling of relief of nasal itching on each day of use (arms A+B).|Speed of action at which the patient feels (subjectively) a decrease in nasal obstruction at D0 and D3 (arms A+B).|Speed of action at which the patient feels (subjectively) a purification of his nasal cavities (sensation of freshness) at D0 and D3 (arms A+B).|Improvement in the patient's quality of life after 7 days of use (arms A+B).|Patient satisfaction with the medical device after 7 days of use (arm A+B).|Facility of use of the medical device after 7 days of use (arm A+B)|Evolution of the overall severity of symptoms (arm A+B).|All adverse events reported by patients using the pocket valve spray after 7 days of use (arm A+B).|Sensations of tingling and transient irritation (arms A+B).","Laboratoires Gilbert|EVAMED","All","12 Years and older   (Child, Adult, Older Adult)","Not Applicable","101","Industry|Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","DEVALPO","September 1, 2022","November 30, 2022","December 7, 2022","August 9, 2022",,"August 9, 2022",,,"https://ClinicalTrials.gov/show/NCT05494346"
578,"NCT05494333","Correlation Between Pulmonary Functions and Physical Fitness in Children With β-thalassemia",,"Recruiting","No Results Available","β-Thalassemia|Pulmonary Function|Physical Fitness","Other: no intervention","assessment of pulmonary functions by spirometer|physical fitness|cardiorespiratory fitness","Cairo University","All","6 Years to 12 Years   (Child)",,"40","Other","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","P.T.REC\012\003478","August 1, 2022","October 1, 2022","December 1, 2022","August 9, 2022",,"August 9, 2022","Esraa Elsayed, Cairo, Egypt",,"https://ClinicalTrials.gov/show/NCT05494333"
579,"NCT05494320","the Effect of ABCC2 Genetic Polymorphism on Neurotoxicity in Gastrointestinal Cancer Patients Receiving Oxaliplatin",,"Recruiting","No Results Available","Gastrointestinal Cancer","Drug: Folfox Protocol","neurotoxicity","Ain Shams University","All","18 Years and older   (Adult, Older Adult)",,"120","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","279","August 15, 2021","August 5, 2022","December 31, 2022","August 9, 2022",,"August 9, 2022","Ain shams university, Cairo, Abassia, Egypt",,"https://ClinicalTrials.gov/show/NCT05494320"
580,"NCT05494307","The Combination of Terbutaline and Danazol as the Treatment of Corticosteroid-resistant/Relapse Immune Thrombocytopenia",,"Not yet recruiting","No Results Available","Immune Thrombocytopenia","Drug: Terbutaline|Drug: Danazol","Overall response|Sustained response|Complete response|Remission|Time to response|Duration of response|Rescue therapy|Associated factors of treatment failure, OR, SR and remission|Number of patients with bleeding|Number of patients with side effects|Relapse|Relapse-free survival","Peking University People's Hospital","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2","228","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","PKU-ITP039","September 1, 2022","September 1, 2023","February 28, 2024","August 9, 2022",,"August 9, 2022",,,"https://ClinicalTrials.gov/show/NCT05494307"
581,"NCT05494294","Comparison of Different De-epithelialization Techniques of Soft Tissue Grafts.",,"Completed","No Results Available","Connective Tissue Graft Harvesting","Procedure: Intraorally de-epithelialization|Procedure: Extraorally de-epithelialization","Recession reduction|amount of deciduous cells|percentage of deciduous cells|Recession Depth (RD)|Keratinized Tissue Height (KTH)|Gingival Thickness (GT)|Recession width (RW)|Probing pocket depth (PD)|Clinical attachment level (CAL)|Keratinized tissue change (KTC)|Wound healing index (WHI)|Tissue appearance (TA)|Dentine hypersensitivity (DH)|Aesthetics (A)|Vestibuler Depth","Hacettepe University","All","18 Years to 60 Years   (Adult)","Not Applicable","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","quality of graft","July 4, 2021","July 30, 2022","August 5, 2022","August 9, 2022",,"August 11, 2022","Hacettepe University, Ankara, Turkey",,"https://ClinicalTrials.gov/show/NCT05494294"
582,"NCT05494281","Serratus Anterior Plane Block to Prevent Chronic Postoperative Pan in Breast Cancer","USB22","Recruiting","No Results Available","Breast Neoplasms|Pain, Postoperative|Pain, Chronic|Post-Mastectomy Chronic Pain Syndrome","Procedure: Serratus Anterior Plane Block with local anesthetic|Procedure: Serratus Anterior Plane Block with saline solution","Chronic postoperative pain at 3 months|chronic postoperative pain intensity|Chronic Pain intensity and quality|Neuropathic pain screening|Morphine consumption","Moroccan Society of Surgery","Female","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","94","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","USB_22 Trial","August 1, 2022","February 1, 2023","July 31, 2023","August 9, 2022",,"August 9, 2022","Anesthesia & Critical care department - National Institut of Oncology in Rabat. Ibn Sina teaching Hospital. Mohammed V university of Rabat, Rabat, Morocco",,"https://ClinicalTrials.gov/show/NCT05494281"
583,"NCT05494268","Effects of Preoperative Oral Carbohydrate Loading on Maternal Thiol-disulfide Homeostasis",,"Not yet recruiting","No Results Available","Thiol Disulfide Homeostasis After Carbohydrate Drink","Drug: Carbohydrate","The comparison of the changes in thiol disulfide values between the groups|Incidence of intraoperative hypotension|Total ephedrine usage","Karamanoğlu Mehmetbey University","Female","18 Years to 45 Years   (Adult)",,"80","Other","Observational","Observational Model: Other|Time Perspective: Prospective","KaramanogluMehmeybeyU","August 8, 2022","September 15, 2022","September 25, 2022","August 9, 2022",,"August 9, 2022",,,"https://ClinicalTrials.gov/show/NCT05494268"
584,"NCT05494255","The Effects of Pre-extubation Single Recruitment Maneuver on Perioperative Atelectasis",,"Recruiting","No Results Available","Pulmonary Atelectasis","Other: Recruitment maneuver","Comparison of the pre-extubation LUS scores (T3)|Comparison of recovery room LUS scores (T4)|Comparison of recovery room PaO2|The effect of deltaLUS (T3-T2) on oxygenation|Length of stay in post anesthesia care unit (PACU)|Length of stay in hospital|Postoperative respiratory complications","Istanbul University","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Diagnostic","2022/1066","August 11, 2022","April 20, 2023","April 25, 2023","August 9, 2022",,"August 15, 2022","Istanbul University Istanbul Faculty of Medicine, Istanbul, Turkey",,"https://ClinicalTrials.gov/show/NCT05494255"
585,"NCT05494242","Single Superior ILM/ERM Flap for the FTMH.",,"Not yet recruiting","No Results Available","Ophthalmopathy","Other: Surgical intervention","Anatomical outcome|Functional outcome","Omer Othman Abdullah|Ibinsina Modern Eye and Retina Center","All","Child, Adult, Older Adult","Not Applicable","5","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","IMER 99","September 1, 2022","November 30, 2022","November 30, 2022","August 9, 2022",,"August 15, 2022",,,"https://ClinicalTrials.gov/show/NCT05494242"
586,"NCT05494229","Autologous Blood for Full-thickness Macular Hole",,"Not yet recruiting","No Results Available","Ophthalmopathy","Other: Pars-plana vitrectomy","Anatomical outcome|Functional outcome","Omer Othman Abdullah|Ibinsina Modern Eye and Retina Center","All","Child, Adult, Older Adult","Not Applicable","5","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IMER 111","September 1, 2022","November 1, 2022","November 1, 2022","August 9, 2022",,"August 15, 2022",,,"https://ClinicalTrials.gov/show/NCT05494229"
587,"NCT05494216","Advanced Sperm Selection Techniques and Their Contribution to Blastocyst Euploidy Rates",,"Recruiting","No Results Available","Sperm DNA Fragmentation|Infertility","Other: PICSI|Other: MACS|Other: Microfluidics","Euploidy rate|Aneuploidy rate|Low mosaic rate|High mosaic rate|Fertilization rate|Cleavage rate|Blastocyst development rate|Blastocyst quality rate","Ganin Fertility Center","All","18 Years to 50 Years   (Adult)","Not Applicable","300","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","GFC-005","August 1, 2022","December 1, 2023","December 1, 2023","August 9, 2022",,"August 15, 2022","Ganin Fertility Center, Cairo, Maadi, Egypt",,"https://ClinicalTrials.gov/show/NCT05494216"
588,"NCT05494203","Multi-omics Study and Drug Intervention Study of Spondyloarthritis",,"Enrolling by invitation","No Results Available","Spondylarthritis","Diagnostic Test: questionnaire survey","Long-term outcomes after treatment","First Affiliated Hospital of Wenzhou Medical University","All","Child, Adult, Older Adult",,"400","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","XiaobingWang","September 2022","December 2022","July 2023","August 9, 2022",,"August 12, 2022","Xiaobing Wang, Wenzhou, Zhejiang, China",,"https://ClinicalTrials.gov/show/NCT05494203"
589,"NCT05494190","The Management of Metastatic Neck Nodes in N2/3 Hypopharyngeal Squamous Cell Carcinoma",,"Not yet recruiting","No Results Available","Hypopharyngeal Carcinoma","Drug: Docetaxel|Drug: Cisplatin|Drug: Capecitabine|Radiation: Concomitant chemoradiotherapy|Procedure: Surgery","Progression-free survival rate|Overall survival rate|Local control|Regional control|Metastasis-free survival|Quality of life (UW-QOL V4.0)|Adverse events","Eye & ENT Hospital of Fudan University|Cancer Institute and Hospital, Chinese Academy of Medical Sciences|Shandong Provincial Hospital|Harbin Medical University Third Affiliated Hospital","All","18 Years to 75 Years   (Adult, Older Adult)","Not Applicable","111","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","EENTHN0706","August 2022","July 2025","July 2025","August 9, 2022",,"August 11, 2022","Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Beijing, China|Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China|Shandong Provincial ENT Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China|Eye & ENT Hospital, Fudan University, Shanghai, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT05494190"
590,"NCT05494177","Comparison of Premium Monovision and Bilateral Implantation of Trifocal Diffractive Intraocular Lenses",,"Recruiting","No Results Available","Presbyopia|Refractive Errors|Cataract","Diagnostic Test: bUDVA, bUIRA, bUNRA, bUICPS, bUNCPS|Diagnostic Test: Contrast sensitivity","Binocular uncorrected distant visual acuity (bUDVA)|Binocular uncorrected intermediate reading acuity (bUIRA)|Binocular uncorrected near reading acuity (bUNRA)|Binocular uncorrected intermediate critical print size (bUICPS)|Binocular uncorrected near critical print size (bUNCPS)|Dysphotopsia symptoms|Contrast sensitivity|Spectacle independence|Subjective satisfaction using Visual Function Index (VF-14) (total score, VF14-Near Vision (NV) score & VF14-Distance Vision (DV) score)","Democritus University of Thrace","All","45 Years to 85 Years   (Adult, Older Adult)",,"100","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","ES13/Th7/07-07-2022","August 1, 2022","December 1, 2022","August 1, 2023","August 9, 2022",,"August 9, 2022","Department of Ophthalmology, University Hospital of Alexandroupolis, Alexandroupolis, Evros, Greece",,"https://ClinicalTrials.gov/show/NCT05494177"
591,"NCT05494164","Nigella Sativa for Selected Outcomes in Chronic Rhinosinusitis",,"Recruiting","No Results Available","Chronic Rhinosinusitis","Other: Nigella sativa nasal oil drops|Drug: standard treatment","Severity of physiological symptoms as measured by Sino-Nasal Outcome Test 22 (SNOT-22)|Sleep quality as measured by Sleep Quality Scale (SQS)|severity of sleep and emotional symptoms as measured by Sino-Nasal Outcome Test 22 (SNOT-22) (sleep and emotional symptoms domains)|patient satisfaction as measured by Treatment Satisfaction Questionnaire with Medications (TSQM)","Cairo University","All","18 Years to 60 Years   (Adult)","Not Applicable","102","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","2022-03","August 7, 2022","February 7, 2023","February 7, 2023","August 9, 2022",,"August 11, 2022","Cairo University, Cairo, Egypt",,"https://ClinicalTrials.gov/show/NCT05494164"
592,"NCT05494151","Metabolic Substrate of Patients With Myocardial Infarction With and Without Modifiable Cardiovascular Risk Factors","Meta-SMuRF","Not yet recruiting","No Results Available","Cardiovascular Diseases|Acute Myocardial Infarction|Acute Coronary Syndrome|Metabolic Disturbance","Diagnostic Test: Investigation of the metabolic substrate","Metabolomic biomarkers associated with SMuRF-less myocardial infraction","Aristotle University Of Thessaloniki","All","25 Years to 80 Years   (Adult, Older Adult)",,"400","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","64000/20-4-2022","October 15, 2022","September 1, 2025","September 1, 2026","August 9, 2022",,"August 11, 2022",,,"https://ClinicalTrials.gov/show/NCT05494151"
593,"NCT05494138","Nutriomics and Artificial Intelligence Nutrition Obesity Cohort",,"Recruiting","No Results Available","Obesity",,"Differences of nutriomics according to obesity phenotypes|Clinical events","Yonsei University","All","19 Years and older   (Adult, Older Adult)",,"650","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","4-2022-0645","July 15, 2022","August 31, 2026","August 31, 2041","August 9, 2022",,"August 9, 2022","Yonsei University Health System, Severance Hospital, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT05494138"
594,"NCT05494125","Effects of Continuous ESP Catheters on Recovery, Pain and Opioid Consumption After Multilevel Spine Surgery",,"Not yet recruiting","No Results Available","Post Operative Pain|Spine Surgery","Other: Ropivacaine|Other: Placebo","Number of patients who require escalation to (ie, a new prescription for) an opioid-iv-patient controlled analgesia (iv-PCA)|Duration of use and dose of opioid-iv-pca (if required)|Post-operative opioid consumption|Numeric rating scale (NRS) pain scores: every 8 hours|Quality of Recovery 15 (QoR15) scores|Duration of ESP catheter(s) use and reasons (if any) for catheter failure or dislodgement|Total dose of ropivacaine delivered|Opioid-related side effects (nausea, vomiting, anti-emetic medication administration, constipation, sedation, administration of naloxone)|Length of hospital stay|Patient satisfaction scale with pain management and ESP catheters|Incidence of ongoing pain and opioid consumption, measured at 3 and 6 months post-surgery","Hospital for Special Surgery, New York","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","44","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Other","2021-1815","September 2022","July 2023","July 2023","August 9, 2022",,"August 9, 2022","Hospital for Special Surgery, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT05494125"
595,"NCT05494112","A Sub-Chronic Evaluation of the Safety of Celastrol in Human Subjects",,"Recruiting","No Results Available","Safety","Dietary Supplement: Celastrol","The effect of celastrol on the function of the liver|EKG evaluation|Glucose (MG/DL)|BUN (MG/DL)|Creatine (MG/DL)|eGFR (ML/MIN/1.73)|CALC BUN/CREAT (Ratio)|Sodium (MEQ/L)|Potassium (MEQ/L)|Chloride (MEQ/L)|Carbon Dioxide (MEQ/L)|Calcium (MG/DL)|Protein, Total (G/DL)|Albumin (G/DL)|CALC Globulin (G/DL)|CALC A/G (Ratio)|Bilirubin, Total (MG/DL)|Alkaline Phosphatase (U/L)|AST (U/L)|ALT (U/L)|WBC (K/UL)|RBC (M/UL)|Hemoglobin (G/DL)|Hematocrit (%)|MCV (fL)|MCH (PG)|MCHC (G/DL)|RDW (%)|Neutrophils (%)|Lymphocytes (%)|Monocytes (%)|Eosinophils (%)|Basophils (%)|Immature Granulocytes (%)|Nucleated RBCS (/100 WBC'S)|Platelet Count (K/UL)|Absolute Neutrophils (K/UL)|Absolute Monocytes (K/UL)|Absolute Eosinophils (K/UL)|Absolute Basophils (K/UL)|Absolute Immature Granulocytes (K/UL)|Absolute Nucleated RBCS (K/UL)|MPV (fL)","Legend Labz, Inc.","All","18 Years to 40 Years   (Adult)","Not Applicable","35","Industry","Interventional","Allocation: N/A|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","AMT-002-2022","May 25, 2022","May 25, 2023","May 25, 2023","August 9, 2022",,"August 9, 2022","Patient Plus Urgent Care, Baton Rouge, Louisiana, United States",,"https://ClinicalTrials.gov/show/NCT05494112"
596,"NCT05494099","Extended Endoscopic Approaches to Non-malignant Maxillary Sinus Lesions Comparative",,"Recruiting","No Results Available","Maxillary Sinus Disease|Approach-Approach Conflict","Procedure: endoscopic maxillary mega-antrostomy|Procedure: Endoscopic Modified Medial Maxillectomy|Procedure: Modified endoscopic pre-lacrimal approach","Intra-operative Endoscopic Assesment|Sino-Nasal Outcome Test 22,. Arabic translation and validation (SNOT-22)","Tanta University","All","Child, Adult, Older Adult",,"75","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","maillary sinus approaches","September 2022","November 2023","January 2024","August 9, 2022",,"August 9, 2022","Faculty of medicine, Tanta, Gharbia Government, Egypt",,"https://ClinicalTrials.gov/show/NCT05494099"
597,"NCT05494086","Dual-Port Laparoscopic Distal Gastrectomy for Gastric Cancer",,"Not yet recruiting","No Results Available","Gastric Cancer","Procedure: DPLDG|Procedure: LDG","Early operative morbidity|5 year overall survival rate","Nanfang Hospital of Southern Medical University","All","18 Years to 75 Years   (Adult, Older Adult)","Not Applicable","300","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NFEC-2022-266","August 1, 2022","December 31, 2024","December 31, 2029","August 9, 2022",,"August 9, 2022","Nanfang Hospital, Guangzhou, Guangdong, China",,"https://ClinicalTrials.gov/show/NCT05494086"
598,"NCT05494073","Anterior Cruciate Ligament Reconstruction Hybrid Remnant Repair Randomized Control Trial",,"Recruiting","No Results Available","Anterior Cruciate Ligament Tear","Procedure: ACL Reconstruction with Hybrid Remnant Repair|Procedure: ACL Reconstruction without Hybrid Remnant Repair","Post-operative imaging (MRI) graft incorporation|Subject proprioceptive ability|Subject quadriceps strength|Patient-reported outcomes (PROMIS forms)|Subject range-of-motion|Return-to-sport (time from surgery)","Henry Ford Health System","All","13 Years to 65 Years   (Child, Adult, Older Adult)","Not Applicable","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","14969","December 13, 2021","December 31, 2023","May 2024","August 9, 2022",,"August 9, 2022","Henry Ford Hospital, Detroit, Michigan, United States",,"https://ClinicalTrials.gov/show/NCT05494073"
599,"NCT05494060","XELOX Combined With Anlotinib and Penpulimab vs XELOX as Adjuvant Therapy in ctDNA Positive Gastric and Esophagogastric Junction Adenocarcinoma","EXPLORING","Not yet recruiting","No Results Available","Carcinoma|Gastrointestinal Diseases|Stomach Cancer|Gastroesophageal-junction Cancer|Digestive System Diseases|Gastric Cancer|Gastrointestinal Neoplasms","Drug: Anlotinib hydrochloride capsule|Drug: Penpulimab Injection|Drug: XELOX","Disease Free Survival (DFS)|Disease Free Survival (DFS) rate at 2 years|Disease Free Survival (DFS) rate at 3 years","The First Affiliated Hospital with Nanjing Medical University|Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","80","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2022-SR-342","August 2022","December 2024","February 2027","August 9, 2022",,"August 9, 2022",,,"https://ClinicalTrials.gov/show/NCT05494060"
600,"NCT05494047","Phase Ⅲ, Clinical Trial to Compare an Inactivated Quadrivalent Influenza Vaccine and a Licensed Vaccine in Chile","TetraFluVac","Recruiting","No Results Available","Influenza|Vaccines","Drug: Tetravalent influenza vaccine developed by Sinovac Biotech Co.","Seroconversion for influenza|Antibody titer 1:40 or more|Cellular immunity-ELISPOT|Cellular immunity-Cytometry|Cellular immunity-Luminex (TM)","Pontificia Universidad Catolica de Chile|Sinovac Biotech (Chile) SpA|Sinovac Biotech Co., Ltd","All","3 Years and older   (Child, Adult, Older Adult)","Phase 3","1600","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","PRO-QINF-3004","July 14, 2022","May 31, 2023","July 31, 2023","August 9, 2022",,"August 9, 2022","Hospital Puerto Montt, Puerto Montt, Los Lagos, Chile|Centro de Investigaciones Médicas Respiratorias (CIMER), Providencia, Metropolitana, Chile|Hospital Clínico UC Christus, Santiago, Metropolitana, Chile|Hospital Félix Bulnes, Santiago, Metropolitana, Chile|Clínica Alemana de Santiago, Vitacura, Metropolitana, Chile",,"https://ClinicalTrials.gov/show/NCT05494047"
601,"NCT05494034","Yield of Implantable Cardiac Monitoring Device in Patients With Acute Ischemic Stroke.",,"Not yet recruiting","No Results Available","Stroke, Acute|Stroke|Stroke, Ischemic|Atrial Fibrillation","Device: Reveal LINQTM","Paroxysmal Atrial Fibrillation > 120 seconds|Paroxysmal Atrial Fibrillation > 6 minutes|anticoagulant initiation|recurrent ischemic strokes|subclinical infracts on follow-up MRI|major hemorrhagic events|stroke subtypes|biomarkers|comparison versus historical cohort","National and Kapodistrian University of Athens","All","40 Years to 100 Years   (Adult, Older Adult)","Not Applicable","200","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","ICM07082022","January 1, 2023","January 1, 2027","January 1, 2030","August 9, 2022",,"August 12, 2022",,,"https://ClinicalTrials.gov/show/NCT05494034"
602,"NCT05494021","China Lung Cancer Screening (CLUS) Study Version 3.0",,"Recruiting","No Results Available","Lung Cancer","Other: Whole-process management software|Device: LDCT detection","The mortality rate of lung cancer|The attendance rate of high-risk individuals|The adherence rate of high-risk individuals|The mortality of all-cause|The detection rate of lung nodules|The incidence rate lung cancer","Shanghai Chest Hospital","All","45 Years to 75 Years   (Adult, Older Adult)","Not Applicable","100000","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Screening","CLUS 3.0","January 1, 2022","December 31, 2026","December 31, 2026","August 9, 2022",,"August 9, 2022","Shanghai Chest hospital, Shanghai, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT05494021"
603,"NCT05494008","Evaluation of Effectiveness and Safety of Korean Herbal Medicine for Post-accident Syndromes After Acute Phase",,"Active, not recruiting","No Results Available","Traffic Accident|Whiplash Syndrome","Procedure: Korean herbal medicine treatment|Procedure: Non-Korean herbal medicine treatment","Numeric Rating Scale(NRS) of post-accident syndromes|Numeric Rating Scale(NRS) of musculoskeletal complaints of post-accident syndromes|Numeric Rating Scale(NRS) of neurological complaints of post-accident syndromes|Numeric Rating Scale(NRS) of psychiatric complaints of post-accident syndromes|Numeric Rating Scale(NRS) of digestive systemic complaints of post-accident syndromes|Numeric Rating Scale(NRS) of general symptoms of post-accident syndromes|Impact of Event Scale-Revised-Korean (IES-R-K)|5-level EuroQol 5-dimension (EQ-5D-5L)|Short-Form-12 Health Survey version2 (SF-12 v2)|Patient Global Impression of Change (PGIC)|Economic evaluation question|Drug Consumption|Adverse events","Jaseng Medical Foundation","All","19 Years to 70 Years   (Adult, Older Adult)","Not Applicable","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","JS-CT-2021-09","July 24, 2021","June 30, 2022","September 15, 2022","August 9, 2022",,"August 9, 2022","Jaseng Hospital of Korean Medicine, Seoul, Gangnam-Gu, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT05494008"
604,"NCT05493995","A Study of Penpulimab and Anlotinib Plus Nab-paclitaxel and Gemcitabine for Advanced Metastatic Pancreatic Cancer.","PAAG","Recruiting","No Results Available","Pancreatic Neoplasms","Drug: Penpulimab|Drug: Anlotinib|Drug: Nab paclitaxel|Drug: Gemcitabine","Objective Response Rate (ORR)|Disease Control Rate (DCR)|Overall Survival (OS)|Progression-free survival (PFS)","The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School|Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","All","18 Years and older   (Adult, Older Adult)","Phase 2","66","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2022-351-02","June 1, 2022","June 30, 2024","December 31, 2024","August 9, 2022",,"August 12, 2022","The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China",,"https://ClinicalTrials.gov/show/NCT05493995"
605,"NCT05493982","Evaluation of the Be Vape Free Curriculum of the Tobacco Prevention Toolkit",,"Not yet recruiting","No Results Available","E-cigarette Use","Behavioral: Stanford Vaping Prevention curriculum","Change in e-cigarette use|Change in intention to use of e-cigarettes scaled score as measured by investigator-originated survey","Stanford University|National Cancer Institute (NCI)","All","10 Years to 20 Years   (Child, Adult)","Not Applicable","10800","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","61965|1R01CA263121","September 15, 2022","August 31, 2025","August 31, 2025","August 9, 2022",,"August 9, 2022","Stanford University, Palo Alto, California, United States",,"https://ClinicalTrials.gov/show/NCT05493982"
606,"NCT05493969","Efficacy and Tolerability of DTG Plus 3TC in HIV Infected Adults With Virologically Suppression and TDF Toxicity",,"Not yet recruiting","No Results Available","Acquired Immunodeficiency Syndrome","Drug: Dolutegravir 50 MG plus lamivudine 300 MG； Dolutegravir/lamivudine (50 MG/300 MG)","Virologic outcomes|HIV-RNA|CD4 counts|bone markers|DEXA|renal markers|eGFR","Shanghai Public Health Clinical Center","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 4","100","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2432","August 2022","August 2025","June 2026","August 9, 2022",,"August 9, 2022",,,"https://ClinicalTrials.gov/show/NCT05493969"
607,"NCT05493956","A Randomised Study of Consolidation CTRT Versus Observation After First Line Chemotherapy in Advanced Gallbladder Cancer","RACE-GB","Recruiting","No Results Available","Gallbladder Cancer Unresectable","Radiation: chemoradiation","Overall survival|Progression free survival|Toxicity due to consolidation chemoradiation|Hepatobiliary symptom index","Sanjay Gandhi Postgraduate Institute of Medical Sciences|American Society of Clinical Oncology","All","20 Years to 75 Years   (Adult, Older Adult)","Not Applicable","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2019-30-IP-108","April 1, 2019","December 2022","February 2023","August 9, 2022",,"August 9, 2022","Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India",,"https://ClinicalTrials.gov/show/NCT05493956"
608,"NCT05493943","P.E.M.F. Therapy of Chronic Wounds",,"Not yet recruiting","No Results Available","Chronic Wounds","Device: Pulsed ElectroMagnetic Field (PEMF) therapy|Other: Pulsed ElectroMagnetic (PEMF) therapy","Time to complete healing|Wound closure|Number and type of adverse events|Device effectiveness","PEMF Systems, Inc.","All","21 Years to 80 Years   (Adult, Older Adult)","Not Applicable","120","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","VA Protocol 5.9","September 15, 2022","December 15, 2023","December 15, 2024","August 9, 2022",,"August 9, 2022",,,"https://ClinicalTrials.gov/show/NCT05493943"
609,"NCT05493930","A Lymph Node Metastasis Predictor (LN-MASTER) in Rectal Cancer",,"Completed","No Results Available","Rectum Cancer","Other: The hospital where the treatment is performed","diagnosis of lymph node metastasis","Peking Union Medical College|The Second Affiliated Hospital of Harbin Medical University|Changhai Hospital","All","Child, Adult, Older Adult",,"6578","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","XWang","January 1, 2010","December 31, 2015","December 31, 2015","August 9, 2022",,"August 9, 2022",,,"https://ClinicalTrials.gov/show/NCT05493930"
610,"NCT05493917","A Real-world Study to Evaluate the Safety and Immunogenicity of a Third-dose Booster After Two Doses of an Inactivated COVID-19 Vaccine",,"Recruiting","No Results Available","COVID-19|Vaccine Reaction","Biological: an inactivated SARS-CoV-2 vaccine named BBIBP-CorV","Geometric mean titers (GMTs)|IgG","Huashan Hospital","All","18 Years and older   (Adult, Older Adult)",,"2000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","KY2021-923","November 3, 2021","December 31, 2022","December 31, 2022","August 9, 2022",,"August 9, 2022","Infectious department of Huashan Hospital, Fudan University, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT05493917"
611,"NCT05493904","PREcise Percutaneous Coronary Intervention for Stent OptimizatION in Treatment of COMPLEX Lesion (PRECISION-COMPLEX)",,"Not yet recruiting","No Results Available","Coronary Artery Disease|Angina Pectoris","Procedure: OCT-guided PCI|Procedure: Angiography-guided PCI|Device: Drug-eluting stent","Suboptimal post-PCI physiological results|Rate of target vessel failure (TVF)|Rate of all-cause death|Rate of cardiac death|Rate of target vessel MI without periprocedural MI|Rate of target vessel MI with periprocedural MI|Rate of target lesion revascularization (TLR)|Rate of target vessel revascularization (TVR)|Rate of any MI|Rate of any revascularization|Rate of stent thrombosis|FFR gain between pre- and post-interventional stages|Trans-stent FFR gradient|Post-interventional non-hyperemic pressure ratios","Chonnam National University Hospital|Abbott Medical Devices","All","18 Years and older   (Adult, Older Adult)","Not Applicable","320","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CNUH-2022-283","September 1, 2022","August 31, 2024","December 31, 2026","August 9, 2022",,"August 11, 2022",,"""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/04/NCT05493904/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT05493904"
612,"NCT05493891","Core Muscle Strength Assessment in Women Who Underwent Cesarean Delivery Using Different Types of Anaesthesia",,"Completed","No Results Available","Core Muscle Strength","Device: Pressure Biofeedback Unit","The maximal voluntary isometric contraction of the transversus abdominis muscle|The maximal voluntary isometric contraction of the lumbar multifidus muscle","South Valley University","Female","18 Years to 35 Years   (Adult)",,"63","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","Core muscle strength","June 28, 2021","January 29, 2022","January 29, 2022","August 9, 2022",,"August 10, 2022","Faculty of physical therapy, South Valley University, Qinā, Qena, Egypt",,"https://ClinicalTrials.gov/show/NCT05493891"
613,"NCT05493878","ITGA2b and SELP Expression in Cancer Pancreas and Biliary Tract Cancer",,"Not yet recruiting","No Results Available","Pancreas Cancer","Diagnostic Test: mRNA expression","Expression levels of ITGA2b and SELP on Tumor Educated PLatelets for diagnosis of pancreatic and biliary cancer|Correlation between expression levels of ITGA2b and SELP on TEPs and the commonly used tumour marker CEA and CA 19-9 in the diagnosis of pancreatic and biliary cancer.","Assiut University","All","Child, Adult, Older Adult",,"128","Other","Observational","Observational Model: Case-Control|Time Perspective: Other","TEPs genes in cancer pancrease","March 2023","March 2024","May 2024","August 9, 2022",,"August 9, 2022",,,"https://ClinicalTrials.gov/show/NCT05493878"
614,"NCT05493865","Parent-Child Single-Session Growth Mindset Intervention on Adolescent Depression and Anxiety Problems",,"Not yet recruiting","No Results Available","Depression, Anxiety","Behavioral: The Parent-Child Single-Session-intervention of Mindset Intelligence, Failure and Emotion (PC-SMILE)","Children's depression and anxiety symptoms|Parental anxiety|Children's perceived control|Children's hopelessness|Children's attitude towards seeking help|Children's psychological well-being|Parents' psychological well-being|Parent-child relationships","The Hong Kong Polytechnic University","All","11 Years to 16 Years   (Child)","Not Applicable","366","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","HSEARS20211009001","January 1, 2023","December 31, 2024","December 31, 2024","August 9, 2022",,"August 9, 2022",,,"https://ClinicalTrials.gov/show/NCT05493865"
615,"NCT05493852","A RWS of the FARAPULSE in A Chinese Population With PAF",,"Not yet recruiting","No Results Available","Paroxysmal Atrial Fibrillation","Device: FARAPULSE Pulsed Field Ablation System","Primary Effectiveness Endpoint|Primary Safety Endpoint|Secondary Effectiveness Endpoints-1|Secondary Effectiveness Endpoints-2|Secondary Effectiveness Endpoints-3|Secondary Safety Endpoints","Boston Scientific Corporation","All","18 Years to 75 Years   (Adult, Older Adult)",,"30","Industry","Observational","Observational Model: Other|Time Perspective: Other","PF109","September 30, 2022","November 30, 2022","December 31, 2023","August 9, 2022",,"August 9, 2022",,,"https://ClinicalTrials.gov/show/NCT05493852"
616,"NCT05493839","A Reverification of the Berlin Definition Plateau Criteria in Golmud",,"Active, not recruiting","No Results Available","Ards",,"ICU mortality|28-days mortality rate|Ventilator Free time|Ventilator time|Hospital length of stay","Southeast University, China","All","18 Years to 80 Years   (Adult, Older Adult)",,"160","Other","Observational","Observational Model: Case-Only|Time Perspective: Retrospective","ARDS in Golmud","June 20, 2022","August 8, 2022","August 30, 2022","August 9, 2022",,"August 9, 2022","Zhongda Hospital, Southeast University, Nanjing, Jiangsu, China",,"https://ClinicalTrials.gov/show/NCT05493839"
617,"NCT05493826","Real World Study on the Use of Cemiplimab in Adult Patients in UK","REACT-CEMI","Active, not recruiting","No Results Available","Cutaneous Squamous Cell Carcinoma","Other: No intervention","Overall response rate (ORR) within 12 months post initiation of cemiplimab|ORR within 6 months post initiation of cemiplimab|Real-world best response within 6- and 12-months post initiation of cemiplimab|Time to best response|Time to partial response|Time to complete response|Disease control rate (DCR) within 6 and 12 months post initiation of cemiplimab|Duration of response (DoR)|Duration of treatment (DoT)|Real-world progression-free survival (rwPFS)|Overall survival (OS)|Demographics|Medical history|Previous treatments|Clinical characteristics outcome|Number of cemiplimab infusions|Proportion of patients where cemiplimab treatment was interrupted, overall and by reason for interruption|Proportion of patients permanently discontinuing treatment, overall and by reason for discontinuation|Distribution of cemiplimab dose administered at initiation|Proportion of patients experiencing immune-related adverse reactions (irARs) of any grade (where reported in notes)|Proportion of patients with cemiplimab treatment interruptions due to experiencing irARs|Duration of treatment interruption for patients experiencing irARs|Proportion of patients treated with anti-inflammatory drugs (e.g., steroids) for irARs, overall and by type of irAR|Initial dose of anti-inflammatory drug (e.g., steroids) used to treat irARs at onset of irARs and for the duration of irARs by steroid type","Sanofi","All","18 Years and older   (Adult, Older Adult)",,"100","Industry","Observational","Observational Model: Cohort|Time Perspective: Retrospective","DUT0052","July 18, 2022","June 19, 2023","June 19, 2023","August 9, 2022",,"August 9, 2022","Sanofi-Aventis UK, Reading, Berkshire, United Kingdom",,"https://ClinicalTrials.gov/show/NCT05493826"
618,"NCT05493813","Total Intravenous Anesthesia Versus Sevoflurane Anesthesia for Endovascular Thrombectomy in Acute Ischemic Stroke",,"Recruiting","No Results Available","Ischemic Stroke, Acute|Thrombectomy|General Anesthesia|Total Intravenous Anesthesia|Postoperative Delirium|Postoperative Cognitive Dysfunction","Behavioral: Cognitive function and delirium evaluation|Behavioral: Neurological functional assessment","Change in Cognitive function and delirium evaluation|Neurological function: National Institute of Health Stroke Scale|Neurological function: modified Rankin scale","Taipei Veterans General Hospital, Taiwan","All","20 Years to 90 Years   (Adult, Older Adult)","Not Applicable","298","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","TPEVGH IRB No.: 2021-04-001B","February 15, 2022","December 30, 2025","December 30, 2025","August 9, 2022",,"August 9, 2022","Taipei Veterans General Hospital, Taipei, Taiwan","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/13/NCT05493813/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT05493813"
619,"NCT05493800","Evaluate the Safety and Efficacy for Oral Mucositis Prevention of MIT-001 in Auto HSCT","Capella","Recruiting","No Results Available","Oral Mucositis|Lymphoma|Multiple Myeloma|Hematologic Cancer","Drug: MIT-001|Drug: normal saline","The incidence of Severe Oral Mucositis(SOM).|The incidence of oral mucositis by WHO OM grading scale|The incidence of oral mucositis based on the maximum severity by WHO OM grading scale|The average grade of oral mucositis by WHO OM grading scale|The duration of oral mucositis by WHO OM grading scale|The incidence of oral mucositis by NCI-CTCAE v5.0 criteria|The average grade of oral mucositis by NCI-CTCAE v5.0 criteria|The mean area under curve(AUC) of score for each question in oral mucositis daily questionnaire(OMDQ)|The proportion of using opioid analgesics|Total cumulative dose of opioid analgesics","MitoImmune Therapeutics","All","19 Years to 70 Years   (Adult, Older Adult)","Phase 2","75","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","MIT001-OM-02","February 1, 2022","October 31, 2023","April 30, 2024","August 9, 2022",,"August 11, 2022","Seoul ST. Mary's Hospital, Seoul, Korea, Republic of|Yeouido ST. Mary's Hospital, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT05493800"
620,"NCT05493787","Nudging Flu Vaccination by Making it Easy for Patients to Schedule a Flu Shot",,"Not yet recruiting","No Results Available","Influenza","Behavioral: Reminder","Flu shot self-scheduling|Flu vaccination","Geisinger Clinic","All","18 Years and older   (Adult, Older Adult)","Not Applicable","120000","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","2022-0500","October 2022","January 2023","January 2023","August 9, 2022",,"August 9, 2022",,,"https://ClinicalTrials.gov/show/NCT05493787"
621,"NCT05493774","Preliminary Exploration of Applying Multi-person Simulation Training to Improve Nurse-led Burn and Scald Nursing Care",,"Not yet recruiting","No Results Available","Virtual Reality|High Fidelity Simulation Training","Other: Multi-person virtual reality simulation scenario training|Other: Multi-person high-fidelity simulation scenario training","Change in knowledge of burn and scald nursing care scale|Change in motivation and attitude toward learning and personal self-efficacy scale|Self-reported measure of satisfaction of learning","Chimei Medical Center","All","20 Years and older   (Adult, Older Adult)","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Other","11105-012","September 1, 2022","December 31, 2022","February 28, 2023","August 9, 2022",,"August 9, 2022",,,"https://ClinicalTrials.gov/show/NCT05493774"
622,"NCT05493761","Effect of Anti-osteoporotic Medications on Nonalcoholic Fatty Liver Disease","OsteoNAFLD","Not yet recruiting","No Results Available","Nonalcoholic Fatty Liver|Osteoporosis, Postmenopausal","Drug: Denosumab|Drug: Alendronate Sodium","Hepatic steatosis: Controlled Attenuation Parameter (CAP) measured with transient elastography (TE).|Hepatic fibrosis: liver stiffness (LS) measured with transient elastography (TE).|Hepatic steatosis non-invasive index: Fatty Liver Index (FLI).|Hepatic steatosis non-invasive index: Hepatic Steatosis Index (HSI).|Hepatic fibrosis non-invasive index: NAFLD fibrosis score (NFS).|Hepatic fibrosis non-invasive index: Fibrosis-4 index (FIB-4).|Hepatic fibrosis non-invasive index: AST-to-Platelet Ratio Index (APRI).|Liver function tests: alanine aminotransferase (ALT).|Liver function tests: aspartate aminotransferase (AST)|Insulin resistance index: Homeostasis Model Assessment - Insulin Resistance (HOMA-IR)|Lipid profile: total cholesterol|Lipid profile: triglycerides|Lipid profile: low-density lipoprotein cholesterol (LDL-C)|Lipid profile: high-density lipoprotein cholesterol (HDL-C)|Serum adipokines: leptin|Serum adipokines: adiponectin","Aristotle University Of Thessaloniki|424 General Military Hospital","Female","40 Years and older   (Adult, Older Adult)","Phase 4","70","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","88235","September 2022","December 2023","December 2024","August 9, 2022",,"August 9, 2022",,,"https://ClinicalTrials.gov/show/NCT05493761"
623,"NCT05493748","Virtual Bladder Training for Overactive Bladder Syndrome in Women. Which Symptom Responds Better?",,"Recruiting","No Results Available","Overactive Bladder Syndrome","Other: Bladder training","Change in King's Health Questionnaire (KHQ) score|Change in International Consultation on Incontinence Questionnaire Short Form (ICIQ-SF) score","Hospital Italiano de Buenos Aires","Female","18 Years and older   (Adult, Older Adult)","Not Applicable","86","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","# 6237 PRIISA 6017","May 1, 2022","October 31, 2023","December 31, 2023","August 9, 2022",,"August 9, 2022","Hospital Italiano de Buenos Aires, Buenos Aires, Argentina",,"https://ClinicalTrials.gov/show/NCT05493748"
624,"NCT05493735","Lidocaine for Pessary Check Pain Reduction",,"Not yet recruiting","No Results Available","Pelvic Organ Prolapse|Stress Urinary Incontinence","Drug: Lidocaine Hcl 2% Jelly|Drug: Placebo Jelly","Change in patient's pain using the visual analog scale (VAS) after pessary removal|Change in patient's pain using the visual analog scale (VAS) after pessary reinsertion|Genital Hiatus with Valsalva","University of South Florida","Female","18 Years and older   (Adult, Older Adult)","Phase 3","96","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","Pro004522","August 2022","February 2023","February 2023","August 9, 2022",,"August 9, 2022",,,"https://ClinicalTrials.gov/show/NCT05493735"
625,"NCT05493722","Optimization of Deep Brain Stimulation Parameters in Patients With Medically Refractory Epilepsy",,"Not yet recruiting","No Results Available","Refractory Epilepsy|Deep Brain Stimulation","Other: PS and OS stimulation order 1|Other: PS and OS stimulation order 2|Other: PS and OS stimulation order 3","Difference in broadband power with different settings|Difference in frequency band-specific low-frequency power (LFP) with different settings|Identify all seizures|Scores on Montreal Cognitive Assessment, MoCA|Scores on epilepsy-specific quality of life questionnaire (QOLIE-10P)","University of Minnesota","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","20","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care","NEUROSURG-2021-29636","August 1, 2023","December 1, 2027","December 1, 2029","August 9, 2022",,"August 9, 2022","University of Minnesota, Minneapolis, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT05493722"
626,"NCT05493709","Efficacy, Safety, and Pharmacokinetics of Leuprolide Mesylate in Subjects With Central Precocious Puberty",,"Not yet recruiting","No Results Available","Puberty; Precocious, Central","Drug: Leuprolide Mesylate, Subcutaneous injection of 42 mg Leuprolide","Efficacy of Leuprolide Mesylate (FP-001 42 mg)|Effect of FP-001 42 mg on bone age progression|Effect of FP-001 42 mg on growth rate|Effect of FP-001 42 mg on physical signs of puberty|Effect of FP-001 42 mg on suppression of physical signs of puberty|Acute-On-Chronic (AOC) phenomenon of serum testosterone and LH","Foresee Pharmaceuticals Co., Ltd.|QPS|GeneScience Pharmaceuticals Co., Ltd.","All","2 Years to 9 Years   (Child)","Phase 3","93","Industry|Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","FP-001-CP-001","October 15, 2022","October 30, 2025","December 31, 2025","August 9, 2022",,"August 9, 2022",,,"https://ClinicalTrials.gov/show/NCT05493709"
627,"NCT05493696","Antigravity Treadmill Training on Gait Characteristics and Balance",,"Completed","No Results Available","Burns","Device: Antigravity treadmill|Other: Traditional physical therapy program","Change in Gait characteristics|Change in Postural stability indices","Umm Al-Qura University","All","18 Years to 35 Years   (Adult)","Not Applicable","55","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","1","June 15, 2022","July 15, 2022","July 28, 2022","August 9, 2022",,"August 9, 2022","Faculty of Applied Medical Sciences, Mecca, Saudi Arabia",,"https://ClinicalTrials.gov/show/NCT05493696"
628,"NCT05493683","Disitamab Vedotin Combined With Tislelizumab in Advanced HER2 Positive Colorectal Cancer",,"Recruiting","No Results Available","Colorectal Neoplasms","Drug: Disitamab vedotin|Drug: Tislelizumab","Objective response rate(ORR)|Progression-free Survival(PFS)|Overall Survival (OS)|Disease control rate (DCR)|Safety and Feasibility|Duration of Response (DOR)","The First Affiliated Hospital with Nanjing Medical University","All","18 Years and older   (Adult, Older Adult)","Phase 2","29","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","KEEP-G 07","August 2022","July 2025","July 2025","August 9, 2022",,"August 9, 2022","Changzhou NO.2 People's Hospital, Changzhou, Jiangsu, China|The Affiliated Huaian No.1 People's Hospital of Nanjing Medical University, Huai'an, Jiangsu, China|The First Affiliated Hospital with Nanjing Medical University, Nanjing, Jiangsu, China|the Third Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China|Xuzhou Central Hospital, Xuzhou, Jiangsu, China|Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT05493683"
629,"NCT05493670","Subthalamic Nucleus Deep Brain Stimulation in Speech Study","SiSS","Recruiting","No Results Available","Parkinson Disease|Dysarthria",,"Neuron Firing Rate|Speech Intelligibility with DBS ON|Speech Intelligibility (stimulation OFF or not applicable)","Jeremy Greenlee|National Institutes of Health (NIH)|University of Pittsburgh|University at Buffalo|Northwestern University|National Institute on Deafness and Other Communication Disorders (NIDCD)|University of Iowa","All","21 Years to 84 Years   (Adult, Older Adult)",,"120","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","202001213|R01DC017718","October 15, 2020","July 2025","July 2025","August 9, 2022",,"August 9, 2022","University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States",,"https://ClinicalTrials.gov/show/NCT05493670"
630,"NCT05493657","Aspirin vs Clopidogrel After TAVR",,"Not yet recruiting","No Results Available","Severe Aortic Stenosis","Drug: Aspirin single antiplatelet therapy|Drug: Clopidogrel single antiplatelet therapy","Incidence of leaflet thrombosis","Yonsei University","All","19 Years and older   (Adult, Older Adult)","Not Applicable","230","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","4-2022-0744","September 15, 2022","July 2024","July 2025","August 9, 2022",,"August 9, 2022","Yonsei University Health System, Severance Hospital, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT05493657"
631,"NCT05493644","A Study About the Selection of Time for Retreatment of Helicobacter Pylori After Eradication Failure",,"Not yet recruiting","No Results Available","Helicobacter Pylori Infection","Other: Remedial treatment within 3 months|Other: Remedial treatment within 3 to 6 months|Other: Remedial treatment within 6 to 12 months|Other: Remedial treatment after 12 months","The most suitable re-eradication time|Eradication rates in three groups","Shandong University","All","18 Years to 70 Years   (Adult, Older Adult)",,"660","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2022-SDU-QILU-G808","September 1, 2022","August 31, 2023","December 31, 2023","August 9, 2022",,"August 9, 2022",,,"https://ClinicalTrials.gov/show/NCT05493644"
632,"NCT05493631","A Phase 1b Study to Assess the Safety, Tolerability, PK and PD of MG1113 in Hemophilia Patient",,"Not yet recruiting","No Results Available","Hemophilia","Biological: MG1113","Number of subject with Adverse events, Adverse Drug Reactions, Serious adverse events and Adverse event of special interest (AESI)|Incidence of Adverse events, Adverse Drug Reactions, Serious adverse events and Adverse event of special interest (AESI)|Severity of Adverse events, Adverse Drug Reactions, Serious adverse events and Adverse event of special interest (AESI)|Incidence of injection site reaction|Severity of injection site reaction|Number of subjects with abnormal Physical examination|Number of subjects with abnormal 12-lead ECG (Ventricular rate in beat/min, Interval for PR in msec, QRS in msec, QTc in msec)|Number of subjects with abnormal Vital signs (Blood pressure in mmHg, Pulse rate in beats/min, Respiration rate in breaths/min, Body temperature in ℃)|Incidence of clinically significant laboratory value abnormalities|Pharmacokinetic assessment - Cmax (Peak plasma concentration)|Pharmacokinetic assessment - Cmin (Minimum plasma concentration)|Pharmacokinetic assessment - AUC (Area under the plasma concentration versus time curve)|Pharmacokinetic assessment - Tmax (Time to maximum plasma concentration after administration)|Pharmacokinetic assessment - half-life (T1/2; the time required to reduce the plasma concentration by half)|Pharmacokinetic assessment - CL/F (apparent clearance)|Pharmacokinetic assessment - Vd/F (apparent volume of distribution)|Pharmacokinetic assessment - Accumulation Index (AUCtau_multiple dose/AUCtau_single dose)|Pharmacodynamic assessment - Free TFPI in plasma in ng/mL|Pharmacodynamic assessment - Residual TFPI activity in unit/mL|Pharmacodynamic assessment - Diluted PT in sec|Pharmacodynamic assessment - Thrombin generation (Lag time in min)|Pharmacodynamic assessment - Thrombin generation (Peak generation in nM)|Pharmacodynamic assessment - Thrombin generation (Endogenous thrombin generation potential [ETP] in nM*min)|Pharmacodynamic assessment - Pro-coagulant effect (D-dimer in ug/mL)|Pharmacodynamic assessment - Pro-coagulant effect (Fibrinogen in mg/dL)|Pharmacodynamic assessment - Pro-coagulant effect (Prothrombin fragments 1+2 in pmol/L)|Immunogenicity assessment - Any formation of anti-drug antibody (ADA) to MG1113|Efficacy Evaluation - Incidence of new bleeding episode","GC Biopharma Corp","Male","19 Years to 60 Years   (Adult)","Phase 1","15","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MG1113_HP_P0101","August 1, 2022","July 31, 2024","December 31, 2024","August 9, 2022",,"August 11, 2022","GC Biopharma Corp., Yongin-si, Gyeonggi-do, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT05493631"
633,"NCT05493618","Pembrolizumab, Belantamab and Dexamethasone in Refractory Multiple Myeloma.",,"Not yet recruiting","No Results Available","Multiple Myeloma, Refractory","Drug: Pembrolizumab|Drug: Belantamab mafodotin|Drug: Dexamethasone","Overall Response Rate (ORR)|Progression-Free Survival (PFS)|Overall Survival (OS)|Time to next treatment|Tolerability and Safety","Hackensack Meridian Health|Merck Sharp & Dohme LLC","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","64","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Pro2022-0093|ISS 60989","December 2022","November 2025","November 2025","August 9, 2022",,"August 9, 2022","Lombardi Comprehensive Cancer Center, Georgetown University, Washington, District of Columbia, United States|John Theurer Cancer Center, Hackensack Meridian Health, Hackensack, New Jersey, United States|Jersey Shore Medical Center, Neptune, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT05493618"
634,"NCT05493605","Cardiac Involvement in Wilson's Disease","WIL-HEART","Not yet recruiting","No Results Available","Wilson's Disease","Procedure: Delivery of a long-term Holter 21 days Or placement of an implantable holter from the outset so syncope","Contrast-enhanced cardiac MRI - Day 0|Transthoracic echocardiography - Day 0|Chest computed tomography scan without contrast - Day 0|Electrocardiogram - Day 0|Clinical examination - Day 0|Blood and urine tests - Day 0|Lying and standing blood pressure tests - Day 0|Implantable loop recorder or ECG holter recorder- Day 21|Transthoracic echocardiography - Year 3|Contrast-enhanced cardiac MRI - Year 3|Chest computed tomography scan without contrast - Year 3|Electrocardiogram - Year 3|Clinical examination - Year 3|Blood and urine tests - Year 3|Lying and standing blood pressure tests - Year 3","Fondation Ophtalmologique Adolphe de Rothschild","All","18 Years and older   (Adult, Older Adult)","Not Applicable","150","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","APS_2021_9","September 2022","September 2025","September 2025","August 9, 2022",,"August 9, 2022",,,"https://ClinicalTrials.gov/show/NCT05493605"
635,"NCT05493592","Pigeon Peas (Cajanus Cajan) : a Natural Anti-inflammatory Facilitating Weight Loss in Obese Patients Returning to Sport?","OBESICA","Not yet recruiting","No Results Available","Severe Obesity","Biological: Standardized physical activity protocol associated with the consumption of Cajanus cajan (EXACAJAN)","Assessment of NLRP3 expression|mRNA expression of caspase-1|mRNA expression of AUC|mRNA expression of IL-1β|mRNA expression of IL18|Plasma level of the pro-inflammatory cytokines IL-1β|Plasma level of the pro-inflammatory cytokines IL18|Plasma level of ultra-sensitive C-reactive Protein|Weight loss assessment|Body mass index assessment|Abdominal perimeter assessment|Hip circumference assessment|Body composition assessment","University Hospital Center of Martinique|GIRCI SOHO","Female","18 Years and older   (Adult, Older Adult)","Not Applicable","124","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","19_RIPH2-29","November 2022","November 2024","September 2025","August 9, 2022",,"August 10, 2022","CHU de Martinique, Fort-de-France, Martinique",,"https://ClinicalTrials.gov/show/NCT05493592"
636,"NCT05493579","Impact of Implant Supported Overdenture on Changes of Electromyographic and Brain Activity",,"Completed","No Results Available","Implant Supported Overdenture","Other: Implant supported overdenture","Brain Activity (EEG)|Cognitive Function (MMSE)","Al-Azhar University","All","65 Years to 69 Years   (Older Adult)","Not Applicable","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","REC-PR-21-08","October 1, 2020","April 1, 2021","July 1, 2021","August 9, 2022",,"August 9, 2022","Faculty of Dentistry. AL Azhar University for Girls, Cairo, Egypt., Cairo, Egypt",,"https://ClinicalTrials.gov/show/NCT05493579"
637,"NCT05493566","Low-Dose Interleukin-2 and Pembrolizumab for the Treatment of Stage IV Non-Small Cell Lung Cancer",,"Not yet recruiting","No Results Available","Lung Non-Small Cell Carcinoma|Stage IV Lung Cancer AJCC v8|Stage IVA Lung Cancer AJCC v8|Stage IVB Lung Cancer AJCC v8","Biological: Aldesleukin|Biological: Pembrolizumab","Immune Response To Combination IL-2 and Pembrolizumab|Objective Response Rate|Progression Free Survival (PFS)|Overall Survival (OS)|Dose-limiting Toxicities (DLTs)|Incidence of Adverse Events (AEs)","Emory University|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","15","Other|NIH","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","STUDY00003612|NCI-2022-00931|WINSHIP5477-21|P30CA138292","September 1, 2022","January 7, 2024","January 7, 2024","August 9, 2022",,"August 9, 2022","Emory University/Winship Cancer Institute, Atlanta, Georgia, United States",,"https://ClinicalTrials.gov/show/NCT05493566"
638,"NCT05493553","Effects of an Intermittent Fasting and Dietary Supplement Regimen on Glycemic Variability",,"Recruiting","No Results Available","Healthy|Impaired Glucose Tolerance","Dietary Supplement: Dietary supplement regimen|Other: Dietary supplement and intermittent fasting regimen","Glycemic variability|Daytime and Overall Blood Glucose Levels|Daytime glycemic variability|Percent of time in range|Percent of time below range|Percent of time above range|Gastrointestinal symptoms","Unicity International, Inc.|Biofortis Innovation Services","All","30 Years to 69 Years   (Adult, Older Adult)","Not Applicable","60","Industry|Other","Interventional","Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Prevention","BIO-2206","August 2022","November 2022","November 2022","August 9, 2022",,"August 9, 2022","Biofortis Clinical Research, Addison, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT05493553"
639,"NCT05493540","Oral Ibuprofen Versus Placebo in Treatment of Patent Ductus Arteriosus (PDA)in Preterm Infants",,"Recruiting","No Results Available","Patent Ductus Arteriosus After Premature Birth|Patent Ductus Arteriosus Conservative Management","Drug: Ibuprofen oral suspension|Drug: Placebo","Incidence of PDA Closure by Echocardiography|Incidence of death during hospitalization|Incidence of Necrotizing Enterocolitis (NEC)|Incidence of Bronchopulmonary dysplasia (BPD)|Incidence of Sepsis|Incidence of Intraventricular hemorrhage (IVH)","Nada Youssef|Ain Shams University","All","1 Hour to 7 Days   (Child)","Phase 2","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","MD 96 2020","April 15, 2021","August 15, 2022","September 1, 2022","August 9, 2022",,"August 9, 2022","Faculty of Medicine Ain Shams University, Cairo, Egypt",,"https://ClinicalTrials.gov/show/NCT05493540"
640,"NCT05493527","Noninvasive High Frequency Oscillatory Ventilation as a Post-extubation Respiratory Support in Neonates",,"Recruiting","No Results Available","Infant, Premature, Diseases|Infant, Newborn, Disease|Respiratory Tract Diseases|RDS","Device: noninvasive high frequency oscillatory ventilation|Device: noninvasive positive pressure ventilation","Re-intubation rate|Days on the assigned non-invasive respiratory support|Days on supplemental oxygen|Duration of admission|Mortality rate|Lung ultrasound score|Co2 change|Oxygen requirement|Incidence of feeding intolerance|Days to reach full intake|Intracranial hemorrhage|Pneumothorax|Incidence of occurrence of Nasal trauma|incidence of bronchopulmonary dysplasia|Severity of respiratory distress|Need for Postnatal Steroids|Chest x ray change","Ain Shams University","All","1 Minute to 1 Month   (Child)","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","MD 90/2020","February 1, 2021","August 15, 2022","August 30, 2022","August 9, 2022",,"August 9, 2022","Neonatal Intensive Care Units (NICUs), Ain Shams University, Cairo, Abbasia, Egypt",,"https://ClinicalTrials.gov/show/NCT05493527"
641,"NCT05493514","Clinical and Instrumental Treatment's Predictors in Subjects With Neurological Diseases Using G-EO Robotic System",,"Recruiting","No Results Available","Multiple Sclerosis|Stroke|Parkinson Disease|Acquired Brain Injury","Device: Robotic Assisted Gait Training with G-EO system","Change in gait speed|Trunk control|Mobility|Strength|Walking Endurance|Walking ability|Activities of daily living|Cognitive function|Balance confidence|Community integration|Gait symmetry (Instrumental index)|Gait regularity (Instrumental index)","Fondazione Don Carlo Gnocchi Onlus","All","18 Years and older   (Adult, Older Adult)",,"260","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","03_06/04/2022","May 13, 2022","April 1, 2027","April 1, 2027","August 9, 2022",,"August 9, 2022","Don Gnocchi Foundation, Milan, Italy",,"https://ClinicalTrials.gov/show/NCT05493514"
642,"NCT05493501","Aumolertinib Alone and With Chemotherapy in Patients With EGFR-Mutant Non-Small Cell Lung Cancer",,"Not yet recruiting","No Results Available","NSCLC","Drug: Aumolertinib|Drug: Osimertinib","Progression Free Survival (PFS)|Overall Survival (OS)|Objective Response Rate (ORR)|Disease Control Rate (DCR)|Tumor Response|Duration of Response (DOR)|ctDNA Clearance|Plasma concentration of aumolertinib|To assess safety in study treatment arms","EQRx International, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 3","420","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","EQ143-301|2022-002674-93","August 2022","May 2027","July 2027","August 9, 2022",,"August 9, 2022",,,"https://ClinicalTrials.gov/show/NCT05493501"
643,"NCT05493488","A Trial to Evaluate the Safety and Efficacy of DBI-001 Gel, DBI-002 Gel, and Aqueous Gel in Subjects With Tinea Pedis",,"Recruiting","No Results Available","Tinea Pedis","Biological: DBI-001 Gel|Biological: DBI-002 Gel|Biological: Aqueous Gel","Change in abundance of T. rubrum based on Quantitative Polymerase Chain Reaction (qPCR)|Number of participants with treatment-related adverse events|Changes in signs and symptoms of T. Pedis|Changes in the signs and symptoms and Investigators Static Global Assessment (ISGA) of Tinea Pedis|Change in abundance of T. rubrum based on qPCR and WGS|Molecular diagnostic qPCR and WGS comparison of DBI-001 Gel, DBI-002 Gel and Aqueous Gel|Bacterial culture comparison of DBI-001 Gel, DBI-002 Gel and Aqueous Gel|Increase or decrease of colony forming units after DBI-001 Gel, DBI-002 Gel application|Correlation between levels of DBI-001 Gel, DBI-002 Gel and abundance of T. rubrum based on qPCR|Correlation between qPCR quantification and KOH for presence of T. rubrum at screening","DermBiont, Inc.","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","24","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CT-210","August 8, 2022","October 31, 2022","December 31, 2022","August 9, 2022",,"August 9, 2022","Oregon Dermatology and Research, Portland, Oregon, United States|Premier Clinical Research, Spokane, Washington, United States",,"https://ClinicalTrials.gov/show/NCT05493488"
644,"NCT05493475","Evaluation of a Novel Intervention to Prevent Polysubstance Overdoses Involving Illicit Stimulants",,"Not yet recruiting","No Results Available","Opiate Overdose|Fentanyl Overdose|Harm Reduction","Behavioral: Fentanyl Test Strips","Key informant interviews|Follow-up questionnaire|Interview|Questionnaire","Nationwide Children's Hospital","All","18 Years and older   (Adult, Older Adult)","Not Applicable","1750","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","Nationwide Children's Hospital","August 2022","April 2024","April 2024","August 9, 2022",,"August 9, 2022",,,"https://ClinicalTrials.gov/show/NCT05493475"
645,"NCT05493462","Intranasal Human FGF-1 for Subjects With Parkinson's Disease",,"Not yet recruiting","No Results Available","Parkinson Disease","Drug: Human FGF-1","Safety and tolerability|Efficacy","Zhittya Genesis Medicine, Inc.","All","40 Years to 80 Years   (Adult, Older Adult)","Phase 1","4","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MROS/457920/INDTP","September 2022","December 2022","December 2022","August 9, 2022",,"August 9, 2022","The Medical Pavilion Bahamas, Nassau, Bahamas",,"https://ClinicalTrials.gov/show/NCT05493462"
646,"NCT05493449","Impact of School Milk Program on Nutritional Status of Primary School Children",,"Recruiting","No Results Available","Milk Intervention on Body Composition and School Attendance","Combination Product: UHT Milk|Combination Product: Flavored Milk","Weight|Height|Total Body Water (TBW)|Body Protein|Minerals|Body Fat Mass (BFM)|Skeletal Muscle Mass (SMM)|Percentage Body Fat (PBF)|Inbody Score|Visceral Fat Level (VFL)|Waist to Hip ratio (WHR)|Attendance percentage|Nutritional deficiency Assessment","University of Veterinary and Animal Sciences, Lahore - Pakistan|University of Education, Lahore|Friesland campina Engro Pakistan","All","4 Years to 16 Years   (Child)","Not Applicable","1000","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Other","School Milk Program","December 1, 2021","November 2022","December 2022","August 9, 2022",,"August 9, 2022","University of Veterinary and Animal Sciences, Lahore, Lahore, Pakistan",,"https://ClinicalTrials.gov/show/NCT05493449"
647,"NCT05493436","The Influence of Obesity to Esophageal Reflux Severity Measured by pH-Metri Impedans on Gastroesophageal Reflux Disease Patients",,"Completed","No Results Available","Disorder of Upper Esophageal Sphincter","Diagnostic Test: MII pH-meter","Composite pH score/DeMesster Score|Acid exposure time|Incidence of Hiatal Hernia|Incidence of Erosive Esophagitis","Indonesia University","All","18 Years to 60 Years   (Adult)",,"98","Other","Observational","Observational Model: Case-Control|Time Perspective: Cross-Sectional","IndonesiaSatu","April 1, 2017","October 1, 2017","July 1, 2018","August 9, 2022",,"August 9, 2022","RSCM, Jakarta, DKI Jakarta, Indonesia","""Study Protocol, Statistical Analysis Plan, and Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/36/NCT05493436/Prot_SAP_ICF_000.pdf","https://ClinicalTrials.gov/show/NCT05493436"
648,"NCT05493423","Confirmatory Study to Assess the V Needle in End-Stage Renal Disease Patients During In-Clinic Hemodialysis","Clinic-SAVER","Not yet recruiting","No Results Available","End Stage Renal Disease","Device: V Needle AV Fistula Set","Percentage of successful hemodialysis sessions with the Hemotek device.|Machine alarm rate (blood alarms only) during hemodialysis therapy sessions, including false alarms.|Achieved blood flow rate during hemodialysis therapy sessions|Clinician's ability to cannulate fistula for each hemodialysis session","Hemotek Medical Inc|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","All","22 Years and older   (Adult, Older Adult)","Not Applicable","15","Industry|NIH","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","CIP 001|5R44DK101253","September 2022","December 2022","February 2023","August 9, 2022",,"August 9, 2022","Davita, San Antonio, Texas, United States",,"https://ClinicalTrials.gov/show/NCT05493423"
649,"NCT05493410","EFFECTS OF INSPIRATORY MUSCLE TRAINING IN POST-COVID-19 PATIENTS",,"Completed","No Results Available","Covid19","Other: TREATMENT GROUP (TG)|Other: CONTROL GROUP (CG)","MIP assessment|S-Index assessment|Assessment of inspiratory muscle endurance|1-MINUTE SIT-TO-STAND TEST","University Vila Velha","All","30 Years to 70 Years   (Adult, Older Adult)","Not Applicable","42","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","49725921.6.0000.5064","August 30, 2021","December 15, 2021","July 25, 2022","August 9, 2022",,"August 9, 2022","Maurício Bona Gracelli, Vila Velha, Espírito Santo, Brazil|Maurício Bona Gracelli, Vitória, Espírito Santo, Brazil",,"https://ClinicalTrials.gov/show/NCT05493410"
650,"NCT05493397","Ultrasound to Detect Vocal Fold Movement in Neurological Disease",,"Recruiting","No Results Available","Neurological Disorder|Ultrasound|Vocal Fold Movement",,"Accuracy of transcutaneous laryngeal US in the diagnosis of vocal fold movement impairment in patients with neurological disease.|Technical and environmental viability of laryngeal US in patients with neurological disease.|Reliability of assessors in capturing and interpreting laryngeal US images for the purpose of vocal fold movement assessment in patients with neurological disease.|Acceptability of transcutaneous laryngeal US to patients with neurological disease.|Diagnostic accuracy and feasibility of laryngeal US between patients of different neurological disease groups|Ability of US to detect other laryngeal pathology in patients with neurological disease.","University College, London","All","18 Years and older   (Adult, Older Adult)",,"50","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","146531","August 1, 2022","July 31, 2023","July 31, 2023","August 9, 2022",,"August 9, 2022","University College London Hospitals, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT05493397"
651,"NCT05493384","Telerehabilitation in Rheumatic Diseases",,"Recruiting","No Results Available","Telerehabilitation","Other: Telerehabilitation Group","Fatigue severity scale|Hospital Anxiety and Depression Scale|Pittsburg Sleep Quality Index|Health Assessment Questionnaire","Gazi University","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","30","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","7099","July 25, 2022","October 20, 2022","November 20, 2022","August 9, 2022",,"August 9, 2022","Songul Baglan Yentur, Elazığ, Turkey",,"https://ClinicalTrials.gov/show/NCT05493384"
652,"NCT05493371","Empagliflozin in Pulmonary Arterial Hypertension","Emphower PoC","Not yet recruiting","No Results Available","Idiopathic Pulmonary Arterial Hypertension","Drug: Empagliflozin 10 MG","Tolerability: the number of patients who have to prematurely discontinue treatment due to intolerability or adverse events.|Feasibility: time needed to include all patients and number of patients needed to screen.|Safety: the number of adverse events (AEs), severe adverse events (SAEs), adverse event of special interest (AESI) and suspected unexpected serious adverse reactions (SUSARs).|Right ventricle ejection fraction (RVEF) measured using MRI|Right ventricle mass measured using MRI|Left ventricle ejection fraction (LVEF) measured using MRI|Stroke volume (SV) measured using MRI|Tricuspid annular plane systolic excursion (TAPSE) measured using transthoracic ultrasound|Estimated sPAP measured using transthoracic ultrasound|Right ventricle fractional area change (RVFAC) measured using transthoracic ultrasound|Blood biomarkers|Blood safety biomarkers|Urine safety biomarkers|Functional class|Six-Minute Walk Distance|Quality of life measured with use of the EMPHASIS-10 questionnaire|Quality of life measured with use of the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) questionnaire","Amsterdam UMC, location VUmc","All","18 Years and older   (Adult, Older Adult)","Phase 2","8","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","81866|2022-002400-20|2022-501512-33-00","November 1, 2022","November 1, 2024","November 1, 2024","August 9, 2022",,"August 9, 2022",,,"https://ClinicalTrials.gov/show/NCT05493371"
653,"NCT05493358","Long-term Outcomes of Open Versus Laparoscopic Distal Gastrectomy for T4a Gastric Cancer",,"Completed","No Results Available","Gastric Cancer","Procedure: Laparoscopic distal gastrectomy","5 year overall survival by Kaplan Mayer|5 year disease-free survival by Kaplan Mayer|1 year overall survival by Kaplan Mayer|3 year overall survival by Kaplan Mayer|1 year disease-free survival by Kaplan Mayer|3 year disease-free survival by Kaplan Mayer|operative morbidity|operative time|operative blood loss|time to flatus|Postoperative hospital length of stay|The percentage of complications with Clavien-Dindo|The percentage of pattern of recurrence/metastasis","University Medical Center Ho Chi Minh City (UMC)","All","15 Years to 90 Years   (Child, Adult, Older Adult)",,"472","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","71/GCN-HĐĐĐ","January 1, 2013","December 31, 2020","June 30, 2022","August 9, 2022",,"August 9, 2022","University Medical Center Ho Chi Minh City, Ho Chi Minh City, Vietnam",,"https://ClinicalTrials.gov/show/NCT05493358"
654,"NCT05493345","Active Communities - Adherence to Physical Activity",,"Recruiting","No Results Available","Diabetes Mellitus, Type 2|Cardiovascular Diseases|Obese","Behavioral: Bridge-building between municipality-based lifestyle programs and community-based physical activities","Feasibility and fidelity|Moderate and vigorous physical activity (MVPA) time|Sitting time|Low-intensity physical activity (LPA) time|Total physical activity (TPA) level|Steps|Six-minute walk distance|Standing balance|Body weight|Fat mass|Fat percentage|Fat free mass|Muscle mass|Body mass index|Mental well-being|Risk of depression|Physical health-related quality of life|Mental health-related quality of life|Perceived stress|Loneliness","Rigshospitalet, Denmark|Steno Diabetes Center Sjaelland|Center for Clinical Research and Prevention","All","18 Years and older   (Adult, Older Adult)",,"60","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","21076311","August 5, 2022","September 1, 2023","August 1, 2024","August 9, 2022",,"August 9, 2022","Centre for Physical Activity Research, Rigshospitalet, Copenhagen, Denmark",,"https://ClinicalTrials.gov/show/NCT05493345"
655,"NCT05493332","HAIC Combined With Donafenib Tosilate and Toripalimab for Unresectable HCC",,"Not yet recruiting","No Results Available","Hepatocellular Carcinoma","Procedure: HAIC(FOLFOX)|Drug: Oxaliplatin|Drug: Leucovorin|Drug: Fluorouracil|Drug: Toripalimab|Drug: Donafenib","Conversion therapy success rate|Conversion therapy success rate based on imageological examination|Objective response rate (ORR)|Disease control rate(DCR）|Progression-free survival（PFS）|Overall survival(OS)|Recurrence-free survival(RFS)|Time to response（TTR）|Safety and tolerability（Adverse Events）|Patient reported outcome（PRO）","Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","93","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2021-KY-128","September 2022","September 2023","September 2024","August 9, 2022",,"August 9, 2022",,,"https://ClinicalTrials.gov/show/NCT05493332"
656,"NCT05493319","Hypopressive Exercise Associated With Strength and Resistance Training in Women Treated for Gynecological Cancer",,"Not yet recruiting","No Results Available","Gynecologic Cancer","Other: Exercises","Change from baseline at 4 weeks in quality of life assessed by a questionnaire|Change from baseline at 4 weeks in sexual function assessed by a questionnaire|Change from baseline at 4 weeks in urinary incontinence assessed by a questionnaire|Change from baseline at 4 weeks in fatigue assessed by a scale","Universidade Federal de Sao Carlos","Female","18 Years to 60 Years   (Adult)","Not Applicable","36","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Supportive Care","UCM","March 1, 2023","May 30, 2023","July 30, 2023","August 9, 2022",,"August 9, 2022","Catholic University of Maule, Talca, Maule, Chile","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/19/NCT05493319/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/19/NCT05493319/ICF_001.pdf","https://ClinicalTrials.gov/show/NCT05493319"
657,"NCT05493306","Evaluation of Telerehabilitation Following Inpatient or Outpatient Rehabilitation Phase II",,"Completed","No Results Available","Oncology|Musculoskeletal Diseases",,"Usability of the telerehabilitation|Feasibility of the telerehabilitation|Acceptance of the telerehabilitation","Pensionsversicherungsanstalt","All","Child, Adult, Older Adult",,"126","Other","Observational","Observational Model: Other|Time Perspective: Prospective","0002 Evaluation Telereha","April 8, 2021","March 31, 2022","June 30, 2022","August 9, 2022",,"August 12, 2022","PVA - Zentrum für ambulante Rehabilitation Graz, Graz, Styria, Austria",,"https://ClinicalTrials.gov/show/NCT05493306"
658,"NCT05493293","Extension Study to Evaluate the Safety and Tolerability of NBI-921352 When Used With Anti-seizure Medications in Adults With Focal Onset Seizures",,"Not yet recruiting","No Results Available","Focal Onset Seizure|Focal Onset Epilepsy","Drug: NBI-921352","The subject incidence of serious treatment-emergent adverse events (TEAEs), TEAEs leading to study treatment discontinuation, and fatal TEAEs|Percentage change from baseline in 28-day focal onset seizure frequency during the treatment period|Treatment response defined as ≥50% reduction in 28-day focal onset seizure frequency during the treatment period compared with baseline","Neurocrine Biosciences","All","18 Years to 67 Years   (Adult, Older Adult)","Phase 2","100","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NBI-921352-FOS2022|2021-004265-12","September 2022","December 2025","December 2025","August 9, 2022",,"August 9, 2022",,,"https://ClinicalTrials.gov/show/NCT05493293"
659,"NCT05493280","Fractionated 1927nm Laser for Hyperpigmentation in Fitzpatrick Skin Phototypes V and VI",,"Not yet recruiting","No Results Available","Hyperpigmentation","Device: MOXI","Change in Clinical Photography|Change in Skin Hyperpigmentation Index (SHI) Scores|Adverse Events|Participant response to pre-post treatment regimens","University of Texas Southwestern Medical Center","All","18 Years to 75 Years   (Adult, Older Adult)","Not Applicable","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","STU-2022-0672","October 2022","March 2023","September 2023","August 9, 2022",,"August 9, 2022","UT Southwestern Medical Center- Dept of Plastic Surgery, Dallas, Texas, United States",,"https://ClinicalTrials.gov/show/NCT05493280"
660,"NCT05493267","A Exploratory Study of Vγ2Vδ2 T Lymphocyte-based Immunotherapy for MDR-TB",,"Recruiting","No Results Available","MDR-TB|Immunotherapy","Drug: Vγ2Vδ2 T lymphocyte-based immunotherapy|Drug: Treatment regimens for MDR-TB","Sputum smear and culture negative conversion|Radiographic changes","Shanghai Pulmonary Hospital, Shanghai, China|Shanghai Public Health Clinical Center|Huashan Hospital|No.85 Hospital, Changning, Shanghai, China","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","L20-209","August 3, 2022","August 3, 2025","August 3, 2027","August 9, 2022",,"August 10, 2022","Shanghai Pulmonary Hospital, Shanghai, China, Shanghai, China|Shanghai Pulmonary Hospital, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT05493267"
661,"NCT05493254","Enhancing Smoking Cessation Via Telehealth Options in Primary Care","E-STOP","Not yet recruiting","No Results Available","Smoking Cessation","Behavioral: Smoking cessation e-visit|Behavioral: Treatment As Usual","Number of participants who utilized smoking cessation treatment|Cigarettes smoking|Quit attempts|Seven-day point prevalence abstinence|E-visit Acceptability|E-visit Adoption","Medical University of South Carolina","All","18 Years and older   (Adult, Older Adult)","Not Applicable","672","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","Pro00113308","August 15, 2022","December 31, 2024","June 1, 2025","August 9, 2022",,"August 9, 2022",,"""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/54/NCT05493254/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/54/NCT05493254/ICF_001.pdf","https://ClinicalTrials.gov/show/NCT05493254"
662,"NCT05493241","Behavioral Activation for Independence in Older Veterans","ACTIVaTE","Not yet recruiting","No Results Available","Functional Independence","Behavioral: Behavioral Activation for Independence in Older Veterans (ACTIVaTE)|Behavioral: Attention control","Enrollment|Retention at 12 weeks|Adherence|Satisfaction at intervention completion|Themes based on Theoretical Framework of Acceptability domains|Satisfaction at study completion|Recruitment|Change in physical functioning as measured by the Ambulatory Measure for Post-Acute Care (AM-PAC) Daily Activities and Basic Mobility Scales|Randomization|Change in cognitive functioning as measured by the Ambulatory Measure for Post-Acute Care (AM-PAC) Applied Cognitive Scale|Fidelity|Change in social functioning as measured by the PROMIS Satisfaction with Social Roles and Activities (Short Form-8a)|Barriers and facilitators|Perceived impact and recommendations","VA Office of Research and Development","All","65 Years and older   (Older Adult)","Not Applicable","58","U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","D3930-W","August 1, 2023","October 31, 2026","October 31, 2026","August 9, 2022",,"August 9, 2022","VA Bedford HealthCare System, Bedford, MA, Bedford, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT05493241"
663,"NCT05493228","Dexmedetomidine Infusion on Intraoperative Propofol,Fentanyl Requirements in Spine Surgery for Pediatric Cancer Patients",,"Recruiting","No Results Available","Spine Cancer|Anesthesia","Drug: Precedex Injectable Product|Drug: Saline","Rate of propofol infusion per hour|Change in MEP amplitude and latency|Depth of anesthesia by bispectral index|change in SSEP amplitude and latency|to access rapid recovery in both arms|to access the event of hypotension in both arms|to access the event of bradycardia in both arms","Children's Cancer Hospital Egypt 57357","All","5 Years to 18 Years   (Child, Adult)","Phase 3","38","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","CCHE-BT005","May 17, 2022","April 17, 2023","October 30, 2023","August 9, 2022",,"August 9, 2022","Children's Cancer Hospital Egypt 57357 Cairo, Egypt, Cairo, Egypt",,"https://ClinicalTrials.gov/show/NCT05493228"
664,"NCT05493215","Imatinib TDM in GIST",,"Not yet recruiting","No Results Available","Gastrointestinal Stromal Tumors","Drug: Imatinib","Incidence of Grade 3/4 adverse events attributable to imatinib per CTCAE v5.0|Percent of patients achieving therapeutic levels of imatinib.|Quality of Life based on the EORTC QLQ-C30|Average dose of imatinib required to achieve therapeutic levels and drug dose over 3 years","Reema A. Patel|University of Kentucky","All","18 Years and older   (Adult, Older Adult)","Phase 2","28","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MCC-22-GI-123","September 2022","December 2024","December 2025","August 9, 2022",,"August 9, 2022","Markey Cancer Center, Lexington, Kentucky, United States",,"https://ClinicalTrials.gov/show/NCT05493215"
665,"NCT05493202","Superovulation And Urinary Concentration of Estrone","SAUCE","Completed","No Results Available","in Vitro Fertilization|Hormone Testing","Device: Mira Fertility Tracker","Correlation of E3G with oocyte retrieval parameters|Correlation of E3G and E2 levels throughout stimulation","Olive Fertility Centre|Quanovate Tech Inc.","Female","21 Years to 45 Years   (Adult)",,"30","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","SAUCE","February 20, 2022","June 13, 2022","July 30, 2022","August 9, 2022",,"August 9, 2022","Olive Fertility Centre, Vancouver, British Columbia, Canada",,"https://ClinicalTrials.gov/show/NCT05493202"
666,"NCT05493189","Assessment of CPR Skills Acquisition and Retention: Impact of Technology and Self-training","TrainCPR","Not yet recruiting","No Results Available","Cardiopulmonary Resuscitation","Other: Additional autonomous training sessions","Change in CPR skills (acquisition)|Difference in CPR skills retention","Universidade do Porto|Faculty of Medicine of the University of Porto","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","150","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","TrainCPR","September 19, 2022","October 31, 2023","December 31, 2023","August 9, 2022",,"August 9, 2022",,,"https://ClinicalTrials.gov/show/NCT05493189"
667,"NCT05493176","A 5-day Dry Immersion Study on 20 Healthy Male Volunteers","VIVALDI2","Not yet recruiting","No Results Available","Weightlessness","Other: Dry immersion","Change in orthostatic tolerance|Change in peak aerobic power (VO2max test)|Change in plasma volume|Change in fluid shift distribution towards the cardiac and cephalic region|Change in vascular endothelium integrity|Change in circadian rhythms of blood pressure|Change in lower limb veins functions|Change in body fluid compartments by bioelectrical impedance analysis|Change in muscle strength|Change in muscle fatigue|Change in muscle volume at calf level|Change in contraction time|Change in serum bone formation markers|Change in serum bone resorption markers|Change in serum cartilage synthesis biomarkers|Change in serum cartilage degradation biomarkers|Change in urine cartilage degradation biomarkers|Change in Resting Metabolic Rate (RMR)|Change in nitrogen balance|Change in fat and lean body mass measured by dual energy x-ray absorptiometry (DEXA)|Change in glucose tolerance (Oral Glucose Tolerance Test)|Change in Core temperature|Change in height|Change in mid cerebral artery (MCA) blood flow velocity|Change in mood|Change in affective states|Change in sleep quality|Change in psychological state: mental health|Change in coping strategies|Change in cerebral autoregulation|Change in Intra Cranial Pressure (ICP)|Change in optic nerve sheath diameter (ONSD) considered as an indirect marker for intracranial pressure (ICP) estimation|Change in the optic nerve fibers thickness|Change in intraocular pressure (IOP)|Change in visual acuity|Change in visual field|Change in the anatomical characteristics of the eye (optical biometry)|Change in the central corneal thickness|Change in the retina by non-mydriatic fundus retinography|Change in the cornea topography|Change in cerebral structures and in venous circulation of the brain by MRI|Change in walking balance|Change in standing balance|Change in motion sickness susceptibility|Change in thrombotic and fibrinolytic processes|Change in respiratory volumes|Change in respiratory flows","Centre National d'Etudes Spatiales|European Space Agency","Male","20 Years to 40 Years   (Adult)","Not Applicable","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","22-282|2022-A00881-42","August 2022","December 2022","December 2022","August 9, 2022",,"August 9, 2022","Medes-Imps, Toulouse, France",,"https://ClinicalTrials.gov/show/NCT05493176"
668,"NCT05493163","Catheter-directed Thrombolysis in Intermediate-high Risk Acute Pulmonary Embolism","PRAGUE-26","Not yet recruiting","No Results Available","Pulmonary Embolism","Drug: Thrombolytic|Drug: Standard anticoagulation","Primary endpoint|Secondary endpoints","Faculty Hospital Kralovske Vinohrady|Charles University|University Hospital Ostrava|University Hospital Olomouc|University Hospital Brno|St. Anne´s University Hospital Brno|General University Hospital in Prague|University Hospital Pilsen|Pardubice Hospital","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 4","558","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PRAGUE-26|2022-002218-18","October 2022","January 2026","January 2028","August 9, 2022",,"August 9, 2022","University Hospital Kralovske Vinohrady, Prague, Czechia",,"https://ClinicalTrials.gov/show/NCT05493163"
669,"NCT05493150","Antalgic Effects of Well-being Treatments in Cancer Care","Well Being","Completed","No Results Available","Cancer|Cancer Pain",,"Pain assesment","Centre Hospitalier de Valence","All","18 Years and older   (Adult, Older Adult)",,"180","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","00006","January 22, 2020","September 30, 2021","December 30, 2021","August 9, 2022",,"August 9, 2022","Ch Valence, Valence, Drome, France",,"https://ClinicalTrials.gov/show/NCT05493150"
670,"NCT05493137","Physical Activity Levels of Parents of Children With Cystic Fibrosis- (PHACTS-CF)","PHACTS-CF","Not yet recruiting","No Results Available","Cystic Fibrosis in Children","Other: No intervention will be provided","GPAQ|CPAQ|YPAQ|Ineb adherence|Lung function","Cambridge University Hospitals NHS Foundation Trust","All","5 Years to 16 Years   (Child)",,"30","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","A096376","October 1, 2022","October 1, 2023","October 1, 2023","August 9, 2022",,"August 9, 2022",,,"https://ClinicalTrials.gov/show/NCT05493137"
671,"NCT05493124","Clinical Study of Manpixiao in the Treatment of Chronic Atrophic Gastritis",,"Recruiting","No Results Available","Chronic Atrophic Gastritis","Drug: Manpixiao|Drug: Active comparator","Pathological improvement rate of gastric mucosa|Gastric mucosal status under gastroscope|Score of main symptoms of stomach system","Beijing University of Chinese Medicine","All","18 Years to 75 Years   (Adult, Older Adult)","Early Phase 1","180","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2021-ZXFZJJ-035","July 1, 2021","December 31, 2023","December 31, 2023","August 9, 2022",,"August 9, 2022","Dongfang Hospital, Beijing University of Chinese Medicine, Beijing, China|Dongzhimen Hospital, Beijing University of TCM, Beijing, China|Zaozhuang Hospital, Beijing University of Chinese Medicine, Beijing, China","""Study Protocol, Statistical Analysis Plan, and Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/24/NCT05493124/Prot_SAP_ICF_000.pdf","https://ClinicalTrials.gov/show/NCT05493124"
672,"NCT05493111","A Long-Term Safety Study Evaluating the Safety and Systemic Exposure of AR-15512","COMET-4","Not yet recruiting","No Results Available","Dry Eye Disease","Drug: AR-15512 Ophthalmic Solution|Drug: Vehicle","Adverse Events|Blood Pressure|Heart Rate|Endothelial cell counts|Hematology, chemistry, and urinalysis|LogMAR Visual Acuity|Early Treatment of Diabetic Retinopathy Study (ETDRS) Visual Acuity|Biomicroscopy|Total ocular staining|Intraocular pressure (IOP)|Dilated fundus exam","Aerie Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 3","270","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","AR-15512-LTSS","November 1, 2022","February 28, 2024","February 28, 2024","August 9, 2022",,"August 9, 2022",,,"https://ClinicalTrials.gov/show/NCT05493111"
673,"NCT05493098","Effectiveness of Dry Needling in People With Episodic Tension-type Headache",,"Not yet recruiting","No Results Available","Episodic Tension-type Headache","Other: dry needling|Other: sham (placebo) dry needling:","Pain level|Active craniocervical range of motion|Functional disability|Frequency of headache:","Iran University of Medical Sciences","All","20 Years to 50 Years   (Adult)","Not Applicable","36","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","IR.IUMS.REC.1400.30","July 30, 2022","July 30, 2023","December 30, 2023","August 9, 2022",,"August 9, 2022",,,"https://ClinicalTrials.gov/show/NCT05493098"
674,"NCT05493085","Quadratus Lumborum vs Caudal Epidural Block for Perioperative Analgesia in Pediatric Patients for Upper Abdominal Surgeries",,"Recruiting","No Results Available","Post Operative Pain, Acute","Procedure: Quadratus lumborum block|Procedure: Caudal epidural injection","Pain score","Ain Shams University","All","2 Years to 8 Years   (Child)","Not Applicable","52","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","FMASU R 69/2022","June 15, 2022","August 2022","August 2022","August 9, 2022",,"August 9, 2022","Ain shams university hospital, Cairo, Abbasia, Egypt",,"https://ClinicalTrials.gov/show/NCT05493085"
675,"NCT05493072","RxConnect User Testing Study",,"Not yet recruiting","No Results Available","Behavior","Other: RxConnect","Number of prescribing errors per scenario|The magnitude of any dose errors (deviation from recommended dosing range)|Time taken to prescribe each medication|Prescribers perceived mental load per prescribing scenario","Imperial College London|National Institute for Health Research, United Kingdom","All","Child, Adult, Older Adult","Not Applicable","50","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science","22CX7758","August 8, 2022","November 11, 2022","November 11, 2022","August 9, 2022",,"August 11, 2022",,,"https://ClinicalTrials.gov/show/NCT05493072"
676,"NCT05493059","Study of Cases of Cutaneous Leishmaniasis Treated With Miltefosine in French Guiana, Retrospective Study","MILT2022","Not yet recruiting","No Results Available","Cutaneous Leishmaniases|Treatment Adherence|Primary Health Care|Drug Evaluation","Other: Data collection|Other: Questionnaires","Disappearance of any lesion without the appearance of a new lesion, 6 months from the start of treatment with miltefosine|Proportion of treatment-emergent adverse events occurring during treatment|Patients' acceptability of treatment assessed after completion of treatment|Impact of Cutaneous Leishmaniasis on quality of life","Centre Hospitalier de Cayenne","All","18 Years and older   (Adult, Older Adult)",,"20","Other","Observational","Observational Model: Case-Only|Time Perspective: Retrospective","2022_028","August 8, 2022","August 8, 2022","October 8, 2022","August 9, 2022",,"August 9, 2022",,,"https://ClinicalTrials.gov/show/NCT05493059"
677,"NCT05493046","Interactive Hand Exercise Game on Grip Strength and Vascular Maturation",,"Not yet recruiting","No Results Available","Muscle Weakness|Angiogenesis","Behavioral: Interactive Hand Exercise Game|Behavioral: Soft ball exercise ( routine care)","Changes in vein diameter|Changes in the depth of the fistula from the epidermis|Changes in brachial artery blood flow rate|Changes in grip strength","Taipei Medical University|Mackay Memorial Hospital","All","20 Years to 70 Years   (Adult, Older Adult)","Not Applicable","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","22MMHIS083e","August 2022","July 2026","July 2026","August 9, 2022",,"August 9, 2022","Hsiao-Yean Chiu, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT05493046"
678,"NCT05493033","Intracorporeal Versus Extracorporeal Anastomotic After Laparoscopic Right Colectomy",,"Not yet recruiting","No Results Available","Colon Cancer","Procedure: Intracorporeal anastomotic after LRC|Procedure: Extracorporeal anastomotic after LRC","Anastomotic leak|Disease-free survival rate|Overall survival|morbidity|Mortality|Duration of surgery|Duration of anastomosis|Surgical incision length|Conversion rate|Pain score (VAS score)|Time to first flatus passage after surgery|Time to first stool passage after surgery|Time to first oral intake|Length of hospital stay after surgery|Specimen quality|Health-related quality of life|health-related quality of life|Incision herniation","Beijing Friendship Hospital","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 3","1158","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","COLOR IV Trial","January 1, 2023","January 1, 2027","January 1, 2030","August 9, 2022",,"August 9, 2022",,,"https://ClinicalTrials.gov/show/NCT05493033"
679,"NCT05493020","The Association Between Watching Mukbang Videos and the Appetite of Children With Cancer",,"Not yet recruiting","No Results Available","Mukbang","Other: Questionnaires set","Appetite|Mukbang Watching Features|Nutritional status|Quality of Life in children with cancer","Sun Yat-sen University","All","3 Years to 18 Years   (Child, Adult)",,"178","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","Mukbang_children with cancer","July 31, 2022","June 30, 2023","July 30, 2023","August 9, 2022",,"August 9, 2022","XIAW, Guangzhou, Guangdong, China",,"https://ClinicalTrials.gov/show/NCT05493020"
680,"NCT05493007","The Efficacy and Safety of Sandbag Self Walking-MSAT on Acute Low Back Pain",,"Active, not recruiting","No Results Available","Low Back Pain","Procedure: Sandbag motion style acupuncture treatment|Procedure: Korean medical treatment","Numeric Rating Scale(NRS) of Low back pain|Visual Analogue Scale (VAS) of Low back pain|Numeric Rating Scale(NRS) of leg pain|Visual Analogue Scale (VAS) of leg pain|Physical examination (Lumbar range of motion)|Oswestry Disability Index (ODI)|EuroQol 5-Dimension (EQ-5D)|EuroQol Visual Analogue Scale (EQ-VAS)|Short Form-12 Health Survey version 2 (SF-12 v2)|Patient Global Impression of Change (PGIC)|The Posttraumatic Stress Disorder Checklist for DSM-5 (PCL-5-K)|Adverse events","Jaseng Medical Foundation","All","19 Years to 70 Years   (Adult, Older Adult)","Not Applicable","104","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","JS-CT-2021-10","July 17, 2021","June 29, 2023","June 29, 2023","August 9, 2022",,"August 9, 2022","Jaseng Hospital of Korean Medicine, Seoul, Gangnam-Gu, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT05493007"
681,"NCT05492994","A Study to Test Different Imaging Techniques in Patients With Different Types of Interstitial Lung Disease",,"Not yet recruiting","No Results Available","Lung Diseases, Interstitial","Diagnostic Test: Spirometry|Diagnostic Test: Diffusing Capacity of the Lung for Carbon Monoxide (DLCO)|Diagnostic Test: Magnetic Resonance Imaging|Diagnostic Test: Chest Computer Tomography|Diagnostic Test: Blood biomarker analysis","Absolute change in Forced Vital Capacity (FVC) % predicted from baseline to week 52|Absolute change in fibrosis extent in % of lung volume determined on chest Computer Tomography (CT) from baseline to week 52","Boehringer Ingelheim","All","40 Years and older   (Adult, Older Adult)","Not Applicable","56","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","0352-2157","September 20, 2022","May 30, 2025","May 30, 2025","August 9, 2022",,"August 9, 2022",,,"https://ClinicalTrials.gov/show/NCT05492994"
682,"NCT05492981","Does an Educational Video for Aneuploidy Screening Improve Informed Choice Among Pregnant Women?","EVA","Active, not recruiting","No Results Available","Aneuploidy|Down Syndrome|Pregnancy Early","Behavioral: Enhanced (intervention) education","Informed choice|Deliberation|Knowledge|Value-consistent behaviour|anxiety|Decisional Conflict","National University Hospital, Singapore","Female","21 Years to 50 Years   (Adult)","Not Applicable","286","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Screening","2020/01123","July 5, 2021","February 24, 2022","July 30, 2022","August 9, 2022",,"August 9, 2022","National University Hospital, Singapore, Singapore",,"https://ClinicalTrials.gov/show/NCT05492981"
683,"NCT05492968","The Effect of Epinephrine, Norepinephrine and Phenylephrine on Intraoperative Hemodynamic Performance","RACE","Not yet recruiting","No Results Available","Cardiac Output, Low|Cardiac Output, High|Perfusion; Complications","Drug: Epinephrin|Drug: Norepinephrine|Drug: Phenylephrine","Intraoperative cardiac output|Secondary Outcome 1: Intraoperative brain regional oxygen saturation|Secondary Outcome 2: Intraoperative tissue regional oxygen saturation","Medical University of Vienna|Medical University of Graz","All","45 Years to 90 Years   (Adult, Older Adult)","Phase 4","225","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","RACE_01","August 1, 2022","August 1, 2024","August 31, 2024","August 9, 2022",,"August 9, 2022",,,"https://ClinicalTrials.gov/show/NCT05492968"
684,"NCT05492955","Implementation of a Combination Intervention for Sustainable Blood Pressure Control","IMPACT-BP","Not yet recruiting","No Results Available","Hypertension","Behavioral: Community Health Worker Care Model|Behavioral: Enhanced Community Health Worker-based with Mobile Health Blood Pressure Monitoring Model|Behavioral: Standard of Care Model","Mean systolic blood pressure change|Achievement of blood pressure control","Brigham and Women's Hospital","All","18 Years and older   (Adult, Older Adult)","Not Applicable","774","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2021P003469","August 2022","February 28, 2024","February 28, 2024","August 9, 2022",,"August 9, 2022","Africa Health Research Institute (AHRI), Mtubatuba, KwaZulu-Natal, South Africa",,"https://ClinicalTrials.gov/show/NCT05492955"
685,"NCT05492942","Records for Alcohol Care Enhancement","RACE","Not yet recruiting","No Results Available","Alcohol Use Disorder (AUD)","Behavioral: Best Practice Advisory (BPA) and Population Health Management (PHM)|Behavioral: Best Practice Advisory (BPA) and Clinical Care Management (CCM)|Behavioral: Best Practice Advisory (BPA) and Population Health Management (PHM) and Clinical Care Management (CCM)","Percent Engaged in Alcohol Use Disorder (AUD) Treatment|Percent Initiated in Alcohol Use Disorder (AUD) Treatment|Percent Prescribed Alcohol Use Disorder (AUD) Medication|Number of Outpatient Visits for Alcohol Use Disorder (AUD)|Number of Visits with an Integrated Behavioral Health Social Worker for Alcohol Use Disorder (AUD)|Number of Referral(s) for Counseling or Specialty Alcohol Use Disorder (AUD) Care|Number Completed Encounter for Alcohol Use Disorder (AUD) Specialty Care|Number of Acute Care Utilization|Number of Acute Care Utilization with an Alcohol-related Diagnosis","Boston Medical Center|National Institute on Alcohol Abuse and Alcoholism (NIAAA)","All","18 Years and older   (Adult, Older Adult)","Not Applicable","128","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","H-42631|4R33AA027597-03","October 2022","May 2024","October 2024","August 9, 2022",,"August 9, 2022",,,"https://ClinicalTrials.gov/show/NCT05492942"
686,"NCT05492929","The Effect of Deep Breathing Exercise and 4-7-8 Breathing Techniques on Anxiety and Quality of Life",,"Completed","No Results Available","Postoperative Complications","Other: The deep breathing group|Other: 4-7-8 breathing technique","State and Trait Anxiety Inventory|Obese-Specific Quality of Life Scale","Ataturk University","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","90","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","vesile18","January 1, 2022","April 1, 2022","July 5, 2022","August 9, 2022",,"August 9, 2022","Atatürk University, Erzurum, Palandöken, Turkey",,"https://ClinicalTrials.gov/show/NCT05492929"
687,"NCT05492916","Integrating Cultural Aspects Into Diabetes Education","INCLUDE","Not yet recruiting","No Results Available","PreDiabetes","Behavioral: Diabetes Prevention Program (DPP)|Behavioral: Community-Supported Agriculture (CSA)","Percentage Change in Body Weight|Change in Weight Efficacy Lifestyle Questionnaire (WEL) Score|Change in Starting the Conversation (STC) Diet Scale Score|Change in International Physical Activity Questionnaire (IPAQ) Short-Version Score|Change in San Francisco Chinese Food Security Module Score","NYU Langone Health|American Diabetes Association","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","150","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","22-00783","February 2023","November 2024","November 2024","August 9, 2022",,"August 9, 2022","NYU Langone Health, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT05492916"
688,"NCT05492903","COMmunity of Practice And Safety Support for Navigating Pain (COMPASS-NP)","COMPASS-NP","Not yet recruiting","No Results Available","Pain Management|Ergonomics|Wounds and Injuries","Behavioral: COMmunity of Practice And Safety Support for Navigating Pain (COMPASS-NP)","Between Groups Difference in Changes in Ratings of Pain Interference with Work|Between Groups Difference in Changes in Ratings of Pain Interference with Life|Between Groups Difference in Changes in Reported Number of Pain/Injury Prevention Actions|Between Groups Difference in Changes in Reported Number of Minor Injuries|Between Groups Difference in Changes in Reported Number of Lost Work Time Injuries|Between Groups Difference in Changes in the Rating of Average Pain Severity|Between Groups Difference in Changes in Ratings of Well-being|Between Groups Difference in Changes in Daily Minutes of Physical Activity|Between Groups Difference in Changes in Average Nightly Sleep Duration|Between Groups Difference in Changes in Average Nightly Sleep Efficiency|Between Groups Difference in Changes in Pain Medication Use|Between Groups Difference in Changes in Risk of Future Opioid Misuse|Between Groups Difference in Changes in Current Opioid Misuse","Oregon Health and Science University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","140","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","e20412","September 2022","September 2025","September 2026","August 9, 2022",,"August 9, 2022",,,"https://ClinicalTrials.gov/show/NCT05492903"
689,"NCT05492890","Continuous Glucose Monitoring for Women With Diabetes Mellitus in the Intrapartum and Postpartum Inpatient Care",,"Not yet recruiting","No Results Available","Diabetes, Gestational","Device: Dexcom G6","Maternal outcome|Neonatal outcomes","Ohio State University","Female","18 Years to 50 Years   (Adult)",,"40","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","2020H0498","August 2022","August 2023","August 2023","August 9, 2022",,"August 9, 2022",,,"https://ClinicalTrials.gov/show/NCT05492890"
690,"NCT05492877","An Efficacy and Safety Study of AZD4831 (MPO Inhibitor) vs Placebo in the Treatment of Moderate to Severe COPD.","CRESCENDO","Not yet recruiting","No Results Available","Chronic Obstructive Pulmonary Disease (COPD)","Drug: AZD4831|Other: Placebo","To evaluate the effect of AZD4831 as compared to placebo on the time to first COPD Composite Exacerbation (CompEx) event.|To assess the pharmacokinetics (PK) of AZD4831 in participants with moderate to severe COPD.|To assess the PK of AZD4831 in participants with moderate to severe COPD|To evaluate the effect of AZD4831 as compared to placebo on the time to first moderate or severe exacerbation.|To assess the effects of AZD4831 as compared to placebo on post-bronchodilator (BD) forced expiratory volume in the first second (FEV1) in participants with moderate to severe COPD.|To assess the effect of AZD4831 compared to placebo on respiratory symptoms in participants with moderate to severe COPD.|To assess the effect of AZD4831 compared to placebo in disease impact in participants with moderate to severe COPD.|To assess the effects of AZD4831 compared to placebo on change in cough frequency measured over a 24-hour period","AstraZeneca","All","40 Years to 80 Years   (Adult, Older Adult)","Phase 2","288","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","D6582C00001","November 6, 2022","April 12, 2024","April 12, 2024","August 9, 2022",,"August 9, 2022",,,"https://ClinicalTrials.gov/show/NCT05492877"
691,"NCT05492864","Correction of Anterior Open Bite With Skeletally Anchored Extrusion Arch",,"Active, not recruiting","No Results Available","Anterior Openbite Malocclusion","Procedure: extrusion of the anterior teeth","Mean change in the overbite and overjet ""Amount of open bite closure"". -Measurements will be done on pretreatment and posttreatment digital study models in millimeters(mm)|Mean change in the Antero-posterior position of permanent maxillary first molar. -Measurements will be done on pretreatment and posttreatment digital study models in millimeters(mm)|Changes that occur in the dentoalveolar vertical development of the upper and lower anterior teeth. -Measurements will be done on pretreatment and posttreatment digital study models in millimeters(mm)|Changes that will occur in the upper and lower arch length, perimeter and intermolar width. -Measurements will be done on pretreatment and posttreatment digital study models in millimeters(mm)|Skeletal, dental and soft tissues changes . Measurements will be done on pretreatment and posttreatment lateral cephalometric radiographs in degree (°)|Skeletal, dental and soft tissues changes . Measurements will be done on pretreatment and posttreatment lateral cephalometric radiographs in millimeters (mm)|Change in the smile of the patients through measuring mean change in the lenght of the upper lip, amount of incisors and gum exposure. Measurements will be done on pretreatment and posttreatment photographs in millimeters (mm).|Stability of the treatment after 1, 2 and 3year(s) through measuring mean change in the overbite. Measurements will be done on digital study models in millimeters(mm)","Mansoura University","All","12 Years to 15 Years   (Child)","Not Applicable","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","9148620","May 19, 2021","August 19, 2022","November 19, 2022","August 9, 2022",,"August 9, 2022","Faculty of dentistry, Mansoura University, Mansoura, El Dakahlia, Egypt",,"https://ClinicalTrials.gov/show/NCT05492864"
692,"NCT05492851","Trial Comparing Three Single Dose Injections for Knee Osteoarthritis",,"Recruiting","No Results Available","Osteoarthritis, Knee","Drug: Zilretta|Drug: Synvisc-One 48 MG in 6 ML Prefilled Syringe|Drug: Monovisc 88 MG Per 4 ML Prefilled Syringe","Knee injury and Osteoarthritis Outcome Score (KOOS) Pain patient reported outcome questionnaire|Knee injury and Osteoarthritis Outcome Score (KOOS) Symptoms patient reported outcome|Knee injury and Osteoarthritis Outcome Score (KOOS) Function in daily living (ADL) patient reported outcome|Knee injury and Osteoarthritis Outcome Score (KOOS) Function in Sport and Recreation (Sport/Rec) patient reported outcome|Knee injury and Osteoarthritis Outcome Score (KOOS) knee related quality of life (QOL) patient reported outcome|Knee injury and Osteoarthritis Outcome Score (KOOS) Pain patient reported outcome","Ohio State University","All","25 Years to 85 Years   (Adult, Older Adult)","Phase 4","165","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","2022H0168","August 2, 2022","January 2024","August 2024","August 9, 2022",,"August 9, 2022","Jameson Crane Sports Medicine Institute, Columbus, Ohio, United States|Ohio State Outpatient Lewis Center, Lewis Center, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT05492851"
693,"NCT05492838","Socket Shield Technique With or Without Flap Elevation",,"Recruiting","No Results Available","Alveolar Bone Resorption","Procedure: Immediate implantation with the Socket Shield Technique","Change from baseline marginal bone loss at 12 months|Change of peri-implant pocket depth between baseline and follow-up periods|Change of modified plaque index between baseline and follow-up periods|Change of modified bleeding index between baseline and follow-up periods|Change in the width of keratinized mucosa between follow-up periods|Change in the mucosal recession between follow-up periods|Change in the mucosal thickness between follow-up periods|Visual analog scale|Oral health impact profile questionnaire|Pink aesthetic score|White aesthetic score","Kutahya Health Sciences University","All","18 Years to 62 Years   (Adult)","Not Applicable","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","02","July 18, 2019","December 2023","December 2024","August 9, 2022",,"August 9, 2022","Kutahya Health Sciences University, Kütahya, Turkey",,"https://ClinicalTrials.gov/show/NCT05492838"
694,"NCT05492825","IMPOWR-ME Project 1: Trial of Yoga and Physical Therapy Onsite at Opioid Treatment Programs",,"Not yet recruiting","No Results Available","Substance Use Disorders|Chronic Pain|Opioid Use Disorder|Back Pain Lower Back Chronic","Other: Yoga|Other: Physical Therapy|Other: Treatment As Usual","Pain Intensity|Illicit opioid use|Health-related quality of life|Pain Interference|Pain Catastrophizing|Perceived stress|Cost effectiveness","Albert Einstein College of Medicine|National Institute on Drug Abuse (NIDA)","All","18 Years and older   (Adult, Older Adult)","Not Applicable","345","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2021-13320|RM1DA055437","September 1, 2022","March 15, 2026","March 15, 2027","August 9, 2022",,"August 9, 2022","Montefiore DoSA Wellness Centers, Bronx, New York, United States",,"https://ClinicalTrials.gov/show/NCT05492825"
695,"NCT05492812","Sedation and Nursing Management in EEG Recording in Children",,"Completed","No Results Available","Electroencephalography|Melatonin|Chloral Hydrate|Hydroxyzine|Sleep Deprivation","Other: Sedation and Nursing Management in EEG Recording in Children|Drug: Chloral Hydrate|Drug: Hydroxyzine|Drug: Melatonin","Success in falling asleep|Sleep Time|Ramsay Sedation Score on electroencephalogram background","Suleyman Demirel University","All","1 Year to 7 Years   (Child)","Not Applicable","180","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","2021","January 1, 2021","December 31, 2021","December 31, 2021","August 9, 2022",,"August 9, 2022","Suleyman Demirel University, Isparta, Turkey",,"https://ClinicalTrials.gov/show/NCT05492812"
696,"NCT05492799","Safety, Tolerability and Efficacy of ICV AX 250 Treatment in MPS IIIB -OLE",,"Not yet recruiting","No Results Available","MPS III B","Drug: AX 250","Primary - neurocognition","Allievex Corporation","All","Child, Adult, Older Adult","Phase 4","15","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","250-401","November 2022","October 2027","December 2027","August 9, 2022",,"August 9, 2022","UCSF Benioff Children's Hospital Oakland, Oakland, California, United States|Fundación Cardio Infantil - Instituto de Cardiología, Bogotá,, Colombia|University Medical Center Hamburg-Eppendorf, Hamburg, Germany|Gazi University Faculty of Medicine, Ankara, Turkey|Great Ormond Street Hospital For Children, NHS Foundation Trust, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT05492799"
697,"NCT05492786","High-risk Influenza Vaccine Alert",,"Not yet recruiting","No Results Available","Influenza","Behavioral: Alert|Behavioral: Salient alert features|Behavioral: High-risk Text|Behavioral: Risk factors","Flu vaccination","Geisinger Clinic","All","18 Years and older   (Adult, Older Adult)","Not Applicable","60000","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention","2022-0502","August 2022","April 2023","April 2023","August 9, 2022",,"August 9, 2022",,,"https://ClinicalTrials.gov/show/NCT05492786"
698,"NCT05492773","Evaluating the Efficacy of Micro-Osteoperforations Technique on the Orthodontic Tooth Movement Acceleration in Moderate Mandibular Anterior Crowding Cases Treated With Clear Aligners",,"Recruiting","No Results Available","Crowding of Anterior Mandibular Teeth","Device: Micro-osteoperforations Technique|Device: Active comparater","Change in Little's Index of Irregularity|Overall treatment Time|Change in the levels of pain|Satisfaction using VAS|Satisfaction with the ease of the procedure|Satisfaction through acceptability of the procedure|Satisfaction through recommending the procedure","Hama University","All","18 Years to 26 Years   (Adult)","Not Applicable","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","Hama University -Ortho","August 10, 2022","November 4, 2022","September 4, 2023","August 9, 2022",,"August 9, 2022","Hama University, Hama, Syrian Arab Republic",,"https://ClinicalTrials.gov/show/NCT05492773"
699,"NCT05492760","Evaluation of Recurrence Risk of Atrial Fibrillation After Cryoballoon Ablation","era-cryo","Not yet recruiting","No Results Available","Atrial Fibrillation","Device: cryoballoon ablation","the time to atrial fibrillation recurrent","Shanghai 10th People's Hospital","All","18 Years to 80 Years   (Adult, Older Adult)",,"600","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","era-cryo","August 1, 2022","July 1, 2023","July 1, 2024","August 9, 2022",,"August 9, 2022",,,"https://ClinicalTrials.gov/show/NCT05492760"
700,"NCT05492747","Kangaroo Care an EffectonTransitionTime From Gavage Feeding","KangarooCare","Completed","No Results Available","Premature Infants","Other: Kangaroo Care an Effect","this study was measured the effects of kangaroo care in the transition period of preterm infants fed by gavage to full oral feeding.","Firat University","All","27 Weeks to 36 Weeks   (Child)","Not Applicable","50","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","Kangaroo Care on Oral Feeding","January 3, 2019","January 28, 2019","November 5, 2019","August 8, 2022",,"August 8, 2022","Didem Coşkun Şimşek, Elazığ, Turkey",,"https://ClinicalTrials.gov/show/NCT05492747"
701,"NCT05492734","A Study to Assess the Feasibility of Non-invasive Dried Blood Sampling",,"Enrolling by invitation","No Results Available","Muscular Dystrophies","Drug: EDG-5506","Difference in area under the concentration-time curve (AUC0-24, AUC0-26, AUC0-144 and AUC0-t) measurements for EDG-5506 in blood collected by capillary blood self-sampling versus venous blood sampling|Plasma maximum measured drug concentration (Cmax) measurements for EDG-5506 in blood collected by capillary blood self-sampling versus venous blood sampling|Time of maximum concentration (Tmax) measurements for EDG-5506 in blood collected by capillary blood self-sampling versus venous blood sampling|Area under the concentration-time curve (AUC0-24, AUC0-26, AUC0-144 and AUC0-t) measurements for EDG-5506 in plasma.|Plasma maximum measured drug concentration (Cmax) measurements for EDG-5506 in plasma.|Time of maximum concentration (Tmax) measurements for EDG-5506 in plasma.|Incidence of treatment-emergent adverse events|Incidence of abnormal clinical laboratory test results|Incidence of abnormal vital signs|Incidence of abnormal electrocardiograms (ECGs)","Edgewise Therapeutics, Inc.","All","19 Years to 55 Years   (Adult)","Phase 1","10","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","EDG-5506-104","August 12, 2022","August 19, 2022","August 19, 2022","August 8, 2022",,"August 8, 2022","Celerion, Inc., Lincoln, Nebraska, United States",,"https://ClinicalTrials.gov/show/NCT05492734"
702,"NCT05492721","Comparing Tissue Adhesives in Port Site Closure",,"Recruiting","No Results Available","Dermatitis, Contact","Device: 2-Octylcyanoacrylate|Device: N-butyl-2-cyanoacrylate","proportion of patients who develop contact dermatitis|mean diameter of erythema|proportion of patients with wound dehiscence|proportion of patients with surgical site infection","The University of Texas Health Science Center, Houston","All","18 Years and older   (Adult, Older Adult)","Phase 3","186","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","HSC-MS-22-0143","June 29, 2022","June 29, 2023","June 29, 2024","August 8, 2022",,"August 12, 2022","Memorial Hermann, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT05492721"
703,"NCT05492708","The Heartland Study",,"Recruiting","No Results Available","Pregnancy Related|Pregnancy Complications|Birth Defect|Gestational Age and Weight Conditions|Spontaneous Abortion|Miscarriage|Exposure to Herbicides",,"Pregnancy loss|Preterm birth|Hypertensive disorders of pregnancy","Heartland Health Research Alliance|Indiana University School of Medicine","Female","18 Years and older   (Adult, Older Adult)",,"2600","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","HHRA-HS-Phase1-2019","January 11, 2020","January 2027","January 2029","August 8, 2022",,"August 8, 2022","Indiana University Medical Center, Indianapolis, Indiana, United States|Franciscan Health Indianapolis, Indianapolis, Indiana, United States|Gundersen Health, La Crosse, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT05492708"
704,"NCT05492695","Tandem OnabotulinumtoxinA Galcanezumab Emerging Therapeutic Headache Elimination Research Study","TOGETHER","Not yet recruiting","No Results Available","Migraine","Drug: Galcanezumab|Other: Placebo","Change in Monthly Migraine Days|Change in Monthly Migraine days|Change in Monthly Headache days|Change in PROMIS Pain Interference scores|Change in Functional Assessment of Migraine Scale - Research (FAMS-R) scores|Change in Functional Assessment of Migraine Scale - Research Supplement (FAMS-RS) scores|Change in Migraine Disability Assessment (MIDAS) scores|Frequency of 50% Responders|Monthly Acute Migraine Medication use","Diamond Headache Clinic","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","150","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","5Q-US-X003","October 1, 2022","October 31, 2024","October 31, 2024","August 8, 2022",,"August 8, 2022",,,"https://ClinicalTrials.gov/show/NCT05492695"
705,"NCT05492682","START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer",,"Not yet recruiting","No Results Available","Melanoma (Skin)|Triple-Negative Breast Cancer|Non-Small Cell Lung Cancer","Drug: PeptiCRAd-1|Drug: Cyclophosphamide|Drug: Pembrolizumab","Measurement of Safety and tolerability indexes (Incidence of TEAEs, SAEs and DLTs as assessed by CTCAE version 5.0 and changes in assessed safety parameters) for PeptiCRAd-1 monotherapy.|Measurement of Safety and tolerability indexes (Incidence of TEAEs, SAEs and DLTs as assessed by CTCAE version 5.0 and changes in assessed safety parameters) for PeptiCRAd-1 and CPI combination.|Measurement of New York Esophageal Squamous Cell Carcinoma-1 (NY-ESO-1) and Melanoma-associated antigen 3 (MAGE A3) specific T-cells in peripheral blood.|Measurement of NY-ESO-1 and MAGE A3 in serum.|To determine the number of tumor infiltrating lymphocytes (TILs) in tumor mass.|To determine objective response rate (ORR).|To determine overall survival.|Correlation between immune activation in peripheral blood and tumor mass and clinical outcome.","Valo Therapeutics Oy","All","18 Years and older   (Adult, Older Adult)","Phase 1","15","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","VALO-001|2021-002529-13","August 2022","October 2023","January 2024","August 8, 2022",,"August 8, 2022",,,"https://ClinicalTrials.gov/show/NCT05492682"
706,"NCT05492669","Intravenous Lidocaine on Chronic Pain in Patients Undergoing Hepatectomy",,"Recruiting","No Results Available","Postoperative Chronic Pain","Drug: Lidocaine Hydrochloride, Injectable|Drug: 0.9% normal saline","The incidence of chronic pain at 3 months postoperatively|The incidence of chronic pain at 6 months , 1 year, 3 year and 5year postoperatively|The levels of inflammatory factors at 24 hours after surgery|The incidence of moderate to severe pain at 24, 48 and 72 hours after surgery at rest and during movement;|The cumulative morphine consumption at 24, 48 and 72 hours postoperatively|The incidence of a composite of postoperative pulmonary complications during|Length of hospital stay|Plasma lidocaine concentration immediately after loading，after surgery and 24-hours postoperatively|The incidence of lidocaine toxicity within 72 hours after operation|Overall survival|Recurrence-free survival|accessible survival","West China Hospital","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2","272","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2019-571","February 27, 2020","July 27, 2024","July 27, 2024","August 8, 2022",,"August 15, 2022","West China Hospital, Chengdu, Sichuan, China",,"https://ClinicalTrials.gov/show/NCT05492669"
707,"NCT05492656","Accuracy of CADx System for White Light Colonic Polyp Characterization","GIC","Recruiting","No Results Available","Colonic Polyp|Adenoma Colon",,"Diagnostic accuracy of CADx in evaluating small colonic polyps|Feasibility of CADx in evaluating small colonic polyps|Sensibility, specificity, VPP and VPN of CADx in OD of colonic polyps","Valduce Hospital","All","18 Years to 85 Years   (Adult, Older Adult)",,"500","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","41/2022","August 5, 2022","November 5, 2022","November 5, 2022","August 8, 2022",,"August 8, 2022","Gastroenterology Unit, Valduce Hospital, Como, Italy",,"https://ClinicalTrials.gov/show/NCT05492656"
708,"NCT05492643","The Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (SYS6006) as Heterologous Booster in Participants Aged 18 Years and Older Vaccinated With Inactivated SARS-CoV-2 Vaccine",,"Not yet recruiting","No Results Available","SARS-CoV-2|Safety|Immunotoxicity","Biological: one dose of the study SARS-CoV-2 mRNA Vaccine (SYS6006)|Other: Cellular Immunity|Other: Humoral Immunity|Other: Safety","Primary Safety Endpoint|Primary Immunogenicity Endpoint|GMT、GMI、SCR of SARS-CoV-2 pseudovirus neutralizing antibody|GMT、GMI、SCR of SARS-CoV-2 S1 protein specific binding IgG antibody|GMT、GMI、SCR of SARS-CoV-2 live virus, pseudovirus neutralizing antibody and S1 protein specific IgG antibody","Zhongnan Hospital","All","18 Years and older   (Adult, Older Adult)","Not Applicable","1000","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","SYS6006-007","August 13, 2022","February 27, 2023","March 1, 2023","August 8, 2022",,"August 11, 2022","Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China",,"https://ClinicalTrials.gov/show/NCT05492643"
709,"NCT05492630","Single and Multiple Dose Safety, Tolerability, PK and Food Effect Study of HEC73077 in Healthy Subjects",,"Recruiting","No Results Available","Diabetic Nephropathy","Drug: HEC73077 tablets|Drug: HEC73077 placebo tablets","Adverse Events|Cmax|AUC0-∞","Sunshine Lake Pharma Co., Ltd.","All","18 Years to 45 Years   (Adult)","Phase 1","138","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","HEC73077-P-01","May 24, 2021","December 15, 2022","February 15, 2023","August 8, 2022",,"August 8, 2022","The First Hospital of Jilin University, Changchun, Jilin, China",,"https://ClinicalTrials.gov/show/NCT05492630"
710,"NCT05492617","Early Detection of de Novo Cancer in Liver Transplant Recipients","DETECT","Completed","No Results Available","De Novo Cancer|Liver Transplant Disorder",,"Incidence and Prevalence of De Novo Cancer in Liver Transplant Recipients|CMV & TTV association with De Novo Cancer in Liver Transplant Recipients|Cell-free DNA fragmentation to identify liver transplant recipients with de novo cancer at an asymptomotic stage","Rigshospitalet, Denmark","All","20 Years to 100 Years   (Adult, Older Adult)",,"3628","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","The DETECT study","January 1, 2010","December 31, 2020","December 31, 2020","August 8, 2022",,"August 8, 2022",,,"https://ClinicalTrials.gov/show/NCT05492617"
711,"NCT05492604","Comparison of FEETME® Soles and GAITRITE® Walkway for the Evaluation of Gait Disorders in CIDP.","ESCAL-PIDC","Not yet recruiting","No Results Available","Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)","Other: Clinical examination|Other: Functional scales|Diagnostic Test: Walking test","Validy of gait velocity|Step length|Pitch attack ratio (heel/toe)|Heel pressure measurements|Walking pace","University Hospital, Bordeaux","All","18 Years and older   (Adult, Older Adult)","Not Applicable","30","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","CHUBX 2022/04","October 1, 2022","April 1, 2024","October 1, 2024","August 8, 2022",,"August 8, 2022",,,"https://ClinicalTrials.gov/show/NCT05492604"
712,"NCT05492591","A Study Exploring Efficacy of Peginterferon in Patients With Herpes Zoster",,"Not yet recruiting","No Results Available","Herpes Zoster","Drug: Peginterferon α1b|Drug: Peginterferon α1b with valacyclovir|Drug: Valacyclovir","Time of stop increasing new blisters/pimples|Time of target herpes begins to scab|Time of complete scabbing of all herpes|Changes in VAS scores on day 1 from baseline|Changes in VAS scores on day 2 from baseline|Changes in VAS scores on day 3 from baseline|Changes in VAS scores on day 4 from baseline|Changes in VAS scores on day 6 from baseline|Changes in VAS scores on day 10 from baseline|Changes in VAS scores on day 14 from baseline|Changes in VAS scores on day 21 from baseline|Changes in VAS scores on day 27 from baseline|Time that VAS score to drop to ≤2|Duration time that VAS score to drop to ≤2|The time that scabs of blisters fall off|Dose of painkiller|Incidence of postherpetic neuralgia","Shanghai Institute Of Biological Products|Chinese Academy of Medical Sciences Dermatology Hospital","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","240","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","SIBP-R01","August 15, 2022","March 30, 2023","July 30, 2023","August 8, 2022",,"August 8, 2022",,,"https://ClinicalTrials.gov/show/NCT05492591"
713,"NCT05492578","Long-Term Safety and Efficacy Evaluation of Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis",,"Not yet recruiting","No Results Available","Dermatitis Atopic","Drug: Amlitelimab","Percentage of participants who experienced treatment-emergent adverse event (TEAE) from baseline during the study|Percentage of participants who experienced treatment-emergent SAEs from baseline during the study|Percentage of participants who experienced treatment-emergent adverse events of special interest (AESI) from baseline during study|Absolute change from KY1005-CT05 (DRI17366) baseline in Eczema Area and Skin Severity Index (EASI) score at each visit in participants entering the study from KY1005-CT05 (DRI17366) Week 24|Percent change from KY1005-CT05 (DRI17366) baseline in EASI score at each visit in participants entering the study from KY1005-CT05 (DRI17366) Week 24|Proportion of participants with EASI75/EASI90/EASI100 from KY1005-CT05 (DRI17366) baseline at each visit in participants entering the study from KY1005-CT05 (DRI17366) Week 24|Proportion of participants with a response of investigator global assessment (IGA) 0 or 1and a reduction from baseline of >= 2 points at each visit in participants entering the study from KY1005-CT05 (DRI17366) Week 24|Absolute change from LTE baseline in EASI score at pre-specified timepoints in all participants entering the study|Percent change from LTE baseline in EASI score at pre-specified timepoints in all participants entering the study|Proportion of participants with EASI50/ EASI75/EASI90/EASI100 at pre-specified timepoints in all participants entering the study|Time to first EASI75/EASI90/EASI100 in those participants who had not achieved it by the time of LTE entry in all participants entering the study|Time to first remission after LTE enrolment (achieving IGA 0/1) in those participants who had not achieved IGA 0/1 by the time of LTE entry in all participants entering the study|Proportion of participants with IGA score 0/1 at each visit in all participants entering the study|Proportion of participants with low disease activity state (e.g., IGA <= 2) at each visit in all participants entering the study|Proportion of participants requiring rescue treatment at each visit: all treatments in all participants entering the study|Proportion of participants requiring rescue treatment at each visit: topical treatments in all participants entering the study|Proportion of participants requiring rescue treatment at each visit: systematic treatments in all participants entering the study|Number of days on topical medication (per patient-year) in all participants entering the study|Change from LTE baseline to prespecified time points through the end of the study: atopic dermatitis control tool (ADCT) in all participants entering the study|Change from LTE baseline to prespecified time points through the end of the study: dermatology life quality index (DLQI) in all participants entering the study|Change from LTE baseline to prespecified time points through the end of the study: patient oriented eczema measure (POEM) in all participants entering the study|Serum amlitelimab concentration assessed at prespecified time points through the end of the study|Anti-amlitelimab antibody titre in participants with positive response|Number of participants with positive anti-drug antibody response","Sanofi","All","18 Years and older   (Adult, Older Adult)","Phase 2","300","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LTS17367|U1111-1269-6490|2021-002344-73","August 17, 2022","December 1, 2025","December 1, 2025","August 8, 2022",,"August 8, 2022",,,"https://ClinicalTrials.gov/show/NCT05492578"
714,"NCT05492565","Seville Cohort of People at Substantial Risk for HIV Infection on Pre-exposure Prophylaxis","SeVIHPrEP","Enrolling by invitation","No Results Available","HIV Infection Primary|Hepatitis, Viral, Human|Sexually Transmitted Infections, Excluding HIV and Hepatitis","Drug: Tenofovir Disoproxil Fumarate 300 MG Oral Tablet","Change from baseline proportion of PrEP users with STI-4c at one year|Incidence of primary HIV infection|Proportion of PrEP users with STI other than STI-4c or HIV|Number of STI|Incidences of STI other than HIV|Sexual behaviour|Adverse events|Adherence to PrEP|Predictors of the incidence of HIV and other STI|Predictors of a change in the proportion of STI-4c","Hospitales Universitarios Virgen del Rocío|Instituto de Biomedicina de Sevilla","All","18 Years and older   (Adult, Older Adult)",,"500","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","SeVIHPrEP Cohort|FIS-PRE-2022-01","January 1, 2020","December 31, 2029","December 31, 2030","August 8, 2022",,"August 8, 2022","Virgen del Rocío University Hospital, Seville, Andalusia, Spain",,"https://ClinicalTrials.gov/show/NCT05492565"
715,"NCT05492552","Cardiovascular Function and Physical Activity in COVID-19","CV-COVID","Recruiting","No Results Available","Coronavirus 2019","Behavioral: Active-at-home-HF","Difference and change in left ventricular global longitudinal strain.|Difference and change in pulse wave velocity.|Difference and change in augmentation index.|Difference and change in resting cardiac output.|Difference and change in maximal cardiac output.|Difference and change in resting heart rate.|Difference and change in maximal heart rate.|Difference and change in resting stroke volume.|Difference and change in maximal stroke volume.|Difference and change in resting systemic vascular resistance.|Difference and change in maximal systemic vascular resistance.|Difference and change in maximal oxygen uptake (VO2 max).|Difference and change in Forced Expiratory Volume 1 (FEV1)/ forced vital capacity (FVC) ratio.|Change in quality of life measured by the SF-36 questionnaire between baseline and post intervention assessment at 12 weeks.|Difference and change in depression, anxiety and stress measured on the DASS-21 questionnaire.|Difference and change in global sleep efficiency.|Change in sleep efficiency.|Difference and change in right ventricular global longitudinal strain.|Difference and change in left atrial strain.|Difference and change in ventricular arterial coupling.|Difference and change in right ventricular diastolic function.|Difference and change in electrocardiography (ECG) R-R interval average.|Difference and change in root mean square of successive ECG RR interval difference (RMSSD).|Difference and change in Standard Deviation Normal RR Intervals (SDNN).|Difference and change in low-frequency power (LF).|Difference and change in high-frequency power (HF).|Difference and change in low-frequency power (LFnu).|Difference and change in low-frequency power (HFnu).","Coventry University","All","50 Years to 85 Years   (Adult, Older Adult)","Not Applicable","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","P125303","April 7, 2022","March 2024","March 2024","August 8, 2022",,"August 10, 2022","Coventry University, Coventry, West Midlands, United Kingdom",,"https://ClinicalTrials.gov/show/NCT05492552"
716,"NCT05492539","Incidence and Risk Factors for Developing Infections in Patients Colonized by CP-KPC","KPC","Recruiting","No Results Available","Carbapenemase-Producing Enterobacteriaceae",,"CRKP infections in CRKP colonized patients|30 day all-cause mortality","Hospital Italiano de Buenos Aires","All","18 Years to 120 Years   (Adult, Older Adult)",,"500","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","3978","July 1, 2022","November 1, 2022","February 3, 2023","August 8, 2022",,"August 8, 2022","Hospital Italiano de Buenos Aires, Ciudad Autonoma de Buenos Aire, Ciudad Autonoma De Buenos Aires, Argentina",,"https://ClinicalTrials.gov/show/NCT05492539"
717,"NCT05492526","The Use of Contextualised Body Data in Cardiac Rehabilitation (CR)","KiCS1","Recruiting","No Results Available","Cardiac Rehabilitation","Device: Ki Monitor without feedback|Device: Ki monitor with contextualised data feedback","Achieving the ACPICR standards for physical activity in a free-living environment objectively measured using the Ki monitor|Exercise test result.|Total calories burned|Completion of cardiac rehabilitation programme","Liverpool University Hospitals NHS Foundation Trust|KiActiv","All","Child, Adult, Older Adult","Not Applicable","130","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","4807","May 7, 2021","May 16, 2022","August 23, 2022","August 8, 2022",,"August 8, 2022","Liverpool University Hospital NHS Foundation Trust, Liverpool, United Kingdom",,"https://ClinicalTrials.gov/show/NCT05492526"
718,"NCT05492513","Constraint-Induced Movement Therapy for Adults Post-Stroke With Mild Upper Extremity Impairment",,"Not yet recruiting","No Results Available","CVA (Cerebrovascular Accident)|Stroke|Upper Extremity Paresis","Behavioral: Grade 1 CI Therapy +Sensory Components","45-Item Motor Activity Log (MAL)|Wolf Motor Function Test (WMFT)|Canadian Occupational Performance Measure (COPM)|Beck Depression Inventory (BDI)|Stroke Impact Scale (SIS)|9 Hole Peg Test (9HPT)|Revised Nottingham Sensory Assessment (rNSA)|Semmes-Weinstein Monofilament Test (SWMT)","University of Alabama at Birmingham","All","18 Years and older   (Adult, Older Adult)","Not Applicable","12","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB-300008653","August 2022","August 2023","November 2023","August 8, 2022",,"August 8, 2022","University of Alabama at Birmingham, Birmingham, Alabama, United States",,"https://ClinicalTrials.gov/show/NCT05492513"
719,"NCT05492500","A Study of Ponsegromab in People With Heart Failure","GARDEN TIMI 74","Not yet recruiting","No Results Available","Heart Failure","Drug: Ponsegromab low dose|Drug: Ponsegromab medium dose|Drug: ponsegromab high dose|Other: Matched placebo","Change from baseline in Kansas City Cardiomyopathy Questionnaire 23 Clinical Summary Score|Change from baseline in Kansas City Cardiomyopathy Questionnaire 23 Overall Summary Score|Change from baseline in Total Symptom Score|Change from baseline in physical limitation|Responses as defined by a ≥5 point increase from baseline in Kansas City Cardiomyopathy Questionnaire 23 Clinical Summary Score|Responses as defined by a ≥5 point increase from baseline in Overall Summary Score|Responses as defined by a ≥5 point increase from baseline in Total Symptom Score|Responses as defined by a ≥5 point increase from baseline in physical limitation|Change from baseline in 6-Minute Walk Distance|Change from baseline in heart failure Daily Diary fatigue score|Change from baseline in PROMIS-Fatigue 7a which will be completed by study participants on an electronic device, so as to compare the effect of ponsegromab versus placebo on fatigue as reported by participants with HF|Incidence of treatment-emergent adverse events|Incidence of treatment-emergent serious adverse events|Incidence of abnormal laboratory results|Incidence of abnormal vital signs","Pfizer|Thrombolysis In Myocardial Infarction (TIMI)","All","18 Years and older   (Adult, Older Adult)","Phase 2","416","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care","C3651011|2022-001809-50","September 22, 2022","July 5, 2024","September 13, 2024","August 8, 2022",,"August 8, 2022",,,"https://ClinicalTrials.gov/show/NCT05492500"
720,"NCT05492487","A Pilot Study on Fertility Conservative Treatment of Atypical Endometrial Hyperplasia in Singapore",,"Recruiting","No Results Available","Endometrial Hyperplasia|Fertility Issues|Disease Regression|Treatment Side Effects","Drug: Mirena|Drug: Megace","Rate of Regression|Time taken for regression of the disease|Patient Acceptability|Side Effects","KK Women's and Children's Hospital","Female","21 Years to 40 Years   (Adult)","Phase 2","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CIRB 2019/2551","January 3, 2020","March 31, 2023","March 31, 2023","August 8, 2022",,"August 8, 2022","National University Hospital, Singapore, Singapore|Singapore General Hospital, Singapore, Singapore|KK Women's and Children's Hospital, Singapore, Singapore",,"https://ClinicalTrials.gov/show/NCT05492487"
721,"NCT05492474","Cranial Ultrasound for Prehospital ICH Diagnosis","CUPID_EMS","Not yet recruiting","No Results Available","Intracerebral Hemorrhage|Acute Ischemic Stroke","Procedure: Cranial Point of Care Ultrasound","Success Rate for cPOCUS Exams","Wake Forest University Health Sciences","All","18 Years and older   (Adult, Older Adult)","Not Applicable","60","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening","IRB00077652","August 2022","July 2023","August 2023","August 8, 2022",,"August 8, 2022","Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT05492474"
722,"NCT05492461","Physician-assisted Dying in Mentally Ill Patients - Which Criteria Are Decisive?",,"Not yet recruiting","No Results Available","Physician-Assisted Suicide",,"Degree of consent to physician-assisted dying in somatic versus mental illness|Degree of consent to physician-assisted dying as a function of other factors|Positioning of the respondents to the SAMS criteria of 2004, 2018 and 2021.|Correlation between the positioning of the respondents on the SAMS criteria of 2004, 2018, and 2021 and the evaluation of the case vignettes|Correlation between the degree of stigmatization and the assessment of physician-assisted dying.|Comparison of the primary and secondary endpoints between the two groups.","Psychiatric Hospital of the University of Basel","All","18 Years to 65 Years   (Adult, Older Adult)",,"20000","Other","Observational","Observational Model: Other|Time Perspective: Prospective","KZS Seed Grant 11/20","August 2022","November 2022","June 2023","August 8, 2022",,"August 8, 2022",,,"https://ClinicalTrials.gov/show/NCT05492461"
723,"NCT05492448","Probiotic on Type 2 Diabetes and Chronic Obstruction Pulmonary Disease",,"Not yet recruiting","No Results Available","Type 2 Diabetes|Chronic Obstructive Pulmonary Disease","Dietary Supplement: Placebo|Dietary Supplement: L. salivarius and L. reuteri|Dietary Supplement: L. reuteri","Changes in concentration of glycated hemoglobin (HbA1c).|Changes in ratio of forced expiratory volume in 1 second (FEV1) and forced vital capacity (FVC).|Changes in concentration of fasting blood sugar.|Changes in concentration of immune cytokines.|Changes in scores of modified medical research council (mMRC).|Changes in scores of COPD assessment test (CAT).|Changes of the composition in gut microbiota.|Changes of the composition in lower respiratory tract microbiota.|Changes of concentration in short-chain fatty acid (SCFA) on plasma.|Changes of concentration in short-chain fatty acid (SCFA) on stool.|Changes in scores of modified Bristol stool form scale.","Glac Biotech Co., Ltd","All","50 Years to 85 Years   (Adult, Older Adult)","Not Applicable","120","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","EMRP12110N","September 30, 2022","September 30, 2023","December 31, 2023","August 8, 2022",,"August 8, 2022","Glac Biotech Co., Ltd., Tainan City, Taiwan",,"https://ClinicalTrials.gov/show/NCT05492448"
724,"NCT05492435","CEEG Changes After Tdcs and Dual-task Training",,"Not yet recruiting","No Results Available","Stroke|Electroencephalogram","Device: transcranial direct current stimulation","Changes in EEG microstates in each stimulation condition|Cognitive function - trail test (TMT) A and B|Cognitive function - clock drawing test|Cognitive function - verbal fluency test (VF).|motor function","Federal University of Paraíba","All","18 Years and older   (Adult, Older Adult)","Not Applicable","35","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","microstates_stroke","September 1, 2022","October 1, 2022","December 1, 2022","August 8, 2022",,"August 15, 2022",,,"https://ClinicalTrials.gov/show/NCT05492435"
725,"NCT05492422","Central Executive Training and Parent Training for ADHD",,"Not yet recruiting","No Results Available","ADHD","Device: Central Executive Training (CET)|Behavioral: Behavioral Parent Training (BPT)","Rapport visuospatial/phonological working memory test|Alabama parenting scale|Parenting sense of competence scale|Parent stress index|Behavior Assessment System for Children|ADHD Rating Scale|ODD symptoms (DSM-based checklist)","Florida State University","All","8 Years to 13 Years   (Child)","Not Applicable","200","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","1R01MH125893","January 2023","December 2027","January 2028","August 8, 2022",,"August 8, 2022","Florida State University, Tallahassee, Florida, United States",,"https://ClinicalTrials.gov/show/NCT05492422"
726,"NCT05492409","Study of Safety and Immunogenicity of GNR-069 With Long-term Use in Patients With ITP",,"Enrolling by invitation","No Results Available","Idiopathic Thrombocytopenic Purpura","Biological: GNR-069","Frequency and severity of adverse events associated with the use of the GNR-069|Number of undesirable events of particular interest in the study (Bleeding;Thrombotic/thromboembolic events)|Number and proportion of patients with antidrug antibodies; titer of antidrug antibodies and their neutralizing activity|Platelet count dynamics at Visits 1-5|Nomber of clinically significant bleeding (≥ grade 2 according to CTCAE 5.0) on Visits 1-5|Frequency of loss of response to treatment|Сhange in ITP-BAT bleeding scores at Visit 27/DTI from baseline at Visit 1","AO GENERIUM","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","160","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","RMP-ITP-III-X","March 28, 2022","June 17, 2023","August 16, 2023","August 8, 2022",,"August 8, 2022","State Budgetary Institution of Healthcare Irkutsk awarded the ""Sign of Honor"" Order Regional Clinical Hospital, Irkutsk, Irkutsk Region, Russian Federation|State Budgetary Health Institution of the Kaluga Region ""Kaluga Regional Clinical Hospital"", Kaluga, Kaluga Region, Russian Federation|State budgetary institution of health care of the Nizhny Novgorod region ""Nizhny Novgorod Regional Clinical Hospital named after N. A. Semashko"", Nizhny Novgorod, Nizhny Novgorod Region, Russian Federation|Llc ""Medis"", Nizhny Novgorod, Nizhny Novgorod Region, Russian Federation|Federal State Budgetary Educational Institution of Higher Education ""Novosibirsk State Medical University"" of the Ministry of Health of the Russian Federation, Novosibirsk, Novosibirsk Region, Russian Federation|Federal State Budgetary Educational Institution of Higher Education ""Bashkir State Medical University"" of the Ministry of Health of the Russian Federation, Ufa, Republic Of Bashkortostan, Russian Federation|Federal State Budgetary Educational Institution of Higher Education ""Rostov State Medical University"" of the Ministry of Health of the Russian Federation, Rostov-on-Don, Rostov Region, Russian Federation|State Health Institution of the Tula Region ""Tula Regional Clinical Hospital"", Tula, Tula Region, Russian Federation|Municipal budgetary institution ""Central City Hospital No. 7"", Ekaterinburg, Russian Federation|State Budgetary Institution of Healthcare of the city of Moscow ""Moscow Clinical Scientific and Practical Center named after A.S. Loginov"" Department of Health of the city of Moscow, Moscow, Russian Federation|Federal State Budget Funded Institution National Medical Research Center of Hematology, Ministry of Health of the Russian Federation (MoH of Russia), Moscow, Russian Federation|State budgetary health care institution of the city of Moscow ""City Clinical Hospital named after V.V. Veresaev of the Department of Health of the City of Moscow"", Moscow, Russian Federation|Federal State Budgetary Institution ""National Medical Research Center named after V.A. Almazov"" of the Ministry of Health of the Russian Federation, Saint Petersburg, Russian Federation",,"https://ClinicalTrials.gov/show/NCT05492409"
727,"NCT05492396","Evaluation of Healing Following Open Gluteus Medius Repair With Biointegrative Implant",,"Recruiting","No Results Available","Hip Injuries|Tendon Injuries|Orthopedic Procedures","Device: Standard gluteus medius repair with Tapestry Biointegrative implant","Assess overall tissue quality by ultrasound assessment|Assess overall tissue thickness by ultrasound assessment|Assess overall tissue organization by ultrasound assessment|Modified Harris Hip Score questionnaire|International Hip Outcome Tool questionnaire","Ohio State University","All","18 Years and older   (Adult, Older Adult)",,"15","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2021H0451","August 1, 2022","January 2024","August 2024","August 8, 2022",,"August 8, 2022","Jameson Crane Sports Medicine Institute, Columbus, Ohio, United States|The Ohio State University Hospital East, Columbus, Ohio, United States|Ohio State Outpatient Care New Albany, Westerville, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT05492396"
728,"NCT05492383","SAvvyWire™ EFficacy and SafEty in Transcatheter Aortic Valve Implantation Procedures (SAFE-TAVI)","SAFE-TAVI","Not yet recruiting","No Results Available","Severe Aortic Stenosis","Device: TAVI","Effective rapid pacing runs translating into a significant systemic pressure drop facilitating an accurate THV deployment|Safety: Absence of major complications related to the SavvyWire™|Successful valve invasive hemodynamic assessment in conjunction with the OptoMonitor 3 (i.e. ventricular pressure and valve gradient), without additional clinical manipulation|Successful valve advancement and positioning to the intended position","Opsens, Inc.","All","18 Years and older   (Adult, Older Adult)","Not Applicable","120","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","PRT-2015-32","September 1, 2022","February 1, 2023","February 1, 2023","August 8, 2022",,"August 8, 2022",,,"https://ClinicalTrials.gov/show/NCT05492383"
729,"NCT05492370","Effects of a Yeast Fermentate (EpiCor) Supplement on Cold or Flu Symptoms in Healthy Children",,"Not yet recruiting","No Results Available","Signs and Symptoms, Respiratory","Dietary Supplement: EpiCor|Dietary Supplement: Placebo","Incidence of cold or flu symptoms|Incidence on cold or flu symptoms from baseline to day 42|Severity of cold or flu symptoms|Duration of cold or flu symptoms|Proportion of children with no cold or flu symptoms|Number of days prior to first cold or flu symptoms|Number of missed school or daycare days due to cold or flu symptoms|Number of well days, related to the absence of cold or flu symptoms|Use of prescription and non-prescription cold/flu medications to treat cold or flu symptoms|Saliva secretory immunoglobulin A concentrations|Quality of life as assessed by the KINDL questionnaire|Safety profile as assessed by Adverse Events (AEs)|Safety profile as assessed by vital sign blood pressure|Safety profile as assessed by vital sign heart rate","Cargill|KGK Science Inc.","All","4 Years to 12 Years   (Child)","Not Applicable","256","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","21CLRFZ02","September 4, 2022","August 10, 2023","August 10, 2023","August 8, 2022",,"August 8, 2022","KGK Science Inc, London, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT05492370"
730,"NCT05492357","Effects of Recurrent Application of i-PRF on Hard and Soft Tissues","i-PRF","Recruiting","No Results Available","i-PRF|A-PRF","Other: injectable platelet-rich fibrin|Other: Advanced Platelet-rich fibrin","Ridge dimensions|Gingival biotype","Cezar Edward Lahham|Arab American University (Palestine)","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PHRC/HC/1151/22","June 15, 2022","August 15, 2022","December 15, 2022","August 8, 2022",,"August 8, 2022","Cezar Lahham, Bethlehem, Palestinian Territory, occupied",,"https://ClinicalTrials.gov/show/NCT05492357"
731,"NCT05492344","Personalized Mechanical Ventilation Guided by UltraSound in Patients With Acute Respiratory Distress Syndrome",,"Not yet recruiting","No Results Available","ARDS, Human|Lung Ultrasound|Mechanical Ventilation","Other: Personalized ventilation|Other: Standard care","All-cause mortality|Ventilator free days|ICU length of stay|ICU mortality|Hospital length of stay|Hospital mortality|Number of patients with Complications|Number of patients with Adjunctive therapies|Number of patients with Rescue therapies","Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","All","18 Years to 100 Years   (Adult, Older Adult)","Not Applicable","538","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","PEGASUS","August 1, 2022","November 1, 2025","November 1, 2025","August 8, 2022",,"August 8, 2022",,,"https://ClinicalTrials.gov/show/NCT05492344"
732,"NCT05492331","A Study of Music Therapy to Support Intrauterine Insemination",,"Recruiting","No Results Available","Intrauterine Insemination","Other: Music Therapy","Change in anxiety|Change in pain score|Pregnancy rate","Mayo Clinic","Female","18 Years and older   (Adult, Older Adult)","Not Applicable","62","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","22-006147","August 3, 2022","May 2023","May 2023","August 8, 2022",,"August 8, 2022","Mayo Clinic in Rochester, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT05492331"
733,"NCT05492318","Perpetrator DDI Potential of Givinostat as Inhibitor and Inducer of CYP3A and P-gp Activity",,"Completed","No Results Available","Drug-Drug Interaction","Drug: ITF2357 Givinostat 10mg/mL|Drug: Midazolam 1Mg/Ml (Pf) Inj Syringe 5Ml|Drug: Midazolam Oral Liquid Product|Drug: Dabigatran Etexilate 75 MG [Pradaxa]|Drug: Clarithromycin 500Mg Tab","Maximum observed plasma concentration (Cmax) for midazolam, 1-hydroxymidazolam, total dabigatran, free dabigatran, givinostat (Part 2 and 3) and its metabolites (Part 3), following single doses of the parent drug|Time of occurrence of Cmax (tmax) for midazolam, 1-hydroxymidazolam, total dabigatran, free dabigatran, givinostat (Part 2 and 3) and its metabolites (Part 3), following single doses of the parent drug|AUC from pre-dose (time zero) to the last sampling time with quantifiable concentrations (AUC0-t) or midazolam, 1-hydroxymidazolam, total dabe, free dabe, givinostat (Part 2&3) and its metabolites (Part 3), following single doses of Givi|Maximum observed plasma concentration at steady state (Cmax,ss) for givinostat and its metabolites using the individual plasma concentration-time profiles|Time of occurrence of Cmax,ss (tmax,ss) for givinostat and its metabolites using the individual plasma concentration-time profiles|AUC during the dosing interval, at steady-state (AUC0-τ,ss) for givinostat and its metabolites using the individual plasma concentration-time profiles|Maximum urinary excretion rate (Rmax) after the first dose and the last dose of Givinostat|Time to Rmax (tumax) after the first dose and the last dose of Givinostat","Italfarmaco","All","18 Years to 55 Years   (Adult)","Phase 1","54","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ITF/2357/55|2021-005756-11","March 21, 2022","May 8, 2022","May 24, 2022","August 8, 2022",,"August 8, 2022","Hospital da Prelada, 3rd Floor & East Wing 4th Floor Rua Sarmento de Beires, Porto, Portugal",,"https://ClinicalTrials.gov/show/NCT05492318"
734,"NCT05492305","Glucagon-like Peptide 1 (GLP1) Receptor Agonists and Mental Health",,"Not yet recruiting","No Results Available","Diabetes Mellitus|Obesity|Mental Health Issue","Drug: GLP-1 receptor agonist","subjective effect of GLP1 receptor agonist on mental health|subjective effect of GLP1 receptor agonist on general wellbeing|subjective effect of GLP1 receptor agonist on eating behaviours|subjective effect of GLP1 receptor agonist on binge eating, if present|mean change in patient health questionnaire 9 (PHQ9) score with GLP1 receptor agonist over 12-16 weeks|mean change in generalised anxiety disorder assessment (GAD) score with GLP1 receptor agonist over 12-16 weeks|mean change in eating disorder examination questionnaire (EDE-Q) score with GLP1 receptor agonist over 12-16 weeks","King's College London","All","18 Years and older   (Adult, Older Adult)",,"20","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","314639","August 2022","June 2023","August 2023","August 8, 2022",,"August 8, 2022",,,"https://ClinicalTrials.gov/show/NCT05492305"
735,"NCT05492292","Long-term Effects of SARS-CoV-2 on the Central Nervous System and One-year Follow-up of ""Long COVID-19"" Patients",,"Recruiting","No Results Available","Long Covid19","Diagnostic Test: Perfusion brain scintigraphy imaging","Difference (1 year versus baseline) in the distribution of hypo-perfused areas in the brain as assessed by cerebral perfusion scintigraphy.","Brugmann University Hospital","All","18 Years and older   (Adult, Older Adult)","Not Applicable","100","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","CHUB-Neuro-Covid Long","August 10, 2021","December 31, 2023","December 31, 2023","August 8, 2022",,"August 8, 2022","CHU Brugmann, Brussels, Belgium",,"https://ClinicalTrials.gov/show/NCT05492292"
736,"NCT05492279","Is Sheep Ghee Cardioprotective?",,"Completed","No Results Available","Cholesterol; Metabolic Disorder|Inflammation","Dietary Supplement: sheep ghee|Dietary Supplement: sunflower oil","LDL cholesterol|total cholesterol|HDL cholesterol|HS-CRP|adverse effect","Shiraz University of Medical Sciences","All","20 Years to 76 Years   (Adult, Older Adult)","Not Applicable","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","98-01-01-22054","February 1, 2020","June 1, 2022","July 1, 2022","August 8, 2022",,"August 8, 2022","Javad Kojuri, Shiraz, Fars, Iran, Islamic Republic of",,"https://ClinicalTrials.gov/show/NCT05492279"
737,"NCT05492266","Expiratory Muscle Strength Training for Hypernasal Speech in Children",,"Not yet recruiting","No Results Available","Velopharyngeal Insufficiency|Velopharyngeal Incompetence Due to Cleft Palate|Inadequate Velopharyngeal Closure|Palatopharyngeal Incompetence|Hypernasality","Device: Expiratory Muscle Strength Training|Device: Maintenance Training","Change in nasalance scores after 6-8 weeks of exercises compared with baseline|Change in perceptual speech symptoms of velopharyngeal dysfunction following 6-8 weeks of exercises compared with baseline|Change in oral pressure following 6-8 weeks of exercises compared with baseline|Change in velopharyngeal flutter following 6-8 weeks of exercises compared with baseline|Change in oral pressure decay following 6-8 weeks of exercises compared with baseline|Change in VELO questionnaire scores following 6-8 weeks of exercises compared with baseline|Resolution of type B tympanogram following 6-8 weeks of exercises compared with baseline.|Resolution of type C tympanogram following 6-8 weeks of exercises compared with baseline.|Resolution of effusion following 6-8 weeks of exercises compared with baseline.|Resolution of retraction following 6-8 weeks of exercises compared with baseline.","Noel Jabbour|National Institute on Deafness and Other Communication Disorders (NIDCD)|University of Pittsburgh","All","5 Years to 17 Years   (Child)","Not Applicable","30","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","STUDY21120032|5R21DC017553-03","August 2022","August 2023","April 2024","August 8, 2022",,"August 8, 2022","UPMC Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT05492266"
738,"NCT05492253","First Complementary Foods and the Infant Gastrointestinal Microbiota",,"Not yet recruiting","No Results Available","Healthy Participants|Infants|Gastrointestinal Microbiota","Other: Infant fruit|Other: Infant vegetable|Other: Infant meat|Other: Infant grain","Change in gastrointestinal microbiota","University of Delaware|American Society for Nutrition Foundation","All","5 Months to 7 Months   (Child)","Not Applicable","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Basic Science","1889964-1","September 1, 2022","October 1, 2023","October 1, 2023","August 8, 2022",,"August 8, 2022","University of Delaware, Newark, Delaware, United States",,"https://ClinicalTrials.gov/show/NCT05492253"
739,"NCT05492240","Advancing Rehabilitation Paradigms for Older Adults in Skilled Nursing Facilities",,"Recruiting","No Results Available","Aging|Functional Recovery|Skilled Nursing Facility|Medically Complex|Deconditioning","Other: i-STRONGER|Other: Usual Care","Change in Gait Speed|Change in Short Physical Performance Battery (SPPB)|Post-discharge Rehospitalization Rate","University of Colorado, Denver|Aegis Therapies, Inc.|National Institute on Aging (NIA)","All","50 Years to 120 Years   (Adult, Older Adult)","Not Applicable","2880","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","20-3068|R01AG072693","July 24, 2022","February 28, 2025","February 28, 2025","August 8, 2022",,"August 8, 2022","University of Colorado Denver, Anschutz Medical Campus, Aurora, Colorado, United States|Aegis Therapies, Frisco, Texas, United States",,"https://ClinicalTrials.gov/show/NCT05492240"
740,"NCT05492227","SARS-CoV-2 Nucleic Acid Detection Kit Clinical Performance Study","CPS CW008","Recruiting","No Results Available","COVID-19|Coronavirus Disease 2019|COVID-19 Pandemic|Diagnoses Disease","Diagnostic Test: Left-overs","Sensitivity of the SARS-CoV-2 NAD Kit|Specificity of the SARS-CoV-2 NAD Kit","TransGen Biotech Co., LTD","All","Child, Adult, Older Adult",,"600","Industry","Observational","Observational Model: Cohort|Time Perspective: Retrospective","CW008","May 10, 2022","August 2022","September 2022","August 8, 2022",,"August 8, 2022","Laura Martínez Rachadell, Madrid, Spain","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/27/NCT05492227/Prot_000.pdf","https://ClinicalTrials.gov/show/NCT05492227"
741,"NCT05492214","The Effect of Time Window for Umbilical Cord Clamping During Cesareans on Offspring Hemoglobin and Maternal Blood Loss",,"Not yet recruiting","No Results Available","Delayed Cord Clamping|Hemoglobin|Blood Loss","Procedure: Delayed cord clamping (30s)|Procedure: Delayed cord clamping (60s)|Procedure: Delayed cord clamping (90s)","The neonatal hemoglobin|The change in maternal hemoglobin|The incidence rate of neonatal anemia|The incidence rate of neonatal jaundice|Apgar score|The incidence rate of neonatal intensive care unit admission|Placental weight|Maternal hemoglobin after the cesarean|Estimated maternal blood loss|The incidence rate of maternal blood transfusion","Peking University|National Natural Science Foundation of China|Liuyang Maternal and Child Health Care Hospital|Women and Children's Health Care Hospital of Huantai","Female","Child, Adult, Older Adult","Not Applicable","360","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","NSFC.82173528","August 2022","January 2023","June 2024","August 8, 2022",,"August 10, 2022","Liuyang Maternal and Child Health Care Hospital, Liuyang, Hunan, China|Women and Children's Health Care Hospital of Huantai, Zibo, Shandong, China","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/14/NCT05492214/SAP_000.pdf","https://ClinicalTrials.gov/show/NCT05492214"
742,"NCT05492201","A Study of LY3873862 in Healthy Participants",,"Not yet recruiting","No Results Available","Healthy","Drug: LY3873862|Drug: Placebo","Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration|Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞]) of LY3873862|PK: Area Under the Concentration versus Time Curve at Steady State (AUCτ) of LY3873862|PK: Maximum Observed Concentration (Cmax) of LY3873862|PK: Time of Maximum observed Concentration (Tmax) of LY3873862","Eli Lilly and Company","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","90","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","18445|J3X-MC-LYGA|2022-000500-36","August 31, 2022","April 17, 2023","April 17, 2023","August 8, 2022",,"August 8, 2022","Hammersmith Medicines Research, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT05492201"
743,"NCT05492188","Neuropathic Pain and Operant Conditioning of Cutaneous Reflexes After SCI",,"Not yet recruiting","No Results Available","Spinal Cord Injuries|Neuropathic Pain|Neurological Injury|Pain","Behavioral: Operant Conditioning of Cutaneous Reflexes","Change in minimum stimulation intensity required to barely detect the sensation (perceived threshold, perT)|Change in minimum intensity at which the sensation covers the maximum area of skin (radiating threshold, RT)|Change in minimum intensity at which the stimulus become painful (pain threshold, PainT)|Change in pain as measured by the McGill Pain Questionnaire (MPQ)|Change in neuropathic pain as measured by the Neuropathic Pain Symptom Inventory (NPSI)|Change in ability to perceive various types of sensations as indicated by Quantitative Sensory Testing (QST)|Change in basic functional independence as measured by the Spinal Cord Independence Measure (SCIM III)|Change in functional independence as measured by the Functional Independence Measure (FIM)|Change in quality of life as measured by Spinal Cord Injury Quality of Life and Participation Questionnaire (SCI-QOL)","Medical University of South Carolina","All","18 Years and older   (Adult, Older Adult)","Not Applicable","15","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","118771","October 1, 2022","October 1, 2025","October 1, 2026","August 8, 2022",,"August 8, 2022",,,"https://ClinicalTrials.gov/show/NCT05492188"
744,"NCT05492175","Proximal- Versus Distal-Prioritized Robotic Practice Plus Kinetic Exergaming in Stroke Rehabilitation",,"Recruiting","No Results Available","Stroke Rehabilitation","Other: robotic practice|Other: kinetic exergaming|Other: conventional therapy","Change from Baseline Fugl-Meyer Assessment (FMA) at 6 weeks and 18 weeks|Change from Baseline 10 meter walk test (10-MWT) at 6 weeks and 18 weeks|Medical Research Council scale (MRC)|Myoton Pro|The ActiGraph GX3 accelerometers (ActiGraph, Shalimar, FL,USA)|Functional Independence Measure (FIM)|Stroke Self-Efficacy Questionnaire (SSEQ)|Adverse events (pain and fatigue)","Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation","All","20 Years to 80 Years   (Adult, Older Adult)","Not Applicable","72","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","10-M-161","February 17, 2022","December 31, 2026","December 31, 2026","August 8, 2022",,"August 8, 2022","Taipei Tzu Chi Hospital, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT05492175"
745,"NCT05492162","An Intervention to Promote Health Students' Well-being","IFPDays","Not yet recruiting","No Results Available","Healthy Lifestyle|Students Wellbeing","Other: well-being promotion intervention","Well-being|Resilience|Self-esteem|Students' Satisfaction","Groupe Hospitalier du Havre","All","18 Years and older   (Adult, Older Adult)","Not Applicable","150","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","IFPDays","September 1, 2022","July 31, 2023","December 31, 2023","August 8, 2022",,"August 8, 2022",,,"https://ClinicalTrials.gov/show/NCT05492162"
746,"NCT05492149","Pulmonary Rehabilitation for COPD Patients: Can Performance Predict Exacerbation?","PREDICT","Not yet recruiting","No Results Available","COPD|COPD Exacerbation|Pulmonary Rehabilitation","Other: Performance follow-up","Correlation between the decrease of performance during pulmonary rehabilitation session and the occurrence of pulmonary exacerbation.|Correlation between the decrease of performance during pulmonary rehabilitation session and the COPD Assessment Test (CAT) questionnaire score.","Groupe Hospitalier du Havre","All","18 Years and older   (Adult, Older Adult)",,"150","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2022-A00210-43","September 1, 2022","September 1, 2024","December 1, 2024","August 8, 2022",,"August 8, 2022",,,"https://ClinicalTrials.gov/show/NCT05492149"
747,"NCT05492136","Unravelling the Impact of Radiofrecuency in Liver Surgery: the Key to Decrease Local Recurrence?","LIVERaTION","Not yet recruiting","No Results Available","Liver Cancer|Cancer, Treatment-Related","Procedure: Additional margin coagulation","Local recurrence","Hospital del Mar","All","18 Years and older   (Adult, Older Adult)","Phase 3","1566","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","Liveration_v2","April 1, 2023","December 31, 2026","December 31, 2027","August 8, 2022",,"August 8, 2022",,,"https://ClinicalTrials.gov/show/NCT05492136"
748,"NCT05492123","Nivolumab-ipilimumab and Chemoradiation for Cervical Cancer",,"Not yet recruiting","No Results Available","Uterine Cervical Neoplasms","Drug: Nivolumab 40 mg in 4 ml Injection|Drug: Ipilimumab 200 MG in 40 ML Injection|Radiation: Chemoradiation","3-year progression-free survival|3-year overall survival|Objective response rate|Response duration|To evaluate health related quality of life (HRQoL): defined as the change from baseline of disease-related symptoms and quality of life of patients undergoing treatment Nivolumab-ipilimumab and Chemoradiation for Cervical Cancer|Evaluate health related quality of life using supplemental cervical cancer module (EORTC CX24) to evaluate patients submitted to treatment with Nivolumab-ipilimumab and Chemoradiation for Cervical Cancer.|Treatment-related toxicity","Hospital Israelita Albert Einstein|Bristol-Myers Squibb|Brava","Female","18 Years to 95 Years   (Adult, Older Adult)","Phase 2","112","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BRAVA- Cervical - SGPP 5031-21","August 1, 2022","August 31, 2026","August 31, 2026","August 8, 2022",,"August 8, 2022","Clinica AMO, Salvador, Bahia, Brazil|CRIO -Centro Regional Integrado de Oncologia, Fortaleza, Ceará, Brazil|Hospital das Clinicas da UFMG, Belo Horizonte, Minas Gerais, Brazil|Hospital Erasto Gaertner, Curitiba, Paraná, Brazil|Multi Oncoclinicas Recife, Recife, Pernambuco, Brazil|Hospital São Lucas - PUCRS, Porto Alegre, Rio Grande Do Sul, Brazil|Universidade Federal de Roraima, Boa Vista, Roraima, Brazil|CEPON - Florianópolis, Florianópolis, Santa Catarina, Brazil|Hospital de Amor, Barretos, São Paulo, Brazil|Hospital De Base de São José do Rio Preto - CIP São José, São José Do Rio Preto, São Paulo, Brazil|INCA - Instituto Nacional do Cancer, Rio De Janeiro, Brazil|ICESP - Instituto do Cancer do Estado de São Paulo, São Paulo, Brazil|AC Camargo Cancer Center, São Paulo, Brazil|Hospital Municipal Vila Santa Catarina, São Paulo, Brazil",,"https://ClinicalTrials.gov/show/NCT05492123"
749,"NCT05492110","Coronary Sinus Reducer Implantation in Patients With Ischaemia and Non-obstructed Coronary Arteries and Coronary Microvascular Dysfunction.","REMEDY-PILOT","Not yet recruiting","No Results Available","Refractory Angina|Microvascular Angina|Microvascular Coronary Artery Disease|Coronary Disease|Angina Pectoris","Device: Coronary sinus reducer|Other: Sham-procedure|Diagnostic Test: Invasive coronary physiology","number of patients consenting to participate in the study.|Premature withdrawal rate including reasons for withdrawal|Change in myocardial perfusion|Canadian Cardiovascular Society (CCS) Angina Score|Seattle Angina Questionnaire (SAQ) score|Short-form 36 (SF-36)|Hospital Anxiety and Depression Scale (HADS)|6-minute walk test (6MWT)|BORG scale of perceived exertion|Safety events - rate of major adverse events","Imperial College London|Bradford Teaching Hospitals NHS Foundation Trust|East and North Hertfordshire NHS Trust|Epsom and St Helier University Hospitals NHS Trust|Guy's and St Thomas' NHS Foundation Trust|Imperial College Healthcare NHS Trust|Kingston Hospital NHS Trust|London North West Healthcare NHS Trust|Oxford University Hospitals NHS Trust|Royal Brompton & Harefield NHS Foundation Trust|St George's University Hospitals NHS Foundation Trust|Liverpool University Hospitals NHS Foundation Trust","All","18 Years and older   (Adult, Older Adult)","Not Applicable","54","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","21IC7301","August 6, 2022","April 6, 2025","August 7, 2025","August 8, 2022",,"August 11, 2022","National Heart and Lung Institute (Brompton Campus), Imperial College London, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT05492110"
750,"NCT05492097","The Effect of Robot-assisted Walking Training on Hemiplegic Individuals",,"Recruiting","No Results Available","Hemiplegia|Gait, Hemiplegic|Motor Function|Balance; Distorted","Behavioral: Exercise Therapy|Behavioral: Exercise Therapy and Robotic Walking Training","The 10-meter walking test|Number of Steps|The Fugl Meyer Rating Scale|The Postural Rating Scale in Stroke Patients|Tineti Balance and Gait Assessment|The Stroke Impact Scale|Brunnstrom motor staging|Functional Ambulation Scale|The Modified Ashworth Scale|Beck Depression Scale","Medipol University","All","40 Years to 70 Years   (Adult, Older Adult)","Not Applicable","40","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","E-10840098-772.02-667","February 14, 2022","August 8, 2022","September 1, 2022","August 8, 2022",,"August 12, 2022","Istanbul Medipol University, Istanbul, Turkey",,"https://ClinicalTrials.gov/show/NCT05492097"
751,"NCT05492084","Personalized Risk of Rapidly Progressive Atherosclerosis","RPA","Completed","No Results Available","Atherosclerosis, Coronary","Other: without Intervention","death, MI, stroke|total mortality","Novosibirsk State Medical University|Novosibirsk State University","All","18 Years to 70 Years   (Adult, Older Adult)",,"202","Other","Observational","Observational Model: Cohort|Time Perspective: Other","L-001","January 1, 2019","January 1, 2019","January 31, 2019","August 8, 2022",,"August 8, 2022","Novosibirsk State Medical University, Novosibirsk, Novosibirskaja Oblast' (oblast'), Russian Federation",,"https://ClinicalTrials.gov/show/NCT05492084"
752,"NCT05492071","Impact of Regional Vibration Application and Flow Mediated Dilation on Brachial Artery Hemodynamics","VMD","Recruiting","No Results Available","Vasodilation|Diabetes Mellitus, Type 2","Device: Local Vibration Application Following Flow Mediated Dilation","Brachial Artery Diameter|Brachial Artery Mean Flow Velocity","Istanbul University","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","90","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","2020/755","August 8, 2022","September 2022","September 2022","August 8, 2022",,"August 10, 2022","Istanbul University, Istanbul Faculty of Medicine, Department of Cardiology, Istanbul, Turkey",,"https://ClinicalTrials.gov/show/NCT05492071"
753,"NCT05492058","Tactile Stimulus, Music Play and Virtual Reality Video Watching During Non-Stress Test on Maternal Anxiety and Fetal Parameters",,"Completed","No Results Available","Fetal Heart Failure|Fetal Movement Disorder","Other: tactile stimulation group|Other: listen music|Other: virtual reality group","Fetal heart rate, fetal movement|Maternal anxiety","Adiyaman University Research Hospital","Female","19 Years to 45 Years   (Adult)","Not Applicable","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","Lokman Hekim University","July 5, 2022","July 7, 2022","July 10, 2022","August 8, 2022",,"August 8, 2022","Lokman hekim University, Çankaya, Ankara, Turkey",,"https://ClinicalTrials.gov/show/NCT05492058"
754,"NCT05492045","A Study to Evaluate D-1553 in Combination Therapy in Non-Small Cell Lung Cancer",,"Not yet recruiting","No Results Available","NSCLC","Drug: D-1553|Drug: Other","Subject incidence of Dose-limiting toxicities (DLT)|Number of subjects participants with adverse events|Antitumor activity of D-1553 in subjects with advanced or metastatic NSCLC with KRASG12C mutation","InventisBio Co., Ltd","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","144","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","D1553-105","September 2022","April 2023","December 2023","August 8, 2022",,"August 15, 2022","Shanghai Chest Hospital, Shanghai, Shanghai, China|Zhejiang Cancer Hospital, Cancer Hospital of the University of Chinese Academy of Sciences, Hangzhou, Zhejiang, China",,"https://ClinicalTrials.gov/show/NCT05492045"
755,"NCT05492032","Cumulative and Booster Effects of Multisession Prefrontal tDCS in Adolescents With ASD",,"Not yet recruiting","No Results Available","Transcranial Direct Current Stimulation|Autistic Spectrum Disorder|Electroencephalography","Device: Active-tDCS|Device: Sham-tDCS","Change in social responsiveness - Social Responsiveness Scale-2nd edition (SRS-2)|Clinical response in tDCS outcome|Change in neuropsychological measures - CANTAB® cognitive tests","The Hong Kong Polytechnic University","All","14 Years to 21 Years   (Child, Adult)","Not Applicable","90","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","HSEARS20220216004","January 2023","September 2025","December 31, 2025","August 8, 2022",,"August 8, 2022","The Hong Kong Polytechnic University, Hung Hom, Kowloon, Hong Kong",,"https://ClinicalTrials.gov/show/NCT05492032"
756,"NCT05492019","Effect of Doxycycline in Levodopa Treated Parkinson's Disease Patients",,"Recruiting","No Results Available","Parkinson Disease","Drug: Doxycycline|Drug: Placebo","Effect of doxycycline on improvement of motor performance and cognitive functions of Parkinson's disease.|High sensitive C-reactive protein","Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh","All","18 Years and older   (Adult, Older Adult)","Phase 2","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","3914","July 1, 2022","January 1, 2023","January 1, 2023","August 8, 2022",,"August 8, 2022","Bangabandhu Sheikh Mujib Medical University (BSMMU), Dhaka, Bangladesh",,"https://ClinicalTrials.gov/show/NCT05492019"
757,"NCT05492006","Immune Response and Affective States of Elderly and 50+ Individuals After Intentional and Indirect Contact With Nature",,"Not yet recruiting","No Results Available","Elderly","Behavioral: Indirect contact with nature|Behavioral: Intentional contact with nature","Change from Baseline Concentration of Cytokines in Soluble Immune Profile at 30 minutes post intervention, within 48 hours post intervention and within 4 weeks post intervention.|Change from baseline percentage and absolute number levels of Cellular Immune Profile at 30 minutes post intervention, within 48 hours post intervention and within 4 weeks post intervention|Change from baseline percentage and absolute number levels of Cellular Immune Profile (others) at 30 minutes post intervention, within 48 hours and within 4 weeks post intervention|Change from baseline affective states at 30 minutes post intervention, within 48 hours post intervention and within 4 weeks post intervention.","Hospital Israelita Albert Einstein|Conselho Nacional de Desenvolvimento Científico e Tecnológico|Paulo de Tarso Ricieri de Lima","All","18 Years and older   (Adult, Older Adult)","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","e-Nature NK","November 2022","August 1, 2023","July 2024","August 8, 2022",,"August 15, 2022","Hospital Israelita Albert Einstein, São Paulo, Brazil",,"https://ClinicalTrials.gov/show/NCT05492006"
758,"NCT05491993","This Trial is a Clinical Performance Validation Study That Will Evaluate the Clinical Agreement of the Sky Medical™ Rapid Antigen Test Comparing the Antigen Rapid Test to RT-PCR",,"Recruiting","No Results Available","COVID-19|Sars-CoV-2 Infection","Diagnostic Test: Sky Medical™ Rapid Antigen Test","Percent Positive Agreement and Negative Percent Agreement","Sky Medical Supplies & Equipments, LLC","All","7 Years and older   (Child, Adult, Older Adult)","Not Applicable","200","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","SKYCOV001-2","February 22, 2022","January 11, 2023","January 11, 2023","August 8, 2022",,"August 8, 2022","American Research Labs, Lake Worth, Florida, United States",,"https://ClinicalTrials.gov/show/NCT05491993"
759,"NCT05491980","Florida Cerebrovascular Disease Biorepository and Genomics Center",,"Recruiting","No Results Available","Cerebrovascular Disease|Ischemic Stroke|Transient Ischemic Attack|Intracerebral Hemorrhage|Aneurysmal Subarachnoid Hemorrhage|Vascular Dementia|Anoxic Brain Injury|Unruptured Intracranial Aneurysm|Carotid Artery Stenosis Symptomatic|Asymptomatic Carotid Artery Stenosis|Non-Aneurysmal Perimesencephalic Subarachnoid Haemorrhage|Cerebral Venous Thrombosis|Moyamoya Disease|Fibromuscular Dysplasia|Subarachnoid Hemorrhage|Leukoaraiosis|Arteriovenous Fistula|Reversible Cerebral Vasoconstriction Syndrome|CADASIL",,"Stroke or TIA","Mayo Clinic","All","18 Years and older   (Adult, Older Adult)",,"5000","Other","Observational","Observational Model: Other|Time Perspective: Prospective","22-002667","August 2022","August 2024","August 2024","August 8, 2022",,"August 8, 2022","Mayo Clinic Florida, Jacksonville, Florida, United States",,"https://ClinicalTrials.gov/show/NCT05491980"
760,"NCT05491967","Comparison of Vascular Risk in Patients Treated for Obstructive Sleep Apnea/Hypopnea Syndrome","SAHOSVAS","Recruiting","No Results Available","Obstructive Sleep Apnea/Hypopnea Syndrome",,"morbimortality vascular criteria","Centre Hospitalier de Valence","All","18 Years and older   (Adult, Older Adult)",,"172","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","00007","March 16, 2021","March 16, 2022","March 16, 2023","August 8, 2022",,"August 12, 2022","Ch Valence, Valence, Drome, France",,"https://ClinicalTrials.gov/show/NCT05491967"
761,"NCT05491954","Continuous Glucose Monitoring for Various Degrees of Glucose Intolerance",,"Not yet recruiting","No Results Available","Diabetes, Gestational","Device: Dexcom G6","Changes in glycemic control over late gestation as measured by A1c|The number of neonatal hypoglycemic episodes","Ohio State University","Female","18 Years to 45 Years   (Adult)",,"72","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2021H0009","August 2022","August 2023","August 2023","August 8, 2022",,"August 9, 2022","The Ohio State University Medical Center, Columbus, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT05491954"
762,"NCT05491941","Assessment for Implementation Methods in Sepsis","AIMS","Recruiting","No Results Available","Sepsis Severe|Septic Shock","Other: Sepsis Bundle","Mortality","Rhode Island Hospital","All","18 Years and older   (Adult, Older Adult)","Not Applicable","10000","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1RO1HL162954-01","July 15, 2022","July 15, 2027","July 15, 2027","August 8, 2022",,"August 8, 2022","Rhode Island Hospital, Providence, Rhode Island, United States",,"https://ClinicalTrials.gov/show/NCT05491941"
763,"NCT05491928","Treatment of Metastatic Cancer in Terminally Diagnosed Patients",,"Available","No Results Available","Metastatic Cancer","Drug: Tempol",,"Matrix Biomed, Inc.","All","Child, Adult, Older Adult",,,"Industry","Expanded Access:Individual Patients",,"MBI-23-01",,,,"August 8, 2022",,"August 8, 2022","UCHealth University of Colorado Cancer Center - Anschutz Medical Campus, Aurora, Colorado, United States",,"https://ClinicalTrials.gov/show/NCT05491928"
764,"NCT05491915","SPRINT® Peripheral Nerve Stimulation for the Treatment of Head Pain",,"Not yet recruiting","No Results Available","Cervicogenic Headache|Occipital Neuralgia","Device: SPRINT Peripheral Nerve Stimulation (PNS) System","Reduction in average pain and/or reduction in pain interference.|Study-Related Adverse Events (AEs)|Reduction in average pain intensity|Reduction in pain interference|Reduction in pain medication usage","SPR Therapeutics, Inc.","All","21 Years and older   (Adult, Older Adult)","Not Applicable","50","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","0156-CSP-000","August 2022","August 2026","August 2026","August 8, 2022",,"August 8, 2022",,,"https://ClinicalTrials.gov/show/NCT05491915"
765,"NCT05491902","Pilot PET Study of Regional Cerebral Protein Synthesis in Alzheimer's",,"Terminated","No Results Available","Alzheimer Disease","Diagnostic Test: [C11] Leucine PET scan|Diagnostic Test: [18F] Flutemetamol PET scan|Diagnostic Test: MRI scan","Regional changes in Protein Synthesis Rate in AD brain compared to age-matched controls|Regional changes in Protein Synthesis Rate in healthy controls|Regional changes in Protein Synthesis Rate in AD patients","University of Manchester|GlaxoSmithKline","All","18 Years and older   (Adult, Older Adult)",,"10","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","16/NW/0705","October 9, 2017","October 15, 2020","October 15, 2020","August 8, 2022",,"August 8, 2022","Wolfson Molecular Imaging Centre (University of Manchester), Manchester, United Kingdom|Salford Royal NHS Foundation Trust, Manchester, United Kingdom",,"https://ClinicalTrials.gov/show/NCT05491902"
766,"NCT05491889","Outcome of Hepatocellular Carcinoma Patients With Portal Vein Thrombosis After Trans-Arterial Chemo Embolization",,"Not yet recruiting","No Results Available","Hepatocellular Carcinoma","Biological: trans arterial chemoembolization","mortality","Assiut University","All","18 Years and older   (Adult, Older Adult)",,"30","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","17101837","October 1, 2022","October 1, 2024","February 1, 2025","August 8, 2022",,"August 8, 2022",,,"https://ClinicalTrials.gov/show/NCT05491889"
767,"NCT05491876","Active Cycle Of Breathing Technique Verses Breathing Exercises In Post ICU COVID-19 Patients",,"Recruiting","No Results Available","Post Covid-19 Patients","Other: Chest physiotherapy with breathing exercises and ACBT|Other: Chest physiotherapy with breathing exercises","SPIROMETRY|PULSE OXIMETRY","Riphah International University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","48","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","REC/RCR & AHS/22/0333","February 15, 2022","July 15, 2022","August 20, 2022","August 8, 2022",,"August 8, 2022","Jinnah Hospital Lahore, Lahore, Punjab, Pakistan",,"https://ClinicalTrials.gov/show/NCT05491876"
768,"NCT05491863","Effects of Trunk Stability Exercises on Hand Function in Children With Cerebral Palsy",,"Completed","No Results Available","Cerebral Palsy","Other: conservative physiotherapy plan|Other: trunk stability exercise plan","Trunk Control Meaurment Scale|ABILHAND-kids (Manual Ability Measure)|CHEQ (Children's hand-use experience's questionnaire)|UE MAL|Manual ability classification system|Modified ash worth scale (MAS)","Riphah International University","All","6 Years to 18 Years   (Child, Adult)","Not Applicable","26","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","REC/RCR & AHS/22/0710","October 28, 2021","February 25, 2022","May 25, 2022","August 8, 2022",,"August 8, 2022","Rising sun institute for special children, Lahore, Punjab, Pakistan",,"https://ClinicalTrials.gov/show/NCT05491863"
769,"NCT05491850","Effects of Moderate Physical Activity on Early Symptoms of Peripheral Diabetic Neuropathy in Type-II Diabetes: A Randomized Clinical Trial",,"Completed","No Results Available","Peripheral Diabetic Neuropathy","Other: Moderate Physical Activity for Peripheral Diabetic Neuropathy","Effect of moderate physical activity on early symptoms of peripheral diabetic neuropathy in type-II diabetes","Riphah International University","All","35 Years to 65 Years   (Adult, Older Adult)","Not Applicable","17","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","RIPHAH/FR&AHS/Letter-0985","October 1, 2021","November 30, 2021","December 25, 2021","August 8, 2022",,"August 8, 2022","RHS Rehabilitation Center, Islamabad, Federal, Pakistan",,"https://ClinicalTrials.gov/show/NCT05491850"
770,"NCT05491837","Effects of Intermittent Hypoxia in Upper and Lower Limb Functions in Persons With Incomplete Spinal Cord Injury",,"Not yet recruiting","No Results Available","Incomplete Spinal Cord Injury","Other: Device induce acute intermittent hypoxia 9 % of Oxygen|Other: Normoxia 21% of oxygen","Upper limb function|upper limb grip strength|Upper limb Pinch strength|Quick DASH to measure upper limb disability|walking performance|walking endurance|lower limb muscle strength|balance|Brain derived Neurotrophic factors (BDNF) to measure plasticity in brain|WHO QOL Urdu version to assess quality of life","Riphah International University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","68","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","RIPHAH/RCRS/REC/Letter-0129","August 8, 2022","August 1, 2023","September 4, 2023","August 8, 2022",,"August 8, 2022","Riphah International University Islamabad, Islamabad, Pakistan",,"https://ClinicalTrials.gov/show/NCT05491837"
771,"NCT05491824","Bio-Repository of DNA in Stroke: an Epidemiological and Genetic Study","BRAINS","Recruiting","No Results Available","Stroke|Stroke, Ischemic|Stroke Hemorrhagic",,"DNA repository of highly phenotyped stroke patients|Identify novel gene loci associated with different types of stroke","Royal Holloway University","All","18 Years and older   (Adult, Older Adult)",,"7500","Other","Observational","Observational Model: Case-Control|Time Perspective: Cross-Sectional","BRAINS","June 11, 2005","December 31, 2023","December 31, 2023","August 8, 2022",,"August 8, 2022","Imperial College London, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT05491824"
772,"NCT05491811","Ensartinib in Combination With Bevacizumab in ALK-positive NSCLC Patients With TP53 Mutation",,"Not yet recruiting","No Results Available","Non-Small Cell Lung Cancer","Drug: Ensartinib|Drug: Bevacizumab","12-month Progression-free Survival (PFS) rate|PFS|Objective Response Rate (ORR)|Duration of Response (DoR)|Overall Survival (OS)|Disease-related symptom improvement","Sun Yat-sen University|First Affiliated Hospital of Wenzhou Medical University|Second Affiliated Hospital, School of Medicine, Zhejiang University|Liaoning Cancer Hospital & Institute|Shenyang Chest Hospital|Harbin Medical University|Hebei Medical University Fourth Hospital|Handan Central Hospital|The First Affiliated Hospital of Soochow University|Jiangsu Cancer Institute & Hospital|The First Affiliated Hospital with Nanjing Medical University|Huai'an First People's Hospital|Wuhan Union Hospital, China","All","18 Years and older   (Adult, Older Adult)","Phase 2","77","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BD-EN-IV010","August 2022","November 2023","December 2026","August 8, 2022",,"August 8, 2022","Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, China",,"https://ClinicalTrials.gov/show/NCT05491811"
773,"NCT05491798","A Big Data-based Cohort Study for Cataract Patients",,"Recruiting","No Results Available","Cataract|Retina Disorder",,"Change of best corrected visual acuity|Accuracy for detection of retinal disorders","Sun Yat-sen University","All","18 Years and older   (Adult, Older Adult)",,"1000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","CCPMOH2021-China-1","July 1, 2020","December 31, 2022","December 31, 2022","August 8, 2022",,"August 8, 2022","Zhognshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, Guangdong, China",,"https://ClinicalTrials.gov/show/NCT05491798"
774,"NCT05491785","Cebranopadol Effects on Ventilatory Drive, Central Nervous System (CNS) and Pain.",,"Recruiting","No Results Available","Pain","Drug: Cebranopadol 600 µg|Drug: Cebranopadol 800 µg|Drug: Cebranopadol 1000 µg|Drug: Oxycodone 30 mg|Drug: Oxycodone 60 mg|Drug: Placebo","Ventilatory response to hypercapnia (VRH) by maximum decrease in minute ventilation (L)|Pupil constriction compared to baseline (mm)|Electrical and pressure pain tests|Adverse event reporting","Tris Pharma, Inc.","All","18 Years to 45 Years   (Adult)","Phase 1","30","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","PARK-104-VRH","July 29, 2022","March 30, 2023","March 30, 2023","August 8, 2022",,"August 8, 2022","Centre for Human Drug Research (CHDR), Leiden, Netherlands|Leiden University Medical Centre (LUMC), Leiden, Netherlands",,"https://ClinicalTrials.gov/show/NCT05491785"
775,"NCT05491772","Multicentric Retrospective Study of Perinatal Mortality","PM-PHD-NTM","Recruiting","No Results Available","Perinatal Morbidity|Morbidity;Perinatal|Stillbirth|ICD",,"International Classification of Disease (10th Revision)- Perinatal Mortalitymaternal condition group|International Classification of Disease (10th Revision)- Perinatal Mortality cause of death|Obstetric history|Mother's age|Type of pregnancy|Antenatal care number of visits|Malaria profilaxis|HIV status|Syphilis test|Mother's LMP|Date of birth|Gestational age|Place of delivery|Onset of labour|Fetal heart sounds on admission|Partograph used|Mode of delivery|Time between decision for action and birth|Apgar Score|Resuscitation|Sex of baby|Birth weight|Date of death|Type of death","Corporacion Parc Tauli|Hospital Sant Joan de Deu|Hospital Clínic Sede Maternitat","All","0 Days to 28 Days   (Child)",,"468","Other","Observational","Observational Model: Case-Only|Time Perspective: Retrospective","Perinatal mortality - pHD NTM","August 5, 2022","December 31, 2022","December 31, 2024","August 8, 2022",,"August 8, 2022","CorporacionPT, Sabadell, Barcelona, Spain",,"https://ClinicalTrials.gov/show/NCT05491772"
776,"NCT05491759","A Study to Determine Optimal Absorption of Single Dose Omega-3",,"Not yet recruiting","No Results Available","Optimal Gastrointestinal Absorption of Omega-3","Drug: Product 1 - AquaCelle Fish Oil Triglyceride|Drug: Product 2 - AquaCelle Fish Oil Ethyl Ester|Drug: Product 3 - Standard Fish Oil Triglyceride","Plasma EPA+DHA as measured by AUC0-24|Cmax|Tmax","RDC Clinical Pty Ltd","All","19 Years and older   (Adult, Older Adult)","Phase 4","24","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Other","BTFISH-22","August 8, 2022","August 8, 2023","October 1, 2023","August 8, 2022",,"August 10, 2022","RDC Global Pty Ltd, Brisbane, Queensland, Australia",,"https://ClinicalTrials.gov/show/NCT05491759"
777,"NCT05491746","Diabetic Retinopathy Tethered Augmented Reality With Eye4 Study","DRTARES","Recruiting","No Results Available","Diabetic Retinopathy|Low Vision","Device: Eye4|Other: Placebo","Visual acuity at distance|Visual acuity at near|Contrast sensitivity","Eyedaptic","All","18 Years and older   (Adult, Older Adult)","Not Applicable","20","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","2","July 1, 2022","December 2022","December 2022","August 8, 2022",,"August 8, 2022","Eyedaptic, Laguna Hills, California, United States",,"https://ClinicalTrials.gov/show/NCT05491746"
778,"NCT05491733","A Bioequivalence Study of APX001 High-load and Low-load Tablets",,"Completed","No Results Available","Invasive Fungal Infections","Drug: APX001|Drug: APX001A","Maximum Observed Plasma Concentration (Cmax)|Time to Reach Maximum Observed Plasma Concentration (Tmax)|Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast)|Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)]|Area Under the Curve From Time Zero to 24 hours (AUC0-24)|Percentage of Area Under the Curve Extrapolated to Infinity (%AUCextra)|Plasma Decay Half-Life (t1/2)|Apparent Terminal Elimination Rate Constant (λz)|Apparent Total clearance, Calculated as Dose/AUCinf (CL/F)|Apparent Volume of Distribution at Terminal Phase (Vz/F)|Number of Participants With Treatment Emergent Treatment-Related Adverse Events (AEs)|Number of Participants With Change From Baseline in Laboratory Tests Results|Number of Participants With Clinically Significant Change in Vital Signs|Number of Participants With Clinically Significant Findings in Electrocardiogram (ECG) Abnormalities|Number of Participants With Abnormalities in Physical Examinations","Pfizer","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","18","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","APX001-108|C4791008","March 2, 2021","May 13, 2021","June 23, 2021","August 8, 2022",,"August 8, 2022","Pharmaceuticals Research Associates, Inc, Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT05491733"
779,"NCT05491720","Electrical Brain Stimulation and Pharmacological Treatments in Autism Spectrum Disorder",,"Active, not recruiting","No Results Available","Autism Spectrum Disorder","Drug: RisperiDONE 1 MG/ML|Device: transcranial direct current stimulation|Drug: Placebo|Device: sham transcranial direct current stimulation","Gilliam Autism Rating Scale (GADS)|verbal fluency task|Theory of mind","The National Brain Mapping Laboratory (NBML)|Ardabil University of Medical Sciences|Leibniz Research Centre for Working Environment and Human Factors|University of Tehran","All","7 Years to 16 Years   (Child)","Phase 1","45","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","IR.ARUMS.REC.1395.20","August 15, 2020","March 15, 2022","August 3, 2022","August 8, 2022",,"August 8, 2022","The National Brain Mapping Laboratory (NBML), Tehran, Iran, Islamic Republic of",,"https://ClinicalTrials.gov/show/NCT05491720"
780,"NCT05491707","Effect of Music on Patients' Anxiety During Lower Limb Arthroplasty Procedures Under Spinal Anaesthesia",,"Recruiting","No Results Available","Anxiety","Other: Music","Describe the pre-operative anxiety scores measured by the visual analogue scale for anxiety|Describe and compare the anxiety scores, on the visual analogue scale for anxiety, at the pre-operative visit (T1) and at skin incision (T3) in the control group.|Describe and compare the anxiety scores, on the visual analogue scale for anxiety, at the pre-operative visit (T1) and at skin incision (T3) in the music group.|Describe and compare the anxiety scores, on the visual analogue scale for anxiety, at each time point (T1-T4) between the control group and the music group.|Describe the difference in the anxiety scores, on the visual analogue scale for anxiety, between male and female patients.|Describe the difference in anxiety scores, on the visual analogue scale for anxiety, between knee and hip arthroplasty.|Describe and compare the total propofol dose between the two groups.|Describe patient satisfaction, assessed by a questionnaire, in the intervention group.","University of Witwatersrand, South Africa","All","18 Years to 105 Years   (Adult, Older Adult)","Not Applicable","58","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M210702|202106_029","January 4, 2022","July 1, 2022","December 2022","August 8, 2022",,"August 8, 2022","Chris Hani Baragwanath Academic hospital, Johannesburg, Gauteng, South Africa",,"https://ClinicalTrials.gov/show/NCT05491707"
781,"NCT05491694","To Evaluate the Efficacy of Toripalimab Combined With Chemotherapy After HIFU Induction in the Treatment of Early Triple-negative Breast Cancer","HIFU","Not yet recruiting","No Results Available","Breast Cancer|TNBC - Triple-Negative Breast Cancer","Drug: Toripalimab|Drug: Epirubicin|Procedure: High Intensity Focused Ultrasoun|Drug: Cyclophosphamide|Drug: Carboplatin|Drug: Nab-paclitaxel","pCR","The First Affiliated Hospital with Nanjing Medical University","Female","18 Years and older   (Adult, Older Adult)","Phase 2","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HIFU202207","September 1, 2022","December 30, 2023","December 30, 2024","August 8, 2022",,"August 8, 2022",,,"https://ClinicalTrials.gov/show/NCT05491694"
782,"NCT05491681","AllogeneiC Expanded Human MSC Therapy in Patients Recovering From COVID-19 Acute Respiratory Distress Trial","ACE_CARD","Not yet recruiting","No Results Available","ARDS, Human","Biological: intravenous delivery of allogeneic bone marrow-derived MSCs","Number of product related adverse events through the duration of the study.|Secondary Endpoint","BioCardia, Inc.","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 1","9","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","05539-A","September 15, 2022","December 31, 2023","March 31, 2024","August 8, 2022",,"August 9, 2022",,,"https://ClinicalTrials.gov/show/NCT05491681"
783,"NCT05491668","Physiological Assessment of Severe Coronary Stenosis for Informing Planned PCI","REFINE PCI","Not yet recruiting","No Results Available","Coronary Artery Disease","Diagnostic Test: Non-hyperemic pressure ratio assessment pre and post PCI","The percentage of physiologically non-significant lesions observed|Correlation of the operator visual angiographic assessment of stenosis severity with quantitative coronary angiography (QCA) and resting non-hyperemic pressure resting indices (NHPR)|Correlation between QCA and NHPR|Correlation of the post-PCI NHPR with burden of angina as assessed via the Seattle Angina Questionnaire at 30 days post PCI|Change in angina as assessed via the Seattle Angina Questionnaire at baseline and 30 days after PCI, need for titration for anti-anginal medications, or need for repeat coronary angiography within 30 days of the procedure.","Beth Israel Deaconess Medical Center|Opsens Medical","All","18 Years and older   (Adult, Older Adult)",,"107","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2022P000479","September 2022","September 2023","September 2023","August 8, 2022",,"August 8, 2022","Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT05491668"
784,"NCT05491655","High Intensity His Bundle Pacing in Heart Failure Patients With Narrow QRS Outcome Study","HIPPOS","Not yet recruiting","No Results Available","Cardiac Conduction System|His Bundle Pacing|Heart Failure|Cardiomyopathies","Device: High Intensity His Bundle pacing","Improvement in left ventricular ejection fraction|Changes in B-type Natriuretic Peptide (BNP)|Changes in Quality of Life Scores|Changes in arrhythmia burden","Miulli General Hospital","All","18 Years to 90 Years   (Adult, Older Adult)","Not Applicable","34","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","MGH_003","September 2022","February 2025","February 2025","August 8, 2022",,"August 8, 2022",,,"https://ClinicalTrials.gov/show/NCT05491655"
785,"NCT05491642","A Study in Male and Female Participants (After Menopause) With Mild to Moderate High Blood Pressure to Learn How Safe the Study Treatment BAY3283142 is, How it Affects the Body and How it Moves Into, Through and Out of the Body After Taking Single and Multiple Doses",,"Not yet recruiting","No Results Available","Chronic Kidney Disease|Hypertension","Drug: BAY3283142|Drug: Placebo to BAY3283142","Number of participants with treatment-emergent adverse events per treatment arm|Area under the concentration versus time curve in a dosing interval (AUCτ) after single dose of BAY3283142 on Day 1|AUCτ after single dose of BAY3283142 on Day 1 divided by dose (AUCτ/D)|Maximum observed drug concentration in measured matrix (Cmax) after single dose of BAY3283142 on Day 1|Cmax after single dose of BAY3283142 on Day 1 divided by dose (Cmax/D)|AUC in a dosing interval after multiple doses of BAY3283142 on Day 12 (AUCτ,md)|AUCτ,md after multiple doses of BAY3283142 on Day 12 divided by dose (AUCτ,md/D)|Maximum observed drug concentration in measured matrix after multiple doses of BAY3283142 on Day 12 (Cmax,md)|Cmax,md after multiple doses of BAY3283142 on Day 12 divided by dose (Cmax,md/D)","Bayer","All","30 Years to 78 Years   (Adult, Older Adult)","Phase 1","54","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","21592|2022-001268-84","August 15, 2022","May 15, 2023","June 26, 2023","August 8, 2022",,"August 8, 2022","Many Locations, Multiple Locations, Bulgaria|Many Locations, Multiple Locations, Germany",,"https://ClinicalTrials.gov/show/NCT05491642"
786,"NCT05491629","Competencies of Operating Room Nurses and Influencing Factors",,"Completed","No Results Available","Competence|Nurse's Role","Other: type of parallel data in a convergent parallel hash pattern (near time)","competence Factors affecting the competence of operating room nurses|factors","Burdur Mehmet Akif Ersoy University|Akdeniz University","All","Child, Adult, Older Adult",,"224","Other","Observational","Observational Model: Case-Only|Time Perspective: Cross-Sectional","AUCAK","March 1, 2020","August 20, 2020","June 20, 2022","August 8, 2022",,"August 8, 2022","Fatma Cebeci, Muratpaşa, Turkey",,"https://ClinicalTrials.gov/show/NCT05491629"
787,"NCT05491616","Nivolumab During Active Surveillance After Neoadjuvant Chemoradiation for Esophageal Cancer: SANO-3 Study","SANO-3","Not yet recruiting","No Results Available","Esophageal Cancer","Drug: Nivolumab","Disease Free survival 18 months|the proportion of patients with locoregional and/or distant metastase|the proportion of patients that undergo esophagectomy|health-related quality of life (HRQOL) at baseline, 3, 6, 12 and 24 months after inclusion|overall survival at 2 years","Erasmus Medical Center","All","18 Years and older   (Adult, Older Adult)","Phase 2","74","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CA209-6KC","October 2022","April 2026","October 2026","August 8, 2022",,"August 8, 2022","Erasmus MC, Rotterdam, Netherlands",,"https://ClinicalTrials.gov/show/NCT05491616"
788,"NCT05491603","A Trial to Evaluate the Safety and Efficacy of DBI-001 Gel, DBI-002 Gel, and Aqueous Gel in Subjects With Onychomycosis",,"Recruiting","No Results Available","Onychomycosis","Biological: DBI-001|Biological: DBI-002|Biological: Aqueous Gel","Change in percentage of involved great toenail(s)|Changes in signs and symptoms of Onychomycosis|Population with completely clear nail growth|Change in Investigator's Static Global Assessment (ISGA)|Length of new clear nail growth|Molecular diagnostic quantitative polymerase chain reaction (qPCR) and whole genome sequencing (WGS) comparison of DBI-001 Gel, DBI-002 Gel and Aqueous Gel on the impact of T. rubrum levels|Change in colony forming units after using DBI-001 Gel or DBI-002 Gel or Aqueous Gel at Weeks 24 and 48|Evaluate the presence of DBI-001, DBI-002 based on qPCR and WGS and Weeks 24 and 48|Evaluate the effect of DBI-001 Gel and DBI-002 Gel on the change in relative abundance and diversity of the cutaneous microbiome of the great toenail(s) from Screening to Weeks 24 and 48 as measured by WGS","DermBiont, Inc.","All","18 Years to 50 Years   (Adult)","Phase 2","60","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CT-206","August 8, 2022","November 30, 2023","November 30, 2023","August 8, 2022",,"August 8, 2022","Minnesota Clinical Study Center, New Brighton, Minnesota, United States|North Sound Dermatology, Mill Creek, Washington, United States",,"https://ClinicalTrials.gov/show/NCT05491603"
789,"NCT05491590","Patient-reported Outcome After Status Epilepticus","POSEIDON","Not yet recruiting","No Results Available","Patient Reported Outcomes|Long Term Outcomes|Status Epilepticus|Intensive Care Unit|Intensive Care Unit Syndrome",,"percentage of global impairment of HRQoL defined by one and/or other of the physical and mental impairments (after dichotomization of the SF 36 summary scores compared to the general population) in patients managed in the ICU for or with SE.|percentage of cognitive/physical and/or mental health impairment defined after dichotomization of i)T-MoCA ,ii) GOS, iii)IADL&ADL, iv)HAD, v)IES-r in patients managed in the ICU for or with SE|percentage of impairement of HRQoL, in 8 dimensions of the generalist of SF 36, and scores in the 7 dimensions of the specific QOLIE 31 in patients managed in intensive care for or with SE.|percentage of impairement of HRQoL, in 8 dimensions of the generalist of SF 36, and scores in the 7 dimensions of the specific QOLIE 31in the SE sub-groups defining (with or without predominant motor signs)|Presence or absence Post-ICU factors associed to the PICs, as defined above in patients managed in the ICU for or with SE.|Presence or absence of the elements associated with the PICs, as defined above, in the subgroups defining SE (SE with orwithout predominant motor signs,).|Presence or absence Post-ICU factors associated of return to work ability in patients managed in the ICU for or with SE.|score of perceived social support by the SSQ6 scale in its 2 dimensions, satisfaction and availability.|percentage of the quality of life impairement in the total population and in in the SE sub-groups patients identified with an previous epilepsy","Versailles Hospital","All","18 Years and older   (Adult, Older Adult)",,"225","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","P21/11 - POSEIDON","September 1, 2022","September 1, 2023","December 1, 2023","August 8, 2022",,"August 8, 2022","CHVersailles, Le Chesnay, Yvelines, France",,"https://ClinicalTrials.gov/show/NCT05491590"
790,"NCT05491577","Factors Associated With an Evolution in the Quality of Life of Diabetic Patients With Chronic, Wound-free Charcot Foot","CHARQUAM","Not yet recruiting","No Results Available","Charcot Joint of Foot|Osteoarthropathy","Other: Filling in the SF-36, FAAM-F, PHQ-9, PHQ-2 and the simplified version of the EPICES score questionnaire","Results of the SF36 questionnaire at inclusion|Results of the FAAM-F questionnaire at inclusion|Results of the SF36 questionnaire at Month 12|Results of the FAAM-F questionnaire at Month 12|Results of the SF36 questionnaire at Month 24|Results of the FAAM-F questionnaire at Month 24|A. Evolution of X-ray measurements of bone and joint deformity of the foot. Lisfranc metatarsal misalignment (Méary's Line)|A. Evolution of the radiologic measurements of bone and joint deformity of the foot: Méary's angle.|A. Evolution of the radiologic measurements of bone and joint deformity of the foot. Calcaneal slope|A. Evolution of the radiologic measurements of bone and joint deformity of the foot. Djian Annonier angle|A. Evolution of the radiologic measurements of bone and joint deformity of the foot. Rearfoot alignment|B. Estimated prevalence of complications of diabetes and comorbidities at inclusion. Retinopathy|B. Estimated prevalence of complications of diabetes and comorbidities at inclusion. Peripheral vegetative neuropathy.|B. Estimated prevalence of complications of diabetes and comorbidities at inclusion. Nephropathy.|B. Estimated prevalence of complications of diabetes and comorbidities at inclusion. Lower extremity arteriopathy|B. Estimated prevalence of complications of diabetes and comorbidities at inclusion. Supra-aortic trunk involvement|B. Estimated prevalence of complications of diabetes and comorbidities at inclusion. Coronary artery disease|B. Estimated prevalence of complications of diabetes and comorbidities at inclusion. Heart failure|B. Estimated prevalence of complications of diabetes and comorbidities at inclusion. History of strokes|B. Estimated prevalence of complications of diabetes and comorbidities at inclusion. Arterial hypertension|B. Estimated prevalence of complications of diabetes and comorbidities at inclusion. Smoking|B. Estimated prevalence of complications of diabetes and comorbidities at inclusion. Alcohol status|B. Estimated prevalence of complications of diabetes and comorbidities at inclusion. Charlson Comorbidity Index|C. Medical and/or surgical treatment for Charcot foot.|D. Incidence of hospitalization|E. Presence of a wound/wounds|E. Presence of an infection|F. Presence of an amputation at inclusion|G. Estimated incidence of amputations|G. Presence of an amputation|H. Precarity of patients with chronic Charcot foot.|I. Depression according to the PHQ-2 self-questionnaire|I. Depression according to the PHQ-9 self-questionnaire|J. Mortality rate|K. Sanders Classification of the Charcot Foot","Centre Hospitalier Universitaire de Nīmes","All","18 Years and older   (Adult, Older Adult)",,"150","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","SI RIPH 2G : 22.01571.000083","October 1, 2022","October 1, 2024","December 31, 2024","August 8, 2022",,"August 8, 2022","Centre Hospitalier de Boulogne-sur-Mer, Boulogne-sur-Mer, Pas-de-Calais, France|Groupement Hospitalier Est, Hôpital Cardiologique Service de Diabétologie 28 Av du Doyen Lépine, Bron, France|CH Sud Francilien Service de Diabétologie 40 Avenue Serge Dassault, Corbeil-Essonnes, France|CHU de Grenoble Service d'Endocrinologie Allée des Sablons Les écrins, Grenoble, France|Hôpital Hôtel dieu Service d'Endocrinologie 26 rue d'Harfleur, Le Creusot, France|CHU Bicêtre Service d'Endocrinologie et Maladies de la reproduction 78 rue du Général Leclerc, Le Kremlin-Bicêtre, France|CH de Lens Unité de Diabétologie-Endocrinologie- Nutrition-Obésité Centre Hospitalier Dr SCHAFFNER 99 rte de La Bassée,, Lens, France|CHRU de Lille Service d'Endocrinologie Diabétologie et Métabolisme, Hôpital Claude Huriez, Rue Polonovski, Lille, France|CHU de la CONCEPTION Service de Nutrition, Diabétologie, Obésité médicale, chirurgicale 47 Bd Baille, Marseille, France|CHU de Montpellier Service des Maladies métaboliques 371 av. Doyen Giraud, Montpellier Cedex, France|GH Pitié Salpétrière Unité de podologie Service de Diabétologie 47-83 Bd de l'Hôpital, Paris, France|GH Paris Saint Joseph Service de Diabétologie et Endocrinologie 185 rue Raymond Losserand, Paris, France|Hôpital Cochin Service de diabétologie 123 Bd de Port Royal, Paris, France|CHU de Lyon Sud Service d'Endocrinologie-Diabète-Nutrition CH Lyon Sud Pavillon médical, Bat 1B 165 chemin du Grand Revoyet, Pierre-Bénite, France|CHU Reims Service d'Endocrinologie, diabète-nutrition Rue du Général Koenig, Reims, France|Hôpitaux Universitaires de Strasbourg Service d'Endocrinologie et Diabétologie 1, place de l'hôpital,, Strasbourg, France|Hôpital DRON Service de diabétologie 135 rue du Président Coty, Tourcoing, France",,"https://ClinicalTrials.gov/show/NCT05491577"
791,"NCT05491564","SoftStitch™ for All-Inside Meniscal Repair: Comparative Analysis of Patient Reported Outcome Measures",,"Not yet recruiting","No Results Available","Meniscus Tear","Device: SoftStitch™","Lysholm Score|Tegner Activity Scale|International Knee Documentation Committee (IKDC) Subjective Measure|Patient-Reported Outcomes Measurement Information System (PROMIS) Global-10|McMurray Test","Arthrex, Inc.","All","18 Years to 55 Years   (Adult)",,"50","Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","AIRR-0065","October 1, 2022","October 1, 2024","October 1, 2024","August 8, 2022",,"August 8, 2022",,,"https://ClinicalTrials.gov/show/NCT05491564"
792,"NCT05491551","Alcohol-ROC-Training","A-ROC-T","Not yet recruiting","No Results Available","Binge Drinking|Heavy Drinking|Young Adult|Heavy Drinker","Behavioral: Mindfulness-Based Treatment-Regulation of Craving|Behavioral: Cognitive-Based Therapy-Regulation of Craving","Change in frequency of heavy drinking days|Change in average estimated blood alcohol concentration (eBAC) per drinking day|Change in alcohol-related negative consequences|Reduction in World Health Organization (WHO) drinking risk level","Yale University|National Institute on Alcohol Abuse and Alcoholism (NIAAA)","All","18 Years to 26 Years   (Adult)","Not Applicable","177","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2000029394|1R01AA029137-01","August 2022","December 2027","December 2027","August 8, 2022",,"August 8, 2022","Yale University, New Haven, Connecticut, United States",,"https://ClinicalTrials.gov/show/NCT05491551"
793,"NCT05491538","Acceptability and Feasibility of Work-Oriented Social-Cognitive Skills Training for Veterans With Serious Mental Illness",,"Not yet recruiting","No Results Available","Schizophrenia|Bipolar Disorder|Depressive Disorder, Major|Stress Disorder, Post-Traumatic","Behavioral: Social Cognition and Interaction Training-Work Edition (SCIT-WE)","Social Adjustment Scale-Self-Report: Short Version (SAS-SR: Short) Change|Recovering Quality of Life (ReQoL)-20 Change|Return to Work Self-Efficacy Scale (RTW-SE) Change|Intrinsic Motivation Inventory - Interest subscale|Intrinsic Motivation Inventory - Value subscale|Client Satisfaction Questionnaire (CSQ-8)|Rate of Treatment Uptake|Completer of Skills Training Intervention|Retention in supported employment|Retention in skills training program|Mentoring and Communication Support Scale (MCSS)|Vocational Efficacy in Trauma Survivors Scale|Work Limitations Questionnaire (WLQ)","VA Office of Research and Development","All","18 Years and older   (Adult, Older Adult)","Not Applicable","20","U.S. Fed","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","D4068-P","December 1, 2022","November 30, 2024","November 30, 2024","August 8, 2022",,"August 8, 2022","Minneapolis VA Health Care System, Minneapolis, MN, Minneapolis, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT05491538"
794,"NCT05491525","A Study of Vibegron in Pediatric Participants 2 Years to Less Than (<) 18 Years of Age With NDO and on CIC","KANGUROO","Not yet recruiting","No Results Available","Neurogenic Detrusor Overactivity","Drug: Vibegron","Change from Baseline in maximum cystometric capacity (MCC) based on bladder filling urodynamics|Change from Baseline in MCC|Change from Baseline in number of overactive detrusor contractions until the end of bladder filling|Change from Baseline in detrusor pressure at the end of bladder filling|Change from Baseline in bladder filling volume until first involuntary/hyperactive detrusor contraction|Change from Baseline in bladder compliance (mL/cm H2O)|Change from Baseline in average first morning catheterized volume|Change from Baseline in average catheterized volume per catheterization|Change from Baseline in average maximum catheterized volume per day|Change from Baseline in average maximum catheterized daytime volume|Change from Baseline in average number of leakage episodes per day|Change from Baseline in estimated number of dry (leakage-free) days/ 7 days|Change from Baseline in Pediatric Incontinence Questionnaire (PIN-Q)|Change from Baseline in Patient Global Impression of Severity (PGI-S) Scale|Change from Baseline in Clinical Global Impression of Change (CGI-C) Scale","Urovant Sciences GmbH","All","2 Years to 17 Years   (Child)","Phase 2|Phase 3","85","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","URO-901-3007","August 2022","March 2027","September 2027","August 8, 2022",,"August 8, 2022",,,"https://ClinicalTrials.gov/show/NCT05491525"
795,"NCT05491512","A Study of Reduced Radiation Therapy and Standard-of-Care Chemotherapy in People With HPV-Positive Throat Cancer",,"Recruiting","No Results Available","HPV|Throat Cancer|Oropharyngeal Carcinoma|Oropharyngeal Cancer|Human Papilloma Virus","Diagnostic Test: 18 F-FMISO PET/CT|Radiation: Radiation|Drug: Cisplatin|Drug: Carboplatin|Drug: 5-fluorouracil","Number of participants with any locoregional recurrences","Memorial Sloan Kettering Cancer Center","All","18 Years and older   (Adult, Older Adult)","Phase 2","71","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","22-215","August 4, 2022","August 4, 2024","August 4, 2024","August 8, 2022",,"August 8, 2022","Memorial Sloan Kettering Cancer Center at Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey, United States|Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown, New Jersey, United States|Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale, New Jersey, United States|Memorial Sloan Kettering Cancer Center at Suffolk-Commack (Limited Protocol Activities), Commack, New York, United States|Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison, New York, United States|Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York, United States|Memorial Sloan Kettering Nassau (Limited Protocol Activities), Uniondale, New York, United States",,"https://ClinicalTrials.gov/show/NCT05491512"
796,"NCT05491499","Assessing the Impact of Exercise Based Intensive Interdisciplinary Pain Treatment (IIPT) on Endogenous Pain Modulation in Youth With Chronic Pain Syndromes",,"Not yet recruiting","No Results Available","Chronic Pain Syndrome|Fibromyalgia|Chronic Headache Disorder|Functional Abdominal Pain Syndrome|Complex Regional Pain Syndromes",,"Change in Offset Analgesia|Change in Control Test Response|Change in Constant Test Response|Change in Cardiovascular Endurance","Boston Children's Hospital|APTA Pediatrics","All","10 Years to 17 Years   (Child)",,"38","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","P00043035","October 2022","September 2023","September 2023","August 8, 2022",,"August 8, 2022","Boston Children's Hospital at Waltham, Waltham, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT05491499"
797,"NCT05491486","Mindfulness, Empathy and the Oxytocinergic System in Persons With Schizophrenia","OXYGEN","Recruiting","No Results Available","Schizophrenia Spectrum and Other Psychotic Disorders","Behavioral: Mindfulness-based Group Therapy","Change in oxytocin levels|Change in empathy levels IRI|Change in empathy levels EQ|Change in SMQ Mindfulness|PSP Social Functioning|Change in PANSS Positive, Negative, and General Symptoms|Change in SNS Negative Symptoms|Change in DASS Depression & Anxiety|Change in CFQ Psychological Flexibility|Change in PANAS Positive and Negative Affect|Change in BIRT Motivation (BMQ)","Charite University, Berlin, Germany|Brain & Behavior Research Foundation","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","OXYGEN2022","June 15, 2022","July 15, 2023","July 15, 2023","August 8, 2022",,"August 8, 2022","Charité - Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany",,"https://ClinicalTrials.gov/show/NCT05491486"
798,"NCT05491473","Negative Pressure in PAP Donor Sites",,"Completed","No Results Available","Breast Reconstruction","Device: Closed incisional negative pressure wound therapy (iNPWT) system","Off-bed time (days)|Drainage amount (ml)|Vacuum ball removed timing|Vancouver Scar Scale (VSS)|Re-open|Donor site acute complication (< 30 days)|Donor site chronic complication (> 30 days)|Donor site revision","Chang Gung Memorial Hospital","Female","Child, Adult, Older Adult",,"25","Other","Observational","Observational Model: Case-Control|Time Perspective: Retrospective","202101649B0","September 23, 2021","April 10, 2022","May 31, 2022","August 8, 2022",,"August 8, 2022","ChangGungMH, Taoyuan, Taiwan",,"https://ClinicalTrials.gov/show/NCT05491473"
799,"NCT05491460","Pharmacokinetics and Point of Care Testing of Direct Oral Anticoagulants Subjects","PHAPOCU","Active, not recruiting","No Results Available","Anticoagulant Therapy","Drug: Apixaban 5 MG Tab|Drug: Dabigatran 150 MG Tab|Drug: Edoxaban 60Mg Tab|Drug: Rivaroxaban 20 MG Tab","Accuracy and specificity of the DOAC Dipstick compare to LC-MSMS|Comparison of qualitative POCT with quantitative LC-MS/MS|Questionnaire on handling and usability","Doasense GmbH","Male","18 Years and older   (Adult, Older Adult)","Phase 1","24","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","PhaKiDo-001","July 1, 2022","December 30, 2023","December 30, 2023","August 8, 2022",,"August 8, 2022","Clincial Research Serivces, Mannheim, Germany",,"https://ClinicalTrials.gov/show/NCT05491460"
800,"NCT05491447","A Clinical Trial of BMX-010 in Adult Subjects With Atopic Dermatitis",,"Not yet recruiting","No Results Available","Atopic Dermatitis","Drug: BMX-010|Drug: Placebo","Change from Baseline in Eczema Area and Severity Index at Week 4|Incidence of treatment emergent adverse events and changes from baseline in vital signs and clinical laboratory parameters|Change from baseline in Eczema Area and Severity Index at weeks 1, 2, and 3.|Proportion of subjects who achieve Eczema Area and Severity Index-50 and Eczema Area and Severity Index -75 at Weeks 1, 2, 3 and 4.|Change from baseline in Body Surface Area x validated Investigator Global Assessment of Atopic Dermatitis scoreat Weeks 1, 2, 3, and 4|Change from baseline in body surface area at Weeks 1, 2, 3, and 4.|Change from baseline in validated Investigator Global Assessment of Atopic Dermatitis at Weeks 1, 2, 3, and 4.|Proportion of subjects who achieve a validated Investigator Global Assessment of Atopic Dermatitis score of Almost clear (1) and/or Clear (0) with a 2-point reduction at Weeks 1, 2, 3, and 4.|Change from baseline in the Pruritus Numerical Rating Scale (NRS) at Weeks 1, 2, 3, and 4.|Change from baseline in Modified Pruritus Numerical Rating Scale (Current Itch Intensity; 30 minutes and 4 hours post-dose) on Day 1.|Measurement of plasma concentrations of BMX-010 in participants receiving active treatment","BioMimetix JV, LLC|Innovaderm Research Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 2","224","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","BMX-DERM-02","October 31, 2022","October 31, 2024","December 31, 2024","August 8, 2022",,"August 8, 2022",,,"https://ClinicalTrials.gov/show/NCT05491447"
801,"NCT05491434","Sarcopenia in Colorectal Cancer Patients, Intervention Study",,"Recruiting","No Results Available","Sarcopenia|Postoperative Complications|Infection;Post Surg Procedure","Dietary Supplement: Protein supplement","to evaluate the rate of post-surgical infectious complications between the group of sarcopenic and non-sarcopenic patients|To asess the rate of post-surgical complications between the group of sarcopenic and non-sarcopenic patients|Overall survival at one year|Quality of life of surgical patients","Hospital Universitari de Bellvitge","All","70 Years and older   (Older Adult)","Not Applicable","370","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","PR137/19","December 1, 2020","December 31, 2022","March 31, 2023","August 8, 2022",,"August 8, 2022","Hospital Universitari de Bellvitge, L'Hospitalet De Llobregat, Barcelona, Spain",,"https://ClinicalTrials.gov/show/NCT05491434"
802,"NCT05491421","A Study of ZT002 in Healthy Participants",,"Not yet recruiting","No Results Available","Type 2 Diabetes Mellitus","Drug: ZT002|Other: Placebo","Safety and tolerability of a single escalation dose of ZT002 through the incidence and severity of treatment emergent adverse events. Number of participants with treatment-emergent adverse events.|Safety and tolerability of a single escalation dose of ZT002 through the incidence severity of serious adverse events. Number of participants with serious adverse events.|The Pharmacokinetics (PK) profile of a single escalation dose of ZT002 in healthy participants. Parameter: Maximum observed plasma concentration of ZT002 (Cmax)|The Pharmacokinetics (PK) profile of a single escalation dose of ZT002 in healthy participants. Parameter: Area under the drug-time curve from 0 h after dosing to the last quantifiable concentration time point (AUC0-last)|The Pharmacokinetics (PK) profile of a single escalation dose of ZT002 in healthy participants. Parameter: Area under the drug-time curve to infinity (AUC0-inf)|The anti-drug antibody (ADA) response through an anti-drug antibody assay|The anti-drug antibody (ADA) response through testing serum or plasma of the participant post dosing","QL Biopharmaceutical Australia Pty Ltd|Novotech (Australia) Pty Limited|Beijing QL Biopharmaceutical Co.,Ltd","All","18 Years to 55 Years   (Adult)","Phase 1","32","Industry","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ZT002","September 5, 2022","February 14, 2023","August 31, 2023","August 8, 2022",,"August 8, 2022",,,"https://ClinicalTrials.gov/show/NCT05491421"
803,"NCT05491408","Effect of Cough Assist Device in COPD Patients Admitted to Respiratory Intensive Care Unit at Assiut University Hospital",,"Not yet recruiting","No Results Available","COPD Exacerbation","Device: Cough assist device","efficacy of Cough Assist Device (CAD) in COPD patients admitted in RICU including need for invasive or Non-invasive ventilation and weaning success.","Assiut University","All","18 Years to 85 Years   (Adult, Older Adult)",,"100","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","cough assist device in ICU","August 1, 2022","December 1, 2023","March 1, 2024","August 8, 2022",,"August 8, 2022",,,"https://ClinicalTrials.gov/show/NCT05491408"
804,"NCT05491395","Hypofractionated Radiotherapy in Breast Cancer Patients With Prosthetic Reconstruction","PROMART","Recruiting","No Results Available","Breast Cancer","Radiation: Hypofractionation","Assess the G3 toxicity rate|Local recurrence|Assessment of quality of life through the EORTC Questionnaires European Organization for Research and Treatment of Cancer, where a high or low score may suggest good quality of life depending on the domain of the questionnaire|Comparison of self-image using the EORTC Questionnaires European Organization for Research and Treatment of Cancer, where a high or low score may suggest good quality of life depending on the domain of the questionnaire|Compare acute and late radiodermatitis rates by Common Terminology Criteria for Adverse Events (CTCAE) 4.0|Dosimetric analysis|Inflammation markers screening - detection of cytokines with the CBA panel|Extracellular vesicles isolation and characterization|Evaluate extracellular vesicles molecular profile","Barretos Cancer Hospital","Female","18 Years and older   (Adult, Older Adult)","Not Applicable","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1","June 27, 2022","May 1, 2026","May 1, 2029","August 8, 2022",,"August 8, 2022","Radiation Oncology Department, Barretos, São Paulo, Brazil",,"https://ClinicalTrials.gov/show/NCT05491395"
805,"NCT05491382","Muscle and Body Temperature Responses During Uphill and Downhill Running",,"Not yet recruiting","No Results Available","Body Temperature Changes|Exercise|Blood Pressure","Procedure: Uphill running|Procedure: Flatland running|Procedure: Downhill running","Core temperature|Skin temperature|Muscle temperature|Whole-body sweat rate (arm 1)|Femoral blood flow (arm 2)|Blood pressure (arm 2)|Perceived muscle pain (arm 3)|Maximal voluntary contraction (arm 3)|Plasma creatinine levels (arm 3)|Oxygen consumption|Local sweat rate|Skin blood flow|Heart rate|Perceived exertion|Thermal comfort","Centura Health|University of Colorado, Colorado Springs","All","18 Years to 45 Years   (Adult)","Not Applicable","44","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","1864889","September 2022","December 2023","September 2024","August 8, 2022",,"August 8, 2022",,,"https://ClinicalTrials.gov/show/NCT05491382"
806,"NCT05491369","Effectiveness of an Epilepsy Application for Self-management in Viet Nam",,"Not yet recruiting","No Results Available","Epilepsy","Other: Epilepsy application","Epilepsy Self-Management Scale (ESMS)|Quality of Life in Epilepsy Inventory (QOLIE-31)|PHQ9 (Patient Health Questionnaire scale)|GAD7 (Generalized Anxiety Disorder scale)","University of Medicine and Pharmacy at Ho Chi Minh City","All","18 Years and older   (Adult, Older Adult)","Not Applicable","140","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Supportive Care","22416 - ĐHYD","August 2022","December 2023","June 2024","August 8, 2022",,"August 10, 2022","Nguyen Tri Phuong Hospital, Ho Chi Minh City, Vietnam|University Medical Center at Ho Chi Minh City, Ho Chi Minh City, Vietnam",,"https://ClinicalTrials.gov/show/NCT05491369"
807,"NCT05491356","Use of Tissue Plasminogen Activator in the Clearance of Chronic Subdural Hematomas",,"Not yet recruiting","No Results Available","Hematoma, Subdural|Fibrinolytic; Hemorrhage","Drug: Tissue Plasminogen Activator|Drug: Placebo","Study Feasibility|Reoperation rate|Volume of chronic subdural hematoma|Rate of adverse events|Length of hospital stay","Hamilton Health Sciences Corporation","All","18 Years to 100 Years   (Adult, Older Adult)","Phase 4","40","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","14724","September 2022","April 2023","April 2023","August 8, 2022",,"August 8, 2022","Hamilton General Hospital, Hamilton, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT05491356"
808,"NCT05491343","Observation vs Progesterone Treatment for Management of Uterine Arteriovenous Malformation",,"Not yet recruiting","No Results Available","Arteriovenous Malformations","Drug: MedroxyPROGESTERone Injection [Depo-Provera]|Device: Other","AVM regression","HaEmek Medical Center, Israel","Female","18 Years to 50 Years   (Adult)","Phase 4","28","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","0060-22EMC","August 2022","December 2022","January 2024","August 8, 2022",,"August 8, 2022",,,"https://ClinicalTrials.gov/show/NCT05491343"
809,"NCT05491330","Bioequivalence Study of Nirmatrelvir & Ritonavir From Copaxid 150 +100 mg Tablets (Eva Pharma, Egypt) Versus Paxlovid 150 + 100 mg Film Coated Tablets (Pfizer Europe, Belgium)",,"Recruiting","No Results Available","Healthy","Drug: Nirmatrelvir 150 mg + Ritonavir 100 mg (Reference first dose)|Drug: Nirmatrelvir 150 mg + Ritonavir 100 mg (test)|Drug: Nirmatrelvir 150 mg + Ritonavir 100 mg (Reference second dose)","Cmax|Time of the maximum plasma concentration (Tmax)","Genuine Research Center, Egypt|Eva Pharma","All","18 Years to 55 Years   (Adult)","Phase 1","30","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other","GRC/1/22/1038","August 2022","August 2022","September 2022","August 8, 2022",,"August 8, 2022","Genuine Research Center GRC, Cairo, Egypt",,"https://ClinicalTrials.gov/show/NCT05491330"
810,"NCT05491317","A Safety and Antitumor Activity Trial of Immunoradiotherapy Combinations as a Treatment Option for Subjects With Metastatic Solid Tumors",,"Not yet recruiting","No Results Available","Non-CNS Tumor","Biological: GEN1042|Drug: Pembrolizumab|Radiation: Radiotherapy","Part 1: Dose limiting toxicities (DLTs)|Part 2: Number of participants with abscopal response in non-irradiated target lesions|Objective response rate (ORR)|Duration of response (DOR)|Disease control rate (DCR)|Progression-free survival (PFS)|Overall survival (OS)|Part 1: Number of participants with abscopal response in non-irradiated target lesions|Incidence and severity of adverse events (AEs)|Number of participants with clinically significant shifts from baseline in safety laboratory parameters|Area under the concentration-time curve (AUC) of GEN1042|Maximum (peak) concentration (Cmax) of GEN1042 after dosing|Elimination half-life (T1/2) of GEN1042|Number of participants with incidence of anti-drug antibodies (ADAs)","Genmab|BioNTech SE","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","75","Industry","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GCT1042-02|2022-000509-29","October 24, 2022","December 2025","February 2026","August 8, 2022",,"August 8, 2022",,,"https://ClinicalTrials.gov/show/NCT05491317"
811,"NCT05491304","Cytokine Guided Risk Stratification and Treatment in Pediatric Hemophagocytic Lymphohistiocytosis",,"Not yet recruiting","No Results Available","Hemophagocytic Lymphohistiocytoses|Cytokine Storm","Drug: Dexamethasone|Drug: Etoposide|Drug: Ruxolitinib","Complete remission (CR)|Overall survival (OS)|overall response rate (ORR)|Mortality|Reactivation rate|Partial remission (PR)|Rate of Early Death","The Children's Hospital of Zhejiang University School of Medicine|The Second Hospital of Anhui Medical University|Union hospital of Fujian Medical University|Children's Hospital of Fudan University|Zunyi Medical College|Hunan Provincial People's Hospital|Tongji Hospital|Children's Hospital of Nanjing Medical University|The Affiliated Hospital of Qingdao University|Qilu Hospital of Shandong University|Shanghai Children's Medical Center|Xinhua Hospital, Shanghai Jiao Tong University School of Medicine|Shanghai Children's Hospital|Shenzhen Children's Hospital|West China Second University Hospital|Children's Hospital Of Soochow University|Second Affiliated Hospital of Wenzhou Medical University|Wuhan Children's Hospital|Institute of Hematology & Blood Diseases Hospital|The Third Xiangya Hospital of Central South University|First Affiliated Hospital, Sun Yat-Sen University","All","1 Day to 18 Years   (Child, Adult)","Phase 4","400","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2022-IRB-057","September 1, 2022","December 31, 2024","December 31, 2025","August 8, 2022",,"August 8, 2022","The Children's Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China",,"https://ClinicalTrials.gov/show/NCT05491304"
812,"NCT05491291","Chronic Wound Care of Lower Limb in M@diCICAT Center at CHU de Martinique","VALRESCIC","Not yet recruiting","No Results Available","Chronic Wounds","Other: Patients with chronic wound of the lower limbs","Cultural adaptation of the RESVECH 2.0 scale.|Psychometric validation of the RESVECH 2.0 scale.","University Hospital Center of Martinique","All","18 Years and older   (Adult, Older Adult)","Not Applicable","120","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","20_RIPH23-27","November 2022","May 2024","August 2024","August 8, 2022",,"August 8, 2022","CHU de Martinique, Fort-de-France, Martinique",,"https://ClinicalTrials.gov/show/NCT05491291"
813,"NCT05491278","Efficacy and Safety of Fospropofol Disodium Versus Propofol for Sedation in Mechanically Ventilated ICU Patients",,"Not yet recruiting","No Results Available","Critical Illness","Drug: Fospropofol disodium for injection|Drug: Propofol","Percentage of time spent reaching sedation goals|Invasive ventilator free time within 7 days|Rate of successful extubation within 7 days|Incidence of unexpected extubation|Proportion of delirium in the ICU|Non-ICU survival time within 28 days|Case fatality rate within 28 days|Percentage of time spent that trial drug was discontinued due to adverse events","Wuhan Union Hospital, China","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","WUHICU202206","August 3, 2022","August 3, 2023","August 3, 2023","August 8, 2022",,"August 8, 2022",,,"https://ClinicalTrials.gov/show/NCT05491278"
814,"NCT05491265","Impact of Intermittent Kangaroo Mother Care Versus Conventional Care Method on Vital Sign and Arterial Oxygen Saturation in Preterm Hospitalized in Neonatal Intensive Care Unit",,"Recruiting","No Results Available","Kangaroo Mother Care Method","Behavioral: Intermittent Kangaroo mother care","Temperature|Heart rate|Oxygen Saturation","Shaheed Zulfiqar Ali Bhutto Medical University|UNICEF","All","28 Weeks to 37 Weeks   (Child)","Not Applicable","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","F.1-1/2015/ERB/SZABMU/955","April 4, 2022","December 3, 2022","December 3, 2022","August 8, 2022",,"August 8, 2022","Pakistan institute of medical sciences, Islamabad, Pakistan",,"https://ClinicalTrials.gov/show/NCT05491265"
815,"NCT05491252","A Randomized Controlled Trial of Patient-Centered Self-Management Intervention in Adults With Type 2 Diabetes Mellitus",,"Active, not recruiting","No Results Available","Type 2 Diabetes","Behavioral: PAtient CEntered Self-Management Intervention (PACE-SMI)","Change in Glycemic Control (HbA1c)|Self Efficacy|Self Care Behaviors","Shifa Tameer-e-Millat University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","612","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","335-21","April 21, 2022","December 2022","December 2022","August 8, 2022",,"August 8, 2022","District Head Quarter (DHQ) Hospital, Faisalabad, Punjab, Pakistan|Allied Hospital, Faisalābad, Punjab, Pakistan|Government General Hospital, Faisalābad, Punjab, Pakistan|Punjab Social Security Hospital, Faisalābad, Punjab, Pakistan",,"https://ClinicalTrials.gov/show/NCT05491252"
816,"NCT05491239","Optimal Postoperative Pain Management After Lung Surgery (OPtriAL)",,"Recruiting","No Results Available","Lung Cancer|Pain, Postoperative|VATS|Locoregional Anaesthesia|Thoracic Epidural","Procedure: Thoracic epidural analgesia|Procedure: Continuous regional paravertebral block|Procedure: Single shot intercostal nerve block","Pain scores|Quality of Recovery (QoR)|cumulative use of opioids and analgesics|postoperative complications|hospitalisation|patient satisfaction|degree of mobility","Maxima Medical Center|ZonMw: The Netherlands Organisation for Health Research and Development|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|Radboud UMC","All","18 Years and older   (Adult, Older Adult)","Not Applicable","450","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NL75375.041.20","March 1, 2021","August 1, 2023","November 1, 2023","August 8, 2022",,"August 8, 2022","Maxima MC, Veldhoven, Netherlands",,"https://ClinicalTrials.gov/show/NCT05491239"
817,"NCT05491226","Reinvigorating TNBC Response to Immunotherapy With Combination Myeloid Inhibition and Radiation",,"Not yet recruiting","No Results Available","TNBC - Triple-Negative Breast Cancer|Breast Cancer","Drug: Pembrolizumab|Radiation: Radiation Therapy|Drug: Axatilimab","Pathological complete response (pCR) rate.|Change in tumor-infiltrating lymphocytes (TILs) from biopsies.|Number of adverse events related to study treatment (pembrolizumab with radiation and axatilimab).|Progression-free survival (PFS).|Event-free survival (EFS).|Overall Survival (OS).|Node clearance.","Stephen Shiao|Merck Sharp & Dohme LLC|Incyte Corporation|Cedars-Sinai Medical Center","Female","18 Years and older   (Adult, Older Adult)","Phase 2","35","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IIT2021-01-Shiao-CSF1Ri","October 1, 2022","October 1, 2024","October 1, 2024","August 8, 2022",,"August 8, 2022",,,"https://ClinicalTrials.gov/show/NCT05491226"
818,"NCT05491213","TELESCOPE- TELEhealth Shared Decision-making COaching",,"Not yet recruiting","No Results Available","Lung Neoplasms","Behavioral: TELESCOPE, Remote Decision Coaching with Navigation Intervention","To assess hared decision making|Tobacco treatment referral","Rutgers, The State University of New Jersey|National Institutes of Health (NIH)","All","18 Years and older   (Adult, Older Adult)","Not Applicable","420","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Screening","CINJ132207|Pro2022000340","September 30, 2022","June 10, 2027","October 10, 2027","August 8, 2022",,"August 8, 2022","Rutgers, Cancer Institute of New Jersey, New Brunswick, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT05491213"
819,"NCT05491200","Comparison Of Reduced DAPT Followed by P2Y12 Inhibitor Monotherapy With Prasugrel vs stAndard Regimen in STEMI Patients",,"Recruiting","No Results Available","ST Elevated Myocardial Infarction|Dual Antiplatelet Therapy","Drug: Prasugrel based short DAPT|Drug: Prasugrel based standard DAPT|Device: OCT guided revascularization|Device: Angio guided revascularization","non inferiority of a Prasugrel-based short DAPT (30-45 days) followed by Prasugrel 11 month monotherapy versus standard 12 month DAPT regimen|superiority of an Optical Coherence Tomography (OCT)-guided revascularization completion as compared to a standard angiography-guided revascularization completion.|Composite of MACCE|BARC type 3 or 5 events","Research Maatschap Cardiologen Rotterdam Zuid|Abbott Medical Devices","All","Child, Adult, Older Adult","Phase 4","1608","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","RM21","July 22, 2022","August 1, 2026","August 1, 2028","August 8, 2022",,"August 8, 2022","Albert Schweitzer ziekenhuis, Dordrecht, Netherlands|Erasmus Medical Center, Rotterdam, Netherlands|Maasstadziekenhuis, Rotterdam, Netherlands",,"https://ClinicalTrials.gov/show/NCT05491200"
820,"NCT05491187","Comparison Between Bupivacaine With and Without Fentanyl in Reducing Pain During Cesarean Delivery Under Spinal Anaesthesia",,"Not yet recruiting","No Results Available","Visceral Pain","Drug: 0.5% bupivacaine heavy|Drug: 0.5% bupivacaine heavy with fentanyl","To compare the incidence of intraoperative visceral pain between two groups|To compare the intraoperative systolic blood pressure, diastolic blood pressure, mean arterial pressure in millimeter of mercury between two groups.|To compare intraoperative heart rate in beats per minute between 2 groups|To compare intraoperative oxygen saturation (SpO2) between 2 groups|To compare the incidence of side effects like nausea, vomiting, respiratory depression, level of sedation, pruritus between two groups|To assess the APGAR score of baby","Tribhuvan University Teaching Hospital, Institute Of Medicine.","Female","18 Years and older   (Adult, Older Adult)","Phase 3","72","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Ra$@","September 2022","January 2023","January 2023","August 8, 2022",,"August 8, 2022",,,"https://ClinicalTrials.gov/show/NCT05491187"
821,"NCT05491174","Mental Health Intervention for Transdiagnostic Groups in the Community",,"Recruiting","No Results Available","Severe Mental Illness","Behavioral: DBT-Informed skills group","Feasibility - Recruitment to the target sample of 30 participants|Feasibility - Retention rates|Feasibility - Outcome measure completion rates|Feasibility - Adherence to group intervention.|Feasibility - Satisfaction Questionnaire|Feasibility - Recruitment to the target sample of between 5 and 10 P-BIFS|Feasibility - P-BIF adherence to intervention protocol|Change in scores on the Clinical Outcomes of Routine Evaluation -10|Change in ratings on DIALOG Scale|Change in scores on Difficulties with Emotional Regulation Scale- 16|Change in scores on DBT- Ways of Coping Checklist - DBT Skills Subscale|Change in score on Distress Tolerance Scale","King's College London|South London and Maudsley NHS Foundation Trust","All","18 Years and older   (Adult, Older Adult)","Not Applicable","35","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","R&D2022/045","August 2022","March 2023","March 2023","August 8, 2022",,"August 8, 2022","South London and Maudsley NHS Foundation Trust, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT05491174"
822,"NCT05491161","The Motility Mother-Child Cohort","MOTILITY","Recruiting","No Results Available","Diet, Healthy|Infant Development","Other: Longitudinal study","Infant gut microbiome composition|Infant gut metabolome|Infant bowel habits|Infant intestinal transit time|Infant dietary patterns|Infant nutrient intake|Total faecal bacteria|Infant body weight|Infant body length|Infant growth|Infant head circumference|Infant fat stores|Infant body composition|Infant urine metabolome","University of Copenhagen|University College Cork|Technische Universität München|Quadram Institute Bioscience|University of Aarhus|Technical University of Denmark","All","18 Years to 40 Years   (Adult)",,"250","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","M241","August 11, 2022","January 1, 2025","July 1, 2027","August 8, 2022",,"August 15, 2022","University of Copenhagen, Department of Nutrition, Exercise and Sports, Copenhagen, Denmark",,"https://ClinicalTrials.gov/show/NCT05491161"
823,"NCT05491148","Study of the Functional State of the Body of Medical Workers in the Intensive Care Unit for Newborns",,"Enrolling by invitation","No Results Available","Сhanges in the Cardiovascular System in Healthcare Workers During Work Shift","Other: work conditions","Heart rate|Blood pressure|Anthropometry (Height)|Anthropometry (Weight)|Body temperature|Electrocardiography|Cognitive functions test 1|Cognitive functions test 2|Cognitive functions test 3|Survey","Federal State Budgetary Scientific Institution ""Izmerov Research Institute of Occupational Health""","All","18 Years to 65 Years   (Adult, Older Adult)",,"17","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","PPE-06","August 29, 2022","September 16, 2022","September 16, 2022","August 8, 2022",,"August 8, 2022","Federal State Budgetary Scientific Institution Izmerov Research Institute of Occupational Health, Moscow, Russian Federation",,"https://ClinicalTrials.gov/show/NCT05491148"
824,"NCT05491135","Hepatocyte Microbeads for Acute Liver Failure","HELP","Not yet recruiting","No Results Available","Acute Liver Failure","Biological: HMB002","Safety: Moderate to severe (including life threatening and death) adverse event occurrences due to product in 1st 52 weeks post procedure|Tolerability: assessed by the proportion of initiated infusion where >80% of the infusion is received by the patient.|Biological activity: Survival with native liver at 24 weeks post treatment.|Change in blood marker levels including haematological, biochemical and coagulation baseline to 52 weeks post treatment.|Change in Quality of life measures from baseline to week 52|Patient survival with native liver at 52 weeks post treatment|Patient survival with transplanted or native liver at 24 and 52 weeks post treatment.","King's College Hospital NHS Trust|Medical Research Council","All","up to 16 Years   (Child)","Phase 1|Phase 2","17","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","3571|2019-000316-29","September 2022","November 2025","May 2026","August 8, 2022",,"August 8, 2022",,,"https://ClinicalTrials.gov/show/NCT05491135"
825,"NCT05491122","The Influence of Fluid Intake on Daily Biological Rhythm and Mental Performance in Healthy Young Adults",,"Not yet recruiting","No Results Available","Healthy|Habitual; Drinking|Stress, Physiological|Stress, Psychological","Behavioral: Increasing or decreasing daily total fluid intake","Cortisol awakening response (CAR)|Urine Osmolality|Change in saliva cortisol to acute psychological stress|Urine colour|Thirst sensation","Liverpool John Moores University|Danone Research","All","18 Years to 35 Years   (Adult)","Not Applicable","54","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","ORION Study 2","September 2022","April 2024","April 2024","August 8, 2022",,"August 8, 2022","Liverpool John Moores University, Liverpool, Merseyside, United Kingdom",,"https://ClinicalTrials.gov/show/NCT05491122"
826,"NCT05491109","Soft Robotic Sock Intervention for Robot-assisted Ankle-foot Mobility in Post-stroke Patients",,"Not yet recruiting","No Results Available","Stroke|DVT|Ankle Contracture","Device: Venous Assistance and Contracture Management System (VACOM)","Modified Ashworth Scale (MAS)|Functional Independent Measure (FIM) - Mobility Part. 2 questionnaires (Stroke Impact Scale (SIS)|Ankle Range of Motion (ROM)|Medical Research Council (MRC) Scale for muscle strength|Fugl-Meyer Assessment - Lower Extremity (FMA-LE)|Functional Ambulation Categories (FAC)|10 meters walk test (10MWT)|functional Magnetic Resonance Imaging (fMRI)|Compression Ultrasound Sonography (U/S) for the lower limbs","National University Hospital, Singapore","All","21 Years to 99 Years   (Adult, Older Adult)","Not Applicable","90","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","2020/01058","September 1, 2022","January 13, 2023","January 13, 2023","August 8, 2022",,"August 10, 2022",,,"https://ClinicalTrials.gov/show/NCT05491109"
827,"NCT05491096","Effects of Proprioceptive Neuromuscular Training on Sensory and Motor Function in Guillain Barre Syndrome",,"Recruiting","No Results Available","Guillain-Barre Syndrome","Other: Proprioceptive Neuromuscular Training|Other: Conventional Physical Therapy","Berg Balance Scale|Time up and go test|One leg stance test","Riphah International University","All","10 Years to 25 Years   (Child, Adult)","Not Applicable","26","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","REC/22/0219 Salma","June 5, 2022","August 1, 2022","September 1, 2022","August 8, 2022",,"August 8, 2022","psrd (pakistan Society for the rehabilitation of the disabled), Lahore, Punjab, Pakistan",,"https://ClinicalTrials.gov/show/NCT05491096"
828,"NCT05491083","Pembrolizumab and ADG106 in Advanced Solid Cancers and Triple Negative Breast Cancer","ComPACT","Not yet recruiting","No Results Available","Advanced Solid Tumor|Triple Negative Breast Cancer","Drug: Pembrolizumab & ADG106 (Phase Ib)|Drug: Pembrolizumab & ADG106 (Phase II)","Number of participant with treatment related toxicities (Phase Ib)|Objective response rate (ORR) in Phase II","National University Hospital, Singapore|Adagene Inc|Merck Sharp & Dohme LLC","All","21 Years to 99 Years   (Adult, Older Adult)","Phase 1|Phase 2","51","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BR01/01/22","October 1, 2022","October 1, 2025","October 1, 2026","August 8, 2022",,"August 8, 2022",,,"https://ClinicalTrials.gov/show/NCT05491083"
829,"NCT05491070","Comparison of Different Vascular Closure Device in TAVI",,"Recruiting","No Results Available","Aortic Valve Stenosis|Transcatheter Aortic Valve Implantation","Device: Vascular closure device (Angio-Seal, Progilde)","Vascular complication|Life threatening bleeding complication|Major or minor bleeding complication without life threatening condition|Bail-out closure device use|Limb ischemia related to TAVI","National Taiwan University Hospital","All","20 Years and older   (Adult, Older Adult)","Not Applicable","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","201711019RINC","March 20, 2018","October 30, 2022","June 30, 2023","August 8, 2022",,"August 8, 2022","National Taiwan University Hospital, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT05491070"
830,"NCT05491057","Treatment Patterns of Neratinib in HER2+ EBC in China",,"Not yet recruiting","No Results Available","Breast Cancer","Drug: Neratinib","Duration of Treatment|Treatment holds and permanent discontinuations time|Patient demographics|Patient characteristics|Time to treatment|Prior adjuvant treatments|Dose adjustments|Dose intensity|Concomitant medication|Incidence of AESI|Type of AESI|Severity of AESI|action taken for AESI","Pierre Fabre Medicament","All","18 Years and older   (Adult, Older Adult)",,"500","Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","PF008","September 30, 2022","December 30, 2025","June 30, 2026","August 8, 2022",,"August 8, 2022","Medical Affair, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT05491057"
831,"NCT05491044","A Study of Orelabrutinib in CLL/SLL Patients Who Are Slowly Responding to Ibrutinib",,"Recruiting","No Results Available","CLL/SLL","Drug: orelabrutinib","ORR at cycle 3 after switched to orelabrutinib|DOR|PFS|OS","Peking University People's Hospital","All","18 Years and older   (Adult, Older Adult)","Phase 2","30","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Slowly responding switch IIT","January 1, 2022","February 28, 2023","June 30, 2023","August 8, 2022",,"August 8, 2022","Department of Hematology, Peking University People's Hospital, Beijing, Beijing, China|Peking University People's Hospital, Beijing, Beijing, China",,"https://ClinicalTrials.gov/show/NCT05491044"
832,"NCT05491031","MRI Biomarkers Predictive of Disability Progression in Patients With Multiple Sclerosis",,"Not yet recruiting","No Results Available","Multiple Sclerosis|Magnetic Resonance Spectroscopy","Other: magnetic resonance spectroscopy","Identify imaging biomarkers at inclusion predictive of disability progression.|Determine the correlation between brain MRI and the concentration of imaging biomarkers (mmols) at 6, 12, 18 and 24 months.|Develop realistic mathematical models of disease progression associated with clinical assessment of disability through dynamics, by the EDSS-plus score (EDSS scale from 0 to 10, T25FW in seconds, 9HPT in seconds).|Develop an artificial intelligence algorithm to identify predictive markers for disability. The artificial intelligence algorithm utilizes patients' clinical (EDSSS-Plus Scale) and radiological (brain MRI) characteristics.","Poitiers University Hospital","All","18 Years and older   (Adult, Older Adult)","Not Applicable","250","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","MR7T-PRADIMS","September 1, 2022","November 1, 2027","March 1, 2028","August 8, 2022",,"August 8, 2022",,,"https://ClinicalTrials.gov/show/NCT05491031"
833,"NCT05491018","Performance for French Pediatric Intensive Care Units","QUAL-REAPED","Not yet recruiting","No Results Available","Severity of Illness Index",,"Survival : yes / no|cost of PICU stay","University Hospital, Lille|Ministry of Health, France","All","up to 18 Years   (Child, Adult)",,"13270","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2018_98|PREPS-18-0433","December 2022","December 2024","December 2024","August 8, 2022",,"August 8, 2022",,,"https://ClinicalTrials.gov/show/NCT05491018"
834,"NCT05491005","The eHealth Diabetes Remission Trial","eDIT","Recruiting","No Results Available","Diabetes Mellitus, Type 2","Behavioral: Total diet replacement|Behavioral: eHealth|Behavioral: Face-to-face","HbA1c|Diabetes remission|Body weight|Achieved weight loss of at least 15 kg|Incremental costs per diabetes remission|Estimated lifetime costs|Estimated lifetime costs per quality-adjusted life-year (QALY)|Fasting blood glucose|P-glucose 120 minutes after the oral glucose tolerance test|Number of prescribed oral anti diabetic medications|Number of prescribed antihypertensive medications|Blood pressure (systolic/diastolic)|Blood pressure|Plasma lipid profile|Liver enzymes|Number of participants that discontinue the intervention|Waist circumference|Relation to food|Estimation of exhaustion|Quality of life accoring to Brunnsviken Brief Quality of Life Scale|Quality of life according to EQ-5D-5L|Eating habits|Estimation of health|Daily steps|Study experience|HbA1c follow-up|Body weight follow-up|Blood pressure follow-up|Usage of diabetes medication follow-up|Usage of hypertension medication follow-up|Diabetes complications follow-up","Umeå University|Region Västerbotten|Edgar Sjölunds Diabetes Foundation","All","20 Years to 70 Years   (Adult, Older Adult)","Not Applicable","104","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","Dnr 2022-02242-01","August 13, 2022","December 31, 2026","December 31, 2026","August 8, 2022",,"August 8, 2022","Bra Liv Råslätt vårdcentral, Jönköping, Sweden|Department of Public Health and Clinical Medicine, Medicine, Umeå, Sweden|Örnsköldsvik hospital, Örnsköldsvik, Sweden",,"https://ClinicalTrials.gov/show/NCT05491005"
835,"NCT05490992","Behavioral Skills Training Methods to Reduce Car Seat Misuse","BSTCPS","Completed","No Results Available","Motor Vehicle Injury","Other: Behavioral Skills Training In-person","child restraint misuse","Pro Consumer Safety - Public Health Behavior Solutions|University of Southern California","All","Child, Adult, Older Adult","Not Applicable","2448","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","BSTCPS2022","June 1, 2015","December 31, 2021","December 31, 2021","August 8, 2022",,"August 8, 2022","Pro Consumer Safety/Pro Car Seat Safety - NHTSA CPS Inspection Station, Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT05490992"
836,"NCT05490979","The Impact of Dyad Exercises on Well-being and Connection in Young Adults",,"Not yet recruiting","No Results Available","Mental Health Wellness 1|Loneliness","Behavioral: Contemplative dyad meditation|Behavioral: Fast friends","Change from Baseline Scores on the Brief Inventory of Thriving at 3 weeks|Change from Baseline Loneliness Scores on the Comprehensive Inventory of Thriving at 3 weeks|Change from Baseline Positive Affect Scores on the Negative And Positive Affect Scale at 3 weeks|Change from Baseline Negative Affect Scores on the Negative And Positive Affect Scale at 3 weeks|Change from Baseline Mindfulness Score on the Five Facet Mindfulness Questionnaire at 3 weeks|Change from Baseline Scores on the Self-Compassion Scale Short-Form at 3 weeks|Change from Baseline Scores on the Toronto Empathy Questionnaire at 3 weeks|Change from Baseline Depression Scores on the Patient Health Questionnaire-9 at 3 weeks|Change from Baseline Scores on the Generalized Anxiety Disorder-7 questionnaire at 3 weeks","University of Pennsylvania","All","18 Years to 35 Years   (Adult)","Not Applicable","180","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","#10085952","September 2022","November 2022","November 2022","August 8, 2022",,"August 8, 2022","University of Pennsylvania, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT05490979"
837,"NCT05490966","Effects of Isometric Muscle Fatigue on Trunk Muscle Stiffness",,"Recruiting","No Results Available","Muscle Tightness","Other: isometric trunk extensor muscles fatigue","Change of trunk extensors muscle stiffness|Change of muscle electromyography mean amplitude","University of Primorska","All","18 Years to 40 Years   (Adult)","Not Applicable","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","SWE_Isometric","September 2022","October 2022","October 2022","August 8, 2022",,"August 10, 2022","University of Primorska, Faculty of Health Sciences, Izola, Slovenia",,"https://ClinicalTrials.gov/show/NCT05490966"
838,"NCT05490953","Enhancing Effect on Tumour Apoptosis With the Use of Pentoxifylline in Patients With Hodgkin Lymphoma",,"Recruiting","No Results Available","Hodgkin Lymphoma","Drug: Pentoxifylline|Drug: Placebo","Peripheral apoptosis (Fortilin)|Peripheral apoptosis (Cytochrome c)|Assessment of the clinical response by positron emission tomography (PET)|Assessment of the clinical response by Computerized Axial Tomography|Assessment of the clinical response|Determination of event-free survival|Assessment of the severity of adverse effects|Correlation of adverse effects with pentoxifylline","University of Guadalajara|Hospital Civil de Guadalajara","All","6 Years to 35 Years   (Child, Adult)","Phase 4","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","CI-03122","July 11, 2022","December 31, 2023","July 1, 2024","August 8, 2022",,"August 8, 2022","Hospital Civil de Guadalajara Fray Antonio Alcalde, Guadalajara, Jalisco, Mexico",,"https://ClinicalTrials.gov/show/NCT05490953"
839,"NCT05490940","Sensory Recovery of Digital Nerves After Microsurgical Epineural Neurorrhaphy Alone or in Combination With Tisseel - RET","RET","Not yet recruiting","No Results Available","Digital Nerve Injuries","Drug: Tisseel®","two point discrimination|Neuroma formation|Grip strength|Active range of motion|Pain with the Numeric Rating Scale (NRS): 0 indicating no and 10 indicating maximum pain|quickDASH score (Disabilities of the Shoulder, Arm and Hand)|STI-Test: (Shape-Texture Identification test)","University Hospital Inselspital, Berne|Baxter Healthcare Corporation","All","18 Years and older   (Adult, Older Adult)","Not Applicable","74","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","2021-02050","August 3, 2022","June 30, 2025","June 30, 2025","August 8, 2022",,"August 8, 2022","Insel Gruppe AG, Bern, Switzerland",,"https://ClinicalTrials.gov/show/NCT05490940"
840,"NCT05490927","Ethnic Microaggressions and Smoking Behaviors Among Latinx Adults",,"Not yet recruiting","No Results Available","Smoking|Discrimination, Racial","Behavioral: Microaggression Recall and Relapse Analogue Task","Smoking Behaviors|Subjective Withdrawal|Urge/Craving|Smoking Lapse Behaviors","University of Houston","All","18 Years and older   (Adult, Older Adult)","Not Applicable","90","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","STUDY00003689","August 1, 2022","July 31, 2024","July 31, 2024","August 8, 2022",,"August 8, 2022",,,"https://ClinicalTrials.gov/show/NCT05490927"
841,"NCT05490914","The Prognostic Factors of COVID-19 ARDS Patients and Their Long-term Follow-up of Pulmonary Function Test",,"Recruiting","No Results Available","COVID-19",,"Primary Outcome of the retrospective cohort|Outcome of the prospective cohort: pulmonary function test will be performed daily by the patients after discharge from NTUH","National Taiwan University Hospital","All","20 Years and older   (Adult, Older Adult)",,"165","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","202005059RIND","July 1, 2020","December 31, 2022","December 31, 2022","August 8, 2022",,"August 8, 2022","National Taiwan University Hospital, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT05490914"
842,"NCT05490901","The Prognostic Role and Diagnostic Efficacy of Exercise Right Heart Catheterization With a Simultaneous Echocardiography in Patients With Dyspnea on Exertion","EX_CATH","Recruiting","No Results Available","Heart Failure With Preserved Ejection Fraction|Chronic Pulmonary Thromboembolism (Disorder)","Diagnostic Test: Exercise hemodynamic test","Proportion of exercise induced pulmonary artery wedge pressure >25 mmHg|Proportion of exercise induced pulmonary hypertension > 30 mmHg|Correlation between peripheral venous pressure and right atrial pressure assumed by echocardiography|Ventilatory mechanics|Aerobic capacity|coronary flow reserve|index of microcirculatory resistance|Lactate level at peak exercise|LA stiffness|change of E/e' between at rest and peak exercise|Rates of rehospitalization due to heart failure|Rates of all-cause death|The change of right ventricular systolic pressure (RVSP) between at rest and peak exercise|change of Tricuspid annular plane systolic excursion (TAPSE) between at rest and peak exercise|change of S' between at rest and peak exercise","Samsung Medical Center","All","19 Years and older   (Adult, Older Adult)",,"400","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","EX_CATH","March 17, 2020","December 31, 2028","June 30, 2029","August 8, 2022",,"August 8, 2022","Samsung Medical Center, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT05490901"
843,"NCT05490888","Single Dose Escalation of PHIN-214 in Child-Pugh A Liver Cirrhotics",,"Recruiting","No Results Available","Cirrhosis, Liver|Liver Fibrosis|Ascites Hepatic","Drug: PHIN-214 Subcutaneous injection","Incidence of dose limiting toxicities|incidence of stopping criteria|incidence of AEs|PK of PHIN-214|AUC of PHIN-214|PK of PHIN-214 metabolite|AUC of PHIN-214 metabolite","PharmaIN","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1","13","Industry","Interventional","Allocation: N/A|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PHIN-001","January 3, 2022","October 31, 2022","December 31, 2022","August 8, 2022",,"August 8, 2022","Arizona Liver Health, Chandler, Arizona, United States|Mayo Clinic, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT05490888"
844,"NCT05490875","Carotid Ultrasound to Identify Head and Neck Cancer Survivors With High Cardiovascular Risk After Radiation Therapy",,"Not yet recruiting","No Results Available","Head and Neck Cancer|Carotid Artery Stenosis|Cardiovascular Complication","Procedure: Carotid ultrasound|Other: Blood draw|Other: Survey","Number of Participants with 50% Stenosis Identified|Change in Intima-Media Thickness (IMT)|Number of Participants with Carotid Intima-Media Thickness (IMT) Increase|Number of Participants with Carotid Plaque Thickness Increase|Number of Participants Identified at High Risk of Cardiovascular Events|Number of Participants with Clinically Significant Carotid Artery Stenosis (Greater than or Equal to 50%) Based on Potential Risk Factors|Number of Participants Enrolled that Receive Study Intervention - Feasibility|Acceptability of Intervention Measure Instrument (Likert scale).|Barriers Survey instrument (Likert scale)|Assessment of Risk Perception Instrument (Likert scale)","Wake Forest University Health Sciences","All","18 Years and older   (Adult, Older Adult)",,"60","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","WFBCCC 98322","November 2022","November 2023","December 2024","August 8, 2022",,"August 8, 2022",,,"https://ClinicalTrials.gov/show/NCT05490875"
845,"NCT05490862","Inflammatory Status of Monocytes in Obesity",,"Recruiting","No Results Available","Obesity|Cardiovascular Diseases","Behavioral: Lifestyle Modification|Behavioral: Traditional Recommendations","Changes of pro-inflammatory macrophages activation|Mitochondrial genome mutations|Changes of body mass|Changes of body fat mass|Changes of skeletal muscle mass|Changes of Serum Cholesterol levels|Framingham Risk Score|Intima-media thickness","Federal State Budgetary Scientific Institution ""Federal Research Centre of Nutrition, Biotechnology|Petrovsky National Research Centre of Surgery","All","50 Years to 80 Years   (Adult, Older Adult)","Not Applicable","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","22-25-00414","January 11, 2022","December 14, 2022","December 14, 2023","August 8, 2022",,"August 8, 2022","Department of Cardiovascular Pathology and Diet, Moscow, Russian Federation",,"https://ClinicalTrials.gov/show/NCT05490862"
846,"NCT05490849","68Ga-HX01 PET in Healthy Volunteers and Malignant Tumors Patients",,"Recruiting","No Results Available","Malignant Neoplasm","Drug: 68Ga-HX01","Visual and semiquantitative assessment of lesions and biodistribution|Radioactivity in the blood and urine samples|Adverse events collection|Tumor markers|Blood routine|Liver function test|Glomerular filtration rate(GFR)|Blood Urea Nitrogen (BUN)","Wuhan Union Hospital, China","All","18 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","100","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","XLan-0799","October 1, 2021","December 31, 2022","December 31, 2022","August 8, 2022",,"August 8, 2022","China, Hubei Province, Wuhan, Hubei, China",,"https://ClinicalTrials.gov/show/NCT05490849"
847,"NCT05490836","Functional Cure Rate of Peg-IFNα-2b Combined With TAF in HBeAg Negative CHB Patients",,"Not yet recruiting","No Results Available","Chronic Hepatitis B","Biological: PEG IFN α-2b; TAF","The rate of HBsAg negative|change in HBsAg level from baseline|The Rate of HBsAg seroconversion|Proportion of patients with HBV DNA Below the detection limit|Number of patients with treatment-related adverse events","Huashan Hospital","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","KY2022-517","September 2022","August 2024","December 2024","August 8, 2022",,"August 8, 2022",,,"https://ClinicalTrials.gov/show/NCT05490836"
848,"NCT05490823","Validation of a Smartphone App for Anemia Screening Among General Population",,"Recruiting","No Results Available","Anemia","Device: A smartphone app for anemia screening","The proportion of accurate, mistaken and missed detection of this smartphone app.","Sun Yat-sen University","All","3 Years to 87 Years   (Child, Adult, Older Adult)","Not Applicable","1000","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","AnemiaApp-2021","December 1, 2018","December 1, 2022","December 1, 2022","August 8, 2022",,"August 8, 2022","Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, Guangdong, China",,"https://ClinicalTrials.gov/show/NCT05490823"
849,"NCT05490810","Effects of Trunk Stabilization Versus Activation Exercises on Pain and Disability in Postpartum Lumbo-pelvic Pain","LPP","Recruiting","No Results Available","Pelvic Pain","Other: Trunk stabilization|Other: Activation exercises","Visual analogue scale|Oswestry disability index","Riphah International University","Female","20 Years to 40 Years   (Adult)","Not Applicable","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","REC/RCR&AHS/22/0517","February 1, 2022","July 29, 2022","July 30, 2022","August 8, 2022",,"August 8, 2022","Jinnah hospital, Lahore, Punjab, Pakistan",,"https://ClinicalTrials.gov/show/NCT05490810"
850,"NCT05490797","Effects of Mobile Application Dexteria Fine Motor Skills on Hand Dexterity and Grip Strength in Chronic Stroke Patients",,"Recruiting","No Results Available","Stroke, Ischemic|Skill, Social|Occlusion","Other: app based training with conventional therapy|Other: conventional therapy","The Nine Hole Peg Test (NHPT)|Fugl-Meyer Motor assessment (FMA)|The Box &Block Test (BBT)|hand dynamometer.","Riphah International University","All","40 Years to 60 Years   (Adult)","Not Applicable","22","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","REC/RCR & AHS/21/0255","January 1, 2022","August 20, 2022","August 20, 2022","August 8, 2022",,"August 8, 2022","Riphah International University, Islamabad, Fedral, Pakistan",,"https://ClinicalTrials.gov/show/NCT05490797"
851,"NCT05490784","Effects of Lee Silverman Voice Treatment BIG on Dynamic Balance in Parkinson's Patients",,"Recruiting","No Results Available","Parkinson Disease|Motor Disorders|Balance; Distorted","Other: Lee Silverman Voice Treatment BIG|Other: conventional treatment","Dynamic Gait Index","Riphah International University","All","40 Years to 70 Years   (Adult, Older Adult)","Not Applicable","26","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","REC/RCR & AHS/21/0253","January 1, 2022","August 20, 2022","August 20, 2022","August 8, 2022",,"August 8, 2022","Riphah International University, Islamabad, Fedral, Pakistan",,"https://ClinicalTrials.gov/show/NCT05490784"
852,"NCT05490771","Testing Copanlisib as a Potential Targeted Treatment in Cancers With PIK3CA Mutations (MATCH-Subprotocol Z1F)",,"Active, not recruiting","No Results Available","Advanced Lymphoma|Advanced Malignant Solid Neoplasm|Hematopoietic and Lymphoid System Neoplasm|Refractory Lymphoma|Refractory Malignant Solid Neoplasm|Refractory Plasma Cell Myeloma","Procedure: Biopsy|Procedure: Computed Tomography|Drug: Copanlisib Hydrochloride|Procedure: Magnetic Resonance Imaging","Overall Response Rate (ORR)|Progression Free Survival (PFS)|Overall survival (OS)|6-month Progression-free Survival (PFS) Rate","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 2","35","NIH","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NCI-2022-06209|EAY131-Z1F|U10CA180820|U24CA196172","June 20, 2018","January 6, 2021","December 31, 2025","August 8, 2022",,"August 8, 2022","ECOG-ACRIN Cancer Research Group, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT05490771"
853,"NCT05490758","Sensorimotor Training and Constraint Induced Movement Therapy on Upper Extremity Function in Children With Hemiplegic CP",,"Completed","No Results Available","Hemiplegic Cerebral Palsy","Other: sensorimotor training|Other: constraint induced movement therapy","nine hole peg test|manual ability classification system","Riphah International University","All","8 Years to 15 Years   (Child)","Not Applicable","24","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","REC/RCR & AHS/22/0718","May 18, 2022","June 15, 2022","June 28, 2022","August 8, 2022",,"August 8, 2022","Rising Sun Institute, Lahore, Punjab, Pakistan",,"https://ClinicalTrials.gov/show/NCT05490758"
854,"NCT05490745","Psychological Intervention for Child Mental Health Based on Parental Reflective Functioning to Enhance Positive Parenting","SK4Parenting+","Recruiting","No Results Available","Externalizing Problems|Internalizing Problems","Behavioral: Skills4Parenting+|Other: Waiting-list (nocebo)","Change (Arm 1) ""Strengths & Difficulties Questionnaire"" (SDQ [6]; Portuguese version [7])|Change (Arm 1) ""Child Behavior Checklist 1½-5 ""(CBCL [8]; Portuguese version [9])|Change (Arm 2) ""Strengths & Difficulties Questionnaire"" (SDQ [6]; Portuguese version [7])|Change (Arm 2) ""Child Behavior Checklist 1½-5 ""(CBCL [8]; Portuguese version [9])|Change (Arm 1) ""COVID-19 Pandemic Impact Questionnaire""|Change (Arm 1) ""Spence Preschool Anxiety Scale"" (SPAS [10]; Portuguese version [11])|Change (Arm 1) ""Parental Practices Interview"" (PPI [12]; Portuguese version [13])|Change (Arm 1) ""Parental Reflective Functioning Questionnaire"" (PRFQ [14]; Portuguese version [15])|(Arm 1) ""Brief Problem Monitor"" (BPM [16]; Portuguese version in publication)|""Skills4Parenting+ Satisfaction Questionnaire""|Change (Arm 2) ""COVID-19 Pandemic Impact Questionnaire""|Change (Arm 2) ""Spence Preschool Anxiety Scale"" (SPAS [10]; Portuguese version [11])|Change (Arm 2) ""Parental Practices Interview"" (PPI [12]; Portuguese version [13])|Change (Arm 2) ""Parental Reflective Functioning Questionnaire"" (PRFQ [14]; Portuguese version [15])|Change (Arm 2) ""Brief Problem Monitor"" (BPM [16]; Portuguese version in publication)","University of Minho|Psychology Research Center (CIPsi)|Psychology Association of the University of Minho (aPsi-UMinho)|ProChild CoLAB - The Collaborative Laboratory against child poverty and social exclusion|Guimaraes City Hall|REN - Redes Energéticas Nacionais, SGPS, S.A|Foundation for Science and Technology (FCT)","All","3 Years to 6 Years   (Child)","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","CEICSH 106/2020|CIPSI-VC-2020-01","February 4, 2021","December 31, 2023","December 31, 2023","August 8, 2022",,"August 8, 2022","University of Minho, Braga, Portugal",,"https://ClinicalTrials.gov/show/NCT05490745"
855,"NCT05490732","Pharmacokinetic Modeling of Methadone","PKMETHAHOME","Not yet recruiting","No Results Available","Toxicomania","Biological: Blood sampling","Peak concentration (Cmax)|C12h-24h concentration|Residual concentration (C0)","University Hospital, Montpellier","All","18 Years to 99 Years   (Adult, Older Adult)","Not Applicable","100","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","21_0614","December 1, 2022","May 1, 2024","December 1, 2024","August 8, 2022",,"August 8, 2022",,,"https://ClinicalTrials.gov/show/NCT05490732"
856,"NCT05490719","A Phase II Study of CRT Combined With QL1706 in ESCC Patients",,"Not yet recruiting","No Results Available","Esophageal Squamous Cell Carcinoma","Drug: QL1706","PFS assessed by investigators|OS|ORR|DoR|The rates and severity of Adverse Events, Serious Adverse Events","Tianjin Medical University Cancer Institute and Hospital","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","50","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","QL1706-IIT-02","August 2022","January 2024","January 2024","August 8, 2022",,"August 8, 2022",,,"https://ClinicalTrials.gov/show/NCT05490719"
857,"NCT05490706","The Influence of Different At-home Exercise Strategies on 24h Glycemic Control",,"Recruiting","No Results Available","Metabolic Disturbance","Behavioral: Bodyweight interval exercise|Behavioral: Walking","24hr Glucose area under the curve|24hr Average glucose concentration|Postprandial dinner glucose response|Postprandial breakfast glucose response|Postprandial lunch glucose response|Nocturnal glucose|Time in hyperglycemia|Time in hypoglycemia|Time in range|Continuous overall net glycemic action (CONGA)|Change in glucose during exercise|Mean amplitude glycemic excursion (MAGE)|Standard deviation (SD)|% coefficient of variation (CV)","University of Toronto","Female","50 Years and older   (Adult, Older Adult)","Not Applicable","50","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","42756-2","July 7, 2022","January 6, 2023","July 6, 2023","August 8, 2022",,"August 8, 2022","University of Toronto, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT05490706"
858,"NCT05490693","The Effect of Virtual Reality Glasses Used During Burn Dressing in Children on Pain, Anxiety and Fear",,"Enrolling by invitation","No Results Available","Randomized","Other: Experimental group","pain, anxiety, fear scores,","Ondokuz Mayıs University","All","5 Years to 10 Years   (Child)",,"1","Other","Observational","Observational Model: Other|Time Perspective: Other","OMU","July 24, 2022","September 5, 2022","October 2, 2022","August 8, 2022",,"August 9, 2022","Omü, Samsun, İlkadım, Turkey|19May University, Samsun, Turkey",,"https://ClinicalTrials.gov/show/NCT05490693"
859,"NCT05490680","A New Sildenafil Oral Film in Patients With Erectile Dysfunction",,"Not yet recruiting","No Results Available","Erectile Dysfunction","Drug: Sildenafil Oral Film 50 mg|Drug: Sildenafil Oral Film 75 mg|Drug: Sildenafil Oral Film 100 mg|Drug: Placebo","Safety of Sildenafil doses versus placebo|Efficacy of Sildenafil 50 mg doses versus placebo - IIEF-EF|Efficacy of Sildenafil 75 mg doses versus placebo - IIEF-EF|Efficacy of Sildenafil 100 mg doses versus placebo - IIEF-EF|Efficacy of Sildenafil 50 mg doses versus placebo - SEP Question 2|Efficacy of Sildenafil 75 mg doses versus placebo - SEP Question 2|Efficacy of Sildenafil 100 mg doses versus placebo - SEP Question 2|Efficacy of Sildenafil 50 mg doses versus placebo - SEP Question 3|Efficacy of Sildenafil 75 mg doses versus placebo - SEP Question 3|Efficacy of Sildenafil 100 mg doses versus placebo - SEP Question 3|Safety TEAE of special interest - headache|Safety TEAE of special interest - dizziness|Safety TEAE of vasomotor drug effects","IBSA Institut Biochimique SA","Male","18 Years and older   (Adult, Older Adult)","Phase 3","600","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","20US-SDF15","November 2022","August 2023","August 2023","August 8, 2022",,"August 8, 2022",,,"https://ClinicalTrials.gov/show/NCT05490680"
860,"NCT05490667","Clinical Study of Anlotinib Combined With Chemotherapy in the Treatment of Unresectable Advanced Desmoid Tumor",,"Not yet recruiting","No Results Available","Desmoid","Drug: Anlotinib","Progression-free survival","Henan Cancer Hospital","All","10 Years to 72 Years   (Child, Adult, Older Adult)","Not Applicable","30","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HN-STS-002","August 20, 2022","July 31, 2024","July 31, 2024","August 8, 2022",,"August 8, 2022","Department of Bone and Soft Tissue ,Henan Cancer Hospital, Zhengzhou, Henan, China",,"https://ClinicalTrials.gov/show/NCT05490667"
861,"NCT05490654","Abdominal Massage for People With Learning Disabilities and Constipation","AMID","Recruiting","No Results Available","Constipation","Procedure: Abdominal Massage","Feasibility of the abdominal massage intervention|Knowles-Eccersley-Scott Symptom Score (KESS)|7 Day Bowel Diary (Non-validated scoring tool)","Glasgow Caledonian University|Baily Thomas Charitable Fund|NHS Greater Glasgow and Clyde","All","16 Years and older   (Child, Adult, Older Adult)","Not Applicable","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","307439","June 14, 2022","July 3, 2023","September 23, 2023","August 8, 2022",,"August 8, 2022","NHS Greater Glasgow & Clyde, Glasgow, Strathclyde, United Kingdom",,"https://ClinicalTrials.gov/show/NCT05490654"
862,"NCT05490641","Know and Own Your Movement-related Metrics Via Wearable Devices","Project KNOWN","Recruiting","No Results Available","Cancer|Survivorship","Behavioral: Glucose-based biofeedback|Behavioral: Standard feedback|Device: Glucose monitoring","Feasibility of delivering personalized glucose-based feedback|Changes in daily physical activity level","The University of Texas at Arlington|American Institute for Cancer Research","All","18 Years and older   (Adult, Older Adult)","Not Applicable","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","2022-0177","September 1, 2022","December 1, 2024","December 1, 2024","August 5, 2022",,"August 10, 2022","The University of Texas at Arlington, Arlington, Texas, United States",,"https://ClinicalTrials.gov/show/NCT05490641"
863,"NCT05490628","The Effects of Cognitive Rehabilitation on Motor Performance, Balance and Fear of Falling in Stroke Patients",,"Not yet recruiting","No Results Available","Stroke|Cognition Disorder|Fear Anxiety","Other: Cognitive Rehabilitation|Other: Conventional Therapy","Montreal Cognitive Assessment|Fugl-Meyer Assessment|Tinetti Balance & Gait Test|Falls Efficacy Scale International (FES-I)|The Timed Up & Go (TUG) Test|10 meter walking test","Istanbul University-Cerrahpasa","All","Child, Adult, Older Adult","Not Applicable","24","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","IstanbulUC-omerfarukakan-001","September 2022","October 2022","December 2022","August 5, 2022",,"August 5, 2022",,,"https://ClinicalTrials.gov/show/NCT05490628"
864,"NCT05490615","The Virtual Mindfulness Study",,"Not yet recruiting","No Results Available","Autism","Behavioral: Virtual Mindfulness","Psychological distress: measured using the Depression and Anxiety Stress Scale (DASS-21)|(i) Autistic Participant Depression and Anxiety: measured using the Depression and Anxiety Stress Scale (DASS-21)|Autistic Participant Self Compassion - measured using Self Compassion Scale-Short Form (SCS-SF)|Autistic Community connectedness (ACC) - measured using Autistic Community Connectedness (ACC) measured using Autistic Community Connectedness Measure (ACC)|Autistic Participant Satisfaction-measured using Intervention Satisfaction Scale (ISS)|Autistic Participant reactivity, observing, acting aware, describing, and non-judgment- measured using Five-Facet Mindfulness Questionnaire- Short Form (FFMQ-SF)","Centre for Addiction and Mental Health","All","18 Years and older   (Adult, Older Adult)","Not Applicable","80","Other","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care",,"September 2022","August 2023","April 2024","August 5, 2022",,"August 5, 2022",,,"https://ClinicalTrials.gov/show/NCT05490615"
865,"NCT05490602","Comparison Study in Different Sutures Techniques in Reduction of Known Abdominoplasty Complications and Improving Patients' Post-operative Outcomes",,"Recruiting","No Results Available","Abdominoplasty","Procedure: Running subcutaneous sutures technique|Procedure: Classical closures","Visual assessment of the wound|Pinch fat of dog ears|Sexual Activity questionnaire","Brugmann University Hospital","Female","18 Years and older   (Adult, Older Adult)",,"100","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","CHUB-Raei Ahmad","March 8, 2022","December 31, 2022","December 31, 2022","August 5, 2022",,"August 5, 2022","CHU Brugmann, Brussels, Belgium",,"https://ClinicalTrials.gov/show/NCT05490602"
866,"NCT05490589","Evaluation of the Implementation of a Parenting Program in Parents With Children Aged 4 to 12 Years and One Parent With an Alcohol Use Disorders","APPROCHILD","Not yet recruiting","No Results Available","Disorders Due to Substance Use","Other: EQUIPE Program","Effectiveness of a parenting program|Score on the different domains of the Parental Stress Index|Evaluation of self-esteem|Evaluation on children's behaviors|Evaluation of alcohol use|Evaluation of severity of alcohol use disorders|Evaluation of the progression of anxiety and depressive symptoms|Evaluation of the quality of life during the follow-up time|Evaluation of acceptability of the study by the participants","University Hospital, Brest","All","18 Years and older   (Adult, Older Adult)","Not Applicable","90","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","29BRC20.0173 (APPROCHILD)","February 1, 2023","February 1, 2025","July 1, 2026","August 5, 2022",,"August 5, 2022",,,"https://ClinicalTrials.gov/show/NCT05490589"
867,"NCT05490576","Tau And Connectomics In TES Study","TACIT","Recruiting","No Results Available","Chronic Traumatic Encephalopathy|Traumatic Encephalopathy|Head Injury Trauma|Cognitive Impairment|Neurodegenerative Diseases","Radiation: [18F] PI-2620 Tau Ligand","To determine if participants that meet the criteria for a Traumatic Encephalopathy Syndrome (TES) diagnosis have a specific tau deposition profile on Positron Emission Tomography (PET) scanning using the PET Tau binding ligand - [18F] PI 2620|Investigate correlations between regions of tau deposition and abnormalities observed on magnetic resonance imaging (MRI)|Investigate whether PET tau imaging with PI-2620 can provide a differential diagnosis between TES and other conditions associated with tauopathies e.g. Alzheimer's disease","Macquarie University, Australia|Omniscient Neurotechnology|Life Molecular Imaging GmbH","All","40 Years to 70 Years   (Adult, Older Adult)","Phase 1","12","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","CNTES01","August 8, 2022","December 22, 2022","December 22, 2022","August 5, 2022",,"August 5, 2022","Macquarie Medical Imaging, Macquarie Park, New South Wales, Australia",,"https://ClinicalTrials.gov/show/NCT05490576"
868,"NCT05490563","STRIDES - a Clinical Research Study of an Investigational New Drug to Treat Spinocerebellar Ataxia","STRIDES","Recruiting","No Results Available","Spinocerebellar Ataxia Type 3","Drug: SLS-005|Drug: Placebo","Primary Efficacy: m-SARA|Efficacy: CGI-S|Efficacy: PGI-S|Efficacy: FARS-ADL|Efficacy: m-SARA|Safety: Adverse Events","Seelos Therapeutics, Inc.","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2|Phase 3","245","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","SLS-005-302","June 3, 2022","June 3, 2024","June 3, 2024","August 5, 2022",,"August 5, 2022","UCLA, Los Angeles, California, United States|University of South Florida, Tampa, Florida, United States",,"https://ClinicalTrials.gov/show/NCT05490563"
869,"NCT05490550","Comparing Insomnia Care As Usual to Digital Augmentation (CICADA)",,"Not yet recruiting","No Results Available","Chronic Insomnia","Behavioral: COAST-enhanced CBTI|Behavioral: Military Treatment Facility Insomnia Care As Usual","Insomnia Severity|Symptoms of Depression|Symptoms of Anxiety|Acceptability of Insomnia Care|Satisfaction with Insomnia Care","Noctem, LLC","All","18 Years and older   (Adult, Older Adult)","Not Applicable","188","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","JW210372","October 2022","December 2023","March 2024","August 5, 2022",,"August 5, 2022",,,"https://ClinicalTrials.gov/show/NCT05490550"
870,"NCT05490537","Cutaneous Acceptability, Comedogenic Potential and Efficacy of Two Cosmetic Products Used in Synergy",,"Completed","No Results Available","Acne",,"change in cutaneous acceptability by the dermatologist with a 5-point scale|change in cutaneous acceptability by the participant with a 5-point scale|change in comedogenic potential|change in Global Evaluation Acne (GEA) score","Cosmetique Active International","All","up to 45 Years   (Child, Adult)",,"46","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","LRP19013-EFFACLAR GEL AND DUO+","January 13, 2021","November 11, 2021","November 11, 2021","August 5, 2022",,"August 9, 2022","Insight Research, Quatre Bornes, Mauritius|Dermscan Poland Sp. z o. o., Gdańsk, Poland",,"https://ClinicalTrials.gov/show/NCT05490537"
871,"NCT05490524","Smart Living Homes: a Pilot RCT of GATEKEEPER System in Cyprus With Patients With Cancer and Dementia","GATEKEEPER","Recruiting","No Results Available","Neoplasms|Cancer|Dementia","Device: GATEKEEPER","Health Related Quality of Life (cancer patients only)|Health status (dementia patients only)|Symptom burden (cancer patients only)|Anxiety (cancer patients only)|Depression (cancer patients only)|System Usability|System Feasibility|Cognitive decline (dementia patients only)|Cognitive function (dementia patients only)|Depression (dementia patients only)|Anxiety (dementia patients only)|Caregiver burden (caregivers only)|Depression (caregivers only)|Anxiety (caregivers only)|Technology acceptance (healthcare professionals only)","Cyprus University of Technology|Pancyprian Federation of Cancer Patients and Friends","All","18 Years to 100 Years   (Adult, Older Adult)","Not Applicable","300","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care","CUT_DN_01","June 1, 2021","March 2023","March 2023","August 5, 2022",,"August 5, 2022","Cyprus University of Technology, Limassol, Cyprus",,"https://ClinicalTrials.gov/show/NCT05490524"
872,"NCT05490511","Drug-gene-nutraceutical Interactions of Cannabidiol and Tacrolimus",,"Not yet recruiting","No Results Available","CBD|Transplant Complication|Kidney Disease, Chronic","Drug: Tacrolimus single dose|Drug: Epidiolex single dose|Drug: Epidiolex steady-state and tacrolimus single dose","The AUC0-Infinity ratio of tacrolimus with cannabidiol divided by tacrolimus alone|Immune cell distribution and signaling as measured by scRNA sequencing","Indiana University","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","72","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","12763","September 2022","September 2027","October 2028","August 5, 2022",,"August 9, 2022",,,"https://ClinicalTrials.gov/show/NCT05490511"
873,"NCT05490498","Study of the Breast Milk Microbiota and Its Influence on the Development of Early and Late Neonatal Bacterial Sepsis Under Three Months of Age.","MINEOS","Recruiting","No Results Available","Neonatal Sepsis","Other: Collection of breast milk","Description of bacterial carriage of breast milk|Comparison of breast milk of infants with neonatal sepsis to infants without neonatal sepsis.|Comparison of milk germs to children's germs.|Comparison of microbiota profiles in breast milk","Assistance Publique Hopitaux De Marseille","Female","Child, Adult, Older Adult","Not Applicable","75","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","2021-11|ID-RCB","July 13, 2022","July 12, 2024","December 12, 2024","August 5, 2022",,"August 5, 2022","Hopital de la Timone, Marseille, France",,"https://ClinicalTrials.gov/show/NCT05490498"
874,"NCT05490485","Camrelizumab Combined With Cisplatin in the Treatment of Advanced Cutaneous Squamous Cell Carcinoma",,"Not yet recruiting","No Results Available","Squamous Cell Carcinoma of the Skin","Drug: Camrelizumab","Progression-free survival|Overall survival","Henan Cancer Hospital","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 2","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ZZCSCC-1","August 5, 2022","July 31, 2024","July 31, 2024","August 5, 2022",,"August 5, 2022","Department of Bone and Soft Tissue ,Henan Cancer Hospital, Zhengzhou, Henan, China",,"https://ClinicalTrials.gov/show/NCT05490485"
875,"NCT05490472","JAB-2485 Activity in Adult Patients With Advanced Solid Tumors",,"Not yet recruiting","No Results Available","Solid Tumors|ER+ Breast Cancer|Triple Negative Breast Cancer, TNBC|ARID1A Gene Mutation|Small Cell Lung Cancer, SCLC","Drug: JAB-2485 (Aurora A inhibitor)","Dose Escalation phase: Number of participants with dose limiting toxicities (DLTs)|Dose Escalation phase: Number of participants with adverse events (AEs)|Dose Expansion phase: Objective Response Rate (ORR)|Dose Expansion phase: Duration of Response (DOR)|Dose Escalation phase: Objective Response Rate (ORR)|Dose Escalation and Dose Expansion phase: Time to response (TTR)|Dose Escalation phase: Duration of Response (DOR)|Dose Escalation and Dose Expansion phase: peak plasma concentration (Cmax)|Dose Escalation and Dose Expansion phase: time to peak plasma concentration(Tmax)|Dose Escalation and Dose Expansion phase: Ctrough|Dose Escalation and Dose Expansion phase: Area under the curve (AUC)|Dose Escalation and Dose Expansion phase: half-life (t½)|Dose Escalation and Dose Expansion phase: total body clearance|Dose Expansion phase: Progression Free Survival (PFS)|Dose Expansion Phase 2a: Overall Survival (OS)|Dose Expansion phase: Disease Control Rate (DCR)|Dose Expansion phase: Number of participants with adverse events (AEs)","Jacobio Pharmaceuticals Co., Ltd.","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","102","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","JAB-2485-1001","August 2022","August 2024","August 2026","August 5, 2022",,"August 5, 2022",,,"https://ClinicalTrials.gov/show/NCT05490472"
876,"NCT05490459","Jewel Electrophysiology (EP) Lab Study",,"Enrolling by invitation","No Results Available","Sudden Cardiac Arrest","Device: Jewel Patch Wearable Cardioverter Defibrillator (P-WCD)","Clinical Effectiveness of the Jewel Patch Wearable Cardioverter Defibrillator (P-WCD)","Element Science, Inc.","All","18 Years and older   (Adult, Older Adult)","Not Applicable","18","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PR-2038","July 28, 2022","December 31, 2022","December 31, 2022","August 5, 2022",,"August 5, 2022","Nemocnice Na Homolce Hospital, Prague, Czechia",,"https://ClinicalTrials.gov/show/NCT05490459"
877,"NCT05490446","A Study of AG-946 in Participants With Anemia Due to Lower-Risk Myelodysplastic Syndromes (LR-MDS)",,"Not yet recruiting","No Results Available","Myelodysplastic Syndromes","Drug: AG-946|Drug: Placebo","Phase 2a: Number of Participants With Hemoglobin (Hb) Response|Phase 2a: Number of Participants With Transfusion Independence During the Core Period|Phase 2b: Number of Participants With Modified Hematologic Improvement-erythroid (mHI-E) Response|Phase 2a: Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), and AEs Leading to Discontinuation During the Core Period|Phase 2a: Number of Participants With Laboratory Abnormalities During the Core Period|Phase 2a: Number of Participants With Hb 1.0+ Response|Phase 2a: Change From Baseline in Hb Concentration During the Core Period|Phase 2a: Number of Participants With ≥1.5-g/dL increase From Baseline in the Hb Concentration at ≥2 Consecutive Time Points From Week 8 through Week 16|Phase 2a: Change from Baseline in Total Transfused Red Blood Cell (RBC) Units During the Core Period|Phase 2a: Number of Participants With ≥50% Reduction in Total Transfused RBC Units for ≥8 Consecutive Weeks During the Core Period Compared With Baseline|Phase 2a: Plasma Concentration of AG-946 During the Core Period|Phase 2a: Maximum (Peak) Concentration (Cmax) of AG-946 During the Core Period|Phase 2a: Time to Cmax (tmax) of AG-946 During the Core Period|Phase 2a: Area Under the Concentration-time Curve From 0 to t Hours (AUC0-t) of AG-946 During the Core Period|Phase 2a: Area Under the Concentration-time Curve From 0 to the End of the Dosing Interval (AUC0-τ) of AG-946 During the Core Period|Phase 2a: Apparent Terminal Elimination Half-life (t½) of AG-946 During the Core Period|Phase 2a: Whole Blood Concentrations of 2,3-diphosphoglycerate (2,3-DPG) During the Core Period|Phase 2a: Whole Blood Concentrations of Adenosine Triphosphate (ATP) During the Core Period|Phase 2b: Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), and AEs Leading to Discontinuation During the Double-blind Period|Phase 2b: Change From Baseline in Hb Concentration During the Double-Blind Period|Phase 2b: Change From Baseline in Total Transfused RBC Units From Week 8 Through Week 24|Phase 2b: Number of Participants With Transfusion Independence during the Double-blind Period|Phase 2b: Time to First mHI-E Response During the Double-blind Period|Phase 2b: Maximum Duration of mHI-E Response for Participants Who Achieved an mHI-E Response During the Double-blind Period|Phase 2b: Plasma Concentration of AG-946 During the Double-blind Period|Phase 2b: Maximum (Peak) Concentration (Cmax) of AG-946 During the Double-blind Period|Phase 2b: Time to Cmax (tmax) of AG-946 During the Double-blind Period|Phase 2b: Area Under the Concentration-time Curve From 0 to t Hours (AUC0-t) of AG-946 During the Double-blind Period|Phase 2b: Area Under the Concentration-time Curve From 0 to the End of the Dosing Interval (AUC0-τ) of AG-946 During the Double-blind Period|Phase 2b: Apparent Terminal Elimination Half-life (t½) of AG-946 During the Double-blind Period|Phase 2b: Whole Blood Concentrations of 2,3-diphosphoglycerate (2,3-DPG) During the Double-blind Period|Phase 2b: Whole Blood Concentrations of Adenosine Triphosphate (ATP) During the Double-blind Period|Phase 2b: Correlation Between AG-946 Plasma Concentration/exposure and Percentage of Participants With mHI-E Response During the Double-blind Period, as Assessed by Regression Analysis|Phase 2b: Correlation Between AG-946 Plasma Concentration/exposure and Change From Baseline in Hb Concentration During the Double-blind Period, as Assessed by Regression Analysis|Phase 2b: Correlation Between AG-946 Plasma Concentration/exposure and Percentage of Participants Having AEs of Clinical Interest During the Double-blind Period, as Assessed by Regression Analysis","Agios Pharmaceuticals, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 2","116","Industry","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","AG946-C-002|2022-500609-42-00","September 15, 2022","November 17, 2025","November 13, 2028","August 5, 2022",,"August 5, 2022",,,"https://ClinicalTrials.gov/show/NCT05490446"
878,"NCT05490433","Robot-assisted vs. Open Nipple-sparing Mastectomy With Immediate Breast Reconstruction","ROM","Not yet recruiting","No Results Available","Breast Cancer","Procedure: robot assisted nipple sparing mastectomy(RNSM)|Procedure: Conventional nipple sparing mastectomy(CNSM)","5-year disease-free survival rate(DFS)|Five-year overall survival (OS) rates|Five-year breast cancer-specific survival (BCSS) rates|Five-year distant recurrence-free survival (DRFS) rates|Five-year locoregional recurrence-free survival (LRFS) rates|Five-year nipple recurrence (NR) rates|Margin positive rates|Open conversion rate (RNSM arm only)|Operation time|Postoperative complication rates in postoperative 30 days|Clavien-Dindo grade of postoperative complications in postoperative 180 days|Implant or graft (flap) loss rates within 1 year from surgery|Patient reported outcomes in postoperative 3 - 12 months from the definitive surgery (patient satisfaction)|Surgeon's satisfaction in postoperative 3 month to 1 year|Cost-effectiveness in postoperative 3 month to 1 year","Yonsei University","Female","19 Years to 70 Years   (Adult, Older Adult)","Not Applicable","790","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","4-2022-0600","October 2022","June 2030","June 2030","August 5, 2022",,"August 10, 2022","Yonsei University Health System, Severance Hospital, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT05490433"
879,"NCT05490420","Effects of Upper Extremity Manual Lymphatic Drainage on Symptom Severity, Hand Functions, Electrophysiological and Ultrasonographic Measurements in Carpal Tunnel Syndrome",,"Not yet recruiting","No Results Available","Carpal Tunnel Syndrome","Other: manual lymphatic drainage (MLD)","Symptom severity|Grip strength|Pressure pain threshold (PPT)|Cross-sectional area of the median nerve|Median nerve conduction velocity","Istanbul Medeniyet University","All","40 Years to 60 Years   (Adult)","Not Applicable","34","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","2022/0344","September 5, 2022","April 3, 2023","May 15, 2023","August 5, 2022",,"August 5, 2022","Emel Mete, Istanbul, Turkey",,"https://ClinicalTrials.gov/show/NCT05490420"
880,"NCT05490407","Role of the ATP7A Transporter in Ovarian Cancer","ATHOC","Recruiting","No Results Available","Gynecologic Cancer|Ovarian Cancer|High Grade Serous Carcinoma|Chemotherapy Effect","Drug: Carboplatin","concentration of ceruloplasmin|expression of ATP7A|concentration of ceruloplasmin after chemotherapy|expresion of ATP7A after chemotherapy","University Medical Centre Ljubljana|University of Ljubljana, Faculty of Medicine, Institute of Pharmacology and Experimental Toxicology","Female","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","30","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening","UMCL","March 17, 2021","May 1, 2023","October 1, 2023","August 5, 2022",,"August 10, 2022","Department of Gynecology, Division of Gynecology and Obstetrics, Ljubljana University Medical Center, Ljubljana, Slovenia|Institute of Pharmacology and Experimental Toxicology, Faculty of Medicine, University of Ljubljana., Ljubljana, Slovenia",,"https://ClinicalTrials.gov/show/NCT05490407"
881,"NCT05490394","Correlation Study of PAI-1 4G/5G Polymorphism and Postoperative AKI in Patients With Aortic Dissection",,"Not yet recruiting","No Results Available","AKI - Acute Kidney Injury|PAI-1 4G/5G Polymorphism|Aortic Dissection",,"moderate to severe AKI","Xijing Hospital","All","18 Years and older   (Adult, Older Adult)",,"255","Other","Observational","Observational Model: Cohort|Time Perspective: Other","KY20212193-F-1","August 2022","August 2023","August 2023","August 5, 2022",,"August 5, 2022",,,"https://ClinicalTrials.gov/show/NCT05490394"
882,"NCT05490381","Preoperative Embolization of Hypervascular Head and Neck Tumors to Improve Surgical Outcomes",,"Not yet recruiting","No Results Available","Malignant Neoplasm in the Head and Neck|Metastatic Malignant Neoplasm in the Head and Neck","Other: Iodixanol|Procedure: Angiogram|Procedure: Arterial Embolization|Drug: Polyvinyl Alcohol|Drug: Ethiodized Oil|Procedure: Computed Tomography|Other: Chart Abstraction","Intraoperative blood loss|Perioperative blood transfusion volume|Surgical procedure time|Success of embolization|Adverse events (AE) related to angiography or embolization","University of Washington|Guerbet","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 1","20","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","RG1121599|NCI-2022-05693|STUDY00009998","December 1, 2022","January 31, 2023","January 31, 2023","August 5, 2022",,"August 15, 2022","Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT05490381"
883,"NCT05490368","Efficacy of Bed Mattress Sensor for Detecting Pre-fall Activities and Preventing Bedside Falls in Elderly in Residential Setting",,"Not yet recruiting","No Results Available","Technology","Device: Bed mattress sensor system","Numbers of bedside fall incidents 6 months before and after the installation of the system and between the two groups|The length of hospital stay due to bedside fall incidents before and after the use of the system and between the two groups|Qualitative measure: Fall characteristics of residents before and after the use of the system and between the two groups|The number of detector alerts made by the sensor|Average time in seconds to turn off the alert|The number of immediate care delivery of the staff upon the alert|Qualitative measure: Views and Comments from the operations residents and/or their family members on the usage of the pre-fall activity sensor|Qualitative measure: Views and Comments from the operations staff on the usage of the pre-fall activity sensor","The University of Hong Kong|Haven of Hope Hospital|The Social Innovation and Entrepreneurship Development Fund, Hong Kong","All","Child, Adult, Older Adult","Not Applicable","25","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","HKU_bedsensor_protocol_v3","August 15, 2022","January 2023","January 2023","August 5, 2022",,"August 15, 2022","Haven of Hope Woo Ping Care & Attention Home, Hong Kong, Hong Kong",,"https://ClinicalTrials.gov/show/NCT05490368"
884,"NCT05490355","Radiofrequency Ablation and Steroid Versus Steroid Alone for Relief of Pain in Patients With Advanced Knee and Hip Osteoarthritis",,"Not yet recruiting","No Results Available","Osteoarthritis, Knee|Osteoarthritis, Hip","Procedure: Radiofrequency Ablation (RFA)|Procedure: Perineural Steroid Injection","Hip Functional score at baseline (pre-procedure)|Hip Functional score at 2 weeks post procedure|Hip Functional score at 3 months post procedure|Hip Functional score at 6 months post procedure|Knee Functional score as measured by standard of care questionnaire for knee OA at baseline (pre-procedure)|Knee Functional score as measured by standard of care questionnaire for knee OA at 2 weeks post procedure|Knee Functional score as measured by standard of care questionnaire for knee OA at 3 months post procedure|Knee Functional score as measured by standard of care questionnaire for knee OA at 6 months post procedure","University of Texas Southwestern Medical Center","All","18 Years to 100 Years   (Adult, Older Adult)","Not Applicable","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","STU-2022-0337","August 2022","August 2024","August 2024","August 5, 2022",,"August 5, 2022","University of Texas Southwestern Medical Center, Dallas, Texas, United States",,"https://ClinicalTrials.gov/show/NCT05490355"
885,"NCT05490342","Effect of SARS-CoV-2 Vaccination in Liver Transplant Recipients",,"Completed","No Results Available","SARS-CoV-2 Vaccination|Liver Transplantation","Diagnostic Test: Immunoassay, by ECLIA, for the quantitative in vitro determination of antibodies (including IgG) to the SARS - CoV - 2 spike protein (S) anti-RBD (receptor-binding domain) in serum and plasma samples.","Rate of positive antibody titer|Rate of highly protective antibody titer|Median antibody titer absolute value","University of Rome Tor Vergata","All","18 Years and older   (Adult, Older Adult)",,"61","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","sperimentazioni PTV 71.22","April 1, 2022","June 30, 2022","June 30, 2022","August 5, 2022",,"August 5, 2022","Policlinico Tor Vergata, Roma, Italy",,"https://ClinicalTrials.gov/show/NCT05490342"
886,"NCT05490329","Addressing Vaccine Hesitancy and Increasing COVID-19 Vaccine Uptake Among African American Young Adults in the South",,"Not yet recruiting","No Results Available","COVID-19|Vaccine Uptake","Behavioral: Tough Talks COVID","COVID Vaccine Uptake at Month 1|COVID Vaccine Uptake at Month 3|COVID Vaccine Confidence|COVID Vaccine Hesitancy","University of North Carolina, Chapel Hill|University of Alabama at Birmingham|National Institute on Minority Health and Health Disparities (NIMHD)","All","18 Years to 29 Years   (Adult)","Not Applicable","360","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","21-1746|R01MD016834","September 2022","January 2025","January 2025","August 5, 2022",,"August 5, 2022","University of Alabama at Birmingham, Birmingham, Alabama, United States|University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT05490329"
887,"NCT05490316","A Study of IBI353 (Orismilast) in Chinese Healthy Adults",,"Not yet recruiting","No Results Available","Healthy Subjects","Drug: IBI353 (Orismilast)|Drug: placebo","Time to Maximal Blood Concentration (Tmax) of IBI353 and its related metabolites.|Maximal Concentration (Cmax) of IBI353 and its related metabolites.|Area Under the Concentration Curve (AUC) of IBI353 and its related metabolites.|Volume of Distribution (Vd/F) of IBI353 and its related metabolites.|Half life time of IBI353 and its related metabolites.|Clearance (CL/F) of IBI353 and its related metabolites.|Accumulation Ratio of IBI353 and its related metabolites.|Incidence of treatment-emergent adverse events (TEAEs), gastrointestinal AEs, and changes of vital signs, lab examinations, physical examinations, ECGs in healthy subjects after drug administration.","Innovent Biologics (Suzhou) Co. Ltd.","All","18 Years to 45 Years   (Adult)","Phase 1","20","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CIBI353A101","September 1, 2022","January 31, 2023","February 28, 2023","August 5, 2022",,"August 5, 2022","Huashan Hospital Affiliated to Fudan University, Shanghai, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT05490316"
888,"NCT05490303","HeartGuide: Preliminary Study","HG-1","Not yet recruiting","No Results Available","Cardiac Disease","Other: recording of the probe position","Probe position|Percentage of matches between algorithm and expert","University Hospital, Bordeaux|DESKi","All","18 Years and older   (Adult, Older Adult)","Not Applicable","90","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","CHUBX 2022/19|2022-A01501-42","September 1, 2022","January 1, 2023","January 1, 2023","August 5, 2022",,"August 5, 2022","CHU de Bordeaux, Bordeaux, France",,"https://ClinicalTrials.gov/show/NCT05490303"
889,"NCT05490290","Medical Imaging Decision And Support","MIDAS","Not yet recruiting","No Results Available","Clinical Decision Support Systems","Other: Active","Appropriateness of diagnostic imaging exams|Absolute number of imaging exams|Medical radiation from diagnostic imaging|Medical costs for diagnostic imaging","University Hospital Augsburg|Erasmus Medical Center|University Hospital Schleswig-Holstein|Johannes Gutenberg University Mainz","All","Child, Adult, Older Adult","Not Applicable","32","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Other","SFV-89-19","August 2022","May 2023","May 2023","August 5, 2022",,"August 5, 2022",,,"https://ClinicalTrials.gov/show/NCT05490290"
890,"NCT05490277","Vibrotactile Coordinated Reset for the Treatment of Chronic Stroke",,"Not yet recruiting","No Results Available","Chronic Stroke","Device: Active Vibrotactile coordinated reset|Device: Sham vibrotactile coordinated reset","Fugl Meyer Assessment of Motor Recovery after Stroke change from baseline, 3 months, 4 months, 7months and 8 months|Neuro Quality of Life Upper Extremity Short Form test change from baseline, 3 months, 4 months, 7months and 8 months|Barthel Index for Activities of Daily Living change from baseline, 3 months, 4 months, 7months and 8 months|Action Research Arm Test change from baseline, 3 months, 4 months, 7months and 8 months|Timed Up and Go test change from baseline, 3 months, 4 months, 7months and 8 months|Neuro Quality of Life Lower Extremity Short Form test change from baseline, 3 months, 4 months, 7months and 8 months","Stanford University","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 1|Phase 2","20","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","65197","September 1, 2022","September 1, 2024","September 1, 2024","August 5, 2022",,"August 10, 2022",,,"https://ClinicalTrials.gov/show/NCT05490277"
891,"NCT05490264","[68Ga]Ga-NOTA-SNA002 (PD-L1 PET Tracer) for PET/CT in Patients With Solid Tumors",,"Not yet recruiting","No Results Available","Solid Tumor|Positron-Emission Tomography(PET)","Biological: [68Ga]Ga-NOTA-SNA002","Incidence of adverse events|Changes of vital signs in participants compared with baseline results.|Changes in laboratory values compared with baseline results.|Immunogenicity Analysis of [68Ga]Ga-NOTA-SNA002|Description of biodistribution patterns of [68Ga]Ga-NOTA-SNA002 on PET|Standard Uptake Value(max) in tumors|Standard Uptake Value(peak) in tumors|Standard Uptake Value(mean) in tumors|Correlation of [68Ga]Ga-NOTA-SNA002 uptake in biopsied tumors with PD-L1 measurement by immunohistochemistry (IHC)","SmartNuclide Biopharma|The First Affiliated Hospital of Soochow University","All","18 Years to 75 Years   (Adult, Older Adult)","Early Phase 1","20","Industry|Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","SN-2022-01","August 1, 2022","December 1, 2022","December 30, 2022","August 5, 2022",,"August 5, 2022","The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China",,"https://ClinicalTrials.gov/show/NCT05490264"
892,"NCT05490251","Stress Reactivity and Nicotine Addiction Among African American and White Smokers",,"Recruiting","No Results Available","Smoking|Smoking Behaviors|Smoking Cessation|Stress Reaction",,"Examining racial differences in acute stress responses|Examining changes in daily cortisol patterns according to race|Examine changes in stress responses and smoking behaviors as it relates to social determinant factors","Medical University of South Carolina|Virginia Commonwealth University|City of Hope Medical Center","Male","18 Years to 75 Years   (Adult, Older Adult)",,"100","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","00116801","June 27, 2022","July 31, 2024","August 31, 2024","August 5, 2022",,"August 5, 2022","Medical University of South Carolina, Charleston, South Carolina, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/51/NCT05490251/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/51/NCT05490251/ICF_001.pdf","https://ClinicalTrials.gov/show/NCT05490251"
893,"NCT05490238","DIStal Versus COnventional Radial Access for COMPLEX Large-bore Percutaneous Coronary Intervention","DISCO COMPLEX","Not yet recruiting","No Results Available","Vascular Access Site Occlusion","Procedure: Complex PCI with Ultimaster Tansei (Terumo Corp., Japan) drug-eluting stent","Incidence of forearm radial artery occlusion|Incidence of vascular access site-related bleeding|Incidence of vascular access site-related complication|Incidence of radial artery spasm|Incidence of distal radial artery occlusion|Total hemostasis time|Incidence of vascular access site-related pain|Incidence of hand dysfunction|Rate of target lesion failure","IGLESIAS Juan Fernando|University Hospital, Geneva","All","18 Years and older   (Adult, Older Adult)","Not Applicable","706","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","2022-0729","September 1, 2023","September 1, 2025","September 1, 2026","August 5, 2022",,"August 5, 2022",,,"https://ClinicalTrials.gov/show/NCT05490238"
894,"NCT05490225","Pivotal Voyager Ark Device Vascular Access Study","ACT II","Not yet recruiting","No Results Available","Dialysis; Complications|Vascular Access Complication","Device: Ark Implantation","Use of the Ark device to obtain arteriovenous access for hemodialysis in subjects who have an uncannulatable AVF.|To evaluate AVF cannulation complications while using the Ark device.","BioTex, Inc.","All","18 Years and older   (Adult, Older Adult)","Not Applicable","82","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Ark Cannulation Trial [ACT] II","May 1, 2023","May 1, 2025","May 1, 2025","August 5, 2022",,"August 5, 2022",,,"https://ClinicalTrials.gov/show/NCT05490225"
895,"NCT05490212","Salivary Profiling in Infants Treated for Suspected Sepsis: The SPITSS Study","SPITSS","Recruiting","No Results Available","Infection; Newborn","Other: Single Molecule Array (SiMoA)","confirmed (culture positive) infection|confirmed (culture positive) infection or clinical infection","Tufts Medical Center|Women and Infants Hospital of Rhode Island|University of Florida|Brigham and Women's Hospital|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","Child, Adult, Older Adult",,"5000","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","13372","October 3, 2019","May 31, 2024","May 31, 2024","August 5, 2022",,"August 5, 2022","University of Florida, Gainesville, Florida, United States|Tufts Medical Center, Boston, Massachusetts, United States|Women and Infants' Hospital, Providence, Rhode Island, United States",,"https://ClinicalTrials.gov/show/NCT05490212"
896,"NCT05490186","Function, Pain, and Alignment Following Knee Replacement for the Treatment of Osteoarthritis",,"Recruiting","No Results Available","Knee Replacement, Total|Pain, Postoperative|Functional Independence","Procedure: Total Knee Replacement","Function|Quality of Life following knee surgery|Pain intensity and effectiveness of analgesics|Satisfaction with knee surgery","North York General Hospital","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","300","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","NYGH REB #21-0043","November 16, 2021","January 31, 2023","January 31, 2024","August 5, 2022",,"August 5, 2022","North York General Hospital, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT05490186"
897,"NCT05490173","The Pilot Experimental Study of the Neuroprotective Effects of Exosomes in Extremely Low Birth Weight Infants",,"Not yet recruiting","No Results Available","Premature Birth|Extreme Prematurity|Preterm Intraventricular Hemorrhage|Hypoxia-Ischemia, Cerebral|Neurodevelopmental Disorders","Other: Exosomes derived from mesenchymal stromal cells (MSCs)","Occurrence and rate of dose limiting toxicity|Rate of death|Occurrence of Other Severe Complications of Prematurity|Need for Ventilatory Support|Changes in Hemodynamics|Feasibility: Administration|Feasibility: Recruitment Efficiency|Feasibility: Recruitment Timing|Feasibility: Participant Retainment|Griffiths-II and Bayley Scales of Infant Development (2nd edition)|Long-term Safety Follow-Up","Federal State Budget Institution Research Center for Obstetrics, Gynecology and Perinatology Ministry of Healthcare","All","1 Day to 3 Days   (Child)","Not Applicable","10","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention","ncagp4382277","September 5, 2022","May 22, 2026","December 28, 2026","August 5, 2022",,"August 5, 2022","Federal State Budget Institution Research Center for Obstetrics, Gynecology and Perinatology Ministry of Healthcare, Moscow, Russian Federation",,"https://ClinicalTrials.gov/show/NCT05490173"
898,"NCT05490160","Alteration of Thrombelastography and Coagulation Function in Patients Undergoing Total Knee Arthroplasty With Intra-articular Tranexamic Acid Administration",,"Not yet recruiting","No Results Available","Arthropathy of Knee","Drug: Tranexamic acid","R time|K time|Alpha angle|Maximal amplitude (MA)|Clot index (CI)|Prothrombin time (PT)|Activated partial thromboplastin time (APTT)|Hemoglobin in g/L|Red blood cell specific volume (HCT)|Fibrinogen in g/L|Platelet count in 10^9g/L","RenJi Hospital","All","Child, Adult, Older Adult",,"54","Other","Observational","Observational Model: Case-Only|Time Perspective: Retrospective","IIT-2022-0059","August 5, 2022","August 20, 2022","August 28, 2022","August 5, 2022",,"August 5, 2022",,,"https://ClinicalTrials.gov/show/NCT05490160"
899,"NCT05490147","Effect of Low Tidal Ventilation on Intraoperative Bleeding in Laparoscopic Major Hepatectomy",,"Not yet recruiting","No Results Available","Ventilator Lung|Liver Cirrhosis|Hepatocellular Carcinoma|Blood Loss, Surgical","Procedure: conventional tidal volume (tidal volume [ml]= ideal body weight [kg]* 10~12) group|Procedure: low tidal (tidal volume [ml]= ideal body weight [kg] * 6~8) volume","Intraoperative blood loss|postoperative lung complications|transfusion amount|postoperative hemoglobin level|postoperative total bilirubin level|postoperative PT INR level|postoperative aspartate aminotransferase level|postoperative alanine aminotransferase level|postoperative serum creatinine level|operation time|amount of crystalloids infused|Satisfaction scale of the operator and participants","Seoul National University Hospital","All","19 Years to 80 Years   (Adult, Older Adult)","Not Applicable","58","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","2206-069-1332","August 8, 2022","August 8, 2023","August 8, 2023","August 5, 2022",,"August 5, 2022","Seoul National University Hospital, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT05490147"
900,"NCT05490134","RM1 Project 1 - tAN Naloxone",,"Not yet recruiting","No Results Available","Analgesia","Drug: Naloxone|Drug: Saline","Thermal Pain Thresholds","Medical University of South Carolina","All","18 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","136","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Pro00122762","October 1, 2022","January 1, 2027","October 1, 2027","August 5, 2022",,"August 5, 2022",,,"https://ClinicalTrials.gov/show/NCT05490134"
901,"NCT05490121","RISE With Residents","RISE Residents","Not yet recruiting","No Results Available","Domestic Violence|Child Maltreatment|Pediatric ALL|Psychiatry|Education, Medical, Graduate","Other: Violence, Evidence, Guidance, Action Project (VEGA) Education Intervention","Number of Residents Who Meet Eligibility Criteria|Number of Residents who Consent|Number of Residents who Complete Assigned Intervention|Number of Residents who Complete Assessments|Child Maltreatment Vignette Scale|Child Maltreatment Knowledge and Skills Questions (Developed by VEGA Team)|The Physician Readiness to Manage Intimate Partner Violence Survey: Preparedness Subscale|Mandatory Reporting Self-Efficacy Scale (MRSES)|Brief Individual Readiness for Change Scale (BIRCS)|Achievement Goals for Work Domain (AGWD)","McMaster University|Royal College of Physicians and Surgeons of Canada","All","18 Years to 100 Years   (Adult, Older Adult)","Not Applicable","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Other","HiREB #14381","August 1, 2022","December 31, 2022","September 30, 2023","August 5, 2022",,"August 5, 2022",,,"https://ClinicalTrials.gov/show/NCT05490121"
902,"NCT05490108","Evaluation of Safety and Immunogenicity of the Recombinant ZR202-CoV and ZR202a-CoV Vaccines in Adults.",,"Recruiting","No Results Available","SARS-CoV-2 Infection|COVID-19","Biological: ZR202-CoV|Biological: ZR202a-CoV|Biological: Comirnaty®","Percentage of subjects reporting solicited AEs within 7 days after each vaccination (Part 1)|Percentage of subjects reporting unsolicited AEs within 28 days after each vaccination (Part 1)|Occurrence of out-of-normal range clinical laboratory test results (including change from baseline values) 14 days post vaccination - (Part 1)|Immunogenicity as assess for SARS-CoV-2 specific neutralizing antibodies titers 28 days after each vaccination as measured by neutralization assay|Percentages of subjects reporting SAEs, AESIs (including COVID-19), MAAEs|Immunogenicity as assess for SARS-CoV-2-specific anti-S protein IgG binding antibodies 28 days after each vaccination as measured by ELISA.","Shanghai Zerun Biotechnology Co.,Ltd","All","18 Years to 55 Years   (Adult)","Phase 1|Phase 2","60","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","202a-COV-2001","June 2, 2022","December 2022","December 2023","August 5, 2022",,"August 5, 2022","Center for Vaccine Development-Mali, Bamako, Mali",,"https://ClinicalTrials.gov/show/NCT05490108"
903,"NCT05490095","Randomized Crossover of SVG101(Dispersible Tab. of Everolimus) and Afinitor 5mg in Healthy Adults",,"Completed","No Results Available","Pharmacokinetics","Drug: SVG101 (T)|Drug: Afinitor (R)","AUCinf of everolimus|Cmax of Everolimus|Cmin,ss,pred of Everolimus|AUClast of Everolimus|Tmax of Everolimus|t1/2 of Everolimus|Vd/F of Everolimus|Clearance of Everolimus|Adverse Events (AEs)","SoVarGen Co., Ltd.","All","19 Years to 55 Years   (Adult)","Phase 1","26","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SVG101-P1-01","July 23, 2021","January 28, 2022","February 7, 2022","August 5, 2022",,"August 5, 2022","Yonsei University Healthcare System, Severance Hospital, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT05490095"
904,"NCT05490082","Mirabegron, Propevirine, Solifenacin for Treatment of Lower Urinary Tract Symptoms During Intravesical BCG Instillation",,"Recruiting","No Results Available","Voiding Disorders","Drug: Mirabegron, Propevirine, Solifenacin","Dysuria","Mansoura University","All","18 Years and older   (Adult, Older Adult)","Phase 3","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment","MD.21.12.576","March 1, 2022","March 2023","October 2023","August 5, 2022",,"August 5, 2022","Urology and Nephrology Center, Mansoura University, Mansoura, Egypt",,"https://ClinicalTrials.gov/show/NCT05490082"
905,"NCT05490069","The Effect of Instant Message Intervention for Psychological Well-being Among Stroke Survivors",,"Active, not recruiting","No Results Available","Stroke|Depressive Symptoms|Mobile Phone Use","Other: iCBT-based EMI","Depressive symptoms (Patient Health Questionnaire-9 [PHQ-9])|Anxiety symptoms (Generalized Anxiety Disorder-7 [GAD-7])|Stress level (Perceived Stress Scale [PSS-4])|Spiritual well-being (Sub-scale of Spirituality Scale for Chinese Elders [SSCE])|Loneliness (UCLA Loneliness Scale [ULS-8])","The University of Hong Kong","All","18 Years and older   (Adult, Older Adult)","Not Applicable","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Other","20-526","October 4, 2021","December 2022","December 2022","August 5, 2022",,"August 5, 2022","Hong Kong PHAB Association, Hong Kong, Hong Kong|Hong Kong Stroke Association, Hong Kong, Hong Kong|NT West Community Rehabilitation Day Centre, Hong Kong, Hong Kong|Queen Mary Hospital, Hong Kong, Hong Kong|The Hong Kong Society for Rehabilitation, Hong Kong, Hong Kong|Tung Wah Hospital, Hong Kong, Hong Kong|United Christian Hospital, Hong Kong, Hong Kong",,"https://ClinicalTrials.gov/show/NCT05490069"
906,"NCT05490056","Adequacy of Antenatal Care and Its Determinants in Assiut District",,"Not yet recruiting","No Results Available","Maternal Care Patterns","Other: no intervention","Adequacy of ANC","Assiut University","Female","15 Years to 49 Years   (Child, Adult)",,"400","Other","Observational","Observational Model: Other|Time Perspective: Cross-Sectional","Adequacy of ANC in Assiut","September 1, 2022","February 1, 2023","July 2024","August 5, 2022",,"August 5, 2022",,,"https://ClinicalTrials.gov/show/NCT05490056"
907,"NCT05490043","A Trial of ATG-101 in Patients With Metastatic/Advanced Solid Tumors and Mature B-cell Non-Hodgkin Lymphomas",,"Recruiting","No Results Available","Advanced Solid Tumor|Metastatic Solid Tumor|Mature B-cell Non-Hodgkin Lymphoma","Drug: ATG-101","AEs/SAEs|DLT (for Dose Escalation Phase only)|ORR|DCR|PFS|OS|The incidence of ADA and NAb|Peak Plasma Concentration (Cmax)|Peak Plasma Concentration（Tmax）","Antengene (Hangzhou) Biologics Co., Ltd.|Antengene Corporation","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1","62","Industry","Interventional","Allocation: N/A|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ATG-101-001-CN","January 30, 2022","August 15, 2024","December 30, 2024","August 5, 2022",,"August 5, 2022","Shandong Cancer Hospital, Jinan, China|The First Affiliated Hospital of Nanchang University, Nanchang, China|Shanghai Dongfang Hospital, Shanghai, China|Henan Cancer Hospital, Zhengzhou, China",,"https://ClinicalTrials.gov/show/NCT05490043"
908,"NCT05490030","Pharmacokinetics of TNO155 in Participants With Mild, Moderate, or Severe Hepatic Impairment Compared to Matched Healthy Participants",,"Not yet recruiting","No Results Available","Hepatic Impairment","Drug: TNO155","Area under the concentration-versus-time curve (AUC) from time zero to the last measurable plasma concentration (AUClast) of TNO155|AUC from time zero to time ""t"" (AUC0-t) of TNO155|AUC from time zero to infinity (AUCinf) of TNO155|Maximum (peak) observed plasma concentration (Cmax) of TNO155|Time to reach maximum observed plasma concentration (Tmax) of TNO155|Elimination half-life (T1/2) of TNO155|Sampling time of the last measurable plasma concentration (Tlast) of TNO155|Apparent plasma clearance (CL/F) of TNO155|Apparent volume of distribution during terminal phase (Vz/F) of TNO155|Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs)|Unbound Cmax (Cmax,u) of TNO155|Unbound AUClast (AUClast,u) of TNO155|Unbound AUCinf (AUCinf,u) of TNO155|Unbound CL/F (CL/F,u) of TNO155|Renal clearance (CLr) of TNO155|Apparent non-renal clearance (CLNR/F) of TNO155|Fraction of dose excreted in urine (fe) of TNO155","Novartis Pharmaceuticals|Pharmaceutical Research Associates|Novartis","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1","48","Industry|Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","CTNO155A12106","August 31, 2022","November 29, 2022","November 29, 2022","August 5, 2022",,"August 5, 2022",,,"https://ClinicalTrials.gov/show/NCT05490030"
909,"NCT05490017","To Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Escalating Single and Multiple Doses of KP104",,"Active, not recruiting","No Results Available","Paroxysmal Nocturnal Hemoglobinuria","Drug: KP104|Drug: Placebo","Number of participants reporting Treatment Emergent Adverse Events (TEAEs)|Number of participants reporting Treatment Emergent Serious Adverse Events (TESAEs)|Number of participants with Dose-limiting toxicities (DLT)|Number of participants reporting AEs of Special interests (AESIs)|Maximum concentration (Cmax) of KP104|Area under the concentration-time profile (AUC) of KP104|Change from baseline in total and free serum C5 levels|Change from baseline in rabbit red blood cell (RBC) assay","Kira Pharmacenticals (US), LLC.","All","18 Years to 55 Years   (Adult)","Phase 1","80","Industry","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","KP104-101","December 30, 2020","May 4, 2022","September 16, 2022","August 5, 2022",,"August 5, 2022","CMAX Clinical Research, Adelaide, Australia",,"https://ClinicalTrials.gov/show/NCT05490017"
910,"NCT05490004","RISE With Veteran Service Providers","RISE Vet","Not yet recruiting","No Results Available","Domestic Violence|Veterans Family|Veterans|Child Maltreatment","Other: Violence, Evidence, Guidance, Action Project (VEGA) Education Intervention","Number of Providers Who Meet Eligibility Criteria|Number of Providers who Consent|Number of Providers who Complete Assigned Intervention|Number of Providers who Complete Assessments|Child Maltreatment Vignette Scale|Child Maltreatment Knowledge and Skills Questions (Developed by VEGA Team)|The Physician Readiness to Manage Intimate Partner Violence Survey: IPV Knowledge|The Physician Readiness to Manage Intimate Partner Violence Survey: Preparedness Subscale|The Physician Readiness to Manage Intimate Partner Violence Survey: Opinions|Mandatory Reporting Self-Efficacy Scale (MRSES)|Brief Individual Readiness for Change Scale","McMaster University|Atlas Institute for Veterans and Families","All","18 Years to 100 Years   (Adult, Older Adult)","Not Applicable","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Other","HiREB # 14243","August 1, 2022","December 31, 2022","September 30, 2023","August 5, 2022",,"August 5, 2022",,,"https://ClinicalTrials.gov/show/NCT05490004"
911,"NCT05489991","A Study of TmPSMA-02 Chimeric Antigen Receptor (CAR) T-cells in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)",,"Not yet recruiting","No Results Available","Metastatic Castration-resistant Prostate Cancer","Biological: TmPSMA-02","Phase 1: To evaluate the safety of TmPSMA-02 in adult patients with mCRPC|Phase 1: To identify the recommended Phase 2 dose of TmPSMA-02 administered in combination with LD chemotherapy|Phase 2: To evaluate the objective response rate (ORR) per Response Evaluation Criteria In Solid Tumors (RECIST) v1.1|Phase 1: To evaluate the preliminary antitumor activity of TmPSMA-02 according to RECIST v1.1 and the PCWG3 criteria|Phase 1: To assess the clinical and manufacturing feasibility of TmPSMA-02|Phase 2: To evaluate the safety and tolerability of TmPSMA-02 in adult patients with mCRPC|Phase 2: Evaluate the anti-tumor activity of TmPSMA-02 according to Prostate Cancer Working Group 3 (PCWG3).|Phase 2: Describe pharmacokinetic factors of TmPSMA-02 in peripheral blood|Phase 2: Evaluate changes in patient reported health-related outcomes following treatment with TmPSMA-02","Tmunity Therapeutics","Male","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","114","Industry","Interventional","Allocation: N/A|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TmPSMA-0201","September 8, 2022","June 18, 2028","January 15, 2032","August 5, 2022",,"August 5, 2022",,,"https://ClinicalTrials.gov/show/NCT05489991"
912,"NCT05489978","Effectiveness of a Stigma Reduction Education Program on Stigma Score and Cervical Cancer Screening Uptake in Nepal",,"Recruiting","No Results Available","Cervical Cancer|Stigma|Screening","Behavioral: ""Stigma Reduction Education Program""","Mean stigma score|Cervical cancer screening uptake","Kathmandu University School of Medical Sciences","Female","30 Years to 60 Years   (Adult)","Not Applicable","306","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Screening","CC2022","June 15, 2022","December 1, 2022","March 1, 2023","August 5, 2022",,"August 5, 2022","Budanilkantha Municipality, Kathmandu, Province-3, Nepal",,"https://ClinicalTrials.gov/show/NCT05489978"
913,"NCT05489965","Gender Disparities in Voice Outcomes After Tracheoesophageal Puncture in Total Laryngectomy Patients (UC Davis)",,"Not yet recruiting","No Results Available","Speech Disorders|Speech Dysfunction|Laryngectomy; Status|Tracheoesophageal Prosthesis|Total Laryngectomy",,"FACT-H&N (Functional Assessment of Cancer Therapy - Head & Neck)|AVHI (Alaryngeal Voice Handicap Index)|GRBAS - Grade, Roughness, Breathiness, Asthenia, and Strain|Sustained phonation time|Fundamental frequency","University of California, San Diego","All","18 Years and older   (Adult, Older Adult)",,"12","Other","Observational","Observational Model: Other|Time Perspective: Other","UCDavis-1509981-2","September 1, 2022","December 1, 2024","June 1, 2025","August 5, 2022",,"August 5, 2022",,,"https://ClinicalTrials.gov/show/NCT05489965"
914,"NCT05489952","Iron Supplementation for Geriatric Hip Fractures",,"Not yet recruiting","No Results Available","Hip Fractures|Fragility Fracture|Osteoporotic Fractures","Drug: iron sucrose and ferrous lactate","6-minute walk distance|Harris hip score|perioperative blood transfusion rate","He Qifei|Shenzhen Second People's Hospital","All","65 Years and older   (Older Adult)","Phase 4","444","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20223357010","August 15, 2022","February 15, 2025","August 15, 2025","August 5, 2022",,"August 5, 2022","Shenzhen Second People's Hospita, Shenzhen, Guangdong, China",,"https://ClinicalTrials.gov/show/NCT05489952"
915,"NCT05489939","Safety and Efficacy of Compound Methyl Salicylate Liniment for Topical Pain: a Multicenter Real-World Study in China",,"Completed","No Results Available","Pain","Drug: The compound methyl salicylate liniment","The adverse events|the self-assessment pain by VAS score","Xiangya Hospital of Central South University","All","3 Years to 75 Years   (Child, Adult, Older Adult)",,"3600","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","GDKH001","May 2014","March 2015","March 2015","August 5, 2022",,"August 5, 2022",,,"https://ClinicalTrials.gov/show/NCT05489939"
916,"NCT05489926","A Study to Explore Pamiparib Treatment in Epithelial Ovarian Cancer After Prior PARPi Exposure",,"Not yet recruiting","No Results Available","Epithelial Ovarian Cancer","Drug: Pamiparib","CBR at 4 months|PFS|ORR|DOR|AE","Zhejiang Cancer Hospital","Female","18 Years and older   (Adult, Older Adult)","Phase 2","15","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PamiAP","August 2022","June 2023","December 2023","August 5, 2022",,"August 5, 2022","Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China",,"https://ClinicalTrials.gov/show/NCT05489926"
917,"NCT05489913","Web Based Cardiac Rehabilitation Support in Coronary Artery Patients",,"Completed","No Results Available","Cardiac Rehabilitation|Healthy Lifestyle|Medication Adherence|Quality of Life|Coronary Artery Disease","Other: cardiac rehabilitation support program","Comparison of the total and sub-dimension total scores of the healthy lifestyle behaviors scale of the patients in the experimental and control groups|Comparison of experimental and control group patients' compliance with medication adherence|Comparison of general quality of life scale index and general quality of life scale vas scores of experimental and control group patients|Comparison of international physical activity questionnaire total scores and physical activity levels of experimental and control group patients|Comparison of body mass index values of experimental and control group patients|Comparison of LDL values of experimental and control group patients|Comparison of smoking status of experimental and control group patients|Post-test Computer System Usability Questionaire Short Version total and sub-dimension scores of the experimental group patients|Comparison of triglyceride values of experimental and control group patients","Semiha ALKAN KAYHAN|Karadeniz Technical University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","70","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","24237859-534","March 1, 2020","May 1, 2020","June 30, 2021","August 5, 2022",,"August 5, 2022","Health Science University Ahi Evren thoracic and cardiovascular surgery training and research hospital, Trabzon, Turkey",,"https://ClinicalTrials.gov/show/NCT05489913"
918,"NCT05489900","Immunomodulatory Effect of Dexmedetomidine as an Adjuvant Drug in Laparoscopic Cholecystectomies",,"Recruiting","No Results Available","Physiological Effects of Drugs","Drug: Dexmedetomidine Hydrochloride","Attenuation of the inflammatory response to trauma|Physiological functions more preserved than the control group","Universidade Federal do Rio de Janeiro","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 3","52","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Prevention","50311621.0.0000.5258","April 1, 2022","July 31, 2022","October 31, 2022","August 5, 2022",,"August 5, 2022","University Hospital Gaffree and Guinle, Rio De Janeiro, Brazil",,"https://ClinicalTrials.gov/show/NCT05489900"
919,"NCT05489887","Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma",,"Not yet recruiting","No Results Available","High-risk Neuroblastoma","Drug: Naxitamab|Drug: Ceritinib","Number of participants with a Very Good Partial Response (VGPR)(+) rate (VGPR + Complete Response (CR) rate)|Objective Response Rate (ORR)|Objective Response Rate (ORR) after two cycles|Number of days that subjects remain alive|Number of days that subjects remain in remission|Objective Response Rate (ORR) after five cycles|Number of participants with treatment-related adverse events","Wake Forest University Health Sciences","All","12 Months to 21 Years   (Child, Adult)","Phase 2","76","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BCC018","August 2022","August 2026","August 2033","August 5, 2022",,"August 5, 2022","Levine Children's Hospital, Charlotte, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT05489887"
920,"NCT05489874","A Real-world Retrospective Study of Disease Outcomes in Non-severe COVID-19 Patient",,"Recruiting","No Results Available","COVID-19 Patient",,"Percentage of patients with COVID-19 progression|Percentage of participants|SARS-CoV-2|SARS-CoV-2 continuous negative|SARS-CoV-2 Ct values|chest CT scan|Length of hospital stay|safety","Shanghai Vinnerna Biosciences Co., Ltd.","All","18 Years and older   (Adult, Older Adult)",,"2000","Industry","Observational","Observational Model: Other|Time Perspective: Retrospective","JT001-013-COVID-19","July 14, 2022","December 30, 2024","December 30, 2024","August 5, 2022",,"August 5, 2022","Ruijin Hospital affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT05489874"
921,"NCT05489861","The Effect of Affirmation and Massage on Babies",,"Not yet recruiting","No Results Available","Attachment|Mother-Infant Interaction|Sleep Quality","Behavioral: M-AM|Behavioral: F-AM","Examining the infant's sleep quality of infant massage and affirmation|Effect on maternal attachment|Effect on paternal attachment","Istanbul University-Cerrahpasa","All","Child, Adult, Older Adult","Not Applicable","45","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Supportive Care","IstanbulUC-NilaySener","August 1, 2022","December 20, 2022","June 30, 2023","August 5, 2022",,"August 5, 2022","Nilay Şener Özovalı, Kadikoy, İstanbul, Turkey",,"https://ClinicalTrials.gov/show/NCT05489861"
922,"NCT05489848","Chemotherapy vs Chemoradiotherapy for Post-operative Endometrial Cancer Patients With P53-mutation",,"Not yet recruiting","No Results Available","Endometrial Cancer","Drug: Paclitaxel|Drug: Carboplatin|Drug: Cisplatin|Radiation: EBRT|Radiation: VBT","the 2-year progression-free survival(PFS)|the 3-year PFS|the 5-year PFS and Overall survival(OS)","Fudan University","Female","18 Years to 85 Years   (Adult, Older Adult)","Phase 2|Phase 3","294","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","EC-2022 -01","August 20, 2022","August 20, 2028","August 20, 2030","August 5, 2022",,"August 5, 2022",,,"https://ClinicalTrials.gov/show/NCT05489848"
923,"NCT05489835","Work-Health-Life-Balance - Mental Resilience, Stability & Healthy Nutrition",,"Not yet recruiting","No Results Available","Psychological Stress|Nutritional Quality|Burn-out Syndrome|Sleep|Depressive Disorder","Behavioral: Nutritional counseling","Stress|Sleep|Body mass index","Medical University of Graz","All","18 Years to 65 Years   (Adult, Older Adult)",,"200","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","EK 34-147 ex 21/22","August 30, 2022","June 30, 2024","December 30, 2024","August 5, 2022",,"August 5, 2022","Medical University of Graz, Graz, Styria, Austria",,"https://ClinicalTrials.gov/show/NCT05489835"
924,"NCT05489822","PMCF Study to Evaluate the VERTICALE® Cervical System in Spine Surgery According to Its Intended Use.",,"Not yet recruiting","No Results Available","Degenerative Disc Disease (DDD)|Instabilities|Trauma|Deformity","Device: VERTICALE® Cervical System","Change of Neck Disability Index (NDI) preoperative (pre-op) compared to 3 month (± 1 month) and 12 months follow-up (± 1 month)|Documentation of Complications|Examination of clinical performance|Device effectiveness/patient satisfaction: Change of arm/shoulder pain using a Numerical Rating Scale|Device effectiveness/patient satisfaction: Change of neck pain using a Numerical Rating Scale|Device effectiveness/patient satisfaction: modified Japanese Orthopaedic Association (mJOA) score for the assessment of a possibly present myelopathy.","Silony Medical GmbH","All","18 Years and older   (Adult, Older Adult)",,"20","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","TDII_2014-003_2.1_103","November 2022","December 2025","December 2025","August 5, 2022",,"August 5, 2022",,,"https://ClinicalTrials.gov/show/NCT05489822"
925,"NCT05489809","Endotracheal Extubation With Suctioning Versus Positive Pressure in Children After General Anaesthesia.",,"Completed","No Results Available","Endotracheal Extubation","Procedure: Endotracheal extubation with suctioning|Procedure: Endotracheal extubation with positive pressure","Endotracheal extubation|Pulse|Oxygen saturation|Blood pressure|Supplemental oxygen|Airway suctioning","Pakistan Navy Station Shifa Hospital","All","1 Year to 12 Years   (Child)","Not Applicable","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","ERC/2022/ANS/2","April 1, 2022","June 30, 2022","July 15, 2022","August 5, 2022",,"August 5, 2022","PNS Shifa Hospital, Karachi, Sind, Pakistan",,"https://ClinicalTrials.gov/show/NCT05489809"
926,"NCT05489796","Bellomic PCA in Laparoscopic Gynecologic Surgery",,"Recruiting","No Results Available","Laparoscopic Gynecological Surgery","Drug: Fentanyl selector|Drug: Fentanyl continuous|Drug: Ketorolac continuous","Change in the occurrence of postoperative nausea|Change in the occurrence of postoperative vomiting|Change in the use of rescue antiemetics|Change of postoperative pain score|Change in the use of rescue analgesics","Seoul National University Bundang Hospital","Female","20 Years to 65 Years   (Adult, Older Adult)","Not Applicable","72","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","B-2110-716-003","June 30, 2022","June 2023","June 2023","August 5, 2022",,"August 5, 2022","Seoul National Univ. Bundang Hospital, Seongnam, Gyeonggi, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT05489796"
927,"NCT05489783","Glioma Developmental and HyperActive Ras Tumor (DHART) Board",,"Recruiting","No Results Available","Glioma",,"Registry of patients with Neurofibromatosis Type 1 (NF1) associated glioma","Memorial Sloan Kettering Cancer Center","All","18 Years and older   (Adult, Older Adult)",,"50","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","22-199","July 29, 2022","July 29, 2025","July 29, 2025","August 5, 2022",,"August 5, 2022","Memorial Sloan Kettering Basking Ridge (All Protocol Activities), Basking Ridge, New Jersey, United States|Memorial Sloan Kettering Monmouth (All protocol activities), Middletown, New Jersey, United States|Memorial Sloan Kettering Bergen (All Protocol Activities), Montvale, New Jersey, United States|Memorial Sloan Kettering Suffolk - Commack (All Protocol Activities), Commack, New York, United States|Memorial Sloan Kettering West Harrison (All Protocol Activities), Harrison, New York, United States|Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York, United States|Memorial Sloan Kettering Nassau (All Protocol Activities), Rockville Centre, New York, United States",,"https://ClinicalTrials.gov/show/NCT05489783"
928,"NCT05489770","BERRY- a Study of Sambucol ® in the Treatment, and Reduction of Symptoms in Participants With Coronavirus 19","BERRY","Completed","No Results Available","COVID-19","Dietary Supplement: Sambucol® Black Elderberry Original (Sambucus nigra) Liquid|Dietary Supplement: Placebo for Sambucol® Black Elderberry Original (Sambucus nigra)","Sambucol reduces the severity of symptoms by at least 30% by day 10 in people who are symptomatic with the SARS-CoV-2 (COVID-19) virus, compared to placebo.|To determine whether Sambucol reduces hospital admissions by day 28.|To determine if Sambucol reduces the severity of symptoms at day 3, 7, 14 and 28 days","East Kent Hospitals University NHS Foundation Trust","All","18 Years to 100 Years   (Adult, Older Adult)","Not Applicable","204","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","2020/COVID19/11","January 5, 2021","May 16, 2022","May 16, 2022","August 5, 2022",,"August 5, 2022","East Kent Hospitals University NHS Foundation trust, Canterbury, Kent, United Kingdom",,"https://ClinicalTrials.gov/show/NCT05489770"
929,"NCT05489757","Quantitative Fluorescence Angiography With ICG for Perfusion Assessment During Surgery","SPY Q-ICG PAS","Recruiting","No Results Available","Esophagus; Fistula|Fistula;Rectal|Complication of Surgical Procedure|Complication,Postoperative","Device: SPY Portable Handheld Imaging (SPY-PHI) System with SPY-QP Software","Maximum intensity of ICG fluorescence|Time to first ICG fluorescence signal|Time-to-peak|Correlation with postoperative outcomes","IRCCS San Raffaele","All","18 Years and older   (Adult, Older Adult)","Not Applicable","239","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","154/INT/2021","February 16, 2022","November 30, 2023","December 31, 2023","August 5, 2022",,"August 5, 2022","Lorenzo Cinelli, Milan, Italy",,"https://ClinicalTrials.gov/show/NCT05489757"
930,"NCT05489744","Human Mass Balance and Biotransformation Study of [14C]Afuresertib",,"Not yet recruiting","No Results Available","Healthy Volunteer","Drug: [14C]Afuresertib","Quantitatively analyze total radioactivity in the excreta.|Pharmacokinetics (PK) analysis of radioactivity in plasma will be measured.|Identify the main biotransformation pathways and the major metabolites by HPLC-MS/MS.|Quantitatively analyze the concentration of Afuresertib and its metabolites by the validated HPLC-MS/MS.|Safety and tolerability of Afuresertib as measured by adverse events (AEs) .","Laekna Limited","Male","18 Years to 45 Years   (Adult)","Phase 1","10","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","LAE002CN1001","August 2022","March 2023","May 2023","August 5, 2022",,"August 5, 2022","The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China",,"https://ClinicalTrials.gov/show/NCT05489744"
931,"NCT05489731","VIC-1911 Combined With Osimertinib for EGFR-TKI Mutant Non-small Cell Lung Cancer","VIC-1911","Not yet recruiting","No Results Available","Advanced Non-small Cell Lung Cancer","Drug: VIC-1911|Drug: Osimertinib Mesylate Tablets","Incidence of treatment emergent adverse events (safety and tolerability)|Pharmacokinetic PK parameters|Time to Response|Disease Control Rate|Progression-Free Survival|Overall Survival","Jiesi Yingda Pharmaceutical Technology (Suzhou) Co., Ltd.","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1","72","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","JSI-1911-102","August 30, 2022","February 24, 2024","April 24, 2024","August 5, 2022",,"August 5, 2022",,,"https://ClinicalTrials.gov/show/NCT05489731"
932,"NCT05489718","A Dose Escalation Study of IBI324 in Subjects With Diabetic Macular Edema",,"Not yet recruiting","No Results Available","Diabetic Macular Edema","Biological: IBI324","Safety evaluation indicators|The incidence of adverse events|Changes in BCVA compared with basline|Changes in CST compared with basline|Pharmacokinetic(PK)profiles,such as half-life time(t1/2)，etc|Immunogenicity evaluation indicators","Innovent Biologics (Suzhou) Co. Ltd.","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 1","21","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CIBI324A101","August 15, 2022","April 8, 2023","October 6, 2023","August 5, 2022",,"August 5, 2022",,,"https://ClinicalTrials.gov/show/NCT05489718"
933,"NCT05489705","A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive HCM)","DISCOVER-HCM","Not yet recruiting","No Results Available","Obstructive Hypertrophic Cardiomyopathy",,"Incidence rate of new or worsening heart failure due to systolic dysfunction among participants with symptomatic obstructive HCM during periods of exposure to mavacamten and other oHCM treatment|Occurrence of arrhythmia|Occurrence of Major Adverse Cardiovascular Events (MACE)|Occurrence of non-fatal acute Myocardial Infarction (MI)|Occurrence of Stroke|Occurrence of hospitalization due to heart failure|Occurrence of cardiovascular mortality|Occurrence of all-cause mortality|Evaluation of functional responses: New York Heart Association (NYHA) function class|Evaluation of functional responses: Left Ventricular Outflow Tract (LVOT) gradient|Evaluation of functional responses: LVEF|Evaluation of patient reported outcome measure: Kansas City Cardiomyopathy Questionnaire 23 (KCCQ-23)|Evaluation of patient reported outcome measure: EuroQol Five Dimensions Questionnaire (5-level) (EQ-5D-5L): Health Utility Index|Evaluation of patient reported outcome measure: EQ-5D-5L: VAS|Evaluation of biomarkers of response: NT-proBNP|Evaluation of biomarkers of response: Cardiac troponin","Bristol-Myers Squibb","All","18 Years and older   (Adult, Older Adult)",,"1500","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","CV027-012","August 15, 2022","July 31, 2029","July 31, 2029","August 5, 2022",,"August 5, 2022",,,"https://ClinicalTrials.gov/show/NCT05489705"
934,"NCT05489692","HAIC Plus Targeted Therapy and/or PD-1 Inhibitors for Unresectable Intrahepatic Cholangiocarcinoma",,"Completed","No Results Available","Intrahepatic Cholangiocarcinoma","Procedure: hepatic arterial infusion chemotherapy (HAIC) of oxaliplatin, fluorouracil, and leucovorin (FOLFOX)","Tumor Response|Overall survival|Progression-free survival|Conversion rate","Sun Yat-sen University","All","18 Years and older   (Adult, Older Adult)",,"43","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","B2022-222-01","September 1, 2017","August 31, 2021","January 31, 2022","August 5, 2022",,"August 10, 2022","Sun Yat-sen University Cancer Center, GuangZhou, Guangdong, China",,"https://ClinicalTrials.gov/show/NCT05489692"
935,"NCT05489679","A Study of AC682 In Chinese Patients With ER+/HER2- Locally Advanced or Metastatic Breast Cancer",,"Not yet recruiting","No Results Available","Breast Cancer","Drug: AC682","Incidence of dose limiting toxicities (DLTs) from AC682 monotherapy|Incidence of treatment emergent adverse events(TEAEs) from AC682 monotherapy|To determine the PK of AC682 after a single dose or multiple doses:|To evaluate the preliminary anti-tumor activity of AC682:","Accutar Biotechnology Inc","Female","18 Years and older   (Adult, Older Adult)","Phase 1","150","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AC682-002","September 1, 2022","July 2023","December 2024","August 5, 2022",,"August 5, 2022","Site 1001, Beijing, China|Site 1003, Hangzhou, China|Site 1002, Tianjin, China",,"https://ClinicalTrials.gov/show/NCT05489679"
936,"NCT05489666","Effects of Vitamin D on Skeletal Muscle Strength in Resistance Trained Adult Females",,"Not yet recruiting","No Results Available","Nutrition Status|Nutritional Requirements|Sports Nutritional Sciences","Dietary Supplement: Nature Made Vitamin D3 5,000 IU, 125mcg|Dietary Supplement: Placebo","Biodex Strength performance change|Serum 25(OH)D status","Auburn University","Female","19 Years to 55 Years   (Adult)","Not Applicable","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","22-306","September 1, 2022","November 30, 2022","February 1, 2023","August 5, 2022",,"August 10, 2022",,,"https://ClinicalTrials.gov/show/NCT05489666"
937,"NCT05489653","Mixed Music Intervention on Sleep Disturbance in Patients With Parkinson's Disease",,"Not yet recruiting","No Results Available","Music Intervention|Sleep Disturbance|Parkinson's Disease","Behavioral: mixed music","Pittsburgh Sleep Quality Index","Taipei Medical University","All","30 Years to 80 Years   (Adult, Older Adult)","Not Applicable","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","N202204014","August 2022","March 2023","March 2023","August 5, 2022",,"August 5, 2022",,,"https://ClinicalTrials.gov/show/NCT05489653"
938,"NCT05489640","A Study in Adults With Hereditary Angioedema (HAE) Who Currently Receive Icatibant at Home",,"Not yet recruiting","No Results Available","Hereditary Angioedema (HAE)","Other: No Intervention","Number of Participants Treated with Icatibant in the Homecare Setting who Were Receiving Prophylaxis Treatment at Index|Number of Participants Treated with Icatibant in the Homecare Setting in Each Prophylactic Treatment Type|Number of Participants Categorized by Their Demographic Characteristics|Number of Participants Categorized by Their Clinical Characteristics|Rate of New HAE Attacks|Frequency of Visits to Accident and Emergency Services Related to an HAE Attack|Time from the Start of Each HAE Attack to Administration of Icatibant in the Homecare Setting|Frequency of Icatibant Administration Following Start of Each HAE Attack|Number of Participants by Treatment Patterns|Number of Participants by Treatment Management Patterns|EQ-5D-5L Score|HAE-QoL Total Score|Angioedema Control Test (AECT) Total Score","Takeda","All","18 Years and older   (Adult, Older Adult)",,"100","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","TAK-667-4002|MACS-2021-061502","August 15, 2022","November 30, 2023","November 30, 2023","August 5, 2022",,"August 5, 2022","Sciensus, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT05489640"
939,"NCT05489627","Medial Collateral Ligament Reconstruction With Anteromedial Reinforcement for Medial and Anteromedial Rotatory Knee Instability",,"Recruiting","No Results Available","Collateral Ligament, Knee; Sprain (Strain), Medial|Anterior Cruciate Ligament Injuries","Procedure: Medial Collateral Ligament Reconstruction With Anteromedial Reinforcement","The functional assessment with the The International Knee Documentation Committee Questionnaire (IKDC)|The functional assessment with the Knee injury and Osteoarthritis Outcome Score","Artromedical Konrad Malinowski Clinic","All","18 Years to 60 Years   (Adult)","Not Applicable","17","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","3-pro-ar-2022","August 31, 2022","December 31, 2025","December 31, 2025","August 5, 2022",,"August 5, 2022","Artromedical Orthopaedic Clinic, Bełchatów, Poland",,"https://ClinicalTrials.gov/show/NCT05489627"
940,"NCT05489614","A Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of Olpasiran in Participants With Normal Renal Function and Participants With Various Degrees of Renal Impairment",,"Not yet recruiting","No Results Available","Renal Impairment","Drug: Olpasiran","Maximum Observed Serum Concentration (Cmax) of Olpasiran|Area Under the Plasma Concentration-time Curve from Time Zero to the Last Quantifiable Concentration (AUClast) of Olpasiran|Area Under the Plasma Concentration-time Curve from Time Zero to Infinity (AUCinf) of Olpasiran|Dialysis Clearance of Drug From Plasma (CLD) of Olpasiran|Area Under the Effect Time Curve (AUEC) of Plasma Lipoprotein a (Lp[a])|Maximum Inhibitory Effect (Imax) of Plasma Lp(a)|Time to Reach Imax of Lp(a)|Number of Participants Who Experience an Adverse Event (AE)|Number of Participants with Clinically Significant Changes in Clinical Laboratory Evaluations|Number of Participants with Clinically Significant Changes in 12-lead Electrocardiogram (ECG) Measurements|Number of Participants with Clinically Significant Changes in Vital Signs","Amgen","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1","32","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","20220010","August 23, 2022","August 9, 2023","August 9, 2023","August 5, 2022",,"August 5, 2022",,,"https://ClinicalTrials.gov/show/NCT05489614"
941,"NCT05489601","Non-intrusive Detection of Temporary Neurologic Impairment by Opioids",,"Completed","No Results Available","Neurologic Impairment by Opioids","Drug: Oxycodone","Eye movement velocity|Pupil area change","Zxerex Corporation","All","21 Years to 59 Years   (Adult)",,"17","Industry","Observational","Observational Model: Case-Control|Time Perspective: Cross-Sectional","OpioidsPhaseI","February 28, 2020","March 29, 2022","March 29, 2022","August 5, 2022",,"August 5, 2022","Mayo Clinic, Scottsdale, Arizona, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/01/NCT05489601/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT05489601"
942,"NCT05489588","The GORE® VIAFORT Vascular Stent Iliofemoral Study",,"Not yet recruiting","No Results Available","Venous Thromboses|Venous Disease|Venous Leg Ulcer|Venous Stasis|Venous Ulcer|Venous Stenosis|Venous Occlusion|Vein Thrombosis|Vein Occlusion|Vein Disease","Device: GORE® VIAFORT Vascular Stent","Composite of safety events|Primary efficacy as assessed by primary patency|Number of subjects with primary patency as confirmed by imaging and adverse events|Number of subjects with secondary patency as confirmed by imaging and adverse events|Number of subjects with clinically driven target lesion revascularization as confirmed by imaging and adverse events|Number of subjects with device fracture as confirmed with imaging|Number of subjects with stent embolization as confirmed with imaging|Number of subjects with device- or procedure-related death|Number of subjects with clinically significant pulmonary embolism as confirmed with imaging and adverse events|Number of subjects with device- or procedure-related vascular injury as confirmed with adverse events|Number of subjects with device- or procedure-related major bleeding events as confirmed with adverse events|Revised Venous Clinical Severity Scale (rVCSS)|Revised Venous Clinical Severity Scale (rVCSS) Pain|Venous Insufficiency Epidemiological and Economic Study - Quality of Life/Symptoms (VEINES-QOL/Sym) VEINES-QOL/Sym|Villalta|5 Level EuroQol-5 Dimension (EQ-5D-5L)|Technical success|Lesion success|Procedural success","W.L.Gore & Associates","All","18 Years and older   (Adult, Older Adult)","Not Applicable","165","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","VNS 21-07","February 2023","April 2025","April 2029","August 5, 2022",,"August 5, 2022",,,"https://ClinicalTrials.gov/show/NCT05489588"
943,"NCT05489575","CPAP for the Treatment of Supine Hypertension",,"Recruiting","No Results Available","Autonomic Failure|Pure Autonomic Failure|Multiple System Atrophy|Parkinson Disease|Supine Hypertension|Neurogenic Orthostatic Hypotension","Device: Active CPAP|Device: Sham CPAP|Other: Sleeping in a head-up tilt (HUT) position","Systolic blood pressure (daytime)|Systolic blood pressure (overnight)|Stroke Volume (daytime)|Natriuretic hormone (daytime)|Nocturnal diuresis (overnight)|Morning orthostatic tolerance (overnight)","Vanderbilt University Medical Center|National Heart, Lung, and Blood Institute (NHLBI)","All","40 Years to 80 Years   (Adult, Older Adult)","Not Applicable","59","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","220821|R01HL161095|200124","June 23, 2022","March 1, 2026","August 31, 2026","August 5, 2022",,"August 5, 2022","Autonomic Dysfunction Center/ Vanderbilt University Medical Center, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT05489575"
944,"NCT05489562","Use of Intraoral Suction and Its Effects on Obstructive Sleep Apnea",,"Not yet recruiting","No Results Available","Obstructive Sleep Apnea of Adult","Device: Intraoral Suction","Number of patients reporting adverse events related to use of intraoral suction to stabilize the tongue as assessed by a survey|Effect on sleep duration|Effect on sleep quality","VA Boston Healthcare System|Massachusetts Institute of Technology","All","18 Years to 75 Years   (Adult, Older Adult)","Not Applicable","40","U.S. Fed|Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","1686683","August 2022","July 2024","October 2024","August 5, 2022",,"August 5, 2022",,,"https://ClinicalTrials.gov/show/NCT05489562"
945,"NCT05489549","Subclinical Transthyretin Cardiac Amyloidosis in V122I TTR Carriers",,"Not yet recruiting","No Results Available","Amyloidosis, Hereditary|Amyloidosis Cardiac|Amyloidosis, Familial|Transthyretin-Related (ATTR) Familial Amyloid Cardiomyopathy|Transthyretin Gene Mutation",,"(Aim 1) Evidence of amyloid infiltration as measured by ECV|(Sub-aim 1) Δ stroke volume index (ΔSVi)|(Aim 1) Late gadolinium enhancement|(Aim 1) Native T1 and T2 mapping|(Aim 1) Post-gadolinium T1 signal intensity|(Aim 1) High resolution cardiac cine imaging for cardiac morphology|(Aim 1) High resolution cardiac cine imaging for global systolic function as ejection fraction|(Aim 1) High resolution cardiac cine imaging for global systolic function as fractional area change|(Aim 1) High resolution cardiac cine imaging for global systolic function via novel feature tracking|(Aim 1) High resolution cardiac cine imaging for global diastolic function via novel feature tracking.|(Aim 1) LV strain from magnetic resonance tissue tagging|(Aim 1) Phase contrast MRI to assess diastolic function by measurement of mitral inflow velocities.|(Aim 1) Phase contrast MRI to assess diastolic function by calculating the E/e' strain rate.|(Sub-aim 1) End diastolic volume index (EDVi, ml/m2) in all 4 chambers|(Sub-aim 1) End systolic volume index (ESVi, ml/m2) in all 4 chambers|(Sub-aim 1) Stroke volume index (SVi, ml/m2, ΔSVi is the primary outcome) in all 4 chambers|(Sub-aim 1) Ejection fraction (LVEF, %) in all 4 chambers|(Sub-aim 1) Longitudinal strain (LS, %)|(Aim 2) TTR concentration|(Aim 2) RBP4 concentration|(Aim 2) Concentration of circulating misfolded TTR oligomers|(Aim 2) TTR kinetic stability","University of Texas Southwestern Medical Center|The Cleveland Clinic|Columbia University|The University of Texas at Arlington","All","30 Years to 80 Years   (Adult, Older Adult)",,"500","Other","Observational","Observational Model: Case-Control|Time Perspective: Cross-Sectional","STU-2022-0404","August 2022","June 30, 2027","June 30, 2027","August 5, 2022",,"August 5, 2022","Columbia University Medical Center, New York, New York, United States|Cleveland Clinic, Cleveland, Ohio, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States",,"https://ClinicalTrials.gov/show/NCT05489549"
946,"NCT05489536","Optimizing Gestational Weight Gain for Prevention of Gestational Diabetes Mellitus in Malaysia",,"Not yet recruiting","No Results Available","Pregnant Women","Behavioral: A web/smartphone-based lifestyle program package","Incidence of GDM|Gestational Weight Gain|Dietary Intake|Physical Activity","Universiti Putra Malaysia|The World Diabetes Foundation","Female","18 Years to 50 Years   (Adult)","Not Applicable","20000","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","UPM19062022","January 1, 2023","December 31, 2023","December 31, 2023","August 5, 2022",,"August 8, 2022","Health Clinics in Southern of Peninsular Malaysia, Johor Bahru, Johor, Malaysia|Health Clinics in Northern of Peninsular Malaysia, Alor Setar, Kedah, Malaysia|Health Clinics in East Coast of Peninsular Malaysia, Kota Bharu, Kelantan, Malaysia|Health Clinics in Southern of Peninsular Malaysia, Melaka, Malacca, Malaysia|Health Clinics in Southern of Peninsular Malaysia, Seremban, Negeri Sembilan, Malaysia|Health Clinics in Northern of Peninsular Malaysia, George Town, Penang, Malaysia|Health Clinics in Central of Peninsular Malaysia, Ipoh, Perak, Malaysia|Health Clinics in Central of Peninsular Malaysia, Petaling Jaya, Selangor, Malaysia|Health Clinics in East Coast of Peninsular Malaysia, Kuala Terengganu, Terengganu, Malaysia",,"https://ClinicalTrials.gov/show/NCT05489536"
947,"NCT05489523","Safety, Efficacy, and Pharmacokinetics of Tafamidis in Patients With Transthyretin-mediated Amyloidosis Post Orthotopic Heart Transplantation",,"Not yet recruiting","No Results Available","Transthyretin Cardiac Amyloidosis","Drug: Tafamidis 61 MG","Serial change from baseline in plasma TTR levels at 12 months|Serial change from baseline in Norfolk QoL-DN at 12 months|Serial change from baseline in Rasch-built Overall Disability Scale (R-ODS) at 12 months|Serial change from baseline in Composite Autonomic Symptom Score (COMPASS-31) at12 months|Serial change from baseline in modified body mass index (mBMI) at 12 months|Number of transplant-specific adverse events|Number of hepatic or renal transplant-specific adverse events|Steady-state plasma concentration of tafamidis in patients undergone HT for end stage ATTR-CA","University of Texas Southwestern Medical Center","All","18 Years to 90 Years   (Adult, Older Adult)","Phase 4","25","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","STU-2022-0583","October 1, 2022","September 30, 2024","September 30, 2024","August 5, 2022",,"August 5, 2022","UT Southwestern Medical Center, Dallas, Texas, United States",,"https://ClinicalTrials.gov/show/NCT05489523"
948,"NCT05489510","PXL-Platinum 330 in Eyes With Corneal Thinning Conditions",,"Not yet recruiting","No Results Available","Corneal Thinning|Keratoconus","Combination Product: Pulsed or continuous lighting","PXL-Platinum 330 system","Vishal Jhanji|University of Pittsburgh","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","300","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","STUDY21040139","September 15, 2022","December 31, 2031","December 31, 2031","August 5, 2022",,"August 5, 2022","UPMC Eye Center, Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT05489510"
949,"NCT05489497","Morbidity After Surgical Treatment of Perforated Ulcer",,"Completed","No Results Available","Peptic Ulcer Perforation","Procedure: Primary closure with or without omental grafting","postoperative medical or surgical complication","University of Monastir","All","18 Years and older   (Adult, Older Adult)",,"116","Other","Observational","Observational Model: Case-Control|Time Perspective: Retrospective","perforated ulcer","January 1, 2010","May 1, 2021","June 1, 2021","August 5, 2022",,"August 5, 2022",,,"https://ClinicalTrials.gov/show/NCT05489497"
950,"NCT05489484","Performance and Safety Evaluation of MD-Shoulder Collagen Medical Device in the Treatment of Rotator Cuff Syndrome","ROPIRAMED","Active, not recruiting","No Results Available","Rotator Cuff Tendinitis|Syndrome Rotator Cuff|Tendinopathy|Tendinoses, Rotator Cuff|Rotator Cuff Injuries","Device: MD-Shoulder Collagen Medical Device","Evaluation, using the Constant-Murley Functional Scale (CMS), score ranges from 0 to 100 points, representing worst and best shoulder function respectively.|Evaluation of MD-Shoulder Collagen Medical Device performance using the Constant-Murley from 0 to 100 points, representing worst and best shoulder function respectively.|Evaluation of MD-Shoulder Collagen Medical Device with Numeric Rating Scale the number between 0 and 10, zero usually represents 'no pain at all' whereas the upper limit represents 'the worst pain ever possible'.|Evaluation of MD-Shoulder Collagen Medical Device with American Shoulder and Elbow Surgeons (ASES)Scores range from 0 to 100 with a score of 0 indicating a worse shoulder condition and 100 indicating a better shoulder condition|Evaluation of MD-Shoulder Collagen Medical Device with simply shoulder test (SST), the items on the scale measure the ability of the affected shoulder to perform work duties, dressing, bathing, lifting, carrying and throwing.|Evaluation of MD-Shoulder Collagen Medical Device with range of motion (ROM) with goniometers measure range of motion in degrees, from zero to 180 or 360, and come in various shapes and sizes to be used on particular joints.|Evaluation of MD-Shoulder Collagen Medical with cuff integrity at mouth 12 compared to day 0 by performing with Magnetic Resonance Imaging (MRI) of the treated shoulder.|Evaluation of MD-Shoulder Collagen Medical with assessment of analgesic drug unit consumption based on clinical diary at various phases of the study.|Evaluation of Adverse Events.","Guna S.p.a","All","18 Years and older   (Adult, Older Adult)","Not Applicable","24","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MDG2021184","July 4, 2022","July 31, 2023","September 30, 2023","August 5, 2022",,"August 9, 2022","Gaetano Pini CTO, Milan, MI, Italy","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/84/NCT05489484/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT05489484"
951,"NCT05489471","A Study to Assess the Impact of an Artificial Intelligence (AI) System on Chest X-ray Reporting",,"Not yet recruiting","No Results Available","Artificial Intelligence","Other: Artificial intelligence review","Radiologist performance review|Lung cancer detection|Lung cancer pathway improvement|Report turnaround times improvement","Hull University Teaching Hospitals NHS Trust|Lunit Inc.","All","16 Years and older   (Child, Adult, Older Adult)",,"20000","Other|Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","R2757","August 2022","July 2023","July 2023","August 5, 2022",,"August 5, 2022",,,"https://ClinicalTrials.gov/show/NCT05489471"
952,"NCT05489458","Predictive Factors for Resection and Survival in Type A Borderline Resectable Pancreatic Ductal Adenocarcinoma Patients After Neoadjuvant Therapy","PF-BARNA","Not yet recruiting","No Results Available","Carcinoma, Pancreatic Ductal","Procedure: Resection|Procedure: No Resection","The number of type A BR-PDAC patients who, after receiving NAT (≥3 cycles), undergo resection.|The evolution of the plasmatic levels of CA 19-9 from starting NAT until the surgical exploration.|The evolution of the degree of vascular involvement in 64-MDCT scans from starting NAT until the surgical exploration.|Overall survival|The evolution of the plasmatic levels of CA 19-9|The evolution of the degree of vascular involvement in 64-MDCT scans|Progression-Free Survival|The number (percentage) of deaths at the end of the observation period.|The number (percentage) of patients presenting disease progression at the end of the observation period.|The number (percentage) of patients presenting stable disease at the end of the observation period.|The number (percentage) of patients considered responders at the end of the observation period.|The number (percentage) of patients surgically explored at the end of the observation period.|The Resection Rate at the end of the observation period.","BUSQUETS, JULI|Hospital Universitari de Bellvitge","All","18 Years and older   (Adult, Older Adult)",,"100","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","HUB-BR-PDAC-2022","September 2022","October 2022","January 2023","August 5, 2022",,"August 5, 2022",,,"https://ClinicalTrials.gov/show/NCT05489458"
953,"NCT05489445","All Inclusive Kodex - EPD Study",,"Recruiting","No Results Available","Atrial Fibrillation","Device: KODEX - EPD","Acute PVI during index procedure.|Long term efficacy|Exploratory","University of Arizona","All","18 Years and older   (Adult, Older Adult)",,"30","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2103636199","September 15, 2021","August 2024","August 2024","August 5, 2022",,"August 5, 2022","Banner - University Medical Center, Phoenix campus, Phoenix, Arizona, United States",,"https://ClinicalTrials.gov/show/NCT05489445"
954,"NCT05489432","PREhabilitation of Candidates for REnal Transplantation","PreCareTx","Not yet recruiting","No Results Available","Prehabilitation|Kidney Transplant Candidates|Frailty","Behavioral: Exercise","Change in frailty status|Change in functional capacity|Change in handgrip strength|Change in Fat Free Mass|Change in Body Mass Index|Change in symptoms of fatigue|Change in symptoms of anxiety|Change in symptoms of depression|Change in Health related Quality of Life","University Medical Center Groningen","All","18 Years and older   (Adult, Older Adult)","Not Applicable","128","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","10812","October 2022","September 2025","September 2025","August 5, 2022",,"August 11, 2022",,,"https://ClinicalTrials.gov/show/NCT05489432"
955,"NCT05489419","Evaluation of Prehabilitation as a Strategy to Minimize Surgical Risk in Pancreatic Surgery: Efficacy and Determining Factors.",,"Recruiting","No Results Available","Pancreatic Neoplasms|Anesthesia","Behavioral: Multimodal Prehabilitation","Efficacy of a multimodal prehabilitation|Evaluation of the adherence to the program|Evaluation of sarcopenia after prehabilitation|Evaluation of the impact on perceived quality of life|Evaluation of the impact on the inflammatory response after the intervention|Evaluation of the impact on the incidence of postoperative complications|Evaluation of complications severity","Hospital Clinic of Barcelona","All","Child, Adult, Older Adult","Not Applicable","56","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","HCB/2020/0477","January 1, 2021","May 30, 2023","May 30, 2023","August 5, 2022",,"August 5, 2022","Hospital Clinic de Barcelona, Barcelona, Spain",,"https://ClinicalTrials.gov/show/NCT05489419"
956,"NCT05489406","Relative Bioavailability Study to Investigate a Potential Interaction Between DTG DT and F/TAF TOS.","UNIVERSALRBA","Not yet recruiting","No Results Available","Hiv","Drug: DTG DT (6 x 5 mg)|Drug: F/TAF TOS (3 x 60/7.5 mg)","The relative bioavailability of TAF and TFV|The relative bioavailability of FTC|The relative bioavailability of DTG|The relative bioavailability of the potential interaction and pharmacokinetics|Adverse events","Radboud University Medical Center|Gilead Sciences","All","18 Years to 55 Years   (Adult)","Phase 1","16","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other","UNIVERSAL RBA","October 1, 2022","November 30, 2022","December 31, 2022","August 5, 2022",,"August 10, 2022",,,"https://ClinicalTrials.gov/show/NCT05489406"
957,"NCT05489393","CureDRPLA Global Patient Registry",,"Recruiting","No Results Available","DRPLA",,"Patient- or caregiver-filled questionnaires","CureDRPLA|Ataxia UK","All","0 Years to 100 Years   (Child, Adult, Older Adult)",,"100","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","CureDRPLA Registry_Version1.0","March 1, 2021","November 1, 2031","November 1, 2031","August 5, 2022",,"August 5, 2022","CureDRPLA, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT05489393"
958,"NCT05489380","Optical Diagnosis Versus Laser Measurement of Polyps' Size During Colonoscopy and Implications for Surveillance",,"Not yet recruiting","No Results Available","Colorectal Polyp","Device: AccuMeasure","Cohens' Kappa coefficient|Number of Participants with adverse events up to 30 days post colonoscopy|Absolute size differences|Time for measurement|Endoscopist advised surveillance interval","Radboud University Medical Center|NYU Langone Health|Universitätsklinikum Hamburg-Eppendorf|Indiana University Health|Tel-Aviv Sourasky Medical Center|Bnai Zion Medical Center","All","18 Years and older   (Adult, Older Adult)","Not Applicable","138","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Screening","NL80961.091.22","October 1, 2022","September 1, 2023","November 1, 2023","August 5, 2022",,"August 10, 2022","Radboud university medical center, Nijmegen, Gelderland, Netherlands",,"https://ClinicalTrials.gov/show/NCT05489380"
959,"NCT05489367","Does COVİD-19 m-RNA Vaccine Affect Fertility and Over Reserve ?",,"Enrolling by invitation","No Results Available","COVID-19 Virus Infection|Ovarian Function Insufficiency|Fertility Disorders|Vaccine Adverse Reaction","Biological: sars cov 2 biontec vaccine","Ovarian reserve tests and fertility status of 74 women before and after vaccination|AMH difference between vaccinated and unvaccinated groups","Gaziosmanpasa Research and Education Hospital","Female","18 Years to 45 Years   (Adult)",,"64","Other","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","GaziosmanpasaTREHm","February 1, 2022","October 20, 2022","November 30, 2022","August 5, 2022",,"August 5, 2022","Gaziosmanpasa Training and Research Hospital, Istanbul, Gaziosmanpaşa, Turkey",,"https://ClinicalTrials.gov/show/NCT05489367"
960,"NCT05489354","mHealth Usage Among Nigeria Women Diagnosed With Breast Cancer Receiving Chemotherapy",,"Not yet recruiting","No Results Available","Breast Cancer","Other: mHealth psychoeducational intervention","Change in self-efficacy|Change in Coping|Change in Anxiety|Change in Depression|Change in Symptom Distress|Change in Quality of Life","Chinese University of Hong Kong","Female","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","126","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Supportive Care","2021.693","September 1, 2022","July 31, 2023","December 1, 2023","August 5, 2022",,"August 8, 2022","Lagos State University Teaching Hospital, Lagos, Nigeria|Lagos University Teaching Hospital, Lagos, Nigeria",,"https://ClinicalTrials.gov/show/NCT05489354"
961,"NCT05489341","Artificial Intelligence and Radiologists at Prostate Cancer Detection in MRI: The PI-CAI Challenge",,"Active, not recruiting","No Results Available","Prostate Cancer","Diagnostic Test: Histopathology and Magnetic Resonance Imaging with Follow-Up|Diagnostic Test: Histopathology and Magnetic Resonance Imaging","AI vs Radiologists from Reader Study|AI vs Radiologists from Clinical Routine|AI vs AI|Radiologists vs Radiologists from Reader Study","Radboud University Medical Center|Ziekenhuisgroep Twente|University Medical Center Groningen|Norwegian University of Science and Technology","Male","18 Years and older   (Adult, Older Adult)",,"5000","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","CMO2016-3045-Project-20011","February 1, 2022","February 2023","May 2023","August 5, 2022",,"August 5, 2022","RadboudUMC, Nijmegen, Gelderland, Netherlands",,"https://ClinicalTrials.gov/show/NCT05489341"
962,"NCT05489328","Safety and Immunogenicity of Pneumococcal Conjugate Formulations in Healthy Adults 18 Through 49 Years of Age",,"Not yet recruiting","No Results Available","Pneumococcal Disease","Other: Candidate-1|Other: Candidate-2|Other: Candidate-3|Other: Candidate-4|Other: Candidate-5|Other: Candidate-6|Other: Candidate Control|Biological: 13vPnC|Biological: PCV15","Percentage of participants reporting prompted local reactions within 7 days after study intervention administration|Percentage of participants reporting prompted systemic events within 7 days after study intervention administration|Percentage of participants reporting Adverse Events (AEs) within 1 month after study intervention administration|Percentage of participants reporting Serious Adverse Events (SAEs) within 1 month after study intervention administration|Pneumococcal opsonophagocytic activity (OPA) geometric mean titers (GMTs)","Pfizer","All","18 Years to 49 Years   (Adult)","Phase 1","405","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","C4801001","August 15, 2022","October 14, 2022","October 14, 2022","August 5, 2022",,"August 5, 2022",,,"https://ClinicalTrials.gov/show/NCT05489328"
963,"NCT05489315","Quantifying the Impact of the Peanut Ball on the Duration of the Active Stage of Labor",,"Recruiting","No Results Available","Labor Onset and Length Abnormalities|Prolonged Labor|Labor Long|Labor; Poor","Device: Positioning with peanut ball|Other: Traditional positioning","Rate of active stage of labor|Cesarean section rate","University of Tennessee Health Science Center","Female","16 Years and older   (Child, Adult, Older Adult)","Not Applicable","400","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","21-08072-FB","July 26, 2021","May 19, 2023","May 19, 2023","August 5, 2022",,"August 5, 2022","Regional One Health Outpatient Center, Memphis, Tennessee, United States|Regional One Health, Memphis, Tennessee, United States|Regional One Health - Hollywood Clinic, Memphis, Tennessee, United States|Regional One Health - Kirby Primary Care Clinic, Memphis, Tennessee, United States","""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/15/NCT05489315/ICF_000.pdf","https://ClinicalTrials.gov/show/NCT05489315"
964,"NCT05489302","Evaluation of Two Protocol of Maxillary Protraction in Class III Adolescent After Using (MSE)",,"Active, not recruiting","No Results Available","Maxillary Protraction in Class III Adolescent After Using (MSE)","Device: Maxillary skeletal expander with protraction face mask with Alt-RAMEC protocol.|Device: Maxillary skeletal expander with protraction face mask with conventional protocol","amount of maxillary protraction","Al-Azhar University","All","13 Years to 17 Years   (Child)","Not Applicable","42","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","828/220","June 20, 2022","December 30, 2022","January 20, 2023","August 5, 2022",,"August 10, 2022","Mohamed Shendy, Cairo, Nasr City, Egypt",,"https://ClinicalTrials.gov/show/NCT05489302"
965,"NCT05489289","A Phase III Study of AK104 as Adjuvant Therapy in HCC With High Risk of Recurrence After Curative Resection",,"Not yet recruiting","No Results Available","Hepatocellular Carcinoma","Biological: AK104|Biological: placebo","Recurrence free survival (RFS) by BICR|12-months recurrence free survival (RFS-12)|24-months recurrence free survival (RFS-24)|Time to recurrence (TTR)|Overall survival (OS)|Types and proportions of adverse events (AEs)","Akeso","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","405","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","AK104-306","September 24, 2022","January 28, 2025","November 1, 2026","August 5, 2022",,"August 5, 2022","Zhongshan Hospital, Fudan University, Shanghai, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT05489289"
966,"NCT05489276","Clinical Trial of TQB2825 in Subjects With CD20 Positive Hematological Tumors",,"Recruiting","No Results Available","Hematological Tumors","Drug: TQB2825 injection","Dose limiting toxicity（DLT）|the maximum tolerated dose (MTD)|Recommended Phase II Dose（RP2D)|Adverse events (AE)|serious adverse events (SAE)|treatment-related adverse events(TRAE)|Elimination half-life (to be used in one-or non- compartmental model) （t1/2)|Tmax|Maximum (peak) plasma drug concentration （Cmax)|Area under the plasma concentration-time curve from time zero to time t （AUC0-t)|Area under the plasma concentration-time curve from time zero to time ∞（AUC0-∞)|Minimum steady-state plasma drug concentration during a dosage interval （Cmin,ss)|Progress Free Survival（PFS)|Disease control rate（DCR)|Duration of Response (DOR)|Overall survival (OS)","Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.|Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1","180","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TQB2825- I-01","March 22, 2022","October 2023","December 2023","August 5, 2022",,"August 5, 2022","Beijing Cancer Hospital, Beijing, Beijing, China",,"https://ClinicalTrials.gov/show/NCT05489276"
967,"NCT05489263","A Predictive Score System for AKI Following Pediatric Cardiac Surgery",,"Recruiting","No Results Available","Congenital Heart Disease|Surgery--Complications|Acute Kidney Injury","Other: No intervention","The Prevalence of Acute Kidney Injury|The incidence of dialysis|The hours of mechanical ventilation|The incidence of reinbutation|The incidence of tracheotomy|The incidence of re-operation|The incidence of mechanical cardiac support|The incidence of mortality|The incidence of pulmonary infection|The cost of medical resources|Intensive Care Unit Discharge Time|Hospital Discharge Time|The relative change of left ventricular ejection fraction (LVEF) from baseline to hospital discharge|The relative change of left ventricular end-diastolic diameter (LVEDD) from baseline to hospital discharge","China National Center for Cardiovascular Diseases","All","0 Days to 18 Years   (Child, Adult)",,"2000","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","2021-LC15","April 1, 2022","May 30, 2023","June 30, 2023","August 5, 2022",,"August 5, 2022","Fuwai Hospital, Beijing, Beijing, China",,"https://ClinicalTrials.gov/show/NCT05489263"
968,"NCT05489250","The PLATON Network","PLATON","Recruiting","No Results Available","Hepatocellular Cancer|Cholangiocarcinoma|Gallbladder Cancer|Pancreatic Cancer|Oesophageal Cancer|Stomach Cancer",,"Frequency of targetable mutations in gastrointestinal cancer patients|Tumor mutations and their impact on treatment decisions in gastrointestinal cancer patients|Overall survival (OS) in genetically defined cohorts in gastrointestinal cancer patients|QoL via EQ-5D-5L questionnaire in genetically defined cohorts in gastrointestinal cancer patients|QoL via EORTC QLQ-C30 questionnaire in genetically defined cohorts in gastrointestinal cancer patients|QoL via EORTC QLQ-BIL21 questionnaire in genetically defined cohorts of CCA and GBCA patients|QoL via EORTC QLQ-HCC18 questionnaire in genetically defined cohorts of HCC patients|QoL via EORTC QLQ-PAN26 questionnaire in genetically defined cohorts of PDCA patients|QoL via EORTC QLQ-STO22 questionnaire in genetically defined cohorts of EC/GC patients","Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest","All","18 Years and older   (Adult, Older Adult)",,"1000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","The PLATON Network","October 28, 2020","May 31, 2032","May 31, 2032","August 5, 2022",,"August 15, 2022","KHNW Frankfurt, Frankfurt, Hessen, Germany|Friedrich-Ebert-Krankenhaus Neumünster, Neumünster, Schleswig-Holstein, Germany|HELIOS Klinikum Bad Saarow, Bad Saarow, Germany|Evangelisches Waldkrankenhaus Spandau, Berlin, Germany|MVZ Oskar-Helene-Heim Berlin, Berlin, Germany|Augusta-Kranken-Anstalt Bochum, Bochum, Germany|Bochum Uni, Bochum, Germany|Klinikum Chemnitz, Chemnitz, Germany|GEFOS - Gesellschaft für onkologische Studien Dortmund, Dortmund, Germany|Onkozentrum Dresden, Dresden, Germany|Ev. Kliniken Essen-Mitte, Klinik für Internistische Onkologie, Essen, Germany|MVZ Onkologische Kooperation Harz, Goslar, Germany|Universitätsklinikum Halle (Saale), Halle, Germany|Hamburg Onkologische Schwerpunktpraxis Eppendorf, Hamburg, Germany|St. Anna Hospital Herne, Herne, Germany|Ortenau Klinikum Lahr-Ettenheim, Lahr, Germany|ÜBAG - MVZ Dr. Vehling-Kaiser GmbH, Landshut, Germany|Langen, Gemeinschaftspraxis für Hämatologie und Onkologie, Langen, Germany|Studienzentrum UnterEms, Leer, Germany|Klinikum Lippe, Lemgo, Germany|Klinikum Ludwigsburg, Ludwigsburg, Germany|Klinik München-Bogenhausen, München, Germany|Münster, Gemeinschaftspraxis für Hämatologie und Onkologie, Münster, Germany|Medius Klinik Osterfildern-Ruit, Ostfildern, Germany|Krankenhaus Barmherzige Brüder, Regensburg, Germany|Klinikum Rheine, Mathias-Spital Rheine, Rheine, Germany|CaritasKlinikum Saarbrücken, Saarbrücken, Germany|Onkologie Bodensee, Singen, Germany|Marien Hospital Witten, Witten, Germany|Klinikum Wolfsburg, Wolfsburg, Germany|Onkologisches Zentrum Wolfsburg-Helmstedt MVZ GmbH, Wolfsburg, Germany",,"https://ClinicalTrials.gov/show/NCT05489250"
969,"NCT05489237","A First-in-human (FIH) Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors",,"Not yet recruiting","No Results Available","Gastrointestinal Stromal Tumor (GIST)|Digestive System Disease|Gastrointestinal Diseases|Metastatic Cancer","Drug: IDRX-42","Phase 1 (Dose Escalation) - Safety and Tolerability (Nature, incidence, and severity of any DLTs)|Phase 1 (Dose Escalation) - Determination of the MTD and/or RP2DS of orally administered IDRX-42|Phase 1b-Number of participants with TEAEs and with laboratory test results|Phase 1b - Objective Response Rate (ORR) mRESIST v1.1|Phase 1 (Dose Escalation)- Number of participants with non-DLT TEAEs and with laboratory test results|Phase 1 (Dose Escalation) - ORR per mRECIST v1.1|Phase 1 (Dose Escalation) - Cmax; Maximum Observed Concentration of IDRX-42|Phase 1 (Dose Escalation) - Tmax; Time of First Occurrence of Maximum Plasma Concentration (Cmax) of IDRX-42|Phase 1 (Dose Escalation) - AUC 0-24; Area Under the Concentration-time Curve from Time Zero to 24 hours for IDRX-42|Phase 1 (Dose Escalation) - Duration of response (DOR) per mRECIST v1.1|Phase 1 (Dose Escalation) - Time to response (TTR) per mRECIST v1.1|Phase 1 (Dose Escalation) - Progression-free survival (PFS), per mRECIST v1.1|Phase 1b- Duration of response (DOR) per mRECIST v1.1|Phase 1b - PFS per mRECIST v1.1|Phase 1b - Clinical benefit rate (CBR) per mRECIST v1.1|Phase 1b - TTR per mRECIST v1.1|Phase 1b - Cmax; Maximum Observed Concentration of IDRX-42|Phase 1b - Tmax; Time of First Occurrence of Maximum Plasma Concentration (Cmax) of IDRX-42|Phase 1b - AUC 0-24; Area Under the Concentration-time Curve from Time Zero to 24 hours for IDRX-42|Phase 1b - Overall survival","IDRx, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 1","143","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IDRX-42-001","August 1, 2022","April 24, 2026","September 13, 2026","August 5, 2022",,"August 5, 2022",,,"https://ClinicalTrials.gov/show/NCT05489237"
970,"NCT05489224","A Study to Compare Efficacy and Safety of CT-P47 and RoActemra in Patients With Rheumatoid Arthritis",,"Not yet recruiting","No Results Available","Rheumatoid Arthritis","Biological: CT-P47|Biological: EU-approved RoActemra","Mean Change from Baseline in Disease Activity Score 28 (DAS28) using Erythrocyte Sedimentation Rate (ESR)|Proportion of Patients Achieving an American College of Rheumatology (ACR)20 response|Proportion of Patients Achieving an ACR50 response|Proportion of Patients Achieving an ACR70 response","Celltrion","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","448","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CT-P47 3.1","August 2022","August 2023","December 2023","August 5, 2022",,"August 10, 2022",,,"https://ClinicalTrials.gov/show/NCT05489224"
971,"NCT05489211","Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours",,"Not yet recruiting","No Results Available","Endometrial Cancer|Gastric Cancer|Metastatic Castration-resistant Prostate Cancer|Ovarian Cancer|Colorectal Cancer","Drug: Datopotamab deruxtecan (Dato-DXd)|Drug: AZD5305|Drug: Durvalumab|Drug: Capecitabine|Drug: 5-Fluorouracil|Drug: Nivolumab|Drug: Carboplatin|Drug: Leucovorin LV|Drug: Bevacizumab","Objective response rate (ORR)|The number of subjects with adverse events/serious adverse events|Progression free survival (PFS)|Duration Of Response (DOR)|Disease Control Rate (DCR)|Best percentage change in tumour size|Anti Drug Antibody (ADA)|Pharmacokinetics of Dato-DXd, Maximum plasma concentration of the drug (Cmax)|Pharmacokinetics of Dato-DXd, The time taken to reach the maximum concentration (Tmax)|Pharmacokinetic Parameter: Area under the plasma concentration- time curve (AUC)|Plasma concentration of Total anti-TROP2 antibody|Plasma concentration of MAAA-1181a","AstraZeneca|Daiichi Sankyo, Inc.","All","18 Years to 130 Years   (Adult, Older Adult)","Phase 2","451","Industry","Interventional","Allocation: N/A|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","D926UC00001","August 3, 2022","June 2, 2025","June 2, 2025","August 5, 2022",,"August 5, 2022","Research Site, Los Angeles, California, United States|Research Site, San Diego, California, United States|Research Site, Santa Rosa, California, United States|Research Site, Indianapolis, Indiana, United States|Research Site, Kansas City, Kansas, United States|Research Site, Boston, Massachusetts, United States|Research Site, Albuquerque, New Mexico, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Columbus, Ohio, United States|Research Site, Portland, Oregon, United States|Research Site, Nashville, Tennessee, United States|Research Site, Nashville, Tennessee, United States|Research Site, Houston, Texas, United States|Research Site, Toronto, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Bordeaux, France|Research Site, Lyon, France|Research Site, Marseille, France|Research Site, Suresnes, France|Research Site, Berlin, Germany|Research Site, Essen, Germany|Research Site, Hannover, Germany|Research Site, München, Germany|Research Site, Regensburg, Germany|Research Site, Firenze, Italy|Research Site, Genova, Italy|Research Site, Milano, Italy|Research Site, Milano, Italy|Research Site, Milan, Italy|Research Site, Napoli, Italy|Research Site, Rome, Italy|Research Site, Seodaemun-gu, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Kraków, Poland|Research Site, Poznań, Poland|Research Site, Warszawa, Poland|Research Site, Basel, Switzerland|Research Site, Bellinzona, Switzerland|Research Site, St. Gallen, Switzerland|Research Site, Liou Ying Township, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taoyuan, Taiwan|Research Site, Samsun, Turkey|Research Site, Cambridge, United Kingdom|Research Site, Dundee, United Kingdom|Research Site, London, United Kingdom|Research Site, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT05489211"
972,"NCT05489198","Cataract Surgery Technique and Ocular Clarity",,"Not yet recruiting","No Results Available","Cataract","Procedure: cataract surgery with Centurion phacoemulsification system|Procedure: cataract surgery with Quatera 700 phacoemulsification system","Straylight|Corneal densitometry|Amount of phaco energy used|Amount of balanced salt solution used|Total surgery time|Uncorrected Distance Visual Acuity|Corrected Distance Visual Acuity|Corneal pachymetry|Presence of corneal oedema|Catquest-9SF|Patient-Perceived Satisfactory Improvement in Vision","Amphia Hospital","All","18 Years and older   (Adult, Older Adult)","Not Applicable","15","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1900","September 2022","September 2023","September 2023","August 5, 2022",,"August 5, 2022",,,"https://ClinicalTrials.gov/show/NCT05489198"
973,"NCT05489185","Clinical Trial to Assess the Efficacy of Tranexamic Acid in Reducing Blood Loss in Hip Fracture Patients.",,"Not yet recruiting","No Results Available","Hip Fractures","Drug: Tranexamic acid|Other: Physiologic saline","Blood transfusion|Total blood loss|Adverse events|Days at hospital","Asociacion Instituto Biodonostia","All","65 Years and older   (Older Adult)","Phase 4","644","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","2020_TRANEXAMICO","September 1, 2022","June 1, 2024","June 1, 2025","August 5, 2022",,"August 5, 2022","Asociación Instituto Biodonostia, San Sebastián, Guipuzcoa, Spain",,"https://ClinicalTrials.gov/show/NCT05489185"
974,"NCT05489172","Mobile Health App to Reduce Diabetes in Latina Women With Prior Gestational Diabetes II",,"Recruiting","No Results Available","Gestational Diabetes Mellitus","Behavioral: Hola Bebe","Sallis Self Efficacy for Healthy Eating|Sallis Self Efficacy for Physical Activity|Weight loss","Environment and Health Group, Inc.","Female","18 Years to 45 Years   (Adult)","Not Applicable","150","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","R44MD009454B|R44MD009454","February 1, 2020","July 31, 2022","July 31, 2023","August 5, 2022",,"August 5, 2022","Environment and Health Group, Cambridge, Massachusetts, United States|Brookside Community Health Center, Jamaica Plain, Massachusetts, United States|Lynn Community Health Center, Lynn, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT05489172"
975,"NCT05489159","Sleep and IR in Transgender Adolescents","ATP","Not yet recruiting","No Results Available","Sleep Disorder|Insulin Resistance|Gender Dysphoria",,"Change in Sleep Duration as measured by actigraphy device.|Change in Subjective Sleep Quality as measured by sleep questionnaires|Change in Objective Sleep Quality as measured by actigraphy device|Change in Insulin Resistance as measured by aggregation of lab results","Duke University","All","12 Years to 18 Years   (Child, Adult)",,"30","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","Pro00110732","September 2022","December 2023","December 2023","August 5, 2022",,"August 5, 2022",,,"https://ClinicalTrials.gov/show/NCT05489159"
976,"NCT05489146","t-RNS After Hand Recovery in Chronic Stroke",,"Completed","No Results Available","Stroke","Device: transcranial random noise stimulation and functional electrical stimulation facilitated task practice","Change from baseline in Fugl Meyer Upper Extremity Scale at post treatment|Change from baseline in Fugl Meyer Upper Extremity Scale at 3 months post treatment|Change from baseline in Wolf Motor Function Test at post treatment|Change from baseline in Wolf Motor Function Test at 3 months post treatment|Change from baseline in Grip Strength at post treatment|Change from baseline in Grip Strength at 3 months post treatment|Change from baseline in Hand subscale of Stroke Impact Scale at post treatment|Change from baseline in Hand subscale of Stroke Impact Scale at 3 months post treatment|Change from baseline in Action Research Arm Test at post treatment|Change from baseline in Action Research Arm Test at 3 months post treatment|Change in baseline in H-reflex at post treatment|Change in baseline in H-reflex at 3 months post treatment|Change in baseline in brain activity at post treatment|Change in baseline in brain activity at 3 months post treatment|Change in baseline in muscle activity at post treatment|Change in baseline in muscle activity at 3 months post treatment|Change in baseline in brain excitability at post treatment|Change in baseline in brain excitability at 3 months post treatment|Change in in baseline in upper extremity kinematics at post treatment|Change in in baseline in upper extremity kinematics at 3 months post treatment","Amit Sethi|Zynex Medical Inc.|Neuroelectrics Corporation|University of Pittsburgh","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","15","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","PRO13090080","January 15, 2015","March 15, 2020","March 15, 2020","August 5, 2022",,"August 9, 2022","Neuromotor Recovery and Rehabilitation Lab, Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT05489146"
977,"NCT05489133","Early Psychological Intervention After Rape","EIR","Recruiting","No Results Available","Post Traumatic Stress Disorder|Rape Sexual Assault|Sexual Dysfunctions, Psychological|Pelvic Floor Myalgia|Pelvic Pain Syndrome|Depression, Anxiety|Sleep Disturbance|Activity, Motor|Cortisol Deficiency","Behavioral: Modified prolonged exposure","PTSD Checklist for DSM-5 (PCL-5)|PTSD Symptom Scale - Interview for DSM-5 (PSS-I-5)|Patient Health Questionnaire-9 (PHQ-9)|General Anxiety Disorder-7 (GAD-7)|Female Sexual Function Index (FSFI)|Bergen insomnia scale (BIS)|EQ-5D-5L|The Amsterdam Hyperactive Pelvic Floor Scale for Women","St. Olavs Hospital|Norwegian University of Science and Technology|The Research Council of Norway|Norwegian Women's Public Health Association (Norske Kvinners Sanitetsforening)|National Centre for Emergency Primary Health Care, NORCE|UiT The Arctic University of Norway","Female","16 Years and older   (Child, Adult, Older Adult)","Not Applicable","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Prevention","348496","June 14, 2022","May 2025","December 2027","August 5, 2022",,"August 5, 2022","Fredrikstad Emergency Medical Agency (legevakt) (Overgrepsmottaket i Østfold), Fredrikstad, Norway|Oslo Emergency Medical Agency (Oslo kommune, Legevakten, Overgrepsmottaket i Oslo), Oslo, Norway|Sandefjord Emergency Medical Agency (Legevakten, Overgrepsmottaket i Vestfold), Sandefjord, Norway|Department of Obstetrics and Gynecology, St. Olavs hospital (Overgrepsmottaket), Trondheim, Norway",,"https://ClinicalTrials.gov/show/NCT05489133"
978,"NCT05489120","Low-Protein Diet With Low-Protein Foods Versus a LPD Without LP Foods in Patients With Chronic Kidney Disease (CKD)",,"Not yet recruiting","No Results Available","Chronic Kidney Disease Stage 3B|Chronic Kidney Disease stage4|Chronic Kidney Disease Stage 5","Other: Consumption of FLAVIS","Effectiveness in terms of protein intake of a LPD with LP foods (FLAVIS products) compared to standard products (LPD without consumption of LP foods)|Protein intake during the 12 months follow-up|Dietary adherence|Dietary compliance for products under study|Effects of the LPD on BMI|Effects of the LPD on weight|Effects of the LPD on body composition: water|Effects of the LPD on body composition: muscles|Effects of the LPD on body composition: body protein content|Effects of the LPD on Blood|Effects of the LPD on Urine|Incidence of Adverse Events [Safety of the LPD]|Patient quality of life|Patient satisfaction with LPD","Dr. Schär AG / SPA|Slb Pharma","All","18 Years and older   (Adult, Older Adult)","Not Applicable","244","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","EFFLAVIS","September 15, 2022","September 15, 2023","September 15, 2025","August 5, 2022",,"August 8, 2022","Cabinet médical du Dr Magnant, Aix-en-Provence, France|Maison du Rein, Bordeaux, France|CHU Gabriel Montpied, Clermont-Ferrand, France|CH Le Mans, Le Mans, France|Hospices Civiles de Lyon, Lyon, France|Hôpital la conception, Marseille, France|CH Mâcon, Mâcon, France|AURA Paris, Paris, France|Hôpital Nord-Ouest, Villefranche-sur-Saône, France",,"https://ClinicalTrials.gov/show/NCT05489120"
979,"NCT05489107","New Local Treatment of Radiation-induced Proctitis","NOTRIP","Recruiting","No Results Available","Radiation Proctitis","Other: Ziverel","Number of Petechiae in the most affected areas of the rectal mucosa.|Assessment of patients' quality of life using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Proctitis Module with 20 Questions (EORTC QLQ-PRT20)","Barmherzige Brüder Vienna","All","18 Years to 99 Years   (Adult, Older Adult)",,"50","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","202207-01","July 1, 2022","July 1, 2023","July 31, 2023","August 5, 2022",,"August 5, 2022","Krankenhaus der Barmherzigen Brüder, Vienna, Austria",,"https://ClinicalTrials.gov/show/NCT05489107"
980,"NCT05489094","The Impact of Nutrition Education and Milk Provision in Fueling the Progress of 1 - 3 Years Old Children",,"Not yet recruiting","No Results Available","Iron-deficiency","Combination Product: Nutrition Education and Growing Up Milk for 1 - 3 years old|Behavioral: Nutrition Education","Impact of milk provision on change from baseline of daily iron intake at 4 month in intervention group vs control group|Impact of milk provision on the adequacy of iron intake based on percentage of recommended daily allowance|Impact of milk provision on the average daily nutrients intake (Energy in kcal)|Impact of milk provision on the average daily nutrients intake (Protein, Carbohydrate, Fat, Fiber & DHA in g)|Impact of milk provision on the average daily nutrients intake (Fe, Ca, P, Zn, Mg, Vit B6 & Vit E in mg)|Impact of milk provision on the average daily nutrients intake (Folic Acid, Vit A, Vit C, Vit D & Vit B12 in μg)|Impact of milk provision on Total hemoglobin Level (SpHb) level using Masimo device|Impact of milk provision on nutritional status (weight, height - WAZ, HAZ, and WHZ)","Danone Specialized Nutrition Indonesia|Indonesian Nutrition Association","All","12 Months to 32 Months   (Child)","Phase 4","196","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","270422","August 31, 2022","February 28, 2023","February 28, 2023","August 5, 2022",,"August 15, 2022",,,"https://ClinicalTrials.gov/show/NCT05489094"
981,"NCT05489081","Implementation Strategy Resource Package for Behavioral Classroom Interventions: Pilot Test",,"Not yet recruiting","No Results Available","Attention Deficit Hyperactivity Disorder Symptoms","Behavioral: Positive Behavior Management Toolkit","Feasibility of Intervention Measure|Acceptability of Intervention Measure (AIM)|Intervention Appropriateness Measure (IAM)|Change in observed teacher use of behavioral classroom management interventions|Change in caregiver-reported Child Functional Impairment|Change in teacher-reported Child Functional Impairment|Change in Academic Productivity|Change in Student-Teacher Relationship|Change in Homework Performance|Change in caregiver-reported ADHD Symptoms|Change in teacher-reported ADHD Symptoms|Change in Academic Success|Change in engagement and Disruptive Direct Behavior Ratings","Children's Hospital of Philadelphia|National Institute of Mental Health (NIMH)","All","4 Years and older   (Child, Adult, Older Adult)","Not Applicable","90","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","22-019825|K23MH122577","September 2022","June 2024","June 2024","August 5, 2022",,"August 5, 2022","Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT05489081"
982,"NCT05489068","Motivational Interviewing at Intake vs Intake as Usual on Client Engagement in Addiction Treatment",,"Recruiting","No Results Available","Substance-Related Disorders|Treatment Adherence","Behavioral: Motivational Interviewing at Intake (MII)|Behavioral: Intake as Usual (IAU)","Number of participants who attended the first outpatient treatment program session based on electronic medical record review|Number of treatment sessions attended during the three-month outpatient treatment program based on electronic medical record review|Number of participants who completed the three-month outpatient treatment program based on electronic medical record review|Change from baseline in client readiness to enter treatment on the University of Rhode Island Change Assessment Scale (URICA) at 1 hour post-intake|Score on therapeutic alliance on the Working Alliance Inventory (WAI) at 1-hour post-intake","University of New Mexico|National Institute on Drug Abuse (NIDA)","All","18 Years and older   (Adult, Older Adult)","Not Applicable","150","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Health Services Research","A22-0014|K23DA052646","March 16, 2022","October 2024","December 2024","August 5, 2022",,"August 5, 2022","Turning Point Recovery Center, Albuquerque, New Mexico, United States",,"https://ClinicalTrials.gov/show/NCT05489068"
983,"NCT05489055","Effects of Contrast Media Temperature on Image Quality and Clinical Adverse Events in Coronary CTA",,"Recruiting","No Results Available","Contrast Media Adverse Reaction","Drug: Iopamidol","Vessel Attenuation|Allergic or allergiclike reaction|Extravasations|Objective image quality - Signal-to-noise ratio(SNR)|Objective image quality -Contrast-to-noise ratio(CNR)|CT Dose Index (CTDI)vol|Physiologic reactions-Urgency desire|Body Mass Index|Subjective image quality|Heart rate|Flow rate|Dose-length product (DLP)","Chongqing Emergency Medical Center|Army Medical Center of PLA","All","18 Years to 90 Years   (Adult, Older Adult)","Not Applicable","500","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","ChongqingEMC","February 1, 2022","January 1, 2023","February 28, 2023","August 5, 2022",,"August 5, 2022","Chongqing Emergency Mediacl Centre, Chongqing, Chonqing, China",,"https://ClinicalTrials.gov/show/NCT05489055"
984,"NCT05489042","Functional Connectivity Alterations in Suicidal Patients Among Opioid Users",,"Recruiting","No Results Available","Substance Abuse|Suicide|Depression","Device: Repetitive Transcranial Magnetic Stimulation (rTMS)|Device: sham rTMS","Functional Connectivity between the orbitofrontal cortex (OFC) and dorsal striatum in opioid users or opioid-related patients versus healthy subjects|rTMS changes in dorsal striatum responses between those receiving active stimulation versus sham stimulation","Baylor College of Medicine|American Foundation for Suicide Prevention|National Institute on Drug Abuse (NIDA)","All","18 Years to 64 Years   (Adult)","Not Applicable","80","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","H-51048|1K25DA055156-01A1|YIG-1-141-20","January 4, 2022","January 4, 2025","January 4, 2026","August 5, 2022",,"August 5, 2022","The Menninger Clinic, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT05489042"
985,"NCT05489029","Peculiarities of Pain in Patients With Gunshot Wounds Depending on the Localization of the Wound at the Stages of Treatment","PPPGWDL","Completed","No Results Available","Chronic Pain","Other: visual analog scale","visual analog scale|pain diagnostic questionnaire|The Hospital Anxiety and Depression Scale|Chaban Quality of Life Scale|Mississippi PTSD scale (military version)","Bogomolets National Medical University","Male","Child, Adult, Older Adult",,"1555","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","№158/23.05.2022","February 24, 2022","May 24, 2022","May 24, 2022","August 5, 2022",,"August 8, 2022","Bogomolets National Medical University, Ministry of Health of Ukraine, Kyiv, Ukraine",,"https://ClinicalTrials.gov/show/NCT05489029"
986,"NCT05489016","HuoXin Pills Intervention on Patients With Coronary Heart Disease After Drug-Coated Balloon Implantation",,"Recruiting","No Results Available","Coronary Heart Disease|Medicine, Chinese Traditional","Drug: Yuekang Huoxin Pills (concentrated pills)|Drug: Yuekang Huoxin Pills (concentrated pills)simulant","QFR|QFR change value|Late Lumen Loss Late lume loss|incidence of main adverse cardiac events composite endpoints incidence of cardiovascular composite endpoints","China National Center for Cardiovascular Diseases|Fuwai Yunnan Cardiovascular Hospital|Fuwai Central China Cardiovascular Hospital","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 4","440","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","2021-1467","August 5, 2022","January 1, 2024","July 13, 2025","August 5, 2022",,"August 8, 2022","Fuwai Hospital, China National Center for Cardiovascular Diseases, Beijing, Beijing, China|Fuwai Central China Cardiovascular Hospital, Zhengzhou, Henan, China|Fuwai Yunnan Cardiovascular Hospital, Kunming, Yunnan, China",,"https://ClinicalTrials.gov/show/NCT05489016"
987,"NCT05489003","Fatigue, Psychological Comorbidity and Quality of Life Among Patients With Chronic Pancreatitis in China.",,"Not yet recruiting","No Results Available","Chronic Pancreatitis",,"The incidence of fatigue among patients with CP in China.|The incidence of anxiety among patients with CP in China.|The incidence of depression among patients with CP in China.|The incidence of quality of life among patients with CP in China.|The influencing factors of fatigue among patients with CP in China.|The influencing factors of anxiety and depression among patients with CP in China.|The influencing factors of depression among patients with CP in China.|The influencing factors of quality of life among patients with CP in China.","Changhai Hospital","All","18 Years and older   (Adult, Older Adult)",,"300","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","XH20220802","August 1, 2022","August 10, 2023","December 31, 2023","August 5, 2022",,"August 5, 2022","Changhai Hospital, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT05489003"
988,"NCT05488990","Efficacy and Safety of Novel Formulations of Topical Calcipotriol in Patients With Mild to Moderate Plaque Psoriasis","AKVANO-AKP01","Completed","No Results Available","Psoriasis Vulgaris","Drug: AKVANO-Calcipotriol formulation 1|Drug: AKVANO-Calcipotriol formulation 2|Drug: AKVANO vehicle formulation 1|Drug: AKVANO vehicle formulation 2|Drug: Daivonex solution|Drug: Daivonex cream","Comparison of AKVANO-Calcipotriol formulations to their corresponding vehicles in terms of change in infiltrate thickness from baseline to Day 12|Comparison of AKVANO-Calcipotriol formulations to their corresponding comparators (Daivonex solution and cream) in terms of change in infiltrate thickness from baseline to Day 12|Comparison of AKVANO-Calcipotriol formulations to their corresponding vehicles and comparators in terms of change in infiltrate thickness and Area under curve (AUC) of change in infiltrate thickness from baseline to Day 8|Clinical assessment of the treatment efficacy of all formulations at day 8|Clinical assessment of the treatment efficacy of all formulations at day 12","Lipidor AB|Bioskin GmbH","All","32 Years to 69 Years   (Adult, Older Adult)","Phase 1|Phase 2","24","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CALC01 / 310905BS|2012-003951-12","March 25, 2013","June 17, 2013","June 17, 2013","August 5, 2022",,"August 5, 2022","bioskin GmbH, Bergmannstrasse 5, Berlin, Germany",,"https://ClinicalTrials.gov/show/NCT05488990"
989,"NCT05488977","The Effects of Endurance Training on Lipedema","LipidEx","Recruiting","No Results Available","Lipedema","Behavioral: Exercise training","Visual analog scale (VAS)|LYMQOL (Lymphoedema Quality of Life) legs|Brief Pain Inventory|Short Form Health Survey-36 (SF-36)|Glucose|HbA1C|Triglycerides|HDL-cholesterol|Total cholesterol|Ferritin|hs-CRP|Interleukin|PF4/CXCL4|TNFalpha|Protein levels in blood|Systolic blood pressure|Diastolic blood pressure|Body weight|Muscle mass|Fat percentage|Resting metabolism|Maximal oxygen uptake","Norwegian University of Science and Technology|St. Olavs Hospital","Female","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","461077","July 1, 2022","December 31, 2024","December 31, 2024","August 5, 2022",,"August 5, 2022","Institute for Circulation and Medical Imaging, NTNU, Trondheim, Norway",,"https://ClinicalTrials.gov/show/NCT05488977"
990,"NCT05488964","Effect of Exercise Training on Breastmilk Composition","MILKSHAKE","Not yet recruiting","No Results Available","Obesity","Behavioral: Exercise","Breastmilk human milk oligosaccharide (HMO) 3'sialyllactose (3'SL)|Breastmilk metabolites|Breastmilk microRNA|Maternal insulin sensitivity|Maternal fasting circulating insulin C-peptide concentrations|Maternal fasting circulating glucose concentrations|Maternal circulating total cholesterol concentrations|Maternal circulating high-density lipoprotein (HDL) concentrations|Maternal circulating low-density lipoprotein (LDL) concentrations|Maternal circulating triglycerides concentrations|Maternal glycated hemoglobin (HbA1c)|Maternal circulating high-sensitivity c-reactive protein|Maternal total body mass|Maternal fat mass|Maternal fat-free mass|Maternal visceral fat area|Maternal waist circumference|Maternal cardiorespiratory fitness|Maternal systolic blood pressure|Maternal diastolic blood pressure|Maternal nutrition|Maternal physical activity|Maternal psychological well-being|Infant total body mass|Infant fat mass|Infant muscle mass|Infant bone density|Infant hydration status|Infant total body mass (trajectories)|Infant length (trajectories)|Infant head circumference (trajectories)|Infant height (trajectories)|Infant gut microbiota|Infant microRNA","Norwegian University of Science and Technology","Female","18 Years and older   (Adult, Older Adult)","Not Applicable","62","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","479236","September 1, 2022","March 1, 2024","March 1, 2026","August 5, 2022",,"August 5, 2022","Dept Circulation and Medical Imaging, EXCAR Exercise Lab, Trondheim, Norway",,"https://ClinicalTrials.gov/show/NCT05488964"
991,"NCT05488951","The Influence of the Otago Exercise Program on Executive Function Among People Living With Mild to Moderate Dementia","ENABLED","Recruiting","No Results Available","Dementia","Other: Otago Exercise Program","Change in the Color Word Stroop Test|Change in the Digit Symbol Substitution Test|Change in the oral Trail Making Test|Change in the Digit Span Forwards and Backwards|Change in the Rey Auditory Verbal Learning Test|Change in the Benton Judgement of Line Orientation|Change in the Boston Naming Test|Change in Health Utilities Index-3|Change in the Visual Analogue Scale|Change in the Geriatric Depression Scale|Change in the short-Falls Efficacy Scale International|Change in Functional Comorbidity Index|Change in body composition (weight (kg))|Change in body composition (fat (%))|Change in body composition (muscle (%))|Change in the Short Physical Performance Battery|Change in dual-task posture (sway area (degrees/s squared))|Change in dual-task posture (root mean square sway (degrees))|Change in dual-task posture (frequency of sway (Hz))|Change in dual-task posture (jerk (m²/s^5))|Change in dual-task posture (mean velocity (m/s))|Change in dual-task posture (path length(m/s²))|Change in dual-task gait (gait speed (m/s))|Change in dual-task gait (double support (%))|Change in dual-task gait (stride length (m))|Change in dual-task gait (upper body range of motion (degrees))|Change in dual-task mobility (task duration (s))|Change in dual-task mobility (turn duration (s))|Change in dual-task mobility (turn velocity (degrees/s))|Change in dual-task mobility (lean angle (degrees))|Change in turning (task duration (s))|Change in turning (turn angle (degrees))|Change in turning (turn velocity (degrees/s))|Change in functional lower extremity strength (task duration (s))|Change in functional lower extremity strength (lean angle (degrees))|Change in hand grip strength|Change in quadriceps grip strength|Change in physical activity (% of time in different levels of physical activity)|Change in physical activity (step count)|Change in physical activity (number of sedentary bouts)|Change in physical activity (time in sedentary bouts (min))|Change in sleep efficiency (total sleep time/total time in bed)|Change in sleep (number of awakenings)|Change in sleep (average awake length (min))|Change in sleep (Sleep Fragmentation Index)|Falls|Change in inflammatory blood biomarkers (Interleukin-6)|Change in inflammatory blood biomarkers (Interleukin-1)|Change in inflammatory blood biomarkers (Tumor Necrosis Factor-α)|Change in kynurenine pathway metabolites (kynurenine)|Change in kynurenine pathway metabolites (tryptophan)|Change in kynurenine pathway metabolites (kynurenic acid)|Change in epigenetics","Augusta University","All","55 Years and older   (Adult, Older Adult)","Not Applicable","42","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","1838020","August 1, 2022","December 31, 2023","December 31, 2023","August 5, 2022",,"August 5, 2022","Augusta University, Augusta, Georgia, United States",,"https://ClinicalTrials.gov/show/NCT05488951"
992,"NCT05488938","Intensive Anti-Scoliosis Postural Intervention for Individuals With Rett Syndrome Supported by a Smartphone Application",,"Active, not recruiting","No Results Available","Rett Syndrome","Other: Rehabilitative Intervention","Scoliosis progression|Adherence to the Program|Gross Motor Function Level|Behavioral Characteristics|Caregivers' Burden","Ariel University|ASST Santi Paolo e Carlo","Female","6 Years to 16 Years   (Child)","Not Applicable","20","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","AU-HEA-ML-20201019","April 1, 2021","September 30, 2023","September 30, 2023","August 5, 2022",,"August 5, 2022","Centro AIRETT Ricerca e Innovazione (CARI), Verona, Italy","""Study Protocol, Statistical Analysis Plan, and Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/38/NCT05488938/Prot_SAP_ICF_000.pdf","https://ClinicalTrials.gov/show/NCT05488938"
993,"NCT05488925","Comparison of Preoperative Analgesics on the Efficacy of Inferior Alveolar Nerve Block.",,"Completed","No Results Available","Symptomatic Irreversible Pulpitis","Drug: Vitamin E|Drug: Diclofenac Sodium|Drug: Piroxicam|Drug: Tramadol","To check the efficacy of preoperative analgesics on inferior alveolar nerve block using Heft-Parker Visual Analogue Scale.","Farjad Zafar|Baqai Medical University","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Supportive Care","BDC/ERB/2021/016","June 21, 2021","February 18, 2022","February 18, 2022","August 5, 2022",,"August 5, 2022","Department of Operative Dentistry, Baqai Dental College, Baqai Medical University., Karachi, Sindh, Pakistan","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/25/NCT05488925/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/25/NCT05488925/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT05488925"
994,"NCT05488912","Fiber-rich Foods, Weight Status, and the Gut Microbiota in NH Hispanic Adults at Risk for Food Insecurity","FIRST","Not yet recruiting","No Results Available","Food Insecurity|Overweight and Obesity",,"Food Insecurity and Access|Fiber Intake|Microbial Richness|Short-Chain Fatty Acids|LPS|Insulin|Glucose|GLP-1|Ghrelin|Fruit, Vegetable, and Whole Grain Intake|Enterotype Classification of Gut Microbiota","University of New Hampshire|New Hampshire Agricultural Experiment Station","All","18 Years to 55 Years   (Adult)",,"60","Other","Observational","Observational Model: Other|Time Perspective: Cross-Sectional","UNH-10-FY2021_49-01","August 2022","August 2023","August 2023","August 5, 2022",,"August 5, 2022",,,"https://ClinicalTrials.gov/show/NCT05488912"
995,"NCT05488899","Ultra Low Iodine Loaded Spectral CT Angiography (CTA)",,"Completed","No Results Available","Peripheral Arterial Disease|Renal Insufficiency","Diagnostic Test: Half iodine Spectral CT|Diagnostic Test: Standard iodine conventional CT","Mean arterial attenuation|Subjective examination quality|Rate of diagnostic quality angiography","University Hospital, Akershus|Oslo Metropolitan University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","216","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Diagnostic","2018_070","January 28, 2019","October 16, 2020","October 16, 2020","August 5, 2022",,"August 5, 2022","Akershus University Hospital, Lørenskog, Viken, Norway","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/99/NCT05488899/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT05488899"
996,"NCT05488886","Bioavailability of Aronia Berry Polyphenols",,"Not yet recruiting","No Results Available","Gut Health|Metabolism|Polyphenols","Dietary Supplement: Whole Aronia Berry Powder Applesauce|Dietary Supplement: Aronia Berry Extract Applesauce|Dietary Supplement: Phospholipid-Polyphenol Applesauce|Other: Low-Polyphenol Control Applesauce","Urinary Polyphenol Catabolite Concentration|Urinary Anthocyanin Concentration|Fecal Polyphenol Catabolite Concentration|Fecal Anthocyanin Concentration|Urine Creatinine Content","University of Wisconsin, Madison","All","18 Years and older   (Adult, Older Adult)","Not Applicable","10","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science","2022-0702|Protocol Version 07/01/2022|A074000","September 2022","February 2023","February 2023","August 5, 2022",,"August 5, 2022","University of Wisconsin, Madison, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT05488886"
997,"NCT05488873","A Study of Topical Pirenzepine or Placebo in Oncology Patients With Chemotherapy Induced Peripheral Neuropathy",,"Not yet recruiting","No Results Available","Chemotherapy-induced Peripheral Neuropathy","Drug: WST-057 Active|Drug: Placebo","Incidence of Treatment-Emergent Adverse Events as assessed by hematology and chemistry blood tests.|Incidence of Treatment-Emergent Adverse Events as assessed by vital signs (blood pressure (diastolic and systolicmmHg), heart rate (beats per minute), respiratory rate (breaths per minute).|Incidence of Treatment-Emergent Adverse Events as assessed by ECG (measuring P Wave, QRS complex, QT interval)|Incidence of Treatment-Emergent Adverse Events as assessed by a dermal assessment (Draize score (scale 0.0-4.0) of the dosing area|Incidence of Treatment-Emergent Adverse Events as assessed by physical examination|Incidence of Treatment-Emergent Adverse Events as assessed by tumor evaluation using RECIST v1.1|Visual Analogue Score (VAS)|Neuropathy Total Symptom Score-6 (NTSS-6)|Functional Assessment of Cancer Therapy/Gynecological Oncology Group-Neurotoxicity-13 (FACT/GOG-Ntx-13)|Patient-Reported Outcomes Measurement Information System (PROMIS)-physical function (short form)|Thermal Quantitative Sensory Testing (Cold)|Utah Early Neuropathy Score (UENS)|Activity and Fear of Falling Measurement (Short FES-I)|Intraepidermal Nerve Fiber Density|Hand Dexterity|Chemotherapy dose modifications as assessed by percentage of patients requiring dose reductions of chemotherapy.|Chemotherapy dose modifications as assessed by the percentage of patients requiring dose delay of chemotherapy.|Chemotherapy dose modifications as assessed by median duration of delays (days) between chemotherapy treatments.|Chemotherapy dose modifications as assessed by the percentage of patients requiring replacement or change to initially prescribed chemotherapy (carboplatin/paclitaxel combination).|Chemotherapy dose modifications as assessed by the percentage of patients stopping chemotherapy before treatment is complete. chemotherapy (carboplatin/paclitaxel combination).|Dose limiting neuropathy as assessed by decrease in chemotherapy-induced peripheral sensory neuropathy ≥ Grade 3.|Dose limiting neuropathy as assessed by decrease in percentage of patients with sensory peripheral neuropathy ≥ Grade 3|Dose limiting neuropathy as assessed by increase in time to onset of sensory peripheral neuropathy ≥ Grade 3.|Dose limiting neuropathy as assessed by decrease in duration of sensory peripheral neuropathy ≥ Grade 3.","WinSanTor, Inc","All","18 Years and older   (Adult, Older Adult)","Phase 2","60","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","WST-PZP-005","August 15, 2022","April 26, 2024","May 30, 2024","August 5, 2022",,"August 5, 2022","Goshen Center for Cancer Care, Goshen, Indiana, United States|Community Cancer Trials of Utah (CCTU), Ogden, Utah, United States",,"https://ClinicalTrials.gov/show/NCT05488873"
998,"NCT05488860","Piezoelectric Drived Microneedling in Treating Refractory Skin Diseases",,"Recruiting","No Results Available","Skin Diseases|Hypertrophic Scar|Keloid|Plantar Wart|Warts|Skin Tumor","Drug: Triamcinolone acetonide(scar)/5-ALA(others)|Procedure: Piezoelectric drived microneedling|Drug: 5-ALA (a photosensitizer for photodynamic therapy).","Short-term response|Long-term response|Pain score during treatment|POSAS(The Patient and Observer Scar Assessment Scale) score","Xiangya Hospital of Central South University","All","16 Years and older   (Child, Adult, Older Adult)","Not Applicable","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","XiangyaDerm0002","July 30, 2022","June 30, 2024","July 31, 2024","August 5, 2022",,"August 5, 2022","Xiangya Hospital, Changsha, China",,"https://ClinicalTrials.gov/show/NCT05488860"
999,"NCT05488847","Opioid-Free Pain Protocol After Shoulder Arthroplasty",,"Recruiting","No Results Available","Shoulder Arthropathy|Shoulder Pain","Drug: Celecoxib|Drug: Pregabalin|Drug: Tramadol|Drug: Dexamethasone|Drug: Acetaminophen|Drug: Ropivicaine|Drug: Epinephrine|Drug: ketoralac|Drug: Tizanidine|Drug: magnesium|Drug: Ibuprofen|Drug: Oxycodone Hydrochloride 5 Mg, Acetaminophen 325 Mg Oral Tablet","Pain levels|Patient-Reported Outcomes scores (PROMs) for upper extremity pain interference|Patient-Reported Outcomes scores (PROMs) for upper extremity function|Patient-Reported Outcomes scores (PROMs) for depression|Complications|Reoperation|Shoulder Range of Motion|Shoulder Strength|Morphine milligram equivalents","Henry Ford Health System","All","18 Years and older   (Adult, Older Adult)","Phase 4","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","15592","June 25, 2022","December 1, 2023","December 1, 2025","August 5, 2022",,"August 5, 2022","Henry Ford Health, Detroit, Michigan, United States",,"https://ClinicalTrials.gov/show/NCT05488847"
1000,"NCT05488834","Nurse-led Pain Management in Adult ICU",,"Completed","No Results Available","Pain Management","Other: Critical-Care Pain Observation Tool","Number of documented pain assessments per 24-hour period|Level of sedation and analgesia|Length of intubation (LOI)|ICU stay|Acceptability|Appropriateness|Feasibility in nursing practice","King Abdulaziz Medical City|Newcastle University|Qassim University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","880","Other","Interventional","Allocation: N/A|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","KingAbdulazizMC","February 1, 2022","June 30, 2022","July 1, 2022","August 5, 2022",,"August 5, 2022","King Abdulaziz Medical City, Riyadh, Saudi Arabia",,"https://ClinicalTrials.gov/show/NCT05488834"
